{"05758e03e251e19d4df2d257acd54a50510bff0c": [["Letter to the EditorThe role of enzymatic debridement in burn care in the COVID-19 pandemic.", [["burn", "DISEASE", 57, 61], ["enzymatic debridement", "TREATMENT", 32, 53], ["burn care", "TREATMENT", 57, 66], ["debridement", "OBSERVATION", 42, 53]]], ["Commentary by the Italian Society of Burn Surgery (SIUST)Letter to the EditorAs healthcare systems worldwide buckle under the weight of facing the COVID-19 pandemic, burn care providers around the globe are faced with continuing essential burn care treatments under these extreme conditions.", [["burn", "DISEASE", 166, 170], ["burn", "DISEASE", 239, 243], ["Burn Surgery", "TREATMENT", 37, 49], ["burn care providers", "TREATMENT", 166, 185], ["continuing essential burn care treatments", "TREATMENT", 218, 259], ["these extreme conditions", "TREATMENT", 266, 290], ["globe", "ANATOMY", 197, 202]]], ["The main challenges reported are acute staff shortages due to infection or quarantine, shortage in operating rooms due to many being dedicated to COVID-19 infected patients providing ICU treatment as well as shortage in operating room supplies and ventilators, and the general need to minimize the burden on healthcare systems.", [["infection", "DISEASE", 62, 71], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 164, 172], ["infection", "PROBLEM", 62, 71], ["ICU treatment", "TREATMENT", 183, 196], ["ventilators", "TREATMENT", 248, 259], ["the burden on healthcare systems", "PROBLEM", 294, 326], ["main", "OBSERVATION_MODIFIER", 4, 8], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["infection", "OBSERVATION", 62, 71]]], ["Due to the above, we have recently seen national and international burn care associations stressing the need for shifting towards non-surgical care of burn patients [1\u00c07] .", [["burn", "DISEASE", 67, 71], ["burn", "DISEASE", 151, 155], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 156, 164], ["international burn care", "TREATMENT", 53, 76], ["shifting towards non-surgical care", "TREATMENT", 113, 147]]], ["Aside from the need to alleviate surgical burden during these times, we, the burn specialists, are currently facing an additional problem associated with burn surgery \u00c0 a nonpredictable acute and severe shortage in blood products due to donation' decrease [8] .", [["blood", "ANATOMY", 215, 220], ["burn", "DISEASE", 154, 158], ["blood", "ORGANISM_SUBSTANCE", 215, 220], ["surgical burden", "PROBLEM", 33, 48], ["burn surgery", "TREATMENT", 154, 166], ["a nonpredictable acute and severe shortage in blood products", "PROBLEM", 169, 229], ["acute", "OBSERVATION_MODIFIER", 186, 191], ["severe", "OBSERVATION_MODIFIER", 196, 202]]], ["This shortage in combination with the limitations stated above is currently almost completely denying us the ability to perform burn surgery in the best logistic conditions.Letter to the EditorItaly is one of the most experienced countries worldwide in the use of rapid enzymatic burn debridement with a concentrate of proteolytic enzymes enriched in Bromelain (NexoBrid 1 ).", [["burn", "DISEASE", 128, 132], ["Bromelain", "CHEMICAL", 351, 360], ["Bromelain", "CHEMICAL", 351, 360], ["Bromelain", "SIMPLE_CHEMICAL", 351, 360], ["proteolytic enzymes", "PROTEIN", 319, 338], ["burn surgery", "TREATMENT", 128, 140], ["rapid enzymatic burn debridement", "TREATMENT", 264, 296], ["proteolytic enzymes", "TREATMENT", 319, 338], ["Bromelain (NexoBrid", "TREATMENT", 351, 370], ["debridement", "OBSERVATION", 285, 296]]], ["Rapid enzymatic debridement has been proven to significantly reduce the utilisation of burn surgery and blood loss in 2 randomized controlled trials and in our five years of extensive clinical experience, part of the >6000 burn patients treated in the US, EU, Israel and India.", [["blood", "ANATOMY", 104, 109], ["burn", "DISEASE", 87, 91], ["blood loss", "DISEASE", 104, 114], ["burn", "DISEASE", 223, 227], ["blood", "ORGANISM_SUBSTANCE", 104, 109], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 228, 236], ["Rapid enzymatic debridement", "TREATMENT", 0, 27], ["burn surgery", "TREATMENT", 87, 99], ["blood loss", "PROBLEM", 104, 114], ["2 randomized controlled trials", "TREATMENT", 118, 148], ["debridement", "OBSERVATION", 16, 27], ["burn", "OBSERVATION", 87, 91]]], ["It is currently the nonsurgical burn debridement modality with the highest level of evidence worldwide.", [["the nonsurgical burn debridement modality", "TREATMENT", 16, 57], ["nonsurgical", "OBSERVATION_MODIFIER", 20, 31], ["burn", "OBSERVATION_MODIFIER", 32, 36], ["debridement", "OBSERVATION", 37, 48]]], ["Burns incidents are not predictable, so especially in the present situation the management even of a limited injury incidents could be more challenging than ever.", [["Burns incidents", "PROBLEM", 0, 15], ["a limited injury", "PROBLEM", 99, 115], ["not", "UNCERTAINTY", 20, 23], ["predictable", "OBSERVATION_MODIFIER", 24, 35]]], ["In view of the above, our combined experience as expressed in the consensus paper of the Italian burn society (SIUST: ITALIAN RECOMMENDATIONS ON ENZYMATIC DEBRIDE-MENT IN BURN SURGERY: statements 10, 23\u00c027) and the developing current situation we have decided to maximize the use of this modality of burn care wherever we feel it is feasible.", [["burn", "DISEASE", 97, 101], ["burn", "DISEASE", 300, 304], ["this modality of burn care", "TREATMENT", 283, 309]]], ["The hospitals increased their NexoBrid 1 stockpiles for the treatment of burn victims, greatly improving our ability to cope with the current situation.Letter to the EditorWe recommend burn care providers worldwide to consider this modality in anticipation for the surge in numbers of COVID-19 patients worldwide and the impact on burn care.", [["burn", "DISEASE", 73, 77], ["burn", "DISEASE", 331, 335], ["patients", "ORGANISM", 294, 302], ["patients", "SPECIES", 294, 302], ["their NexoBrid 1 stockpiles", "TREATMENT", 24, 51], ["burn victims", "PROBLEM", 73, 85], ["burn care providers", "TREATMENT", 185, 204], ["this modality", "TREATMENT", 227, 240], ["COVID", "TREATMENT", 285, 290], ["burn care", "TREATMENT", 331, 340]]]], "9d05e50fd0ffb17e63a9e9c17f76f36324bcba3e": [["BackgroundImmunization protects people, especially international travelers, against infectious diseases that may be encountered abroad and prevents the spread of these diseases between and within countries (WHO, 2013) .", [["infectious diseases", "DISEASE", 84, 103], ["people", "ORGANISM", 32, 38], ["people", "SPECIES", 32, 38], ["infectious diseases", "PROBLEM", 84, 103], ["these diseases", "PROBLEM", 162, 176], ["diseases", "OBSERVATION", 168, 176]]], ["Evidence indicates that immunization has significantly reduced the global burden of infectious diseases, disability, and death (WHO 2018; Centers for Disease Control, 2017) .", [["infectious diseases", "DISEASE", 84, 103], ["disability", "DISEASE", 105, 115], ["death", "DISEASE", 121, 126], ["immunization", "TREATMENT", 24, 36], ["infectious diseases", "PROBLEM", 84, 103], ["global", "OBSERVATION_MODIFIER", 67, 73], ["burden", "OBSERVATION_MODIFIER", 74, 80], ["infectious", "OBSERVATION", 84, 94]]], ["Despite the usefulness of vaccination, its sub-optimal uptake among international travel populations remains a significant public health challenge.", [["vaccination", "TREATMENT", 26, 37], ["significant", "OBSERVATION_MODIFIER", 111, 122]]], ["Selcuk et al. (2016) report that about 45 percent of Turkish business travelers to Africa had not taken at least one of the recommended vaccines.", [["travelers", "ORGANISM", 70, 79]]], ["Frew, McGeorge, Grant, and de Wildt (2016) also observed that 40 percent of 1680 backpackers who were visiting Thailand had sub-optimally vaccinated against hepatitis B. Sub-optimal vaccination undermines global vaccine coverage, breaks herd immunity and fosters disease outbreak and spread .", [["hepatitis", "DISEASE", 157, 166], ["hepatitis B.", "TREATMENT", 157, 169], ["Sub-optimal vaccination", "TREATMENT", 170, 193], ["global vaccine coverage", "TREATMENT", 205, 228], ["fosters disease outbreak", "PROBLEM", 255, 279]]], ["Travelers without protection against vaccine-preventable diseases (VPDs) may get become sick when exposed.", [["vaccine-preventable diseases", "DISEASE", 37, 65], ["VPDs", "DISEASE", 67, 71], ["preventable diseases", "PROBLEM", 45, 65]]], ["In the case of contagious diseases, they might facilitate the disease spread while traveling and upon returning home (Poulos, Curran, Anastassopoulou, & De Moerlooze, 2018) .", [["contagious diseases", "PROBLEM", 15, 34], ["the disease spread", "PROBLEM", 58, 76], ["contagious", "OBSERVATION_MODIFIER", 15, 25], ["diseases", "OBSERVATION", 26, 34]]], ["Based on data from the GeoSentinel Surveillance Network from 49 specialized travel/tropical medicine clinics on six continents, Boggild et al. (2010) reported various VPDs among 37,542 travelers who returned home.", [["VPDs", "DISEASE", 167, 171]]], ["These ranged from enteric (typhoid and paratyphoid) fever, hepatitis, influenza, yellow fever, varicella, measles, pertussis to bacterial meningitis.", [["enteric (typhoid and paratyphoid) fever", "DISEASE", 18, 57], ["hepatitis", "DISEASE", 59, 68], ["influenza", "DISEASE", 70, 79], ["yellow fever", "DISEASE", 81, 93], ["varicella", "DISEASE", 95, 104], ["measles", "DISEASE", 106, 113], ["pertussis", "DISEASE", 115, 124], ["bacterial meningitis", "DISEASE", 128, 148], ["yellow fever", "SPECIES", 81, 93], ["pertussis", "SPECIES", 115, 124], ["enteric (typhoid", "PROBLEM", 18, 34], ["paratyphoid", "PROBLEM", 39, 50], ["fever", "PROBLEM", 52, 57], ["hepatitis", "PROBLEM", 59, 68], ["influenza", "PROBLEM", 70, 79], ["yellow fever", "PROBLEM", 81, 93], ["varicella", "PROBLEM", 95, 104], ["measles", "PROBLEM", 106, 113], ["pertussis", "PROBLEM", 115, 124], ["bacterial meningitis", "PROBLEM", 128, 148], ["enteric", "ANATOMY", 18, 25], ["hepatitis", "OBSERVATION", 59, 68], ["yellow fever", "OBSERVATION", 81, 93], ["varicella", "ANATOMY", 95, 104], ["bacterial", "OBSERVATION_MODIFIER", 128, 137], ["meningitis", "OBSERVATION", 138, 148]]], ["After its outbreak in Wuhan, the 2019 coronavirus disease is confirmed to have spread globally through international travelers.BackgroundSystematic reviews have shown that people's concerns towards vaccination are significant factors for under vaccination (Larson, Jarrett, Eckersberger, Smith, & Paterson, 2014) .", [["coronavirus disease", "DISEASE", 38, 57], ["coronavirus", "ORGANISM", 38, 49], ["people", "ORGANISM", 172, 178], ["coronavirus", "SPECIES", 38, 49], ["people", "SPECIES", 172, 178], ["2019 coronavirus", "SPECIES", 33, 49], ["the 2019 coronavirus disease", "PROBLEM", 29, 57], ["coronavirus disease", "OBSERVATION", 38, 57]]], ["These concerns are varied and include vaccine safety and efficacy misconceptions, mistrust, lack of information, and faith compatibility issues (Karafillakis & Larson, 2017) .", [["vaccine safety", "TREATMENT", 38, 52]]], ["The term 'vaccination concern' is used rather than 'vaccine concern' because people's apprehensions about immunization include not only vaccines but its related systems and actors.", [["people", "ORGANISM", 77, 83], ["people", "SPECIES", 77, 83], ["immunization", "TREATMENT", 106, 118], ["vaccines", "TREATMENT", 136, 144]]], ["Travel medicine studies (Crockett & Keystone, 2005; Lammert et al., 2016) exploring reasons for the variable vaccine uptake among travelers have reported some concerns; however, they are piecemeal and patchy.", [["the variable vaccine uptake", "PROBLEM", 96, 123], ["piecemeal", "OBSERVATION", 187, 196], ["patchy", "OBSERVATION_MODIFIER", 201, 207]]], ["Though these studies are helpful, the fragmented nature of the findings does little to explain the theoretical depth of the concept of travel vaccination concerns.BackgroundBehavioral scientists assert that individuals' perceptions about objects, including their concerns, are multifaceted.", [["these studies", "TEST", 7, 20]]], ["It implies that to have a proper understanding of vaccination concerns (especially one that can inform behavioral intervention), a conceptually grounded approach to studying it is required.", [["behavioral intervention", "TREATMENT", 103, 126]]], ["Currently, a psychometric measurement scale that can be used to assess vaccination attitudes and beliefs, including concerns among international travel populations is almost non-existing.", [["a psychometric measurement scale", "TEST", 11, 43]]], ["This implies that tourists' concerns about vaccination have mostly been looked at as mono indicators, not as multi-dimensional constructs.", [["vaccination", "TREATMENT", 43, 54]]], ["The investigation of vaccination concerns as a mono indicator, arguably, is not only conceptually narrow but may constrain an in-depth understanding of what constitutes travel vaccination concern, its antecedents, and outcomes.", [["vaccination", "TREATMENT", 21, 32]]], ["This situation risks weak clinical and theoretical usefulness of research findings on this subject.BackgroundThere exist useful measures with undertones of vaccination concerns in the general vaccine literature, including the vaccine confidence scale (Gilkey et al., 2014) , vaccine conspiracy belief scale (Shapiro, Holding, Perez, Amsel, & Rosberger, 2017) , vaccine hesitancy scale (Larson et al., 2015; Shapiro et al., 2017) and anti-vax scale (Martin & Petrie, 2017) .", [["vaccination", "TREATMENT", 156, 167], ["the vaccine confidence scale", "TREATMENT", 222, 250]]], ["But beyond the children centered and allied nature of the measures, they are not travel context-specific and could be significantly problematic using them as proxies.", [["children", "ORGANISM", 15, 23], ["children", "SPECIES", 15, 23]]], ["The use of proxy theoretical measures and constructs is usual in all research domains, including vaccination studies.", [["proxy theoretical measures", "TREATMENT", 11, 37], ["vaccination studies", "TEST", 97, 116]]], ["We propose that the characterization of travel vaccination concerns may be unique, relative to those measures developed for everyday life settings or children immunization.", [["children", "ORGANISM", 150, 158], ["children", "SPECIES", 150, 158], ["travel vaccination", "TREATMENT", 40, 58], ["everyday life settings", "TREATMENT", 124, 146], ["children immunization", "TREATMENT", 150, 171]]], ["International tourism involves a movement away from one's home across national and international boundaries over some time and defined by discretionary time and income.", [["tourism", "OBSERVATION", 14, 21]]], ["This and, perhaps, among other reasons, suggest that the concerns of tourists about travel vaccination would be different from everyday vaccination concerns as international travel could present peculiar situations.BackgroundThe current study focuses on an essential but ignored phenomenon in tourism and public health research -vaccination for international travel.", [["travel vaccination", "TREATMENT", 84, 102], ["The current study", "TEST", 225, 242]]], ["The study fills the void of no existing measure for travel vaccination concerns by conceptualizing the concept of travel vaccination concern and proposes a scale that measures it.", [["The study", "TEST", 0, 9], ["travel vaccination", "TREATMENT", 52, 70], ["travel vaccination", "TREATMENT", 114, 132], ["a scale", "TREATMENT", 154, 161]]], ["It aims to consolidate the bits of measures in the literature through a critical synthesis and analysis of previous findings, online text mining, field interviews, and surveys to propose a psychometric scale for travel vaccination concerns (referred to as TRAVAC scale).", [["previous findings", "TEST", 107, 124], ["a psychometric scale", "TEST", 187, 207], ["travel vaccination", "TREATMENT", 212, 230]]], ["The aim to develop this scale suggests that a successful development would be of great value for international tourism research.", [["this scale", "TEST", 19, 29]]], ["It offers an understanding of what it means to be concerned about travel vaccination and provides insights on its limits and specific dimensions as a psychometric concept.", [["travel vaccination", "TREATMENT", 66, 84]]], ["A right scale provides conceptual clarity and a more theoretically informed basis for gauging travel vaccination sentiments, their influence on vaccination uptake.", [["A right scale", "TREATMENT", 0, 13], ["gauging travel vaccination sentiments", "TREATMENT", 86, 123], ["right", "ANATOMY_MODIFIER", 2, 7]]], ["It also allows for the comparison of findings across personal characteristics, contexts, and over time.BackgroundOn the practical usefulness of the scale, its facets could aid public health practitioners, travel medicine professionals in particular, to target and tailor interventions for addressing specific anti-travel vaccination concerns among their clients.", [["tailor interventions", "TREATMENT", 264, 284], ["specific anti-travel vaccination", "TREATMENT", 300, 332]]], ["Targeted and tailored interventions are both deemed not only practical and persuasive in addressing audience-specific concerns when compared to generic messages, but useful for addressing health inequities because they engage individuals' values, beliefs and identity structures (Padela, Malik, Vu, Quinn, & Peek, 2018) .", [["tailored interventions", "TREATMENT", 13, 35]]], ["Therefore, we are of the view that anti-travel vaccination sentiments should be studied independently of general anti-vaccination attitudes to better understand and proffer context recommendations for managing them.", [["anti-travel vaccination sentiments", "TREATMENT", 35, 69]]], ["Drawing inferences from public vaccination contexts for the design of interventions to deal with travel-specific vaccination sentiments could result in a poor match of solution for the problem, making the spread of VPDs through international travelers unabated.Risk perception in tourism-emphasis on perceived health riskBroadly, the literature classifies tourism risk into absolute and perceived.", [["VPDs", "DISEASE", 215, 219], ["public vaccination contexts", "TREATMENT", 24, 51], ["interventions", "TREATMENT", 70, 83], ["the problem", "PROBLEM", 181, 192]]], ["Absolute risk denotes an objective assessment of potential hazards and the magnitude of their consequences.", [["an objective assessment", "TEST", 22, 45]]], ["In this view, absolute risk does not vary from person to person, but the subjective risk does.", [["person", "SPECIES", 47, 53], ["person", "SPECIES", 57, 63]]], ["First is uncertainty about the decision, and the second is the uncertainty about the consequence of the action.Risk perception in tourism-emphasis on perceived health riskThe second side of the debate argues for a distinction between risk and uncertainty, albeit most researchers combine both terms in their studies yet do not often indicate the differences between the two concepts.", [["their studies", "TEST", 302, 315]]], ["With uncertainty, there is partial knowledge or no known probabilities of the outcome and severity of the perceived harm.", [["no", "UNCERTAINTY", 48, 50]]], ["In contrast, with risk, some measure of likelihood can be assigned to the possible adverse outcome (An, Lee, & Noh, 2010) .Risk perception in tourism-emphasis on perceived health riskNevertheless, common among the concepts is that both draw attention to some inherent loss in a choice situation.", [["some inherent loss", "PROBLEM", 254, 272]]], ["People have ignored the risk and uncertainty associated with decisions and ultimately derived benefit from them (Hillen, Gutheil, Strout, Smets, & Han, 2017) .", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["The second unanimity is that risk and uncertainty are multi-dimensional in occurrence, meaning that people can associate different levels of risk nand uncertainity with the same event implying a varied conception of potential losses.", [["people", "ORGANISM", 100, 106], ["people", "SPECIES", 100, 106], ["potential losses", "PROBLEM", 216, 232]]], ["Natural disasters, terrorist attacks, financial crises, and the outbreak of diseases are some of these hazards (Hajibaba, Gretzel, Leisch, & Dolnicar, 2015; Quintal, Lee, & Soutar, 2010) .", [["terrorist attacks", "PROBLEM", 19, 36], ["financial crises", "PROBLEM", 38, 54], ["diseases", "PROBLEM", 76, 84], ["disasters", "OBSERVATION", 8, 17]]], ["Risk and tourism are, therefore, inseparable.", [["tourism", "OBSERVATION", 9, 16]]], ["It is projected that about 30-50% of travelers return home ill or injured (Wang, Liu-Lastres, Ritchie, & Mills, 2019) .", [["travelers", "ORGANISM", 37, 46]]], ["Tourism-related health risks comprise infectious and non-infectious diseases, accidents, injuries, impairments, and even death (Pratt, Tolkach, & Kirillova, 2019) .", [["infectious and non-infectious diseases", "DISEASE", 38, 76], ["accidents", "DISEASE", 78, 87], ["injuries", "DISEASE", 89, 97], ["death", "DISEASE", 121, 126], ["non-infectious diseases", "PROBLEM", 53, 76], ["injuries", "PROBLEM", 89, 97], ["impairments", "PROBLEM", 99, 110], ["infectious", "OBSERVATION", 38, 48], ["non-infectious", "OBSERVATION_MODIFIER", 53, 67]]], ["HIV and AIDS, Zika, Ebola, SARS, swine flu (HINI) and Coronavirus are some examples of diseases tourists are susceptible to depending on the travel destination.", [["HIV and AIDS", "DISEASE", 0, 12], ["Zika", "DISEASE", 14, 18], ["Ebola", "DISEASE", 20, 25], ["SARS", "DISEASE", 27, 31], ["swine flu", "DISEASE", 33, 42], ["HINI", "DISEASE", 44, 48], ["Ebola", "ORGANISM", 20, 25], ["swine flu", "ORGANISM", 33, 42], ["HIV", "SPECIES", 0, 3], ["Ebola", "SPECIES", 20, 25], ["swine flu", "SPECIES", 33, 42], ["HIV", "SPECIES", 0, 3], ["swine flu", "SPECIES", 33, 42], ["HIV", "PROBLEM", 0, 3], ["AIDS", "PROBLEM", 8, 12], ["Zika", "PROBLEM", 14, 18], ["Ebola", "PROBLEM", 20, 25], ["SARS", "PROBLEM", 27, 31], ["swine flu (HINI)", "PROBLEM", 33, 49], ["Coronavirus", "PROBLEM", 54, 65], ["diseases", "PROBLEM", 87, 95], ["diseases", "OBSERVATION", 87, 95]]], ["Others include typhoid, hepatitis A and B, influenza, rabies, yellow fever, polio, meningitis and malaria.", [["typhoid, hepatitis A and B", "DISEASE", 15, 41], ["influenza", "DISEASE", 43, 52], ["rabies", "DISEASE", 54, 60], ["yellow fever", "DISEASE", 62, 74], ["polio", "DISEASE", 76, 81], ["meningitis", "DISEASE", 83, 93], ["malaria", "DISEASE", 98, 105], ["hepatitis A", "ORGANISM", 24, 35], ["B", "CANCER", 40, 41], ["rabies", "ORGANISM", 54, 60], ["influenza", "SPECIES", 43, 52], ["yellow fever", "SPECIES", 62, 74], ["hepatitis A", "SPECIES", 24, 35], ["typhoid", "PROBLEM", 15, 22], ["hepatitis A and B", "PROBLEM", 24, 41], ["influenza", "PROBLEM", 43, 52], ["rabies", "PROBLEM", 54, 60], ["yellow fever", "PROBLEM", 62, 74], ["polio", "PROBLEM", 76, 81], ["meningitis", "PROBLEM", 83, 93], ["malaria", "PROBLEM", 98, 105], ["typhoid", "OBSERVATION", 15, 22], ["hepatitis", "OBSERVATION", 24, 33], ["meningitis", "OBSERVATION", 83, 93], ["malaria", "OBSERVATION", 98, 105]]], ["The emergence and re-emergence of these diseases, in part, are attributed to overseas travel (Aubry et al., 2012) .Risk perception in tourism-emphasis on perceived health riskThe intersection between international travel and the risk of diseases is due to the inexorable increasing scale of international tourism (UNWTO, 2020), differences in environmental conditions (i.e., weather conditions, water, sanitation and hygiene [WASH] ) between countries, and tourists' attitudes and behaviors (Jonas, Mansfeld, Paz, & Potasman, 2011) .", [["these diseases", "PROBLEM", 34, 48], ["diseases", "PROBLEM", 237, 245], ["diseases", "OBSERVATION", 40, 48], ["diseases", "OBSERVATION", 237, 245]]], ["For example, tourism spaces offer suitable environments for people to engage in sexually risky behavior (especially casual sex), making those involved vulnerable to sexually transmitted infections (Omondi & Ryan, 2017) .", [["sexually risky behavior", "DISEASE", 80, 103], ["sexually transmitted infections", "DISEASE", 165, 196], ["people", "ORGANISM", 60, 66], ["people", "SPECIES", 60, 66]]], ["Strangely, the majority of previous studies conclude that perceived health risk is ranked low among travelers (Frew et al., 2016; Jonas et al., 2011; Lammert et al., 2016; Wang et al., 2019) .", [["previous studies", "TEST", 27, 43]]], ["The low credence given by tourists to health risk is due to their apparent high vulnerability to other hazards such as crime relative to health risks (Jonas et al., 2011) .", [["low credence", "OBSERVATION_MODIFIER", 4, 16]]], ["Dioko and Harrill (2019) affirm that aggregate statistics on travelers who return home sick, fatalities of tourism-related deaths, and disability are scarce.Risk perception in tourism-emphasis on perceived health riskNevertheless, inferring from the few available statistics, it is obvious that the micro and macro-economic burden of health risks are enormous.", [["deaths", "DISEASE", 123, 129], ["disability", "DISEASE", 135, 145], ["the micro and macro-economic burden of health risks", "PROBLEM", 295, 346]]], ["Significant drops in destination arrivals and business traffic such as passenger traffic, attraction visitation numbers, and hotel occupancy are some of the adverse impacts of disease outbreaks.", [["Significant drops", "PROBLEM", 0, 17], ["disease outbreaks", "PROBLEM", 176, 193], ["drops", "OBSERVATION_MODIFIER", 12, 17], ["disease", "OBSERVATION", 176, 183]]], ["The current COVID-19 pandemic, has so far accounted for over 18 million infections, and 600,000 deaths worldwide.", [["infections", "DISEASE", 72, 82], ["deaths", "DISEASE", 96, 102], ["The current COVID", "TEST", 0, 17], ["pandemic", "PROBLEM", 21, 29]]], ["Its impacts on economies have equally been devastating, and the tourism and the hospitality sector is currently one of the most affected sectors with international tourist arrivals likely to decline between 20 and 30%, valued between US$300-450 billion.", [["impacts", "OBSERVATION_MODIFIER", 4, 11], ["devastating", "OBSERVATION_MODIFIER", 43, 54]]], ["Firms ceased to operate; others curtailed their operations to a portion of their capacity, and millions of employees have lost their jobs (UNWTO, 2020; Worldometer, 2020) .Risk perception in tourism-emphasis on perceived health riskThere are variations in visitors' perceived risk of specific diseases and across destinations.", [["specific diseases", "PROBLEM", 284, 301], ["diseases", "OBSERVATION", 293, 301]]], ["Africa, South America, the Middle East, and Asia are risky for infectious diseases (Kozak, Crotts, & Law, 2007) .", [["infectious diseases", "DISEASE", 63, 82], ["infectious diseases", "PROBLEM", 63, 82], ["Middle", "ANATOMY_MODIFIER", 27, 33]]], ["In a rating of destination health risks, destination induced hazards (water quality, health care quality, food safety, disease infection) were ranked high.", [["infection", "DISEASE", 127, 136], ["health care quality", "TREATMENT", 85, 104], ["disease infection", "PROBLEM", 119, 136]]], ["Semi-controlled hazards (physical injury, the safety of extreme adventure facilities, environmental, physical conditions) were rated as moderate health hazards, and fully controlled hazards (sexually transmitted diseases and drug and drug abuse) were the least ranked.", [["sexually transmitted diseases", "DISEASE", 191, 220], ["drug and drug abuse", "DISEASE", 225, 244], ["Semi-controlled hazards (physical injury", "PROBLEM", 0, 40]]], ["While water quality and food safety have the inherent perceived risk of VPDs, tourists' under-estimation of their likelihood of disease infection and sexually transmitted diseases are attributed to they having greater control over such hazards (Jonas et al., 2011) .", [["VPDs", "DISEASE", 72, 76], ["infection", "DISEASE", 136, 145], ["sexually transmitted diseases", "DISEASE", 150, 179], ["disease infection", "PROBLEM", 128, 145], ["sexually transmitted diseases", "PROBLEM", 150, 179], ["disease", "OBSERVATION", 128, 135]]], ["Perceived greater control over health risks perhaps is born out of their lack of information on the full spectrum of actual vulnerability and severity, and complacency.Risk perception in tourism-emphasis on perceived health riskSimilarly, previous studies have underscored that risk perceptions vary by travelers' socio-demographic, psychographic, and trip characteristics.", [["previous studies", "TEST", 239, 255], ["greater", "OBSERVATION_MODIFIER", 10, 17]]], ["Kozak et al. (2007) observed that tourists from China, Singapore, and Malaysia were more concerned about infectious diseases, terrorist attacks, and natural disasters when compared to others.", [["infectious diseases", "DISEASE", 105, 124], ["terrorist attacks", "DISEASE", 126, 143], ["infectious diseases", "PROBLEM", 105, 124]]], ["Gender, length of stay, trip motivation, the purpose of visit, and travel experience are some underlying reasons for the observed variations.", [["length", "OBSERVATION_MODIFIER", 8, 14]]], ["Young independent, curious, adventurous, and rural-based travelers, such as backpackers, are less concerned about travel risk, health risk in particular when compared to mass tourists.", [["travelers", "ORGANISM", 57, 66]]], ["Males also perceive less risk when compared to females (Lepp & Gibson, 2003) .Risk perception in tourism-emphasis on perceived health riskBackpackers generally have a high tolerance for risk when compared to other normative tourists.", [["less risk", "OBSERVATION_MODIFIER", 20, 29]]], ["But there are a limited number of dedicated studies on their travel health risks.", [["dedicated studies", "TEST", 34, 51]]], ["The few studies concluded that their most significant concerns when traveling abroad are zoonotic diseases, sexually transmitted diseases (STIs), and hygiene issues (Hunter-Jones, Jeffs, & Smith, 2008; Dahlman & Stafstr\u00f6m, 2013; Adam, 2015; Badu-Baiden, Boakye, & Otoo, 2016) .", [["zoonotic diseases", "DISEASE", 89, 106], ["sexually transmitted diseases", "DISEASE", 108, 137], ["STIs", "DISEASE", 139, 143], ["The few studies", "TEST", 0, 15], ["zoonotic diseases", "PROBLEM", 89, 106], ["sexually transmitted diseases (STIs)", "PROBLEM", 108, 144]]], ["Marked differences, however, exist based on gender, country of origin, and other demographic characteristics.", [["differences", "OBSERVATION_MODIFIER", 7, 18], ["origin", "ANATOMY_MODIFIER", 63, 69]]], ["Backpackers' vulnerabilities to these health risks are due to their explorative and drifter lifestyle, abusive alcohol and drug use, and patronage of sub-standard accommodation facilities (Steffen & Connor, 2005) .", [["alcohol", "CHEMICAL", 111, 118], ["alcohol", "CHEMICAL", 111, 118]]], ["Regarding their perceived VPDs, Frew et al. (2016) reported that the majority of their sampled backpackers in Thailand considered themselves vulnerable to hepatitis B, albeit about 44% differed.", [["hepatitis B", "DISEASE", 155, 166], ["hepatitis B", "PROBLEM", 155, 166], ["hepatitis", "OBSERVATION", 155, 164]]], ["For UK backpackers to Africa, the majority are worried about contracting yellow fever, rabies, and dengue fever, but only a third perceived themselves prone to contracting meningitis and thus vaccinated (Goodman, Masuet-Aumatell, Halbert, & Zuckerman, 2014) .", [["yellow fever", "DISEASE", 73, 85], ["rabies", "DISEASE", 87, 93], ["dengue fever", "DISEASE", 99, 111], ["meningitis", "DISEASE", 172, 182], ["contracting yellow fever", "PROBLEM", 61, 85], ["rabies", "PROBLEM", 87, 93], ["dengue fever", "PROBLEM", 99, 111], ["contracting meningitis", "PROBLEM", 160, 182], ["meningitis", "OBSERVATION", 172, 182]]], ["The literature also considers people visiting friends and relatives (VFR), those with preexisting medical conditions, and those who are immunocompromised as at-risk populations.", [["people", "ORGANISM", 30, 36], ["people", "SPECIES", 30, 36], ["immunocompromised", "PROBLEM", 136, 153]]], ["Immunocompromised travelers are more vulnerable to infections due to their immune system's deficits and their chance of attenuating responses to vaccines.", [["infections", "DISEASE", 51, 61], ["travelers", "ORGANISM", 18, 27], ["Immunocompromised travelers", "PROBLEM", 0, 27], ["infections", "PROBLEM", 51, 61], ["their immune system's deficits", "PROBLEM", 69, 99], ["vaccines", "TREATMENT", 145, 153]]], ["For instance, the risk of diseases is higher among travelers living with HIV, asplenia, cancer, diabetes, cardiopulmonary diseases, and inflammatory disease than those without preexisting medical conditions (Dekkiche, de Valli\u00e8re, D'Acremont, & Genton, 2016) .Travel vaccines, vaccination, and immunizationTravel to different places can expose one to diseases and their associated consequences.", [["cancer", "ANATOMY", 88, 94], ["cardiopulmonary", "ANATOMY", 106, 121], ["HIV", "DISEASE", 73, 76], ["asplenia", "DISEASE", 78, 86], ["cancer", "DISEASE", 88, 94], ["diabetes", "DISEASE", 96, 104], ["cardiopulmonary diseases", "DISEASE", 106, 130], ["inflammatory disease", "DISEASE", 136, 156], ["cancer", "CANCER", 88, 94], ["HIV", "SPECIES", 73, 76], ["HIV", "SPECIES", 73, 76], ["diseases", "PROBLEM", 26, 34], ["HIV", "PROBLEM", 73, 76], ["asplenia", "PROBLEM", 78, 86], ["cancer", "PROBLEM", 88, 94], ["diabetes", "PROBLEM", 96, 104], ["cardiopulmonary diseases", "PROBLEM", 106, 130], ["inflammatory disease", "PROBLEM", 136, 156], ["preexisting medical conditions", "PROBLEM", 176, 206], ["Travel vaccines", "TREATMENT", 260, 275], ["vaccination", "TREATMENT", 277, 288], ["immunization", "TREATMENT", 294, 306], ["diseases", "OBSERVATION", 26, 34], ["asplenia", "OBSERVATION", 78, 86], ["cancer", "OBSERVATION", 88, 94], ["cardiopulmonary", "ANATOMY", 106, 121], ["diseases", "OBSERVATION", 122, 130], ["inflammatory", "OBSERVATION_MODIFIER", 136, 148]]], ["Thus, it necessitates immunization, which is the uptake of a vaccine against a disease pathogen(s) before traveling to an endemic destination.", [["immunization", "TREATMENT", 22, 34], ["a vaccine", "TREATMENT", 59, 68], ["a disease pathogen", "PROBLEM", 77, 95], ["an endemic destination", "TREATMENT", 119, 141], ["endemic", "OBSERVATION_MODIFIER", 122, 129]]], ["A vaccine is a biological preparation administered into a person's body to elicit an immune response(s) against the disease (s) for which the vaccine is intended.", [["body", "ANATOMY", 67, 71], ["body", "ORGANISM_SUBDIVISION", 67, 71], ["person", "SPECIES", 58, 64], ["A vaccine", "TREATMENT", 0, 9], ["a biological preparation", "TREATMENT", 13, 37], ["a person's body", "TREATMENT", 56, 71], ["the disease (s", "PROBLEM", 112, 126], ["the vaccine", "TREATMENT", 138, 149]]], ["\"A vaccine typically contains an agent that resembles a disease-causing microorganism, such as viruses or bacteria, and is often made from weakened or killed forms of the microbe, toxins, or surface proteins.", [["surface", "ANATOMY", 191, 198], ["surface proteins", "PROTEIN", 191, 207], ["A vaccine", "TREATMENT", 1, 10], ["an agent", "TREATMENT", 30, 38], ["a disease", "PROBLEM", 54, 63], ["microorganism", "PROBLEM", 72, 85], ["viruses", "PROBLEM", 95, 102], ["bacteria", "PROBLEM", 106, 114], ["toxins", "PROBLEM", 180, 186], ["surface proteins", "PROBLEM", 191, 207], ["disease", "OBSERVATION", 56, 63]]], ["The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and remember it so that the immune system can easily recognize and destroy any of these microorganisms that it later encounters\" (WHO 2018:1).", [["body", "ANATOMY", 25, 29], ["body", "ORGANISM_SUBDIVISION", 25, 29], ["immune system", "ANATOMICAL_SYSTEM", 32, 45]]], ["Vaccines sometimes contain preservatives or antibiotics to preserve the vaccine or adjuvants to stimulate an immune response.", [["Vaccines", "TREATMENT", 0, 8], ["preservatives", "TREATMENT", 27, 40], ["antibiotics", "TREATMENT", 44, 55], ["the vaccine", "TREATMENT", 68, 79], ["adjuvants", "TREATMENT", 83, 92]]], ["Vaccines are administered either through needle injections, by mouth, or by aerosol.", [["mouth", "ANATOMY", 63, 68], ["mouth", "ORGANISM_SUBDIVISION", 63, 68], ["Vaccines", "TREATMENT", 0, 8], ["needle injections", "TREATMENT", 41, 58], ["mouth", "ANATOMY", 63, 68]]], ["Drawing from the preceding WHO's the definition of a vaccine, we consider travel vaccination as an attempt to expose the body of a traveler to a vaccineweakened or killed form of the pathogen that causes illnesssuch as viruses or bacteriaor its toxins or one of its surface proteins.", [["body", "ANATOMY", 121, 125], ["surface", "ANATOMY", 266, 273], ["illnesssuch", "DISEASE", 204, 215], ["body", "ORGANISM_SUBDIVISION", 121, 125], ["surface proteins", "PROTEIN", 266, 282], ["a vaccine", "TREATMENT", 51, 60], ["travel vaccination", "TREATMENT", 74, 92], ["a vaccineweakened", "TREATMENT", 143, 160], ["the pathogen", "PROBLEM", 179, 191], ["illnesssuch", "PROBLEM", 204, 215], ["viruses", "PROBLEM", 219, 226], ["bacteriaor its toxins", "PROBLEM", 230, 251]]], ["The vaccine induces acquired immunity so that when the individual's body encounters the real disease-causing agent, it is ready to mount a defense.Travel vaccines, vaccination, and immunizationBeyond the individual level, vaccines create herd immunity.", [["body", "ANATOMY", 68, 72], ["body", "ORGANISM_SUBDIVISION", 68, 72], ["herd", "ORGANISM_SUBDIVISION", 238, 242], ["The vaccine", "TREATMENT", 0, 11], ["the real disease", "PROBLEM", 84, 100], ["agent", "TREATMENT", 109, 114], ["Travel vaccines", "TREATMENT", 147, 162], ["vaccination", "TREATMENT", 164, 175], ["immunization", "TREATMENT", 181, 193], ["vaccines", "TREATMENT", 222, 230]]], ["Herd immunity is especially crucial for safeguarding individuals at risk, including infants and immune-compromised persons who cannot be vaccinated due to age or medical reasons.", [["infants", "ORGANISM", 84, 91], ["persons", "ORGANISM", 115, 122], ["infants", "SPECIES", 84, 91], ["persons", "SPECIES", 115, 122]]], ["However, the trepidation about herd immunity is the 'free rider' problem, where some people intentionally choose not to vaccinate with the intent of benefiting from those who are immune (Yaqub, Castle-Clarke, Sevdalis, & Chataway, 2014).", [["people", "ORGANISM", 85, 91], ["people", "SPECIES", 85, 91]]], ["Stern and Markel (2005) view that despite vaccination and immunization often being used interchangeably in practice, the latter is a more inclusive term, which refers to the development of adequate immunity to a disease as a result of the administration of a vaccine.Travel vaccines, vaccination, and immunizationSpecific to travel, there are three classes of vaccines, namely routine, required, and recommended vaccines (WHO, 2013) .", [["vaccination", "TREATMENT", 42, 53], ["immunization", "TREATMENT", 58, 70], ["a disease", "PROBLEM", 210, 219], ["a vaccine", "TREATMENT", 257, 266], ["Travel vaccines", "TREATMENT", 267, 282], ["vaccination", "TREATMENT", 284, 295], ["vaccines", "TREATMENT", 360, 368]]], ["Routine vaccines are recommended at specific periods for everyone and are usually part of most national immunization programs.", [["Routine vaccines", "TREATMENT", 0, 16], ["most national immunization programs", "TREATMENT", 90, 125]]], ["Examples of routine vaccines are hepatitis A and B, rotavirus, DTaP, tetanus, pneumococcal, HPV, flu, polio, and meningococcal.", [["hepatitis A and B", "DISEASE", 33, 50], ["tetanus", "DISEASE", 69, 76], ["pneumococcal, HPV, flu, polio", "DISEASE", 78, 107], ["hepatitis A", "ORGANISM", 33, 44], ["B", "GENE_OR_GENE_PRODUCT", 49, 50], ["rotavirus", "ORGANISM", 52, 61], ["DTaP", "GENE_OR_GENE_PRODUCT", 63, 67], ["pneumococcal", "ORGANISM", 78, 90], ["HPV", "ORGANISM", 92, 95], ["pneumococcal", "SPECIES", 78, 90], ["hepatitis A", "SPECIES", 33, 44], ["rotavirus", "SPECIES", 52, 61], ["pneumococcal", "SPECIES", 78, 90], ["HPV", "SPECIES", 92, 95], ["routine vaccines", "TREATMENT", 12, 28], ["hepatitis A", "PROBLEM", 33, 44], ["rotavirus", "PROBLEM", 52, 61], ["DTaP", "TREATMENT", 63, 67], ["tetanus", "PROBLEM", 69, 76], ["pneumococcal", "PROBLEM", 78, 90], ["HPV", "PROBLEM", 92, 95], ["flu", "PROBLEM", 97, 100], ["polio", "PROBLEM", 102, 107], ["meningococcal", "PROBLEM", 113, 126]]], ["Most adults in some countries have received all their routine vaccines as children, which has significantly provided herd immunity to populations in those countries to diseases prevented by routine vaccines.", [["children", "ORGANISM", 74, 82], ["children", "SPECIES", 74, 82], ["routine vaccines", "TREATMENT", 54, 70], ["routine vaccines", "TREATMENT", 190, 206]]], ["However, international travelers must be up-to-date with routine vaccines because under-vaccination rates are still prevalent in some countries (Centers for Disease Control, 2017; WHO, 2017) .", [["routine vaccines", "TREATMENT", 57, 73], ["vaccination rates", "TREATMENT", 88, 105]]], ["Required immunizations are mandatory vaccines travelers are expected to take before entering designated destinations based on international health regulations.", [["immunizations", "TREATMENT", 9, 22], ["mandatory vaccines", "TREATMENT", 27, 45]]], ["For example, yellow fever vaccination is necessary for travelers of over nine months of age arriving or in transit of at least 12 h through countries at risk to Ghana; and meningococcal and polio are required for pilgrims to Saudi Arabia.", [["yellow fever", "DISEASE", 13, 25], ["meningococcal and polio", "DISEASE", 172, 195], ["yellow fever", "ORGANISM", 13, 25], ["meningococcal", "SPECIES", 172, 185], ["yellow fever vaccination", "PROBLEM", 13, 37], ["meningococcal and polio", "TREATMENT", 172, 195], ["yellow", "OBSERVATION_MODIFIER", 13, 19], ["fever", "OBSERVATION", 20, 25]]], ["Unlike required vaccines, recommended vaccines are not mandatory.", [["vaccines", "TREATMENT", 16, 24], ["vaccines", "TREATMENT", 38, 46]]], ["They are often suggested to international tourists based on disease risk endemicity, meaning that the disease is significantly present in the location of travel (Crockett & Keystone, 2005) .The concept and potential facets of vaccination concernThe literature provides evidence that people have concerns about vaccination.", [["people", "ORGANISM", 283, 289], ["people", "SPECIES", 283, 289], ["disease risk endemicity", "PROBLEM", 60, 83], ["the disease", "PROBLEM", 98, 109], ["disease", "OBSERVATION", 102, 109]]], ["Vaccination concern has often been studied using related terms such as risk and uncertainty, worry, anxiety, fear, constraints, and morality (see Karafillakis & Larson, 2017; Larson, Paterson, & Erondu, 2012) .", [["anxiety", "DISEASE", 100, 107], ["Vaccination", "TREATMENT", 0, 11], ["anxiety", "PROBLEM", 100, 107]]], ["Discerning vaccination concerns through its related concepts mentioned above are understandable because it may be difficult to observe it directly.", [["Discerning vaccination concerns", "PROBLEM", 0, 31]]], ["Some studies have used these concern-related terms interchangeably without providing their conceptual differences, which may not only result in theoretical inconsistencies but limit the comparison of research findings.", [["Some studies", "TEST", 0, 12]]], ["For instance, Karafillakis and Larson (2017) make no differentiation between the terms 'risk' and 'uncertainty,' 'fear,' 'worry' and 'anxiety' using them interchangeably in their study, which is quite problematic.", [["anxiety", "DISEASE", 134, 141], ["'anxiety'", "PROBLEM", 133, 142], ["their study", "TEST", 173, 184]]], ["We stick to the term vaccination concern and operationalize it as apprehensions that people hold about travel vaccination, which are either perceptual, real or a combination of these, potentially limiting them from embracing vaccines wholeheartedly.", [["people", "ORGANISM", 85, 91], ["people", "SPECIES", 85, 91], ["travel vaccination", "TREATMENT", 103, 121], ["embracing vaccines", "TREATMENT", 215, 233]]], ["We elect that those who vaccinate and those who refuse vaccines can be concerned about certain aspects of travel vaccination (Yaqub et al., 2014) .The concept and potential facets of vaccination concernPrevious research mentions various facets of travel vaccination concerns, some of which are related to vaccines, vaccination-related institutions, and the involved individuals themselves.", [["vaccines", "TREATMENT", 55, 63], ["travel vaccination", "TREATMENT", 247, 265], ["vaccines", "TREATMENT", 305, 313], ["facets", "OBSERVATION_MODIFIER", 173, 179]]], ["Though piecemeal across the multiple studies, the most common concerns include safety, efficacy, cost, access, and time (Crockett & Keystone, 2005; Steffen & Conner; Lammert et al., 2016) .", [["the multiple studies", "TEST", 24, 44], ["piecemeal", "OBSERVATION", 7, 16]]], ["Different longitudinal and systematic review studies among tourists and the general population across different vaccines and countries have noted that vaccine safety and efficacy concerns are the most reported (Crockett & Keystone, 2005; Karafillakis & Larson, 2017) .", [["different vaccines", "TREATMENT", 102, 120], ["vaccine safety", "TREATMENT", 151, 165]]], ["Vaccine safety concern is the feeling that travel vaccination results or will result in harmful outcomes and efficacy concern is the fear that vaccines do not or will not perform as desired or expected (Yaqub et al., 2014) .", [["Vaccine", "TREATMENT", 0, 7], ["vaccines", "TREATMENT", 143, 151]]], ["Vaccine safety and efficacy issues running through the findings of these travel and non-travel context studies imply that these concerns are prevalent across travel and non-travel settings and different vaccines.", [["Vaccine safety", "TREATMENT", 0, 14], ["efficacy issues", "PROBLEM", 19, 34], ["non-travel context studies", "TEST", 84, 110], ["non-travel settings", "TREATMENT", 169, 188], ["different vaccines", "TREATMENT", 193, 211]]], ["The prominence of such matters is due to people's general perception that the risks of vaccination outweigh their benefits (Karafillakis & Larson, 2017) .The concept and potential facets of vaccination concernSpecific types of concerns about vaccine safety and efficacy are, however, identified for the different studies.", [["people", "ORGANISM", 41, 47], ["people", "SPECIES", 41, 47], ["vaccination", "TREATMENT", 87, 98], ["vaccine safety", "TREATMENT", 242, 256], ["the different studies", "TEST", 299, 320], ["prominence", "OBSERVATION_MODIFIER", 4, 14]]], ["For instance, Crockett and Keystone (2005) realized that travelers' vaccine safety and efficacy concerns manifest in the form of fear of side effects of vaccination, mistrust of vaccine efficacy, and fear of the pain of injection.", [["pain", "DISEASE", 212, 216], ["travelers' vaccine", "TREATMENT", 57, 75], ["vaccination", "TREATMENT", 153, 164], ["vaccine efficacy", "TREATMENT", 178, 194], ["the pain of injection", "PROBLEM", 208, 229]]], ["Among Hajj pilgrims, previous studies have found that doubts regarding vaccine effectiveness are a critical reason that accounts for their low uptake of the influenza vaccine (Bish, Yardley, Nicoll, & Michie, 2011) .", [["influenza", "DISEASE", 157, 166], ["previous studies", "TEST", 21, 37], ["vaccine effectiveness", "TREATMENT", 71, 92], ["the influenza vaccine", "TREATMENT", 153, 174]]], ["Karafillakis and Larson's (2017) synthesis of human vaccine studies between 2004 and 2014, on the other hand, noted perceived low effectiveness of vaccines, lack of evidence of the effectiveness of vaccines and injection pain as significant concerns.", [["pain", "DISEASE", 221, 225], ["human", "ORGANISM", 46, 51], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 46, 51], ["Karafillakis", "TEST", 0, 12], ["human vaccine studies", "TEST", 46, 67], ["vaccines", "TREATMENT", 147, 155], ["vaccines", "TREATMENT", 198, 206], ["injection pain", "PROBLEM", 211, 225], ["significant concerns", "PROBLEM", 229, 249]]], ["The perception that vaccines cause the disease they prevent and worry about vaccine adjuvants are also noted.", [["vaccines", "TREATMENT", 20, 28], ["the disease", "PROBLEM", 35, 46], ["vaccine adjuvants", "TREATMENT", 76, 93], ["disease", "OBSERVATION", 39, 46]]], ["Anti-vaccine activists, for instance, claim that ingredients, such as mercury, ether, antifreeze, formaldehyde, and aborted fetal tissues contained in vaccines, are toxic (Kata, 2012) .The concept and potential facets of vaccination concernOther safety and efficacy concerns border on fear, anxieties, and related adverse events that accompany vaccines' uptake.", [["fetal tissues", "ANATOMY", 124, 137], ["mercury", "CHEMICAL", 70, 77], ["formaldehyde", "CHEMICAL", 98, 110], ["mercury", "CHEMICAL", 70, 77], ["ether", "CHEMICAL", 79, 84], ["formaldehyde", "CHEMICAL", 98, 110], ["mercury", "SIMPLE_CHEMICAL", 70, 77], ["ether", "SIMPLE_CHEMICAL", 79, 84], ["formaldehyde", "SIMPLE_CHEMICAL", 98, 110], ["fetal tissues", "TISSUE", 124, 137], ["formaldehyde", "TREATMENT", 98, 110], ["aborted fetal tissues", "PROBLEM", 116, 137], ["vaccination concernOther safety", "TREATMENT", 221, 252], ["fear", "PROBLEM", 285, 289], ["anxieties", "PROBLEM", 291, 300], ["related adverse events", "PROBLEM", 306, 328], ["fetal tissues", "ANATOMY", 124, 137]]], ["The fear of vaccination is a feeling of nervousness induced by perceived danger.", [["nervousness", "DISEASE", 40, 51], ["nervousness", "PROBLEM", 40, 51]]], ["On the other hand, anxiety is a manifestation of fear in response to the anticipation or experience of taking a vaccine.", [["anxiety", "DISEASE", 19, 26], ["anxiety", "PROBLEM", 19, 26], ["a vaccine", "TREATMENT", 110, 119]]], ["Evidence exists that a significant number of people are anxious during pre-travel consultations about injection before actual vaccination.", [["people", "ORGANISM", 45, 51], ["people", "SPECIES", 45, 51], ["anxious", "PROBLEM", 56, 63], ["injection", "TREATMENT", 102, 111], ["actual vaccination", "TREATMENT", 119, 137], ["significant", "OBSERVATION_MODIFIER", 23, 34], ["number", "OBSERVATION_MODIFIER", 35, 41]]], ["In Noble, Farquharson, O'Dwyer, and Behrens' (2013) study sample of 105 people from London, they estimated the prevalence of injection anxiety to be more than 39 percent.", [["anxiety", "DISEASE", 135, 142], ["people", "ORGANISM", 72, 78], ["people", "SPECIES", 72, 78], ["injection anxiety", "PROBLEM", 125, 142]]], ["A systematic review by Loharikar et al. (2018) identified fainting, dizziness, palpitations, giddiness, headache, hyperventilation, and weakness as some anxiety-related symptoms following immunization (Loharikar et al., 2018) .", [["fainting", "DISEASE", 58, 66], ["dizziness", "DISEASE", 68, 77], ["palpitations", "DISEASE", 79, 91], ["giddiness", "DISEASE", 93, 102], ["headache", "DISEASE", 104, 112], ["hyperventilation", "DISEASE", 114, 130], ["weakness", "DISEASE", 136, 144], ["anxiety", "DISEASE", 153, 160], ["fainting", "PROBLEM", 58, 66], ["dizziness", "PROBLEM", 68, 77], ["palpitations", "PROBLEM", 79, 91], ["giddiness", "PROBLEM", 93, 102], ["headache", "PROBLEM", 104, 112], ["hyperventilation", "PROBLEM", 114, 130], ["weakness", "PROBLEM", 136, 144], ["some anxiety", "PROBLEM", 148, 160], ["related symptoms", "PROBLEM", 161, 177], ["immunization", "TREATMENT", 188, 200], ["weakness", "OBSERVATION", 136, 144]]], ["Implicated vaccines included tetanus, diphtheria, hepatitis B, oral cholera, human papillomavirus, and influenza A (H1N1).", [["oral", "ANATOMY", 63, 67], ["tetanus, diphtheria, hepatitis B", "DISEASE", 29, 61], ["oral cholera", "DISEASE", 63, 75], ["human papillomavirus", "DISEASE", 77, 97], ["influenza A", "DISEASE", 103, 114], ["diphtheria,", "ORGANISM", 38, 49], ["hepatitis B", "ORGANISM", 50, 61], ["oral cholera", "ORGANISM", 63, 75], ["human", "ORGANISM", 77, 82], ["papillomavirus", "ORGANISM", 83, 97], ["influenza A (H1N1)", "ORGANISM", 103, 121], ["human", "SPECIES", 77, 82], ["papillomavirus", "SPECIES", 83, 97], ["hepatitis B", "SPECIES", 50, 61], ["human papillomavirus", "SPECIES", 77, 97], ["Implicated vaccines", "TREATMENT", 0, 19], ["tetanus", "PROBLEM", 29, 36], ["diphtheria", "PROBLEM", 38, 48], ["hepatitis B", "PROBLEM", 50, 61], ["oral cholera", "PROBLEM", 63, 75], ["human papillomavirus", "TREATMENT", 77, 97], ["influenza", "PROBLEM", 103, 112]]], ["Fear of needles, injection injury, and anecdotes of being sick of the disease(s) vaccinated against have also been reported in the literature (Nir, Paz, Sabo, & Potasman, 2003) .The concept and potential facets of vaccination concernThe literature further highlights the cost and time involved in travel vaccination as major concerns (Gautret, Tantawichien, Hai, & Piyaphanee, 2011; Goodman et al., 2014; Poulos et al., 2018; Wang et al., 2019) .", [["needles", "ANATOMY", 8, 15], ["Fear of needles", "PROBLEM", 0, 15], ["injection injury", "PROBLEM", 17, 33], ["the disease", "PROBLEM", 66, 77], ["needles", "OBSERVATION_MODIFIER", 8, 15], ["disease", "OBSERVATION", 70, 77]]], ["These two factors reflect affordability concerns, which are the inability of individuals to afford travel vaccination, both in terms of financial and non-financial costs (Thomson, Robinson, & Vall\u00e9e-Tourangeau, 2016) .", [["travel vaccination", "TREATMENT", 99, 117]]], ["Time constraints become an issue whenever multiple doses of a vaccine are required (Steffen & Connor, 2005) .The concept and potential facets of vaccination concernTravel vaccinees, mainly backpackers and volunteer tourists, have often lamented that vaccination services are expensive, time-wasting, and inconveniencing.", [["wasting", "DISEASE", 291, 298], ["a vaccine", "TREATMENT", 60, 69], ["vaccination concernTravel vaccinees", "TREATMENT", 145, 180], ["vaccination services", "TREATMENT", 250, 270]]], ["(2014) study among Australian Hajj pilgrims and that of Goodman's (2014) among UK travelers to meningitis belts in Africa identified financial and time constraints as the underlying reasons for those who refused influenza and meningococcal vaccine respectively.", [["meningitis", "DISEASE", 95, 105], ["influenza", "DISEASE", 212, 221], ["UK", "ORGANISM", 79, 81], ["meningococcal", "SPECIES", 226, 239], ["meningitis", "PROBLEM", 95, 105], ["influenza", "PROBLEM", 212, 221], ["meningococcal vaccine", "TREATMENT", 226, 247]]], ["The refusers indicated that they were too busy to get the vaccine; likewise, the vaccines were too expensive.", [["the vaccine", "TREATMENT", 54, 65], ["the vaccines", "TREATMENT", 77, 89]]], ["Those traveling for volunteerism and backpacking purposes were more likely to under-vaccinate than those traveling for business and visiting friends and relatives (VFR).", [["volunteerism and backpacking purposes", "TEST", 20, 57]]], ["In addition to Australian travelers to Southeast Asian destinations perception that the rabies vaccine comes with side effects, they reported that (1) the rabies vaccination is scarce in travel clinics; (2) the vaccination is expensive; (3) obtaining rabies vaccine (multiple intakes) is time-consuming; and (4) GP service only provides generic health consultations, not specific for travel-related health consultation (Wang et al., 2019) .The concept and potential facets of vaccination concernUsing data from the Global TravEpiNet, though Lammert et a.", [["rabies", "DISEASE", 155, 161], ["rabies", "ORGANISM", 88, 94], ["rabies", "ORGANISM", 155, 161], ["rabies", "ORGANISM", 251, 257], ["rabies", "SPECIES", 88, 94], ["rabies", "SPECIES", 155, 161], ["rabies", "SPECIES", 251, 257], ["the rabies vaccine", "TREATMENT", 84, 102], ["rabies vaccine", "TREATMENT", 251, 265]]], ["(2016) observed that cost and time were rarely cited as an underlying reason for the refusal of the studied (influenza, meningococcal, typhoid, hepatitis A, tetanus, polio, rabies, yellow fever and Japanese encephalitis) vaccines among international travelers, except for Japanese encephalitis and influenza.", [["influenza", "DISEASE", 109, 118], ["meningococcal, typhoid, hepatitis A", "DISEASE", 120, 155], ["tetanus", "DISEASE", 157, 164], ["polio", "DISEASE", 166, 171], ["rabies", "DISEASE", 173, 179], ["yellow fever", "DISEASE", 181, 193], ["Japanese encephalitis", "DISEASE", 198, 219], ["Japanese encephalitis", "DISEASE", 272, 293], ["influenza", "DISEASE", 298, 307], ["hepatitis A", "ORGANISM", 144, 155], ["rabies", "ORGANISM", 173, 179], ["yellow fever", "ORGANISM", 181, 193], ["meningococcal", "SPECIES", 120, 133], ["hepatitis A", "SPECIES", 144, 155], ["Japanese encephalitis", "SPECIES", 272, 293], ["influenza", "PROBLEM", 109, 118], ["meningococcal", "PROBLEM", 120, 133], ["typhoid", "PROBLEM", 135, 142], ["hepatitis A", "PROBLEM", 144, 155], ["tetanus", "PROBLEM", 157, 164], ["polio", "PROBLEM", 166, 171], ["rabies", "PROBLEM", 173, 179], ["yellow fever", "PROBLEM", 181, 193], ["Japanese encephalitis) vaccines", "TREATMENT", 198, 229], ["Japanese encephalitis", "PROBLEM", 272, 293], ["influenza", "PROBLEM", 298, 307], ["encephalitis", "OBSERVATION", 281, 293]]], ["None of these studies, however, pointed out why the Japanese encephalitis is considered expensive.", [["encephalitis", "DISEASE", 61, 73], ["these studies", "TEST", 8, 21], ["the Japanese encephalitis", "PROBLEM", 48, 73], ["encephalitis", "OBSERVATION", 61, 73]]], ["However, the reason could be gleaned from Karafillakis and Larson's (2017) assertion that the vaccine is difficult to produce and needed in multiple doses with several boosters for long-term protection.The concept and potential facets of vaccination concernVaccination cost and time concerns mirror access concerns.", [["Karafillakis", "PROBLEM", 42, 54], ["the vaccine", "TREATMENT", 90, 101], ["several boosters", "TREATMENT", 160, 176], ["long-term protection", "TREATMENT", 181, 201], ["vaccination concernVaccination cost", "TREATMENT", 238, 273]]], ["Therefore, access in the context of vaccination relates to the ability of individuals to quickly reach and/or to be reached by recommended vaccines.", [["individuals", "ORGANISM", 74, 85], ["access", "TREATMENT", 11, 17], ["vaccination", "TREATMENT", 36, 47], ["vaccines", "TREATMENT", 139, 147]]], ["\"The degree to which individuals know the need for, and availability of, recommended vaccines and their objective benefits and risks\" is referred to as awareness (Thomson et al., 2016 (Thomson et al., , p.", [["vaccines", "TREATMENT", 85, 93]]], ["Awareness factors include the availability of information, knowledge of vaccines, and vaccination schedule.", [["vaccines", "TREATMENT", 72, 80], ["vaccination schedule", "TREATMENT", 86, 106]]], ["Unfortunately, issues of vaccine information deficit (including not knowing where to locate appropriate vaccines), information overload, conflict messages, and misunderstanding of available information are reported in the literature (Karafillakis & Larson, 2017) .", [["vaccine information deficit", "PROBLEM", 25, 52]]], ["In that case, trust for the institutions involved in the manufacture and delivery of vaccines is as crucial as the vaccines themselves.", [["the manufacture", "TREATMENT", 53, 68], ["delivery of vaccines", "TREATMENT", 73, 93]]], ["Literature notes that mistrust and decreasing confidence in vaccines and vaccination-related institutions among the general public remain pronounced.", [["mistrust", "PROBLEM", 22, 30], ["vaccines", "TREATMENT", 60, 68], ["vaccination", "TREATMENT", 73, 84], ["decreasing", "OBSERVATION_MODIFIER", 35, 45], ["pronounced", "OBSERVATION", 138, 148]]], ["In their critical review, they (Yaqub et al., 2014) realized that distrust of doctors, government, and pharmaceutical companies' is the reason for hesitancy and outright refusal of vaccination.", [["hesitancy", "PROBLEM", 147, 156], ["vaccination", "TREATMENT", 181, 192]]], ["Trust is an individual's attitude based on personal beliefs about the features of another (Mayer, Davis, & Schoorman, 1995) ; therefore, people may behave in a certain way while assuming others will react by their expectations.", [["people", "ORGANISM", 137, 143], ["people", "SPECIES", 137, 143]]], ["Likewise, researchers churn out findings that only highlight the benefits of vaccines while ignoring safety issues (Ehrenstein et al., 2010) .The concept and potential facets of vaccination concernAutonomy implies the capability to make informed decisions devoid of interference and force.", [["vaccines", "TREATMENT", 77, 85], ["vaccination concernAutonomy", "TREATMENT", 178, 205]]], ["This understanding of freedom among people has led to contestations, hesitancy, and sometimes refusals of vaccines.", [["people", "ORGANISM", 36, 42], ["people", "SPECIES", 36, 42], ["vaccines", "TREATMENT", 106, 114]]], ["These oppositions are rooted in the interpretation of vaccination mandate policies, rules, and regulations as lacking liberalism and naturalism.", [["vaccination mandate policies", "TREATMENT", 54, 82]]], ["Vaccination mandates, mass campaigns, limited exemptions, penalties refusing vaccines are some aspects of vaccinations contested (Attwell & Smith, 2018) .", [["Vaccination mandates", "TREATMENT", 0, 20], ["mass campaigns", "PROBLEM", 22, 36], ["vaccines", "TREATMENT", 77, 85]]], ["Table 1 presents a summarized list of the potential dimensions and their definitions.Relationship between concerns and travel vaccinationPeople respond in varied ways towards vaccination, depending on their concerns.", [["People", "ORGANISM", 137, 143], ["People", "SPECIES", 137, 143], ["travel vaccination", "TREATMENT", 119, 137], ["vaccination", "TREATMENT", 175, 186]]], ["The Strategic Advisory Group of Experts (SAGE) considers individuals' responses towards vaccine uptake as a continuum, oscillating between complete refusals of vaccines to outright acceptance and maybe context, time, population, and vaccine-specific (WHO, 2013) .", [["vaccines", "TREATMENT", 160, 168]]], ["Acceptance denotes the act of consenting to vaccination without any reservations.", [["vaccination", "TREATMENT", 44, 55]]], ["It involves the adoption and endorsement of vaccination to other people.Relationship between concerns and travel vaccinationOn the other hand, refusal refers to a complete rejection of vaccination (MacDonald, 2015) .", [["people", "ORGANISM", 65, 71], ["people", "SPECIES", 65, 71], ["vaccination", "TREATMENT", 44, 55]]], ["The SAGE identifies two forms, each for acceptance and refusal of vaccination, which are indicators of heterogeneities in peoples' reactions toward immunization.", [["vaccination", "TREATMENT", 66, 77], ["immunization", "TREATMENT", 148, 160]]], ["These are an outright refusal of some or all vaccines and outright acceptance of some or all vaccines (WHO, 2013) .", [["all vaccines", "TREATMENT", 41, 53]]], ["The term vaccine hesitancy is characterized by a lack of conceptual clarity, which is attributed to the attempt to use hesitation to explain all partial or non-vaccination as well as a lack of a clear distinction in its determinants (Bedford et al., 2017) .", [["The term vaccine hesitancy", "PROBLEM", 0, 26], ["hesitation", "TREATMENT", 119, 129], ["all partial or non-vaccination", "PROBLEM", 141, 171]]], ["The widely cited definition of vaccination hesitancy is by SAGE: \"a delay in acceptance or refusal of vaccine despite the availability of vaccine services\" (WHO, 2013) .Relationship between concerns and travel vaccinationPrevious studies (including Steffen & Connor, 2005; Crockett & Keystone, 2005; Lammert et al., 2016; Wang et al., 2019) have concluded that vaccine concerns reduce travelers' willingness to vaccinate.", [["vaccine", "TREATMENT", 102, 109], ["Previous studies", "TEST", 221, 237], ["widely", "OBSERVATION_MODIFIER", 4, 10]]], ["Nevertheless, most of the studies that have tried to analyze the effect of concerns on vaccine uptake have hardly measured the latter as a rate.", [["the studies", "TEST", 22, 33], ["vaccine uptake", "PROBLEM", 87, 101]]], ["Vaccine uptake rate is a measure of coverage that seeks to understand the proportion of vaccines taken by an individual out of the number recommended (WHO, 2017) .", [["Vaccine uptake rate", "TREATMENT", 0, 19], ["vaccines", "TREATMENT", 88, 96]]], ["Uptake rate is also crucial for appreciating the extent to which individuals' concerns can undermine their acceptance of vaccination or otherwise.", [["Uptake rate", "TEST", 0, 11], ["vaccination", "TREATMENT", 121, 132]]], ["An appraisal of the impact of specific concerns on vaccine uptake shows disparate and contradictory findings.", [["vaccine uptake", "TEST", 51, 65], ["disparate and contradictory findings", "PROBLEM", 72, 108]]], ["Regarding safety and efficacy concerns and vaccine uptake, Crockett and Keystone (2005) concluded that the more concerned travelers are with these, the higher their likelihood of refusing vaccines.", [["travelers", "ORGANISM", 122, 131], ["vaccine uptake", "PROBLEM", 43, 57], ["refusing vaccines", "TREATMENT", 179, 196]]], ["The study identified a lack of confidence in vaccines' efficacy, the perceived unsafety of vaccines, adverse effects, injection anxiety, and cost as significant reasons for sub-optimal vaccination.", [["anxiety", "DISEASE", 128, 135], ["The study", "TEST", 0, 9], ["vaccines' efficacy", "TREATMENT", 45, 63], ["the perceived unsafety of vaccines", "TREATMENT", 65, 99], ["adverse effects", "PROBLEM", 101, 116], ["injection anxiety", "PROBLEM", 118, 135], ["sub-optimal vaccination", "TREATMENT", 173, 196]]], ["Among Hajj pilgrims, previous studies found that doubts regarding vaccine effectiveness are an essential reason that accounts for their low uptake of the influenza vaccine (Bish et al., 2011) .Relationship between concerns and travel vaccinationCost and time concerns have also been reported as limiting factors of vaccination adoption (Gautret et al., 2011; Goodman et al., 2014; Poulos et al., 2018) .", [["influenza", "DISEASE", 154, 163], ["previous studies", "TEST", 21, 37], ["vaccine effectiveness", "TREATMENT", 66, 87], ["the influenza vaccine", "TREATMENT", 150, 171]]], ["Cost especially is a significant constraint to the uptake of vaccines among international travelers, because out-of-pocket expenditure is higher for travel-related vaccines than for routine immunizations.", [["a significant constraint", "PROBLEM", 19, 43], ["vaccines", "TREATMENT", 61, 69], ["travel-related vaccines", "TREATMENT", 149, 172], ["routine immunizations", "TREATMENT", 182, 203]]], ["However, those traveling for volunteerism and backpacking purposes under-vaccinated more than those who did for business and to visit friends and relatives (VFR).", [["volunteerism and backpacking purposes", "TREATMENT", 29, 66]]], ["Among Australian Hajj pilgrims and UK travelers to meningitis belts in Africa, Barasheed et al. (2014) and Goodman (2014) identified financial and time constraints as the causal reasons for those who refused the vaccines, respectively.", [["meningitis", "DISEASE", 51, 61], ["meningitis", "PROBLEM", 51, 61], ["the vaccines", "TREATMENT", 208, 220]]], ["The refusers indicated that they were too busy to get the vaccine before traveling.", [["the vaccine", "TREATMENT", 54, 65]]], ["Likewise, they considered the vaccines too expensive.", [["the vaccines", "TREATMENT", 26, 38]]], ["Lammert et al. (2016) , on the other hand, observed that cost and time were rarely cited as an underlying reason for the refusal of the vaccines they studied except for the Japanese encephalitis vaccine.", [["encephalitis", "DISEASE", 182, 194], ["the vaccines", "TREATMENT", 132, 144], ["the Japanese encephalitis vaccine", "TREATMENT", 169, 202]]], ["None of these studies, however, pointed out why the Japanese encephalitis vaccine is considered expensive.", [["encephalitis", "DISEASE", 61, 73], ["these studies", "TEST", 8, 21], ["the Japanese encephalitis vaccine", "TREATMENT", 48, 81]]], ["However, the reason could be gleaned from Karafillakis and Larson's (2017) assertion that the vaccine is difficult to produce and needed in multiple doses with several boosters for long-term protection.", [["Karafillakis", "PROBLEM", 42, 54], ["the vaccine", "TREATMENT", 90, 101], ["several boosters", "TREATMENT", 160, 176], ["long-term protection", "TREATMENT", 181, 201]]], ["The next section of the study discusses the methodology used for empirically formulating and testing the TRAVAC scale.Research designAn exploratory quantitative-dominant (QUAN + qual) sequential mixed methods design incorporating qualitative and quantitative data collection and analysis were employed (Johnson & Onwuegbuzie, 2004) .", [["the study", "TEST", 20, 29], ["the TRAVAC scale", "TREATMENT", 101, 117], ["sequential mixed methods design", "PROBLEM", 184, 215], ["quantitative data collection", "TEST", 246, 274], ["dominant", "OBSERVATION_MODIFIER", 161, 169]]], ["This was because the study had to go through the process of developing a new survey measurement instrument and validating it as a scale.", [["the study", "TEST", 17, 26], ["a new survey measurement instrument", "TEST", 71, 106], ["new", "OBSERVATION_MODIFIER", 73, 76]]], ["A multi-stage recursive psychometric procedure proposed by Churchill (1979) for developing and validating scales was adopted.", [["A multi-stage recursive psychometric procedure", "TREATMENT", 0, 46]]], ["The process involved four studies of five stages: item generation, item purification, evaluation of the latent structure, testing the nomological and predictive validity of the measurement scale, and scale replication.", [["item purification", "TEST", 67, 84], ["evaluation", "TEST", 86, 96], ["the measurement scale", "TEST", 173, 194]]], ["Previous studies have widely used this procedure (e.g., Chen et al., 2014; Larsen, Brun, & \u00d8gaard, 2009; Wen et al., 2018) across various disciplines.", [["Previous studies", "TEST", 0, 16], ["this procedure", "TREATMENT", 34, 48]]], ["Fig. 1 illustrates the research design and how the integration of methods was done in the study.", [["the study", "TEST", 86, 95]]], ["The details of each of the stages and the results are described in the subsequent paragraphs.Stage 1: item generation and purificationThe item generation process consisted of two independent steps: literature review and qualitative data gathering and analyses.", [["purification", "TREATMENT", 122, 134], ["qualitative data", "TEST", 220, 236]]], ["The generation of the items was guided by the principle of saturation (a situation where new significant views ceased to emerge) (Guest, Bunce, & Johnson, 2006; Mason, 2010) .Stage 1: item generation and purification3.2.1.1.", [["purification3.2", "TREATMENT", 204, 219]]], ["The first stage commenced with an extensive review of related studies to gather the initial pool of potential measure items.", [["related studies", "TEST", 54, 69]]], ["The widely applied Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) framework was adapted to guide the systematic review (Fig. 2) and measurement item identification.", [["Systematic reviews", "TEST", 49, 67], ["measurement item identification", "TEST", 161, 192]]], ["Concepts related to travel vaccination and concerns and existing vaccination attitude scales were reviewed.", [["travel vaccination", "TREATMENT", 20, 38], ["existing vaccination attitude scales", "TEST", 56, 92]]], ["Notably, most of the vaccine-based reviewed articles were drawn from the following journals: Vaccine, Travel Medicine and Infectious Diseases, and Social Science and Medicine.", [["Infectious Diseases", "DISEASE", 122, 141], ["the vaccine", "TREATMENT", 17, 28]]], ["The inclusion of a document was decided by a careful review of the Table 1 Potential constructs of the travel vaccination concern scale drawn from the literature and qualitative data.", [["the travel vaccination", "TREATMENT", 99, 121], ["qualitative data", "TEST", 166, 182]]], ["Inability to optimally obtain, process, understand and make an informed vaccination decision Karafillakis and Larson (2017) Autonomy concernStage 1: item generation and purificationFeeling that vaccination and its related policies are limiting one's liberty, autonomy and/or freedom Dubov and Phung (2015) ; Attwell and Smith (2018); Rossen et al. (2019) abstract or executive summary.", [["purification", "TREATMENT", 169, 181]]], ["This resulted in an initial pool of 36 items after removing duplicates.Stage 1: item generation and purification3.2.1.2.", [["purification3.2", "TREATMENT", 100, 115]]], ["The first stage in the qualitative data collection involved unsolicited online text/sentiment mining from the Vaccine Sentimeter via HealthMap.", [["the Vaccine", "TREATMENT", 106, 117]]], ["The text mining was meant to draw global anti-travel vaccination sentiments to corroborate, enrich, and reduce the bias associated with field-based qualitative data (Powell et al., 2016) .", [["global anti-travel vaccination sentiments", "TREATMENT", 34, 75]]], ["The platform has been used by several researchers (including Larson et al., 2014; Larson et al., 2016; Powell et al., 2016) , and its usefulness and reliability for tracking global vaccine concerns confirmed.", [["tracking global vaccine concerns", "PROBLEM", 165, 197]]], ["Based on a text processing algorithm, HealthMap automatically assigns a title, date, source, Uniform Resource Locator (URL), plain text content, location(s), and disease to each report.", [["a text processing algorithm", "TEST", 9, 36]]], ["The search was adapted mainly to focus on only reports relating to anti-travel vaccination sentiments about human vaccines.", [["human", "ORGANISM", 108, 113], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 108, 113], ["anti-travel vaccination sentiments", "TREATMENT", 67, 101], ["human vaccines", "TREATMENT", 108, 122]]], ["Similar to the literature review, the search terms included a combination of Boolean terms such as travel immunization or vaccination, and concerns, perceptions, worries, doubts, risks, uncertainties, safety concerns and sentiments.", [["Boolean terms", "TREATMENT", 77, 90], ["travel immunization", "TREATMENT", 99, 118], ["vaccination", "TREATMENT", 122, 133]]], ["The extraction included all forms of comments without time or language restriction, but all non-English comments were translated into English using Google Translate .", [["The extraction", "TREATMENT", 0, 14]]], ["In total, 1235 online posts were extracted.Field qualitative interviews.After the approval of the study protocol by the Institutional Review Board (IRB) of the University of Cape Coast, we commenced the second stage of the field-based qualitative data collection.", [["the study protocol", "TEST", 94, 112]]], ["In-depth interviews (IDI) with 20 inbound tourists were conducted using an IDI guide.", [["20 inbound tourists", "TREATMENT", 31, 50], ["an IDI guide", "TREATMENT", 72, 84]]], ["The guide was made up of three sections.", [["sections", "ANATOMY", 31, 39]]], ["Section A addressed questions on the demographic characteristics of the interview participants, including their sex, educational status, and country of residence.", [["participants", "SPECIES", 82, 94]]], ["The IDI guide maintained flexibility and openness so that interviews were adapted to situations.", [["flexibility", "OBSERVATION_MODIFIER", 25, 36]]], ["The guide's content validity was reviewed by the second and third authors of the study and an additional faculty member with expertise in qualitative research.", [["the study", "TEST", 77, 86]]], ["The assessment was meant for them to assess the extent to which the questions measure what they intended to.", [["The assessment", "TEST", 0, 14]]], ["Subsequently, the guide was pre-tested among three (3) international students who visited the University of Cape Coast in August 2016 for exchange programs.", [["exchange programs", "TREATMENT", 138, 155]]], ["The assessment led to additions of probes where necessary.Field qualitative interviews.The actual field interviews, facilitated by the Lead Author, were conducted between April and June 2017 in Cape Coast.", [["The assessment", "TEST", 0, 14]]], ["The participants were purposively sampled and approached using a broad and heterogeneous approach.", [["participants", "ORGANISM", 4, 16], ["participants", "SPECIES", 4, 16], ["a broad and heterogeneous approach", "TREATMENT", 63, 97], ["heterogeneous", "OBSERVATION_MODIFIER", 75, 88]]], ["A purposive sampling of varied groups (considering their region of residence: Europe, Africa, America, etc.; and sex: males and females) was done.", [["A purposive sampling of varied groups", "TREATMENT", 0, 37]]], ["The interviews were intended to verify and beef-up the already generated items from the literature review and the netnography.", [["the netnography", "TEST", 110, 125]]], ["Meetings were scheduled at the respondents' convenience, mostly in public areas of attraction sites, restaurants, and hotels and lasted for between 30 and 50 min.", [["attraction sites", "OBSERVATION", 83, 99]]], ["Note: QUANT stands for Quantitative and qual stands for Qualitative, and upper case shows where emphasis lay.Data analysis and results.Regarding the online comments, the names of those to whom statements were directed were removed from the dataset; likewise, all HTML tags.", [["Qualitative, and upper case", "TEST", 56, 83], ["Data analysis", "TEST", 109, 122]]], ["However, all image files, mainly meme images, were retained.", [["all image files", "TEST", 9, 24], ["mainly meme images", "TEST", 26, 44]]], ["Meme image text was retained for analysis because they indicated the severity and varying opinions of negative comments in the language people chose to use when discussing vaccination sentiments.", [["people", "ORGANISM", 136, 142], ["people", "SPECIES", 136, 142], ["analysis", "TEST", 33, 41]]], ["The field interview data, on the other hand, was transcribed verbatim by listening to the tapes.", [["The field interview data", "TEST", 0, 24]]], ["Both transcribers verified and resolved inconsistencies in codes.", [["resolved", "OBSERVATION_MODIFIER", 31, 39], ["inconsistencies", "OBSERVATION_MODIFIER", 40, 55]]], ["Summaries of text from the netnography and field interviews were analyzed in NVIVO 12 using both inductive and deductive reasoning.Data analysis and results.Since the qualitative data were meant to draw out additional measurement items for the TRAVAC scale, the data processing began with the researchers independently gleaning and summarizing the negative sentiments about travel vaccination (Table 3) .Data analysis and results.This was done by inspecting the most mentioned negative Boolean terms about vaccination in the word cloud and tree.", [["Data analysis", "TEST", 131, 144], ["the TRAVAC scale", "TREATMENT", 240, 256], ["Data analysis", "TEST", 404, 417], ["vaccination", "TREATMENT", 506, 517], ["tree", "ANATOMY_MODIFIER", 540, 544]]], ["It is crucial to first \"ignore the literature of theory and fact on the area under study, to assure that the Field Interview I don't think vaccines must be taken all the time, especially when traveling.MaleField Interview I seriously doubt that receiving a travel vaccine is the best way to stay healthy when basic holiday sanitation should be enough.MaleField Interview \u2026 I'm just going to come out and say it: I personally don't believe in getting vaccinated to the hilt before traveling.FemaleOnline https://www.theprofessionalhobo.com/travel-vaccinations-yes-or -no/ I'm not a conspiracy theorist, but neither will I dismiss the idea that not all travel vaccinations are recommended with our best intentions as the first priorityMaleField InterviewMaleTravel vaccines are a way of making money by health organizations.MaleMale Field Interview They are costly and usually not covered by insurance.", [["vaccines", "TREATMENT", 139, 147], ["a travel vaccine", "TREATMENT", 255, 271], ["basic holiday sanitation", "TREATMENT", 309, 333], ["all travel vaccinations", "TREATMENT", 647, 670], ["MaleTravel vaccines", "TREATMENT", 752, 771]]], ["The questions were then re-worded with the help of the topic words/phrases (Table 4) to match the context of travel vaccination.Stage 2: item purificationThe second stage comprised expert review and exploratory factor analysis of the measurement items to purify the pool of questions.", [["travel vaccination", "TREATMENT", 109, 127], ["item purification", "TEST", 137, 154], ["exploratory factor analysis", "TEST", 199, 226]]], ["The experts included two academics with expertise in travel vaccine studies and scale development; two members of the Strategic Advisory Group of Experts (SAGE) on immunization and two travel medicine professionals.", [["immunization", "TREATMENT", 164, 176]]], ["SAGE is the primary advisory group to WHO on vaccines and immunization.", [["vaccines", "TREATMENT", 45, 53], ["immunization", "TREATMENT", 58, 70]]], ["The questionnaire was designed and administered in the English language since most inbound tourists to Ghana read and write in English.Methods and results for study 2-quantitative study3.3.1.", [["study", "TEST", 159, 164]]], ["Stage 3: dimensionality determination of the measurement scale 3.3.1.1.", [["dimensionality determination", "TEST", 9, 37], ["the measurement scale", "TEST", 41, 62]]], ["Data collection instrument and procedure.", [["Data collection instrument", "TEST", 0, 26], ["procedure", "TREATMENT", 31, 40]]], ["This stage comprised the collection of survey data to explore the dimensional structure of the TRAVAC scale.", [["survey data", "TEST", 39, 50], ["the TRAVAC scale", "TREATMENT", 91, 107]]], ["The data were collected from 300 inbound tourists to Ghana between September and December 2017, using a convenience sampling technique, but 250 questionnaires were found useful for analysis.", [["The data", "TEST", 0, 8], ["a convenience sampling technique", "TEST", 102, 134], ["analysis", "TEST", 181, 189]]], ["For those who visited the attractions in groups, two people on average were chosen to participate in the study.", [["people", "ORGANISM", 53, 59], ["people", "SPECIES", 53, 59], ["the study", "TEST", 101, 110]]], ["The survey was structured into four sections (Sections A to D).", [["sections", "ANATOMY", 36, 44]]], ["Section A contained a filter question, which sought to determine whether the individual had been interviewed on the same subject in the other attraction sites to prevent duplicate respondents.", [["a filter", "TREATMENT", 20, 28], ["filter", "OBSERVATION", 22, 28]]], ["A checklist of vaccines that tourists to Ghana are expected to be up-to-date on was provided to the respondents to self-report by indicating those vaccines they had fully or partially taken or not taken at all.", [["vaccines", "TREATMENT", 15, 23]]], ["The list of vaccines was adapted from WHO's (2018) list of recommended vaccines for travelers to Ghana.", [["vaccines", "TREATMENT", 12, 20], ["vaccines", "TREATMENT", 71, 79]]], ["These are routine vaccines (MMR vaccine, diphtheria-tetanus-pertussis (DTP) vaccine, varicella vaccine, and polio vaccine), mandatory vaccines (yellow fever vaccine), and recommended vaccines (hepatitis A, hepatitis B, typhoid, meningitis, and rabies).", [["diphtheria-tetanus-pertussis", "CHEMICAL", 41, 69], ["DTP", "CHEMICAL", 71, 74], ["varicella", "DISEASE", 85, 94], ["yellow fever", "DISEASE", 144, 156], ["hepatitis A, hepatitis B", "DISEASE", 193, 217], ["typhoid", "DISEASE", 219, 226], ["meningitis", "DISEASE", 228, 238], ["rabies", "DISEASE", 244, 250], ["diphtheria-tetanus-pertussis", "ORGANISM", 41, 69], ["DTP", "ORGANISM", 71, 74], ["varicella", "ORGANISM", 85, 94], ["hepatitis A", "ORGANISM", 193, 204], ["hepatitis B", "ORGANISM", 206, 217], ["diphtheria-tetanus-pertussis", "SPECIES", 41, 69], ["diphtheria-tetanus-pertussis", "SPECIES", 41, 69], ["hepatitis A", "SPECIES", 193, 204], ["rabies", "SPECIES", 244, 250], ["routine vaccines", "TREATMENT", 10, 26], ["MMR vaccine", "TREATMENT", 28, 39], ["diphtheria", "PROBLEM", 41, 51], ["tetanus-pertussis", "TREATMENT", 52, 69], ["DTP) vaccine", "TREATMENT", 71, 83], ["varicella vaccine", "TREATMENT", 85, 102], ["polio vaccine", "TREATMENT", 108, 121], ["mandatory vaccines", "TREATMENT", 124, 142], ["yellow fever vaccine", "TREATMENT", 144, 164], ["vaccines", "TREATMENT", 183, 191], ["hepatitis A", "PROBLEM", 193, 204], ["hepatitis B", "PROBLEM", 206, 217], ["typhoid", "PROBLEM", 219, 226], ["meningitis", "PROBLEM", 228, 238], ["rabies", "PROBLEM", 244, 250]]], ["The elicitation method used for determining their vaccination status is similar to that employed by the WHO (2012) and Lammert et al. (2016) for collecting immunization data.", [["The elicitation method", "TREATMENT", 0, 22], ["collecting immunization data", "TEST", 145, 173]]], ["Section B measured their views on travel vaccination concerns on a rating scale of 0-10, where 0 meant not concerned at all and ten represented highly concerned.", [["travel vaccination", "TREATMENT", 34, 52], ["a rating scale", "TEST", 65, 79]]], ["Perceptions and attitudes vary with different vaccines; for instance, hep B vaccine is not the same as yellow fever vaccine (Karafillakis & Larson, 2017) .", [["fever", "DISEASE", 110, 115], ["hep B", "ORGANISM", 70, 75], ["different vaccines", "TREATMENT", 36, 54], ["hep B vaccine", "TREATMENT", 70, 83]]], ["Section C of the survey elicited data on their responses toward vaccination, including perceived benefits of vaccines, hesitancy toward vaccination and whether they would recommend vaccines to others.", [["the survey", "TEST", 13, 23], ["vaccination", "TREATMENT", 64, 75], ["vaccines", "TREATMENT", 109, 117], ["hesitancy toward vaccination", "TREATMENT", 119, 147], ["vaccines", "TREATMENT", 181, 189]]], ["These were also gauged using the ranking scale of 0-10.", [["the ranking scale", "TEST", 29, 46]]], ["The measurement items in section B were drawn from Study 1.", [["The measurement items in section B", "TEST", 0, 34], ["Study", "TEST", 51, 56]]], ["Both respondents who ever vaccinated against a disease and those who ever under-vaccinated were sampled to minimize bias in the views.Data analysis and results.The data were first presented using descriptive statistics to offer an understanding of the characteristics of the sample.", [["a disease", "PROBLEM", 45, 54], ["Data analysis", "TEST", 134, 147]]], ["About 58 percent of the exploratory sample were female.", [["the exploratory sample", "TEST", 20, 42]]], ["However, a slightly higher proportion of males (32.19%) than females (29.0%) were married.", [["slightly", "OBSERVATION_MODIFIER", 11, 19], ["higher", "OBSERVATION_MODIFIER", 20, 26]]], ["The average age of the respondents was 28 years.", [["average", "OBSERVATION_MODIFIER", 4, 11]]], ["The average number of past trips among the respondents was 12.", [["average", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18]]], ["Detailed characteristics of the respondents are found in Table 5 .Data analysis and results.An Exploratory Factor Analysis (EFA) was used to explore the dimensional structure of the measure and remove poorly fitting items.", [["Data analysis", "TEST", 66, 79], ["An Exploratory Factor Analysis", "TEST", 92, 122], ["EFA", "TEST", 124, 127]]], ["The Kaiser-Meyer-Olkin (KMO) measure of sampling adequacy (\u22650.80) and Bartlett's Test of Sphericity (\u03c72 = 3868.12; P < 0.001) showed that the 250 observations were suitable for EFA.", [["EFA", "CHEMICAL", 177, 180], ["sampling adequacy", "TEST", 40, 57], ["Bartlett's Test", "TEST", 70, 85], ["Sphericity", "TEST", 89, 99], ["P", "TEST", 115, 116], ["EFA", "TEST", 177, 180]]], ["The rotation method used was Promax employing the maximum likelihood method.", [["The rotation method", "TREATMENT", 0, 19]]], ["This is because this rotational method is in sync with the rotational method used in covariance-based confirmatory factor analysis (CFA), the analytical technique used to confirm the explored dimensions in the third study.", [["the rotational method", "TREATMENT", 55, 76], ["confirmatory factor analysis", "TEST", 102, 130], ["the analytical technique", "TEST", 138, 162], ["the third study", "TEST", 206, 221]]], ["Eigenvalue greater than 1 was the criteria used for determining the number of factors extracted.", [["greater", "OBSERVATION_MODIFIER", 11, 18]]], ["A \u22650.5 loading on a primary factor, a communality of \u22650.6 and non-cross loading on any other factor at \u22650.40 was the threshold for retaining an item under a dimension (Hair, Black, Babin, & Anderson, 2010) .", [["a communality", "TEST", 36, 49]]], ["A total of 18 items were dropped for having item-to-dimension loadings less than 0.50 and or inter-dimension cross-loading greater than 0.5.", [["inter-dimension cross-loading", "TEST", 93, 122]]], ["The Cronbach's alpha score for each factor was higher than 0.70, suggesting a satisfactory inter-item-dimension convergent validity (Hair et al., 2010) .", [["Cronbach's alpha", "GENE_OR_GENE_PRODUCT", 4, 20], ["The Cronbach's alpha score", "TEST", 0, 26], ["each factor", "TEST", 31, 42]]], ["Given the exploratory nature of the first stage of the analysis, the factors were tentatively labeled Dimension 1, Dimension 2, through to Dimension 6.", [["the analysis", "TEST", 51, 63]]], ["Details of the percentage of variance explained by each dimension and corresponding Eigenvalue are presented in Table 6 .Methods and results for study 3-quantitative study3.4.1.", [["study", "TEST", 145, 150], ["quantitative study3", "TEST", 153, 172]]], ["Stage 4-validation of the draft measure: confirmation of the latent structure 3.4.1.1.", [["the latent structure", "TEST", 57, 77]]], ["Data collection.", [["Data collection", "TEST", 0, 15]]], ["The second set of 905 completed questionnaires out of 1032 was used to confirm and refine the structural validity of the six-factor solution extracted in the EFA, using CFA in AMOS.", [["the six-factor solution", "TREATMENT", 117, 140]]], ["The 905 respondents, if estimated based on the six latent constructs and 28 observed variables; an estimated statistical power of 0.95 and a Hoelter's statistic of 0.01 probability levels and a non-response rate of 10% using G-Power (Adongo et al., 2018) , was a satisfactorily conservative sample size for the analysis.", [["a Hoelter's statistic", "TEST", 139, 160], ["a non-response rate", "TEST", 192, 211], ["the analysis", "TEST", 307, 319]]], ["As a rule of thumb, the literature suggests that at the very least, a regression factor should correspond to 10 sample cases (Byrne, 2010) .", [["thumb", "ORGANISM_SUBDIVISION", 13, 18], ["a regression factor", "PROBLEM", 68, 87], ["thumb", "ANATOMY", 13, 18]]], ["This means that a minimum of 220 responses is deemed adequate for performing the proposed analysis.", [["the proposed analysis", "TEST", 77, 98]]], ["The data collection procedure in Study 3 was similar to that for Study 2 described earlier, except that the data were disproportionately (50%:50%) collected from Ghana and online.", [["The data collection procedure in Study", "TEST", 0, 38], ["Study", "TEST", 65, 70], ["the data", "TEST", 104, 112]]], ["This means that the methodology for the survey data in Ghana was the same as Study 2, narrated in section 3.3.1.1.", [["the survey data", "TEST", 36, 51]]], ["But additional variables of interest (Appendix A) and a pre-travel travel-sample were included.", [["a pre-travel travel-sample", "TEST", 54, 80]]], ["The characteristics of the validation sample were similar to those of Study 2 ( Table 5 ).", [["the validation sample", "TEST", 23, 44], ["Study", "TEST", 70, 75]]], ["Given that pre-travelers are an unknown population and difficult to recruit, snowball sampling was used to collect data from them.", [["snowball sampling", "TEST", 77, 94]]], ["We distributed the message to participate in the survey, including the link to the online designed questionnaire to a complied email list of initially identified people who were planning their trips abroad for the year, mainly to Africa and Asia.", [["people", "ORGANISM", 162, 168], ["people", "SPECIES", 162, 168]]], ["Collecting part of the validation data online was meant to minimize the biases that characterize data from the same destination.", [["the validation data", "TEST", 19, 38]]], ["Data from pre-travelers were also included at the validation stage to reduce the bias that may portray views drawn from people who were already traveling.", [["people", "ORGANISM", 120, 126], ["people", "SPECIES", 120, 126], ["Data from pre-travelers", "TEST", 0, 23]]], ["People's opinions about vaccination are likely to be different before, during, and after the event.Data analysis.The 905 observations were randomly divided into two sub-samples: comprising a calibration (n = 452) and validation sample (n = 453) using STATA 15 draw a sample technique.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["vaccination", "TREATMENT", 24, 35], ["Data analysis", "TEST", 99, 112], ["a calibration", "TEST", 189, 202], ["validation sample", "TEST", 217, 234], ["a sample technique", "TEST", 265, 283]]], ["Similar sample splitting approaches have been used by previous scale development studies (Chen et al., 2014; Kim, Ritchie, & McCormick, 2012) .", [["Similar sample splitting approaches", "TREATMENT", 0, 35]]], ["Descriptive scores of the measures for the univariate skewness and kurtosis showed that the ratings are within tolerable thresholds of \u2212 /+1 (Table 7) , and suitable for the co-variance-based CFA.Data analysis.The CFA was used to confirm and refine (where necessary) the structural validity of the factor solution extracted from the EFA.", [["EFA", "CHEMICAL", 333, 336], ["the univariate skewness", "TEST", 39, 62], ["kurtosis", "TEST", 67, 75], ["Data analysis", "TEST", 196, 209], ["the factor solution", "TREATMENT", 294, 313], ["CFA", "OBSERVATION", 192, 195], ["CFA", "ANATOMY", 214, 217], ["EFA", "OBSERVATION_MODIFIER", 333, 336]]], ["The technique was selected over the alternative component-based CFA for three main reasons.", [["The technique", "TREATMENT", 0, 13], ["CFA", "ANATOMY", 64, 67]]], ["The main reason is that the data were normally distributed.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["distributed", "OBSERVATION_MODIFIER", 47, 58]]], ["Another reason was that the Adongo et al. confirmatory data for this study was 905 cases, one which exceeded the recommended sample size threshold for the use of component-based CFA as it risks convergence validity and improper factor solutions (Byrne, Lam, & Fielding, 2008) .", [["confirmatory data", "TEST", 42, 59], ["this study", "TEST", 64, 74], ["component-based CFA", "TREATMENT", 162, 181], ["improper factor solutions", "PROBLEM", 219, 244], ["CFA", "ANATOMY", 178, 181], ["Lam", "ANATOMY", 253, 256]]], ["Component-based CFA works well with small sample sizes (less than 200 cases) source.", [["small sample sizes", "PROBLEM", 36, 54], ["CFA", "OBSERVATION", 16, 19]]], ["The last reason was that covariance-based CFA is more robust and stringent for model validation, especially in the early stages of theory development, compared to component-based CFA (Byrne, 2010 (Hair, Hult, Ringle, & Sarstedt, 2017; Hu & Bentler, 1999) .Results of the CFA.An initial attempt to fit the calibration model showed that the loadings scores of two items, one relating to 'dimension 1 \u2032 and the other 'dimension 2 \u2032 , were lesser than 0.50; hence, modifications were conducted based on the indices.", [["model validation", "TEST", 79, 95], ["the calibration model", "TEST", 301, 322], ["the loadings scores", "TEST", 335, 354], ["the indices", "TEST", 499, 510], ["CFA", "ANATOMY", 42, 45], ["more robust", "OBSERVATION_MODIFIER", 49, 60], ["CFA", "ANATOMY", 179, 182], ["CFA", "ANATOMY", 271, 274], ["lesser", "OBSERVATION_MODIFIER", 436, 442]]], ["Afterward, all measurement items had significant regression (p < 0.001) coefficients between 0.50 and 0.85 for both the calibration and validation models, which demonstrated unidimensionality across all dimensions.", [["all measurement items", "TEST", 11, 32], ["significant regression", "PROBLEM", 37, 59], ["the calibration and validation models", "TEST", 116, 153], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["regression", "OBSERVATION_MODIFIER", 49, 59], ["all", "OBSERVATION_MODIFIER", 199, 202], ["dimensions", "OBSERVATION_MODIFIER", 203, 213]]], ["The composite reliability scores of the dimensions, as shown in Table 8 , also ranged between 0.70 and 0.85, indicating adequate internal consistency in the measurement dimensions (Hair et al., 2010) .", [["composite", "OBSERVATION_MODIFIER", 4, 13], ["reliability", "OBSERVATION_MODIFIER", 14, 25], ["adequate", "OBSERVATION_MODIFIER", 120, 128], ["internal consistency", "OBSERVATION", 129, 149]]], ["(Table 9) .Results of the CFA.Adequate discriminant validity is attained since each latent dimension shared more variance with its observed items than it did with other dimensions, as shown in Table 10 (Fornell & Larcker, 1981) .", [["CFA", "ANATOMY", 26, 29], ["discriminant", "OBSERVATION_MODIFIER", 39, 51], ["validity", "OBSERVATION", 52, 60]]], ["Based on each dimension's content, they were labeled as efficacy, safety, cost, time, access, and autonomy concerns.Stage 5-stage 5-Common method biases.Both pre and post techniques were employed to minimize and check for the presence of common method biases in the models (Podsakoff, MacKenzie, Lee, & Podsakoff, 2003) .", [["Stage 5-stage 5", "PROBLEM", 116, 131], ["stage 5", "OBSERVATION_MODIFIER", 124, 131]]], ["Second, the study made use of several items, which were intermixed to minimize the consistency motif.", [["the study", "TEST", 8, 17]]], ["Third, Harman's single factor test, where all items were constrained to load on one factor, was conducted during the EFA and CFA stages (Adongo et al., 2018) .", [["Harman's single factor test", "TEST", 7, 34]]], ["In the EFA, an unrotated factor solution was employed while in the CFA, a marker factor approach was used.", [["EFA", "CHEMICAL", 7, 10], ["an unrotated factor solution", "TREATMENT", 12, 40], ["a marker factor approach", "TREATMENT", 72, 96], ["EFA", "OBSERVATION_MODIFIER", 7, 10], ["CFA", "ANATOMY", 67, 70]]], ["Both estimations justified that a single factor did not sufficiently capture the covariance of the items and the percentage of variance explained in each case was 35% and 37%, respectively.", [["a single factor", "PROBLEM", 32, 47]]], ["With the measures adopted, it was envisaged that method bias was minimal and would not risk the conclusions drawn from the study.Stage 6-structural invariance test.A structural invariance test was conducted to determine if the six dimensions of the TRAVAC scale vary across types of vaccines and different stages of travel, pre-travel and during the trip.", [["the study", "TEST", 119, 128], ["structural invariance test", "TEST", 137, 163], ["A structural invariance test", "TEST", 164, 192], ["the TRAVAC scale", "TREATMENT", 245, 261], ["vaccines", "TREATMENT", 283, 291]]], ["Stage 7-construct and nomological validity.", [["Stage 7-construct and nomological validity", "PROBLEM", 0, 42]]], ["Nomological validity assesses the extent to which a scale measures the specific dimensions it is designed to measure.", [["Nomological validity", "TEST", 0, 20], ["a scale", "TEST", 50, 57], ["extent", "OBSERVATION_MODIFIER", 34, 40]]], ["A second-order structural equation was modeled to determine the construct validity: predictive share of each of the dimensions to the TRAVAC scale.", [["the TRAVAC scale", "TREATMENT", 130, 146]]], ["Construct validity assesses the degree to which conceptually defined measurable dimensions gauge the theoretical concept they are theorized to explain (Reich, Beck, & Price, 2018) .", [["Construct validity", "TEST", 0, 18]]], ["All the five fit indices showed that the second-order factor structure fitted the data very well, and the dimensions are measuring what they are purported to be studying, and demonstrating the structural validity of the hierarchical CFA (Table 8 ).", [["hierarchical", "ANATOMY_MODIFIER", 220, 232], ["CFA", "ANATOMY", 233, 236]]], ["This outcome supports modeling vaccination concern as a second-order factor structure.", [["modeling vaccination", "TREATMENT", 22, 42]]], ["This suggests that all vaccination concern dimensions significantly matter to travelers.", [["all vaccination", "TREATMENT", 19, 34]]], ["Only respondents eligible for at least a vaccine of the ten vaccines recommended for visitors to Ghana were included in the study (see section 3.3.1.1).", [["a vaccine", "TREATMENT", 39, 48], ["the ten vaccines", "TREATMENT", 52, 68], ["the study", "TEST", 120, 129]]], ["The respondents excluded were persons (1) that had pre-existing immunity for the vaccines under consideration as defined by a positive serology, or a history of vaccination or (2) if a health professional considered them immune based on their clinical review or if they had a medical contraindication to the vaccine (Lammert et al., 2016) .Stage 6-structural invariance test.The analytical technique used for probing the effect of international tourists' travel vaccination concerns on their vaccine uptake rate was a fractional beta regression since the denominator, the number of vaccines taken is unknown given the differences in eligibility rates.", [["persons", "ORGANISM", 30, 37], ["persons", "SPECIES", 30, 37], ["the vaccines", "TREATMENT", 77, 89], ["a positive serology", "PROBLEM", 124, 143], ["structural invariance test", "TEST", 348, 374], ["The analytical technique", "TREATMENT", 375, 399], ["international tourists' travel vaccination", "TREATMENT", 431, 473], ["a fractional beta regression", "PROBLEM", 516, 544], ["vaccines", "TREATMENT", 582, 590]]], ["The vaccination uptake rate for each eligible respondent for the current trip/ itinerary to Ghana was determined by dividing the number of vaccines taken by the respondent by the number of vaccines he or she is eligible to receive.", [["The vaccination uptake rate", "TEST", 0, 27], ["vaccines", "TREATMENT", 139, 147], ["vaccines", "TREATMENT", 189, 197]]], ["The fractional regression technique based on its high stability and robustness was chosen over the other alternative methods to estimate the influence of vaccination concerns on uptake rate.", [["The fractional regression technique", "TREATMENT", 0, 35], ["uptake rate", "TEST", 178, 189], ["high stability", "OBSERVATION_MODIFIER", 49, 63]]], ["The yellow vaccine was excluded from the regression analysis because inbound visitors to Ghana are mandated to take the vaccine, which implies that the reason for its uptake is already known.Stage 6-structural invariance test.3.4.1.7.2.", [["The yellow vaccine", "TREATMENT", 0, 18], ["the regression analysis", "TEST", 37, 60], ["structural invariance test", "TEST", 199, 225], ["yellow vaccine", "OBSERVATION", 4, 18]]], ["Out of the ten vaccines, the average vaccination eligibility rate was 5.47, with those eligible for six (6) vaccines being the majority (18.78).", [["the average vaccination eligibility rate", "TEST", 25, 65], ["vaccines", "TREATMENT", 108, 116]]], ["About 17.46 percent of the respondents were eligible to take seven (7) vaccines, followed by those qualified for five (5) vaccines, while those who were not eligible for any of the vaccines were 3.76 percent.", [["vaccines", "TREATMENT", 71, 79], ["vaccines", "TREATMENT", 122, 130], ["the vaccines", "TREATMENT", 177, 189]]], ["In relative terms, Table 11 indicates that the vaccine that most of the respondents were eligible for was the yellow fever vaccine (14.79%), followed by hepatitis B (13.40%), hepatitis A (13.13%), and the least being seasonal influenza vaccine (4.25%).", [["fever", "DISEASE", 117, 122], ["hepatitis B", "DISEASE", 153, 164], ["hepatitis A", "DISEASE", 175, 186], ["influenza", "DISEASE", 226, 235], ["hepatitis B", "ORGANISM", 153, 164], ["hepatitis A", "ORGANISM", 175, 186], ["hepatitis B", "SPECIES", 153, 164], ["hepatitis A", "SPECIES", 175, 186], ["the vaccine", "TREATMENT", 43, 54], ["the yellow fever vaccine", "PROBLEM", 106, 130], ["hepatitis B", "TEST", 153, 164], ["hepatitis A", "TEST", 175, 186], ["seasonal influenza vaccine", "TREATMENT", 217, 243]]], ["It was quite surprising that some people (about 5%) still visited Ghana without taking the yellow fever vaccine despite it being mandatory.", [["fever", "DISEASE", 98, 103], ["people", "ORGANISM", 34, 40], ["people", "SPECIES", 34, 40], ["the yellow fever vaccine", "TREATMENT", 87, 111]]], ["The next highest uptake is among those who were eligible for hepatitis B (86.08%), hepatitis A most under-vaccinated was the seasonal flu vaccine (72.71%).", [["hepatitis B", "DISEASE", 61, 72], ["hepatitis A", "DISEASE", 83, 94], ["hepatitis B", "ORGANISM", 61, 72], ["hepatitis A", "ORGANISM", 83, 94], ["hepatitis B", "SPECIES", 61, 72], ["hepatitis B", "PROBLEM", 61, 72], ["hepatitis A", "PROBLEM", 83, 94], ["the seasonal flu vaccine", "TREATMENT", 121, 145]]], ["The rabies vaccine placed second (66.52%), followed by polio (48.40%) and typhoid (38.45%) vaccines.", [["typhoid", "DISEASE", 74, 81], ["rabies", "ORGANISM", 4, 10], ["The rabies vaccine", "TREATMENT", 0, 18], ["polio", "TEST", 55, 60], ["typhoid", "PROBLEM", 74, 81]]], ["Lammert et al. (2016) , in a similar study among outbound travelers from Table 10 Inter-construct correlation by the square root of the Average Variance Extracted (AVE).Efficacy concernSafety concerns Cost concern Time concern Access concern Ethical concerns CS VS CS VS CS VS CS VS CS VS CS VS Efficacy concern 0.82 0.79 Safety concern 0.57** 0.30** 0.72 0.70 Cost concern 0.31** 0.30** 0.31** 0.38** 0.70 0.81 Time concern 0.31** 0.45** 0.47** 0.46** 0.31* 0.30** 0.71 0.70 Access concern 0.21* 0.27** 0.11 0.22** 0.04 0.07 0.19* 0.20** 0.74 0.72 Autonomy concern 0.11 0.12* 0.08 the US, identified the meningococcal and rabies vaccines as two of the three most refused vaccines, aside from the Japanese Encephalitis vaccine.", [["rabies", "DISEASE", 623, 629], ["Encephalitis", "DISEASE", 706, 718], ["meningococcal", "SPECIES", 605, 618], ["rabies", "SPECIES", 623, 629], ["a similar study", "TEST", 27, 42], ["CS", "TEST", 265, 267], ["CS", "TEST", 271, 273], ["VS", "TEST", 274, 276], ["CS", "TEST", 277, 279], ["VS", "TEST", 280, 282], ["CS", "TEST", 283, 285], ["VS", "TEST", 286, 288], ["CS", "TEST", 289, 291], ["VS", "TEST", 292, 294], ["Efficacy", "TEST", 295, 303], ["concern", "TEST", 304, 311], ["Autonomy", "TEST", 549, 557], ["the US", "TEST", 582, 588], ["the meningococcal and rabies vaccines", "TREATMENT", 601, 638], ["vaccines", "TREATMENT", 672, 680], ["the Japanese Encephalitis vaccine", "TREATMENT", 693, 726], ["meningococcal", "OBSERVATION", 605, 618]]], ["The TRAVAC scale significantly explained about 28% percent of the variance in the tourists' uptake rate of their eligible vaccines during their trip to Ghana.", [["The TRAVAC scale", "TREATMENT", 0, 16], ["their eligible vaccines", "TREATMENT", 107, 130]]], ["In contrast, the single-item measure explained only a percent of the variation in their uptake.", [["variation", "OBSERVATION_MODIFIER", 69, 78]]], ["A unit increase in each of the concerns undermines the uptake rate of travel vaccines.", [["A unit increase", "TREATMENT", 0, 15], ["travel vaccines", "TREATMENT", 70, 85], ["increase", "OBSERVATION_MODIFIER", 7, 15]]], ["The significant relationships observed among the dimensions of the TRAVAC scale, and vaccine uptake rate confirms the predictive validity of the scale (Table 12) .", [["the TRAVAC scale", "TREATMENT", 63, 79], ["vaccine uptake rate", "TEST", 85, 104], ["significant", "OBSERVATION_MODIFIER", 4, 15]]], ["While the other dimensions had a negative relationship with uptake rate, cost concern relates to the uptake rate positively (\u03b2 = 0.07; p < 0.05).", [["uptake rate", "TEST", 60, 71], ["the uptake rate", "TEST", 97, 112]]], ["The observation is indicative that cost concern towards travel vaccination does not undermine vaccination rate.Predictive validity of the TRAVAC scale among a segment-based tourist-study 43.4.2.1.", [["travel vaccination", "TREATMENT", 56, 74], ["the TRAVAC scale", "TREATMENT", 134, 150]]], ["Data and analysis.", [["Data and analysis", "TEST", 0, 17]]], ["Further validation of the scale involved testing its predictive validity using a different segment of international tourists, backpackers.", [["the scale", "TEST", 22, 31]]], ["A distinct population for assessing the predictive validity of scale guards against same population bias and proves the usefulness of the scale across different segments of international travel populations (Adam, Taale, & Adongo, 2020; Churchill, 1979; Reich et al., 2018) .", [["distinct", "OBSERVATION_MODIFIER", 2, 10], ["population", "OBSERVATION", 11, 21]]], ["Ghana is one of the main backpacker destinations in Africa (Adam, 2015; Dayour et al., 2019) .", [["main", "OBSERVATION_MODIFIER", 20, 24]]], ["The backpacker sample was filtered using the self-identification approach proxied by the purpose of the visit (Dayour et al., 2019) .", [["The backpacker sample", "TREATMENT", 0, 21]]], ["'Backpackers' vaccination hesitancy and uptake of the meningococcal vaccine for their current trip to Ghana served as the outcome variables to test the predictive validity of the TRAVAC scale.", [["meningococcal", "SPECIES", 54, 67], ["'Backpackers' vaccination hesitancy", "TREATMENT", 0, 35], ["the meningococcal vaccine", "TREATMENT", 50, 75], ["the TRAVAC scale", "TREATMENT", 175, 191]]], ["Meningitis is one of the diseases Ghana is considered endemic.", [["Meningitis", "DISEASE", 0, 10], ["Meningitis", "PROBLEM", 0, 10], ["the diseases Ghana", "PROBLEM", 21, 39], ["endemic", "PROBLEM", 54, 61], ["diseases", "OBSERVATION", 25, 33], ["endemic", "OBSERVATION_MODIFIER", 54, 61]]], ["Besides, the literature has reported high rates of refusal of the meningococcal vaccine among international travelers (Pavli, Katerelos, Smeti, & Maltezou, 2016) .", [["the meningococcal vaccine", "TREATMENT", 62, 87]]], ["Only backpackers who visited Ghana between December and March of the studied period were sampled for the predictive validity analysis.", [["the predictive validity analysis", "TEST", 101, 133]]], ["This period is the season that travelers visiting Ghana are vulnerable to meningitis (WHO, 2018) .Predictive validity of the TRAVAC scale among a segment-based tourist-study 4In this context, hesitancy described individuals' doubts, indecision, and reluctance toward vaccination (Shapiro et al., 2017) .", [["meningitis", "DISEASE", 74, 84], ["meningitis", "PROBLEM", 74, 84], ["the TRAVAC scale", "TREATMENT", 121, 137], ["meningitis", "OBSERVATION", 74, 84]]], ["It was measured using three items: \"I felt reluctant to take the recommended meningococcal vaccine for this trip,\" \"I felt undecided whether to take the meningococcal vaccine for this trip,\" 'Before I take a particular vaccine I often search for information until I am well convinced of its usefulness\" adapted from past studies (Bedford et al., 2017; Larson et al., 2015) .", [["meningococcal vaccine", "TREATMENT", 77, 98], ["the meningococcal vaccine", "TREATMENT", 149, 174]]], ["The respondents' extent of vaccine hesitancy was measured on a ranking scale of 0-10.", [["vaccine hesitancy", "PROBLEM", 27, 44], ["a ranking scale", "TEST", 61, 76], ["extent", "OBSERVATION_MODIFIER", 17, 23]]], ["Together, the items demonstrated strong uni-dimensionality in principal component analysis with factor loadings ranging from 0.843 to 0.932, and the Cronbach alpha (\u03b1) was 0.824.", [["Cronbach alpha", "GENE_OR_GENE_PRODUCT", 149, 163], ["factor loadings", "TEST", 96, 111], ["the Cronbach alpha", "TEST", 145, 163], ["strong", "OBSERVATION_MODIFIER", 33, 39], ["loadings", "OBSERVATION_MODIFIER", 103, 111]]], ["Uptake of the meningococcal vaccine was measured as a dichotomous variable, which is fully vaccinated and under-vaccinated and coded as zero and one, respectively.", [["the meningococcal vaccine", "TREATMENT", 10, 35], ["meningococcal vaccine", "OBSERVATION", 14, 35]]], ["Only backpackers eligible for the meningococcal vaccine uptake for their current trip were included in the analysis.", [["meningococcal", "SPECIES", 34, 47], ["backpackers", "TREATMENT", 5, 16], ["the meningococcal vaccine uptake", "TREATMENT", 30, 62], ["the analysis", "TEST", 103, 115]]], ["The six dimensions of the TRAVAC scale, on the other hand, served as the predictive variables.", [["the TRAVAC scale", "TREATMENT", 22, 38], ["six", "OBSERVATION_MODIFIER", 4, 7], ["dimensions", "OBSERVATION_MODIFIER", 8, 18]]], ["Their relationship with backpackers' vaccination hesitancy was estimated using an OLS regression, and with the uptake of meningococcal vaccine using a binary logistic regression.", [["meningococcal", "SPECIES", 121, 134], ["backpackers' vaccination hesitancy", "TREATMENT", 24, 58], ["an OLS regression", "PROBLEM", 79, 96], ["meningococcal vaccine", "TREATMENT", 121, 142], ["a binary logistic regression", "TREATMENT", 149, 177]]], ["A comparative competing predictive model was assessed using a single-item measure of travel vaccination concern: \"Overall, I am concerned about taking travel vaccines\" as the explanatory variable.", [["travel vaccines", "TREATMENT", 151, 166]]], ["(Table 12) showed that all dimensions of the scale together explained about 13 percent of the variance in backpackers' uptake of the meningococcal vaccine, whereas the single-item measure explained only 1 percent (odds = 0.91; p > 0.05) of the variance in their uptake.", [["meningococcal", "SPECIES", 133, 146], ["the meningococcal vaccine", "TREATMENT", 129, 154], ["odds", "TEST", 214, 218]]], ["The dimensions also explained 17 percent of the variation in backpackers' hesitancy towards travel vaccination while the single item explained two percent.", [["the variation in backpackers' hesitancy", "PROBLEM", 44, 83], ["travel vaccination", "TREATMENT", 92, 110]]], ["The significant relationships observed among the dimensions of the scale and between the dependent variables broadens and stresses the nomological and predictive validity of the TRAVAC scale.", [["the scale", "TREATMENT", 63, 72], ["the TRAVAC scale", "TREATMENT", 174, 190], ["significant", "OBSERVATION_MODIFIER", 4, 15]]], ["The resultsAll the six concern dimensions have a significant positive relationship with the backpackers' vaccine uptake attitude (hesitancy) and a negative association with their uptake of the meningococcal vaccine except for autonomy concerns.", [["meningococcal", "SPECIES", 193, 206], ["the backpackers' vaccine", "TREATMENT", 88, 112], ["the meningococcal vaccine", "TREATMENT", 189, 214], ["autonomy concerns", "PROBLEM", 226, 243], ["significant", "OBSERVATION_MODIFIER", 49, 60], ["positive", "OBSERVATION", 61, 69]]], ["The results mean that most of the dimensions of the TRAVAC scale stimulate under-vaccination and should not be taken for granted.DiscussionImmunization against infectious diseases is one of the surest ways overseas travelers can safeguard themselves against these diseases abroad.", [["infectious diseases", "DISEASE", 160, 179], ["the TRAVAC scale", "TREATMENT", 48, 64], ["vaccination", "TREATMENT", 81, 92], ["infectious diseases", "PROBLEM", 160, 179], ["these diseases", "PROBLEM", 258, 272]]], ["However, people remain concerned about various aspects of vaccination.", [["people", "ORGANISM", 9, 15], ["people", "SPECIES", 9, 15], ["vaccination", "TREATMENT", 58, 69]]], ["With the current research, we aimed to offer the community of travel medicine researchers and practitioners a standardized psychometric scale that would enable them to assess travel vaccination concerns reliably and objectively.", [["travel medicine", "TREATMENT", 62, 77], ["a standardized psychometric scale", "TREATMENT", 108, 141]]], ["The four studies conducted converge with evidence of a six-dimensional scale.", [["The four studies", "TEST", 0, 16], ["a six-dimensional scale", "TREATMENT", 53, 76]]], ["The dimensions are safety, efficacy, cost, time, access, and autonomy concerns.DiscussionWhile the remaining four dimensions of the scale are conceptually unique, the facets of the safety and efficacy dimensions share some commonalities with the measurement items of some of the general vaccination concern related scales.", [["dimensions", "OBSERVATION_MODIFIER", 4, 14], ["facets", "OBSERVATION_MODIFIER", 167, 173]]], ["These scales include the (1) 'harm' and 'trust' dimensions of the three-factor vaccination confidence scale (Gilkey et al., 2014) , (2) the one-dimensional, vaccine conspiracy beliefs scale (Shapiro et al., 2018) and (4) 'mistrust' and 'worries about unforeseen future effects' 'preference for natural immunity' dimensions of the four-factor vaccination attitudes examination scale by Martin and Petrie (2017) .", [["'harm' and 'trust' dimensions", "TREATMENT", 29, 58]]], ["Despite the similar constructs, the measure items of these two dimensions of the TRAVAC scale are travel-context specific.", [["the TRAVAC scale", "TREATMENT", 77, 93], ["two", "OBSERVATION_MODIFIER", 59, 62], ["dimensions", "OBSERVATION_MODIFIER", 63, 73]]], ["Beyond these dimensional differences and similarities highlighted between the general vaccination-concern related scales and the TRAVAC scale, the determinants of these intersections and uniqueness of the current scale are discussed in the ensuing paragraphs.DiscussionQuestioning vaccine efficacy and safety are the most common concerns in the literature, although protective efficacy lapses are shown to be few (Karafillakis & Larson, 2017; Steffen & Connor, 2005) .", [["the general vaccination", "TREATMENT", 74, 97], ["the TRAVAC scale", "TREATMENT", 125, 141], ["DiscussionQuestioning vaccine efficacy", "TREATMENT", 259, 297], ["protective efficacy lapses", "PROBLEM", 366, 392]]], ["This uncertainty has been partly attributed to the development of new medical technologies, including vaccines, which outpace the provision of evidence regarding their benefits and harms (Hillen et al., 2017) .", [["new medical technologies", "TREATMENT", 66, 90], ["vaccines", "TREATMENT", 102, 110], ["partly attributed to", "UNCERTAINTY", 26, 46], ["new", "OBSERVATION_MODIFIER", 66, 69]]], ["Other safety and efficacy concerns result from mistrust about vaccines and related institutions, historical conspiracies, and misconceptions about immunization, fueled by religious orientations, political, economic, and cultural issues (Grabenstein, 2013; Yaqub et al., 2014) .", [["vaccines", "TREATMENT", 62, 70], ["immunization", "TREATMENT", 147, 159]]], ["However, in the context of international tourism, the literature currently provides no explanation for vaccine safety and efficacy sentiments by travelers.", [["vaccine safety", "TREATMENT", 103, 117], ["no explanation for", "UNCERTAINTY", 84, 102]]], ["The reasons for possible spillover of vaccine safety and efficacy concerns into travel context.", [["spillover of vaccine safety", "TREATMENT", 25, 52]]], ["This would especially be true if an individual is already leery of travel vaccinations or perceives less or no control over adverse events following immunization.DiscussionTravelers are advised by the WHO to consult their GMs four to six weeks before departure to receive necessary vaccines.", [["travel vaccinations", "TREATMENT", 67, 86], ["immunization", "TREATMENT", 149, 161], ["necessary vaccines", "TREATMENT", 272, 290]]], ["Vaccinating within schedule ensures adequate immunity against travel-associated VPDs.", [["VPDs", "DISEASE", 80, 84], ["VPDs", "PATHOLOGICAL_FORMATION", 80, 84]]], ["The majority of travelers obey the early uptake of vaccine directive by the WHO and are unlikely to experience adverse effects of vaccination during the trip.", [["travelers", "ORGANISM", 16, 25], ["vaccine directive", "TREATMENT", 51, 68], ["vaccination", "TREATMENT", 130, 141]]], ["But, a few them do not as they consult on the day of departure or a day before and are likely to express fear of side effects while abroad (Boubaker et al., 2016) .", [["side effects", "PROBLEM", 113, 125]]], ["If those tourists who vaccinate within the recommended schedules are part of those who express side-effects sentiments, those feelings might be uninformed fear given that they are highly unlikely to experience adverse effects during the actual trip.DiscussionThe third and fourth dimensions of the TRAVAC scale are time and cost concerns.", [["the TRAVAC scale", "TREATMENT", 294, 310]]], ["Both concerns are associated with a perceived loss of time convenience and monetary cost in accessing travel vaccines.", [["monetary cost", "TREATMENT", 75, 88], ["accessing travel vaccines", "TREATMENT", 92, 117]]], ["Time and cost concerns from the supply-side are linked to vaccination services and on the demand-side, unaffordability.", [["vaccination services", "TREATMENT", 58, 78]]], ["Unaffordability denotes the inability of travelers to access vaccination, both in terms of financial and non-financial costs due to due to resource scarcity (Thomson et al., 2016) .", [["access vaccination", "TREATMENT", 54, 72]]], ["When people are resource constrained, they become overly focused on the resource and conscious about the cost to acquire goods and services, which make them feel cognitively taxed (Hamilton, Mittal, Shah, Thompson, & Griskevicius, 2019) .DiscussionEvery consumer has a reservation price, which is the maximum amount that he or she is willing and ready to pay for a product or service.", [["people", "ORGANISM", 5, 11], ["people", "SPECIES", 5, 11]]], ["Broadly, a multiplicity of factors may account for the cost concerns associated with travel vaccination.", [["the cost concerns", "PROBLEM", 51, 68], ["travel vaccination", "TREATMENT", 85, 103]]], ["The primary reason is that most travel vaccines are currently not covered by routine vaccination programs and care plans, denoting that the individual has to bear the full fee associated with each vaccination (Steffen & Connor, 2005) .", [["travel vaccines", "TREATMENT", 32, 47], ["routine vaccination programs", "TREATMENT", 77, 105]]], ["Routine vaccines are most often part of national immunization programs and thus benefit from subsidies of governments and other funding agencies (Crockett & Keystone, 2005) .", [["Routine vaccines", "TREATMENT", 0, 16], ["national immunization programs", "TREATMENT", 40, 70]]], ["A web search shows that travel vaccines can cost as much $195USD for Yellow Fever, $300 for Cholera, $339 for Human Papilloma Virus (HPV), $350 per injection of Japanese Encephalitis (two doses series required),[https://www.kelsey-seybold. com/medical-services-and-specialties/travel-clinic/price-list].DiscussionOther sources of vaccination cost include transport to travel clinics and administrative services (Favin, Steinglass, Fields, Banerjee, & Sawhney, 2012) .", [["Fever", "DISEASE", 76, 81], ["Cholera", "DISEASE", 92, 99], ["Human Papilloma Virus", "DISEASE", 110, 131], ["Encephalitis", "DISEASE", 170, 182], ["Human Papilloma Virus", "ORGANISM", 110, 131], ["HPV", "ORGANISM", 133, 136], ["Human Papilloma Virus", "SPECIES", 110, 131], ["Human Papilloma Virus", "SPECIES", 110, 131], ["HPV", "SPECIES", 133, 136], ["A web search", "TEST", 0, 12], ["travel vaccines", "TREATMENT", 24, 39], ["Yellow Fever", "PROBLEM", 69, 81], ["Cholera", "PROBLEM", 92, 99], ["Human Papilloma Virus", "PROBLEM", 110, 131], ["Japanese Encephalitis", "PROBLEM", 161, 182]]], ["Cost may disproportionately impact backpackers' uptake of vaccination than other international travelers because of some reasons.", [["vaccination", "TREATMENT", 58, 69]]], ["Backpackers are often financially constrained because (1) most of them are gap-year students and unemployed (Dayour, Adongo, & Taale, 2016) ; (2) they travel to multiple destinations, which increase the range of vaccines needed, and (3) they travel to destinations with diseases that are expensive to vaccinate.DiscussionThe amount of time spent accessing travel vaccines may equally depend on a multiplicity of factors such as distance to a clinic, waiting time in consultation, and type of vaccine involved (Favin et al., 2012) .", [["diseases", "PROBLEM", 270, 278], ["travel vaccines", "TREATMENT", 356, 371]]], ["For instance, it may sometimes require extra time for travel health practitioners to educate patients about the safety, efficacy, and usefulness of vaccines before administration, which has implications on time convenience.", [["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["vaccines", "TREATMENT", 148, 156]]], ["Besides vaccinations, the available time and income resources are competed for by other activities such as planning for flights and accommodation.", [["vaccinations", "TREATMENT", 8, 20]]], ["Any event that has the potential to limit the optimal use of these resources, depending on priorities, would raise concerns.", [["these resources", "TREATMENT", 61, 76]]], ["The finding on cost and time concerns could indicate that tourists' do not significantly allocate their disposable time and income to vaccination relative to other components (such as airfares) -crowding out effect during trip planning.", [["vaccination", "TREATMENT", 134, 145], ["crowding out effect", "PROBLEM", 195, 214]]], ["Previous studies (including Dolnicar, 2008) in different travel settings shave noted competing relationships among discretionary income and time expenditure.DiscussionThe fifth dimension, access concern, denotes individuals' inability to find necessary vaccines and/or information relating to vaccination.", [["Previous studies", "TEST", 0, 16], ["necessary vaccines", "TREATMENT", 243, 261], ["vaccination", "TREATMENT", 293, 304]]], ["This concern suggests essential awareness among tourists that vaccines are needed when they are traveling abroad only that they are unable to access them.", [["vaccines", "TREATMENT", 62, 70]]], ["In the context of travel vaccination, this finding provides an answer to Lydon et al. 's (2017) question that \"are essential vaccines always available when needed?", [["travel vaccination", "TREATMENT", 18, 36], ["essential vaccines", "TREATMENT", 115, 133]]], ["Further, the finding reinforces that access to vaccines remains a significant constraint to immunization among international travelers, an observation supported by previous studies (Lammert et al., 2016; Lydon et al., 2017) .", [["access to vaccines", "TREATMENT", 37, 55], ["immunization", "TREATMENT", 92, 104], ["an observation", "TEST", 136, 150]]], ["For example, the latter research notes that vaccine stock out remains a pervasive challenge at national and sub-national levels and is attributable to government funding delays, delays in procurement processes, poor forecasting, and stock management.", [["vaccine stock", "TREATMENT", 44, 57], ["a pervasive challenge", "PROBLEM", 70, 91], ["stock management", "TREATMENT", 233, 249], ["attributable to", "UNCERTAINTY", 135, 150], ["government funding", "OBSERVATION", 151, 169]]], ["The policy concerns with the unreliable supply of vaccines are that it can directly or indirectly heighten cost and time concerns risking under-vaccinations.", [["vaccines", "TREATMENT", 50, 58]]], ["In another breadth, we infer that the concern about the unavailability of vaccines and related information signals their admittance of the need for vaccination, the extent of their search effort to acquire recommended vaccines, and their readiness to adopt vaccines made available.DiscussionThe last dimension, which is autonomy concern, has to do with the feeling that some travel vaccination policies are depriving of one's health-seeking freedom.", [["vaccines", "TREATMENT", 74, 82], ["vaccination", "TREATMENT", 148, 159], ["vaccines", "TREATMENT", 218, 226], ["adopt vaccines", "TREATMENT", 251, 265]]], ["Autonomy in healthcare is a long-standing issue but more palpable today, maybe because of the revolution of patientcentered medicine, which calls for provider-patient active co-creation of health and freedom of choice for the patient (Elg, Engstr&m, Witell, & Poksinska, 2012) .", [["patient", "ORGANISM", 159, 166], ["patient", "ORGANISM", 226, 233], ["patient", "SPECIES", 159, 166], ["patient", "SPECIES", 226, 233], ["a long-standing issue", "PROBLEM", 26, 47]]], ["This freedom has become a central part of an individual's health decisions with any potential inhibitions to this freedom likely to face resistance.", [["resistance", "OBSERVATION", 137, 147]]], ["Some of the respondents claimed that international travel is a conduit that \"immunization social order\" -institutions, laws, pharmaceuticals biotechnologies, and social practices\" (Kirkland, 2016b) use to impose certain vaccines on people.", [["people", "ORGANISM", 232, 238], ["people", "SPECIES", 232, 238], ["a conduit", "TREATMENT", 61, 70]]], ["These sentiments somewhat reflect Kirkland's (Kirkland, 2016b) view of rising 'vaccine social activism and critical movements' against vaccination.", [["Kirkland's", "PROBLEM", 34, 44], ["rising 'vaccine", "TREATMENT", 71, 86]]], ["They argue that though mandates may be useful in guiding and constraining individual's vaccination decisions for communal welfare, they can generate lousy publicity leading to hesitancy and refusals of vaccines that are non-mandatory.", [["hesitancy", "PROBLEM", 176, 185], ["vaccines", "TREATMENT", 202, 210]]], ["Even though only a few vaccines are required during travel, travelers who are concerned about vaccine mandates may refuse recommended vaccines to signify their displeasure against the mandates.", [["a few vaccines", "TREATMENT", 17, 31], ["vaccine mandates", "TREATMENT", 94, 110], ["vaccines", "TREATMENT", 134, 142]]], ["Such opposition may be legitimate, but in principle, mandates are appropriate where there are potentials of hesitancy and suboptimal decisions, which result in collective effects.", [["may be", "UNCERTAINTY", 16, 22]]], ["The choice to accept a particular vaccine or not is an individual decision, but the underlying consequences linked to the decision is a common issue (Kasperbauer, 2017) .Theoretical conclusions and implicationsA comprehensive scale for measuring travelers' concerns about vaccination for international travel, which hitherto was not available in the travel medicine literature, is proposed.", [["a particular vaccine", "TREATMENT", 21, 41], ["A comprehensive scale", "TEST", 210, 231], ["vaccination", "TREATMENT", 272, 283]]], ["Six main concerns: safety, efficacy, cost, time, access, and autonomy, are revealed which manifest in the form of perceived risks and uncertainties, worry, anxiety and fear about vaccination outcomes, access constraints, and ethics/morality about vaccination mandates.", [["anxiety", "DISEASE", 156, 163], ["anxiety", "PROBLEM", 156, 163], ["vaccination outcomes", "TREATMENT", 179, 199], ["vaccination mandates", "TREATMENT", 247, 267]]], ["The finding confirms a prior expectation that travelers' vaccination concerns are multi-dimensional in nature, which are either cognitive, emotional, or combined and should be studied as such.", [["travelers' vaccination", "TREATMENT", 46, 68]]], ["The proposed scale represents a significant contribution to the literature regarding the conceptualization of travel vaccination concerns, its theoretical bounds, and specific dimensions as a psychometric concept.", [["travel vaccination", "TREATMENT", 110, 128], ["significant", "OBSERVATION_MODIFIER", 32, 43]]], ["The all-encompassing nature of the TRAVAC scale is advantageous for tailored-studies because of the availability of different vaccines for different travel-related diseases, each of which could evoke specific concerns.", [["the TRAVAC scale", "TREATMENT", 31, 47], ["tailored-studies", "TEST", 68, 84], ["different vaccines", "TREATMENT", 116, 134], ["related diseases", "PROBLEM", 156, 172]]], ["Such extensiveness of the scale makes it more theoretically relevant for ascertaining travel vaccination concerns and identifying their antecedents, moderators and implications for uptake irrespective of the type of vaccine and tourist studied.Theoretical conclusions and implicationsMethodologically, we further argue and conclude that the measure for international travel vaccination concerns is unique in character and construction, given that their travel-space informed their vaccination sentiments.", [["vaccine", "TREATMENT", 216, 223], ["international travel vaccination", "TREATMENT", 353, 385]]], ["This conclusion suggests that though some measures of antitravel vax sentiments and public vax sentiments, such as safety and efficacy, maybe conceptually intersecting, they are distinct and should not be used as proxies without careful adaptation.Theoretical conclusions and implicationsThe TRAVAC scale reliably predicts the vaccine uptake rate and uptake of specific vaccines among mainstream and specific tourists' segments though variation is observed in the impact of the cost dimension.", [["antitravel vax sentiments", "TREATMENT", 54, 79], ["public vax sentiments", "TREATMENT", 84, 105], ["The TRAVAC scale", "TREATMENT", 288, 304], ["the vaccine uptake rate", "TEST", 323, 346], ["specific vaccines", "TREATMENT", 361, 378], ["variation", "OBSERVATION_MODIFIER", 435, 444], ["cost", "OBSERVATION_MODIFIER", 478, 482]]], ["The prediction implies that heightening concerns towards vaccination for travel is associated with an increased likelihood of under-vaccination.", [["vaccination", "TREATMENT", 57, 68]]], ["This reinforces earlier conclusions that concerns significantly predict attitudes and behavior, such as hesitancy and refusal, toward travel vaccination.", [["travel vaccination", "TREATMENT", 134, 152]]], ["Therefore, the TRAVAC scale could be used as an efficient and effective measure for identifying vaccination resistors and their underlying concerns.Management implicationsThe study's findings have relevance for travel medicine and public health practitioners on several issues regarding vaccination for travel.", [["the TRAVAC scale", "TREATMENT", 11, 27], ["vaccination resistors", "TREATMENT", 96, 117], ["The study", "TEST", 171, 180], ["travel medicine", "TREATMENT", 211, 226], ["vaccination", "TREATMENT", 287, 298]]], ["These include surveillance of concerns, pre-travel counseling programs, care and access plans, wait-time management strategies and vaccine formulation.", [["pre-travel counseling programs", "TREATMENT", 40, 70], ["wait-time management strategies", "TREATMENT", 95, 126], ["vaccine formulation", "TREATMENT", 131, 150]]], ["The TRAVAC scale not only calls for the need but represents a comprehensive quick assessment tool for clinicians in assessing and resolving concerns about vaccination for travel.", [["The TRAVAC scale", "TREATMENT", 0, 16]]], ["Given that commonalities exist in some of the dimensions of anti-travel sentiments and general vaccine sentiments, two practical lessons are learned.", [["anti-travel sentiments", "TREATMENT", 60, 82], ["general vaccine sentiments", "TREATMENT", 87, 113]]], ["First, it signals that the scale is adaptable for identifying the concerns that people (both public and travel populations) have about vaccines and, by extension, the reasons underlying their vaccination hesitancy and refusal.", [["people", "ORGANISM", 80, 86], ["people", "SPECIES", 80, 86], ["vaccines", "TREATMENT", 135, 143], ["their vaccination hesitancy", "PROBLEM", 186, 213]]], ["The comprehensiveness of the scale and its significant explanatory ability for vaccine uptake attitudes and behavior make it more clinically relevant for different travelers and vaccines.", [["the scale", "TEST", 25, 34], ["vaccine uptake attitudes", "PROBLEM", 79, 103], ["vaccines", "TREATMENT", 178, 186]]], ["Second, strategies for resolving the concerns identified by the TRAVAC scale should be broad in scope and cover the six-dimensions, which could potentially be useful for both the general public and international travelers to engender pro-vaccination behavior.", [["the TRAVAC scale", "TREATMENT", 60, 76]]], ["The varied nature of the concerns also suggests the need to develop a travel vaccination sentiments tracker.", [["a travel vaccination sentiments tracker", "TREATMENT", 68, 107]]], ["The WHO needs to institutionalize a dedicated smart system, potentially similar to the Vaccine Sentimeter, for continuous surveillance of travelers' vaccination concerns for swift resolution given that attitudes change with time.", [["travelers' vaccination", "TREATMENT", 138, 160]]], ["The TRAVAC scale can be a useful, handy, and comprehensive foundational framework for structuring this intelligent system.Management implicationsThe fact that concerns undermine the vaccine uptake rate among international travel populations further holds management implications and requires innovative schemes to help resolve the specific concerns identified.", [["The TRAVAC scale", "TREATMENT", 0, 16], ["the vaccine uptake rate", "TREATMENT", 178, 201], ["management implications", "TREATMENT", 255, 278], ["innovative schemes", "TREATMENT", 292, 310]]], ["The provision of evidence, accessible, and transparent travel-based information on vaccine risk and benefits could be useful in minimizing the vaccination safety and efficacy concerns, which manifested in the form of misconceptions, falsehoods, and myths.", [["falsehoods", "DISEASE", 233, 243], ["vaccine risk", "TREATMENT", 83, 95], ["the vaccination safety", "TREATMENT", 139, 161]]], ["Instead of countering the sentiments by myth-busting measures, these concerns need to be surrounded with the appropriate information, in support of vaccination.", [["myth-busting measures", "TREATMENT", 40, 61], ["vaccination", "TREATMENT", 148, 159]]], ["Ubiquitous web channels, including clinic's official websites or government consulates and the CDC, could be leveraged for mass campaigns.", [["mass campaigns", "PROBLEM", 123, 137]]], ["Understanding how tourists use social media platforms such as TripAdvisor and capitalizing on their ubiquity could be useful in listening to and tactically resolving concerns.Management implicationsCost concern is positively related to vaccine uptake, which denotes that cost is not necessarily a significant disincentive to vaccine uptake among the majority of travelers.", [["travelers", "ORGANISM", 362, 371], ["vaccine uptake", "PROBLEM", 236, 250], ["a significant disincentive to vaccine uptake", "PROBLEM", 295, 339]]], ["It is reasoned that perhaps among the majority of international travelers, the perceived benefits of immunization outweigh the monetary cost of vaccines.", [["immunization", "TREATMENT", 101, 113], ["the monetary cost of vaccines", "TREATMENT", 123, 152]]], ["The provision of information by travel medicine stakeholders that enables international travelers to appreciate the importance of vaccinations could compensate for their perceived financial loss and stimulate uptake.", [["vaccinations", "TREATMENT", 130, 142], ["their perceived financial loss and stimulate uptake", "PROBLEM", 164, 215]]], ["Because of the role that individuals or clusters who refuse vaccines play in disease outbreaks, other measures should be taken to tackle the identified cost concerns directly, especially for those who travel on limited budgets.", [["vaccines", "TREATMENT", 60, 68], ["disease outbreaks", "PROBLEM", 77, 94]]], ["Stakeholders, such as the WHO, Global Alliance for Vaccines and Immunization (Gavi) and governments, in their health care plans could introduce financial incentive measures to make vaccines more affordable and accessible to international travelers.", [["Vaccines", "TREATMENT", 51, 59], ["Immunization", "TREATMENT", 64, 76], ["financial incentive measures", "TREATMENT", 144, 172], ["vaccines", "TREATMENT", 181, 189]]], ["Travel vaccines can be offered for free or at discounted rates.", [["Travel vaccines", "TREATMENT", 0, 15]]], ["Though some sporadic studies have pointed out the potential crowding-out effects of incentives, evidence indicates that compliance and coverage increase when vaccines are offered at discounted prices (Blank, Schwenkglenks, & Szucs, 2012) .Management implicationsDiscounted vaccination could contribute towards bridging income inequality as a determinant of immunization among tourists because they are often faced with budgetary constraints.", [["some sporadic studies", "TEST", 7, 28], ["vaccines", "TREATMENT", 158, 166], ["immunization", "TREATMENT", 357, 369]]], ["Backpackers, in particular, are always looking for ways to manage their travel budgets, and hence having a reduced cost of medicine can be handy.", [["Backpackers", "TREATMENT", 0, 11], ["a reduced cost of medicine", "TREATMENT", 105, 131]]], ["If tourism is seen as a public good or human right, and under-vaccination is a hazard to the general public's health and well-being, travelers should be motivated to take vaccines by making them affordable.", [["human", "ORGANISM", 39, 44], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44], ["right", "ANATOMY_MODIFIER", 45, 50]]], ["Besides, travelers are strongly advised and encouraged to take up insurance schemes that cover most or all travel vaccines.", [["insurance schemes", "TREATMENT", 66, 83], ["all travel vaccines", "TREATMENT", 103, 122]]], ["Insurance covers indeed reduce the cost concerns of travel vaccination when compared to out-of-pocket payment.", [["travel vaccination", "TREATMENT", 52, 70]]], ["Tourists could also adopt advanced pre-holiday vaccination research and discount/subsidies-hunting methods.", [["advanced pre-holiday vaccination research", "TREATMENT", 26, 67]]], ["Aside from budgets for flights, the UNWTO, travel agencies, and destination management organizations (DMOs) should educate tourists for them to think of their health first and the obligation to consider travel vaccination as one of the components of their travel budgets.", [["travel vaccination", "TREATMENT", 203, 221]]], ["The international travelers' perceived time loss in accessing vaccination services provides opportunities for recasting the re(design) of clinical situations, service processes, and vaccine formulation.", [["accessing vaccination services", "TREATMENT", 52, 82], ["vaccine formulation", "TREATMENT", 182, 201]]], ["Pearce (2020:6) notes that \"despite the best planning efforts of tourists and those who provide services for them, there are often passages of time where people have to wait or occupy themselves before the resource they seek is accessed.\"", [["people", "ORGANISM", 154, 160], ["people", "SPECIES", 154, 160]]], ["These strategies can be employed by clinics to manage travelers' frustrations about it being time-wasting to access travel vaccines.", [["wasting", "DISEASE", 98, 105], ["travel vaccines", "TREATMENT", 116, 131]]], ["Pre-informing them of the waiting period of the vaccination process, scheduling appointments, encouraging wait-time empathy, and leveraging destructive entertaining activities during the waiting period could be useful.Management implicationsThis study supports the call for pharmaceutical companies and biomedical engineers to introduce smart, needle-free injection devices as well as reduce dose regimens into single-administration vaccines without compromising efficacy.", [["the vaccination process", "TREATMENT", 44, 67], ["This study", "TEST", 241, 251], ["smart, needle-free injection devices", "TREATMENT", 337, 373], ["reduce dose regimens", "TREATMENT", 385, 405], ["single-administration vaccines", "TREATMENT", 411, 441], ["destructive", "OBSERVATION_MODIFIER", 140, 151]]], ["This helps to reduce the fear and anxiety associated with vaccines given by injections, shorten administration time, reduce the cost of travel vaccinations and improve patient adherence as fewer shots and visits would be required to provide immunity (McHugh, Guarecuco, Langer, & Jaklenec, 2015; Taberner, Hogan, & Hunter, 2012) .", [["anxiety", "DISEASE", 34, 41], ["patient", "ORGANISM", 168, 175], ["patient", "SPECIES", 168, 175], ["the fear", "PROBLEM", 21, 29], ["anxiety", "PROBLEM", 34, 41], ["vaccines", "TREATMENT", 58, 66], ["travel vaccinations", "TREATMENT", 136, 155]]], ["The smart needles are also beneficial from a healthcare expenditure and financial sustainability perspective as patients would have to pay for fewer travel clinical visits as it would be for low upfront financial investments by governments and insurance companies (McHugh et al., 2015) .Management implicationsAccess concerns, which manifest in the form of ignorance of needed vaccines and lack of reliable information on which travel clinics to find all required vaccines, can be resolved by instituting a smart vaccine finder and advisory system, which directs them to the appropriate places.", [["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["The smart needles", "TREATMENT", 0, 17], ["vaccines", "TREATMENT", 377, 385], ["vaccines", "TREATMENT", 464, 472]]], ["Tourism service providers such as airlines, trip advisor, Airbnb, and travel bloggers in collaboration with WHO, CDC, and travel clinics could post the vaccine finder pop-up, such as that of the HealthMap Vaccine Finder by WHO, for those who are searching for information on travel vaccination.", [["travel vaccination", "TREATMENT", 275, 293]]], ["This service would enable travelers to explore and identify clinics that stock all needed vaccines and compare prices for best deals.", [["vaccines", "TREATMENT", 90, 98]]], ["By implication, this would help reduce immunization fees, not to mention the time convenience.", [["immunization fees", "TREATMENT", 39, 56]]], ["More importantly, the WHO, Gavi, pharmaceutical companies, and travel clinics should ensure that travel vaccines are readily available and accessible.", [["travel vaccines", "TREATMENT", 97, 112]]], ["This can be done by improving the forecasting accuracy of vaccines' demand and supply to minimize stockouts or, at best, eliminate them (Lydon et al., 2017) .", [["vaccines' demand", "TREATMENT", 58, 74]]], ["DMOs through their travel booking data could help these agencies plan their stocks by signaling how many travelers from each originating country are likely to be vaccinating and for which diseases.", [["travelers", "ORGANISM", 105, 114]]], ["However, further studies are required to verify the stockout experiences from the perspective of the vaccine service providers since the reality may be different.", [["further studies", "TEST", 9, 24]]], ["Finally, it is recommended that vaccine mandates be supplemented by broader efforts to increase public trust and support for vaccines while seeking a balance between rights and public safety.Limitation and directions for future researchThe current study is an exploratory attempt to propose a measurement scale for gauging international tourists' travel vaccination concerns.", [["vaccine mandates", "TREATMENT", 32, 48], ["vaccines", "TREATMENT", 125, 133], ["The current study", "TEST", 236, 253], ["a measurement scale", "TEST", 291, 310]]], ["Though the study took into consideration matters toward a wide range of specific travel vaccines, its attempt to propose a generic scale for gauging travel vaccination concerns could be an over universalization of the reality.", [["the study", "TEST", 7, 16], ["specific travel vaccines", "TREATMENT", 72, 96], ["a generic scale", "TREATMENT", 121, 136], ["gauging travel vaccination", "TREATMENT", 141, 167]]], ["Further vaccinespecific studies are required to validate various aspects of the scale, given that perceptions and attitudes vary significantly with different vaccines and respondents' characteristics.", [["Further vaccinespecific studies", "TEST", 0, 31], ["the scale", "TEST", 76, 85], ["different vaccines", "TREATMENT", 148, 166]]], ["This will help further insights into the antecedents of the TRAVAC scale and especially how the scale relates to group normative.", [["the TRAVAC scale", "TREATMENT", 56, 72]]], ["Exploring how the scale plays out during this COVID-19 period, especially its implication for the uptake of a potential COVID-19 vaccine among travelers, would be another exciting avenue of research.Limitation and directions for future researchIt is essential to note that some respondents were recruited into the study while they were traveling.", [["a potential COVID-19 vaccine", "TREATMENT", 108, 136], ["the study", "TEST", 310, 319]]], ["Moreover, while some of them had received some vaccines, others had not at all.", [["some vaccines", "TREATMENT", 42, 55]]], ["Since people have reasons for the decisions they take, those who had received some vaccines before traveling were likely to lower their concerns compared to those who did not receive any vaccine.", [["people", "ORGANISM", 6, 12], ["people", "SPECIES", 6, 12], ["some vaccines", "TREATMENT", 78, 91], ["any vaccine", "TREATMENT", 183, 194]]], ["Travel blogs, TripAdvisor, and similar sites, from which some qualitative data were drawn for the study, might contain inflated sentiments, which could have undermined the credibility of the data.", [["TripAdvisor", "TREATMENT", 14, 25], ["the study", "TEST", 94, 103], ["inflated", "OBSERVATION", 119, 127]]], ["However, we think that this is less likely to compromise the usefulness of the findings because of the rigorous nature of our research methodology and the fact that personal concerns, no matter how minute or exaggerated they are, have noteworthy negative implications for the uptake of vaccines.", [["the uptake of vaccines", "TREATMENT", 272, 294], ["less likely", "UNCERTAINTY", 31, 42]]], ["Future research into the competing alternatives to travel vaccination time and income spending and the extent of competition could provide insights into potential cross-sectoral integration of travel vaccination services.Declaration of competing interestThe authors declare that we have no known competing financial interests or personal relationships that could have appeared to influence the findings reported in this paper.", [["travel vaccination services", "TREATMENT", 193, 220]]], ["His focuses on health and travel medicine, consumer and managerial economics, data science and program evaluation in hospitality and tourism.Declaration of competing interestKwesi Edem Amenumey is working at the Department of Hospitality and Tourism Management, University of Cape Coast, Ghana.", [["program evaluation", "TEST", 95, 113]]], ["His research focuses on the leisure and hospitality aspects of tourism and wellness.Declaration of competing interestAkwesi Kume-Kyereme is a Public Health person and working at the Department of Population and Health, University of Cape Coast.", [["person", "SPECIES", 156, 162]]], ["His research focuses on the geography surrounding public health, sexual and reproductive health and disability.Declaration of competing interestEve Dub\u00e9 is a medical anthropologist working at Quebec National Institute of Public Health.", [["sexual and reproductive health and disability", "DISEASE", 65, 110]]]], "PMC7260529": [["IntroductionSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or coronavirus disease 2019 (COVID-19) is a global pandemic outbreak, the world is facing today.", [["Acute Respiratory Syndrome Coronavirus", "DISEASE", 19, 57], ["coronavirus disease", "DISEASE", 76, 95], ["COVID-19", "CHEMICAL", 102, 110], ["SARS-CoV-2", "ORGANISM", 61, 71], ["coronavirus", "ORGANISM", 76, 87], ["IntroductionSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2", "SPECIES", 0, 71], ["Acute Respiratory Syndrome", "PROBLEM", 19, 45], ["Coronavirus 2", "PROBLEM", 46, 59], ["SARS", "TEST", 61, 65], ["CoV", "TEST", 66, 69], ["coronavirus disease", "PROBLEM", 76, 95], ["COVID", "TEST", 102, 107], ["a global pandemic outbreak", "PROBLEM", 115, 141], ["Acute", "OBSERVATION_MODIFIER", 19, 24], ["Respiratory Syndrome", "OBSERVATION", 25, 45], ["coronavirus", "ANATOMY", 76, 87], ["global", "OBSERVATION_MODIFIER", 117, 123], ["pandemic", "OBSERVATION", 124, 132]]], ["The virus, which migrated from Bats to human being in Wuhan, the capital of Hubei province of China, has influenced more than 180 countries of the world.", [["human", "ORGANISM", 39, 44], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44], ["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["capital", "OBSERVATION_MODIFIER", 65, 72]]], ["The first patient was reported on 8 December 2019, in Wuhan by the Chinese administration [1].", [["patient", "ORGANISM", 10, 17], ["patient", "SPECIES", 10, 17]]], ["A month later, the first death from the virus was reported on 9 January 2020.", [["death", "DISEASE", 25, 30], ["the first death", "PROBLEM", 15, 30], ["the virus", "PROBLEM", 36, 45]]], ["On the same day, world health organization (WHO) declared that a novel coronavirus diseases has been identified and is expanding multi-laterally everyday [2].", [["coronavirus diseases", "DISEASE", 71, 91], ["coronavirus", "ORGANISM", 71, 82], ["a novel coronavirus diseases", "PROBLEM", 63, 91], ["coronavirus diseases", "OBSERVATION", 71, 91]]], ["The virus which started from China, migrated to the third world and first case in Thailand was reported on 13 January 2020 [3].", [["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9]]], ["The Chinese authorities tried to contain the virus by imposing certain strict actions including airport closures, highway closures, railway interruptions, public gathering suspension, halting public transport, closure of shops, mass activities and any other activity which accounts for social gatherings were brought to an immediate halt.", [["the virus", "PROBLEM", 41, 50], ["airport closures", "TREATMENT", 96, 112], ["public gathering suspension", "TREATMENT", 155, 182], ["halting public transport", "TREATMENT", 184, 208], ["closure of shops", "TREATMENT", 210, 226], ["mass activities", "PROBLEM", 228, 243], ["mass", "OBSERVATION", 228, 232]]], ["All of these measures where employed to minimize the effect of community level transmission of the disease [4].", [["the disease", "PROBLEM", 95, 106]]], ["The Chinese authorities took over the control of the situation and collected data from 2018 International Air Transport Association (IATA) to identify and check the infectious disease vulnerability indexes (IDVIs) in new countries where the virus might have transmitted outside China [5].", [["the infectious disease vulnerability indexes", "PROBLEM", 161, 205], ["the virus", "PROBLEM", 237, 246], ["infectious", "OBSERVATION", 165, 175]]], ["It should be noted that IDVI has a range of [0, 1], higher the value of IDVI, lower is the risk of disease transmission and vulnerability.", [["disease transmission", "PROBLEM", 99, 119], ["vulnerability", "PROBLEM", 124, 137], ["lower", "OBSERVATION_MODIFIER", 78, 83], ["disease", "OBSERVATION", 99, 106]]], ["The vrius affected more than 85,000 Chinese population and the initial destinations affected were Hong Kong, Bangkok, Tokyo and Taipei, all having an IDVI above 0.65 [6].IntroductionThough numerous efforts have been brought into place, but still the virus was not controlled and by 19 January 2020, numerous cases across the world were reported [3].", [["Chinese population", "PROBLEM", 36, 54], ["the virus", "PROBLEM", 246, 255]]], ["WHO declared the disease as an emergency situation for the whole world on 31 January 2020 and by 11 March 2020, it was declared as a new threatening global pandemic [4].", [["the disease", "PROBLEM", 13, 24], ["disease", "OBSERVATION", 17, 24]]], ["As of 12 May 2020, almost 4,006,257 have been reported across the globe with a total death count (DC) of 278,892 amounting for a daily increase of 26% and 28% increase in confirmed cases (CC) to deaths per day [6].", [["DC", "ANATOMY", 98, 100], ["death", "DISEASE", 85, 90], ["CC", "CHEMICAL", 188, 190], ["deaths", "DISEASE", 195, 201], ["a total death count", "TEST", 77, 96], ["globe", "ANATOMY", 66, 71]]], ["The virus which started from China, has engulfed almost every country of the world, with the most affected region being the European continent [7].", [["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9]]], ["Average estimates have also been drawn to calibrate and design COVID-19 transmission models, before further investigation and pandemic control measures can be implemented [8].", [["design COVID", "TEST", 56, 68], ["transmission models", "TEST", 72, 91], ["further investigation", "TEST", 100, 121], ["pandemic control measures", "TREATMENT", 126, 151]]], ["It can also be noted that the virus started from a single individual but it migrated to cluster level and in present situation, is enormously increases as a community level transmission system [11].IntroductionIndia the second most populous country of the world with 1.3 billions people to serve, having an average household income ranked at 112th out of 164 countries by the world bank and with a 150th rank in global health care by world economic forum.", [["people", "ORGANISM", 280, 286], ["people", "SPECIES", 280, 286], ["the virus", "PROBLEM", 26, 35], ["virus", "OBSERVATION", 30, 35], ["enormously", "OBSERVATION_MODIFIER", 131, 141], ["increases", "OBSERVATION_MODIFIER", 142, 151]]], ["This critical condition was under the scanner of the whole world, when the COVID-19 pandemic first set foot on Indian soil [9].", [["foot", "ORGANISM_SUBDIVISION", 103, 107], ["the COVID", "TEST", 71, 80], ["foot", "ANATOMY", 103, 107]]], ["The first case was reported on 30 January 2020 and it was expected that India will not be able to survive the heat and due to lack of essential services, life of millions of people will be at stake.", [["people", "ORGANISM", 174, 180], ["people", "SPECIES", 174, 180]]], ["With a recovery rate of 31.7%, a total of 22455 people have been recovered and discharged whereas 2293 people suffered from death [10].", [["death", "DISEASE", 124, 129], ["people", "ORGANISM", 48, 54], ["people", "ORGANISM", 103, 109], ["people", "SPECIES", 48, 54], ["people", "SPECIES", 103, 109], ["a recovery rate", "TEST", 5, 20]]], ["If we compare the same figures with the third world, USA has a total number of confirmed cases amounting to 1,271,645 with an increase rate of 25,000 persons per day and a death count of 76,916 in the same period.", [["death", "DISEASE", 172, 177], ["persons", "SPECIES", 150, 157], ["a death count", "TEST", 170, 183]]], ["Spain with a total of 224,390 confirmed cases versus 26,621 deaths, Russian Federation having 221,344 confirmed cases versus 2009 death cases and a daily increase of more than 10,000 cases.", [["deaths", "DISEASE", 60, 66], ["death", "DISEASE", 130, 135]]], ["United Kingdom stands at fourth place with 219,187 confirmed cases versus 33,854 deaths, and China where the pandemic began is amounts for 84,450 confirmed cases versus a death count of 4643 people [6].", [["deaths", "DISEASE", 81, 87], ["death", "DISEASE", 171, 176], ["people", "SPECIES", 191, 197], ["a death count", "TEST", 169, 182]]], ["The major reason for such little affect of COVID-19 on India, is due to the timely response from the respective central and state governments.IntroductionSince the first day of the outbreak in India, the Indian govt. has been scanning each and every person coming to the country from China and people who had any Chinese travel history in the past few days.", [["people", "ORGANISM", 294, 300], ["person", "SPECIES", 250, 256], ["people", "SPECIES", 294, 300], ["COVID", "TEST", 43, 48]]], ["Important measures included timely response to provide health care facilities, contact tracing, extensive testing, community mobilization and others have helped to contain virus and keep a low mortality rate.", [["contact tracing", "TEST", 79, 94], ["extensive testing", "TEST", 96, 113], ["community mobilization", "TREATMENT", 115, 137], ["virus", "PROBLEM", 172, 177], ["a low mortality rate", "PROBLEM", 187, 207]]], ["Odisha, Kerela and Tamil Nadu has a long history of natural disasters and precautionary measures have already been taken by the government.", [["natural disasters", "TREATMENT", 52, 69], ["precautionary measures", "TREATMENT", 74, 96]]], ["A cluster containment strategy has also been employed to diagnose and contain the virus.", [["A cluster containment strategy", "TREATMENT", 0, 30], ["the virus", "PROBLEM", 78, 87], ["virus", "OBSERVATION", 82, 87]]], ["This has been done by surveying, detecting and contact tracing of about 3 km of area where more than three patients are diagnosed [9].IntroductionThe potential effect of COVID-19 have prompted various studies on the characteristics of the coronavirus and a large number of studies are under processing to estimate the possible devastation by the virus and to derive a vaccine for its cure.", [["COVID-19", "CHEMICAL", 170, 178], ["coronavirus", "DISEASE", 239, 250], ["COVID-19", "CHEMICAL", 170, 178], ["patients", "ORGANISM", 107, 115], ["COVID-19", "GENE_OR_GENE_PRODUCT", 170, 178], ["coronavirus", "ORGANISM", 239, 250], ["patients", "SPECIES", 107, 115], ["contact tracing", "TEST", 47, 62], ["COVID", "TEST", 170, 175], ["various studies", "TEST", 193, 208], ["the coronavirus", "PROBLEM", 235, 250], ["devastation", "PROBLEM", 327, 338], ["the virus", "PROBLEM", 342, 351], ["a vaccine", "TREATMENT", 366, 375], ["large", "OBSERVATION_MODIFIER", 257, 262]]], ["It has also been found that the virus has an adverse effect on elderly people as well as for people who are suffering from some kind of infectious diseases such a heart attacks, respiratory diseases, and others, and it a big concern for the authorities to keep a check on the virus so that minimum harm can be done [12].", [["heart", "ANATOMY", 163, 168], ["respiratory", "ANATOMY", 178, 189], ["infectious diseases", "DISEASE", 136, 155], ["heart attacks", "DISEASE", 163, 176], ["respiratory diseases", "DISEASE", 178, 198], ["people", "ORGANISM", 71, 77], ["people", "ORGANISM", 93, 99], ["heart", "ORGAN", 163, 168], ["people", "SPECIES", 71, 77], ["people", "SPECIES", 93, 99], ["the virus", "PROBLEM", 28, 37], ["infectious diseases", "PROBLEM", 136, 155], ["a heart attacks", "PROBLEM", 161, 176], ["respiratory diseases", "PROBLEM", 178, 198], ["the virus", "PROBLEM", 272, 281], ["virus", "OBSERVATION", 32, 37], ["adverse", "OBSERVATION_MODIFIER", 45, 52], ["effect", "OBSERVATION_MODIFIER", 53, 59], ["infectious", "OBSERVATION", 136, 146], ["heart", "ANATOMY", 163, 168], ["attacks", "OBSERVATION", 169, 176], ["respiratory diseases", "OBSERVATION", 178, 198]]], ["Various studies have been conducted by researchers across the world to estimate the possible impact of coronavirus.", [["coronavirus", "DISEASE", 103, 114], ["coronavirus", "ORGANISM", 103, 114], ["Various studies", "TEST", 0, 15], ["coronavirus", "PROBLEM", 103, 114], ["coronavirus", "OBSERVATION", 103, 114]]], ["The major studies include stochastic simulations [13], Weibull distribution model [14], exponential growth model [16], lognormal distribution [15] and others [17].", [["The major studies", "TEST", 0, 17], ["stochastic simulations", "TEST", 26, 48], ["Weibull distribution model", "TEST", 55, 81], ["exponential growth model", "TEST", 88, 112]]], ["The studies were able to predict an average incubation period of 5.1 days and a total of 14 days quarantine necessary for analysing the virus within a person [13].", [["person", "SPECIES", 151, 157], ["The studies", "TEST", 0, 11]]], ["But none of these studies could estimate the exact reproduction rate and hence not much has been done to predict how the virus will effect in the coming weeks or so.", [["these studies", "TEST", 12, 25], ["the virus", "PROBLEM", 117, 126]]], ["Also, all of the studies have been done on China and not much work has been done with respect to the Indian sub-continent.IntroductionIn present work, a new genetic programming based model (GP) [18] for times series prediction of the COVID-19 scenarios in India has been proposed to estimate the possible spread of the virus.", [["the studies", "TEST", 13, 24], ["the COVID", "TEST", 230, 239], ["the virus", "PROBLEM", 315, 324], ["virus", "OBSERVATION", 319, 324]]], ["The dataset for evaluation is taken from [19].", [["evaluation", "TEST", 16, 26]]], ["GP is an enhanced version of genetic algorithm (GA) [20], in which new solutions are generated as computer based programs rather than simple binary strings [21].", [["genetic algorithm", "TEST", 29, 46]]], ["The GEP model has been used to predict the total number of cases in India based on five major parameters, these include confirmed cases (CC), and death count (DC).", [["DC", "ANATOMY", 159, 161], ["death", "DISEASE", 146, 151], ["DC", "CELL_TYPE", 159, 161], ["death count", "TEST", 146, 157]]], ["The temperature and humidity data has been taken from Indian weather reports available at [25].", [["The temperature", "TEST", 0, 15], ["humidity data", "TEST", 20, 33]]], ["A major reason for using GEP modeling is that this approach is more efficient as compared to classical techniques and are more stable in comparison to artificial neural networks.", [["neural networks", "ANATOMY", 162, 177], ["neural networks", "MULTI-TISSUE_STRUCTURE", 162, 177], ["GEP modeling", "TEST", 25, 37], ["this approach", "TREATMENT", 46, 59], ["classical techniques", "TEST", 93, 113], ["more", "OBSERVATION_MODIFIER", 122, 126], ["stable", "OBSERVATION_MODIFIER", 127, 133]]], ["Also, GEP based models generate simple prediction equations which can be optimized as per the end user requirements.", [["simple prediction equations", "PROBLEM", 32, 59]]], ["Another reason for using GEP, is that these models do not need any prior information to develop prediction equations.", [["prediction equations", "TEST", 96, 116]]], ["Thus in present work, GEP models are proposed based on the raw data taken from authentic sources since 24 March 2020.IntroductionThe paper is organized into 4 sections, first section include the introduction as discussed above.", [["the introduction", "TREATMENT", 191, 207]]], ["In section 2, technical preliminaries and model analysis is presented, providing details on the basics of GEP and proposed GEP model.", [["GEP", "CANCER", 106, 109], ["GEP", "CANCER", 123, 126], ["technical preliminaries and model analysis", "TEST", 14, 56]]], ["Section 3, provides the various results and discussion related to different scenarios of COVID-19.", [["COVID-19", "CHEMICAL", 89, 97], ["COVID", "TEST", 89, 94]]], ["This section further includes the model validation, comparative study and variable importance of all the component, for all the states, which are required for the accurate performance of the proposed GEP model.", [["GEP", "CANCER", 200, 203], ["the model validation", "TEST", 30, 50], ["comparative study", "TEST", 52, 69]]], ["Apart from that analysis with respect to percentage humidity, effect of temperature and variables on COVID-19 has also been discussed.", [["COVID-19", "CHEMICAL", 101, 109], ["COVID-19", "CHEMICAL", 101, 109], ["that analysis", "TEST", 11, 24], ["temperature", "TEST", 72, 83], ["COVID", "TEST", 101, 106]]], ["Here new equations or simply computer based programming models are created in order to find a relationship between the input and output variables.", [["output variables", "TEST", 129, 145]]], ["It is basically a computer based program and creates a tree like structure commonly referred to as bree-based GP model and are declared in a functional programming language [22].", [["a tree like structure", "PROBLEM", 53, 74]]], ["Overall, GP is a hierarchical structure with functions and terminals.", [["terminals", "CELLULAR_COMPONENT", 59, 68], ["GP", "PROTEIN", 9, 11], ["GP", "OBSERVATION_MODIFIER", 9, 11], ["hierarchical structure", "OBSERVATION", 17, 39]]], ["The latest version of GP modelling is the GEP, which uses a fixed length character string instead of classical tree representation of a GP model.", [["a fixed length character string", "TREATMENT", 58, 89], ["tree representation", "OBSERVATION", 111, 130], ["GP model", "OBSERVATION", 136, 144]]], ["The new structure consists of five major components namely function set, control parameters, terminal condition, fitness function and a terminal set.", [["new", "OBSERVATION_MODIFIER", 4, 7], ["structure", "OBSERVATION", 8, 17], ["five", "OBSERVATION_MODIFIER", 30, 34], ["major", "OBSERVATION_MODIFIER", 35, 40], ["components", "OBSERVATION_MODIFIER", 41, 51]]], ["The major advantage of using this kind of methodology is that it is extremely simple and works at chromosome level.", [["chromosome", "ANATOMY", 98, 108], ["chromosome", "CELLULAR_COMPONENT", 98, 108]]], ["It also consists of multi-genic properties and can be used for evolution of complex and nonlinear sub-programming models [31].", [["complex and nonlinear sub-programming models", "PROBLEM", 76, 120]]], ["Each GEP model consists of a list of fixed length symbols, a function set (e.g.+,-, \u00d7 , /,Log) and a terminal set (e.g.a,b,c,7).", [["a function set", "TEST", 59, 73]]], ["Thus in terms of both terminal set and function set, a GEP can be an invention of multiple chromosomes which are capable of representation in the form of any parse tree.", [["chromosomes", "ANATOMY", 91, 102], ["chromosomes", "CELLULAR_COMPONENT", 91, 102], ["chromosomes", "DNA", 91, 102], ["multiple chromosomes", "PROBLEM", 82, 102], ["terminal", "OBSERVATION_MODIFIER", 22, 30], ["tree", "ANATOMY_MODIFIER", 164, 168]]], ["To decode this information, Karva language is used at chromosome level [32] and a simple gene in Karva language is given by(1)/Log++c3ab where a, b and c are variables and 3 is a constant.", [["chromosome", "ANATOMY", 54, 64], ["chromosome", "CELLULAR_COMPONENT", 54, 64]]], ["The above formulated model can then be evolved in the form of a simple ETs as given by Figure 1.", [["a simple ETs", "TREATMENT", 62, 74]]], ["This expression is the root of ET, which reads through the functional node and finally to the terminal node.", [["root", "ANATOMY", 23, 27], ["node", "ANATOMY", 70, 74], ["terminal node", "ANATOMY", 94, 107], ["terminal node", "MULTI-TISSUE_STRUCTURE", 94, 107], ["root", "OBSERVATION_MODIFIER", 23, 27], ["node", "OBSERVATION", 70, 74], ["terminal", "ANATOMY_MODIFIER", 94, 102], ["node", "OBSERVATION", 103, 107]]]], "87dda3063b97a87338264b45ae16045e46cb237b": [["IntroductionThe Chikungunya virus (CHIKV), an arthropod-borne virus (arbovirus), is a single-stranded positive-sense RNA virus with three genotypes.", [["Chikungunya virus (CHIKV)", "DISEASE", 16, 41], ["Chikungunya virus", "ORGANISM", 16, 33], ["CHIKV", "ORGANISM", 35, 40], ["arthropod-borne virus", "ORGANISM", 46, 67], ["Chikungunya virus", "SPECIES", 16, 33], ["arthropod-borne virus", "SPECIES", 46, 67], ["Chikungunya virus", "SPECIES", 16, 33], ["CHIKV", "SPECIES", 35, 40], ["arthropod-borne virus", "SPECIES", 46, 67], ["The Chikungunya virus", "PROBLEM", 12, 33], ["CHIKV", "PROBLEM", 35, 40], ["an arthropod-borne virus (arbovirus", "PROBLEM", 43, 78], ["a single-stranded positive-sense RNA virus", "PROBLEM", 84, 126], ["Chikungunya virus", "OBSERVATION", 16, 33]]], ["The virus is of the Alphavirus genus in the Togaviridae family [1, 2] .", [["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["Alphavirus genus", "OBSERVATION", 20, 36]]], ["CHIKV has been shown to infect and be transmitted by Ae. aegyptii and Ae. albopictus mosquitoes.", [["CHIKV", "ORGANISM", 0, 5], ["Ae. aegyptii", "ORGANISM", 53, 65], ["Ae. albopictus mosquitoes", "ORGANISM", 70, 95], ["Ae. aegyptii", "SPECIES", 53, 65], ["Ae. albopictus", "SPECIES", 70, 84], ["CHIKV", "SPECIES", 0, 5], ["Ae. aegyptii", "SPECIES", 53, 65], ["Ae. albopictus", "SPECIES", 70, 84], ["CHIKV", "PROBLEM", 0, 5]]], ["It was identified in East Africa in the early 1950s and since then has caused epidemics in continental Africa, the Indian Ocean region, and countries of Southeast Asia such as India, where since 2006 suspected cases have been estimated to be 1.39 million, and Singapore [3] [4] [5] [6] .", [["epidemics", "PROBLEM", 78, 87], ["East", "OBSERVATION_MODIFIER", 21, 25], ["Africa", "OBSERVATION_MODIFIER", 26, 32], ["continental Africa", "OBSERVATION", 91, 109]]], ["The only reported outbreak outside these areas was in Italy in the Emilia Romagna region in 2007.", [["outbreak", "OBSERVATION_MODIFIER", 18, 26], ["areas", "OBSERVATION_MODIFIER", 41, 46], ["Emilia Romagna", "ANATOMY", 67, 81]]], ["Small nonepidemic imported cases have been reported in other regions such as North America, France and Japan, which were caused by travelers returning from affected areas [7] [8] [9] .IntroductionThe epidemic occurring on La Reunion Island in the Indian Ocean remains the most devastating of all CHIKV outbreaks where over one-third of the population was affected [10] .", [["CHIKV", "SPECIES", 296, 301], ["Small nonepidemic imported cases", "PROBLEM", 0, 32], ["all CHIKV outbreaks", "PROBLEM", 292, 311], ["epidemic", "OBSERVATION_MODIFIER", 200, 208], ["most", "OBSERVATION_MODIFIER", 272, 276], ["devastating", "OBSERVATION_MODIFIER", 277, 288], ["all", "OBSERVATION_MODIFIER", 292, 295], ["CHIKV", "OBSERVATION", 296, 301]]], ["During this outbreak, the CHIKV acquired a genetic mutation allowing the new vector Ae. albopictus mosquito to carry the virus where previously CHIKV only circulated in Ae. aegyptii mosquitoes [10, 11] .", [["CHIKV", "DISEASE", 26, 31], ["CHIKV", "ORGANISM", 26, 31], ["Ae. albopictus mosquito", "ORGANISM", 84, 107], ["CHIKV", "ORGANISM", 144, 149], ["aegyptii mosquitoes", "ORGANISM", 173, 192], ["aegyptii", "SPECIES", 173, 181], ["CHIKV", "SPECIES", 26, 31], ["Ae. albopictus", "SPECIES", 84, 98], ["CHIKV", "SPECIES", 144, 149], ["aegyptii", "SPECIES", 173, 181], ["the CHIKV", "PROBLEM", 22, 31], ["a genetic mutation", "PROBLEM", 41, 59], ["the virus", "PROBLEM", 117, 126]]], ["The Ae. albopictus differs in susceptibility to various genetically different isolates of the virus compared to the Ae. aegyptii [12] .", [["Ae. albopictus", "ORGANISM", 4, 18], ["Ae. aegyptii", "ORGANISM", 116, 128], ["Ae. aegyptii", "SPECIES", 116, 128], ["Ae. albopictus", "SPECIES", 4, 18], ["Ae. aegyptii", "SPECIES", 116, 128], ["the virus", "PROBLEM", 90, 99]]], ["CHIKV is now of global health concern since expansion of mosquito vectors has created potential for the Chikungunya virus to spread to temperate areas as Ae. albopitcus inhabits regions in North America and Europe [2, 13] .IntroductionCHIKV infection is clinically characterized by the sudden appearance of high fever, rash, headache, nausea, vomiting, myalgia and arthalgia or severe joint pain.", [["joint", "ANATOMY", 385, 390], ["CHIKV", "DISEASE", 0, 5], ["Chikungunya", "DISEASE", 104, 115], ["infection", "DISEASE", 241, 250], ["fever", "DISEASE", 312, 317], ["rash", "DISEASE", 319, 323], ["headache", "DISEASE", 325, 333], ["nausea", "DISEASE", 335, 341], ["vomiting", "DISEASE", 343, 351], ["myalgia", "DISEASE", 353, 360], ["arthalgia", "DISEASE", 365, 374], ["joint pain", "DISEASE", 385, 395], ["CHIKV", "ORGANISM", 0, 5], ["Chikungunya virus", "ORGANISM", 104, 121], ["joint", "ORGANISM_SUBDIVISION", 385, 390], ["CHIKV", "SPECIES", 0, 5], ["Chikungunya virus", "SPECIES", 104, 121], ["Ae. albopitcus", "SPECIES", 154, 168], ["CHIKV", "PROBLEM", 0, 5], ["expansion of mosquito vectors", "TREATMENT", 44, 73], ["the Chikungunya virus", "PROBLEM", 100, 121], ["IntroductionCHIKV infection", "PROBLEM", 223, 250], ["high fever", "PROBLEM", 307, 317], ["rash", "PROBLEM", 319, 323], ["headache", "PROBLEM", 325, 333], ["nausea", "PROBLEM", 335, 341], ["vomiting", "PROBLEM", 343, 351], ["myalgia", "PROBLEM", 353, 360], ["arthalgia", "PROBLEM", 365, 374], ["severe joint pain", "PROBLEM", 378, 395], ["infection", "OBSERVATION", 241, 250], ["high", "OBSERVATION_MODIFIER", 307, 311], ["fever", "OBSERVATION", 312, 317], ["severe", "OBSERVATION_MODIFIER", 378, 384], ["joint", "ANATOMY", 385, 390], ["pain", "OBSERVATION", 391, 395]]], ["Severe joint pain is the defining symptom of CHIKV disease [11] .", [["joint", "ANATOMY", 7, 12], ["joint pain", "DISEASE", 7, 17], ["CHIKV disease", "DISEASE", 45, 58], ["joint", "MULTI-TISSUE_STRUCTURE", 7, 12], ["CHIKV", "ORGANISM", 45, 50], ["CHIKV", "SPECIES", 45, 50], ["Severe joint pain", "PROBLEM", 0, 17], ["CHIKV disease", "PROBLEM", 45, 58], ["joint", "ANATOMY", 7, 12], ["pain", "OBSERVATION", 13, 17], ["CHIKV", "OBSERVATION", 45, 50]]], ["The word Chikungunya originated from the Tanzanian and Mozambique region of Africa meaning that which bends up.", [["Chikungunya", "DISEASE", 9, 20], ["The word Chikungunya", "PROBLEM", 0, 20]]], ["A bent posture is often taken by those in severe joint pain after being infected with CHIKV.", [["joint", "ANATOMY", 49, 54], ["pain", "DISEASE", 55, 59], ["CHIKV", "DISEASE", 86, 91], ["joint", "ORGANISM_SUBDIVISION", 49, 54], ["CHIKV", "ORGANISM", 86, 91], ["CHIKV", "SPECIES", 86, 91], ["A bent posture", "PROBLEM", 0, 14], ["severe joint pain", "PROBLEM", 42, 59], ["CHIKV", "PROBLEM", 86, 91], ["bent posture", "OBSERVATION", 2, 14], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["joint", "ANATOMY", 49, 54], ["pain", "OBSERVATION", 55, 59]]], ["CHIKV symptoms start 4 to 7 days after exposure and most resolve within the acute phase of the disease.", [["CHIKV", "ORGANISM", 0, 5], ["CHIKV", "SPECIES", 0, 5], ["CHIKV symptoms", "PROBLEM", 0, 14], ["the disease", "PROBLEM", 91, 102], ["acute phase", "OBSERVATION_MODIFIER", 76, 87], ["disease", "OBSERVATION", 95, 102]]], ["Although the acute phase lasts approximately 2 weeks, joint pain can persist for months or years following initial infection [1, 14, 15] .", [["joint", "ANATOMY", 54, 59], ["pain", "DISEASE", 60, 64], ["infection", "DISEASE", 115, 124], ["joint", "MULTI-TISSUE_STRUCTURE", 54, 59], ["the acute phase", "PROBLEM", 9, 24], ["joint pain", "PROBLEM", 54, 64], ["initial infection", "PROBLEM", 107, 124], ["acute", "OBSERVATION_MODIFIER", 13, 18], ["phase", "OBSERVATION_MODIFIER", 19, 24], ["joint", "ANATOMY", 54, 59], ["infection", "OBSERVATION", 115, 124]]], ["Minimal research has been done investigating the immune response following CHIKV infection.", [["CHIKV infection", "DISEASE", 75, 90], ["CHIKV", "ORGANISM", 75, 80], ["CHIKV", "SPECIES", 75, 80], ["CHIKV infection", "PROBLEM", 75, 90], ["CHIKV", "OBSERVATION_MODIFIER", 75, 80], ["infection", "OBSERVATION", 81, 90]]], ["Currently, there is no CHIKV specific therapeutic available.IntroductionThe Italian outbreak of CHIKV spread through communities surrounding the city of Ravenna during August to October 2007 and also involved the major Italian city of Bologna [15, 16] .", [["CHIKV", "DISEASE", 96, 101], ["CHIKV", "ORGANISM", 96, 101], ["CHIKV", "SPECIES", 23, 28], ["CHIKV", "SPECIES", 96, 101], ["CHIKV", "PROBLEM", 23, 28], ["CHIKV", "PROBLEM", 96, 101], ["no", "UNCERTAINTY", 20, 22], ["CHIKV", "OBSERVATION", 23, 28], ["CHIKV", "OBSERVATION", 96, 101]]], ["A recorded 254 people were identified to be infected through the Ae. albopictus mosquito which has inhabited the Emilia Romagna region since 1990 [14, 17, 18] .", [["people", "ORGANISM", 15, 21], ["people", "SPECIES", 15, 21], ["Ae. albopictus", "SPECIES", 65, 79], ["infected", "OBSERVATION", 44, 52], ["Emilia", "ANATOMY_MODIFIER", 113, 119]]], ["The virus brought to the Emilia Romagna region by a traveler returning from a CHIKV affected country was of the Central/East African genotype and matched most closely (100% amino acid identity) with the IND-06 virus isolated from the Reunion Island outbreak [14, 17] .", [["amino acid", "CHEMICAL", 173, 183], ["amino acid", "CHEMICAL", 173, 183], ["Emilia Romagna", "ORGANISM", 25, 39], ["amino acid", "AMINO_ACID", 173, 183], ["IND-06 virus", "ORGANISM", 203, 215], ["CHIKV", "SPECIES", 78, 83], ["IND-06 virus", "SPECIES", 203, 215], ["The virus", "PROBLEM", 0, 9], ["amino acid identity", "TEST", 173, 192], ["the IND", "TREATMENT", 199, 206], ["virus", "PROBLEM", 210, 215], ["virus", "OBSERVATION", 4, 9], ["Emilia", "ANATOMY_MODIFIER", 25, 31], ["Reunion", "OBSERVATION_MODIFIER", 234, 241], ["Island", "OBSERVATION_MODIFIER", 242, 248]]], ["The amino acid identity confirmed that this virus included a substitution mutation in the E1 envelope protein (E1-A226V) [19] which is important for viral entry into host cells.", [["cells", "ANATOMY", 171, 176], ["amino acid", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 4, 14], ["amino acid", "AMINO_ACID", 4, 14], ["E1-A226V) [19]", "GENE_OR_GENE_PRODUCT", 111, 125], ["host cells", "CELL", 166, 176], ["E1 envelope protein", "PROTEIN", 90, 109], ["E1", "PROTEIN", 111, 113], ["A226V", "PROTEIN", 114, 119], ["host cells", "CELL_TYPE", 166, 176], ["The amino acid identity", "TEST", 0, 23], ["this virus", "PROBLEM", 39, 49], ["a substitution mutation", "PROBLEM", 59, 82], ["the E1 envelope protein", "TEST", 86, 109], ["host cells", "OBSERVATION", 166, 176]]], ["This mutation was acquired during the 2005-2006 Indian Ocean CHIKV outbreak and increased the virus's infectivity to the Ae. albopictus mosquito [20] .IntroductionCytokines are important immune mediators that conduct immune responses.", [["Ae. albopictus", "ORGANISM", 121, 135], ["Cytokines", "GENE_OR_GENE_PRODUCT", 163, 172], ["Cytokines", "PROTEIN", 163, 172], ["Ae. albopictus", "SPECIES", 121, 135], ["CHIKV", "SPECIES", 61, 66], ["Ae. albopictus", "SPECIES", 121, 135], ["This mutation", "PROBLEM", 0, 13], ["the virus's infectivity", "PROBLEM", 90, 113], ["IntroductionCytokines", "TREATMENT", 151, 172], ["immune mediators", "TREATMENT", 187, 203]]], ["Recently, cytokine profiles have been investigated in CHIKV infected humans by two groups [21, 22] .", [["CHIKV infected", "DISEASE", 54, 68], ["CHIKV", "ORGANISM", 54, 59], ["humans", "ORGANISM", 69, 75], ["cytokine", "PROTEIN", 10, 18], ["humans", "SPECIES", 69, 75], ["CHIKV", "SPECIES", 54, 59], ["humans", "SPECIES", 69, 75], ["cytokine profiles", "TEST", 10, 27], ["CHIKV", "OBSERVATION", 54, 59]]], ["Ng and colleagues established cytokine profiles from 10 CHIKV patients that were infected during the Singapore 2007 CHIKV outbreak [22] .", [["CHIKV", "ORGANISM", 56, 61], ["patients", "ORGANISM", 62, 70], ["cytokine", "PROTEIN", 30, 38], ["patients", "SPECIES", 62, 70], ["CHIKV", "SPECIES", 56, 61], ["Singapore 2007 CHIKV", "SPECIES", 101, 121], ["cytokine profiles", "TEST", 30, 47]]], ["Although this study reported that IL-1b, IL-6 and RANTES were correlated with severe acute phase CHIKV disease, cytokine profiles were not determined for the progression and convalescence of the disease.", [["IL-1b", "GENE_OR_GENE_PRODUCT", 34, 39], ["IL-6", "GENE_OR_GENE_PRODUCT", 41, 45], ["RANTES", "GENE_OR_GENE_PRODUCT", 50, 56], ["CHIKV", "ORGANISM", 97, 102], ["IL", "PROTEIN", 34, 36], ["IL-6", "PROTEIN", 41, 45], ["RANTES", "PROTEIN", 50, 56], ["cytokine", "PROTEIN", 112, 120], ["CHIKV", "SPECIES", 97, 102], ["this study", "TEST", 9, 19], ["IL", "TEST", 34, 36], ["severe acute phase CHIKV disease", "PROBLEM", 78, 110], ["cytokine profiles", "TEST", 112, 129], ["the disease", "PROBLEM", 191, 202], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["acute", "OBSERVATION_MODIFIER", 85, 90], ["phase", "OBSERVATION_MODIFIER", 91, 96], ["CHIKV disease", "OBSERVATION", 97, 110], ["disease", "OBSERVATION", 195, 202]]], ["Here we investigated cytokine profiles during the acute phase and 6-and 12-month follow-up of CHIKV infected patients of the Italian 2007 outbreak.", [["CHIKV infected", "DISEASE", 94, 108], ["CHIKV", "ORGANISM", 94, 99], ["patients", "ORGANISM", 109, 117], ["cytokine", "PROTEIN", 21, 29], ["patients", "SPECIES", 109, 117], ["CHIKV", "SPECIES", 94, 99], ["cytokine profiles", "TEST", 21, 38], ["the acute phase", "TEST", 46, 61], ["CHIKV", "PROBLEM", 94, 99]]], ["Since CHIKV disease can have severe acute phase symptoms and be followed by persistent symptoms in the convalescence phase it was important to investigate the immune response responsible for these maladies.", [["CHIKV disease", "DISEASE", 6, 19], ["CHIKV", "ORGANISM", 6, 11], ["CHIKV", "SPECIES", 6, 11], ["CHIKV disease", "PROBLEM", 6, 19], ["severe acute phase symptoms", "PROBLEM", 29, 56], ["persistent symptoms", "PROBLEM", 76, 95], ["these maladies", "PROBLEM", 191, 205], ["severe", "OBSERVATION_MODIFIER", 29, 35], ["acute", "OBSERVATION_MODIFIER", 36, 41]]], ["Furthermore, the Italian CHIKV included the A226V mutation and the Singapore virus did not.", [["CHIKV", "DISEASE", 25, 30], ["CHIKV", "ORGANISM", 25, 30], ["A226V", "GENE_OR_GENE_PRODUCT", 44, 49], ["Italian CHIKV", "SPECIES", 17, 30], ["Singapore virus", "SPECIES", 67, 82], ["the A226V mutation", "TREATMENT", 40, 58], ["the Singapore virus", "PROBLEM", 63, 82]]], ["Furthermore, we analysed the relationship between cytokine levels and patient severity, and IgG levels linking high CXCL9, CXCL10 and IgG levels with disease severity.", [["patient", "ORGANISM", 70, 77], ["IgG", "GENE_OR_GENE_PRODUCT", 92, 95], ["CXCL9", "GENE_OR_GENE_PRODUCT", 116, 121], ["CXCL10", "GENE_OR_GENE_PRODUCT", 123, 129], ["IgG", "GENE_OR_GENE_PRODUCT", 134, 137], ["cytokine", "PROTEIN", 50, 58], ["IgG", "PROTEIN", 92, 95], ["CXCL9", "PROTEIN", 116, 121], ["CXCL10", "PROTEIN", 123, 129], ["IgG", "PROTEIN", 134, 137], ["patient", "SPECIES", 70, 77], ["cytokine levels", "TEST", 50, 65], ["patient severity", "TEST", 70, 86], ["IgG levels", "TEST", 92, 102], ["CXCL10", "TEST", 123, 129], ["IgG levels", "TEST", 134, 144], ["disease severity", "PROBLEM", 150, 166]]], ["Therefore, the results presented here are virus specific and reflect previously unreported cytokine profiles which may be important for the development of future therapeutics for CHIKV outbreaks.Ethics statementPatients all gave written consent to the participation in scientific studies.", [["CHIKV", "DISEASE", 179, 184], ["CHIKV", "ORGANISM", 179, 184], ["Patients", "ORGANISM", 211, 219], ["cytokine", "PROTEIN", 91, 99], ["Patients", "SPECIES", 211, 219], ["CHIKV", "SPECIES", 179, 184], ["virus", "PROBLEM", 42, 47], ["previously unreported cytokine profiles", "PROBLEM", 69, 108], ["future therapeutics", "TREATMENT", 155, 174], ["CHIKV outbreaks", "PROBLEM", 179, 194], ["scientific studies", "TEST", 269, 287]]], ["Permission to perform scientific studies was given by Comitato Etico di Area Vasta Romagna Et IRSTof the Servizio Sanitario Regionale Emilia-Romagna, Italy.ObjectivesSince the immune response during CHIKV disease has not been extensively investigated, our objectives were to create a clear clinical picture of CHIKV disease at the acute phase and during convalescence at 6-and 12-month follow-up by cytokine profiling.", [["CHIKV disease", "DISEASE", 199, 212], ["CHIKV disease", "DISEASE", 310, 323], ["CHIKV", "ORGANISM", 199, 204], ["CHIKV", "ORGANISM", 310, 315], ["cytokine", "PROTEIN", 399, 407], ["CHIKV", "SPECIES", 199, 204], ["CHIKV", "SPECIES", 310, 315], ["scientific studies", "TEST", 22, 40], ["CHIKV disease", "PROBLEM", 199, 212], ["CHIKV disease", "PROBLEM", 310, 323], ["cytokine profiling", "TEST", 399, 417], ["CHIKV", "OBSERVATION", 310, 315], ["acute phase", "OBSERVATION_MODIFIER", 331, 342]]], ["To achieve this objective, we investigated the cytokine profiles from patients at the acute phase and at 6-and 12-month follow-up.ParticipantsIncluded patients were from the region of Emilia-Romagna in north-east Italy suspected to be infected with CHIKV since they showed symptoms such as myalgia, severe back and joint pain, headache, and skin rash.", [["back", "ANATOMY", 306, 310], ["joint", "ANATOMY", 315, 320], ["skin", "ANATOMY", 341, 345], ["CHIKV", "DISEASE", 249, 254], ["myalgia", "DISEASE", 290, 297], ["back and joint pain", "DISEASE", 306, 325], ["headache", "DISEASE", 327, 335], ["skin rash", "DISEASE", 341, 350], ["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 151, 159], ["CHIKV", "ORGANISM", 249, 254], ["joint", "ORGANISM_SUBDIVISION", 315, 320], ["skin", "ORGAN", 341, 345], ["cytokine", "PROTEIN", 47, 55], ["patients", "SPECIES", 70, 78], ["Participants", "SPECIES", 130, 142], ["patients", "SPECIES", 151, 159], ["CHIKV", "SPECIES", 249, 254], ["the cytokine profiles", "TEST", 43, 64], ["CHIKV", "PROBLEM", 249, 254], ["symptoms", "PROBLEM", 273, 281], ["myalgia", "PROBLEM", 290, 297], ["severe back and joint pain", "PROBLEM", 299, 325], ["headache", "PROBLEM", 327, 335], ["skin rash", "PROBLEM", 341, 350], ["infected", "OBSERVATION", 235, 243], ["severe", "OBSERVATION_MODIFIER", 299, 305], ["back", "ANATOMY", 306, 310], ["joint", "ANATOMY", 315, 320], ["pain", "OBSERVATION", 321, 325], ["skin", "ANATOMY", 341, 345], ["rash", "OBSERVATION", 346, 350]]], ["Collaboration with the regional microbiology reference laboratory of Bologna University and the Department of Infectious and Parasitic Diseases of the National Institute of Health in Rome was initiated and identified the patients as having CHIKV.", [["Infectious and Parasitic Diseases", "DISEASE", 110, 143], ["CHIKV", "DISEASE", 240, 245], ["patients", "ORGANISM", 221, 229], ["CHIKV", "ORGANISM", 240, 245], ["patients", "SPECIES", 221, 229], ["CHIKV", "SPECIES", 240, 245], ["CHIKV", "PROBLEM", 240, 245], ["Infectious", "OBSERVATION", 110, 120], ["Parasitic", "OBSERVATION_MODIFIER", 125, 134]]], ["The clinical criteria was described as acute onset of fever (.38.5uC) and severe arthralgia not explained by other medical conditions.", [["fever", "DISEASE", 54, 59], ["arthralgia", "DISEASE", 81, 91], ["fever", "PROBLEM", 54, 59], ["uC", "PROBLEM", 66, 68], ["severe arthralgia", "PROBLEM", 74, 91], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["fever", "OBSERVATION", 54, 59], ["severe", "OBSERVATION_MODIFIER", 74, 80], ["arthralgia", "OBSERVATION", 81, 91]]], ["CHIKV infection was confirmed by one or more of the acute phase tests: virus isolation, reverse transcriptase-PCR (RT-PCR) positive for CHIKV nsp1 gene, seroconversion to virus-specific serum antibodies collected at least 1 to 3 weeks apart, or presence of virus-specific IgM antibodies in a single serum sample collected [15] .", [["serum", "ANATOMY", 186, 191], ["serum sample", "ANATOMY", 299, 311], ["CHIKV infection", "DISEASE", 0, 15], ["CHIKV", "ORGANISM", 0, 5], ["CHIKV", "ORGANISM", 136, 141], ["nsp1", "GENE_OR_GENE_PRODUCT", 142, 146], ["serum", "ORGANISM_SUBSTANCE", 186, 191], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 272, 286], ["serum", "ORGANISM_SUBSTANCE", 299, 304], ["reverse transcriptase", "PROTEIN", 88, 109], ["CHIKV nsp1 gene", "DNA", 136, 151], ["serum antibodies", "PROTEIN", 186, 202], ["IgM antibodies", "PROTEIN", 272, 286], ["CHIKV", "SPECIES", 0, 5], ["CHIKV", "SPECIES", 136, 141], ["CHIKV infection", "PROBLEM", 0, 15], ["the acute phase tests", "TEST", 48, 69], ["virus isolation", "TREATMENT", 71, 86], ["reverse transcriptase", "TEST", 88, 109], ["PCR", "TEST", 110, 113], ["RT-PCR", "TEST", 115, 121], ["CHIKV nsp1 gene", "PROBLEM", 136, 151], ["seroconversion to virus", "PROBLEM", 153, 176], ["specific serum antibodies", "TEST", 177, 202], ["virus", "PROBLEM", 257, 262], ["specific IgM antibodies", "TEST", 263, 286], ["a single serum sample", "TEST", 290, 311], ["infection", "OBSERVATION", 6, 15]]], ["Acute CHIKV patient samples were determined to be in the viral stage if the sample was PCR positive for CHIKV (7 patients), in the IgM antibody initiation stage if the sample was PCR negative, IgM positive, IgG negative (6 patients) or in the seroconversion stage (22 patients) if the sample was PCR negative, IgM positive and IgG positive.", [["samples", "ANATOMY", 20, 27], ["sample", "ANATOMY", 76, 82], ["sample", "ANATOMY", 168, 174], ["sample", "ANATOMY", 285, 291], ["CHIKV", "ORGANISM", 6, 11], ["patient", "ORGANISM", 12, 19], ["CHIKV", "ORGANISM", 104, 109], ["patients", "ORGANISM", 113, 121], ["IgM", "GENE_OR_GENE_PRODUCT", 193, 196], ["IgG", "GENE_OR_GENE_PRODUCT", 207, 210], ["patients", "ORGANISM", 223, 231], ["patients", "ORGANISM", 268, 276], ["IgM", "GENE_OR_GENE_PRODUCT", 310, 313], ["IgG", "GENE_OR_GENE_PRODUCT", 327, 330], ["IgM antibody", "PROTEIN", 131, 143], ["IgM", "PROTEIN", 193, 196], ["IgG", "PROTEIN", 207, 210], ["IgM", "PROTEIN", 310, 313], ["IgG", "PROTEIN", 327, 330], ["patient", "SPECIES", 12, 19], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 223, 231], ["patients", "SPECIES", 268, 276], ["CHIKV", "SPECIES", 6, 11], ["CHIKV", "SPECIES", 104, 109], ["Acute CHIKV patient samples", "PROBLEM", 0, 27], ["the viral stage", "PROBLEM", 53, 68], ["the sample", "TEST", 72, 82], ["PCR", "TEST", 87, 90], ["CHIKV", "PROBLEM", 104, 109], ["the IgM antibody", "TEST", 127, 143], ["the sample", "TEST", 164, 174], ["PCR", "TEST", 179, 182], ["IgM", "TEST", 193, 196], ["IgG", "TEST", 207, 210], ["the seroconversion stage", "TEST", 239, 263], ["the sample", "TEST", 281, 291], ["PCR", "TEST", 296, 299], ["IgM", "TEST", 310, 313], ["IgG", "TEST", 327, 330], ["CHIKV", "OBSERVATION", 6, 11]]], ["The samples were considered to be high IgG if the IgG level was greater than 6400 (6 months) (31 patients high out of 50) or greater than 3200 (12 months) (20 patients out of 50).", [["samples", "ANATOMY", 4, 11], ["samples", "CANCER", 4, 11], ["IgG", "GENE_OR_GENE_PRODUCT", 39, 42], ["IgG", "GENE_OR_GENE_PRODUCT", 50, 53], ["patients", "ORGANISM", 97, 105], ["patients", "ORGANISM", 159, 167], ["IgG", "PROTEIN", 39, 42], ["IgG", "PROTEIN", 50, 53], ["patients", "SPECIES", 97, 105], ["patients", "SPECIES", 159, 167], ["The samples", "TEST", 0, 11], ["high IgG", "TEST", 34, 42], ["the IgG level", "TEST", 46, 59]]], ["IgG levels below or equal to these thresholds were considered low IgG.", [["IgG", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgG", "GENE_OR_GENE_PRODUCT", 66, 69], ["IgG", "PROTEIN", 0, 3], ["IgG", "PROTEIN", 66, 69], ["IgG levels", "TEST", 0, 10], ["these thresholds", "TEST", 29, 45], ["low IgG", "PROBLEM", 62, 69]]], ["CHIKV patients were considered to be non-symptomatic (15 patients out of 50 at the 6-month follow-up; 34 patients out of 50 at the 12 month follow-up), have mild symptoms (21 patients out of 50 a the 6 month follow-up; 14 patients out of 50 at the 12 month followup), or have severe symptoms (14 patients out of 50 at the 6 month follow-up; 2 patients out of 50 at the 12 month follow-up) based on their responses to a questionnaire at the time of sampling which was based on: articular pain, muscle pain, mono-arthritis, oligoarthritis, symmetric polyarthritis, asymmetric polyarthritis, tenosynovitis, arthralgia and fibromyalgia.", [["articular", "ANATOMY", 477, 486], ["muscle", "ANATOMY", 493, 499], ["articular pain", "DISEASE", 477, 491], ["muscle pain", "DISEASE", 493, 504], ["mono-arthritis", "DISEASE", 506, 520], ["oligoarthritis", "DISEASE", 522, 536], ["polyarthritis", "DISEASE", 548, 561], ["polyarthritis", "DISEASE", 574, 587], ["tenosynovitis", "DISEASE", 589, 602], ["arthralgia", "DISEASE", 604, 614], ["fibromyalgia", "DISEASE", 619, 631], ["CHIKV", "ORGANISM", 0, 5], ["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 57, 65], ["patients", "ORGANISM", 105, 113], ["patients", "ORGANISM", 175, 183], ["patients", "ORGANISM", 222, 230], ["patients", "ORGANISM", 296, 304], ["patients", "ORGANISM", 343, 351], ["articular", "TISSUE", 477, 486], ["muscle", "ORGAN", 493, 499], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 105, 113], ["patients", "SPECIES", 175, 183], ["patients", "SPECIES", 222, 230], ["patients", "SPECIES", 296, 304], ["patients", "SPECIES", 343, 351], ["CHIKV", "SPECIES", 0, 5], ["CHIKV", "PROBLEM", 0, 5], ["non-symptomatic", "PROBLEM", 37, 52], ["mild symptoms", "PROBLEM", 157, 170], ["severe symptoms", "PROBLEM", 276, 291], ["articular pain", "PROBLEM", 477, 491], ["muscle pain", "PROBLEM", 493, 504], ["mono-arthritis", "PROBLEM", 506, 520], ["oligoarthritis", "PROBLEM", 522, 536], ["symmetric polyarthritis", "PROBLEM", 538, 561], ["asymmetric polyarthritis", "PROBLEM", 563, 587], ["tenosynovitis", "PROBLEM", 589, 602], ["arthralgia", "PROBLEM", 604, 614], ["fibromyalgia", "PROBLEM", 619, 631], ["mild", "OBSERVATION_MODIFIER", 157, 161], ["severe", "OBSERVATION_MODIFIER", 276, 282], ["articular", "ANATOMY", 477, 486], ["muscle", "ANATOMY", 493, 499], ["oligoarthritis", "OBSERVATION", 522, 536], ["symmetric", "OBSERVATION_MODIFIER", 538, 547], ["polyarthritis", "OBSERVATION", 548, 561], ["asymmetric", "OBSERVATION_MODIFIER", 563, 573], ["polyarthritis", "OBSERVATION", 574, 587], ["tenosynovitis", "OBSERVATION", 589, 602], ["arthralgia", "OBSERVATION", 604, 614], ["fibromyalgia", "OBSERVATION", 619, 631]]], ["Control samples were collected from 10 healthy volunteers screened for symptoms of viral infection.Patient sample collectionBlood samples were collected from consenting CHIKV positive patients at the time of diagnosis.", [["samples", "ANATOMY", 8, 15], ["sample", "ANATOMY", 107, 113], ["Blood samples", "ANATOMY", 124, 137], ["viral infection", "DISEASE", 83, 98], ["Control samples", "CANCER", 0, 15], ["volunteers", "ORGANISM", 47, 57], ["Blood samples", "ORGANISM_SUBSTANCE", 124, 137], ["CHIKV", "ORGANISM", 169, 174], ["patients", "ORGANISM", 184, 192], ["Patient", "SPECIES", 99, 106], ["patients", "SPECIES", 184, 192], ["CHIKV", "SPECIES", 169, 174], ["Control samples", "TEST", 0, 15], ["symptoms", "PROBLEM", 71, 79], ["viral infection", "PROBLEM", 83, 98], ["Patient sample collectionBlood samples", "TEST", 99, 137], ["viral", "OBSERVATION_MODIFIER", 83, 88], ["infection", "OBSERVATION", 89, 98]]], ["Viral infection was determined as described above.", [["Viral infection", "DISEASE", 0, 15], ["Viral", "ORGANISM", 0, 5], ["Viral infection", "PROBLEM", 0, 15], ["infection", "OBSERVATION", 6, 15]]], ["Two follow-up samples were then collected from each patient at the 6-month evaluation and the 12-monthAuthor SummaryChikungunya virus (CHIKV) is transmitted by mosquitoes and causes a human disease clinically characterized by sudden appearance of high fever, rash, headache, nausea, and severe joint pain (the defining symptom).", [["samples", "ANATOMY", 14, 21], ["joint", "ANATOMY", 294, 299], ["Chikungunya virus (CHIKV) is transmitted by mosquitoes", "DISEASE", 116, 170], ["fever", "DISEASE", 252, 257], ["rash", "DISEASE", 259, 263], ["headache", "DISEASE", 265, 273], ["nausea", "DISEASE", 275, 281], ["joint pain", "DISEASE", 294, 304], ["patient", "ORGANISM", 52, 59], ["Chikungunya virus", "ORGANISM", 116, 133], ["CHIKV", "ORGANISM", 135, 140], ["human", "ORGANISM", 184, 189], ["joint", "ORGANISM_SUBDIVISION", 294, 299], ["patient", "SPECIES", 52, 59], ["Chikungunya virus", "SPECIES", 116, 133], ["human", "SPECIES", 184, 189], ["Chikungunya virus", "SPECIES", 116, 133], ["CHIKV", "SPECIES", 135, 140], ["human", "SPECIES", 184, 189], ["evaluation", "TEST", 75, 85], ["Chikungunya virus", "PROBLEM", 116, 133], ["CHIKV", "PROBLEM", 135, 140], ["a human disease", "PROBLEM", 182, 197], ["high fever", "PROBLEM", 247, 257], ["rash", "PROBLEM", 259, 263], ["headache", "PROBLEM", 265, 273], ["nausea", "PROBLEM", 275, 281], ["severe joint pain", "PROBLEM", 287, 304], ["the defining symptom", "PROBLEM", 306, 326], ["high", "OBSERVATION_MODIFIER", 247, 251], ["fever", "OBSERVATION", 252, 257], ["severe", "OBSERVATION_MODIFIER", 287, 293], ["joint", "ANATOMY", 294, 299], ["pain", "OBSERVATION", 300, 304]]], ["Chikungunya was identified in Africa and the word Chikungunya means that which bends up, describing the bent posture of CHIKV patients while in severe pain.", [["Chikungunya", "DISEASE", 0, 11], ["Chikungunya", "DISEASE", 50, 61], ["CHIKV", "DISEASE", 120, 125], ["pain", "DISEASE", 151, 155], ["Chikungunya", "ORGANISM", 0, 11], ["CHIKV", "ORGANISM", 120, 125], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["CHIKV", "SPECIES", 120, 125], ["Chikungunya", "PROBLEM", 0, 11], ["CHIKV", "PROBLEM", 120, 125], ["severe pain", "PROBLEM", 144, 155], ["CHIKV", "OBSERVATION", 120, 125], ["severe", "OBSERVATION_MODIFIER", 144, 150], ["pain", "OBSERVATION", 151, 155]]], ["CHIKV, a current problem in Africa, Indian Ocean region, and Southeast Asia, is now spreading to temperate regions of North America, France and Italy.", [["CHIKV", "DISEASE", 0, 5], ["CHIKV", "ORGANISM", 0, 5], ["CHIKV", "SPECIES", 0, 5], ["CHIKV", "PROBLEM", 0, 5]]], ["Presently, the immune response for CHIKV infection remains largely uninvestigated and no treatment is available.", [["CHIKV infection", "DISEASE", 35, 50], ["CHIKV", "ORGANISM", 35, 40], ["CHIKV", "SPECIES", 35, 40], ["CHIKV infection", "PROBLEM", 35, 50], ["treatment", "TREATMENT", 89, 98]]], ["We investigated cytokine profiles at diagnosis and follow-up of CHIKV infected patients during the Italian 2007 outbreak and associated cytokine levels with antibody level and symptom severity.", [["CHIKV infected", "DISEASE", 64, 78], ["CHIKV", "ORGANISM", 64, 69], ["patients", "ORGANISM", 79, 87], ["cytokine", "PROTEIN", 16, 24], ["cytokine", "PROTEIN", 136, 144], ["patients", "SPECIES", 79, 87], ["CHIKV", "SPECIES", 64, 69], ["cytokine profiles", "TEST", 16, 33], ["CHIKV", "PROBLEM", 64, 69], ["cytokine levels", "TEST", 136, 151], ["antibody level", "TEST", 157, 171], ["symptom severity", "PROBLEM", 176, 192]]], ["Cytokines, important immune mediators, are often drug targets.", [["Cytokines", "PROTEIN", 0, 9], ["immune mediators", "PROTEIN", 21, 37], ["Cytokines", "TREATMENT", 0, 9]]], ["Since CHIKV symptoms can persist for months or years following infection it is important to investigate possible drug targets to alleviate discomfort.", [["CHIKV symptoms", "DISEASE", 6, 20], ["infection", "DISEASE", 63, 72], ["CHIKV", "ORGANISM", 6, 11], ["CHIKV", "SPECIES", 6, 11], ["CHIKV symptoms", "PROBLEM", 6, 20], ["infection", "PROBLEM", 63, 72], ["drug targets", "TREATMENT", 113, 125], ["discomfort", "PROBLEM", 139, 149]]], ["We found cytokine profiles that describe the initial infection and recovery phase.", [["infection", "DISEASE", 53, 62], ["cytokine", "PROTEIN", 9, 17], ["cytokine profiles", "PROBLEM", 9, 26], ["the initial infection", "PROBLEM", 41, 62], ["cytokine profiles", "OBSERVATION", 9, 26], ["infection", "OBSERVATION", 53, 62]]], ["We determined the cytokines CXCL9/MIG and CXCL10/IP-10 as well as antibody levels were associated with symptom severity.", [["CXCL9", "GENE_OR_GENE_PRODUCT", 28, 33], ["MIG", "GENE_OR_GENE_PRODUCT", 34, 37], ["CXCL10", "GENE_OR_GENE_PRODUCT", 42, 48], ["IP-10", "GENE_OR_GENE_PRODUCT", 49, 54], ["cytokines", "PROTEIN", 18, 27], ["CXCL9", "PROTEIN", 28, 33], ["MIG", "PROTEIN", 34, 37], ["CXCL10", "PROTEIN", 42, 48], ["IP-10", "PROTEIN", 49, 54], ["the cytokines CXCL9", "TEST", 14, 33], ["MIG", "TEST", 34, 37], ["CXCL10/IP", "TEST", 42, 51], ["antibody levels", "TEST", 66, 81], ["symptom severity", "PROBLEM", 103, 119]]], ["These results reflect previously unreported cytokine profiles which may be important for the development of future therapeutics for CHIKV outbreaks.Author SummaryInflammatory Cytokines Resolve Chikungunya Disease www.plosntds.org evaluation.", [["CHIKV", "DISEASE", 132, 137], ["Chikungunya Disease", "DISEASE", 193, 212], ["CHIKV", "ORGANISM", 132, 137], ["cytokine", "PROTEIN", 44, 52], ["Cytokines", "PROTEIN", 175, 184], ["CHIKV", "SPECIES", 132, 137], ["previously unreported cytokine profiles", "PROBLEM", 22, 61], ["future therapeutics", "TREATMENT", 108, 127], ["CHIKV outbreaks", "PROBLEM", 132, 147], ["Chikungunya Disease", "PROBLEM", 193, 212], ["plosntds.org evaluation", "TEST", 217, 240], ["cytokine profiles", "OBSERVATION", 44, 61]]], ["After sampling, serum was extracted and immediately frozen at 280uC until serum analysis.CBASerum samples were analyzed for cytokine levels using BD TM Cytometric Bead Array (CBA) Human Chemokine Kit, Human Inflammatory Cytokine Kit, and Human Th1/Th2 Cytokine Kit (BD Biosciences) according to the manufacturer's instructions for a total of 13 cytokines.", [["serum", "ANATOMY", 16, 21], ["serum", "ANATOMY", 74, 79], ["CBASerum samples", "ANATOMY", 89, 105], ["serum", "ORGANISM_SUBSTANCE", 16, 21], ["serum", "ORGANISM_SUBSTANCE", 74, 79], ["CBASerum samples", "CANCER", 89, 105], ["Human", "ORGANISM", 180, 185], ["Kit", "GENE_OR_GENE_PRODUCT", 196, 199], ["Human", "ORGANISM", 201, 206], ["Kit", "GENE_OR_GENE_PRODUCT", 229, 232], ["Human", "ORGANISM", 238, 243], ["cytokine", "PROTEIN", 124, 132], ["BD TM Cytometric Bead Array (CBA) Human Chemokine Kit", "PROTEIN", 146, 199], ["Human Inflammatory Cytokine Kit", "PROTEIN", 201, 232], ["Human Th1/Th2 Cytokine Kit", "PROTEIN", 238, 264], ["cytokines", "PROTEIN", 345, 354], ["Human", "SPECIES", 180, 185], ["Human", "SPECIES", 201, 206], ["Human", "SPECIES", 238, 243], ["Human", "SPECIES", 180, 185], ["Human", "SPECIES", 201, 206], ["sampling", "TEST", 6, 14], ["serum", "TEST", 16, 21], ["serum analysis", "TEST", 74, 88], ["CBASerum samples", "TEST", 89, 105], ["cytokine levels", "TEST", 124, 139], ["BD TM", "TEST", 146, 151], ["Human Chemokine Kit", "TEST", 180, 199], ["Human Inflammatory Cytokine Kit", "TEST", 201, 232], ["Human Th1/Th2 Cytokine Kit (BD Biosciences", "TREATMENT", 238, 280]]], ["Capture Beads were added to the serum sample followed by the PE detection reagent.", [["serum sample", "ANATOMY", 32, 44], ["serum", "ORGANISM_SUBSTANCE", 32, 37], ["Capture Beads", "TREATMENT", 0, 13], ["the serum sample", "TEST", 28, 44], ["the PE detection reagent", "TREATMENT", 57, 81], ["PE", "OBSERVATION", 61, 63]]], ["The samples were then incubated for 3 hours at room temperature and washed with the assay Wash Buffer and resuspended again in Wash Buffer for analysis on the Flow Cytometer.", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11], ["the assay Wash Buffer", "TREATMENT", 80, 101], ["the Flow Cytometer", "TEST", 155, 173]]], ["CBAs were then run on a BD FACSCalibur Flow Cytometer.Statistical analysisCBA data was analysed using SPSS statistical software.", [["CBAs", "SIMPLE_CHEMICAL", 0, 4], ["a BD FACSCalibur Flow Cytometer", "TREATMENT", 22, 53], ["Statistical analysisCBA data", "TEST", 54, 82], ["SPSS statistical software", "TEST", 102, 127]]], ["Boxwhisker plots were created from the CBA FACS raw data.", [["Boxwhisker plots", "PROBLEM", 0, 16], ["the CBA FACS", "TEST", 35, 47]]], ["Sixmonth and 12-month samples were compared to the acute samples using the non-parametric two-tailed Wilcoxon signedrank test for related samples to determine statistical significance.", [["samples", "ANATOMY", 22, 29], ["the acute samples", "TEST", 47, 64], ["tailed Wilcoxon signedrank test", "TEST", 94, 125]]], ["Each acute phase, 6-month and 12-month cytokine sample sets were statistically compared to healthy control CBA data using the non-parametric two-tailed Mann Whitney Test for unrelated samples.ResultsCHIKV resolution is associated with differential cytokine programs of increasing and decreasing trends CHIKV causes a disease of crippling joint pain that has affected most of Asia and has demonstrated the capability to spread to nontropical areas such as Europe and parts of North America [1] .", [["samples", "ANATOMY", 184, 191], ["joint", "ANATOMY", 338, 343], ["CHIKV", "DISEASE", 302, 307], ["joint pain", "DISEASE", 338, 348], ["CHIKV", "ORGANISM", 302, 307], ["joint", "ORGANISM_SUBDIVISION", 338, 343], ["cytokine", "PROTEIN", 39, 47], ["cytokine", "PROTEIN", 248, 256], ["CHIKV", "SPECIES", 302, 307], ["cytokine sample sets", "TEST", 39, 59], ["unrelated samples", "TEST", 174, 191], ["differential cytokine programs", "TREATMENT", 235, 265], ["a disease of crippling joint pain", "PROBLEM", 315, 348], ["the capability", "PROBLEM", 401, 415], ["associated with", "UNCERTAINTY", 219, 234], ["differential", "OBSERVATION_MODIFIER", 235, 247], ["increasing", "OBSERVATION_MODIFIER", 269, 279], ["decreasing", "OBSERVATION_MODIFIER", 284, 294], ["crippling", "OBSERVATION_MODIFIER", 328, 337], ["joint", "ANATOMY", 338, 343]]], ["Cytokines are inflammatory mediators and their balance is often associated with inflammatory disease [23] .", [["Cytokines", "PROTEIN", 0, 9], ["inflammatory mediators", "PROTEIN", 14, 36], ["inflammatory mediators", "PROBLEM", 14, 36], ["inflammatory disease", "PROBLEM", 80, 100], ["inflammatory", "OBSERVATION_MODIFIER", 14, 26], ["inflammatory", "OBSERVATION_MODIFIER", 80, 92]]], ["Previously, the cytokine profiles of acute phase CHIKV patients have been examined [22] .", [["CHIKV", "ORGANISM", 49, 54], ["patients", "ORGANISM", 55, 63], ["cytokine", "PROTEIN", 16, 24], ["patients", "SPECIES", 55, 63], ["CHIKV", "SPECIES", 49, 54], ["the cytokine profiles", "TEST", 12, 33], ["acute phase CHIKV", "PROBLEM", 37, 54], ["acute", "OBSERVATION_MODIFIER", 37, 42]]], ["Here we profiled cytokine levels in acute phase and 6-and 12month follow-up CHIKV patient serum samples to determine a cytokine signature that may correlate with acute symptoms, following persistent joint pain and/or disease resolution.", [["serum samples", "ANATOMY", 90, 103], ["joint", "ANATOMY", 199, 204], ["pain", "DISEASE", 205, 209], ["CHIKV", "ORGANISM", 76, 81], ["patient", "ORGANISM", 82, 89], ["serum samples", "ORGANISM_SUBSTANCE", 90, 103], ["joint", "MULTI-TISSUE_STRUCTURE", 199, 204], ["cytokine", "PROTEIN", 17, 25], ["cytokine", "PROTEIN", 119, 127], ["patient", "SPECIES", 82, 89], ["CHIKV", "SPECIES", 76, 81], ["cytokine levels", "TEST", 17, 32], ["acute phase", "TEST", 36, 47], ["serum samples", "TEST", 90, 103], ["a cytokine signature", "TEST", 117, 137], ["acute symptoms", "PROBLEM", 162, 176], ["persistent joint pain", "PROBLEM", 188, 209], ["disease resolution", "PROBLEM", 217, 235], ["acute phase", "OBSERVATION_MODIFIER", 36, 47], ["may correlate with", "UNCERTAINTY", 143, 161], ["acute", "OBSERVATION_MODIFIER", 162, 167], ["persistent", "OBSERVATION_MODIFIER", 188, 198], ["joint", "ANATOMY", 199, 204], ["pain", "OBSERVATION", 205, 209]]], ["Blood samples were collected from 50 patients suffering from CHIKV infections during the 2007 Italian outbreak.", [["Blood samples", "ANATOMY", 0, 13], ["CHIKV infections", "DISEASE", 61, 77], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["patients", "ORGANISM", 37, 45], ["CHIKV", "ORGANISM", 61, 66], ["patients", "SPECIES", 37, 45], ["CHIKV", "SPECIES", 61, 66], ["Blood samples", "TEST", 0, 13], ["CHIKV infections", "PROBLEM", 61, 77], ["CHIKV infections", "OBSERVATION", 61, 77]]], ["Serum separated from whole blood was analyzed by cytokine bead analysis (CBA) for 13 cytokines with the intention of determining a cytokine profile during CHIKV acute phase and disease convalescence.", [["Serum", "ANATOMY", 0, 5], ["whole blood", "ANATOMY", 21, 32], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["blood", "ORGANISM_SUBSTANCE", 27, 32], ["cytokine", "PROTEIN", 49, 57], ["cytokines", "PROTEIN", 85, 94], ["cytokine", "PROTEIN", 131, 139], ["CHIKV", "SPECIES", 155, 160], ["Serum", "TEST", 0, 5], ["whole blood", "TEST", 21, 32], ["cytokine bead analysis", "TEST", 49, 71], ["CBA", "TEST", 73, 76], ["a cytokine profile", "TEST", 129, 147], ["CHIKV acute phase", "PROBLEM", 155, 172], ["disease convalescence", "PROBLEM", 177, 198]]], ["Three cytokine profiles emerged from our data: decreasing, increasing and no-trend.ResultsThe first trend showed cytokine levels significantly higher in the acute samples compared to the follow-up time points revealing a decreasing pattern as patients left the acute phase.", [["samples", "ANATOMY", 163, 170], ["patients", "ORGANISM", 243, 251], ["cytokine", "PROTEIN", 6, 14], ["cytokine", "PROTEIN", 113, 121], ["patients", "SPECIES", 243, 251], ["Three cytokine profiles", "TEST", 0, 23], ["our data", "TEST", 37, 45], ["cytokine levels", "TEST", 113, 128], ["the acute samples", "PROBLEM", 153, 170], ["a decreasing pattern", "PROBLEM", 219, 239], ["decreasing", "OBSERVATION_MODIFIER", 47, 57], ["increasing", "OBSERVATION_MODIFIER", 59, 69], ["higher", "OBSERVATION_MODIFIER", 143, 149], ["acute", "OBSERVATION_MODIFIER", 157, 162], ["decreasing", "OBSERVATION_MODIFIER", 221, 231], ["left", "ANATOMY_MODIFIER", 252, 256], ["acute", "OBSERVATION_MODIFIER", 261, 266]]], ["CXCL9/MIG (CXCL9), IL-6, CCL2/MCP-1(CXCL2) and CXCL10/IP-10 (CXCL10) cytokines had significantly decreased at both 6-month and 12-month follow-ups ( Figure 1) .", [["CXCL9", "GENE_OR_GENE_PRODUCT", 0, 5], ["MIG", "GENE_OR_GENE_PRODUCT", 6, 9], ["CXCL9", "GENE_OR_GENE_PRODUCT", 11, 16], ["IL-6", "GENE_OR_GENE_PRODUCT", 19, 23], ["CCL2", "GENE_OR_GENE_PRODUCT", 25, 29], ["MCP-1", "GENE_OR_GENE_PRODUCT", 30, 35], ["CXCL2", "GENE_OR_GENE_PRODUCT", 36, 41], ["CXCL10", "GENE_OR_GENE_PRODUCT", 47, 53], ["IP-10", "GENE_OR_GENE_PRODUCT", 54, 59], ["CXCL10", "GENE_OR_GENE_PRODUCT", 61, 67], ["CXCL9", "PROTEIN", 0, 5], ["MIG", "PROTEIN", 6, 9], ["CXCL9", "PROTEIN", 11, 16], ["IL-6", "PROTEIN", 19, 23], ["CCL2", "PROTEIN", 25, 29], ["MCP-1", "PROTEIN", 30, 35], ["CXCL2", "PROTEIN", 36, 41], ["CXCL10", "PROTEIN", 47, 53], ["CXCL10", "PROTEIN", 61, 67], ["cytokines", "PROTEIN", 69, 78], ["CXCL9", "TEST", 0, 5], ["MIG", "TEST", 6, 9], ["CXCL9", "TEST", 11, 16], ["IL", "TEST", 19, 21], ["CCL2", "TEST", 25, 29], ["MCP", "TEST", 30, 33], ["CXCL2", "TEST", 36, 41], ["CXCL10/IP", "TEST", 47, 56], ["CXCL10) cytokines", "TEST", 61, 78]]], ["Interestingly, some patients had extremely high levels in the acute phase; CXCL9 and CXCL10 levels decreased 1000 fold to 10,000 fold during convalescence.", [["patients", "ORGANISM", 20, 28], ["CXCL9", "GENE_OR_GENE_PRODUCT", 75, 80], ["CXCL10", "GENE_OR_GENE_PRODUCT", 85, 91], ["CXCL9", "PROTEIN", 75, 80], ["CXCL10", "PROTEIN", 85, 91], ["patients", "SPECIES", 20, 28], ["extremely high levels", "PROBLEM", 33, 54], ["CXCL9", "TEST", 75, 80], ["CXCL10 levels", "TEST", 85, 98]]], ["Furthermore, the decreasing trends for IL-6, CXCL9, and CXCL10 reached similar levels as those of the community control levels (shown by dotted line).", [["IL-6", "GENE_OR_GENE_PRODUCT", 39, 43], ["CXCL9", "GENE_OR_GENE_PRODUCT", 45, 50], ["CXCL10", "GENE_OR_GENE_PRODUCT", 56, 62], ["IL-6", "PROTEIN", 39, 43], ["CXCL9", "PROTEIN", 45, 50], ["CXCL10", "PROTEIN", 56, 62], ["IL", "TEST", 39, 41], ["CXCL9", "TEST", 45, 50], ["CXCL10", "TEST", 56, 62], ["the community control levels", "TEST", 98, 126], ["decreasing", "OBSERVATION_MODIFIER", 17, 27]]], ["CCL2 levels decreased significantly lower than the control levels by 12 months.", [["CCL2", "GENE_OR_GENE_PRODUCT", 0, 4], ["CCL2", "PROTEIN", 0, 4], ["CCL2 levels", "TEST", 0, 11], ["decreased", "OBSERVATION_MODIFIER", 12, 21], ["significantly", "OBSERVATION_MODIFIER", 22, 35], ["lower", "OBSERVATION_MODIFIER", 36, 41]]], ["Taken together, this data demonstrated that CXCL9, IL-6, CCL2 and CXCL10 were initially increased with acute CHIKV infection and decreased over time.ResultsThe second cytokine trend that emerged described cytokines that significantly increased following the acute phase.", [["CHIKV infection", "DISEASE", 109, 124], ["CXCL9", "GENE_OR_GENE_PRODUCT", 44, 49], ["IL-6", "GENE_OR_GENE_PRODUCT", 51, 55], ["CCL2", "GENE_OR_GENE_PRODUCT", 57, 61], ["CXCL10", "GENE_OR_GENE_PRODUCT", 66, 72], ["CHIKV", "ORGANISM", 109, 114], ["CXCL9", "PROTEIN", 44, 49], ["IL-6", "PROTEIN", 51, 55], ["CCL2", "PROTEIN", 57, 61], ["CXCL10", "PROTEIN", 66, 72], ["cytokine", "PROTEIN", 167, 175], ["cytokines", "PROTEIN", 205, 214], ["CHIKV", "SPECIES", 109, 114], ["this data", "TEST", 16, 25], ["CXCL9", "TEST", 44, 49], ["IL", "TEST", 51, 53], ["CCL2", "TEST", 57, 61], ["CXCL10", "TEST", 66, 72], ["acute CHIKV infection", "PROBLEM", 103, 124], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["acute", "OBSERVATION_MODIFIER", 103, 108], ["CHIKV", "OBSERVATION_MODIFIER", 109, 114], ["infection", "OBSERVATION", 115, 124], ["decreased", "OBSERVATION_MODIFIER", 129, 138]]], ["Cytokine profiles that were markedly lower in the acute phase and subsequently increased included IL-1b, TNF-a, IL-12, IL-5, IL-10 and IFN-c ( Figure 2 ).", [["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["IL-1b", "GENE_OR_GENE_PRODUCT", 98, 103], ["TNF-a", "GENE_OR_GENE_PRODUCT", 105, 110], ["IL-12", "GENE_OR_GENE_PRODUCT", 112, 117], ["IL-5", "GENE_OR_GENE_PRODUCT", 119, 123], ["IL-10", "GENE_OR_GENE_PRODUCT", 125, 130], ["IFN-c", "GENE_OR_GENE_PRODUCT", 135, 140], ["Cytokine", "PROTEIN", 0, 8], ["TNF", "PROTEIN", 105, 108], ["IL", "PROTEIN", 125, 127], ["IFN", "PROTEIN", 135, 138], ["Cytokine profiles", "TEST", 0, 17], ["IL", "TEST", 98, 100], ["TNF", "TEST", 105, 108], ["IL", "TEST", 112, 114], ["IL", "TEST", 119, 121], ["IL", "TEST", 125, 127], ["IFN", "TEST", 135, 138], ["markedly", "OBSERVATION_MODIFIER", 28, 36], ["lower", "OBSERVATION_MODIFIER", 37, 42], ["acute phase", "OBSERVATION_MODIFIER", 50, 61], ["increased", "OBSERVATION_MODIFIER", 79, 88]]], ["The cytokine increase was more gradual than the previous decreasing trend, where fold changes were generally closer to 2.", [["cytokine", "PROTEIN", 4, 12], ["The cytokine increase", "PROBLEM", 0, 21], ["fold changes", "PROBLEM", 81, 93], ["cytokine", "OBSERVATION_MODIFIER", 4, 12], ["increase", "OBSERVATION_MODIFIER", 13, 21], ["more", "OBSERVATION_MODIFIER", 26, 30], ["gradual", "OBSERVATION_MODIFIER", 31, 38], ["decreasing", "OBSERVATION_MODIFIER", 57, 67], ["trend", "OBSERVATION_MODIFIER", 68, 73]]], ["Both the 6-and 12-month follow-up were statistically increased compared to acute values for IL-5 levels.", [["IL-5", "GENE_OR_GENE_PRODUCT", 92, 96], ["IL", "PROTEIN", 92, 94], ["acute values", "TEST", 75, 87], ["increased", "OBSERVATION_MODIFIER", 53, 62], ["acute", "OBSERVATION_MODIFIER", 75, 80]]], ["IL-1b, TNF-a, IL-12, IL-10 and IFN-c had significantly increased by 12 months.", [["IL-1b", "GENE_OR_GENE_PRODUCT", 0, 5], ["TNF-a", "GENE_OR_GENE_PRODUCT", 7, 12], ["IL-12", "GENE_OR_GENE_PRODUCT", 14, 19], ["IL-10", "GENE_OR_GENE_PRODUCT", 21, 26], ["IFN-c", "GENE_OR_GENE_PRODUCT", 31, 36], ["IL", "PROTEIN", 0, 2], ["TNF", "PROTEIN", 7, 10], ["IFN", "PROTEIN", 31, 34], ["IL", "TEST", 0, 2], ["TNF", "TEST", 7, 10], ["IL", "TEST", 14, 16], ["IL", "TEST", 21, 23], ["IFN", "TEST", 31, 34]]], ["Even though the average for these cytokines had also risen by 6 months it was not significant.", [["cytokines", "PROTEIN", 34, 43], ["these cytokines", "TEST", 28, 43], ["not", "UNCERTAINTY", 78, 81], ["significant", "OBSERVATION_MODIFIER", 82, 93]]], ["Furthermore, the increasing trends for TNF-a, IL-5, and IL-10 reached similar levels to the community control levels (shown by dotted line) and IFN-c reached significantly higher than controls at 12 months.", [["TNF-a", "GENE_OR_GENE_PRODUCT", 39, 44], ["IL-5", "GENE_OR_GENE_PRODUCT", 46, 50], ["IL-10", "GENE_OR_GENE_PRODUCT", 56, 61], ["IFN-c", "GENE_OR_GENE_PRODUCT", 144, 149], ["TNF", "PROTEIN", 39, 42], ["IL", "PROTEIN", 56, 58], ["IFN", "PROTEIN", 144, 147], ["TNF", "TEST", 39, 42], ["IL", "TEST", 46, 48], ["IL", "TEST", 56, 58], ["IFN", "TEST", 144, 147], ["increasing", "OBSERVATION_MODIFIER", 17, 27]]], ["Interestingly, although IL-1b and IL-12 increased through the observed time, these cytokines stayed significantly lower than those of the controls.", [["IL-1b", "GENE_OR_GENE_PRODUCT", 24, 29], ["IL-12", "GENE_OR_GENE_PRODUCT", 34, 39], ["IL", "PROTEIN", 24, 26], ["IL-12", "PROTEIN", 34, 39], ["cytokines", "PROTEIN", 83, 92], ["IL", "TEST", 24, 26], ["IL", "TEST", 34, 36], ["these cytokines", "TEST", 77, 92]]], ["This data showed that cytokines IL-1b, TNF-a, IL-12, IL-5, IL-10 and IFN-c increased in the convalescence phase of CHIKV infection.ResultsNo significant change was seen for IL-2, IL-4, and IL-8 from the acute phase to the 12-month follow-up ( Figure 3 ).", [["CHIKV infection", "DISEASE", 115, 130], ["IL-1b", "GENE_OR_GENE_PRODUCT", 32, 37], ["TNF-a", "GENE_OR_GENE_PRODUCT", 39, 44], ["IL-12", "GENE_OR_GENE_PRODUCT", 46, 51], ["IL-5", "GENE_OR_GENE_PRODUCT", 53, 57], ["IL-10", "GENE_OR_GENE_PRODUCT", 59, 64], ["IFN-c", "GENE_OR_GENE_PRODUCT", 69, 74], ["CHIKV", "ORGANISM", 115, 120], ["IL-2", "GENE_OR_GENE_PRODUCT", 173, 177], ["IL-4", "GENE_OR_GENE_PRODUCT", 179, 183], ["IL-8", "GENE_OR_GENE_PRODUCT", 189, 193], ["cytokines", "PROTEIN", 22, 31], ["TNF", "PROTEIN", 39, 42], ["IFN-c", "PROTEIN", 69, 74], ["IL", "PROTEIN", 173, 175], ["IL", "PROTEIN", 179, 181], ["IL-8", "PROTEIN", 189, 193], ["CHIKV", "SPECIES", 115, 120], ["This data", "TEST", 0, 9], ["cytokines IL", "TEST", 22, 34], ["TNF", "TEST", 39, 42], ["IL", "TEST", 46, 48], ["IL", "TEST", 53, 55], ["IL", "TEST", 59, 61], ["IFN", "TEST", 69, 72], ["CHIKV infection", "PROBLEM", 115, 130], ["significant change", "PROBLEM", 141, 159], ["IL", "TEST", 173, 175], ["increased", "OBSERVATION_MODIFIER", 75, 84], ["CHIKV infection", "OBSERVATION", 115, 130], ["No", "UNCERTAINTY", 138, 140], ["significant", "OBSERVATION_MODIFIER", 141, 152], ["change", "OBSERVATION", 153, 159]]], ["Interestingly, IL-2 reached similar levels to those of the controls where IL-8 and IL-4 remained significantly raised and lowered, respectively.", [["IL-2", "GENE_OR_GENE_PRODUCT", 15, 19], ["IL-8", "GENE_OR_GENE_PRODUCT", 74, 78], ["IL-4", "GENE_OR_GENE_PRODUCT", 83, 87], ["IL-2", "PROTEIN", 15, 19], ["IL", "PROTEIN", 83, 85], ["IL", "TEST", 74, 76], ["IL", "TEST", 83, 85]]], ["The median of CXCL10 in the viral stage was approximately 7000 pg/ml and dropped to less than 1000 pg/ml after seroconversion.", [["CXCL10", "GENE_OR_GENE_PRODUCT", 14, 20], ["CXCL10", "PROTEIN", 14, 20], ["CXCL10", "TEST", 14, 20], ["seroconversion", "PROBLEM", 111, 125], ["median", "OBSERVATION_MODIFIER", 4, 10], ["viral stage", "OBSERVATION_MODIFIER", 28, 39]]], ["Interestingly, the IL-10 median decreased by 3 fold from the viral stage to the seroconversion stage.ResultsNext we sought to determine if the high levels of IgG in the follow-up phases were also significantly associated with cytokine levels compared to the cytokine levels of patients with low levels of IgG.", [["IL-10", "GENE_OR_GENE_PRODUCT", 19, 24], ["IgG", "GENE_OR_GENE_PRODUCT", 158, 161], ["patients", "ORGANISM", 277, 285], ["IgG", "GENE_OR_GENE_PRODUCT", 305, 308], ["IL", "PROTEIN", 19, 21], ["IgG", "PROTEIN", 158, 161], ["cytokine", "PROTEIN", 226, 234], ["cytokine", "PROTEIN", 258, 266], ["IgG", "PROTEIN", 305, 308], ["patients", "SPECIES", 277, 285], ["the IL", "TREATMENT", 15, 21], ["the seroconversion stage", "PROBLEM", 76, 100], ["the high levels of IgG", "PROBLEM", 139, 161], ["cytokine levels", "TEST", 226, 241], ["the cytokine levels", "TEST", 254, 273], ["low levels of IgG", "PROBLEM", 291, 308], ["viral stage", "OBSERVATION_MODIFIER", 61, 72], ["seroconversion", "OBSERVATION", 80, 94]]], ["The patients were put into an IgG high group (H) or an IgG low group (L) and the levels of each cytokine were statistically compared for each group using the Mann-Whitney U Test.", [["patients", "ORGANISM", 4, 12], ["IgG", "PROTEIN", 30, 33], ["IgG", "PROTEIN", 55, 58], ["cytokine", "PROTEIN", 96, 104], ["patients", "SPECIES", 4, 12], ["an IgG", "TEST", 52, 58]]], ["In the 6-month follow-up phase CXCL9, CXCL10 and Il-6 were found to be statistically different between the high IgG group and the low IgG group ( Figure 5A ).", [["CXCL9", "GENE_OR_GENE_PRODUCT", 31, 36], ["CXCL10", "GENE_OR_GENE_PRODUCT", 38, 44], ["Il-6", "GENE_OR_GENE_PRODUCT", 49, 53], ["IgG", "GENE_OR_GENE_PRODUCT", 112, 115], ["CXCL9", "PROTEIN", 31, 36], ["CXCL10", "PROTEIN", 38, 44], ["Il-6", "PROTEIN", 49, 53], ["IgG group", "PROTEIN", 112, 121], ["IgG group", "PROTEIN", 134, 143], ["CXCL9", "TEST", 31, 36], ["CXCL10", "TEST", 38, 44], ["Il", "TEST", 49, 51], ["the high IgG group", "PROBLEM", 103, 121], ["low IgG", "OBSERVATION_MODIFIER", 130, 137]]], ["High levels of all 3 cytokines were associated with high levels of IgG antibodies.", [["IgG antibodies", "GENE_OR_GENE_PRODUCT", 67, 81], ["cytokines", "PROTEIN", 21, 30], ["IgG antibodies", "PROTEIN", 67, 81], ["High levels of all 3 cytokines", "PROBLEM", 0, 30], ["high levels of IgG antibodies", "PROBLEM", 52, 81], ["IgG antibodies", "OBSERVATION", 67, 81]]], ["IL-10 is also shown for comparison since it was statistically significant during the acute phase breakdown and the 12-month follow-up.", [["IL-10", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL", "PROTEIN", 0, 2], ["the acute phase breakdown", "PROBLEM", 81, 106], ["acute", "OBSERVATION_MODIFIER", 85, 90], ["phase", "OBSERVATION_MODIFIER", 91, 96]]], ["Interestingly, in the 12-month follow-up phase, CXCL9 was found to be statistically higher in the IgG high group where IL-10 was significantly lower in the high IgG group ( Figure 5B ).", [["CXCL9", "GENE_OR_GENE_PRODUCT", 48, 53], ["IL-10", "GENE_OR_GENE_PRODUCT", 119, 124], ["CXCL9", "PROTEIN", 48, 53], ["IgG", "PROTEIN", 98, 101], ["IL", "PROTEIN", 119, 121], ["IgG group", "PROTEIN", 161, 170], ["CXCL9", "TEST", 48, 53], ["the IgG", "TEST", 94, 101], ["IL", "TEST", 119, 121], ["higher", "OBSERVATION_MODIFIER", 84, 90]]], ["CXCL10 is shown for comparison at 12 months although it was not significantly different between the IgG high and IgG low groups.", [["CXCL10", "GENE_OR_GENE_PRODUCT", 0, 6], ["IgG", "GENE_OR_GENE_PRODUCT", 100, 103], ["CXCL10", "PROTEIN", 0, 6], ["IgG", "PROTEIN", 100, 103], ["IgG", "PROTEIN", 113, 116], ["CXCL10", "TEST", 0, 6], ["the IgG", "TEST", 96, 103], ["significantly different", "OBSERVATION_MODIFIER", 64, 87]]], ["In summary, the results suggested that CXCL9, CXCL10 and Il-6 were associated with IgG levels in the 6-month follow-up phase and CXCL9 and IL-10 in the 12month follow-up phase.ResultsInflammatory Cytokines Resolve Chikungunya Disease www.plosntds.org CXCL10, CXCL9 and IgG levels are possible biomarkers of CHIKV disease severity IL-1b, IL-6 and RANTES were found to be associated with symptom severity of the Singapore 2007 CHIKV outbreak [22] .", [["Chikungunya", "DISEASE", 214, 225], ["CXCL9", "GENE_OR_GENE_PRODUCT", 39, 44], ["CXCL10", "GENE_OR_GENE_PRODUCT", 46, 52], ["Il-6", "GENE_OR_GENE_PRODUCT", 57, 61], ["IgG", "GENE_OR_GENE_PRODUCT", 83, 86], ["CXCL9", "GENE_OR_GENE_PRODUCT", 129, 134], ["IL-10", "GENE_OR_GENE_PRODUCT", 139, 144], ["CXCL10", "GENE_OR_GENE_PRODUCT", 251, 257], ["CXCL9", "GENE_OR_GENE_PRODUCT", 259, 264], ["IgG", "GENE_OR_GENE_PRODUCT", 269, 272], ["CHIKV", "ORGANISM", 307, 312], ["IL-1b", "GENE_OR_GENE_PRODUCT", 330, 335], ["IL-6", "GENE_OR_GENE_PRODUCT", 337, 341], ["RANTES", "GENE_OR_GENE_PRODUCT", 346, 352], ["CXCL9", "PROTEIN", 39, 44], ["CXCL10", "PROTEIN", 46, 52], ["Il-6", "PROTEIN", 57, 61], ["IgG", "PROTEIN", 83, 86], ["CXCL9", "PROTEIN", 129, 134], ["IL", "PROTEIN", 139, 141], ["Inflammatory Cytokines", "PROTEIN", 183, 205], ["CXCL10", "PROTEIN", 251, 257], ["CXCL9", "PROTEIN", 259, 264], ["IgG", "PROTEIN", 269, 272], ["IL-6", "PROTEIN", 337, 341], ["RANTES", "PROTEIN", 346, 352], ["CHIKV", "SPECIES", 307, 312], ["Singapore 2007 CHIKV", "SPECIES", 410, 430], ["CXCL9", "TEST", 39, 44], ["CXCL10", "TEST", 46, 52], ["Il", "TEST", 57, 59], ["IgG levels", "TEST", 83, 93], ["CXCL9", "TEST", 129, 134], ["IL", "TEST", 139, 141], ["Inflammatory Cytokines", "PROBLEM", 183, 205], ["Chikungunya Disease", "PROBLEM", 214, 233], ["CXCL10", "TEST", 251, 257], ["CXCL9", "TEST", 259, 264], ["IgG levels", "TEST", 269, 279], ["biomarkers", "TEST", 293, 303], ["CHIKV disease severity IL", "PROBLEM", 307, 332], ["IL", "TEST", 337, 339], ["RANTES", "TEST", 346, 352], ["Inflammatory", "OBSERVATION_MODIFIER", 183, 195]]], ["After determining the cytokine profiles of our Italian 2007 CHIKV patients during their disease resolution, we next sought to determine the association between symptom severity and cytokine levels.", [["CHIKV", "DISEASE", 60, 65], ["CHIKV", "ORGANISM", 60, 65], ["patients", "ORGANISM", 66, 74], ["cytokine", "PROTEIN", 22, 30], ["cytokine", "PROTEIN", 181, 189], ["patients", "SPECIES", 66, 74], ["Italian 2007 CHIKV", "SPECIES", 47, 65], ["symptom severity", "PROBLEM", 160, 176], ["cytokine levels", "TEST", 181, 196]]], ["Patients were determined to be non-symptomatic (N), to have mild symptoms (M) or to have severe symptoms (S) depending on their responses to a questionnaire.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["non-symptomatic", "PROBLEM", 31, 46], ["mild symptoms", "PROBLEM", 60, 73], ["severe symptoms", "PROBLEM", 89, 104], ["mild", "OBSERVATION_MODIFIER", 60, 64], ["severe", "OBSERVATION_MODIFIER", 89, 95]]], ["The cytokine levels were then grouped by symptom level and a Mann-Whitney U test was used to determine significance among the severity groups for each cytokine.", [["cytokine", "PROTEIN", 4, 12], ["cytokine", "PROTEIN", 151, 159], ["The cytokine levels", "TEST", 0, 19], ["symptom level", "TEST", 41, 54], ["a Mann-Whitney U test", "TEST", 59, 80]]], ["CXCL10 and CXCL9 were found to be significantly increased in the patients with mild and severe symptoms at 6 months following initial infection compared to the patients reporting no symptoms ( Figure 6A) .", [["infection", "DISEASE", 134, 143], ["CXCL10", "GENE_OR_GENE_PRODUCT", 0, 6], ["CXCL9", "GENE_OR_GENE_PRODUCT", 11, 16], ["patients", "ORGANISM", 65, 73], ["patients", "ORGANISM", 160, 168], ["CXCL10", "PROTEIN", 0, 6], ["CXCL9", "PROTEIN", 11, 16], ["patients", "SPECIES", 65, 73], ["patients", "SPECIES", 160, 168], ["CXCL10", "TEST", 0, 6], ["CXCL9", "TEST", 11, 16], ["mild and severe symptoms", "PROBLEM", 79, 103], ["initial infection", "PROBLEM", 126, 143], ["symptoms", "PROBLEM", 182, 190], ["significantly", "OBSERVATION_MODIFIER", 34, 47], ["increased", "OBSERVATION_MODIFIER", 48, 57], ["mild", "OBSERVATION_MODIFIER", 79, 83], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["infection", "OBSERVATION", 134, 143]]], ["A 2 fold difference was seen between the medians of the non-symptomatic and severe patients for CXCL10 and a 5 fold difference for CXCL9.", [["patients", "ORGANISM", 83, 91], ["CXCL10", "GENE_OR_GENE_PRODUCT", 96, 102], ["CXCL9", "GENE_OR_GENE_PRODUCT", 131, 136], ["CXCL10", "PROTEIN", 96, 102], ["CXCL9", "PROTEIN", 131, 136], ["patients", "SPECIES", 83, 91], ["A 2 fold difference", "PROBLEM", 0, 19], ["CXCL10", "TEST", 96, 102], ["a 5 fold difference", "PROBLEM", 107, 126], ["CXCL9", "TEST", 131, 136], ["2 fold", "OBSERVATION_MODIFIER", 2, 8], ["difference", "OBSERVATION", 9, 19], ["non-symptomatic", "OBSERVATION_MODIFIER", 56, 71], ["severe", "OBSERVATION_MODIFIER", 76, 82]]], ["No statistical difference was seen for any of the 13 cytokines profiled for the 12-month follow-up.", [["cytokines", "PROTEIN", 53, 62], ["statistical", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25]]], ["CXCL10 and CXCL9 at 12 months are shown for comparison ( Figure 6B ).", [["CXCL10", "GENE_OR_GENE_PRODUCT", 0, 6], ["CXCL9", "GENE_OR_GENE_PRODUCT", 11, 16], ["CXCL10", "PROTEIN", 0, 6], ["CXCL9", "PROTEIN", 11, 16], ["CXCL10", "TEST", 0, 6], ["CXCL9", "TEST", 11, 16]]], ["Moreover, we analyzed the IgG levels at the 6-month follow-up in patients with no symptoms, mild symptoms, and severe symptoms.", [["IgG", "GENE_OR_GENE_PRODUCT", 26, 29], ["patients", "ORGANISM", 65, 73], ["IgG", "PROTEIN", 26, 29], ["patients", "SPECIES", 65, 73], ["the IgG levels", "TEST", 22, 36], ["symptoms", "PROBLEM", 82, 90], ["mild symptoms", "PROBLEM", 92, 105], ["severe symptoms", "PROBLEM", 111, 126], ["severe", "OBSERVATION_MODIFIER", 111, 117]]], ["The results showed IgG levels were statistically increased with Figure 1 .", [["IgG", "GENE_OR_GENE_PRODUCT", 19, 22], ["IgG", "PROTEIN", 19, 22], ["IgG levels", "TEST", 19, 29]]], ["Acute phase CHIKV disease was associated with high levels of IL-6, CXCL9, CCL2, CXCL10.", [["CHIKV disease", "DISEASE", 12, 25], ["CHIKV", "ORGANISM", 12, 17], ["IL-6", "GENE_OR_GENE_PRODUCT", 61, 65], ["CXCL9", "GENE_OR_GENE_PRODUCT", 67, 72], ["CCL2", "GENE_OR_GENE_PRODUCT", 74, 78], ["CXCL10", "GENE_OR_GENE_PRODUCT", 80, 86], ["IL-6", "PROTEIN", 61, 65], ["CXCL9", "PROTEIN", 67, 72], ["CCL2", "PROTEIN", 74, 78], ["CXCL10", "PROTEIN", 80, 86], ["CHIKV", "SPECIES", 12, 17], ["Acute phase CHIKV disease", "PROBLEM", 0, 25], ["IL", "TEST", 61, 63], ["CXCL9", "TEST", 67, 72], ["CXCL10", "TEST", 80, 86], ["phase", "OBSERVATION_MODIFIER", 6, 11], ["CHIKV", "OBSERVATION", 12, 17], ["CCL2", "ANATOMY", 74, 78]]], ["Cytokine Bead Array analysis of CHIKV patient serum samples showed high levels of IL-6, CXCL9, CCL2 and CXCL-10 are associated with acute disease phase and decreased with patient convalescence.", [["serum samples", "ANATOMY", 46, 59], ["CHIKV", "ORGANISM", 32, 37], ["patient", "ORGANISM", 38, 45], ["serum", "ORGANISM_SUBSTANCE", 46, 51], ["IL-6", "GENE_OR_GENE_PRODUCT", 82, 86], ["CXCL9", "GENE_OR_GENE_PRODUCT", 88, 93], ["CCL2", "GENE_OR_GENE_PRODUCT", 95, 99], ["CXCL-10", "GENE_OR_GENE_PRODUCT", 104, 111], ["patient", "ORGANISM", 171, 178], ["IL-6", "PROTEIN", 82, 86], ["CXCL9", "PROTEIN", 88, 93], ["CCL2", "PROTEIN", 95, 99], ["CXCL", "PROTEIN", 104, 108], ["patient", "SPECIES", 38, 45], ["patient", "SPECIES", 171, 178], ["CHIKV", "SPECIES", 32, 37], ["Cytokine Bead Array analysis", "TEST", 0, 28], ["CHIKV patient serum samples", "TEST", 32, 59], ["IL", "TEST", 82, 84], ["CXCL9", "TEST", 88, 93], ["CCL2", "TEST", 95, 99], ["CXCL", "TEST", 104, 108], ["acute disease phase", "PROBLEM", 132, 151], ["associated with", "UNCERTAINTY", 116, 131], ["acute", "OBSERVATION_MODIFIER", 132, 137], ["disease", "OBSERVATION", 138, 145], ["decreased", "OBSERVATION_MODIFIER", 156, 165]]], ["Six-month and one-year cytokine levels were analysed for statistical significance using the Wilcoxon test for Significance by comparing with acute levels.", [["cytokine", "PROTEIN", 23, 31], ["cytokine levels", "TEST", 23, 38], ["the Wilcoxon test", "TEST", 88, 105], ["acute levels", "TEST", 141, 153]]], ["All samples were also analyzed for significance against healthy controls by the Mann-Whitney U test.", [["samples", "ANATOMY", 4, 11], ["All samples", "TEST", 0, 11]]], ["The cross symbol indicates a p-value less than 0.05 for 6-and 12-month groups compared to acute values and star symbol indicates a p-value less than 0.05 for acute, 6-and 12-month groups compared to control values.", [["a p-value", "TEST", 27, 36], ["acute values", "TEST", 90, 102], ["star symbol", "TEST", 107, 118], ["a p-value", "TEST", 129, 138]]], ["The dotted line indicates the median of healthy control cytokine levels.", [["cytokine", "PROTEIN", 56, 64], ["The dotted line", "TREATMENT", 0, 15]]], ["Taken together, these results suggested CXCL10, CXCL9 and IgG to be possible markers of CHIKV severity during early phases of disease resolution.DiscussionCHIKV disease is a self-limiting disease caused by an alphavirus of the Togaviridae family.", [["DiscussionCHIKV disease", "DISEASE", 145, 168], ["CXCL10", "GENE_OR_GENE_PRODUCT", 40, 46], ["CXCL9", "GENE_OR_GENE_PRODUCT", 48, 53], ["IgG", "GENE_OR_GENE_PRODUCT", 58, 61], ["CHIKV", "ORGANISM", 88, 93], ["Togaviridae", "GENE_OR_GENE_PRODUCT", 227, 238], ["CXCL10", "PROTEIN", 40, 46], ["CXCL9", "PROTEIN", 48, 53], ["IgG", "PROTEIN", 58, 61], ["CHIKV", "SPECIES", 88, 93], ["CXCL10", "TEST", 40, 46], ["CXCL9", "TEST", 48, 53], ["IgG", "TEST", 58, 61], ["CHIKV severity", "PROBLEM", 88, 102], ["disease resolution", "PROBLEM", 126, 144], ["DiscussionCHIKV disease", "PROBLEM", 145, 168], ["a self-limiting disease", "PROBLEM", 172, 195], ["CHIKV", "OBSERVATION", 88, 93], ["self-limiting", "OBSERVATION_MODIFIER", 174, 187], ["disease", "OBSERVATION", 188, 195], ["alphavirus", "OBSERVATION", 209, 219]]], ["Although historically the virus only caused a disease of mild symptoms, a recent outbreak on La Reunion Island caused significant mortality due to genetic alterations [1, 20, 22, 25, 26] .", [["the virus", "PROBLEM", 22, 31], ["a disease of mild symptoms", "PROBLEM", 44, 70], ["genetic alterations", "PROBLEM", 147, 166], ["virus", "OBSERVATION", 26, 31], ["mild", "OBSERVATION_MODIFIER", 57, 61], ["symptoms", "OBSERVATION", 62, 70]]], ["Here we have investigated the immune response of an Italian population infected with the Indian Ocean genotype of CHIKV and have generated a cytokine signature for the initial infection to convalescence phase of CHIKV disease, the signature of viral and antibody production phases, and identified cytokines raised in patients with severe symptoms.", [["infection", "DISEASE", 176, 185], ["CHIKV disease", "DISEASE", 212, 225], ["CHIKV", "ORGANISM", 114, 119], ["CHIKV", "ORGANISM", 212, 217], ["patients", "ORGANISM", 317, 325], ["cytokine", "PROTEIN", 141, 149], ["cytokines", "PROTEIN", 297, 306], ["patients", "SPECIES", 317, 325], ["CHIKV", "SPECIES", 114, 119], ["CHIKV", "SPECIES", 212, 217], ["CHIKV", "PROBLEM", 114, 119], ["a cytokine signature", "PROBLEM", 139, 159], ["the initial infection", "PROBLEM", 164, 185], ["CHIKV disease", "PROBLEM", 212, 225], ["viral and antibody production phases", "TEST", 244, 280], ["cytokines", "PROBLEM", 297, 306], ["severe symptoms", "PROBLEM", 331, 346], ["infection", "OBSERVATION", 176, 185], ["CHIKV disease", "OBSERVATION", 212, 225]]], ["We found that initial Significance by comparing with acute phase values.", [["acute phase values", "TEST", 53, 71]]], ["As well, samples were analyzed for significance against healthy controls by the Mann-Whitney U test.", [["samples", "ANATOMY", 9, 16], ["samples", "TEST", 9, 16]]], ["The cross symbol indicates a p-value (Wilcoxon test) less than 0.05 for 6-and 12-month groups compared to acute values and star symbol indicates a p-value (Mann-Whitney U test) less than 0.05 acute, 6-and 12-month groups compared to control values.", [["a p-value (Wilcoxon test", "TEST", 27, 51], ["acute values", "TEST", 106, 118], ["a p-value", "TEST", 145, 154], ["Whitney U test", "TEST", 161, 175]]], ["The dotted line indicates the median of healthy control cytokine levels.", [["cytokine", "PROTEIN", 56, 64], ["The dotted line", "TREATMENT", 0, 15]]], ["Acute (A), 6-month follow-up (6), and 12-month follow-up (12 infection and the subsequent convalescence were described by a set of decreasing and increasing cytokines.", [["infection", "DISEASE", 61, 70], ["cytokines", "PROTEIN", 157, 166], ["12 infection", "PROBLEM", 58, 70], ["increasing cytokines", "PROBLEM", 146, 166], ["increasing", "OBSERVATION_MODIFIER", 146, 156], ["cytokines", "OBSERVATION", 157, 166]]], ["Furthermore, we have shown that CXCL10 and IL-10 levels were associated with the viral stage of the acute phase and CXCL10 and CXCL9 with high IgG levels of the 6-month follow-up.", [["CXCL10", "GENE_OR_GENE_PRODUCT", 32, 38], ["IL-10", "GENE_OR_GENE_PRODUCT", 43, 48], ["CXCL10", "GENE_OR_GENE_PRODUCT", 116, 122], ["CXCL9", "GENE_OR_GENE_PRODUCT", 127, 132], ["CXCL10", "PROTEIN", 32, 38], ["CXCL10", "PROTEIN", 116, 122], ["CXCL9", "PROTEIN", 127, 132], ["IgG", "PROTEIN", 143, 146], ["CXCL10 and IL-10 levels", "TEST", 32, 55], ["CXCL10", "TEST", 116, 122], ["CXCL9", "TEST", 127, 132], ["high IgG levels", "TEST", 138, 153], ["viral stage", "OBSERVATION_MODIFIER", 81, 92], ["acute", "OBSERVATION_MODIFIER", 100, 105]]], ["As well, CXCL10 and CXCL9 were markers of symptom severity.", [["CXCL10", "GENE_OR_GENE_PRODUCT", 9, 15], ["CXCL9", "GENE_OR_GENE_PRODUCT", 20, 25], ["CXCL10", "PROTEIN", 9, 15], ["CXCL9", "PROTEIN", 20, 25], ["CXCL10", "TEST", 9, 15], ["CXCL9", "TEST", 20, 25], ["symptom severity", "PROBLEM", 42, 58]]], ["Importantly, these identified signatures depict the immunological programs and may be key to the development of therapeutics for the frequently reemerging CHIKV disease.DiscussionOur analysis has indentified 2 cytokine profiles that followed disease onset and continued with disease progression/convalescence.", [["CHIKV disease", "DISEASE", 155, 168], ["CHIKV", "ORGANISM", 155, 160], ["cytokine", "PROTEIN", 210, 218], ["CHIKV", "SPECIES", 155, 160], ["therapeutics", "TREATMENT", 112, 124], ["CHIKV disease", "PROBLEM", 155, 168], ["DiscussionOur analysis", "TEST", 169, 191], ["2 cytokine profiles", "PROBLEM", 208, 227], ["disease onset", "PROBLEM", 242, 255], ["disease progression", "PROBLEM", 275, 294], ["convalescence", "PROBLEM", 295, 308], ["CHIKV", "OBSERVATION", 155, 160]]], ["We found CXCL9, CXCL10, CCL2 and IL-6 levels were high in the acute phase and decreased as patients convalesced.", [["CXCL9", "GENE_OR_GENE_PRODUCT", 9, 14], ["CXCL10", "GENE_OR_GENE_PRODUCT", 16, 22], ["CCL2", "GENE_OR_GENE_PRODUCT", 24, 28], ["IL-6", "GENE_OR_GENE_PRODUCT", 33, 37], ["patients", "ORGANISM", 91, 99], ["CXCL9", "PROTEIN", 9, 14], ["CXCL10", "PROTEIN", 16, 22], ["CCL2", "PROTEIN", 24, 28], ["patients", "SPECIES", 91, 99], ["CXCL9", "TEST", 9, 14], ["CXCL10", "TEST", 16, 22], ["CCL2", "TEST", 24, 28], ["IL", "TEST", 33, 35], ["CXCL9", "OBSERVATION", 9, 14], ["high", "OBSERVATION_MODIFIER", 50, 54], ["acute phase", "OBSERVATION_MODIFIER", 62, 73], ["decreased", "OBSERVATION_MODIFIER", 78, 87]]], ["Conversely, the trend for TNF-a, IL-1b, IL-2, IL-5 and IL-12 were low initially and increased as patients began to recover from acute illness.", [["acute illness", "DISEASE", 128, 141], ["TNF-a", "GENE_OR_GENE_PRODUCT", 26, 31], ["IL-1b", "GENE_OR_GENE_PRODUCT", 33, 38], ["IL-2", "GENE_OR_GENE_PRODUCT", 40, 44], ["IL-5", "GENE_OR_GENE_PRODUCT", 46, 50], ["IL-12", "GENE_OR_GENE_PRODUCT", 55, 60], ["patients", "ORGANISM", 97, 105], ["TNF", "PROTEIN", 26, 29], ["IL", "PROTEIN", 55, 57], ["patients", "SPECIES", 97, 105], ["TNF", "TEST", 26, 29], ["IL", "TEST", 33, 35], ["IL", "TEST", 40, 42], ["IL", "TEST", 46, 48], ["IL", "TEST", 55, 57], ["acute illness", "PROBLEM", 128, 141], ["acute", "OBSERVATION_MODIFIER", 128, 133], ["illness", "OBSERVATION", 134, 141]]], ["High levels of CXCL9, CXCL10, CCL2, and IL-6 in the acute phase possibly indicated an inflammatory program initiating adaptive T-cell immunity [27] .", [["T-cell", "ANATOMY", 127, 133], ["CXCL9", "GENE_OR_GENE_PRODUCT", 15, 20], ["CXCL10", "GENE_OR_GENE_PRODUCT", 22, 28], ["CCL2", "GENE_OR_GENE_PRODUCT", 30, 34], ["IL-6", "GENE_OR_GENE_PRODUCT", 40, 44], ["T-cell", "CELL", 127, 133], ["CXCL9", "PROTEIN", 15, 20], ["CXCL10", "PROTEIN", 22, 28], ["CCL2", "PROTEIN", 30, 34], ["IL-6", "PROTEIN", 40, 44], ["CXCL9", "TEST", 15, 20], ["CXCL10", "TEST", 22, 28], ["CCL2", "TEST", 30, 34], ["IL", "TEST", 40, 42], ["an inflammatory program", "PROBLEM", 83, 106], ["inflammatory", "OBSERVATION", 86, 98]]], ["CXCL9 and CXCL10 are both chemokines induced by IFN-c and are part of the chemokine program that regulates the migration of monocytes/ macrophages, memory T cells and NK cells and are associated with the polarization of T cells [27] .", [["monocytes", "ANATOMY", 124, 133], ["macrophages", "ANATOMY", 135, 146], ["memory T cells", "ANATOMY", 148, 162], ["NK cells", "ANATOMY", 167, 175], ["T cells", "ANATOMY", 220, 227], ["CXCL9", "GENE_OR_GENE_PRODUCT", 0, 5], ["CXCL10", "GENE_OR_GENE_PRODUCT", 10, 16], ["IFN-c", "GENE_OR_GENE_PRODUCT", 48, 53], ["monocytes", "CELL", 124, 133], ["macrophages", "CELL", 135, 146], ["memory T cells", "CELL", 148, 162], ["NK cells", "CELL", 167, 175], ["T cells", "CELL", 220, 227], ["CXCL9", "PROTEIN", 0, 5], ["CXCL10", "PROTEIN", 10, 16], ["chemokines", "PROTEIN", 26, 36], ["IFN-c", "PROTEIN", 48, 53], ["chemokine", "PROTEIN", 74, 83], ["monocytes", "CELL_TYPE", 124, 133], ["macrophages", "CELL_TYPE", 135, 146], ["memory T cells", "CELL_TYPE", 148, 162], ["NK cells", "CELL_TYPE", 167, 175], ["T cells", "CELL_TYPE", 220, 227], ["CXCL9", "TEST", 0, 5], ["CXCL10", "TEST", 10, 16], ["the chemokine program", "TREATMENT", 70, 91], ["monocytes", "TEST", 124, 133], ["macrophages", "PROBLEM", 135, 146], ["NK cells", "PROBLEM", 167, 175], ["migration", "OBSERVATION_MODIFIER", 111, 120], ["macrophages", "ANATOMY", 135, 146], ["NK cells", "OBSERVATION", 167, 175]]], ["IL-6, a pleiotropic cytokine, has a destructive role in rheumatoid arthritis (RA), contributing to joint inflammation as well as joint pain [28, 29] .", [["joint", "ANATOMY", 99, 104], ["joint", "ANATOMY", 129, 134], ["rheumatoid arthritis", "DISEASE", 56, 76], ["RA", "DISEASE", 78, 80], ["inflammation", "DISEASE", 105, 117], ["joint pain", "DISEASE", 129, 139], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["joint", "MULTI-TISSUE_STRUCTURE", 99, 104], ["joint", "MULTI-TISSUE_STRUCTURE", 129, 134], ["IL-6", "PROTEIN", 0, 4], ["pleiotropic cytokine", "PROTEIN", 8, 28], ["a pleiotropic cytokine", "TREATMENT", 6, 28], ["rheumatoid arthritis", "PROBLEM", 56, 76], ["joint inflammation", "PROBLEM", 99, 117], ["joint pain", "PROBLEM", 129, 139], ["destructive", "OBSERVATION_MODIFIER", 36, 47], ["rheumatoid arthritis", "OBSERVATION", 56, 76], ["RA", "ANATOMY", 78, 80], ["joint", "ANATOMY", 99, 104], ["inflammation", "OBSERVATION", 105, 117], ["joint", "ANATOMY", 129, 134]]], ["The increased IL-6 levels in the acute phase of our study may be the initiating factor of the severe joint pain symptoms reported in CHIKV patients which mimics RA.", [["joint", "ANATOMY", 101, 106], ["joint pain", "DISEASE", 101, 111], ["CHIKV", "DISEASE", 133, 138], ["RA", "DISEASE", 161, 163], ["IL-6", "GENE_OR_GENE_PRODUCT", 14, 18], ["joint", "ORGANISM_SUBDIVISION", 101, 106], ["CHIKV", "ORGANISM", 133, 138], ["patients", "ORGANISM", 139, 147], ["IL-6", "PROTEIN", 14, 18], ["patients", "SPECIES", 139, 147], ["CHIKV", "SPECIES", 133, 138], ["The increased IL", "TREATMENT", 0, 16], ["our study", "TEST", 48, 57], ["the severe joint pain symptoms", "PROBLEM", 90, 120], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["IL", "OBSERVATION_MODIFIER", 14, 16], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["joint", "ANATOMY", 101, 106]]], ["Furthermore, IL-6 is important during acute phases of the disease by acting as an important immune mediator of fever activating muscle metabolism to increase core body temperature [28] .", [["muscle", "ANATOMY", 128, 134], ["body", "ANATOMY", 163, 167], ["fever", "DISEASE", 111, 116], ["IL-6", "GENE_OR_GENE_PRODUCT", 13, 17], ["muscle", "ORGAN", 128, 134], ["body", "ORGANISM_SUBDIVISION", 163, 167], ["IL-6", "PROTEIN", 13, 17], ["the disease", "PROBLEM", 54, 65], ["fever activating muscle metabolism", "PROBLEM", 111, 145], ["core body temperature", "TEST", 158, 179]]], ["Since fever is a common symptom of acute CHIKV disease, it is highly probable that the high IL-6 levels were contributing to the acute fever and the IL-6 decreasing trend followed patient core body temperature as it returned to resting temperature in the follow-up.DiscussionA second host immune response profile was characterized by TNF-a, IL-1b, Il-10, Il-12, IFN-c and IL-5, which increased from the acute phase into convalescence.", [["body", "ANATOMY", 193, 197], ["fever", "DISEASE", 6, 11], ["CHIKV disease", "DISEASE", 41, 54], ["fever", "DISEASE", 135, 140], ["CHIKV", "ORGANISM", 41, 46], ["IL-6", "GENE_OR_GENE_PRODUCT", 92, 96], ["IL-6", "GENE_OR_GENE_PRODUCT", 149, 153], ["patient", "ORGANISM", 180, 187], ["body", "ORGANISM_SUBDIVISION", 193, 197], ["TNF-a", "GENE_OR_GENE_PRODUCT", 334, 339], ["IL-1b", "GENE_OR_GENE_PRODUCT", 341, 346], ["Il-10", "GENE_OR_GENE_PRODUCT", 348, 353], ["Il-12", "GENE_OR_GENE_PRODUCT", 355, 360], ["IFN-c", "GENE_OR_GENE_PRODUCT", 362, 367], ["IL-5", "GENE_OR_GENE_PRODUCT", 372, 376], ["IL-6", "PROTEIN", 92, 96], ["IL", "PROTEIN", 149, 151], ["TNF", "PROTEIN", 334, 337], ["IFN", "PROTEIN", 362, 365], ["IL", "PROTEIN", 372, 374], ["patient", "SPECIES", 180, 187], ["CHIKV", "SPECIES", 41, 46], ["fever", "PROBLEM", 6, 11], ["acute CHIKV disease", "PROBLEM", 35, 54], ["the acute fever", "PROBLEM", 125, 140], ["the IL", "TEST", 145, 151], ["resting temperature", "TEST", 228, 247], ["TNF", "TEST", 334, 337], ["IL", "TEST", 341, 343], ["Il", "TEST", 348, 350], ["Il", "TEST", 355, 357], ["IFN", "TEST", 362, 365], ["IL", "TEST", 372, 374], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["CHIKV disease", "OBSERVATION", 41, 54], ["highly probable", "UNCERTAINTY", 62, 77], ["acute", "OBSERVATION_MODIFIER", 129, 134], ["fever", "OBSERVATION", 135, 140]]], ["Interestingly, TNF-a and IL-1b, which are known to co-induce the other's expression, are both involved in chronic inflammatory diseases such as RA, chronic hepatitis B and C infection [23, 29, 30] .", [["RA", "DISEASE", 144, 146], ["chronic hepatitis B and C infection", "DISEASE", 148, 183], ["TNF-a", "GENE_OR_GENE_PRODUCT", 15, 20], ["IL-1b", "GENE_OR_GENE_PRODUCT", 25, 30], ["TNF", "PROTEIN", 15, 18], ["IL-1b", "PROTEIN", 25, 30], ["TNF", "TEST", 15, 18], ["chronic inflammatory diseases", "PROBLEM", 106, 135], ["chronic hepatitis B", "PROBLEM", 148, 167], ["C infection", "PROBLEM", 172, 183], ["chronic", "OBSERVATION_MODIFIER", 106, 113], ["inflammatory", "OBSERVATION", 114, 126], ["RA", "ANATOMY", 144, 146], ["chronic", "OBSERVATION_MODIFIER", 148, 155], ["hepatitis", "OBSERVATION", 156, 165]]], ["Importantly, TNF-a and IL-1b are main contributors to joint pain, which is the major symptom of RA.", [["joint", "ANATOMY", 54, 59], ["pain", "DISEASE", 60, 64], ["RA", "DISEASE", 96, 98], ["TNF-a", "GENE_OR_GENE_PRODUCT", 13, 18], ["IL-1b", "GENE_OR_GENE_PRODUCT", 23, 28], ["joint", "MULTI-TISSUE_STRUCTURE", 54, 59], ["TNF", "PROTEIN", 13, 16], ["IL", "PROTEIN", 23, 25], ["TNF", "TEST", 13, 16], ["joint pain", "PROBLEM", 54, 64], ["joint", "ANATOMY", 54, 59], ["pain", "OBSERVATION", 60, 64], ["RA", "ANATOMY", 96, 98]]], ["An internal balance of TNF-a or IL-1b levels is imperative as mis-regulation of either has been shown to be a major proponent of chronic diseases (RA).", [["chronic diseases", "DISEASE", 129, 145], ["RA", "DISEASE", 147, 149], ["TNF-a", "GENE_OR_GENE_PRODUCT", 23, 28], ["IL-1b", "GENE_OR_GENE_PRODUCT", 32, 37], ["TNF", "PROTEIN", 23, 26], ["IL", "PROTEIN", 32, 34], ["TNF", "TEST", 23, 26], ["a or IL-1b levels", "TEST", 27, 44], ["chronic diseases", "PROBLEM", 129, 145], ["internal", "OBSERVATION_MODIFIER", 3, 11], ["balance", "OBSERVATION", 12, 19], ["chronic", "OBSERVATION_MODIFIER", 129, 136], ["diseases", "OBSERVATION", 137, 145], ["RA", "ANATOMY", 147, 149]]], ["Our data indicated that these cytokines increased significantly during patient convalescence above those of the control group, but were not statistically changed in patients reporting mild or severe symptoms.", [["patient", "ORGANISM", 71, 78], ["patients", "ORGANISM", 165, 173], ["cytokines", "PROTEIN", 30, 39], ["patient", "SPECIES", 71, 78], ["patients", "SPECIES", 165, 173], ["Our data", "TEST", 0, 8], ["these cytokines", "PROBLEM", 24, 39], ["mild or severe symptoms", "PROBLEM", 184, 207], ["cytokines", "OBSERVATION", 30, 39], ["increased", "OBSERVATION_MODIFIER", 40, 49], ["mild", "OBSERVATION_MODIFIER", 184, 188], ["severe", "OBSERVATION_MODIFIER", 192, 198]]], ["These data may imply that the increased levels of TNF-a and IL-1b in the convalescence phase were not a major contributor of chronic damage causing persistent severe joint pain symptoms during the Italian outbreak even though these cytokines have previously been found to play a destructive role in chronic inflammatory diseases.", [["joint", "ANATOMY", 166, 171], ["pain", "DISEASE", 172, 176], ["TNF-a", "GENE_OR_GENE_PRODUCT", 50, 55], ["IL-1b", "GENE_OR_GENE_PRODUCT", 60, 65], ["joint", "ORGANISM_SUBDIVISION", 166, 171], ["TNF", "PROTEIN", 50, 53], ["IL-1b", "PROTEIN", 60, 65], ["cytokines", "PROTEIN", 232, 241], ["the increased levels of TNF", "PROBLEM", 26, 53], ["chronic damage", "PROBLEM", 125, 139], ["persistent severe joint pain symptoms", "PROBLEM", 148, 185], ["chronic inflammatory diseases", "PROBLEM", 299, 328], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["chronic", "OBSERVATION_MODIFIER", 125, 132], ["damage", "OBSERVATION", 133, 139], ["persistent", "OBSERVATION_MODIFIER", 148, 158], ["severe", "OBSERVATION_MODIFIER", 159, 165], ["joint", "ANATOMY", 166, 171], ["destructive", "OBSERVATION_MODIFIER", 279, 290], ["chronic", "OBSERVATION_MODIFIER", 299, 306], ["inflammatory", "OBSERVATION", 307, 319]]], ["Furthermore, TNF-a immunomodulators have previously been used as a common treatment for RA and IL-1b immunomodulators are effective with other chronic diseases such as systemiconset juvenile idiopathic arthritis and in adult onset Still's diseases [29, 31] .", [["RA", "DISEASE", 88, 90], ["chronic diseases", "DISEASE", 143, 159], ["juvenile idiopathic arthritis", "DISEASE", 182, 211], ["Still's diseases", "DISEASE", 231, 247], ["TNF", "GENE_OR_GENE_PRODUCT", 13, 16], ["IL-1b", "GENE_OR_GENE_PRODUCT", 95, 100], ["TNF", "PROTEIN", 13, 16], ["TNF", "TEST", 13, 16], ["a immunomodulators", "TREATMENT", 17, 35], ["a common treatment", "TREATMENT", 65, 83], ["RA", "PROBLEM", 88, 90], ["IL-1b immunomodulators", "TREATMENT", 95, 117], ["other chronic diseases", "PROBLEM", 137, 159], ["systemiconset juvenile idiopathic arthritis", "PROBLEM", 168, 211], ["Still's diseases", "PROBLEM", 231, 247], ["chronic", "OBSERVATION_MODIFIER", 143, 150], ["diseases", "OBSERVATION", 151, 159], ["juvenile", "OBSERVATION_MODIFIER", 182, 190], ["idiopathic", "OBSERVATION_MODIFIER", 191, 201], ["arthritis", "OBSERVATION", 202, 211]]], ["Taken together, these findings suggest TNF-a and IL-1b therapies would not be effective controlling the prolonged symptoms of CHIKV disease since the raised levels during convalescence were not associated with patient severity.", [["CHIKV disease", "DISEASE", 126, 139], ["TNF-a", "GENE_OR_GENE_PRODUCT", 39, 44], ["IL-1b", "GENE_OR_GENE_PRODUCT", 49, 54], ["CHIKV", "ORGANISM", 126, 131], ["patient", "ORGANISM", 210, 217], ["TNF", "PROTEIN", 39, 42], ["patient", "SPECIES", 210, 217], ["CHIKV", "SPECIES", 126, 131], ["TNF", "TEST", 39, 42], ["a and IL-1b therapies", "TREATMENT", 43, 64], ["the prolonged symptoms", "PROBLEM", 100, 122], ["CHIKV disease", "PROBLEM", 126, 139], ["CHIKV", "OBSERVATION", 126, 131], ["not associated with", "UNCERTAINTY", 190, 209]]], ["Previously, cytokine profiles have been analyzed from patients during an Asian outbreak of CHIKV [22] .", [["CHIKV", "DISEASE", 91, 96], ["patients", "ORGANISM", 54, 62], ["CHIKV", "ORGANISM", 91, 96], ["cytokine", "PROTEIN", 12, 20], ["patients", "SPECIES", 54, 62], ["CHIKV", "SPECIES", 91, 96], ["cytokine profiles", "TEST", 12, 29], ["CHIKV", "PROBLEM", 91, 96]]], ["Ng and colleagues, investigated 30 cytokines and growth factors from 10 acute phase CHIKV patients, determined that the levels of 8 cytokines, 2 chemokines and 3 growth factors were significantly raised in patients compared to those of the control group.", [["CHIKV", "ORGANISM", 84, 89], ["patients", "ORGANISM", 90, 98], ["3 growth factors", "GENE_OR_GENE_PRODUCT", 160, 176], ["patients", "ORGANISM", 206, 214], ["cytokines", "PROTEIN", 35, 44], ["growth factors", "PROTEIN", 49, 63], ["cytokines", "PROTEIN", 132, 141], ["chemokines", "PROTEIN", 145, 155], ["growth factors", "PROTEIN", 162, 176], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 206, 214], ["CHIKV", "SPECIES", 84, 89], ["the levels", "TEST", 116, 126], ["cytokines", "TEST", 132, 141], ["2 chemokines", "TEST", 143, 155], ["3 growth factors", "PROBLEM", 160, 176]]], ["In accordance with their data, IL-6, CXCL9 and CXCL10 were also increased in the acute phase of our patients as compared to control.", [["IL-6", "GENE_OR_GENE_PRODUCT", 31, 35], ["CXCL9", "GENE_OR_GENE_PRODUCT", 37, 42], ["CXCL10", "GENE_OR_GENE_PRODUCT", 47, 53], ["patients", "ORGANISM", 100, 108], ["IL-6", "PROTEIN", 31, 35], ["CXCL9", "PROTEIN", 37, 42], ["CXCL10", "PROTEIN", 47, 53], ["patients", "SPECIES", 100, 108], ["IL", "TEST", 31, 33], ["CXCL9", "TEST", 37, 42], ["CXCL10", "TEST", 47, 53], ["acute phase", "OBSERVATION_MODIFIER", 81, 92]]], ["Since the results from the previous study did not follow the patients during convalescence, our study added significant insight to the progression of CHIKV disease.", [["CHIKV disease", "DISEASE", 150, 163], ["patients", "ORGANISM", 61, 69], ["CHIKV", "ORGANISM", 150, 155], ["patients", "SPECIES", 61, 69], ["CHIKV", "SPECIES", 150, 155], ["the previous study", "TEST", 23, 41], ["our study", "TEST", 92, 101], ["CHIKV disease", "PROBLEM", 150, 163], ["progression", "OBSERVATION_MODIFIER", 135, 146], ["CHIKV disease", "OBSERVATION", 150, 163]]], ["We found that these three cytokine levels decreased as the patients convalesced as discussed above.", [["patients", "ORGANISM", 59, 67], ["cytokine", "PROTEIN", 26, 34], ["patients", "SPECIES", 59, 67], ["these three cytokine levels", "TEST", 14, 41]]], ["Conversely, we found CCL2 also to be increased in the acute phase compared to that of the control group, which was unchanged in the Ng study.", [["CCL2", "GENE_OR_GENE_PRODUCT", 21, 25], ["CCL2", "PROTEIN", 21, 25], ["CCL2", "TEST", 21, 25], ["the Ng study", "TEST", 128, 140], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["acute phase", "OBSERVATION_MODIFIER", 54, 65], ["unchanged", "OBSERVATION_MODIFIER", 115, 124]]], ["Furthermore, Ng et al. found IL-5 and IL-10 were significantly increased in the acute phase where our data indicated that IL-5 and IL-10 were initially low and below control levels and increased following the acute phase.", [["IL-5", "GENE_OR_GENE_PRODUCT", 29, 33], ["IL-10", "GENE_OR_GENE_PRODUCT", 38, 43], ["IL-5", "GENE_OR_GENE_PRODUCT", 122, 126], ["IL-10", "GENE_OR_GENE_PRODUCT", 131, 136], ["IL", "PROTEIN", 29, 31], ["IL", "PROTEIN", 38, 40], ["IL", "PROTEIN", 122, 124], ["IL", "PROTEIN", 131, 133], ["Ng et al", "TREATMENT", 13, 21], ["IL", "TEST", 29, 31], ["IL", "TEST", 38, 40], ["our data", "TEST", 98, 106], ["IL", "TEST", 122, 124], ["IL", "TEST", 131, 133], ["increased", "OBSERVATION_MODIFIER", 63, 72], ["increased", "OBSERVATION_MODIFIER", 185, 194]]], ["These discrepancies can possibly be explained by the patient populations: the Ng study patients and our patients were from significantly varied genetic backgrounds (Asian and European, respectively).", [["patient", "ORGANISM", 53, 60], ["patients", "ORGANISM", 87, 95], ["patients", "ORGANISM", 104, 112], ["patient", "SPECIES", 53, 60], ["patients", "SPECIES", 87, 95], ["patients", "SPECIES", 104, 112], ["the Ng study", "TEST", 74, 86], ["possibly be explained", "UNCERTAINTY", 24, 45]]], ["Therefore, differences in immune response may reflect variations in immunological genetic programs.", [["immune response", "OBSERVATION", 26, 41], ["may reflect", "UNCERTAINTY", 42, 53]]], ["As well, the virus that caused the two outbreaks also differed genetically.", [["the virus", "PROBLEM", 9, 18], ["virus", "OBSERVATION", 13, 18], ["two", "OBSERVATION_MODIFIER", 35, 38], ["outbreaks", "OBSERVATION", 39, 48]]], ["Even though the virus that caused the Singapore outbreak was the same genotype as the Italian virus, the virus that infected the Italian patients had the A226V mutation in the E1 gene which was acquired on La Reunion Island [19] .", [["patients", "ORGANISM", 137, 145], ["A226V", "GENE_OR_GENE_PRODUCT", 154, 159], ["E1", "GENE_OR_GENE_PRODUCT", 176, 178], ["E1 gene", "DNA", 176, 183], ["patients", "SPECIES", 137, 145], ["Italian virus", "SPECIES", 86, 99], ["the virus", "PROBLEM", 12, 21], ["the Italian virus", "PROBLEM", 82, 99], ["the virus", "PROBLEM", 101, 110], ["the A226V mutation", "PROBLEM", 150, 168], ["virus", "OBSERVATION", 16, 21]]], ["Although the impact of this mutation has been shown to increase vector infectivity [20] , the mutation has not been investigated on the human or mammalian immune response.DiscussionPreviously, we have identified 3 stages of the acute phase of WNV; a viral stage, antibody initiation stage, and seroconversion stage [24] .", [["WNV", "DISEASE", 243, 246], ["human", "ORGANISM", 136, 141], ["WNV", "ORGANISM", 243, 246], ["human", "SPECIES", 136, 141], ["human", "SPECIES", 136, 141], ["WNV", "SPECIES", 243, 246], ["this mutation", "PROBLEM", 23, 36], ["the mutation", "PROBLEM", 90, 102], ["the acute phase of WNV", "PROBLEM", 224, 246], ["a viral stage, antibody initiation stage", "PROBLEM", 248, 288], ["seroconversion stage", "PROBLEM", 294, 314], ["acute", "OBSERVATION_MODIFIER", 228, 233], ["WNV", "OBSERVATION", 243, 246], ["viral stage", "OBSERVATION_MODIFIER", 250, 261]]], ["As the viral load decreased in the WNV patients, IgM antibody levels were initiated and followed by IgM conversion to IgG, thereby marking the 3 stages of the acute phase.", [["WNV", "ORGANISM", 35, 38], ["patients", "ORGANISM", 39, 47], ["IgM antibody", "GENE_OR_GENE_PRODUCT", 49, 61], ["IgM", "GENE_OR_GENE_PRODUCT", 100, 103], ["IgG", "GENE_OR_GENE_PRODUCT", 118, 121], ["IgM antibody", "PROTEIN", 49, 61], ["IgM", "PROTEIN", 100, 103], ["IgG", "PROTEIN", 118, 121], ["patients", "SPECIES", 39, 47], ["WNV", "SPECIES", 35, 38], ["the viral load", "TEST", 3, 17], ["IgM antibody levels", "TEST", 49, 68], ["IgG", "TEST", 118, 121], ["viral load", "OBSERVATION", 7, 17], ["acute", "OBSERVATION_MODIFIER", 159, 164]]], ["From this work we were able to identify the stages of the CHIKV patients and compare their respective serum cytokine levels.", [["serum", "ANATOMY", 102, 107], ["CHIKV", "ORGANISM", 58, 63], ["patients", "ORGANISM", 64, 72], ["serum", "ORGANISM_SUBSTANCE", 102, 107], ["cytokine", "PROTEIN", 108, 116], ["patients", "SPECIES", 64, 72], ["CHIKV", "SPECIES", 58, 63], ["their respective serum cytokine levels", "TEST", 85, 123], ["CHIKV", "OBSERVATION", 58, 63]]], ["We found CXCL10 and IL-10 levels decreased as patients progressed through the viral stage to seroconversion.", [["CXCL10", "GENE_OR_GENE_PRODUCT", 9, 15], ["IL-10", "GENE_OR_GENE_PRODUCT", 20, 25], ["patients", "ORGANISM", 46, 54], ["CXCL10", "PROTEIN", 9, 15], ["patients", "SPECIES", 46, 54], ["CXCL10", "TEST", 9, 15], ["IL", "TEST", 20, 22], ["the viral stage", "PROBLEM", 74, 89], ["seroconversion", "PROBLEM", 93, 107], ["viral stage", "OBSERVATION_MODIFIER", 78, 89], ["seroconversion", "OBSERVATION", 93, 107]]], ["Since CXCL10 is often correlated with viral load, this observation was not surprising [32] .", [["CXCL10", "GENE_OR_GENE_PRODUCT", 6, 12], ["CXCL10", "PROTEIN", 6, 12], ["CXCL10", "TEST", 6, 12], ["viral load", "PROBLEM", 38, 48], ["this observation", "TEST", 50, 66]]], ["High IL-10 levels in the viral stage may act in an effort to control the IFN-c program [33] shown by high CXCL10 levels.", [["IL-10", "GENE_OR_GENE_PRODUCT", 5, 10], ["IFN-c", "GENE_OR_GENE_PRODUCT", 73, 78], ["CXCL10", "GENE_OR_GENE_PRODUCT", 106, 112], ["IL", "PROTEIN", 5, 7], ["IFN", "PROTEIN", 73, 76], ["CXCL10", "PROTEIN", 106, 112], ["High IL", "TREATMENT", 0, 7], ["the viral stage", "PROBLEM", 21, 36], ["viral stage", "OBSERVATION_MODIFIER", 25, 36]]], ["Furthermore, plasma levels of CCL2, IL-6 as well as CXCL10 have all been correlated with viral loads in virus infected individuals [24, 34, 35] .", [["plasma", "ANATOMY", 13, 19], ["plasma", "ORGANISM_SUBSTANCE", 13, 19], ["CCL2", "GENE_OR_GENE_PRODUCT", 30, 34], ["IL-6", "GENE_OR_GENE_PRODUCT", 36, 40], ["CXCL10", "GENE_OR_GENE_PRODUCT", 52, 58], ["CCL2", "PROTEIN", 30, 34], ["IL-6", "PROTEIN", 36, 40], ["CXCL10", "PROTEIN", 52, 58], ["plasma levels", "TEST", 13, 26], ["CCL2", "TEST", 30, 34], ["IL", "TEST", 36, 38], ["CXCL10", "TEST", 52, 58], ["viral loads in virus infected individuals", "PROBLEM", 89, 130], ["CCL2", "ANATOMY", 30, 34]]], ["It is possible that the decrease of CCL2 and IL-6 we observed subsequent to the acute phase [14] correlated with viral clearance, although not with antibody levels.", [["CCL2", "GENE_OR_GENE_PRODUCT", 36, 40], ["IL-6", "GENE_OR_GENE_PRODUCT", 45, 49], ["CCL2", "PROTEIN", 36, 40], ["IL-6", "PROTEIN", 45, 49], ["the decrease of CCL2", "PROBLEM", 20, 40], ["viral clearance", "TEST", 113, 128], ["antibody levels", "TEST", 148, 163], ["decrease", "OBSERVATION_MODIFIER", 24, 32]]], ["Analysis of the cytokine/antibody response was carried on to the 6-and 12-month follow-up where we grouped the patients on their IgG levels.", [["patients", "ORGANISM", 111, 119], ["IgG", "GENE_OR_GENE_PRODUCT", 129, 132], ["cytokine", "PROTEIN", 16, 24], ["IgG", "PROTEIN", 129, 132], ["patients", "SPECIES", 111, 119], ["the cytokine/antibody response", "TEST", 12, 42], ["their IgG levels", "TEST", 123, 139]]], ["CXCL9, CXCL10 and IL-6 were raised in the patients with increased IgG levels at 6 months and CXCL9 at the 12month follow-up.", [["CXCL9", "GENE_OR_GENE_PRODUCT", 0, 5], ["CXCL10", "GENE_OR_GENE_PRODUCT", 7, 13], ["IL-6", "GENE_OR_GENE_PRODUCT", 18, 22], ["patients", "ORGANISM", 42, 50], ["IgG", "GENE_OR_GENE_PRODUCT", 66, 69], ["CXCL9", "GENE_OR_GENE_PRODUCT", 93, 98], ["CXCL9", "PROTEIN", 0, 5], ["CXCL10", "PROTEIN", 7, 13], ["IL-6", "PROTEIN", 18, 22], ["IgG", "PROTEIN", 66, 69], ["CXCL9", "PROTEIN", 93, 98], ["patients", "SPECIES", 42, 50], ["CXCL9", "TEST", 0, 5], ["CXCL10", "TEST", 7, 13], ["IL", "TEST", 18, 20], ["increased IgG levels", "PROBLEM", 56, 76], ["CXCL9", "TEST", 93, 98]]], ["These proinflammatory cytokine associations with high IgG levels may represent the persistence of an active immune system.DiscussionCXCL9 and CXCL10 as well as high IgG levels were found to be biomarkers of severe CHIKV symptoms.", [["immune system", "ANATOMY", 108, 121], ["CHIKV symptoms", "DISEASE", 214, 228], ["IgG", "GENE_OR_GENE_PRODUCT", 54, 57], ["immune system", "ANATOMICAL_SYSTEM", 108, 121], ["DiscussionCXCL9", "GENE_OR_GENE_PRODUCT", 122, 137], ["CXCL10", "GENE_OR_GENE_PRODUCT", 142, 148], ["IgG", "GENE_OR_GENE_PRODUCT", 165, 168], ["CHIKV", "ORGANISM", 214, 219], ["proinflammatory cytokine", "PROTEIN", 6, 30], ["IgG", "PROTEIN", 54, 57], ["DiscussionCXCL9", "PROTEIN", 122, 137], ["CXCL10", "PROTEIN", 142, 148], ["IgG", "PROTEIN", 165, 168], ["CHIKV", "SPECIES", 214, 219], ["These proinflammatory cytokine associations", "PROBLEM", 0, 43], ["high IgG levels", "PROBLEM", 49, 64], ["an active immune system", "PROBLEM", 98, 121], ["CXCL10", "TEST", 142, 148], ["high IgG levels", "TEST", 160, 175], ["severe CHIKV symptoms", "PROBLEM", 207, 228], ["proinflammatory", "OBSERVATION_MODIFIER", 6, 21], ["active", "OBSERVATION_MODIFIER", 101, 107], ["immune system", "OBSERVATION", 108, 121], ["severe", "OBSERVATION_MODIFIER", 207, 213], ["CHIKV", "OBSERVATION", 214, 219]]], ["Previously, CXCL10 has been associated with severe viral disease supporting a role for CXCL10 in severe CHIKV disease [34] [35] [36] [37] .", [["viral disease", "DISEASE", 51, 64], ["CHIKV disease", "DISEASE", 104, 117], ["CXCL10", "GENE_OR_GENE_PRODUCT", 12, 18], ["CXCL10", "GENE_OR_GENE_PRODUCT", 87, 93], ["CXCL10", "PROTEIN", 12, 18], ["CXCL10", "PROTEIN", 87, 93], ["CHIKV", "SPECIES", 104, 109], ["CXCL10", "TEST", 12, 18], ["severe viral disease", "PROBLEM", 44, 64], ["CXCL10 in severe CHIKV disease", "PROBLEM", 87, 117], ["associated with", "UNCERTAINTY", 28, 43], ["severe", "OBSERVATION_MODIFIER", 44, 50], ["viral disease", "OBSERVATION", 51, 64]]], ["These studies did not find an association with CXCL9 and severity as seen in our CHIKV patients.", [["CHIKV", "DISEASE", 81, 86], ["CXCL9", "GENE_OR_GENE_PRODUCT", 47, 52], ["CHIKV", "ORGANISM", 81, 86], ["patients", "ORGANISM", 87, 95], ["CXCL9", "PROTEIN", 47, 52], ["patients", "SPECIES", 87, 95], ["CHIKV", "SPECIES", 81, 86], ["These studies", "TEST", 0, 13], ["CXCL9 and severity", "PROBLEM", 47, 65]]], ["Our findings suggest high CXCL10 and CXCL9 associated with severity to be a unique signature of CHIKV.", [["CHIKV", "DISEASE", 96, 101], ["CXCL10", "GENE_OR_GENE_PRODUCT", 26, 32], ["CXCL9", "GENE_OR_GENE_PRODUCT", 37, 42], ["CHIKV", "ORGANISM", 96, 101], ["CXCL10", "PROTEIN", 26, 32], ["CXCL9", "PROTEIN", 37, 42], ["CHIKV", "SPECIES", 96, 101], ["high CXCL10 and CXCL9", "PROBLEM", 21, 42], ["severity", "PROBLEM", 59, 67], ["CHIKV", "PROBLEM", 96, 101], ["high CXCL10", "OBSERVATION_MODIFIER", 21, 32], ["CHIKV", "OBSERVATION", 96, 101]]], ["Interestingly, not only are CXCL10 and CXCL9 expressed in RA and other arthritis related disease patients [38] [39] [40] [41] , but they have been shown to be biomarkers for RA symptoms, implying a similar mechanism for joint destruction in CHIKV disease [42] .", [["RA", "ANATOMY", 58, 60], ["joint", "ANATOMY", 220, 225], ["RA", "DISEASE", 58, 60], ["arthritis", "DISEASE", 71, 80], ["RA", "DISEASE", 174, 176], ["CHIKV disease", "DISEASE", 241, 254], ["CXCL10", "GENE_OR_GENE_PRODUCT", 28, 34], ["CXCL9", "GENE_OR_GENE_PRODUCT", 39, 44], ["RA", "CANCER", 58, 60], ["patients", "ORGANISM", 97, 105], ["joint", "TISSUE", 220, 225], ["CHIKV", "ORGANISM", 241, 246], ["CXCL10", "PROTEIN", 28, 34], ["CXCL9", "PROTEIN", 39, 44], ["patients", "SPECIES", 97, 105], ["CHIKV", "SPECIES", 241, 246], ["CXCL10", "TEST", 28, 34], ["CXCL9", "TEST", 39, 44], ["other arthritis", "PROBLEM", 65, 80], ["RA symptoms", "PROBLEM", 174, 185], ["joint destruction", "PROBLEM", 220, 237], ["CHIKV disease", "PROBLEM", 241, 254], ["not only", "UNCERTAINTY", 15, 23], ["CXCL10", "OBSERVATION", 28, 34], ["RA", "ANATOMY", 58, 60], ["arthritis", "OBSERVATION", 71, 80], ["joint", "ANATOMY", 220, 225], ["destruction", "OBSERVATION", 226, 237], ["CHIKV", "OBSERVATION", 241, 246]]], ["Moreover, CXCL9 and CXCL10 may be contributors of persistent immune activation in CHIKV disease leading to chronic symptoms, which implies cytokine immunomodulation may significantly improve patient treatment and recovery.", [["CHIKV disease", "DISEASE", 82, 95], ["CXCL9", "GENE_OR_GENE_PRODUCT", 10, 15], ["CXCL10", "GENE_OR_GENE_PRODUCT", 20, 26], ["CHIKV", "ORGANISM", 82, 87], ["patient", "ORGANISM", 191, 198], ["CXCL9", "PROTEIN", 10, 15], ["CXCL10", "PROTEIN", 20, 26], ["cytokine", "PROTEIN", 139, 147], ["patient", "SPECIES", 191, 198], ["CHIKV", "SPECIES", 82, 87], ["CXCL9", "TEST", 10, 15], ["CXCL10", "TEST", 20, 26], ["persistent immune activation", "PROBLEM", 50, 78], ["CHIKV disease", "PROBLEM", 82, 95], ["chronic symptoms", "PROBLEM", 107, 123], ["cytokine immunomodulation", "TREATMENT", 139, 164], ["patient treatment", "TREATMENT", 191, 208], ["persistent", "OBSERVATION_MODIFIER", 50, 60], ["immune activation", "OBSERVATION", 61, 78], ["CHIKV disease", "OBSERVATION", 82, 95], ["chronic", "OBSERVATION_MODIFIER", 107, 114], ["symptoms", "OBSERVATION", 115, 123], ["cytokine immunomodulation", "OBSERVATION", 139, 164]]], ["Importantly, CXCL10 also has prognostic value in the treatment of viral hepatitis where CXCL10 levels follow disease recovery [43] supporting our finding and proposes a prognostic role for CXCL10 in CHIKV.", [["viral hepatitis", "DISEASE", 66, 81], ["CHIKV", "DISEASE", 199, 204], ["CXCL10", "GENE_OR_GENE_PRODUCT", 13, 19], ["CXCL10", "GENE_OR_GENE_PRODUCT", 88, 94], ["CXCL10", "GENE_OR_GENE_PRODUCT", 189, 195], ["CHIKV", "ORGANISM", 199, 204], ["CXCL10", "PROTEIN", 13, 19], ["CXCL10", "PROTEIN", 88, 94], ["CXCL10", "PROTEIN", 189, 195], ["CHIKV", "SPECIES", 199, 204], ["prognostic value", "TEST", 29, 45], ["viral hepatitis", "PROBLEM", 66, 81], ["CXCL10 levels", "TEST", 88, 101], ["CXCL10 in CHIKV", "TREATMENT", 189, 204], ["viral hepatitis", "OBSERVATION", 66, 81]]], ["Furthermore, our data puts forth CXCL10 and CXCL9 as possible drug targets for treatment of CHIKV symptoms in the convalescence phase due to the association with severity; however, further investigation is needed on CXCL10 and CXCL9 efficacy.", [["CHIKV symptoms", "DISEASE", 92, 106], ["CXCL10", "GENE_OR_GENE_PRODUCT", 33, 39], ["CXCL9", "GENE_OR_GENE_PRODUCT", 44, 49], ["CHIKV", "ORGANISM", 92, 97], ["CXCL10", "GENE_OR_GENE_PRODUCT", 216, 222], ["CXCL9", "GENE_OR_GENE_PRODUCT", 227, 232], ["CXCL10", "PROTEIN", 33, 39], ["CXCL9", "PROTEIN", 44, 49], ["CXCL10", "PROTEIN", 216, 222], ["CXCL9", "PROTEIN", 227, 232], ["CHIKV", "SPECIES", 92, 97], ["our data", "TEST", 13, 21], ["CXCL10", "TEST", 33, 39], ["CXCL9", "TREATMENT", 44, 49], ["drug targets", "TREATMENT", 62, 74], ["CHIKV symptoms", "PROBLEM", 92, 106], ["severity", "PROBLEM", 162, 170], ["further investigation", "TEST", 181, 202], ["CXCL10", "TEST", 216, 222], ["CXCL9 efficacy", "TEST", 227, 241]]], ["In addition, not only are the identified cytokines useful as possible drug targets but the cytokine signatures described can also be applied when testing newly developed CHIKV therapeutics.", [["CHIKV", "ORGANISM", 170, 175], ["cytokines", "PROTEIN", 41, 50], ["cytokine", "PROTEIN", 91, 99], ["CHIKV", "SPECIES", 170, 175], ["drug targets", "PROBLEM", 70, 82], ["the cytokine signatures", "PROBLEM", 87, 110], ["CHIKV therapeutics", "TREATMENT", 170, 188]]], ["As CHIKV therapeutics are evaluated in the CHIKV disease model, cytokine profiles can be used as an output for determining the efficacy of the novel therapeutics.DiscussionThe synovial mast cell remains an important component during RA joint destruction by the exocytosis of intracellular granules containing inflammatory mediators.", [["synovial mast cell", "ANATOMY", 176, 194], ["joint", "ANATOMY", 236, 241], ["intracellular granules", "ANATOMY", 275, 297], ["CHIKV", "ORGANISM", 3, 8], ["synovial mast cell", "CELL", 176, 194], ["RA joint", "MULTI-TISSUE_STRUCTURE", 233, 241], ["intracellular granules", "CELLULAR_COMPONENT", 275, 297], ["cytokine", "PROTEIN", 64, 72], ["synovial mast cell", "CELL_TYPE", 176, 194], ["inflammatory mediators", "PROTEIN", 309, 331], ["CHIKV", "SPECIES", 3, 8], ["CHIKV", "SPECIES", 43, 48], ["CHIKV therapeutics", "TREATMENT", 3, 21], ["cytokine profiles", "TREATMENT", 64, 81], ["an output", "TEST", 97, 106], ["the novel therapeutics", "TREATMENT", 139, 161], ["The synovial mast cell", "PROBLEM", 172, 194], ["RA joint destruction", "PROBLEM", 233, 253], ["intracellular granules containing inflammatory mediators", "PROBLEM", 275, 331], ["synovial", "ANATOMY", 176, 184], ["mast cell", "OBSERVATION", 185, 194], ["important", "OBSERVATION_MODIFIER", 206, 215], ["component", "OBSERVATION_MODIFIER", 216, 225], ["joint", "ANATOMY", 236, 241], ["destruction", "OBSERVATION", 242, 253], ["intracellular granules", "OBSERVATION", 275, 297], ["inflammatory mediators", "OBSERVATION", 309, 331]]], ["Currently, mast cell activation through FccRs by high levels of circulating IgG antibodies is hypothesized to contribute to the pathological destruction of synovium in RA [44] [45] [46] .", [["mast cell", "ANATOMY", 11, 20], ["synovium", "ANATOMY", 156, 164], ["mast cell", "CELL", 11, 20], ["FccRs", "GENE_OR_GENE_PRODUCT", 40, 45], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 76, 90], ["synovium", "TISSUE", 156, 164], ["FccRs", "PROTEIN", 40, 45], ["circulating IgG antibodies", "PROTEIN", 64, 90], ["mast cell activation", "TEST", 11, 31], ["FccRs", "TEST", 40, 45], ["circulating IgG antibodies", "TEST", 64, 90], ["the pathological destruction of synovium in RA", "PROBLEM", 124, 170], ["mast cell activation", "OBSERVATION", 11, 31], ["synovium", "ANATOMY", 156, 164]]], ["In addition, antibody immune complex formation within the joint stabilizing inflammatory mediators, such as chemokines and complement proteins, is another possible low IgG level group (L) and a high IgG level group (H).", [["joint", "ANATOMY", 58, 63], ["antibody immune complex", "GENE_OR_GENE_PRODUCT", 13, 36], ["joint", "MULTI-TISSUE_STRUCTURE", 58, 63], ["complement proteins", "GENE_OR_GENE_PRODUCT", 123, 142], ["IgG", "GENE_OR_GENE_PRODUCT", 168, 171], ["antibody immune complex", "PROTEIN", 13, 36], ["inflammatory mediators", "PROTEIN", 76, 98], ["chemokines", "PROTEIN", 108, 118], ["complement proteins", "PROTEIN", 123, 142], ["IgG", "PROTEIN", 168, 171], ["IgG", "PROTEIN", 199, 202], ["antibody immune complex formation", "PROBLEM", 13, 46], ["inflammatory mediators", "PROBLEM", 76, 98], ["complement proteins", "TEST", 123, 142], ["low IgG level", "PROBLEM", 164, 177], ["antibody immune", "OBSERVATION", 13, 28], ["joint", "ANATOMY", 58, 63], ["inflammatory", "OBSERVATION_MODIFIER", 76, 88]]], ["Cytokine Bead Array analysis of the serum samples showed a significant difference in CXCL9, CXCL10 and IL-6 between patients with high and low IgG levels at the 6-month time point.", [["serum samples", "ANATOMY", 36, 49], ["serum samples", "ORGANISM_SUBSTANCE", 36, 49], ["CXCL9", "GENE_OR_GENE_PRODUCT", 85, 90], ["CXCL10", "GENE_OR_GENE_PRODUCT", 92, 98], ["IL-6", "GENE_OR_GENE_PRODUCT", 103, 107], ["patients", "ORGANISM", 116, 124], ["IgG", "GENE_OR_GENE_PRODUCT", 143, 146], ["Cytokine", "PROTEIN", 0, 8], ["CXCL9", "PROTEIN", 85, 90], ["CXCL10", "PROTEIN", 92, 98], ["IL-6", "PROTEIN", 103, 107], ["IgG", "PROTEIN", 143, 146], ["patients", "SPECIES", 116, 124], ["Cytokine Bead Array analysis", "TEST", 0, 28], ["the serum samples", "TEST", 32, 49], ["CXCL9", "TEST", 85, 90], ["CXCL10", "TEST", 92, 98], ["IL", "TEST", 103, 105], ["high and low IgG levels", "PROBLEM", 130, 153], ["significant", "OBSERVATION_MODIFIER", 59, 70], ["difference", "OBSERVATION", 71, 81], ["low IgG", "OBSERVATION_MODIFIER", 139, 146]]], ["Twelve-month follow-up CHIKV patient samples showed a significant difference in CXCL9 and IL-10 between low (1) and high (2) IgG groups.", [["samples", "ANATOMY", 37, 44], ["CHIKV", "ORGANISM", 23, 28], ["patient", "ORGANISM", 29, 36], ["CXCL9", "GENE_OR_GENE_PRODUCT", 80, 85], ["IL-10", "GENE_OR_GENE_PRODUCT", 90, 95], ["CXCL9", "PROTEIN", 80, 85], ["IL", "PROTEIN", 90, 92], ["IgG", "PROTEIN", 125, 128], ["patient", "SPECIES", 29, 36], ["CHIKV", "SPECIES", 23, 28], ["CHIKV patient samples", "TEST", 23, 44], ["CXCL9", "TEST", 80, 85], ["IL", "TEST", 90, 92], ["high (2) IgG groups", "PROBLEM", 116, 135], ["significant", "OBSERVATION_MODIFIER", 54, 65], ["difference", "OBSERVATION_MODIFIER", 66, 76]]], ["A Mann-Whitney U test was used to determine significance among the IgG groups.", [["IgG", "PROTEIN", 67, 70], ["U test", "TEST", 15, 21]]], ["The cross symbol indicates a p-value less than 0.05. doi:10.1371/journal.pntd.0001279.g005DiscussionInflammatory Cytokines Resolve Chikungunya Disease www.plosntds.org Figure 6 .", [["Chikungunya Disease", "DISEASE", 131, 150], ["Cytokines", "PROTEIN", 113, 122], ["a p-value", "TEST", 27, 36], ["Chikungunya Disease", "PROBLEM", 131, 150]]], ["CHIKV disease severity is associated with high CXCL10, CXCL9 and IgG levels at the 6-month time point.", [["CHIKV disease", "DISEASE", 0, 13], ["CHIKV", "ORGANISM", 0, 5], ["CXCL10", "GENE_OR_GENE_PRODUCT", 47, 53], ["CXCL9", "GENE_OR_GENE_PRODUCT", 55, 60], ["IgG", "GENE_OR_GENE_PRODUCT", 65, 68], ["CXCL10", "PROTEIN", 47, 53], ["CXCL9", "PROTEIN", 55, 60], ["IgG", "PROTEIN", 65, 68], ["CHIKV", "SPECIES", 0, 5], ["CHIKV disease severity", "PROBLEM", 0, 22], ["high CXCL10", "PROBLEM", 42, 53], ["CXCL9", "TEST", 55, 60], ["IgG levels", "TEST", 65, 75]]], ["CHIKV patients were determined to be nonsymptomatic (N), to have mild symptoms (M) or to have severe symptoms (S).", [["CHIKV", "ORGANISM", 0, 5], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["CHIKV", "SPECIES", 0, 5], ["CHIKV", "PROBLEM", 0, 5], ["mild symptoms", "PROBLEM", 65, 78], ["severe symptoms", "PROBLEM", 94, 109], ["mild", "OBSERVATION_MODIFIER", 65, 69], ["severe", "OBSERVATION_MODIFIER", 94, 100]]], ["The cytokine and IgG levels were then grouped by symptom level and a Mann-Whitney U test was used to determine significance among the severity groups.", [["IgG", "GENE_OR_GENE_PRODUCT", 17, 20], ["cytokine", "PROTEIN", 4, 12], ["IgG", "PROTEIN", 17, 20], ["The cytokine and IgG levels", "TEST", 0, 27], ["symptom level", "TEST", 49, 62], ["a Mann-Whitney U test", "TEST", 67, 88]]], ["CXCL10, CXCL9 and IgG were found to be significantly increased in the patients with mild and severe symptoms at 6 months following initial infection.", [["infection", "DISEASE", 139, 148], ["CXCL10", "GENE_OR_GENE_PRODUCT", 0, 6], ["CXCL9", "GENE_OR_GENE_PRODUCT", 8, 13], ["IgG", "GENE_OR_GENE_PRODUCT", 18, 21], ["patients", "ORGANISM", 70, 78], ["CXCL10", "PROTEIN", 0, 6], ["CXCL9", "PROTEIN", 8, 13], ["IgG", "PROTEIN", 18, 21], ["patients", "SPECIES", 70, 78], ["CXCL10", "TEST", 0, 6], ["CXCL9", "TEST", 8, 13], ["IgG", "TEST", 18, 21], ["mild and severe symptoms", "PROBLEM", 84, 108], ["initial infection", "PROBLEM", 131, 148], ["significantly", "OBSERVATION_MODIFIER", 39, 52], ["increased", "OBSERVATION_MODIFIER", 53, 62], ["mild", "OBSERVATION_MODIFIER", 84, 88], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["infection", "OBSERVATION", 139, 148]]], ["The cross symbol indicates a p-value less than 0.05. doi:10.1371/journal.pntd.0001279.g006DiscussionInflammatory Cytokines Resolve Chikungunya Disease www.plosntds.org facet of pathogenesis during RA [47, 48] .", [["Chikungunya Disease", "DISEASE", 131, 150], ["RA", "DISEASE", 197, 199], ["Cytokines", "PROTEIN", 113, 122], ["a p-value", "TEST", 27, 36], ["Chikungunya Disease", "PROBLEM", 131, 150], ["Chikungunya Disease", "OBSERVATION", 131, 150]]], ["We found high concentrations of IgG to be associated with symptom severity in CHIKV patients.", [["CHIKV", "DISEASE", 78, 83], ["IgG", "GENE_OR_GENE_PRODUCT", 32, 35], ["CHIKV", "ORGANISM", 78, 83], ["patients", "ORGANISM", 84, 92], ["IgG", "PROTEIN", 32, 35], ["patients", "SPECIES", 84, 92], ["CHIKV", "SPECIES", 78, 83], ["high concentrations of IgG", "PROBLEM", 9, 35], ["symptom severity", "PROBLEM", 58, 74], ["high concentrations", "OBSERVATION_MODIFIER", 9, 28]]], ["Similar IgG mediated mechanisms leading to synovium destruction and severe pain experienced by CHIKV patients are possible.", [["synovium", "ANATOMY", 43, 51], ["synovium destruction", "DISEASE", 43, 63], ["pain", "DISEASE", 75, 79], ["CHIKV", "DISEASE", 95, 100], ["IgG", "GENE_OR_GENE_PRODUCT", 8, 11], ["synovium", "TISSUE", 43, 51], ["CHIKV", "ORGANISM", 95, 100], ["patients", "ORGANISM", 101, 109], ["IgG", "PROTEIN", 8, 11], ["patients", "SPECIES", 101, 109], ["CHIKV", "SPECIES", 95, 100], ["Similar IgG mediated mechanisms", "PROBLEM", 0, 31], ["synovium destruction", "PROBLEM", 43, 63], ["severe pain", "PROBLEM", 68, 79], ["leading to", "UNCERTAINTY", 32, 42], ["synovium", "ANATOMY", 43, 51], ["destruction", "OBSERVATION", 52, 63], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["pain", "OBSERVATION", 75, 79]]], ["Taken together with the roles of IgG in RA, our findings support the need for further investigation into the contribution of IgG levels and mast cells to CHIKV symptoms.DiscussionWe have found that the cytokines investigated had one of two immunologically important profiles during CHIKV disease onset and convalescence; furthermore, CXCL10 and CXCL9 were makers of disease severity.", [["mast cells", "ANATOMY", 140, 150], ["IgG", "GENE_OR_GENE_PRODUCT", 33, 36], ["IgG", "GENE_OR_GENE_PRODUCT", 125, 128], ["mast cells", "CELL", 140, 150], ["CHIKV", "ORGANISM", 154, 159], ["CHIKV", "ORGANISM", 282, 287], ["CXCL10", "GENE_OR_GENE_PRODUCT", 334, 340], ["CXCL9", "GENE_OR_GENE_PRODUCT", 345, 350], ["IgG", "PROTEIN", 33, 36], ["IgG", "PROTEIN", 125, 128], ["mast cells", "CELL_TYPE", 140, 150], ["cytokines", "PROTEIN", 202, 211], ["CXCL10", "PROTEIN", 334, 340], ["CXCL9", "PROTEIN", 345, 350], ["CHIKV", "SPECIES", 154, 159], ["CHIKV", "SPECIES", 282, 287], ["IgG in RA", "TREATMENT", 33, 42], ["further investigation", "TEST", 78, 99], ["IgG levels", "PROBLEM", 125, 135], ["mast cells", "PROBLEM", 140, 150], ["CHIKV symptoms", "PROBLEM", 154, 168], ["the cytokines", "TEST", 198, 211], ["CHIKV disease onset", "PROBLEM", 282, 301], ["CXCL10", "TEST", 334, 340], ["CXCL9", "TEST", 345, 350], ["disease severity", "PROBLEM", 366, 382], ["RA", "ANATOMY", 40, 42], ["mast cells", "OBSERVATION", 140, 150]]], ["By identifying the immune profiles, we have created a clearer clinical picture of CHIKV disease.", [["CHIKV disease", "DISEASE", 82, 95], ["CHIKV", "ORGANISM", 82, 87], ["CHIKV", "SPECIES", 82, 87], ["CHIKV disease", "PROBLEM", 82, 95], ["CHIKV disease", "OBSERVATION", 82, 95]]], ["Importantly, further investigation is needed to correlate these profiles with disease onset and progression to use the cytokine profiles as biomarkers for severity and symptom persistence.", [["cytokine", "PROTEIN", 119, 127], ["further investigation", "TEST", 13, 34], ["disease onset", "PROBLEM", 78, 91], ["the cytokine profiles", "TEST", 115, 136], ["biomarkers", "TEST", 140, 150], ["severity", "PROBLEM", 155, 163], ["symptom persistence", "PROBLEM", 168, 187]]], ["The data presented here suggest that with further investigation, immunomodulators may significantly enhance patient recovery.", [["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 108, 115], ["further investigation", "TEST", 42, 63], ["immunomodulators", "TREATMENT", 65, 81]]]], "13008946cb455acb8d1c9b29788991b7c3cf8fc5": [["IntroductionScutellaria baicalensis (S. baicalensis) Georgi (Huangqin in Chinese) is one of the most widely used traditional Chinese herbal medicines, and is officially listed in the Chinese Pharmacopoeia.", [["IntroductionScutellaria baicalensis", "CHEMICAL", 0, 35], ["Huangqin", "CHEMICAL", 61, 69], ["IntroductionScutellaria baicalensis", "ORGANISM", 0, 35], ["S. baicalensis", "ORGANISM", 37, 51], ["IntroductionScutellaria baicalensis", "SPECIES", 0, 35], ["S. baicalensis", "SPECIES", 37, 51], ["IntroductionScutellaria baicalensis", "SPECIES", 0, 35], ["S. baicalensis", "SPECIES", 37, 51], ["IntroductionScutellaria baicalensis", "TREATMENT", 0, 35], ["traditional Chinese herbal medicines", "TREATMENT", 113, 149]]], ["Its roots have been used for anti-inflammation, anticancer, treating bacterial and viral infections of the respiratory and the gastrointestinal tract, cleaning away heat, moistening aridity, purging fire, detoxifying toxicosis, reducing the total cholesterol level and decreasing blood pressures.", [["roots", "ANATOMY", 4, 9], ["anticancer", "ANATOMY", 48, 58], ["respiratory", "ANATOMY", 107, 118], ["gastrointestinal tract", "ANATOMY", 127, 149], ["blood", "ANATOMY", 280, 285], ["bacterial and viral infections of the respiratory and the gastrointestinal tract", "DISEASE", 69, 149], ["toxicosis", "DISEASE", 217, 226], ["cholesterol", "CHEMICAL", 247, 258], ["cholesterol", "CHEMICAL", 247, 258], ["roots", "ORGAN", 4, 9], ["anticancer", "CANCER", 48, 58], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 127, 149], ["cholesterol", "SIMPLE_CHEMICAL", 247, 258], ["blood", "ORGANISM_SUBSTANCE", 280, 285], ["anti-inflammation", "TREATMENT", 29, 46], ["anticancer", "TREATMENT", 48, 58], ["bacterial and viral infections of the respiratory and the gastrointestinal tract", "PROBLEM", 69, 149], ["detoxifying toxicosis", "PROBLEM", 205, 226], ["the total cholesterol level", "TEST", 237, 264], ["decreasing blood pressures", "PROBLEM", 269, 295], ["roots", "OBSERVATION_MODIFIER", 4, 9], ["viral", "OBSERVATION_MODIFIER", 83, 88], ["infections", "OBSERVATION", 89, 99], ["respiratory", "ANATOMY", 107, 118], ["gastrointestinal tract", "ANATOMY", 127, 149], ["pressures", "OBSERVATION_MODIFIER", 286, 295]]], ["This herb also possesses cholagogic, diuretic, and cathartic actions.", [["diuretic", "TREATMENT", 37, 45], ["cathartic actions", "TREATMENT", 51, 68]]], ["Some concentrated composite herbal preparations that contain S. baicalensis Georgi as a major ingredient in their prescriptions are widely used in oriental countries [1] [2] [3] [4] .", [["S. baicalensis Georgi", "ORGANISM", 61, 82], ["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 166, 181], ["S. baicalensis", "SPECIES", 61, 75], ["S. baicalensis", "SPECIES", 61, 75], ["Some concentrated composite herbal preparations", "TREATMENT", 0, 47], ["concentrated", "OBSERVATION_MODIFIER", 5, 17], ["composite", "OBSERVATION_MODIFIER", 18, 27], ["herbal preparations", "OBSERVATION_MODIFIER", 28, 47], ["baicalensis Georgi", "OBSERVATION", 64, 82]]], ["S. baicalensis Georgi contains a variety of flavones, phenylethanoids, amino acids, sterols and essential oils.", [["oils", "ANATOMY", 106, 110], ["S. baicalensis Georgi", "CHEMICAL", 0, 21], ["phenylethanoids", "CHEMICAL", 54, 69], ["amino acids", "CHEMICAL", 71, 82], ["sterols", "CHEMICAL", 84, 91], ["flavones", "CHEMICAL", 44, 52], ["phenylethanoids", "CHEMICAL", 54, 69], ["amino acids", "CHEMICAL", 71, 82], ["sterols", "CHEMICAL", 84, 91], ["S. baicalensis", "ORGANISM", 0, 14], ["Georgi", "ORGANISM", 15, 21], ["flavones", "SIMPLE_CHEMICAL", 44, 52], ["phenylethanoids", "SIMPLE_CHEMICAL", 54, 69], ["amino acids", "SIMPLE_CHEMICAL", 71, 82], ["sterols", "SIMPLE_CHEMICAL", 84, 91], ["S. baicalensis", "SPECIES", 0, 14], ["S. baicalensis", "SPECIES", 0, 14], ["flavones", "TREATMENT", 44, 52], ["phenylethanoids", "TREATMENT", 54, 69], ["amino acids", "TREATMENT", 71, 82], ["sterols and essential oils", "TREATMENT", 84, 110], ["baicalensis Georgi", "OBSERVATION", 3, 21]]], ["Its dried roots contain over 30 kinds of flavonoids, such as baicalin, baicalein, wogonin, wogonin 7-O-glucuronide, oroxylin A, and oroxylin A 7-O-glucuronide.", [["roots", "ANATOMY", 10, 15], ["baicalin", "CHEMICAL", 61, 69], ["baicalein", "CHEMICAL", 71, 80], ["wogonin", "CHEMICAL", 82, 89], ["wogonin 7-O-glucuronide", "CHEMICAL", 91, 114], ["oroxylin A", "CHEMICAL", 116, 126], ["oroxylin A 7-O-glucuronide", "CHEMICAL", 132, 158], ["flavonoids", "CHEMICAL", 41, 51], ["baicalin", "CHEMICAL", 61, 69], ["baicalein", "CHEMICAL", 71, 80], ["wogonin", "CHEMICAL", 82, 89], ["wogonin 7-O-glucuronide", "CHEMICAL", 91, 114], ["oroxylin A", "CHEMICAL", 116, 126], ["oroxylin A 7-O-glucuronide", "CHEMICAL", 132, 158], ["roots", "ORGAN", 10, 15], ["flavonoids", "SIMPLE_CHEMICAL", 41, 51], ["baicalin", "SIMPLE_CHEMICAL", 61, 69], ["baicalein", "SIMPLE_CHEMICAL", 71, 80], ["wogonin", "SIMPLE_CHEMICAL", 82, 89], ["wogonin 7-O-glucuronide", "SIMPLE_CHEMICAL", 91, 114], ["oroxylin A", "SIMPLE_CHEMICAL", 116, 126], ["oroxylin A 7-O-glucuronide", "SIMPLE_CHEMICAL", 132, 158], ["flavonoids", "TREATMENT", 41, 51], ["baicalin", "TREATMENT", 61, 69], ["baicalein", "TREATMENT", 71, 80], ["wogonin", "TREATMENT", 82, 89], ["wogonin", "TREATMENT", 91, 98], ["glucuronide", "TREATMENT", 103, 114], ["oroxylin A", "TREATMENT", 116, 126], ["oroxylin", "TREATMENT", 132, 140], ["glucuronide", "TREATMENT", 147, 158], ["dried roots", "OBSERVATION", 4, 15]]], ["Baicalin, baicalein, wogonin and oroxylin A are the main active components in S. baicalensis Georgi [5] [6] [7] [8] .", [["Baicalin", "CHEMICAL", 0, 8], ["baicalein", "CHEMICAL", 10, 19], ["wogonin", "CHEMICAL", 21, 28], ["oroxylin A", "CHEMICAL", 33, 43], ["Baicalin", "CHEMICAL", 0, 8], ["baicalein", "CHEMICAL", 10, 19], ["wogonin", "CHEMICAL", 21, 28], ["oroxylin A", "CHEMICAL", 33, 43], ["Baicalin", "SIMPLE_CHEMICAL", 0, 8], ["baicalein", "SIMPLE_CHEMICAL", 10, 19], ["wogonin", "SIMPLE_CHEMICAL", 21, 28], ["oroxylin A", "SIMPLE_CHEMICAL", 33, 43], ["S. baicalensis", "ORGANISM", 78, 92], ["5] [6] [7] [8]", "SIMPLE_CHEMICAL", 101, 115], ["S. baicalensis", "SPECIES", 78, 92], ["S. baicalensis", "SPECIES", 78, 92], ["Baicalin", "TREATMENT", 0, 8], ["baicalein", "TREATMENT", 10, 19], ["wogonin", "TREATMENT", 21, 28], ["oroxylin", "TREATMENT", 33, 41], ["baicalein", "OBSERVATION_MODIFIER", 10, 19]]], ["Baicalin is the most abundant component, and has anti-allergic [9] , antiinflammatory [10] , anti-HIV [11, 12] , anti-tumor [13] [14] [15] , antioxidant and free radical scavenging [16, 17] , and anti-SARS coronavirus effects [18] .", [["Baicalin", "CHEMICAL", 0, 8], ["[13] [14] [15]", "CHEMICAL", 124, 138], ["Baicalin", "CHEMICAL", 0, 8], ["Baicalin", "SIMPLE_CHEMICAL", 0, 8], ["antiinflammatory [10]", "SIMPLE_CHEMICAL", 69, 90], ["anti-HIV", "SIMPLE_CHEMICAL", 93, 101], ["11, 12]", "SIMPLE_CHEMICAL", 103, 110], ["anti-tumor [13] [14] [15]", "SIMPLE_CHEMICAL", 113, 138], ["antioxidant", "SIMPLE_CHEMICAL", 141, 152], ["free radical scavenging [16, 17]", "SIMPLE_CHEMICAL", 157, 189], ["HIV", "SPECIES", 98, 101], ["HIV", "SPECIES", 98, 101], ["Baicalin", "TREATMENT", 0, 8], ["antiinflammatory", "TREATMENT", 69, 85], ["anti-HIV", "TREATMENT", 93, 101], ["antioxidant", "TREATMENT", 141, 152], ["free radical scavenging", "TREATMENT", 157, 180], ["anti-SARS coronavirus effects", "TREATMENT", 196, 225], ["most abundant", "OBSERVATION_MODIFIER", 16, 29], ["component", "OBSERVATION_MODIFIER", 30, 39]]], ["Baicalein possesses anti-HIV [11, 12] , anti-tumor [15] , antioxidant and free radical scavenging effects [16, 17] .", [["Baicalein", "CHEMICAL", 0, 9], ["Baicalein", "CHEMICAL", 0, 9], ["Baicalein", "SIMPLE_CHEMICAL", 0, 9], ["11, 12]", "SIMPLE_CHEMICAL", 30, 37], ["anti-tumor [15]", "SIMPLE_CHEMICAL", 40, 55], ["free radical", "SIMPLE_CHEMICAL", 74, 86], ["Baicalein possesses anti-HIV", "TREATMENT", 0, 28], ["antioxidant", "TREATMENT", 58, 69], ["free radical scavenging effects", "TREATMENT", 74, 105]]], ["Wogonin has anti-respiratory syncytial virus [19] , anti-hepatitis B virus [20] , anti-tumor [15] , antioxidant and free radical scavenging effects [17] .", [["Wogonin", "CHEMICAL", 0, 7], ["anti-hepatitis B virus [20]", "CHEMICAL", 52, 79], ["Wogonin", "GENE_OR_GENE_PRODUCT", 0, 7], ["anti-respiratory syncytial virus", "ORGANISM", 12, 44], ["anti-hepatitis B virus", "ORGANISM", 52, 74], ["anti-tumor [15]", "SIMPLE_CHEMICAL", 82, 97], ["antioxidant", "SIMPLE_CHEMICAL", 100, 111], ["free radical", "SIMPLE_CHEMICAL", 116, 128], ["anti-hepatitis B virus", "SPECIES", 52, 74], ["anti-hepatitis B virus", "SPECIES", 52, 74], ["Wogonin", "TREATMENT", 0, 7], ["anti-respiratory syncytial virus", "PROBLEM", 12, 44], ["anti-hepatitis B virus", "PROBLEM", 52, 74], ["antioxidant", "TREATMENT", 100, 111], ["free radical scavenging effects", "TREATMENT", 116, 147], ["syncytial virus", "OBSERVATION", 29, 44]]], ["Oroxylin A has anti-respiratory syncytial virus activity [19] .IntroductionThe quantitative and qualitative determination of pharmaceutical components is critical in all stages of drug discovery.", [["Oroxylin A", "CHEMICAL", 0, 10], ["Oroxylin A", "CHEMICAL", 0, 10], ["Oroxylin A", "SIMPLE_CHEMICAL", 0, 10], ["anti-respiratory syncytial virus", "ORGANISM", 15, 47], ["Oroxylin", "TREATMENT", 0, 8], ["anti-respiratory syncytial virus activity", "PROBLEM", 15, 56], ["pharmaceutical components", "TREATMENT", 125, 150], ["all stages", "OBSERVATION_MODIFIER", 166, 176]]], ["Biological analyses in support of ADME (absorption, distribution, metabolism and excretion), pharmacokinetic, and toxicokinetic studies are crucial in the drug selection and optimization processes [21] .", [["ADME", "CHEMICAL", 34, 38], ["toxicokinetic studies", "TEST", 114, 135]]], ["A variety of separation techniques have been employed for the quantitative determination of S. baicalensis active components in various matrices.", [["S. baicalensis", "ORGANISM", 92, 106], ["S. baicalensis", "SPECIES", 92, 106], ["S. baicalensis", "SPECIES", 92, 106], ["separation techniques", "TREATMENT", 13, 34], ["S. baicalensis active components", "PROBLEM", 92, 124], ["baicalensis active", "OBSERVATION", 95, 113]]], ["These techniques include high-performance liquid chromatography (HPLC), high-speed counter-current chromatography (HSCCC), thin layer chromatography (TLC), capillary electrophoresis (CE), and micellar electrokinetic capillary chromatography (MEKC).", [["These techniques", "TEST", 0, 16], ["HPLC", "TEST", 65, 69], ["current chromatography", "TEST", 91, 113], ["thin layer chromatography", "TEST", 123, 148], ["TLC", "TEST", 150, 153], ["capillary electrophoresis", "TEST", 156, 181], ["micellar electrokinetic capillary chromatography", "TEST", 192, 240]]], ["Fig. 1 shows chemical structures of six S. baicalensis active components.", [["S. baicalensis", "ORGANISM", 40, 54], ["S. baicalensis", "SPECIES", 40, 54], ["S. baicalensis", "SPECIES", 40, 54], ["baicalensis", "OBSERVATION_MODIFIER", 43, 54], ["active", "OBSERVATION_MODIFIER", 55, 61], ["components", "OBSERVATION_MODIFIER", 62, 72]]], ["This review provides an overview of separation, detection, and identification methods employed for these active components in various types of samples.High-performance liquid chromatographyHigh-performance liquid chromatographic (HPLC) methods have been widely applied to the separation and determination of S. baicalensis Georgi active components in various matrices.", [["samples", "ANATOMY", 143, 150], ["samples", "CANCER", 143, 150], ["S. baicalensis", "ORGANISM", 308, 322], ["S. baicalensis", "SPECIES", 308, 322], ["S. baicalensis", "SPECIES", 308, 322], ["these active components", "PROBLEM", 99, 122], ["High-performance liquid chromatography", "TREATMENT", 151, 189], ["High-performance liquid chromatographic (HPLC) methods", "TREATMENT", 189, 243], ["the separation", "TREATMENT", 272, 286], ["S. baicalensis", "PROBLEM", 308, 322], ["baicalensis Georgi active", "OBSERVATION", 311, 336], ["various matrices", "OBSERVATION", 351, 367]]], ["Analyses of plant and raw medical material samples are discussed first, followed by medicinal preparations, and then biological fluids (blood and urine) samples.Analysis of plant and raw medical materialsThe active components must be extracted from plant or raw medical material samples prior to analysis by HPLC.", [["blood", "ANATOMY", 136, 141], ["urine", "ANATOMY", 146, 151], ["samples", "ANATOMY", 153, 160], ["blood", "ORGANISM_SUBSTANCE", 136, 141], ["urine", "ORGANISM_SUBSTANCE", 146, 151], ["blood and urine) samples", "TEST", 136, 160], ["analysis", "TEST", 296, 304], ["HPLC", "TEST", 308, 312], ["active", "OBSERVATION_MODIFIER", 208, 214]]], ["Several extraction techniques have been developed [22] [23] [24] .", [["Several extraction techniques", "TREATMENT", 0, 29]]], ["Solid-phase extraction (SPE) is a commonly employed sample preparation method for drug compounds in complex matrices.", [["sample", "ANATOMY", 52, 58], ["Solid-phase extraction", "TREATMENT", 0, 22], ["drug compounds in complex matrices", "PROBLEM", 82, 116], ["phase", "OBSERVATION_MODIFIER", 6, 11]]], ["SPE is used to selectively remove interfering matrix components, leading to reduced time required for chromatographic method development and improved assay selectivity, accuracy, and sensitivity.", [["matrix", "ANATOMY", 46, 52], ["SPE", "CHEMICAL", 0, 3], ["interfering matrix components", "TREATMENT", 34, 63], ["chromatographic method development", "TREATMENT", 102, 136], ["accuracy", "TEST", 169, 177], ["sensitivity", "TEST", 183, 194]]], ["A method combining solid-phase extraction and reversed phase high-performance liquid chromatography was recently developed for simultaneous isolation and determination of flavanes (baicalin, baicalein, chrysin, scutellarein) and some phenolic acids in aerial and underground parts of S. baicalensis Georgi [22] .", [["flavanes", "CHEMICAL", 171, 179], ["baicalin", "CHEMICAL", 181, 189], ["baicalein", "CHEMICAL", 191, 200], ["chrysin", "CHEMICAL", 202, 209], ["scutellarein", "CHEMICAL", 211, 223], ["phenolic acids", "CHEMICAL", 234, 248], ["flavanes", "CHEMICAL", 171, 179], ["baicalin", "CHEMICAL", 181, 189], ["baicalein", "CHEMICAL", 191, 200], ["chrysin", "CHEMICAL", 202, 209], ["scutellarein", "CHEMICAL", 211, 223], ["phenolic acids", "CHEMICAL", 234, 248], ["flavanes", "SIMPLE_CHEMICAL", 171, 179], ["baicalin", "SIMPLE_CHEMICAL", 181, 189], ["baicalein", "SIMPLE_CHEMICAL", 191, 200], ["chrysin", "SIMPLE_CHEMICAL", 202, 209], ["scutellarein", "SIMPLE_CHEMICAL", 211, 223], ["phenolic acids", "SIMPLE_CHEMICAL", 234, 248], ["S. baicalensis", "ORGANISM", 284, 298], ["S. baicalensis", "SPECIES", 284, 298], ["S. baicalensis", "SPECIES", 284, 298], ["A method combining solid-phase extraction", "TREATMENT", 0, 41], ["performance liquid chromatography", "TEST", 66, 99], ["simultaneous isolation", "TREATMENT", 127, 149], ["flavanes", "TREATMENT", 171, 179], ["baicalin", "TREATMENT", 181, 189], ["baicalein", "TREATMENT", 191, 200], ["chrysin", "TREATMENT", 202, 209], ["scutellarein", "TREATMENT", 211, 223], ["some phenolic acids", "TREATMENT", 229, 248], ["phenolic acids", "OBSERVATION", 234, 248], ["baicalensis Georgi", "OBSERVATION", 287, 305]]], ["The application of optimized enrichment conditions, elaborated on octadecyl and quaternary amine BakerBond microcolumns, led to the extraction of both groups of analytes with recoveries >95% and variation coefficients <5%.", [["octadecyl", "CHEMICAL", 66, 75], ["octadecyl and quaternary amine", "CHEMICAL", 66, 96], ["octadecyl", "SIMPLE_CHEMICAL", 66, 75], ["quaternary amine BakerBond", "SIMPLE_CHEMICAL", 80, 106], ["optimized enrichment conditions", "TREATMENT", 19, 50], ["octadecyl and quaternary amine BakerBond microcolumns", "TREATMENT", 66, 119], ["the extraction", "TREATMENT", 128, 142], ["recoveries", "TEST", 175, 185], ["variation coefficients", "TEST", 195, 217], ["enrichment conditions", "OBSERVATION", 29, 50]]], ["Supercritical fluid extraction (SFE) is another widely used technique for extraction of active components from plant or raw medical material samples, in which supercritical carbon dioxide is often used as an extraction solvent.", [["samples", "ANATOMY", 141, 148], ["carbon dioxide", "CHEMICAL", 173, 187], ["carbon dioxide", "CHEMICAL", 173, 187], ["carbon dioxide", "SIMPLE_CHEMICAL", 173, 187], ["Supercritical fluid extraction", "TREATMENT", 0, 30], ["extraction", "TREATMENT", 74, 84], ["active components", "PROBLEM", 88, 105], ["supercritical carbon dioxide", "TREATMENT", 159, 187], ["an extraction solvent", "TREATMENT", 205, 226], ["fluid extraction", "OBSERVATION", 14, 30], ["active", "OBSERVATION_MODIFIER", 88, 94]]], ["The use of carbon dioxide has the following advantages: chemically inert, low toxicity, no pollution problem, and shorter concentration time.", [["carbon dioxide", "CHEMICAL", 11, 25], ["toxicity", "DISEASE", 78, 86], ["carbon dioxide", "CHEMICAL", 11, 25], ["carbon dioxide", "SIMPLE_CHEMICAL", 11, 25], ["carbon dioxide", "TREATMENT", 11, 25], ["chemically inert", "PROBLEM", 56, 72], ["low toxicity", "PROBLEM", 74, 86]]], ["Under supercritical conditions, the solubility and diffusivity of the analytes in extraction fluid are increased, leading to improved extraction.", [["the solubility", "TREATMENT", 32, 46], ["the analytes in extraction fluid", "TREATMENT", 66, 98], ["supercritical conditions", "OBSERVATION", 6, 30], ["fluid", "OBSERVATION", 93, 98], ["increased", "OBSERVATION_MODIFIER", 103, 112], ["improved", "OBSERVATION_MODIFIER", 125, 133]]], ["For the extraction of polar or ionic compounds, organic solvents are added as modifiers or the compounds are first derivatized to decrease their polarity.", [["the extraction", "TREATMENT", 4, 18], ["polar or ionic compounds", "TREATMENT", 22, 46], ["organic solvents", "TREATMENT", 48, 64], ["polar", "OBSERVATION_MODIFIER", 22, 27], ["ionic compounds", "OBSERVATION", 31, 46]]], ["SFE was applied to the extraction of baicalin, baicalein and wogonin from S. baicalensis [23] .", [["baicalin", "CHEMICAL", 37, 45], ["baicalein", "CHEMICAL", 47, 56], ["wogonin", "CHEMICAL", 61, 68], ["baicalin", "CHEMICAL", 37, 45], ["baicalein", "CHEMICAL", 47, 56], ["wogonin", "CHEMICAL", 61, 68], ["baicalin", "SIMPLE_CHEMICAL", 37, 45], ["baicalein", "SIMPLE_CHEMICAL", 47, 56], ["wogonin", "SIMPLE_CHEMICAL", 61, 68], ["S. baicalensis", "ORGANISM", 74, 88], ["S. baicalensis", "SPECIES", 74, 88], ["S. baicalensis", "SPECIES", 74, 88], ["baicalin", "TREATMENT", 37, 45], ["baicalein", "TREATMENT", 47, 56], ["wogonin", "TREATMENT", 61, 68]]], ["The optimal conditions of SFE were as follows: supercritical carbon dioxide-methanol-water (20:2.1:0.9), 50 \u2022 C and 200 bar.", [["carbon dioxide-methanol", "CHEMICAL", 61, 84], ["carbon dioxide", "CHEMICAL", 61, 75], ["methanol", "CHEMICAL", 76, 84], ["carbon dioxide", "SIMPLE_CHEMICAL", 61, 75], ["supercritical carbon dioxide", "TREATMENT", 47, 75]]], ["The SFE method gave high yields of the three flavanoids in shorter time than ultrasonic or percolation extraction.", [["flavanoids", "CHEMICAL", 45, 55], ["The SFE method", "TREATMENT", 0, 14], ["ultrasonic or percolation extraction", "TREATMENT", 77, 113]]], ["Pressurized liquid extraction (PLE) with methanol as solvent was proposed for the extraction of baicalein from Scutellariae radix [24] .", [["methanol", "CHEMICAL", 41, 49], ["baicalein", "CHEMICAL", 96, 105], ["Scutellariae radix", "CHEMICAL", 111, 129], ["methanol", "CHEMICAL", 41, 49], ["baicalein", "CHEMICAL", 96, 105], ["methanol", "SIMPLE_CHEMICAL", 41, 49], ["baicalein", "SIMPLE_CHEMICAL", 96, 105], ["Scutellariae radix", "SPECIES", 111, 129], ["Pressurized liquid extraction", "TREATMENT", 0, 29], ["methanol as solvent", "TREATMENT", 41, 60], ["the extraction of baicalein from Scutellariae radix", "TREATMENT", 78, 129]]], ["The comparable performance of PLE with reference to Soxhlet extraction was due to the higher diffusion rate and higher solubility of analyte in the solvent as a result of the higher temperature.", [["PLE", "CHEMICAL", 30, 33], ["Soxhlet extraction", "TREATMENT", 52, 70], ["the higher diffusion rate", "PROBLEM", 82, 107], ["analyte in the solvent", "TREATMENT", 133, 155], ["the higher temperature", "PROBLEM", 171, 193]]], ["At high temperature, the strong solute-matrix interaction in the plant materials caused by van der Waals forces, hydrogen bonding and dipole attractions between solute molecules and active sites on the matrix were disrupted.", [["matrix", "ANATOMY", 202, 208], ["hydrogen", "CHEMICAL", 113, 121], ["hydrogen", "CHEMICAL", 113, 121], ["matrix", "CELLULAR_COMPONENT", 39, 45], ["hydrogen", "SIMPLE_CHEMICAL", 113, 121], ["solute molecules", "SIMPLE_CHEMICAL", 161, 177], ["matrix", "CELLULAR_COMPONENT", 202, 208], ["high temperature", "PROBLEM", 3, 19], ["the strong solute-matrix interaction", "TREATMENT", 21, 57], ["van der Waals forces", "TREATMENT", 91, 111], ["hydrogen bonding and dipole attractions between solute molecules", "TREATMENT", 113, 177], ["high temperature", "OBSERVATION_MODIFIER", 3, 19], ["strong", "OBSERVATION_MODIFIER", 25, 31], ["active", "OBSERVATION_MODIFIER", 182, 188], ["sites", "OBSERVATION_MODIFIER", 189, 194]]], ["To reduce the use of organic solvent, pressurized hot water extraction (PHWE) was developed for the extraction of baicalein from Scutellariae radix [24] .", [["baicalein", "CHEMICAL", 114, 123], ["Scutellariae radix", "CHEMICAL", 129, 147], ["baicalein", "CHEMICAL", 114, 123], ["baicalein", "SIMPLE_CHEMICAL", 114, 123], ["Scutellariae radix", "SPECIES", 129, 147], ["organic solvent", "TREATMENT", 21, 36], ["pressurized hot water extraction", "TREATMENT", 38, 70], ["the extraction of baicalein from Scutellariae radix", "TREATMENT", 96, 147]]], ["Ethanol as organic modifier was added into the liquid used in PHWE.", [["Ethanol", "CHEMICAL", 0, 7], ["Ethanol", "CHEMICAL", 0, 7], ["Ethanol", "SIMPLE_CHEMICAL", 0, 7], ["PHWE", "SIMPLE_CHEMICAL", 62, 66], ["Ethanol", "TREATMENT", 0, 7], ["organic modifier", "TREATMENT", 11, 27]]], ["PHWE was carried out dynamically at a flow-rate of 1 ml min \u22121 , temperature between 95 and 140 \u2022 C, an applied pressure of 10-20 bar and extraction time of 40 min.", [["temperature", "TEST", 65, 76]]], ["Although baicalein was insoluble in water, the results showed that water with a small proportion (20%) of ethanol at a temperature below its boiling point and a small applied pressure was able to extract an equivalent amount of baicalein from medicinal plant compared with Soxhlet extraction with aqueous organic solvent.", [["baicalein", "CHEMICAL", 9, 18], ["ethanol", "CHEMICAL", 106, 113], ["baicalein", "CHEMICAL", 228, 237], ["baicalein", "CHEMICAL", 9, 18], ["ethanol", "CHEMICAL", 106, 113], ["baicalein", "CHEMICAL", 228, 237], ["baicalein", "SIMPLE_CHEMICAL", 9, 18], ["water", "SIMPLE_CHEMICAL", 36, 41], ["water", "SIMPLE_CHEMICAL", 67, 72], ["ethanol", "SIMPLE_CHEMICAL", 106, 113], ["baicalein", "SIMPLE_CHEMICAL", 228, 237], ["a small applied pressure", "TREATMENT", 159, 183], ["baicalein from medicinal plant", "TREATMENT", 228, 258], ["Soxhlet extraction", "TREATMENT", 273, 291], ["aqueous organic solvent", "TREATMENT", 297, 320], ["insoluble", "OBSERVATION_MODIFIER", 23, 32], ["small", "OBSERVATION_MODIFIER", 80, 85], ["small", "OBSERVATION_MODIFIER", 161, 166], ["equivalent", "OBSERVATION_MODIFIER", 207, 217], ["amount", "OBSERVATION_MODIFIER", 218, 224], ["baicalein", "OBSERVATION_MODIFIER", 228, 237], ["medicinal plant", "OBSERVATION", 243, 258], ["organic solvent", "OBSERVATION", 305, 320]]], ["The results obtained by PHWE were in agreement with those using PLE with methanol as the extraction solvent.Analysis of plant and raw medical materialsSeveral methods have been proposed for the determination of S. baicalensis Georgi active components in plant or raw medical material samples by HPLC [25] [26] [27] [28] [29] .", [["methanol", "CHEMICAL", 73, 81], ["methanol", "CHEMICAL", 73, 81], ["PHWE", "SIMPLE_CHEMICAL", 24, 28], ["methanol", "SIMPLE_CHEMICAL", 73, 81], ["S. baicalensis", "ORGANISM", 211, 225], ["[25] [26] [27] [28] [29]", "SIMPLE_CHEMICAL", 300, 324], ["S. baicalensis", "SPECIES", 211, 225], ["S. baicalensis", "SPECIES", 211, 225], ["methanol", "TREATMENT", 73, 81], ["the extraction solvent", "TREATMENT", 85, 107], ["Several methods", "TREATMENT", 151, 166], ["S. baicalensis", "PROBLEM", 211, 225], ["HPLC", "TEST", 295, 299]]], ["Baicalin was determined by HPLC on a Hypersil C 18 column (25 cm \u00d7 4.6 mm i.d.) with methanol/0.04% H 3 PO 4 (23:27) as mobile phase (1 ml min \u22121 ) and detection at 280 nm [25] .", [["Baicalin", "CHEMICAL", 0, 8], ["methanol", "CHEMICAL", 85, 93], ["H", "CHEMICAL", 100, 101], ["Baicalin", "CHEMICAL", 0, 8], ["methanol", "CHEMICAL", 85, 93], ["H 3 PO 4", "CHEMICAL", 100, 108], ["Baicalin", "SIMPLE_CHEMICAL", 0, 8], ["methanol", "SIMPLE_CHEMICAL", 85, 93], ["Baicalin", "TREATMENT", 0, 8], ["a Hypersil C 18 column", "TREATMENT", 35, 57], ["methanol", "TREATMENT", 85, 93]]], ["The method was applied to the determination of baicalin in the raw medical materials and two different processing drugs of S. baicalensis, and the contents of baicalin were 6.8, 6.0 and 6.73%, respectively.", [["baicalin", "CHEMICAL", 47, 55], ["baicalin", "CHEMICAL", 159, 167], ["baicalin", "CHEMICAL", 47, 55], ["baicalin", "CHEMICAL", 159, 167], ["baicalin", "SIMPLE_CHEMICAL", 47, 55], ["S. baicalensis", "ORGANISM", 123, 137], ["baicalin", "SIMPLE_CHEMICAL", 159, 167], ["S. baicalensis", "SPECIES", 123, 137], ["S. baicalensis", "SPECIES", 123, 137], ["The method", "TREATMENT", 0, 10], ["baicalin", "TREATMENT", 47, 55], ["S. baicalensis", "TREATMENT", 123, 137], ["baicalin", "TEST", 159, 167], ["baicalensis", "ANATOMY", 126, 137]]], ["In another method, two components were determined by HPLC in a single run on an YMC-Pack ODS A-132 column (15 cm \u00d7 6 mm i.d.) with methanol/0.1M phosphate buffer as mobile phase (1:1 for baicalin and wogonin, or 17:8 for baicalein and wogonin 7-O-glucuronide) and detection at 270 nm [26] .", [["0.1M phosphate", "CHEMICAL", 140, 154], ["baicalin", "CHEMICAL", 187, 195], ["wogonin", "CHEMICAL", 200, 207], ["baicalein", "CHEMICAL", 221, 230], ["wogonin", "CHEMICAL", 235, 242], ["7-O-glucuronide", "CHEMICAL", 243, 258], ["methanol", "CHEMICAL", 131, 139], ["phosphate", "CHEMICAL", 145, 154], ["baicalin", "CHEMICAL", 187, 195], ["wogonin", "CHEMICAL", 200, 207], ["baicalein", "CHEMICAL", 221, 230], ["wogonin", "CHEMICAL", 235, 242], ["7-O-glucuronide", "CHEMICAL", 243, 258], ["methanol", "SIMPLE_CHEMICAL", 131, 139], ["baicalin", "SIMPLE_CHEMICAL", 187, 195], ["wogonin", "SIMPLE_CHEMICAL", 200, 207], ["baicalein", "SIMPLE_CHEMICAL", 221, 230], ["wogonin 7-O-glucuronide", "SIMPLE_CHEMICAL", 235, 258], ["an YMC", "TEST", 77, 83], ["methanol/0.1M phosphate buffer", "TREATMENT", 131, 161], ["baicalin", "TREATMENT", 187, 195], ["wogonin", "TREATMENT", 200, 207], ["baicalein", "TREATMENT", 221, 230], ["wogonin", "TEST", 235, 242]]], ["The method was applied to the comparative study of the concentrations of four flavonoids in two Scutellaria species (S.).", [["flavonoids", "CHEMICAL", 78, 88], ["flavonoids", "CHEMICAL", 78, 88], ["flavonoids", "SIMPLE_CHEMICAL", 78, 88], ["The method", "TREATMENT", 0, 10], ["the comparative study", "TEST", 26, 47], ["four flavonoids", "PROBLEM", 73, 88], ["Scutellaria species", "OBSERVATION", 96, 115]]], ["The concentrations of baicalin, baicalein, wogonin and wogonin 7-O-glucuronide were 12.77, 3.53, 0.93 and 3.56 and 14.40, 3.08, 0.97 and 2.99%, respectively in S. planipes and S. baicalensis.", [["baicalin", "CHEMICAL", 22, 30], ["baicalein", "CHEMICAL", 32, 41], ["wogonin", "CHEMICAL", 43, 50], ["wogonin", "CHEMICAL", 55, 62], ["7-O-glucuronide", "CHEMICAL", 63, 78], ["baicalin", "CHEMICAL", 22, 30], ["baicalein", "CHEMICAL", 32, 41], ["wogonin", "CHEMICAL", 43, 50], ["wogonin", "CHEMICAL", 55, 62], ["7-O-glucuronide", "CHEMICAL", 63, 78], ["baicalin", "SIMPLE_CHEMICAL", 22, 30], ["baicalein", "SIMPLE_CHEMICAL", 32, 41], ["wogonin", "SIMPLE_CHEMICAL", 43, 50], ["wogonin 7-O-glucuronide", "SIMPLE_CHEMICAL", 55, 78], ["S. planipes", "ORGANISM", 160, 171], ["S. baicalensis", "ORGANISM", 176, 190], ["S. planipes", "SPECIES", 160, 171], ["S. baicalensis", "SPECIES", 176, 190], ["S. planipes", "SPECIES", 160, 171], ["S. baicalensis", "SPECIES", 176, 190], ["baicalin", "TREATMENT", 22, 30], ["baicalein", "TREATMENT", 32, 41], ["wogonin", "TREATMENT", 43, 50], ["wogonin", "TEST", 55, 62], ["glucuronide", "TEST", 67, 78], ["concentrations", "OBSERVATION_MODIFIER", 4, 18], ["baicalin", "ANATOMY", 22, 30], ["baicalensis", "OBSERVATION_MODIFIER", 179, 190]]], ["Actually, more components could be determined simultaneously by HPLC [27] [28] [29] .", [["HPLC", "TEST", 64, 68]]], ["The three components, baicalin, baicalein and wogonin in Scutellariae radix were determined by HPLC on a 10 m ODS Hypersil column (25 cm \u00d7 4.6 mm i.d.) with gradient elution of acetonitrile and 0.1 M H 3 PO 4 as mobile phase and detection at 280 nm [27] .", [["baicalin", "CHEMICAL", 22, 30], ["baicalein", "CHEMICAL", 32, 41], ["wogonin", "CHEMICAL", 46, 53], ["Scutellariae radix", "CHEMICAL", 57, 75], ["acetonitrile", "CHEMICAL", 177, 189], ["baicalin", "CHEMICAL", 22, 30], ["baicalein", "CHEMICAL", 32, 41], ["wogonin", "CHEMICAL", 46, 53], ["acetonitrile", "CHEMICAL", 177, 189], ["H 3 PO 4", "CHEMICAL", 200, 208], ["baicalin", "SIMPLE_CHEMICAL", 22, 30], ["baicalein", "SIMPLE_CHEMICAL", 32, 41], ["wogonin", "SIMPLE_CHEMICAL", 46, 53], ["Scutellariae radix", "ORGANISM", 57, 75], ["acetonitrile", "SIMPLE_CHEMICAL", 177, 189], ["Scutellariae radix", "SPECIES", 57, 75], ["baicalin", "TREATMENT", 22, 30], ["baicalein", "TREATMENT", 32, 41], ["wogonin in Scutellariae radix", "TREATMENT", 46, 75], ["a 10 m ODS Hypersil column", "TREATMENT", 103, 129], ["gradient elution of acetonitrile", "TREATMENT", 157, 189], ["baicalin", "OBSERVATION_MODIFIER", 22, 30], ["baicalein", "OBSERVATION_MODIFIER", 32, 41], ["wogonin", "OBSERVATION_MODIFIER", 46, 53], ["Scutellariae radix", "ANATOMY", 57, 75]]], ["The six main bioactive components, baicalein, baicalin, wogonin, wogonin glucuronide, oroxylin-A and oroxylin-A glucuronide in Scutellariae radix could be determined simultaneously by ion-pair highperformance liquid chromatography on a stainless-steel column (15 cm \u00d7 4 mm i.d.) packed with TSK gel LS-410 (5 m) with aqueous 32% acetonitrile, containing 5 mM tetrapentylammonium bromide, as mobile phase, adjusted to pH 4 with H 3 PO 4 [28] .", [["baicalein", "CHEMICAL", 35, 44], ["baicalin", "CHEMICAL", 46, 54], ["wogonin", "CHEMICAL", 56, 63], ["wogonin glucuronide", "CHEMICAL", 65, 84], ["oroxylin-A", "CHEMICAL", 86, 96], ["oroxylin-A glucuronide", "CHEMICAL", 101, 123], ["Scutellariae radix", "CHEMICAL", 127, 145], ["LS-410", "CHEMICAL", 299, 305], ["acetonitrile", "CHEMICAL", 329, 341], ["tetrapentylammonium bromide", "CHEMICAL", 359, 386], ["baicalein", "CHEMICAL", 35, 44], ["baicalin", "CHEMICAL", 46, 54], ["wogonin", "CHEMICAL", 56, 63], ["wogonin glucuronide", "CHEMICAL", 65, 84], ["oroxylin-A", "CHEMICAL", 86, 96], ["oroxylin-A glucuronide", "CHEMICAL", 101, 123], ["acetonitrile", "CHEMICAL", 329, 341], ["tetrapentylammonium bromide", "CHEMICAL", 359, 386], ["H 3 PO", "CHEMICAL", 427, 433], ["baicalein", "SIMPLE_CHEMICAL", 35, 44], ["baicalin", "SIMPLE_CHEMICAL", 46, 54], ["wogonin", "SIMPLE_CHEMICAL", 56, 63], ["wogonin", "SIMPLE_CHEMICAL", 65, 72], ["glucuronide", "SIMPLE_CHEMICAL", 73, 84], ["oroxylin-A", "SIMPLE_CHEMICAL", 86, 96], ["oroxylin-A glucuronide", "SIMPLE_CHEMICAL", 101, 123], ["Scutellariae", "ORGANISM", 127, 139], ["radix", "ORGANISM", 140, 145], ["acetonitrile", "SIMPLE_CHEMICAL", 329, 341], ["tetrapentylammonium bromide", "SIMPLE_CHEMICAL", 359, 386], ["Scutellariae radix", "SPECIES", 127, 145], ["baicalein", "TREATMENT", 35, 44], ["baicalin", "TREATMENT", 46, 54], ["wogonin", "TREATMENT", 56, 63], ["wogonin glucuronide", "TREATMENT", 65, 84], ["oroxylin", "TREATMENT", 86, 94], ["oroxylin", "TREATMENT", 101, 109], ["A glucuronide in Scutellariae radix", "TREATMENT", 110, 145], ["a stainless-steel column", "TREATMENT", 234, 258], ["TSK gel LS", "TEST", 291, 301], ["aqueous 32% acetonitrile", "TREATMENT", 317, 341], ["5 mM tetrapentylammonium bromide", "TREATMENT", 354, 386], ["pH", "TEST", 417, 419], ["six", "OBSERVATION_MODIFIER", 4, 7], ["main", "OBSERVATION_MODIFIER", 8, 12], ["bioactive components", "OBSERVATION", 13, 33], ["baicalein", "OBSERVATION_MODIFIER", 35, 44], ["steel column", "OBSERVATION_MODIFIER", 246, 258]]], ["Oroxylin-A and its glucuronide were separated for the first time.", [["Oroxylin-A", "CHEMICAL", 0, 10], ["glucuronide", "CHEMICAL", 19, 30], ["Oroxylin-A and its glucuronide", "CHEMICAL", 0, 30], ["Oroxylin-A", "SIMPLE_CHEMICAL", 0, 10], ["glucuronide", "SIMPLE_CHEMICAL", 19, 30], ["Oroxylin", "TREATMENT", 0, 8], ["its glucuronide", "TREATMENT", 15, 30]]], ["The method was one of the best methods for the simultaneous determination of main active components in S. baicalensis Georgi.", [["S. baicalensis Georgi", "ORGANISM", 103, 124], ["S. baicalensis", "SPECIES", 103, 117], ["S. baicalensis", "SPECIES", 103, 117], ["baicalensis Georgi", "OBSERVATION", 106, 124]]], ["In another study, flavonoid constituents of the roots of S. baicalensis Georgi were determined by HPLC on a column ( [29] .", [["roots", "ANATOMY", 48, 53], ["flavonoid", "CHEMICAL", 18, 27], ["flavonoid", "CHEMICAL", 18, 27], ["flavonoid", "SIMPLE_CHEMICAL", 18, 27], ["roots", "ORGAN", 48, 53], ["S. baicalensis", "ORGANISM", 57, 71], ["Georgi", "ORGANISM", 72, 78], ["S. baicalensis", "SPECIES", 57, 71], ["S. baicalensis", "SPECIES", 57, 71], ["another study", "TEST", 3, 16], ["flavonoid constituents", "OBSERVATION", 18, 40], ["roots", "ANATOMY", 48, 53], ["baicalensis Georgi", "OBSERVATION", 60, 78]]], ["By a combination of two mobile phases, total 11 flavonoids were separated in two runs.", [["flavonoids", "CHEMICAL", 48, 58], ["flavonoids", "SIMPLE_CHEMICAL", 48, 58], ["total 11 flavonoids", "TREATMENT", 39, 58]]], ["In addition, the content of the main flavonoids in the roots of S. baicalensis Georgi cultivated in Central Europe was evaluated by an HPLC method with gradient of acetonitrile in mobile phase [30] .", [["roots", "ANATOMY", 55, 60], ["flavonoids", "CHEMICAL", 37, 47], ["S. baicalensis Georgi", "CHEMICAL", 64, 85], ["acetonitrile", "CHEMICAL", 164, 176], ["flavonoids", "CHEMICAL", 37, 47], ["acetonitrile", "CHEMICAL", 164, 176], ["flavonoids", "SIMPLE_CHEMICAL", 37, 47], ["roots", "ORGAN", 55, 60], ["S. baicalensis", "ORGANISM", 64, 78], ["Georgi", "ORGANISM", 79, 85], ["acetonitrile", "SIMPLE_CHEMICAL", 164, 176], ["S. baicalensis", "SPECIES", 64, 78], ["S. baicalensis", "SPECIES", 64, 78], ["the main flavonoids", "PROBLEM", 28, 47], ["an HPLC method", "TEST", 132, 146], ["main", "OBSERVATION_MODIFIER", 32, 36], ["flavonoids", "OBSERVATION", 37, 47], ["roots", "ANATOMY", 55, 60], ["baicalensis Georgi", "OBSERVATION", 67, 85]]], ["The main components of the roots were baicalin (8.12% of dry root mass) and wogonin glucuronide (2.52%).", [["roots", "ANATOMY", 27, 32], ["baicalin", "CHEMICAL", 38, 46], ["wogonin glucuronide", "CHEMICAL", 76, 95], ["baicalin", "CHEMICAL", 38, 46], ["wogonin glucuronide", "CHEMICAL", 76, 95], ["roots", "ORGAN", 27, 32], ["baicalin", "SIMPLE_CHEMICAL", 38, 46], ["root", "ORGANISM_SUBDIVISION", 61, 65], ["wogonin glucuronide", "SIMPLE_CHEMICAL", 76, 95], ["baicalin", "TREATMENT", 38, 46], ["dry root mass", "PROBLEM", 57, 70], ["wogonin glucuronide", "TREATMENT", 76, 95], ["main", "OBSERVATION_MODIFIER", 4, 8], ["roots", "ANATOMY", 27, 32], ["baicalin", "OBSERVATION_MODIFIER", 38, 46], ["root", "OBSERVATION_MODIFIER", 61, 65], ["mass", "OBSERVATION", 66, 70]]], ["The content of flavonoids was comparable with the content in plants cultivated in natural localities.Analysis of medicinal preparationsBecause baicalin is the main bioactive constituent of S. baicalensis Georgi, many reports have been published on the determination of baicalin by HPLC methods in different traditional Chinese medicinal preparations, such as No. 1 cold capsulae [31] , Qingxiewan [32] , Yizhangxiao capsule [33] , heat-clearing decoction [34] , Fructus Sophorae pills [35] , compound Houttuynia cordata granules [36] , Qinghouyan granules [37] , twelve baicalin-containing preparations such as pills, tablets and injection solutions [38] , Biyankang tablets [39] , and Huanglian Shangqing Wan [40] .", [["flavonoids", "CHEMICAL", 15, 25], ["baicalin", "CHEMICAL", 143, 151], ["baicalin", "CHEMICAL", 269, 277], ["decoction [34] , Fructus Sophorae pills [35] , compound Houttuynia cordata", "CHEMICAL", 445, 519], ["baicalin", "CHEMICAL", 570, 578], ["flavonoids", "CHEMICAL", 15, 25], ["baicalin", "CHEMICAL", 143, 151], ["baicalin", "CHEMICAL", 269, 277], ["baicalin", "CHEMICAL", 570, 578], ["flavonoids", "SIMPLE_CHEMICAL", 15, 25], ["baicalin", "SIMPLE_CHEMICAL", 143, 151], ["S. baicalensis", "ORGANISM", 189, 203], ["Georgi", "ORGANISM", 204, 210], ["baicalin", "SIMPLE_CHEMICAL", 269, 277], ["Qinghouyan", "SIMPLE_CHEMICAL", 536, 546], ["granules", "ORGANISM_SUBSTANCE", 547, 555], ["baicalin", "SIMPLE_CHEMICAL", 570, 578], ["pills", "SIMPLE_CHEMICAL", 611, 616], ["tablets", "SIMPLE_CHEMICAL", 618, 625], ["S. baicalensis", "SPECIES", 189, 203], ["Houttuynia cordata", "SPECIES", 501, 519], ["S. baicalensis", "SPECIES", 189, 203], ["Houttuynia cordata", "SPECIES", 501, 519], ["flavonoids", "PROBLEM", 15, 25], ["medicinal preparations", "TREATMENT", 113, 135], ["baicalin", "TREATMENT", 143, 151], ["baicalin", "TREATMENT", 269, 277], ["heat-clearing decoction", "TREATMENT", 431, 454], ["Fructus Sophorae pills", "TREATMENT", 462, 484], ["compound Houttuynia cordata granules", "PROBLEM", 492, 528], ["Qinghouyan granules", "TREATMENT", 536, 555], ["twelve baicalin-containing preparations", "TREATMENT", 563, 602], ["Biyankang tablets", "TREATMENT", 657, 674], ["flavonoids", "OBSERVATION", 15, 25], ["baicalensis Georgi", "OBSERVATION", 192, 210]]], ["HPLC methods have been also applied to the determination of baicalin and chlorogenic acid in Yinhuang oral liquid [41] , baicalin and berberine in Wanshi Niuhuang Qingxin Wan [42] , baicalin and puerarin in medicinal preparations [43] , baicalin, sennoside A and glycyrrhizin in Niuhuangjiedupian [44] , baicalin, paeoniflorin and ferulic acid in Dang-Guei-San [45] .", [["oral", "ANATOMY", 102, 106], ["baicalin", "CHEMICAL", 60, 68], ["chlorogenic acid", "CHEMICAL", 73, 89], ["Yinhuang", "CHEMICAL", 93, 101], ["baicalin", "CHEMICAL", 121, 129], ["berberine", "CHEMICAL", 134, 143], ["baicalin", "CHEMICAL", 182, 190], ["puerarin", "CHEMICAL", 195, 203], ["baicalin", "CHEMICAL", 237, 245], ["sennoside A", "CHEMICAL", 247, 258], ["glycyrrhizin", "CHEMICAL", 263, 275], ["Niuhuangjiedupian [44] ,", "CHEMICAL", 279, 303], ["baicalin", "CHEMICAL", 304, 312], ["paeoniflorin", "CHEMICAL", 314, 326], ["ferulic acid", "CHEMICAL", 331, 343], ["baicalin", "CHEMICAL", 60, 68], ["chlorogenic acid", "CHEMICAL", 73, 89], ["baicalin", "CHEMICAL", 121, 129], ["berberine", "CHEMICAL", 134, 143], ["baicalin", "CHEMICAL", 182, 190], ["puerarin", "CHEMICAL", 195, 203], ["baicalin", "CHEMICAL", 237, 245], ["sennoside A", "CHEMICAL", 247, 258], ["glycyrrhizin", "CHEMICAL", 263, 275], ["Niuhuangjiedupian", "CHEMICAL", 279, 296], ["baicalin", "CHEMICAL", 304, 312], ["paeoniflorin", "CHEMICAL", 314, 326], ["ferulic acid", "CHEMICAL", 331, 343], ["baicalin", "SIMPLE_CHEMICAL", 60, 68], ["chlorogenic acid", "SIMPLE_CHEMICAL", 73, 89], ["Yinhuang", "SIMPLE_CHEMICAL", 93, 101], ["oral", "ORGANISM_SUBDIVISION", 102, 106], ["baicalin", "SIMPLE_CHEMICAL", 121, 129], ["berberine", "SIMPLE_CHEMICAL", 134, 143], ["baicalin", "SIMPLE_CHEMICAL", 182, 190], ["puerarin", "SIMPLE_CHEMICAL", 195, 203], ["[43]", "SIMPLE_CHEMICAL", 230, 234], ["baicalin", "SIMPLE_CHEMICAL", 237, 245], ["sennoside A", "SIMPLE_CHEMICAL", 247, 258], ["glycyrrhizin", "SIMPLE_CHEMICAL", 263, 275], ["Niuhuangjiedupian [44]", "SIMPLE_CHEMICAL", 279, 301], ["baicalin", "SIMPLE_CHEMICAL", 304, 312], ["paeoniflorin", "SIMPLE_CHEMICAL", 314, 326], ["ferulic acid", "SIMPLE_CHEMICAL", 331, 343], ["HPLC methods", "TREATMENT", 0, 12], ["baicalin", "TREATMENT", 60, 68], ["chlorogenic acid in Yinhuang oral liquid", "TREATMENT", 73, 113], ["baicalin", "TREATMENT", 121, 129], ["berberine", "TREATMENT", 134, 143], ["baicalin", "TREATMENT", 182, 190], ["puerarin in medicinal preparations", "TREATMENT", 195, 229], ["baicalin", "TREATMENT", 237, 245], ["sennoside A", "TREATMENT", 247, 258], ["glycyrrhizin in Niuhuangjiedupian", "TREATMENT", 263, 296], ["baicalin", "TREATMENT", 304, 312], ["paeoniflorin", "TREATMENT", 314, 326], ["ferulic acid", "TREATMENT", 331, 343]]], ["In these methods, reversed-phase columns such as C 18 are the most frequently used.", [["reversed-phase columns", "TREATMENT", 18, 40]]], ["Mobile phases usually consist of a combination of an acidic buffer (or an aqueous phase with an acid H 3 PO 4 or acetic acid as additive) and an organic solvent component, usually methanol or acetonitrile.", [["H", "CHEMICAL", 101, 102], ["PO 4 or acetic acid", "CHEMICAL", 105, 124], ["acetonitrile", "CHEMICAL", 192, 204], ["H 3 PO 4", "CHEMICAL", 101, 109], ["acetic acid", "CHEMICAL", 113, 124], ["methanol", "CHEMICAL", 180, 188], ["acetonitrile", "CHEMICAL", 192, 204], ["acetic acid", "SIMPLE_CHEMICAL", 113, 124], ["methanol", "SIMPLE_CHEMICAL", 180, 188], ["acetonitrile", "SIMPLE_CHEMICAL", 192, 204], ["an acidic buffer", "TREATMENT", 50, 66], ["an aqueous phase", "TREATMENT", 71, 87], ["an acid H", "TREATMENT", 93, 102], ["acetic acid", "TREATMENT", 113, 124], ["an organic solvent component", "TREATMENT", 142, 170], ["acetonitrile", "TREATMENT", 192, 204]]], ["The use of an acid modifier is to suppress ionization of the acidic groups and interactions of these groups with residual traces of metals in the stationary phase that are detrimental to peak shape.Analysis of medicinal preparationsSeveral bioactive components from S. baicalensis Georgi could be determined simultaneously in medicinal preparations by HPLC [46, 47] .", [["S. baicalensis", "ORGANISM", 266, 280], ["Georgi", "ORGANISM", 281, 287], ["S. baicalensis", "SPECIES", 266, 280], ["S. baicalensis", "SPECIES", 266, 280], ["an acid modifier", "TREATMENT", 11, 27], ["the acidic groups", "TREATMENT", 57, 74], ["medicinal preparations", "TREATMENT", 210, 232], ["Several bioactive components", "PROBLEM", 232, 260], ["S. baicalensis Georgi", "TREATMENT", 266, 287], ["peak shape", "OBSERVATION", 187, 197], ["bioactive", "OBSERVATION_MODIFIER", 240, 249], ["components", "OBSERVATION_MODIFIER", 250, 260], ["baicalensis Georgi", "OBSERVATION", 269, 287]]], ["Two components, baicalin and baicalein in processed Scutellariae radix and its pharmaceutical preparations (e.g. slices for infusion) were determined by HPLC on a column (15 cm \u00d7 6 mm i.d.) of ODS with THF-dioxane-methanol-n-propanol-acetic acid-5% H 3 PO 4 -H 2 O (145:125:50:20:20:2:638) as mobile phase (1.5 ml min \u22121 ) and detection at 274 nm [46] .", [["slices", "ANATOMY", 113, 119], ["baicalin", "CHEMICAL", 16, 24], ["baicalein", "CHEMICAL", 29, 38], ["Scutellariae radix", "CHEMICAL", 52, 70], ["THF-dioxane-methanol-n-propanol-acetic acid", "CHEMICAL", 202, 245], ["H", "CHEMICAL", 249, 250], ["PO 4 -H 2 O", "CHEMICAL", 253, 264], ["baicalin", "CHEMICAL", 16, 24], ["baicalein", "CHEMICAL", 29, 38], ["THF-dioxane-methanol-n-propanol-acetic acid", "CHEMICAL", 202, 245], ["H 3 PO 4 -H 2 O", "CHEMICAL", 249, 264], ["baicalin", "SIMPLE_CHEMICAL", 16, 24], ["baicalein", "SIMPLE_CHEMICAL", 29, 38], ["Scutellariae radix", "ORGANISM", 52, 70], ["THF-dioxane-methanol-n-propanol-acetic acid", "SIMPLE_CHEMICAL", 202, 245], ["H 3 PO 4 -H 2 O", "SIMPLE_CHEMICAL", 249, 264], ["baicalin", "TREATMENT", 16, 24], ["baicalein in processed Scutellariae radix", "TREATMENT", 29, 70], ["its pharmaceutical preparations", "TREATMENT", 75, 106], ["infusion)", "TREATMENT", 124, 133], ["a column", "TREATMENT", 161, 169], ["ODS", "TEST", 193, 196], ["THF", "TREATMENT", 202, 205], ["dioxane", "TREATMENT", 206, 213], ["methanol", "TREATMENT", 214, 222], ["n-propanol", "TREATMENT", 223, 233], ["acetic acid", "TREATMENT", 234, 245], ["baicalin", "OBSERVATION_MODIFIER", 16, 24], ["baicalein", "OBSERVATION_MODIFIER", 29, 38], ["Scutellariae radix", "OBSERVATION", 52, 70]]], ["Three components, baicalin, baicalein and wogonin in traditional decoctions and commercial extracts of Scutellariae radix were determined by HPLC with ethyl paraben as internal standard [47] .", [["extracts", "ANATOMY", 91, 99], ["baicalin", "CHEMICAL", 18, 26], ["baicalein", "CHEMICAL", 28, 37], ["wogonin", "CHEMICAL", 42, 49], ["Scutellariae radix", "CHEMICAL", 103, 121], ["ethyl paraben", "CHEMICAL", 151, 164], ["baicalin", "CHEMICAL", 18, 26], ["baicalein", "CHEMICAL", 28, 37], ["wogonin", "CHEMICAL", 42, 49], ["ethyl paraben", "CHEMICAL", 151, 164], ["baicalin", "SIMPLE_CHEMICAL", 18, 26], ["baicalein", "SIMPLE_CHEMICAL", 28, 37], ["wogonin", "SIMPLE_CHEMICAL", 42, 49], ["extracts", "ORGANISM_SUBSTANCE", 91, 99], ["Scutellariae radix", "ORGANISM", 103, 121], ["ethyl paraben", "SIMPLE_CHEMICAL", 151, 164], ["Scutellariae radix", "SPECIES", 103, 121], ["baicalin", "TREATMENT", 18, 26], ["baicalein", "TREATMENT", 28, 37], ["wogonin", "TREATMENT", 42, 49], ["traditional decoctions", "TREATMENT", 53, 75], ["commercial extracts", "TREATMENT", 80, 99], ["Scutellariae radix", "TREATMENT", 103, 121], ["baicalin", "OBSERVATION_MODIFIER", 18, 26], ["baicalein", "OBSERVATION_MODIFIER", 28, 37], ["wogonin", "OBSERVATION_MODIFIER", 42, 49]]], ["The analytes were separated on a 5 m Inertsil ODS-2 column (25 cm \u00d7 4.6 mm i.d.) with acetonitrile-0.005% phosphoric acid (9:16) as mobile phase (1 ml min \u22121 ) and detection at 270 nm.", [["acetonitrile", "CHEMICAL", 86, 98], ["phosphoric acid", "CHEMICAL", 106, 121], ["acetonitrile", "CHEMICAL", 86, 98], ["phosphoric acid", "CHEMICAL", 106, 121], ["phosphoric acid", "SIMPLE_CHEMICAL", 106, 121], ["a 5 m Inertsil ODS", "TREATMENT", 31, 49], ["acetonitrile", "TREATMENT", 86, 98]]], ["The method was used to compare the absorption of baicalin, baicalein, wogonoside and wogonin between traditional decoction and a commercial powder preparation of Scutellariae radix [48] .", [["baicalin", "CHEMICAL", 49, 57], ["baicalein", "CHEMICAL", 59, 68], ["wogonoside", "CHEMICAL", 70, 80], ["wogonin", "CHEMICAL", 85, 92], ["Scutellariae radix", "CHEMICAL", 162, 180], ["baicalin", "CHEMICAL", 49, 57], ["baicalein", "CHEMICAL", 59, 68], ["wogonoside", "CHEMICAL", 70, 80], ["wogonin", "CHEMICAL", 85, 92], ["baicalin", "SIMPLE_CHEMICAL", 49, 57], ["baicalein", "SIMPLE_CHEMICAL", 59, 68], ["wogonoside", "SIMPLE_CHEMICAL", 70, 80], ["wogonin", "SIMPLE_CHEMICAL", 85, 92], ["Scutellariae radix", "SPECIES", 162, 180], ["The method", "TREATMENT", 0, 10], ["baicalin", "TREATMENT", 49, 57], ["baicalein", "TREATMENT", 59, 68], ["wogonoside", "TREATMENT", 70, 80], ["wogonin", "TREATMENT", 85, 92], ["traditional decoction", "TREATMENT", 101, 122], ["a commercial powder preparation of Scutellariae radix", "TREATMENT", 127, 180]]], ["The bioavailability of wogonin/wogonoside was about two times when compared with that of baicalein/baicalin from either traditional decoction or the commercial preparation.", [["wogonin", "CHEMICAL", 23, 30], ["wogonoside", "CHEMICAL", 31, 41], ["baicalein", "CHEMICAL", 89, 98], ["baicalin", "CHEMICAL", 99, 107], ["wogonin", "CHEMICAL", 23, 30], ["wogonoside", "CHEMICAL", 31, 41], ["baicalein", "CHEMICAL", 89, 98], ["baicalin", "CHEMICAL", 99, 107], ["wogonin", "SIMPLE_CHEMICAL", 23, 30], ["wogonoside", "SIMPLE_CHEMICAL", 31, 41], ["baicalein", "SIMPLE_CHEMICAL", 89, 98], ["baicalin", "SIMPLE_CHEMICAL", 99, 107], ["wogonin/wogonoside", "TREATMENT", 23, 41], ["baicalein/baicalin", "TREATMENT", 89, 107], ["traditional decoction", "TREATMENT", 120, 141], ["the commercial preparation", "TREATMENT", 145, 171]]], ["The flavone bioavailability from commercial preparation was significantly lower by 44.2 \u00b1 0.1% for baicalin/baicalein and by 42.3 \u00b1 0.1% for wogonoside/wogonin than those from traditional decoction.Analysis of medicinal preparationsFor compound medicinal preparations, simultaneous determination of many bioactive constituents is needed for quality control.", [["flavone", "CHEMICAL", 4, 11], ["baicalin", "CHEMICAL", 99, 107], ["baicalein", "CHEMICAL", 108, 117], ["wogonoside", "CHEMICAL", 141, 151], ["wogonin", "CHEMICAL", 152, 159], ["flavone", "CHEMICAL", 4, 11], ["baicalin", "CHEMICAL", 99, 107], ["baicalein", "CHEMICAL", 108, 117], ["wogonoside", "CHEMICAL", 141, 151], ["wogonin", "CHEMICAL", 152, 159], ["flavone", "SIMPLE_CHEMICAL", 4, 11], ["baicalin", "SIMPLE_CHEMICAL", 99, 107], ["baicalein", "SIMPLE_CHEMICAL", 108, 117], ["wogonoside", "SIMPLE_CHEMICAL", 141, 151], ["wogonin", "SIMPLE_CHEMICAL", 152, 159], ["The flavone bioavailability", "TREATMENT", 0, 27], ["baicalin/baicalein", "TEST", 99, 117], ["wogonoside/wogonin", "PROBLEM", 141, 159], ["traditional decoction", "TREATMENT", 176, 197], ["medicinal preparations", "TREATMENT", 210, 232], ["compound medicinal preparations", "TREATMENT", 236, 267], ["many bioactive constituents", "TREATMENT", 299, 326], ["quality control", "TREATMENT", 341, 356], ["decoction", "OBSERVATION", 188, 197]]], ["The six components, paeoniflorin, cinnamic acid, baicalin, baicalein, wogonin and glycyrrhizin in medicinal preparation Chai-Hu-Kuei-Chih-Tang were determined by HPLC [49] .", [["paeoniflorin", "CHEMICAL", 20, 32], ["cinnamic acid", "CHEMICAL", 34, 47], ["baicalin", "CHEMICAL", 49, 57], ["baicalein", "CHEMICAL", 59, 68], ["wogonin", "CHEMICAL", 70, 77], ["glycyrrhizin", "CHEMICAL", 82, 94], ["Chai-Hu-Kuei-Chih-Tang", "CHEMICAL", 120, 142], ["paeoniflorin", "CHEMICAL", 20, 32], ["cinnamic acid", "CHEMICAL", 34, 47], ["baicalin", "CHEMICAL", 49, 57], ["baicalein", "CHEMICAL", 59, 68], ["wogonin", "CHEMICAL", 70, 77], ["glycyrrhizin", "CHEMICAL", 82, 94], ["paeoniflorin", "SIMPLE_CHEMICAL", 20, 32], ["cinnamic acid", "SIMPLE_CHEMICAL", 34, 47], ["baicalin", "SIMPLE_CHEMICAL", 49, 57], ["baicalein", "SIMPLE_CHEMICAL", 59, 68], ["wogonin", "SIMPLE_CHEMICAL", 70, 77], ["glycyrrhizin", "SIMPLE_CHEMICAL", 82, 94], ["Chai-Hu-Kuei-Chih-Tang", "SIMPLE_CHEMICAL", 120, 142], ["The six components", "TREATMENT", 0, 18], ["paeoniflorin", "TREATMENT", 20, 32], ["cinnamic acid", "TREATMENT", 34, 47], ["baicalin", "TREATMENT", 49, 57], ["baicalein", "TREATMENT", 59, 68], ["wogonin", "TREATMENT", 70, 77], ["glycyrrhizin", "TREATMENT", 82, 94], ["Chai-Hu-Kuei", "TEST", 120, 132]]], ["Commercial powdered sample was ultrasonicated with 70% methanol and filtered.", [["sample", "ANATOMY", 20, 26], ["methanol", "CHEMICAL", 55, 63], ["methanol", "CHEMICAL", 55, 63], ["methanol", "SIMPLE_CHEMICAL", 55, 63], ["Commercial powdered sample", "TREATMENT", 0, 26], ["70% methanol", "TREATMENT", 51, 63]]], ["The filtrate was analysed on a Cosmosil 5 C 18 -AR column (25 cm \u00d7 4.6 mm i.d.) with linear gradient elution of acetonitrile/aqueous 20 mM H 3 PO 4 as mobile phase and UV detection.", [["acetonitrile", "CHEMICAL", 112, 124], ["H", "CHEMICAL", 139, 140], ["acetonitrile", "CHEMICAL", 112, 124], ["H 3 PO 4", "CHEMICAL", 139, 147], ["acetonitrile", "SIMPLE_CHEMICAL", 112, 124], ["a Cosmosil 5 C 18 -AR column", "TREATMENT", 29, 57], ["linear gradient elution", "TREATMENT", 85, 108], ["acetonitrile/aqueous", "TREATMENT", 112, 132], ["UV detection", "TEST", 168, 180], ["filtrate", "OBSERVATION", 4, 12]]], ["The seven constituents, gentiopicroside, mangiferin, palmatine, berberine, baicalin, wogonin and glycyrrhizin in the traditional Chinese medicinal preparation Sann-Joong-Kuey-Jian-Tang could also be determined by HPLC [50] .", [["gentiopicroside", "CHEMICAL", 24, 39], ["mangiferin", "CHEMICAL", 41, 51], ["palmatine", "CHEMICAL", 53, 62], ["berberine", "CHEMICAL", 64, 73], ["baicalin", "CHEMICAL", 75, 83], ["wogonin", "CHEMICAL", 85, 92], ["glycyrrhizin", "CHEMICAL", 97, 109], ["Sann-Joong-Kuey-Jian-Tang", "CHEMICAL", 159, 184], ["gentiopicroside", "CHEMICAL", 24, 39], ["mangiferin", "CHEMICAL", 41, 51], ["palmatine", "CHEMICAL", 53, 62], ["berberine", "CHEMICAL", 64, 73], ["baicalin", "CHEMICAL", 75, 83], ["wogonin", "CHEMICAL", 85, 92], ["glycyrrhizin", "CHEMICAL", 97, 109], ["gentiopicroside", "SIMPLE_CHEMICAL", 24, 39], ["mangiferin", "SIMPLE_CHEMICAL", 41, 51], ["palmatine", "SIMPLE_CHEMICAL", 53, 62], ["berberine", "SIMPLE_CHEMICAL", 64, 73], ["baicalin", "SIMPLE_CHEMICAL", 75, 83], ["wogonin", "SIMPLE_CHEMICAL", 85, 92], ["glycyrrhizin", "SIMPLE_CHEMICAL", 97, 109], ["Jian-Tang", "SIMPLE_CHEMICAL", 175, 184], ["gentiopicroside", "TREATMENT", 24, 39], ["mangiferin", "TREATMENT", 41, 51], ["palmatine", "TREATMENT", 53, 62], ["berberine", "TREATMENT", 64, 73], ["baicalin", "TREATMENT", 75, 83], ["wogonin", "TREATMENT", 85, 92], ["glycyrrhizin", "TREATMENT", 97, 109]]], ["Decoctions of the crude drug and concentrated preparations were diluted with aqueous 70% methanol, mixed with n-propylparaben as internal standard and analysed on a Cosmosil 5C 18 -MS column (15 cm \u00d7 4.6 mm i.d.) with gradient elution of 0.03% H 3 PO 4 /acetonitrile as mobile phase and detection at 254 nm.", [["methanol", "CHEMICAL", 89, 97], ["n-propylparaben", "CHEMICAL", 110, 125], ["Cosmosil", "CHEMICAL", 165, 173], ["H 3 PO 4 /acetonitrile", "CHEMICAL", 244, 266], ["methanol", "CHEMICAL", 89, 97], ["n-propylparaben", "CHEMICAL", 110, 125], ["H 3 PO 4", "CHEMICAL", 244, 252], ["acetonitrile", "CHEMICAL", 254, 266], ["methanol", "SIMPLE_CHEMICAL", 89, 97], ["n-propylparaben", "SIMPLE_CHEMICAL", 110, 125], ["acetonitrile", "SIMPLE_CHEMICAL", 254, 266], ["the crude drug", "TREATMENT", 14, 28], ["aqueous 70% methanol", "TREATMENT", 77, 97], ["a Cosmosil 5C", "TREATMENT", 163, 176], ["gradient elution", "TREATMENT", 218, 234]]], ["The chromatogram is shown in Fig. 2 .", [["The chromatogram", "TEST", 0, 16], ["Fig", "OBSERVATION_MODIFIER", 29, 32]]], ["In another method, twelve constituents, baicalin, baicalein, wogonin, wogonin 7-O-glucuronide, oroxylin A 7-O-glucuronide, sennoside A, sennoside B, emodin, aloe-emodin, glycyrrhizin, ferulic acid and caffeic acid in a Chinese herbal preparation I-Tzu-Tang were determined simultaneously by HPLC on a 5 m reversed-phase Cosmosil 5C 18 -AR column (25 cm \u00d7 4.6 mm i.d.) eluted at a flow rate of 0.8 ml min \u22121 with a linear solvent gradient of tetrabutylammonium bromide/phosphorate buffer/methonal/acetonitrile as mobile phase and diode array detection at 254 nm [51] .", [["baicalin", "CHEMICAL", 40, 48], ["baicalein", "CHEMICAL", 50, 59], ["wogonin", "CHEMICAL", 61, 68], ["wogonin", "CHEMICAL", 70, 77], ["7-O-glucuronide", "CHEMICAL", 78, 93], ["oroxylin A 7-O-glucuronide", "CHEMICAL", 95, 121], ["sennoside A", "CHEMICAL", 123, 134], ["sennoside B", "CHEMICAL", 136, 147], ["emodin", "CHEMICAL", 149, 155], ["aloe-emodin", "CHEMICAL", 157, 168], ["glycyrrhizin", "CHEMICAL", 170, 182], ["ferulic acid", "CHEMICAL", 184, 196], ["caffeic acid", "CHEMICAL", 201, 213], ["I-Tzu-Tang", "CHEMICAL", 246, 256], ["tetrabutylammonium bromide", "CHEMICAL", 441, 467], ["phosphorate", "CHEMICAL", 468, 479], ["methonal/acetonitrile", "CHEMICAL", 487, 508], ["baicalin", "CHEMICAL", 40, 48], ["baicalein", "CHEMICAL", 50, 59], ["wogonin", "CHEMICAL", 61, 68], ["wogonin 7-O-glucuronide", "CHEMICAL", 70, 93], ["oroxylin A 7-O-glucuronide", "CHEMICAL", 95, 121], ["sennoside A", "CHEMICAL", 123, 134], ["sennoside B", "CHEMICAL", 136, 147], ["emodin", "CHEMICAL", 149, 155], ["aloe-emodin", "CHEMICAL", 157, 168], ["glycyrrhizin", "CHEMICAL", 170, 182], ["ferulic acid", "CHEMICAL", 184, 196], ["caffeic acid", "CHEMICAL", 201, 213], ["tetrabutylammonium bromide", "CHEMICAL", 441, 467], ["phosphorate", "CHEMICAL", 468, 479], ["acetonitrile", "CHEMICAL", 496, 508], ["baicalin", "SIMPLE_CHEMICAL", 40, 48], ["baicalein", "SIMPLE_CHEMICAL", 50, 59], ["wogonin", "SIMPLE_CHEMICAL", 61, 68], ["wogonin 7-O-glucuronide", "SIMPLE_CHEMICAL", 70, 93], ["oroxylin A 7-O-glucuronide", "SIMPLE_CHEMICAL", 95, 121], ["sennoside A", "SIMPLE_CHEMICAL", 123, 134], ["sennoside B", "SIMPLE_CHEMICAL", 136, 147], ["emodin", "SIMPLE_CHEMICAL", 149, 155], ["aloe-emodin", "SIMPLE_CHEMICAL", 157, 168], ["glycyrrhizin", "SIMPLE_CHEMICAL", 170, 182], ["ferulic acid", "SIMPLE_CHEMICAL", 184, 196], ["caffeic acid", "SIMPLE_CHEMICAL", 201, 213], ["I-Tzu-Tang", "SIMPLE_CHEMICAL", 246, 256], ["tetrabutylammonium bromide", "SIMPLE_CHEMICAL", 441, 467], ["phosphorate", "SIMPLE_CHEMICAL", 468, 479], ["methonal", "SIMPLE_CHEMICAL", 487, 495], ["acetonitrile", "SIMPLE_CHEMICAL", 496, 508], ["baicalin", "TREATMENT", 40, 48], ["baicalein", "TREATMENT", 50, 59], ["wogonin", "TREATMENT", 61, 68], ["wogonin", "TREATMENT", 70, 77], ["glucuronide", "TREATMENT", 82, 93], ["oroxylin", "TREATMENT", 95, 103], ["glucuronide", "TREATMENT", 110, 121], ["sennoside A", "TREATMENT", 123, 134], ["sennoside B", "TREATMENT", 136, 147], ["emodin", "TREATMENT", 149, 155], ["aloe-emodin", "TREATMENT", 157, 168], ["glycyrrhizin", "TREATMENT", 170, 182], ["ferulic acid", "TREATMENT", 184, 196], ["caffeic acid", "TREATMENT", 201, 213], ["a Chinese herbal preparation", "TREATMENT", 217, 245], ["a 5 m reversed-phase Cosmosil 5C", "TREATMENT", 299, 331], ["a flow rate", "TEST", 378, 389], ["a linear solvent gradient", "TREATMENT", 412, 437], ["tetrabutylammonium bromide", "TREATMENT", 441, 467], ["phosphorate buffer", "TREATMENT", 468, 486], ["methonal/acetonitrile", "TREATMENT", 487, 508], ["diode array detection", "TEST", 529, 550]]], ["The chromatogram is shown in Fig. 3 .", [["The chromatogram", "TEST", 0, 16], ["Fig", "OBSERVATION_MODIFIER", 29, 32]]], ["Furthermore, a method was developed for the simultaneous determination of 14 constituents, baicalin, baicalein, wogonin, wogonoside, oroxylin-A glucoside, orxylin-A, paconiflorin, glycyrrhizic acid, glycyrrhetinic acid, liquiritin, isoliquirition, liquiritigenin, isoliquiritigenin and ononin in the traditional Chinese medicinal preparation Huangqin-Tang by HPLC [52] .", [["baicalin", "CHEMICAL", 91, 99], ["baicalein", "CHEMICAL", 101, 110], ["wogonin", "CHEMICAL", 112, 119], ["wogonoside", "CHEMICAL", 121, 131], ["oroxylin-A glucoside", "CHEMICAL", 133, 153], ["orxylin-A", "CHEMICAL", 155, 164], ["paconiflorin", "CHEMICAL", 166, 178], ["glycyrrhizic acid", "CHEMICAL", 180, 197], ["glycyrrhetinic acid", "CHEMICAL", 199, 218], ["liquiritin", "CHEMICAL", 220, 230], ["isoliquirition", "CHEMICAL", 232, 246], ["liquiritigenin", "CHEMICAL", 248, 262], ["isoliquiritigenin", "CHEMICAL", 264, 281], ["ononin", "CHEMICAL", 286, 292], ["Huangqin-Tang", "CHEMICAL", 342, 355], ["baicalin", "CHEMICAL", 91, 99], ["baicalein", "CHEMICAL", 101, 110], ["wogonin", "CHEMICAL", 112, 119], ["wogonoside", "CHEMICAL", 121, 131], ["oroxylin-A glucoside", "CHEMICAL", 133, 153], ["orxylin-A", "CHEMICAL", 155, 164], ["paconiflorin", "CHEMICAL", 166, 178], ["glycyrrhizic acid", "CHEMICAL", 180, 197], ["glycyrrhetinic acid", "CHEMICAL", 199, 218], ["liquiritin", "CHEMICAL", 220, 230], ["isoliquirition", "CHEMICAL", 232, 246], ["liquiritigenin", "CHEMICAL", 248, 262], ["isoliquiritigenin", "CHEMICAL", 264, 281], ["ononin", "CHEMICAL", 286, 292], ["baicalin", "SIMPLE_CHEMICAL", 91, 99], ["baicalein", "SIMPLE_CHEMICAL", 101, 110], ["wogonin", "SIMPLE_CHEMICAL", 112, 119], ["wogonoside", "SIMPLE_CHEMICAL", 121, 131], ["oroxylin-A glucoside", "SIMPLE_CHEMICAL", 133, 153], ["orxylin-A", "SIMPLE_CHEMICAL", 155, 164], ["paconiflorin", "SIMPLE_CHEMICAL", 166, 178], ["glycyrrhizic acid", "SIMPLE_CHEMICAL", 180, 197], ["glycyrrhetinic acid", "SIMPLE_CHEMICAL", 199, 218], ["liquiritin", "SIMPLE_CHEMICAL", 220, 230], ["isoliquirition", "SIMPLE_CHEMICAL", 232, 246], ["liquiritigenin", "SIMPLE_CHEMICAL", 248, 262], ["isoliquiritigenin", "SIMPLE_CHEMICAL", 264, 281], ["ononin", "SIMPLE_CHEMICAL", 286, 292], ["Huangqin-Tang", "SIMPLE_CHEMICAL", 342, 355], ["the simultaneous determination", "TEST", 40, 70], ["baicalin", "TREATMENT", 91, 99], ["baicalein", "TREATMENT", 101, 110], ["wogonin", "TREATMENT", 112, 119], ["wogonoside", "TREATMENT", 121, 131], ["oroxylin", "TREATMENT", 133, 141], ["A glucoside", "TREATMENT", 142, 153], ["orxylin", "TREATMENT", 155, 162], ["paconiflorin", "TREATMENT", 166, 178], ["glycyrrhizic acid", "TREATMENT", 180, 197], ["glycyrrhetinic acid", "TREATMENT", 199, 218], ["liquiritin", "TREATMENT", 220, 230], ["isoliquirition", "TREATMENT", 232, 246], ["liquiritigenin", "TREATMENT", 248, 262], ["isoliquiritigenin", "TREATMENT", 264, 281], ["ononin", "TREATMENT", 286, 292]]], ["Huangqin-Tang samples were mixed and boiled with water, centrifuged then concentrated and analysed on a 5 m Wakosil II 5C 18 -AR column (15 cm \u00d7 4.6 mm i.d.), methanol/acetic acid and H 2 O/acetic acid as mobile phase with gradient elution and diode array detection from 200 to 400 nm.Analysis of biological fluidsOnly a few reports have been published for the determination of the active components from S. baicalensis Georgi in biological fluids (blood and urine) samples.", [["samples", "ANATOMY", 14, 21], ["blood", "ANATOMY", 449, 454], ["urine", "ANATOMY", 459, 464], ["samples", "ANATOMY", 466, 473], ["Huangqin", "CHEMICAL", 0, 8], ["Wakosil II", "CHEMICAL", 108, 118], ["methanol/acetic acid", "CHEMICAL", 159, 179], ["H 2 O/acetic acid", "CHEMICAL", 184, 201], ["methanol", "CHEMICAL", 159, 167], ["acetic acid", "CHEMICAL", 168, 179], ["H 2 O", "CHEMICAL", 184, 189], ["acetic acid", "CHEMICAL", 190, 201], ["methanol/acetic acid", "SIMPLE_CHEMICAL", 159, 179], ["H 2 O/acetic acid", "SIMPLE_CHEMICAL", 184, 201], ["S. baicalensis", "ORGANISM", 405, 419], ["Georgi", "ORGANISM", 420, 426], ["blood", "ORGANISM_SUBSTANCE", 449, 454], ["urine", "ORGANISM_SUBSTANCE", 459, 464], ["S. baicalensis", "SPECIES", 405, 419], ["S. baicalensis", "SPECIES", 405, 419], ["Huangqin-Tang samples", "TREATMENT", 0, 21], ["methanol/acetic acid", "TREATMENT", 159, 179], ["acetic acid", "TEST", 190, 201], ["gradient elution", "TREATMENT", 223, 239], ["diode array detection", "TEST", 244, 265], ["biological fluids", "TREATMENT", 297, 314], ["the active components", "PROBLEM", 378, 399], ["blood and urine) samples", "TEST", 449, 473], ["baicalensis Georgi", "OBSERVATION", 408, 426]]], ["Baicalin in rabbits' plasma was determined by a reversedphase HPLC [53, 54] .", [["plasma", "ANATOMY", 21, 27], ["Baicalin", "CHEMICAL", 0, 8], ["Baicalin", "CHEMICAL", 0, 8], ["Baicalin", "SIMPLE_CHEMICAL", 0, 8], ["rabbits", "ORGANISM", 12, 19], ["plasma", "ORGANISM_SUBSTANCE", 21, 27], ["rabbits", "SPECIES", 12, 19], ["rabbits", "SPECIES", 12, 19], ["Baicalin", "TREATMENT", 0, 8], ["a reversedphase HPLC", "TEST", 46, 66]]], ["The sample (0.2 ml) was vortex-mixed with 4-nitrobenzoic acid (internal standard) and acetonitrile.", [["sample", "ANATOMY", 4, 10], ["4-nitrobenzoic acid", "CHEMICAL", 42, 61], ["acetonitrile", "CHEMICAL", 86, 98], ["4-nitrobenzoic acid", "CHEMICAL", 42, 61], ["acetonitrile", "CHEMICAL", 86, 98], ["4-nitrobenzoic acid", "SIMPLE_CHEMICAL", 42, 61], ["acetonitrile", "SIMPLE_CHEMICAL", 86, 98], ["nitrobenzoic acid", "TREATMENT", 44, 61], ["acetonitrile", "TREATMENT", 86, 98]]], ["The supernatant was analysed on a 5 m Dimonsil C 18 column (20 cm \u00d7 4.6 mm i.d.) with methanol-H 2 O-H 3 PO 4 (25:25:0.1) as mobile phase (1 ml min \u22121 ) and detection at 277 nm.", [["supernatant", "ANATOMY", 4, 15], ["methanol-H 2 O-H", "CHEMICAL", 86, 102], ["methanol", "CHEMICAL", 86, 94], ["H 2 O-H 3 PO 4", "CHEMICAL", 95, 109], ["methanol-H 2 O-H 3 PO 4", "SIMPLE_CHEMICAL", 86, 109], ["a 5 m Dimonsil C 18 column", "TREATMENT", 32, 58], ["methanol-H", "TREATMENT", 86, 96]]], ["In another study, the metabolites of baicalein in human urine were determined by HPLC on a 4 m ODS column (15 cm \u00d7 3.9 mm i.d.) with acetonitrile-0.08 M formic acid (1:4) as mobile phase (1 ml min \u22121 ) and photodiode array detection at 315.6 nm [55] .", [["urine", "ANATOMY", 56, 61], ["baicalein", "CHEMICAL", 37, 46], ["acetonitrile", "CHEMICAL", 133, 145], ["formic acid", "CHEMICAL", 153, 164], ["baicalein", "CHEMICAL", 37, 46], ["acetonitrile", "CHEMICAL", 133, 145], ["formic acid", "CHEMICAL", 153, 164], ["baicalein", "SIMPLE_CHEMICAL", 37, 46], ["human", "ORGANISM", 50, 55], ["urine", "ORGANISM_SUBSTANCE", 56, 61], ["formic acid", "SIMPLE_CHEMICAL", 153, 164], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["another study", "TEST", 3, 16], ["the metabolites of baicalein in human urine", "TEST", 18, 61], ["HPLC", "TEST", 81, 85], ["a 4 m ODS column", "TREATMENT", 89, 105], ["acetonitrile", "TEST", 133, 145], ["formic acid", "TEST", 153, 164], ["photodiode array detection", "TEST", 206, 232]]], ["Three main metabolites of baicalein were identified and found to be in agreement with previous studies.", [["baicalein", "CHEMICAL", 26, 35], ["baicalein", "CHEMICAL", 26, 35], ["baicalein", "SIMPLE_CHEMICAL", 26, 35], ["previous studies", "TEST", 86, 102], ["main", "OBSERVATION_MODIFIER", 6, 10], ["metabolites", "OBSERVATION_MODIFIER", 11, 22], ["baicalein", "OBSERVATION_MODIFIER", 26, 35]]], ["In addition, the flavonoids in human urine after administration of a medicinal preparation Shosaiko-to were determined by HPLC [56] [57] [58] .", [["urine", "ANATOMY", 37, 42], ["flavonoids", "CHEMICAL", 17, 27], ["Shosaiko", "CHEMICAL", 91, 99], ["flavonoids", "CHEMICAL", 17, 27], ["flavonoids", "SIMPLE_CHEMICAL", 17, 27], ["human", "ORGANISM", 31, 36], ["urine", "ORGANISM_SUBSTANCE", 37, 42], ["Shosaiko", "SIMPLE_CHEMICAL", 91, 99], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["the flavonoids in human urine", "PROBLEM", 13, 42], ["a medicinal preparation Shosaiko", "TREATMENT", 67, 99]]], ["An ODS or a Chiracel column (25 cm \u00d7 4.6 mm i.d.) was used for nonchiral or chiral analysis, respectively.", [["An ODS", "TEST", 0, 6], ["a Chiracel column", "TREATMENT", 10, 27], ["nonchiral or chiral analysis", "TEST", 63, 91], ["ODS", "OBSERVATION", 3, 6]]], ["Mobile phases used included acetonitrile/H 2 O/acetic acid for flavonoids, isopropanol/H 2 O/acetic acid for racemic liquiritin, or nhexane/ethanol/acetic acid for chiral analysis.", [["acetonitrile/H 2 O/acetic acid", "CHEMICAL", 28, 58], ["flavonoids", "CHEMICAL", 63, 73], ["isopropanol", "CHEMICAL", 75, 86], ["H 2 O/acetic acid", "CHEMICAL", 87, 104], ["racemic liquiritin", "CHEMICAL", 109, 127], ["nhexane", "CHEMICAL", 132, 139], ["ethanol", "CHEMICAL", 140, 147], ["acetic acid", "CHEMICAL", 148, 159], ["acetonitrile", "CHEMICAL", 28, 40], ["H 2 O", "CHEMICAL", 41, 46], ["acetic acid", "CHEMICAL", 47, 58], ["flavonoids", "CHEMICAL", 63, 73], ["isopropanol", "CHEMICAL", 75, 86], ["H 2 O", "CHEMICAL", 87, 92], ["acetic acid", "CHEMICAL", 93, 104], ["racemic liquiritin", "CHEMICAL", 109, 127], ["nhexane", "CHEMICAL", 132, 139], ["ethanol", "CHEMICAL", 140, 147], ["acetic acid", "CHEMICAL", 148, 159], ["acetonitrile/H 2 O/acetic acid", "SIMPLE_CHEMICAL", 28, 58], ["flavonoids", "SIMPLE_CHEMICAL", 63, 73], ["isopropanol", "SIMPLE_CHEMICAL", 75, 86], ["H 2 O/acetic acid", "SIMPLE_CHEMICAL", 87, 104], ["racemic liquiritin", "SIMPLE_CHEMICAL", 109, 127], ["nhexane", "SIMPLE_CHEMICAL", 132, 139], ["ethanol", "SIMPLE_CHEMICAL", 140, 147], ["acetic acid", "SIMPLE_CHEMICAL", 148, 159], ["acetonitrile/H", "TREATMENT", 28, 42], ["acetic acid", "TREATMENT", 47, 58], ["flavonoids", "TREATMENT", 63, 73], ["isopropanol", "TREATMENT", 75, 86], ["acetic acid", "TREATMENT", 93, 104], ["racemic liquiritin", "TREATMENT", 109, 127], ["nhexane", "TREATMENT", 132, 139], ["ethanol", "TREATMENT", 140, 147], ["acetic acid", "TREATMENT", 148, 159], ["chiral analysis", "TEST", 164, 179]]], ["Detection was at 279, 275, and 295 nm for davidigenin and liquiritin, wogonin and oroxylin A and baicalein, and for dihydrowogonin and dihydrooroxylin A, respectively.", [["davidigenin", "CHEMICAL", 42, 53], ["liquiritin", "CHEMICAL", 58, 68], ["wogonin", "CHEMICAL", 70, 77], ["oroxylin A", "CHEMICAL", 82, 92], ["baicalein", "CHEMICAL", 97, 106], ["dihydrowogonin", "CHEMICAL", 116, 130], ["dihydrooroxylin A", "CHEMICAL", 135, 152], ["davidigenin", "CHEMICAL", 42, 53], ["liquiritin", "CHEMICAL", 58, 68], ["wogonin", "CHEMICAL", 70, 77], ["oroxylin A", "CHEMICAL", 82, 92], ["baicalein", "CHEMICAL", 97, 106], ["dihydrowogonin", "CHEMICAL", 116, 130], ["dihydrooroxylin A", "CHEMICAL", 135, 152], ["davidigenin", "SIMPLE_CHEMICAL", 42, 53], ["liquiritin", "SIMPLE_CHEMICAL", 58, 68], ["wogonin", "SIMPLE_CHEMICAL", 70, 77], ["oroxylin A", "SIMPLE_CHEMICAL", 82, 92], ["baicalein", "SIMPLE_CHEMICAL", 97, 106], ["dihydrowogonin", "SIMPLE_CHEMICAL", 116, 130], ["dihydrooroxylin A", "SIMPLE_CHEMICAL", 135, 152], ["Detection", "TEST", 0, 9], ["davidigenin", "TREATMENT", 42, 53], ["liquiritin", "TREATMENT", 58, 68], ["wogonin", "TREATMENT", 70, 77], ["oroxylin", "TREATMENT", 82, 90], ["baicalein", "TREATMENT", 97, 106], ["dihydrowogonin", "TREATMENT", 116, 130]]], ["Four flavonoids, liquiritigenin, baicalein, wogonin and oroxylin A, were found both in the urine and Shosaiko-to.", [["urine", "ANATOMY", 91, 96], ["flavonoids", "CHEMICAL", 5, 15], ["liquiritigenin", "CHEMICAL", 17, 31], ["baicalein", "CHEMICAL", 33, 42], ["wogonin", "CHEMICAL", 44, 51], ["oroxylin A", "CHEMICAL", 56, 66], ["flavonoids", "CHEMICAL", 5, 15], ["liquiritigenin", "CHEMICAL", 17, 31], ["baicalein", "CHEMICAL", 33, 42], ["wogonin", "CHEMICAL", 44, 51], ["oroxylin A", "CHEMICAL", 56, 66], ["flavonoids", "SIMPLE_CHEMICAL", 5, 15], ["liquiritigenin", "SIMPLE_CHEMICAL", 17, 31], ["baicalein", "SIMPLE_CHEMICAL", 33, 42], ["wogonin", "SIMPLE_CHEMICAL", 44, 51], ["oroxylin A", "SIMPLE_CHEMICAL", 56, 66], ["urine", "ORGANISM_SUBSTANCE", 91, 96], ["Four flavonoids", "TREATMENT", 0, 15], ["liquiritigenin", "TREATMENT", 17, 31], ["baicalein", "TREATMENT", 33, 42], ["wogonin", "TREATMENT", 44, 51], ["oroxylin", "TREATMENT", 56, 64], ["flavonoids", "OBSERVATION", 5, 15], ["urine", "ANATOMY", 91, 96]]], ["The glycosides in Shosaiko-to were absorbed after microflora hydrolysis.", [["Shosaiko", "CHEMICAL", 18, 26], ["glycosides", "SIMPLE_CHEMICAL", 4, 14], ["Shosaiko", "SIMPLE_CHEMICAL", 18, 26], ["The glycosides", "TREATMENT", 0, 14], ["microflora hydrolysis", "TREATMENT", 50, 71]]], ["Two flavanones, S-dihydrowogonin and S-dihydrooroxylin A, were identified as the metabolites of wogonin and oroxylin A, respectively.Analysis of biological fluidsAlthough UV detection is still the most widely used, electrochemical detection is employed for improved specificity and sensitivity.", [["flavanones", "CHEMICAL", 4, 14], ["S-dihydrowogonin", "CHEMICAL", 16, 32], ["S-dihydrooroxylin A", "CHEMICAL", 37, 56], ["wogonin", "CHEMICAL", 96, 103], ["oroxylin A", "CHEMICAL", 108, 118], ["flavanones", "CHEMICAL", 4, 14], ["S-dihydrowogonin", "CHEMICAL", 16, 32], ["S-dihydrooroxylin A", "CHEMICAL", 37, 56], ["wogonin", "CHEMICAL", 96, 103], ["oroxylin A", "CHEMICAL", 108, 118], ["flavanones", "SIMPLE_CHEMICAL", 4, 14], ["S-dihydrowogonin", "SIMPLE_CHEMICAL", 16, 32], ["S-dihydrooroxylin A", "SIMPLE_CHEMICAL", 37, 56], ["wogonin", "SIMPLE_CHEMICAL", 96, 103], ["oroxylin A", "SIMPLE_CHEMICAL", 108, 118], ["Two flavanones", "TREATMENT", 0, 14], ["S-dihydrowogonin", "TREATMENT", 16, 32], ["S-dihydrooroxylin A", "TREATMENT", 37, 56], ["wogonin", "TREATMENT", 96, 103], ["oroxylin A", "TREATMENT", 108, 118], ["biological fluids", "TREATMENT", 145, 162], ["UV detection", "TEST", 171, 183], ["electrochemical detection", "TEST", 215, 240]]], ["Baicalin and baicalein in rat plasma were determined by HPLC with electrochemical detection [59] .", [["plasma", "ANATOMY", 30, 36], ["Baicalin", "CHEMICAL", 0, 8], ["baicalein", "CHEMICAL", 13, 22], ["Baicalin", "CHEMICAL", 0, 8], ["baicalein", "CHEMICAL", 13, 22], ["Baicalin", "SIMPLE_CHEMICAL", 0, 8], ["baicalein", "SIMPLE_CHEMICAL", 13, 22], ["rat", "ORGANISM", 26, 29], ["plasma", "ORGANISM_SUBSTANCE", 30, 36], ["rat", "SPECIES", 26, 29], ["rat", "SPECIES", 26, 29], ["Baicalin", "TREATMENT", 0, 8], ["baicalein in rat plasma", "TREATMENT", 13, 36], ["electrochemical detection", "TEST", 66, 91], ["baicalein", "OBSERVATION_MODIFIER", 13, 22]]], ["Baicalin was extracted from plasma by SPE with 2,3dihydroxynaphthalene as internal standard; baicalein was extracted at low or high concentration by SPE or liquid-liquid extraction with quercetin as internal standard.", [["plasma", "ANATOMY", 28, 34], ["Baicalin", "CHEMICAL", 0, 8], ["SPE", "CHEMICAL", 38, 41], ["2,3dihydroxynaphthalene", "CHEMICAL", 47, 70], ["baicalein", "CHEMICAL", 93, 102], ["SPE", "CHEMICAL", 149, 152], ["quercetin", "CHEMICAL", 186, 195], ["Baicalin", "CHEMICAL", 0, 8], ["2,3dihydroxynaphthalene", "CHEMICAL", 47, 70], ["baicalein", "CHEMICAL", 93, 102], ["quercetin", "CHEMICAL", 186, 195], ["Baicalin", "SIMPLE_CHEMICAL", 0, 8], ["plasma", "ORGANISM_SUBSTANCE", 28, 34], ["2,3dihydroxynaphthalene", "SIMPLE_CHEMICAL", 47, 70], ["baicalein", "SIMPLE_CHEMICAL", 93, 102], ["quercetin", "SIMPLE_CHEMICAL", 186, 195], ["Baicalin", "TREATMENT", 0, 8], ["2,3dihydroxynaphthalene", "TREATMENT", 47, 70], ["baicalein", "TREATMENT", 93, 102], ["liquid-liquid extraction", "TREATMENT", 156, 180], ["quercetin", "TREATMENT", 186, 195]]], ["The ana-lyte was determined on a stainless steel Nova-Pak column (15 cm \u00d7 3.5 mm i.d.) of octadecylsilane C 18 (4 m), operated at 50 \u2022 C, with a mobile phase (1.2 ml min \u22121 ) of 0.1 M H 3 PO 4 -acetic acid-THF (800:80:57) for baicalin or a mobile phase (0.8 ml min \u22121 ) of 0.2 M H 3 PO 4 -methanol-THF (500:250:34) for baicalein.", [["octadecylsilane", "CHEMICAL", 90, 105], ["PO 4 -acetic acid-THF", "CHEMICAL", 188, 209], ["baicalin", "CHEMICAL", 226, 234], ["H", "CHEMICAL", 279, 280], ["PO 4 -methanol-THF", "CHEMICAL", 283, 301], ["baicalein", "CHEMICAL", 319, 328], ["octadecylsilane C 18", "CHEMICAL", 90, 110], ["H 3 PO 4 -acetic acid", "CHEMICAL", 184, 205], ["THF", "CHEMICAL", 206, 209], ["baicalin", "CHEMICAL", 226, 234], ["H 3 PO 4 -methanol-THF", "CHEMICAL", 279, 301], ["baicalein", "CHEMICAL", 319, 328], ["ana-lyte", "SIMPLE_CHEMICAL", 4, 12], ["H 3 PO 4 -acetic acid-THF", "SIMPLE_CHEMICAL", 184, 209], ["baicalin", "SIMPLE_CHEMICAL", 226, 234], ["H 3 PO 4 -methanol-THF", "SIMPLE_CHEMICAL", 279, 301], ["baicalein", "SIMPLE_CHEMICAL", 319, 328], ["a stainless steel Nova-Pak column", "TREATMENT", 31, 64], ["octadecylsilane C", "TEST", 90, 107], ["-acetic acid", "TEST", 193, 205], ["baicalin", "TREATMENT", 226, 234], ["a mobile phase", "TREATMENT", 238, 252], ["baicalein", "TREATMENT", 319, 328]]], ["Following separation baicalin and baicalein were oxidized at a vitreous C electrode to permit selective electrochemical detection.", [["baicalin", "CHEMICAL", 21, 29], ["baicalein", "CHEMICAL", 34, 43], ["baicalin", "CHEMICAL", 21, 29], ["baicalein", "CHEMICAL", 34, 43], ["baicalin", "SIMPLE_CHEMICAL", 21, 29], ["baicalein", "SIMPLE_CHEMICAL", 34, 43], ["separation baicalin", "TREATMENT", 10, 29], ["baicalein", "TREATMENT", 34, 43], ["a vitreous C electrode", "TREATMENT", 61, 83], ["selective electrochemical detection", "TEST", 94, 129]]], ["The method was more sensitive than the HPLC method with UV detection.High-speed counter-current chromatographyHigh-speed counter-current chromatography (HSCCC) is a unique liquid-liquid partition chromatography that uses no solid support matrix.", [["matrix", "CELLULAR_COMPONENT", 238, 244], ["The method", "TEST", 0, 10], ["the HPLC method", "TEST", 35, 50], ["UV detection", "TEST", 56, 68], ["current chromatography", "TEST", 88, 110], ["a unique liquid-liquid partition chromatography", "TREATMENT", 163, 210], ["solid support matrix", "TREATMENT", 224, 244]]], ["Therefore, it eliminates irreversible adsorptive loss of samples onto the solid support matrix used in the conventional chromatographic column.", [["samples", "ANATOMY", 57, 64], ["irreversible adsorptive loss of samples", "PROBLEM", 25, 64], ["the solid support matrix", "TREATMENT", 70, 94], ["irreversible", "OBSERVATION_MODIFIER", 25, 37], ["adsorptive", "OBSERVATION_MODIFIER", 38, 48], ["loss", "OBSERVATION_MODIFIER", 49, 53], ["solid support matrix", "OBSERVATION", 74, 94], ["chromatographic column", "OBSERVATION", 120, 142]]], ["The method has been successfully applied to the analysis and separation of various natural products [60] [61] [62] .", [["[60] [61] [62]", "SIMPLE_CHEMICAL", 100, 114], ["The method", "TREATMENT", 0, 10], ["the analysis", "TEST", 44, 56]]], ["In our laboratory, HSCCC has been applied to the isolation and purification of several bioactive compounds from the Chinese medical plants, such as tanshinones and salvianolic acid B in Salvia miltiorrhiza Bunge [63, 64] , salidroside in Rhodiola sachalinensis A. Bor [65] , shikonin in Lithospermum erythrorhizon Sieb. et Zucc.", [["HSCCC", "CHEMICAL", 19, 24], ["tanshinones", "CHEMICAL", 148, 159], ["salvianolic acid B", "CHEMICAL", 164, 182], ["Salvia miltiorrhiza Bunge [63, 64]", "CHEMICAL", 186, 220], ["salidroside", "CHEMICAL", 223, 234], ["shikonin", "CHEMICAL", 275, 283], ["tanshinones", "CHEMICAL", 148, 159], ["salvianolic acid B", "CHEMICAL", 164, 182], ["salidroside", "CHEMICAL", 223, 234], ["shikonin", "CHEMICAL", 275, 283], ["HSCCC", "CANCER", 19, 24], ["tanshinones", "SIMPLE_CHEMICAL", 148, 159], ["salvianolic acid B", "SIMPLE_CHEMICAL", 164, 182], ["Salvia miltiorrhiza", "ORGANISM", 186, 205], ["63, 64]", "SIMPLE_CHEMICAL", 213, 220], ["salidroside", "SIMPLE_CHEMICAL", 223, 234], ["Rhodiola sachalinensis", "ORGANISM", 238, 260], ["shikonin", "SIMPLE_CHEMICAL", 275, 283], ["Lithospermum erythrorhizon Sieb", "ORGANISM", 287, 318], ["Salvia miltiorrhiza", "SPECIES", 186, 205], ["Rhodiola sachalinensis", "SPECIES", 238, 260], ["Lithospermum erythrorhizon", "SPECIES", 287, 313], ["Salvia miltiorrhiza", "SPECIES", 186, 205], ["Rhodiola sachalinensis", "SPECIES", 238, 260], ["Lithospermum erythrorhizon", "SPECIES", 287, 313], ["the isolation", "TREATMENT", 45, 58], ["purification", "TREATMENT", 63, 75], ["several bioactive compounds", "PROBLEM", 79, 106], ["the Chinese medical plants", "TREATMENT", 112, 138], ["tanshinones", "TREATMENT", 148, 159], ["salidroside", "TREATMENT", 223, 234], ["shikonin", "TREATMENT", 275, 283], ["et Zucc", "TREATMENT", 320, 327], ["Salvia miltiorrhiza", "ANATOMY", 186, 205]]], ["[66] , chlorogenic acid in Flos Lonicerae [67] , glycyrrhizin in Glycyrrhiza uralensis Fisch [68] .High-speed counter-current chromatographyBaicalin was separated and purified from S. baicalensis Georgi by HSCCC [4] .", [["[66] , chlorogenic acid", "CHEMICAL", 0, 23], ["Flos Lonicerae [67]", "CHEMICAL", 27, 46], ["glycyrrhizin", "CHEMICAL", 49, 61], ["Baicalin", "CHEMICAL", 140, 148], ["chlorogenic acid", "CHEMICAL", 7, 23], ["glycyrrhizin", "CHEMICAL", 49, 61], ["Baicalin", "CHEMICAL", 140, 148], ["[66] , chlorogenic acid", "SIMPLE_CHEMICAL", 0, 23], ["Flos Lonicerae [67]", "SIMPLE_CHEMICAL", 27, 46], ["glycyrrhizin", "SIMPLE_CHEMICAL", 49, 61], ["Glycyrrhiza uralensis", "ORGANISM", 65, 86], ["Baicalin", "SIMPLE_CHEMICAL", 140, 148], ["S. baicalensis", "ORGANISM", 181, 195], ["Georgi", "ORGANISM", 196, 202], ["Glycyrrhiza uralensis", "SPECIES", 65, 86], ["S. baicalensis", "SPECIES", 181, 195], ["Glycyrrhiza uralensis", "SPECIES", 65, 86], ["S. baicalensis", "SPECIES", 181, 195], ["chlorogenic acid in Flos Lonicerae", "TREATMENT", 7, 41], ["glycyrrhizin", "TREATMENT", 49, 61], ["current chromatography", "TEST", 118, 140], ["Baicalin", "TREATMENT", 140, 148], ["baicalensis Georgi", "OBSERVATION", 184, 202]]], ["Crude baicalin was obtained by extraction with methanol-water (70:30) from S. baicalensis Georgi.", [["baicalin", "CHEMICAL", 6, 14], ["methanol", "CHEMICAL", 47, 55], ["baicalin", "CHEMICAL", 6, 14], ["methanol", "CHEMICAL", 47, 55], ["baicalin", "SIMPLE_CHEMICAL", 6, 14], ["methanol-water", "SIMPLE_CHEMICAL", 47, 61], ["S. baicalensis Georgi", "ORGANISM", 75, 96], ["S. baicalensis", "SPECIES", 75, 89], ["S. baicalensis", "SPECIES", 75, 89], ["Crude baicalin", "TREATMENT", 0, 14], ["methanol-water", "TREATMENT", 47, 61], ["baicalensis Georgi", "OBSERVATION", 78, 96]]], ["The separation was performed in two steps with a two-phase solvent system composed of n-butanol-water (1:1), in which the lower phase was used as the mobile phase at a flow-rate of 1.0 ml min \u22121 in the head-to-tail elution mode.", [["head", "ANATOMY", 202, 206], ["n-butanol-water", "CHEMICAL", 86, 101], ["n-butanol", "CHEMICAL", 86, 95], ["n-butanol-water", "SIMPLE_CHEMICAL", 86, 101], ["head", "ORGANISM_SUBDIVISION", 202, 206], ["The separation", "TREATMENT", 0, 14], ["a two-phase solvent system", "TREATMENT", 47, 73], ["n-butanol-water", "TREATMENT", 86, 101], ["head", "ANATOMY", 202, 206], ["tail elution", "OBSERVATION", 210, 222]]], ["The HSCCC chromatogram is shown in Fig. 4 .", [["The HSCCC chromatogram", "TEST", 0, 22]]], ["A total of 37.0 mg of baicalin at 96.5% purity was yielded from 200 mg of the crude baicalin (containing 21.6% baicalin) with 86.0% recovery.", [["baicalin", "CHEMICAL", 22, 30], ["baicalin", "CHEMICAL", 84, 92], ["baicalin", "CHEMICAL", 111, 119], ["baicalin", "CHEMICAL", 22, 30], ["baicalin", "CHEMICAL", 84, 92], ["baicalin", "CHEMICAL", 111, 119], ["baicalin", "SIMPLE_CHEMICAL", 22, 30], ["baicalin", "SIMPLE_CHEMICAL", 84, 92], ["baicalin", "SIMPLE_CHEMICAL", 111, 119], ["baicalin", "TREATMENT", 22, 30], ["the crude baicalin", "TREATMENT", 74, 92]]], ["The simultaneous separation and purification of several active components in S. baicalensis Georgi by HSCCC in a single run is being investigated in our laboratory.Thin layer chromatographyThin layer chromatography (TLC) is a quick, convenient, and inexpensive technique widely employed for pharmaceutical analyses.", [["HSCCC", "CHEMICAL", 102, 107], ["S. baicalensis Georgi", "ORGANISM", 77, 98], ["HSCCC", "CELL", 102, 107], ["S. baicalensis", "SPECIES", 77, 91], ["S. baicalensis", "SPECIES", 77, 91], ["The simultaneous separation", "TREATMENT", 0, 27], ["purification", "TREATMENT", 32, 44], ["several active components", "PROBLEM", 48, 73], ["Thin layer chromatography", "TEST", 164, 189], ["Thin layer chromatography", "TEST", 189, 214], ["inexpensive technique", "TREATMENT", 249, 270], ["pharmaceutical analyses", "TEST", 291, 314], ["simultaneous", "OBSERVATION_MODIFIER", 4, 16], ["separation", "OBSERVATION_MODIFIER", 17, 27], ["several", "OBSERVATION_MODIFIER", 48, 55], ["active", "OBSERVATION_MODIFIER", 56, 62], ["components", "OBSERVATION_MODIFIER", 63, 73], ["baicalensis Georgi", "OBSERVATION", 80, 98], ["TLC", "ANATOMY", 216, 219]]], ["The main advantage of TLC is its ability to assay many samples in parallel on a single TLC or high-performance TLC plate, leading to a large increase in sample throughput compared with the column techniques such as HPLC.", [["samples", "ANATOMY", 55, 62], ["sample", "ANATOMY", 153, 159], ["TLC", "TREATMENT", 22, 25], ["a single TLC", "TEST", 78, 90], ["high-performance TLC plate", "TREATMENT", 94, 120], ["a large increase in sample throughput", "PROBLEM", 133, 170], ["the column techniques", "TREATMENT", 185, 206], ["HPLC", "TEST", 215, 219], ["main", "OBSERVATION_MODIFIER", 4, 8], ["TLC", "OBSERVATION", 22, 25], ["large", "OBSERVATION_MODIFIER", 135, 140], ["increase", "OBSERVATION_MODIFIER", 141, 149]]], ["However, it also possesses several limitations including lower separation efficiency and capacity compared with the column separation.Thin layer chromatographyA method was developed for the separation of baicalin, baicalein, wogonin, and oroxylin A in Scutellariae radix by high-performance TLC on phenyldimethylethoxysilanetreated silica plates with methanol-phosphate buffer (pH 6.2) as mobile phase [69] .", [["baicalin", "CHEMICAL", 204, 212], ["baicalein", "CHEMICAL", 214, 223], ["wogonin", "CHEMICAL", 225, 232], ["oroxylin A", "CHEMICAL", 238, 248], ["Scutellariae radix", "CHEMICAL", 252, 270], ["phenyldimethylethoxysilanetreated silica", "CHEMICAL", 298, 338], ["methanol-phosphate", "CHEMICAL", 351, 369], ["baicalin", "CHEMICAL", 204, 212], ["baicalein", "CHEMICAL", 214, 223], ["wogonin", "CHEMICAL", 225, 232], ["oroxylin A", "CHEMICAL", 238, 248], ["phenyldimethylethoxysilanetreated silica", "CHEMICAL", 298, 338], ["methanol", "CHEMICAL", 351, 359], ["phosphate", "CHEMICAL", 360, 369], ["baicalin", "SIMPLE_CHEMICAL", 204, 212], ["baicalein", "SIMPLE_CHEMICAL", 214, 223], ["wogonin", "SIMPLE_CHEMICAL", 225, 232], ["oroxylin A", "SIMPLE_CHEMICAL", 238, 248], ["Scutellariae", "ORGANISM", 252, 264], ["radix", "ORGANISM", 265, 270], ["methanol-phosphate buffer", "SIMPLE_CHEMICAL", 351, 376], ["lower separation efficiency and capacity", "PROBLEM", 57, 97], ["the column separation", "TREATMENT", 112, 133], ["Thin layer chromatography", "TEST", 134, 159], ["baicalin", "TREATMENT", 204, 212], ["baicalein", "TREATMENT", 214, 223], ["wogonin", "TREATMENT", 225, 232], ["oroxylin A in Scutellariae radix", "TREATMENT", 238, 270], ["phenyldimethylethoxysilanetreated silica plates", "TREATMENT", 298, 345], ["methanol-phosphate buffer", "TREATMENT", 351, 376], ["pH", "TEST", 378, 380], ["several", "OBSERVATION_MODIFIER", 27, 34], ["lower", "OBSERVATION_MODIFIER", 57, 62], ["separation efficiency", "OBSERVATION", 63, 84], ["capacity", "OBSERVATION_MODIFIER", 89, 97], ["column separation", "OBSERVATION", 116, 133]]], ["Quantitative determination of the Thin layer chromatography has been widely applied to separation and determination of baicalin in medicinal preparations, such as, Qingkailing injection solution [70] , Xiaochaihutang oral liquid [71] , injections and tablets [72] , fast-acting anti-diarrhoeal tablet [73] , and antibiotics [74] .", [["oral", "ANATOMY", 217, 221], ["baicalin", "CHEMICAL", 119, 127], ["baicalin", "CHEMICAL", 119, 127], ["baicalin", "SIMPLE_CHEMICAL", 119, 127], ["Qingkailing", "SIMPLE_CHEMICAL", 164, 175], ["oral", "ORGANISM_SUBDIVISION", 217, 221], ["the Thin layer chromatography", "TREATMENT", 30, 59], ["baicalin in medicinal preparations", "TREATMENT", 119, 153], ["Qingkailing injection solution", "TREATMENT", 164, 194], ["Xiaochaihutang oral liquid", "TREATMENT", 202, 228], ["fast-acting anti-diarrhoeal tablet", "TREATMENT", 266, 300], ["antibiotics", "TREATMENT", 312, 323]]], ["TLC methods have been also applied to the separation of baicalin and berberine sulfate in HHK injection solution [75] , baicalin and emodin in Fangfeng Tongsheng pills [76] , and baicalin and chlorogenic acid in Yinhuang tablets and injection solutions [77, 78] and in Tongkangtai oral-medication solution [79] .Thin layer chromatographyBaicalein and wogonin in the Korean crude drug preparation Soshiho Tang were separated by TLC on Silica gel 60 with benzene-ethyl acetate (1:1) as mobile phase and detection with 20% H 2 SO 4 as spray reagent and heating at 110 \u2022 C [80] .", [["oral", "ANATOMY", 281, 285], ["baicalin", "CHEMICAL", 56, 64], ["berberine sulfate", "CHEMICAL", 69, 86], ["HHK", "CHEMICAL", 90, 93], ["baicalin", "CHEMICAL", 120, 128], ["emodin", "CHEMICAL", 133, 139], ["baicalin", "CHEMICAL", 179, 187], ["chlorogenic acid", "CHEMICAL", 192, 208], ["Yinhuang", "CHEMICAL", 212, 220], ["Baicalein", "CHEMICAL", 337, 346], ["wogonin", "CHEMICAL", 351, 358], ["Silica gel", "CHEMICAL", 434, 444], ["benzene-ethyl acetate", "CHEMICAL", 453, 474], ["H 2 SO 4", "CHEMICAL", 520, 528], ["baicalin", "CHEMICAL", 56, 64], ["berberine sulfate", "CHEMICAL", 69, 86], ["baicalin", "CHEMICAL", 120, 128], ["emodin", "CHEMICAL", 133, 139], ["baicalin", "CHEMICAL", 179, 187], ["chlorogenic acid", "CHEMICAL", 192, 208], ["Baicalein", "CHEMICAL", 337, 346], ["wogonin", "CHEMICAL", 351, 358], ["Silica gel", "CHEMICAL", 434, 444], ["benzene-ethyl acetate", "CHEMICAL", 453, 474], ["H 2 SO 4", "CHEMICAL", 520, 528], ["baicalin", "SIMPLE_CHEMICAL", 56, 64], ["berberine sulfate", "SIMPLE_CHEMICAL", 69, 86], ["HHK", "SIMPLE_CHEMICAL", 90, 93], ["baicalin", "SIMPLE_CHEMICAL", 120, 128], ["emodin", "SIMPLE_CHEMICAL", 133, 139], ["Fangfeng", "SIMPLE_CHEMICAL", 143, 151], ["baicalin", "SIMPLE_CHEMICAL", 179, 187], ["chlorogenic acid", "SIMPLE_CHEMICAL", 192, 208], ["Yinhuang", "SIMPLE_CHEMICAL", 212, 220], ["oral", "ORGANISM_SUBDIVISION", 281, 285], ["Baicalein", "SIMPLE_CHEMICAL", 337, 346], ["wogonin", "SIMPLE_CHEMICAL", 351, 358], ["benzene-ethyl acetate", "SIMPLE_CHEMICAL", 453, 474], ["H 2 SO 4", "SIMPLE_CHEMICAL", 520, 528], ["TLC methods", "TREATMENT", 0, 11], ["baicalin", "TREATMENT", 56, 64], ["berberine sulfate in HHK injection solution", "TREATMENT", 69, 112], ["baicalin", "TREATMENT", 120, 128], ["emodin in Fangfeng Tongsheng pills", "TREATMENT", 133, 167], ["baicalin", "TREATMENT", 179, 187], ["chlorogenic acid in Yinhuang tablets", "TREATMENT", 192, 228], ["Tongkangtai oral-medication solution", "TREATMENT", 269, 305], ["Thin layer chromatographyBaicalein", "TREATMENT", 312, 346], ["wogonin", "TREATMENT", 351, 358], ["the Korean crude drug preparation Soshiho Tang", "TREATMENT", 362, 408], ["TLC on Silica gel", "TREATMENT", 427, 444], ["benzene-ethyl acetate", "TREATMENT", 453, 474], ["layer", "OBSERVATION_MODIFIER", 317, 322], ["chromatographyBaicalein", "OBSERVATION", 323, 346], ["wogonin", "OBSERVATION_MODIFIER", 351, 358]]], ["In another method, baicalin, ibuprofen, rhein and berberine hydrochloride in Sanhuang tablets were determined by TLC scanning method [81] .", [["baicalin", "CHEMICAL", 19, 27], ["ibuprofen", "CHEMICAL", 29, 38], ["rhein", "CHEMICAL", 40, 45], ["berberine hydrochloride", "CHEMICAL", 50, 73], ["baicalin", "CHEMICAL", 19, 27], ["ibuprofen", "CHEMICAL", 29, 38], ["rhein", "CHEMICAL", 40, 45], ["berberine hydrochloride", "CHEMICAL", 50, 73], ["baicalin", "SIMPLE_CHEMICAL", 19, 27], ["ibuprofen", "SIMPLE_CHEMICAL", 29, 38], ["rhein", "SIMPLE_CHEMICAL", 40, 45], ["berberine", "SIMPLE_CHEMICAL", 50, 59], ["hydrochloride", "SIMPLE_CHEMICAL", 60, 73], ["Sanhuang tablets", "SIMPLE_CHEMICAL", 77, 93], ["baicalin", "TREATMENT", 19, 27], ["ibuprofen", "TREATMENT", 29, 38], ["rhein", "TREATMENT", 40, 45], ["berberine hydrochloride", "TREATMENT", 50, 73], ["Sanhuang tablets", "TREATMENT", 77, 93]]], ["The powdered sample was extracted by Soxhlet with 95% ethanol.", [["sample", "ANATOMY", 13, 19], ["ethanol", "CHEMICAL", 54, 61], ["ethanol", "CHEMICAL", 54, 61], ["ethanol", "SIMPLE_CHEMICAL", 54, 61], ["The powdered sample", "TREATMENT", 0, 19], ["Soxhlet", "TREATMENT", 37, 44]]], ["The diluted extract was subjected to TLC on silica gel with benzene-ethyl acetate-acetic acid (150:50:3) as mobile phase and detection by scanning at 430 and 425 nm for determining ibuprofen and rhein, respectively; this TLC plate was then heated at 80 \u2022 C for 10 min and developed with CHCl 3 -ethyl acetate-methanol-formic acid (7:3:1:1) for separating berberine hydrochloride and baicalin.", [["extract", "ANATOMY", 12, 19], ["silica gel", "CHEMICAL", 44, 54], ["benzene-ethyl acetate-acetic acid", "CHEMICAL", 60, 93], ["ibuprofen", "CHEMICAL", 181, 190], ["rhein", "CHEMICAL", 195, 200], ["CHCl 3 -ethyl acetate-methanol-formic acid", "CHEMICAL", 287, 329], ["berberine hydrochloride", "CHEMICAL", 355, 378], ["baicalin", "CHEMICAL", 383, 391], ["silica gel", "CHEMICAL", 44, 54], ["benzene-ethyl acetate-acetic acid", "CHEMICAL", 60, 93], ["ibuprofen", "CHEMICAL", 181, 190], ["rhein", "CHEMICAL", 195, 200], ["CHCl 3 -ethyl acetate", "CHEMICAL", 287, 308], ["methanol", "CHEMICAL", 309, 317], ["formic acid", "CHEMICAL", 318, 329], ["berberine hydrochloride", "CHEMICAL", 355, 378], ["baicalin", "CHEMICAL", 383, 391], ["silica", "SIMPLE_CHEMICAL", 44, 50], ["benzene-ethyl acetate-acetic acid", "SIMPLE_CHEMICAL", 60, 93], ["150:50:3", "SIMPLE_CHEMICAL", 95, 103], ["ibuprofen", "SIMPLE_CHEMICAL", 181, 190], ["rhein", "SIMPLE_CHEMICAL", 195, 200], ["CHCl 3 -ethyl acetate-methanol-formic acid", "SIMPLE_CHEMICAL", 287, 329], ["berberine hydrochloride", "SIMPLE_CHEMICAL", 355, 378], ["baicalin", "SIMPLE_CHEMICAL", 383, 391], ["The diluted extract", "TREATMENT", 0, 19], ["TLC on silica gel", "TREATMENT", 37, 54], ["benzene", "TREATMENT", 60, 67], ["ethyl acetate", "TREATMENT", 68, 81], ["acetic acid", "TREATMENT", 82, 93], ["scanning", "TEST", 138, 146], ["ibuprofen", "TREATMENT", 181, 190], ["rhein", "TREATMENT", 195, 200], ["this TLC plate", "TREATMENT", 216, 230], ["CHCl", "TEST", 287, 291], ["ethyl acetate", "TREATMENT", 295, 308], ["methanol-formic acid", "TREATMENT", 309, 329], ["separating berberine hydrochloride", "TREATMENT", 344, 378], ["baicalin", "TREATMENT", 383, 391]]], ["Detection was at 420 and 280 nm for berberine hydrochloride and baicalin, respectively.Capillary electrophoresisCapillary electrophoresis (CE) is based on different mobilities of ions in electric field, and is applied to the analysis of charged species.", [["berberine hydrochloride", "CHEMICAL", 36, 59], ["baicalin", "CHEMICAL", 64, 72], ["berberine hydrochloride", "CHEMICAL", 36, 59], ["baicalin", "CHEMICAL", 64, 72], ["berberine", "SIMPLE_CHEMICAL", 36, 45], ["baicalin", "SIMPLE_CHEMICAL", 64, 72], ["Detection", "TEST", 0, 9], ["berberine hydrochloride", "TREATMENT", 36, 59], ["baicalin", "TREATMENT", 64, 72], ["Capillary electrophoresisCapillary electrophoresis", "TEST", 87, 137], ["charged species", "PROBLEM", 237, 252], ["charged species", "OBSERVATION", 237, 252]]], ["CE is a separation technique of high efficiency with low sample and solvent consumption.", [["CE", "CHEMICAL", 0, 2], ["high efficiency", "PROBLEM", 32, 47], ["high efficiency", "OBSERVATION", 32, 47]]], ["It has been widely used for separation of both large and small drug molecules.", [["both large and small drug molecules", "PROBLEM", 42, 77], ["both", "OBSERVATION_MODIFIER", 42, 46], ["large", "OBSERVATION_MODIFIER", 47, 52], ["small", "OBSERVATION_MODIFIER", 57, 62], ["drug molecules", "OBSERVATION", 63, 77]]], ["This method, however, has low sensitivity and low reproducibility compared with HPLC methods [21, 82] .Capillary electrophoresisCE with electrochemical detection operated in amperometric mode can provide higher sensitivity and selectivity than CE with UV detection.", [["This method", "TEST", 0, 11], ["low sensitivity", "PROBLEM", 26, 41], ["low reproducibility", "PROBLEM", 46, 65], ["HPLC methods", "TEST", 80, 92], ["Capillary electrophoresisCE", "TEST", 103, 130], ["electrochemical detection", "TEST", 136, 161], ["UV detection", "TEST", 252, 264], ["low sensitivity", "OBSERVATION_MODIFIER", 26, 41], ["low reproducibility", "OBSERVATION_MODIFIER", 46, 65]]], ["Baicalin and baicalein were determined by capillary electrophoresis with electrochemical detection [83] .", [["Baicalin", "CHEMICAL", 0, 8], ["baicalein", "CHEMICAL", 13, 22], ["Baicalin", "CHEMICAL", 0, 8], ["baicalein", "CHEMICAL", 13, 22], ["Baicalin", "SIMPLE_CHEMICAL", 0, 8], ["baicalein", "SIMPLE_CHEMICAL", 13, 22], ["capillary", "TISSUE", 42, 51], ["Baicalin", "TREATMENT", 0, 8], ["baicalein", "TREATMENT", 13, 22], ["capillary electrophoresis", "TEST", 42, 67], ["electrochemical detection", "TEST", 73, 98], ["baicalein", "OBSERVATION", 13, 22]]], ["The two analytes could be well separated within 8 min in a capillary (40 cm \u00d7 25 m i.d.) operated at a separation voltage of 12 kV, with 100 mM borate buffer (pH 9.0) as running buffer.", [["capillary", "ANATOMY", 59, 68], ["borate", "CHEMICAL", 144, 150], ["capillary", "TISSUE", 59, 68], ["a separation voltage", "TEST", 101, 121], ["100 mM borate buffer", "TREATMENT", 137, 157], ["pH", "TEST", 159, 161], ["running buffer", "TREATMENT", 170, 184]]], ["The working electrode was a 300 m diameter carbon disc electrode at a potential of 0.90 V. The method was employed for the differentiation of Scutellariae radix from Astragali radix.", [["Scutellariae radix", "CHEMICAL", 142, 160], ["carbon", "CHEMICAL", 43, 49], ["Scutellariae radix", "ORGANISM", 142, 160], ["Astragali radix", "ORGANISM", 166, 181], ["Astragali radix", "SPECIES", 166, 181], ["Scutellariae radix", "SPECIES", 142, 160], ["The working electrode", "TREATMENT", 0, 21], ["a 300 m diameter carbon disc electrode", "TREATMENT", 26, 64], ["The method", "TREATMENT", 91, 101], ["Scutellariae radix", "TREATMENT", 142, 160], ["electrode", "OBSERVATION_MODIFIER", 12, 21], ["Scutellariae radix", "OBSERVATION", 142, 160], ["Astragali radix", "ANATOMY", 166, 181]]], ["Scutellariae radix contains a great deal of baicalin and baicalein that are not present in Astragali radix, so both these crude drugs can be differentiated by determining their baicalin and baicalein contents.", [["Scutellariae radix", "CHEMICAL", 0, 18], ["baicalin", "CHEMICAL", 44, 52], ["baicalein", "CHEMICAL", 57, 66], ["baicalin", "CHEMICAL", 177, 185], ["baicalein", "CHEMICAL", 190, 199], ["baicalin", "CHEMICAL", 44, 52], ["baicalein", "CHEMICAL", 57, 66], ["baicalin", "CHEMICAL", 177, 185], ["baicalein", "CHEMICAL", 190, 199], ["Scutellariae radix", "ORGANISM", 0, 18], ["baicalin", "SIMPLE_CHEMICAL", 44, 52], ["baicalein", "SIMPLE_CHEMICAL", 57, 66], ["Astragali radix", "ORGANISM", 91, 106], ["baicalin", "SIMPLE_CHEMICAL", 177, 185], ["baicalein", "SIMPLE_CHEMICAL", 190, 199], ["Scutellariae radix", "SPECIES", 0, 18], ["Astragali radix", "SPECIES", 91, 106], ["Astragali radix", "SPECIES", 91, 106], ["Scutellariae radix", "TREATMENT", 0, 18], ["baicalin and baicalein", "TREATMENT", 44, 66], ["Astragali radix", "TREATMENT", 91, 106], ["these crude drugs", "TREATMENT", 116, 133], ["radix", "OBSERVATION_MODIFIER", 13, 18], ["great", "OBSERVATION_MODIFIER", 30, 35], ["baicalin", "OBSERVATION", 44, 52], ["baicalein", "OBSERVATION", 57, 66], ["not present", "UNCERTAINTY", 76, 87], ["Astragali radix", "ANATOMY", 91, 106], ["baicalein contents", "OBSERVATION", 190, 208]]], ["A similar method was applied to simultaneous determination of baicalein, baicalin and quercetin in Scutellariae radix and its preparations [84] .", [["baicalein", "CHEMICAL", 62, 71], ["baicalin", "CHEMICAL", 73, 81], ["quercetin", "CHEMICAL", 86, 95], ["Scutellariae radix", "CHEMICAL", 99, 117], ["baicalein", "CHEMICAL", 62, 71], ["baicalin", "CHEMICAL", 73, 81], ["quercetin", "CHEMICAL", 86, 95], ["baicalein", "SIMPLE_CHEMICAL", 62, 71], ["baicalin", "SIMPLE_CHEMICAL", 73, 81], ["quercetin", "SIMPLE_CHEMICAL", 86, 95], ["Scutellariae radix", "ORGANISM", 99, 117], ["A similar method", "TREATMENT", 0, 16], ["baicalein", "TREATMENT", 62, 71], ["baicalin", "TREATMENT", 73, 81], ["quercetin in Scutellariae radix", "TREATMENT", 86, 117], ["Scutellariae radix", "ANATOMY", 99, 117]]], ["The similar method was also used to the determination of baicalein, baicalin, and chlorogenic acid in traditional medicinal preparation Yinhuang oral liquid [85] .Capillary electrophoresisCE with UV detection, however, is more widely employed than CE with electrochemical detection.", [["oral", "ANATOMY", 145, 149], ["baicalein", "CHEMICAL", 57, 66], ["baicalin", "CHEMICAL", 68, 76], ["chlorogenic acid", "CHEMICAL", 82, 98], ["Yinhuang", "CHEMICAL", 136, 144], ["baicalein", "CHEMICAL", 57, 66], ["baicalin", "CHEMICAL", 68, 76], ["chlorogenic acid", "CHEMICAL", 82, 98], ["baicalein", "SIMPLE_CHEMICAL", 57, 66], ["baicalin", "SIMPLE_CHEMICAL", 68, 76], ["chlorogenic acid", "SIMPLE_CHEMICAL", 82, 98], ["oral", "ORGANISM_SUBDIVISION", 145, 149], ["baicalein", "TREATMENT", 57, 66], ["baicalin", "TREATMENT", 68, 76], ["chlorogenic acid", "TREATMENT", 82, 98], ["traditional medicinal preparation", "TREATMENT", 102, 135], ["Capillary electrophoresisCE", "TEST", 163, 190], ["UV detection", "TEST", 196, 208], ["electrochemical detection", "TEST", 256, 281]]], ["Baicalin in prescriptions containing S. baicalensis Georgi was determined by high-performance capillary electrophoresis [86] .", [["Baicalin", "CHEMICAL", 0, 8], ["Baicalin", "CHEMICAL", 0, 8], ["Baicalin", "SIMPLE_CHEMICAL", 0, 8], ["S. baicalensis", "ORGANISM", 37, 51], ["Georgi", "ORGANISM", 52, 58], ["S. baicalensis", "SPECIES", 37, 51], ["S. baicalensis", "SPECIES", 37, 51], ["Baicalin in prescriptions", "TREATMENT", 0, 25], ["capillary electrophoresis", "TEST", 94, 119], ["baicalensis Georgi", "OBSERVATION", 40, 58]]], ["The sample solution with p-nitrobenzoic acid as internal standard was analysed on an uncoated quartz column (39.5 cm \u00d7 50 m; effective length 34.8 cm), operated at an applied voltage of 17 kV, with 40 mM borax buffer (pH 9) as running buffer and detection at 285 nm.", [["sample", "ANATOMY", 4, 10], ["p-nitrobenzoic acid", "CHEMICAL", 25, 44], ["p-nitrobenzoic acid", "CHEMICAL", 25, 44], ["quartz", "CHEMICAL", 94, 100], ["p-nitrobenzoic acid", "SIMPLE_CHEMICAL", 25, 44], ["The sample solution", "TREATMENT", 0, 19], ["p-nitrobenzoic acid", "TREATMENT", 25, 44], ["an uncoated quartz column", "TREATMENT", 82, 107], ["length", "TEST", 135, 141], ["40 mM borax buffer", "TREATMENT", 198, 216], ["quartz column", "OBSERVATION", 94, 107]]], ["In another method, two constituents, baicalin and chlorogenic acid in Yinhuang granules were determined by CE [87] .", [["Yinhuang granules", "ANATOMY", 70, 87], ["baicalin", "CHEMICAL", 37, 45], ["chlorogenic acid", "CHEMICAL", 50, 66], ["baicalin", "CHEMICAL", 37, 45], ["chlorogenic acid", "CHEMICAL", 50, 66], ["baicalin", "SIMPLE_CHEMICAL", 37, 45], ["chlorogenic acid", "SIMPLE_CHEMICAL", 50, 66], ["Yinhuang", "SIMPLE_CHEMICAL", 70, 78], ["granules", "ORGANISM_SUBSTANCE", 79, 87], ["baicalin", "TREATMENT", 37, 45], ["chlorogenic acid in Yinhuang granules", "PROBLEM", 50, 87], ["chlorogenic acid", "OBSERVATION", 50, 66]]], ["The sample solution with p-nitrobenzoic acid as internal standard was analysed on a bare fused-silica capillary (47 cm \u00d7 50 m i.d.; effective length 40 cm), operated at an applied voltage of 25 kV, with 25 mM borax at pH 8.5 as running buffer and detection at 310 nm.", [["sample", "ANATOMY", 4, 10], ["p-nitrobenzoic acid", "CHEMICAL", 25, 44], ["borax", "CHEMICAL", 209, 214], ["p-nitrobenzoic acid", "CHEMICAL", 25, 44], ["silica", "CHEMICAL", 95, 101], ["p-nitrobenzoic acid", "SIMPLE_CHEMICAL", 25, 44], ["capillary", "TISSUE", 102, 111], ["The sample solution", "TREATMENT", 0, 19], ["p-nitrobenzoic acid", "TREATMENT", 25, 44], ["a bare fused-silica capillary", "TREATMENT", 82, 111], ["pH", "TEST", 218, 220]]], ["A method was developed for the simultaneous determination of three constituents, baicalin, chlorogenic acid and caffeic acid in seven traditional Chinese medicinal preparations containing Honeysuckle flower and/or Scutellariae radix by capillary zone electrophoresis [88] .", [["flower", "ANATOMY", 200, 206], ["baicalin", "CHEMICAL", 81, 89], ["chlorogenic acid", "CHEMICAL", 91, 107], ["caffeic acid", "CHEMICAL", 112, 124], ["baicalin", "CHEMICAL", 81, 89], ["chlorogenic acid", "CHEMICAL", 91, 107], ["caffeic acid", "CHEMICAL", 112, 124], ["baicalin", "SIMPLE_CHEMICAL", 81, 89], ["chlorogenic acid", "SIMPLE_CHEMICAL", 91, 107], ["caffeic acid", "SIMPLE_CHEMICAL", 112, 124], ["Honeysuckle", "ORGANISM", 188, 199], ["flower", "ORGANISM_SUBDIVISION", 200, 206], ["Scutellariae radix", "ORGANISM", 214, 232], ["capillary", "TISSUE", 236, 245], ["Scutellariae radix", "SPECIES", 214, 232], ["A method", "TEST", 0, 8], ["baicalin", "TREATMENT", 81, 89], ["chlorogenic acid", "TREATMENT", 91, 107], ["caffeic acid", "TREATMENT", 112, 124], ["Chinese medicinal preparations", "TREATMENT", 146, 176], ["Honeysuckle flower", "TREATMENT", 188, 206], ["Scutellariae radix", "TREATMENT", 214, 232], ["capillary zone electrophoresis", "TEST", 236, 266]]], ["The analytes were separated successfully within 3.5 min using 10 mM borate buffer (pH 8.6).", [["borate", "CHEMICAL", 68, 74], ["The analytes", "TREATMENT", 0, 12], ["10 mM borate buffer", "TREATMENT", 62, 81], ["pH", "TEST", 83, 85]]], ["Furthermore, the six bioactive constituents in San-Huang-Hsieh-Hsin-Tang were determined by CE [89] .", [["San-Huang-Hsieh-Hsin-Tang", "SIMPLE_CHEMICAL", 47, 72], ["bioactive", "OBSERVATION_MODIFIER", 21, 30], ["constituents", "OBSERVATION_MODIFIER", 31, 43]]], ["The sample solution with methyltriphenylphosphonium iodide as internal standard was injected hydrostatically for 5 s into a fused-silica capillary (80 cm \u00d7 75 m i.d.; 72.5 cm to detector) for separation at 25 kV and detection at 254 nm.", [["sample", "ANATOMY", 4, 10], ["methyltriphenylphosphonium iodide", "CHEMICAL", 25, 58], ["methyltriphenylphosphonium iodide", "CHEMICAL", 25, 58], ["silica", "CHEMICAL", 130, 136], ["methyltriphenylphosphonium iodide", "SIMPLE_CHEMICAL", 25, 58], ["capillary", "TISSUE", 137, 146], ["The sample solution", "TREATMENT", 0, 19], ["methyltriphenylphosphonium iodide", "TREATMENT", 25, 58], ["internal standard", "TREATMENT", 62, 79], ["a fused-silica capillary", "TREATMENT", 122, 146], ["separation", "TEST", 192, 202], ["detection", "TEST", 216, 225], ["silica capillary", "ANATOMY", 130, 146]]], ["The run buffer contained 50 mM sodium cholate, 50 mM NaH 2 PO 4 , 4.25 mM sodium borate and 40% acetonitrile.", [["sodium cholate", "CHEMICAL", 31, 45], ["NaH", "CHEMICAL", 53, 56], ["sodium borate", "CHEMICAL", 74, 87], ["acetonitrile", "CHEMICAL", 96, 108], ["sodium cholate", "CHEMICAL", 31, 45], ["NaH 2 PO", "CHEMICAL", 53, 61], ["sodium borate", "CHEMICAL", 74, 87], ["acetonitrile", "CHEMICAL", 96, 108], ["sodium cholate", "SIMPLE_CHEMICAL", 31, 45], ["sodium borate", "SIMPLE_CHEMICAL", 74, 87], ["acetonitrile", "SIMPLE_CHEMICAL", 96, 108], ["The run buffer", "TREATMENT", 0, 14], ["50 mM sodium cholate", "TREATMENT", 25, 45], ["4.25 mM sodium borate", "TREATMENT", 66, 87], ["40% acetonitrile", "TREATMENT", 92, 108]]], ["Separation of berberine, palmatine, baicalin, serinoside B, emodin, and sennoside A was achieved in 20 min.", [["berberine", "CHEMICAL", 14, 23], ["palmatine", "CHEMICAL", 25, 34], ["baicalin", "CHEMICAL", 36, 44], ["serinoside B", "CHEMICAL", 46, 58], ["emodin", "CHEMICAL", 60, 66], ["sennoside A", "CHEMICAL", 72, 83], ["berberine", "CHEMICAL", 14, 23], ["palmatine", "CHEMICAL", 25, 34], ["baicalin", "CHEMICAL", 36, 44], ["serinoside B", "CHEMICAL", 46, 58], ["emodin", "CHEMICAL", 60, 66], ["sennoside A", "CHEMICAL", 72, 83], ["berberine", "SIMPLE_CHEMICAL", 14, 23], ["palmatine", "SIMPLE_CHEMICAL", 25, 34], ["baicalin", "SIMPLE_CHEMICAL", 36, 44], ["serinoside B", "SIMPLE_CHEMICAL", 46, 58], ["emodin", "SIMPLE_CHEMICAL", 60, 66], ["sennoside A", "SIMPLE_CHEMICAL", 72, 83], ["berberine", "TREATMENT", 14, 23], ["palmatine", "TREATMENT", 25, 34], ["baicalin", "TREATMENT", 36, 44], ["serinoside B", "TREATMENT", 46, 58], ["emodin", "TREATMENT", 60, 66], ["sennoside A", "TREATMENT", 72, 83], ["berberine", "OBSERVATION_MODIFIER", 14, 23], ["palmatine", "ANATOMY", 25, 34]]], ["A similar method was applied to the determination of these six bioactive components in Hsiao-Cheng-Chi-Tang [90] .Micellar electrokinetic capillary chromatographyMicellar electrokinetic capillary chromatography (MEKC) is based on partition between bulk solution and micelle moving in opposite direction to analyte, and is used to determine neutrals.", [["micelle", "SIMPLE_CHEMICAL", 266, 273], ["A similar method", "TREATMENT", 0, 16], ["Micellar electrokinetic capillary chromatography", "TEST", 114, 162], ["Micellar electrokinetic capillary chromatography", "TEST", 162, 210], ["partition between bulk solution", "TREATMENT", 230, 261], ["capillary chromatography", "OBSERVATION", 138, 162]]], ["MEKC was employed as alternatives to HPLC for separations of some special samples such as enantiomeric mixtures and very polar compounds [21, 82] .", [["samples", "ANATOMY", 74, 81], ["MEKC", "TREATMENT", 0, 4], ["HPLC", "TEST", 37, 41], ["some special samples", "PROBLEM", 61, 81]]], ["MEKC with UV detection has been widely employed for S. baicalensis active components.Micellar electrokinetic capillary chromatographyBaicalein, baicalin, wogonin and acteoside in wild and cultivated S. baicalensis roots were determined by MEKC [91] .", [["roots", "ANATOMY", 214, 219], ["UV", "CHEMICAL", 10, 12], ["Baicalein", "CHEMICAL", 133, 142], ["baicalin", "CHEMICAL", 144, 152], ["wogonin", "CHEMICAL", 154, 161], ["acteoside", "CHEMICAL", 166, 175], ["Baicalein", "CHEMICAL", 133, 142], ["baicalin", "CHEMICAL", 144, 152], ["wogonin", "CHEMICAL", 154, 161], ["acteoside", "CHEMICAL", 166, 175], ["S. baicalensis", "ORGANISM", 52, 66], ["Baicalein", "SIMPLE_CHEMICAL", 133, 142], ["baicalin", "SIMPLE_CHEMICAL", 144, 152], ["wogonin", "SIMPLE_CHEMICAL", 154, 161], ["acteoside", "SIMPLE_CHEMICAL", 166, 175], ["S. baicalensis", "ORGANISM", 199, 213], ["roots", "ORGANISM", 214, 219], ["S. baicalensis", "SPECIES", 52, 66], ["S. baicalensis", "SPECIES", 199, 213], ["S. baicalensis", "SPECIES", 52, 66], ["S. baicalensis", "SPECIES", 199, 213], ["MEKC", "TEST", 0, 4], ["UV detection", "TREATMENT", 10, 22], ["S. baicalensis active components", "PROBLEM", 52, 84], ["Micellar electrokinetic capillary chromatographyBaicalein", "TREATMENT", 85, 142], ["baicalin", "TREATMENT", 144, 152], ["wogonin", "TREATMENT", 154, 161], ["acteoside", "TREATMENT", 166, 175], ["baicalensis", "OBSERVATION_MODIFIER", 55, 66], ["active", "OBSERVATION_MODIFIER", 67, 73], ["components", "OBSERVATION_MODIFIER", 74, 84], ["baicalensis roots", "OBSERVATION", 202, 219]]], ["The analysis of plant extracts was carried out on a fused silica capillary column (82 cm \u00d7 50 m i.d.; 70 cm to detection window) at 25 \u2022 C with buffer (pH 8.73) consisting of 30 mM SDS, 10 mM NaH 2 PO 4 and 15 mM Na 2 B 4 O 7, siphon injection (25 mm, 30 s), an applied voltage of 30 kV and UV detection at 275 or 350 nm.", [["extracts", "ANATOMY", 22, 30], ["NaH", "CHEMICAL", 192, 195], ["Na", "CHEMICAL", 213, 215], ["silica", "CHEMICAL", 58, 64], ["SDS", "CHEMICAL", 181, 184], ["NaH", "CHEMICAL", 192, 195], ["Na 2 B", "CHEMICAL", 213, 219], ["plant extracts", "ORGANISM_SUBSTANCE", 16, 30], ["The analysis", "TEST", 0, 12], ["plant extracts", "TREATMENT", 16, 30], ["a fused silica capillary column", "TREATMENT", 50, 81], ["pH", "TEST", 152, 154], ["30 mM SDS", "TEST", 175, 184], ["mM NaH", "TEST", 189, 195], ["Na", "TEST", 213, 215], ["siphon injection", "TREATMENT", 227, 243], ["an applied voltage", "TEST", 259, 277], ["UV detection", "TEST", 291, 303]]], ["The method can be used for the quality control of Scutellariae radix in a shorter analysis period than HPLC.", [["Scutellariae radix", "CHEMICAL", 50, 68], ["Scutellariae radix", "ORGANISM", 50, 68], ["The method", "TREATMENT", 0, 10], ["Scutellariae radix", "TREATMENT", 50, 68], ["HPLC", "TEST", 103, 107]]], ["In another study, the six flavonoids, baicalin, baicalein, wogonin 7-O-glucuronide, wogonin, oroxylin A 7-O-glucuronide, and oroxylin A in Scutellariae radix were determined by MEKC [92] .", [["flavonoids", "CHEMICAL", 26, 36], ["baicalin", "CHEMICAL", 38, 46], ["baicalein", "CHEMICAL", 48, 57], ["wogonin", "CHEMICAL", 59, 66], ["7-O-glucuronide", "CHEMICAL", 67, 82], ["wogonin", "CHEMICAL", 84, 91], ["oroxylin A 7-O-glucuronide", "CHEMICAL", 93, 119], ["oroxylin A", "CHEMICAL", 125, 135], ["flavonoids", "CHEMICAL", 26, 36], ["baicalin", "CHEMICAL", 38, 46], ["baicalein", "CHEMICAL", 48, 57], ["wogonin", "CHEMICAL", 59, 66], ["7-O-glucuronide", "CHEMICAL", 67, 82], ["wogonin", "CHEMICAL", 84, 91], ["oroxylin A 7-O-glucuronide", "CHEMICAL", 93, 119], ["oroxylin A", "CHEMICAL", 125, 135], ["flavonoids", "SIMPLE_CHEMICAL", 26, 36], ["baicalin", "SIMPLE_CHEMICAL", 38, 46], ["baicalein", "SIMPLE_CHEMICAL", 48, 57], ["wogonin 7-O-glucuronide", "SIMPLE_CHEMICAL", 59, 82], ["wogonin", "SIMPLE_CHEMICAL", 84, 91], ["oroxylin A 7-O-glucuronide", "SIMPLE_CHEMICAL", 93, 119], ["oroxylin A", "SIMPLE_CHEMICAL", 125, 135], ["Scutellariae radix", "ORGANISM", 139, 157], ["Scutellariae radix", "SPECIES", 139, 157], ["another study", "TEST", 3, 16], ["the six flavonoids", "TREATMENT", 18, 36], ["baicalin", "TREATMENT", 38, 46], ["baicalein", "TREATMENT", 48, 57], ["wogonin", "TREATMENT", 59, 66], ["glucuronide", "TREATMENT", 71, 82], ["wogonin", "TREATMENT", 84, 91], ["oroxylin", "TREATMENT", 93, 101], ["glucuronide", "TREATMENT", 108, 119], ["oroxylin A in Scutellariae radix", "TREATMENT", 125, 157]]], ["The extract with salicylic acid as internal standard was analysed on a fused-silica capillary (1 m \u00d7 75 m i.d.; 95.4 cm to detector) at 20 \u2022 C with an electrolyte of pH 9.7 containing 20 mM SDS, 10 mM sodium dihydrogen phosphate and 12.5 mM sodium borate, an applied voltage of 30 kV and detection at 275 nm.", [["extract", "ANATOMY", 4, 11], ["salicylic acid", "CHEMICAL", 17, 31], ["sodium dihydrogen phosphate", "CHEMICAL", 201, 228], ["sodium borate", "CHEMICAL", 241, 254], ["salicylic acid", "CHEMICAL", 17, 31], ["silica", "CHEMICAL", 77, 83], ["SDS", "CHEMICAL", 190, 193], ["sodium dihydrogen phosphate", "CHEMICAL", 201, 228], ["sodium borate", "CHEMICAL", 241, 254], ["salicylic acid", "SIMPLE_CHEMICAL", 17, 31], ["capillary", "TISSUE", 84, 93], ["sodium dihydrogen phosphate", "SIMPLE_CHEMICAL", 201, 228], ["sodium borate", "SIMPLE_CHEMICAL", 241, 254], ["salicylic acid", "TREATMENT", 17, 31], ["a fused-silica capillary", "TREATMENT", 69, 93], ["an electrolyte of pH", "TEST", 148, 168], ["mM sodium dihydrogen phosphate", "TEST", 198, 228], ["mM sodium borate", "TEST", 238, 254], ["an applied voltage", "TEST", 256, 274], ["detection", "TEST", 288, 297]]], ["A similar method was used for the simultaneous determination of these six flavonoids in Scutellariae radix by MEKC with UV detection at 254 nm [93] .Micellar electrokinetic capillary chromatographyFor medicinal preparations, baicalin, chlorogenic acid and forsythin in Shuanghuanglian oral liquid were deter-mined by MEKC on a bare fused-silica capillary (60 cm \u00d7 50 m i.d.) operated at an applied voltage of 15 kV, using borate buffer, SDS and acetonitrile as background electrolyte and UV detection [94] .", [["oral", "ANATOMY", 285, 289], ["Scutellariae radix", "CHEMICAL", 88, 106], ["baicalin", "CHEMICAL", 225, 233], ["chlorogenic acid", "CHEMICAL", 235, 251], ["forsythin", "CHEMICAL", 256, 265], ["MEKC", "CHEMICAL", 317, 321], ["borate buffer", "CHEMICAL", 422, 435], ["SDS and acetonitrile", "CHEMICAL", 437, 457], ["flavonoids", "CHEMICAL", 74, 84], ["baicalin", "CHEMICAL", 225, 233], ["chlorogenic acid", "CHEMICAL", 235, 251], ["forsythin", "CHEMICAL", 256, 265], ["silica", "CHEMICAL", 338, 344], ["borate", "CHEMICAL", 422, 428], ["SDS", "CHEMICAL", 437, 440], ["acetonitrile", "CHEMICAL", 445, 457], ["flavonoids", "SIMPLE_CHEMICAL", 74, 84], ["Scutellariae radix", "ORGANISM", 88, 106], ["baicalin", "SIMPLE_CHEMICAL", 225, 233], ["chlorogenic acid", "SIMPLE_CHEMICAL", 235, 251], ["forsythin", "SIMPLE_CHEMICAL", 256, 265], ["oral", "ORGANISM_SUBDIVISION", 285, 289], ["capillary", "TISSUE", 345, 354], ["SDS", "SIMPLE_CHEMICAL", 437, 440], ["acetonitrile", "SIMPLE_CHEMICAL", 445, 457], ["A similar method", "TREATMENT", 0, 16], ["these six flavonoids", "TREATMENT", 64, 84], ["UV detection", "TEST", 120, 132], ["Micellar electrokinetic capillary chromatography", "TEST", 149, 197], ["medicinal preparations", "TREATMENT", 201, 223], ["baicalin", "TREATMENT", 225, 233], ["chlorogenic acid", "TREATMENT", 235, 251], ["forsythin in Shuanghuanglian oral liquid", "TREATMENT", 256, 296], ["a bare fused-silica capillary", "TREATMENT", 325, 354], ["borate buffer", "TREATMENT", 422, 435], ["SDS", "TREATMENT", 437, 440], ["acetonitrile", "TREATMENT", 445, 457], ["background electrolyte", "TEST", 461, 483], ["UV detection", "TEST", 488, 500], ["capillary chromatography", "OBSERVATION", 173, 197]]], ["In another method, four constituents, baicalein, baicalin, wogonin and wogonin 7-O-glucuronide in traditional Chinese medicinal preparations were determined by MEKC [95] .", [["baicalein", "CHEMICAL", 38, 47], ["baicalin", "CHEMICAL", 49, 57], ["wogonin", "CHEMICAL", 59, 66], ["wogonin", "CHEMICAL", 71, 78], ["7-O-glucuronide", "CHEMICAL", 79, 94], ["baicalein", "CHEMICAL", 38, 47], ["baicalin", "CHEMICAL", 49, 57], ["wogonin", "CHEMICAL", 59, 66], ["wogonin", "CHEMICAL", 71, 78], ["7-O-glucuronide", "CHEMICAL", 79, 94], ["baicalein", "SIMPLE_CHEMICAL", 38, 47], ["baicalin", "SIMPLE_CHEMICAL", 49, 57], ["wogonin", "SIMPLE_CHEMICAL", 59, 66], ["wogonin 7-O-glucuronide", "SIMPLE_CHEMICAL", 71, 94], ["baicalein", "TREATMENT", 38, 47], ["baicalin", "TREATMENT", 49, 57], ["wogonin", "TREATMENT", 59, 66], ["wogonin", "TREATMENT", 71, 78], ["glucuronide", "TREATMENT", 83, 94]]], ["The sample solution with salicylic acid as internal standard was analysed on a fused-silica capillary (100 cm \u00d7 75 m i.d.; 95.4 cm to detection window) at 20 \u2022 C with an applied voltage of 30 kV, an electrolyte of 20 mM SDS/10 mM sodium dihydrogen phosphate/12.5 mM sodium borate buffer and detection at 275 nm.", [["sample", "ANATOMY", 4, 10], ["salicylic acid", "CHEMICAL", 25, 39], ["sodium dihydrogen phosphate", "CHEMICAL", 230, 257], ["sodium borate", "CHEMICAL", 266, 279], ["salicylic acid", "CHEMICAL", 25, 39], ["silica", "CHEMICAL", 85, 91], ["SDS", "CHEMICAL", 220, 223], ["sodium dihydrogen phosphate", "CHEMICAL", 230, 257], ["sodium borate", "CHEMICAL", 266, 279], ["salicylic acid", "SIMPLE_CHEMICAL", 25, 39], ["capillary", "TISSUE", 92, 101], ["sodium dihydrogen phosphate", "SIMPLE_CHEMICAL", 230, 257], ["sodium borate", "SIMPLE_CHEMICAL", 266, 279], ["The sample solution", "TREATMENT", 0, 19], ["salicylic acid", "TREATMENT", 25, 39], ["a fused-silica capillary", "TREATMENT", 77, 101], ["an applied voltage", "TEST", 167, 185], ["an electrolyte", "TEST", 196, 210], ["SDS", "TEST", 220, 223], ["sodium dihydrogen phosphate", "TEST", 230, 257], ["mM sodium borate buffer", "TREATMENT", 263, 286], ["detection", "TEST", 291, 300]]], ["Injection was performed at 3 psi for 1 s.", [["Injection", "TREATMENT", 0, 9]]], ["A method was developed for the simultaneous determination of ten constituents, baicalin, wogonin 7-O-glucuronide, oroxylin A 7-O-glucuronide, baicalein, wogonin, oroxylin A, berberine, palmatine, coptisine and epiberberine in the scute-coptis herb couple by MEKC with a photodiode array detector operating at 270 nm [96] .", [["baicalin", "CHEMICAL", 79, 87], ["wogonin", "CHEMICAL", 89, 96], ["7-O-glucuronide", "CHEMICAL", 97, 112], ["oroxylin A 7-O-glucuronide", "CHEMICAL", 114, 140], ["baicalein", "CHEMICAL", 142, 151], ["wogonin", "CHEMICAL", 153, 160], ["oroxylin A", "CHEMICAL", 162, 172], ["berberine", "CHEMICAL", 174, 183], ["palmatine", "CHEMICAL", 185, 194], ["coptisine", "CHEMICAL", 196, 205], ["epiberberine", "CHEMICAL", 210, 222], ["baicalin", "CHEMICAL", 79, 87], ["wogonin 7-O-glucuronide", "CHEMICAL", 89, 112], ["oroxylin A 7-O-glucuronide", "CHEMICAL", 114, 140], ["baicalein", "CHEMICAL", 142, 151], ["wogonin", "CHEMICAL", 153, 160], ["oroxylin A", "CHEMICAL", 162, 172], ["berberine", "CHEMICAL", 174, 183], ["palmatine", "CHEMICAL", 185, 194], ["coptisine", "CHEMICAL", 196, 205], ["epiberberine", "CHEMICAL", 210, 222], ["baicalin", "SIMPLE_CHEMICAL", 79, 87], ["wogonin 7-O-glucuronide", "SIMPLE_CHEMICAL", 89, 112], ["oroxylin A 7-O-glucuronide", "SIMPLE_CHEMICAL", 114, 140], ["baicalein", "SIMPLE_CHEMICAL", 142, 151], ["wogonin", "SIMPLE_CHEMICAL", 153, 160], ["oroxylin A", "SIMPLE_CHEMICAL", 162, 172], ["berberine", "SIMPLE_CHEMICAL", 174, 183], ["palmatine", "SIMPLE_CHEMICAL", 185, 194], ["coptisine", "SIMPLE_CHEMICAL", 196, 205], ["epiberberine", "SIMPLE_CHEMICAL", 210, 222], ["scute-coptis", "SPECIES", 230, 242], ["baicalin", "TREATMENT", 79, 87], ["wogonin", "TREATMENT", 89, 96], ["glucuronide", "TREATMENT", 101, 112], ["oroxylin A", "TREATMENT", 114, 124], ["glucuronide", "TREATMENT", 129, 140], ["baicalein", "TREATMENT", 142, 151], ["wogonin", "TREATMENT", 153, 160], ["oroxylin A", "TREATMENT", 162, 172], ["berberine", "TREATMENT", 174, 183], ["palmatine", "TREATMENT", 185, 194], ["coptisine", "TREATMENT", 196, 205], ["epiberberine", "TREATMENT", 210, 222], ["a photodiode array detector", "TREATMENT", 268, 295]]], ["The carrier composed of a buffer solution (5 mM sodium berate, 15 mM sodium dihydrogenphosphate and 50 mM sodium cholate) and acetonitrile (3:2) was found to be the most suitable electrolyte for this separation, whereby the contents of these compounds in the herb couple and herb couple containing Chinese herbal preparations could be determined within 30 min.", [["sodium berate", "CHEMICAL", 48, 61], ["sodium dihydrogenphosphate", "CHEMICAL", 69, 95], ["sodium cholate", "CHEMICAL", 106, 120], ["acetonitrile", "CHEMICAL", 126, 138], ["sodium berate", "CHEMICAL", 48, 61], ["sodium dihydrogenphosphate", "CHEMICAL", 69, 95], ["sodium cholate", "CHEMICAL", 106, 120], ["acetonitrile", "CHEMICAL", 126, 138], ["sodium berate", "SIMPLE_CHEMICAL", 48, 61], ["sodium dihydrogenphosphate", "SIMPLE_CHEMICAL", 69, 95], ["sodium cholate", "SIMPLE_CHEMICAL", 106, 120], ["acetonitrile", "SIMPLE_CHEMICAL", 126, 138], ["a buffer solution", "TREATMENT", 24, 41], ["5 mM sodium berate", "TREATMENT", 43, 61], ["15 mM sodium dihydrogenphosphate", "TREATMENT", 63, 95], ["50 mM sodium cholate)", "TREATMENT", 100, 121], ["acetonitrile", "TREATMENT", 126, 138], ["this separation", "TREATMENT", 195, 210], ["Chinese herbal preparations", "TREATMENT", 298, 325]]], ["The electropherogram is shown in Fig. 5 .", [["The electropherogram", "TEST", 0, 20]]], ["Furthermore, the twelve constituents, baicalin, baicalein, wogonin, wogonin 7-O-glucuronide, oroxylin A 7-O-glucuronide, sennoside A, sennoside B, emodin, aloe-emodin, glycyrrhizin, ferulic acid and caffeic acid in a Chinese herbal preparation I-Tzu-Tang could be determined simultaneously by MEKC on a fusedsilica capillary tube (70 cm \u00d7 75 m i.d.; 62.5 cm to detection window) at 30 \u2022 C with an applied voltage of 20 kV, an electrolyte solution consisting of 18 mM SDS, 2 mM sodium cholate, 12.5 mM Na 2 B 4 O 7 and 10 mM NaH 2 PO 4 and detection at 254 nm [51] .", [["baicalin", "CHEMICAL", 38, 46], ["baicalein", "CHEMICAL", 48, 57], ["wogonin", "CHEMICAL", 59, 66], ["wogonin", "CHEMICAL", 68, 75], ["7-O-glucuronide", "CHEMICAL", 76, 91], ["oroxylin A 7-O-glucuronide", "CHEMICAL", 93, 119], ["sennoside A", "CHEMICAL", 121, 132], ["sennoside B", "CHEMICAL", 134, 145], ["emodin", "CHEMICAL", 147, 153], ["aloe-emodin", "CHEMICAL", 155, 166], ["glycyrrhizin", "CHEMICAL", 168, 180], ["ferulic acid", "CHEMICAL", 182, 194], ["caffeic acid", "CHEMICAL", 199, 211], ["I-Tzu-Tang", "CHEMICAL", 244, 254], ["sodium cholate", "CHEMICAL", 477, 491], ["Na", "CHEMICAL", 501, 503], ["NaH 2 PO 4", "CHEMICAL", 524, 534], ["baicalin", "CHEMICAL", 38, 46], ["baicalein", "CHEMICAL", 48, 57], ["wogonin", "CHEMICAL", 59, 66], ["wogonin 7-O-glucuronide", "CHEMICAL", 68, 91], ["oroxylin A 7-O-glucuronide", "CHEMICAL", 93, 119], ["sennoside A", "CHEMICAL", 121, 132], ["sennoside B", "CHEMICAL", 134, 145], ["emodin", "CHEMICAL", 147, 153], ["aloe-emodin", "CHEMICAL", 155, 166], ["glycyrrhizin", "CHEMICAL", 168, 180], ["ferulic acid", "CHEMICAL", 182, 194], ["caffeic acid", "CHEMICAL", 199, 211], ["SDS", "CHEMICAL", 467, 470], ["sodium cholate", "CHEMICAL", 477, 491], ["Na 2 B", "CHEMICAL", 501, 507], ["NaH 2 PO 4", "CHEMICAL", 524, 534], ["baicalin", "SIMPLE_CHEMICAL", 38, 46], ["baicalein", "SIMPLE_CHEMICAL", 48, 57], ["wogonin", "SIMPLE_CHEMICAL", 59, 66], ["wogonin 7-O-glucuronide", "SIMPLE_CHEMICAL", 68, 91], ["oroxylin A 7-O-glucuronide", "SIMPLE_CHEMICAL", 93, 119], ["sennoside A", "SIMPLE_CHEMICAL", 121, 132], ["sennoside B", "SIMPLE_CHEMICAL", 134, 145], ["emodin", "SIMPLE_CHEMICAL", 147, 153], ["aloe-emodin", "SIMPLE_CHEMICAL", 155, 166], ["glycyrrhizin", "SIMPLE_CHEMICAL", 168, 180], ["ferulic acid", "SIMPLE_CHEMICAL", 182, 194], ["caffeic acid", "SIMPLE_CHEMICAL", 199, 211], ["Tzu-Tang", "SIMPLE_CHEMICAL", 246, 254], ["fusedsilica capillary tube", "TISSUE", 303, 329], ["sodium cholate", "SIMPLE_CHEMICAL", 477, 491], ["baicalin", "TREATMENT", 38, 46], ["baicalein", "TREATMENT", 48, 57], ["wogonin", "TREATMENT", 59, 66], ["wogonin", "TREATMENT", 68, 75], ["glucuronide", "TREATMENT", 80, 91], ["oroxylin", "TREATMENT", 93, 101], ["glucuronide", "TREATMENT", 108, 119], ["sennoside A", "TREATMENT", 121, 132], ["sennoside B", "TREATMENT", 134, 145], ["emodin", "TREATMENT", 147, 153], ["aloe-emodin", "TREATMENT", 155, 166], ["glycyrrhizin", "TREATMENT", 168, 180], ["ferulic acid", "TREATMENT", 182, 194], ["caffeic acid", "TREATMENT", 199, 211], ["a Chinese herbal preparation", "TREATMENT", 215, 243], ["a fusedsilica capillary tube", "TREATMENT", 301, 329], ["an applied voltage", "TEST", 394, 412], ["an electrolyte solution", "TEST", 423, 446], ["sodium", "TEST", 477, 483], ["cholate", "TEST", 484, 491], ["Na", "TEST", 501, 503], ["mM NaH", "TEST", 521, 527], ["detection", "TEST", 539, 548], ["capillary tube", "OBSERVATION", 315, 329]]], ["Injection was performed at 2 psi for 1 s.", [["Injection", "TREATMENT", 0, 9]]], ["The electropherogram is shown in Fig. 6 .", [["The electropherogram", "TEST", 0, 20], ["Fig", "OBSERVATION_MODIFIER", 33, 36]]], ["The contents of these components in an unpretreated I-Tzu-Tang extract could be determined in a shorter time by MEKC (14 min) than by HPLC (50 min) (Fig. 3) .", [["I-Tzu-Tang extract", "CHEMICAL", 52, 70], ["components", "OBSERVATION_MODIFIER", 22, 32]]], ["Moreover, all 11 components of I-Tzu-Tang could be determined by MEKC (Fig. 6B ), but only eight components could be determined by HPLC owing to serious interference from some impurities (Fig. 3B) .", [["I-Tzu-Tang", "CHEMICAL", 31, 41], ["I-Tzu-Tang", "GENE_OR_GENE_PRODUCT", 31, 41], ["serious interference", "PROBLEM", 145, 165]]], ["Compared with the HPLC method, the MEKC method is more attractive, especially owing to its shorter running time, and therefore should be useful for the determination of large numbers of samples and for quality control in pharmaceutical plants.High-performance liquid chromatography-mass spectrometryHigh-performance liquid chromatography-mass spectrometry is applied for the separation and identification of unknown mixtures in simple or complex matrices.", [["samples", "ANATOMY", 186, 193], ["the HPLC method", "TEST", 14, 29], ["the MEKC method", "TEST", 31, 46], ["large numbers of samples", "PROBLEM", 169, 193], ["liquid chromatography", "TEST", 260, 281], ["mass spectrometry", "PROBLEM", 282, 299], ["High-performance liquid chromatography", "TREATMENT", 299, 337], ["mass spectrometry", "PROBLEM", 338, 355], ["the separation", "TREATMENT", 371, 385], ["unknown mixtures", "PROBLEM", 408, 424], ["pharmaceutical plants", "OBSERVATION", 221, 242]]], ["The main advantages of HPLC-MS are its high speed and sensitivity compared with other hyphenated identification techniques such as HPLC-nuclear magnetic resonance (NMR) and HPLC-infrared.", [["HPLC", "TEST", 23, 27], ["MS", "PROBLEM", 28, 30], ["HPLC", "TEST", 131, 135], ["NMR", "TEST", 164, 167], ["HPLC", "TEST", 173, 177], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["In most situations, HPLC-MS/MS or HPLC-(MS) n is preferred over HPLC-MS for the structure elucidation of unknown mixtures, because multistage MS can provide additional information on fragmented ions, facilitating structural assignments [21] .High-performance liquid chromatography-mass spectrometryThe active components in the traditional Chinese medicine Xietin decoction were separated and identified of by liquid chromatography-mass spectrometry [97] .", [["Xietin decoction", "CHEMICAL", 356, 372], ["Xietin", "SIMPLE_CHEMICAL", 356, 362], ["HPLC", "TEST", 20, 24], ["MS", "PROBLEM", 25, 27], ["MS", "PROBLEM", 28, 30], ["HPLC", "TEST", 34, 38], ["unknown mixtures", "PROBLEM", 105, 121], ["multistage MS", "PROBLEM", 131, 144], ["fragmented ions", "PROBLEM", 183, 198], ["liquid chromatography", "TEST", 259, 280], ["mass spectrometry", "PROBLEM", 281, 298], ["The active components", "PROBLEM", 298, 319], ["the traditional Chinese medicine Xietin decoction", "TREATMENT", 323, 372], ["liquid chromatography", "TEST", 409, 430], ["mass spectrometry", "PROBLEM", 431, 448], ["active", "OBSERVATION_MODIFIER", 302, 308], ["components", "OBSERVATION_MODIFIER", 309, 319]]], ["The analytes were separated on an YWC ODS-AQ column (5 cm \u00d7 2 mm i.d.) with linear gradient elution of H 2 O/ammonium acetate/formic acid/methanol as mobile phase and atmosphericpressure-ionization tandem MS detection operating in multiple reaction monitoring.", [["H 2 O/ammonium acetate", "CHEMICAL", 103, 125], ["formic acid", "CHEMICAL", 126, 137], ["H 2 O", "CHEMICAL", 103, 108], ["ammonium acetate", "CHEMICAL", 109, 125], ["formic acid", "CHEMICAL", 126, 137], ["methanol", "CHEMICAL", 138, 146], ["H 2 O/ammonium acetate", "SIMPLE_CHEMICAL", 103, 125], ["formic acid", "SIMPLE_CHEMICAL", 126, 137], ["methanol", "SIMPLE_CHEMICAL", 138, 146], ["The analytes", "TEST", 0, 12], ["an YWC ODS-AQ column", "TREATMENT", 31, 51], ["linear gradient elution", "TREATMENT", 76, 99], ["ammonium acetate", "TREATMENT", 109, 125], ["formic acid/methanol", "TREATMENT", 126, 146], ["atmosphericpressure-ionization tandem MS detection", "TREATMENT", 167, 217], ["multiple reaction monitoring", "TEST", 231, 259]]], ["Nine active ingredients, rhein, aloe-emodin, physcion, baicalin, wogonoside, berberine, coptine, jatrorrhizine and palmatine were simultaneously determined.", [["rhein", "CHEMICAL", 25, 30], ["aloe-emodin", "CHEMICAL", 32, 43], ["physcion", "CHEMICAL", 45, 53], ["baicalin", "CHEMICAL", 55, 63], ["wogonoside", "CHEMICAL", 65, 75], ["berberine", "CHEMICAL", 77, 86], ["coptine", "CHEMICAL", 88, 95], ["jatrorrhizine", "CHEMICAL", 97, 110], ["palmatine", "CHEMICAL", 115, 124], ["rhein", "CHEMICAL", 25, 30], ["aloe-emodin", "CHEMICAL", 32, 43], ["physcion", "CHEMICAL", 45, 53], ["baicalin", "CHEMICAL", 55, 63], ["wogonoside", "CHEMICAL", 65, 75], ["berberine", "CHEMICAL", 77, 86], ["coptine", "CHEMICAL", 88, 95], ["jatrorrhizine", "CHEMICAL", 97, 110], ["palmatine", "CHEMICAL", 115, 124], ["rhein", "SIMPLE_CHEMICAL", 25, 30], ["aloe-emodin", "SIMPLE_CHEMICAL", 32, 43], ["physcion", "SIMPLE_CHEMICAL", 45, 53], ["baicalin", "SIMPLE_CHEMICAL", 55, 63], ["wogonoside", "SIMPLE_CHEMICAL", 65, 75], ["berberine", "SIMPLE_CHEMICAL", 77, 86], ["coptine", "SIMPLE_CHEMICAL", 88, 95], ["jatrorrhizine", "SIMPLE_CHEMICAL", 97, 110], ["palmatine", "SIMPLE_CHEMICAL", 115, 124], ["rhein", "TREATMENT", 25, 30], ["aloe-emodin", "TREATMENT", 32, 43], ["physcion", "TREATMENT", 45, 53], ["baicalin", "TREATMENT", 55, 63], ["wogonoside", "TREATMENT", 65, 75], ["berberine", "TREATMENT", 77, 86], ["coptine", "TREATMENT", 88, 95], ["jatrorrhizine", "TREATMENT", 97, 110], ["palmatine", "TREATMENT", 115, 124], ["active", "OBSERVATION_MODIFIER", 5, 11], ["ingredients", "OBSERVATION", 12, 23], ["palmatine", "ANATOMY", 115, 124]]], ["Wogonin in rat plasma was determined by liquid chromatography-tandem mass spectrometry [98] .", [["plasma", "ANATOMY", 15, 21], ["Wogonin", "CHEMICAL", 0, 7], ["Wogonin", "CHEMICAL", 0, 7], ["Wogonin", "SIMPLE_CHEMICAL", 0, 7], ["rat", "ORGANISM", 11, 14], ["plasma", "ORGANISM_SUBSTANCE", 15, 21], ["rat", "SPECIES", 11, 14], ["rat", "SPECIES", 11, 14], ["Wogonin in rat plasma", "TEST", 0, 21], ["liquid chromatography", "TEST", 40, 61], ["tandem mass spectrometry", "PROBLEM", 62, 86]]], ["The analyte with daidzein as internal standard was determined on a 5 m Diamonsil C 18 column (25 cm \u00d7 4.6 mm i.d.) with acetonitrile-H 2 O-formic acid (80:20:1) as mobile phase (0.8 ml min \u22121 ) and tandem positive-ion atmospheric pressure chemical ionization MS detection operated in selectedreaction monitoring mode.", [["daidzein", "CHEMICAL", 17, 25], ["acetonitrile-H 2 O-formic acid", "CHEMICAL", 120, 150], ["daidzein", "CHEMICAL", 17, 25], ["acetonitrile", "CHEMICAL", 120, 132], ["H 2 O-formic acid", "CHEMICAL", 133, 150], ["daidzein", "SIMPLE_CHEMICAL", 17, 25], ["acetonitrile-H 2 O-formic acid", "SIMPLE_CHEMICAL", 120, 150], ["daidzein", "TREATMENT", 17, 25], ["a 5 m Diamonsil C 18 column", "TREATMENT", 65, 92], ["acetonitrile", "TEST", 120, 132], ["formic acid", "TEST", 139, 150], ["mobile phase", "TEST", 164, 176], ["tandem", "TEST", 198, 204], ["ion atmospheric pressure", "TREATMENT", 214, 238], ["MS detection", "TEST", 259, 271]]], ["In another method, wogonin and its major metabolite in rat plasma was determined by liquid chromatography-tandem mass spectrometry [99] .", [["plasma", "ANATOMY", 59, 65], ["wogonin", "CHEMICAL", 19, 26], ["wogonin", "CHEMICAL", 19, 26], ["wogonin", "SIMPLE_CHEMICAL", 19, 26], ["rat", "ORGANISM", 55, 58], ["plasma", "ORGANISM_SUBSTANCE", 59, 65], ["rat", "SPECIES", 55, 58], ["rat", "SPECIES", 55, 58], ["wogonin", "TREATMENT", 19, 26], ["liquid chromatography", "TEST", 84, 105], ["tandem mass spectrometry", "PROBLEM", 106, 130]]], ["Only one conjugated metabolite with glucuronic acid was identified by chromatographic and electrospray multi-stage MS assay (Fig. 7) .", [["glucuronic acid", "CHEMICAL", 36, 51], ["glucuronic acid", "CHEMICAL", 36, 51], ["glucuronic acid", "SIMPLE_CHEMICAL", 36, 51], ["glucuronic acid", "TEST", 36, 51], ["glucuronic acid", "OBSERVATION", 36, 51]]], ["A derivatization reaction with 2-chlorethanol further demonstrated that the metabolite was wogonin 7\u2424d-glucuronide, not wogonin 5\u2424-d-glucuronide.", [["2-chlorethanol", "CHEMICAL", 31, 45], ["wogonin 7\u2424d-glucuronide", "CHEMICAL", 91, 114], ["wogonin 5\u2424-d-glucuronide", "CHEMICAL", 120, 144], ["2-chlorethanol", "CHEMICAL", 31, 45], ["wogonin 7\u2424d-glucuronide", "CHEMICAL", 91, 114], ["wogonin 5\u2424-d-glucuronide", "CHEMICAL", 120, 144], ["2-chlorethanol", "SIMPLE_CHEMICAL", 31, 45], ["wogonin", "SIMPLE_CHEMICAL", 91, 98], ["7\u2424d-glucuronide", "SIMPLE_CHEMICAL", 99, 114], ["wogonin", "SIMPLE_CHEMICAL", 120, 127], ["5\u2424-d-glucuronide", "SIMPLE_CHEMICAL", 128, 144], ["A derivatization reaction", "PROBLEM", 0, 25], ["the metabolite", "TEST", 72, 86], ["wogonin", "TEST", 91, 98], ["glucuronide", "TREATMENT", 103, 114], ["wogonin", "TEST", 120, 127], ["glucuronide", "TREATMENT", 133, 144]]], ["Other conjugated metabolites, e.g., sulfates and glucosides, were not detected.", [["sulfates", "CHEMICAL", 36, 44], ["glucosides", "CHEMICAL", 49, 59], ["sulfates", "SIMPLE_CHEMICAL", 36, 44], ["glucosides", "SIMPLE_CHEMICAL", 49, 59], ["Other conjugated metabolites", "TEST", 0, 28], ["glucosides", "TREATMENT", 49, 59]]], ["The plasma concentration of free wogonin was determined using atmospheric pressure chemical ionization source in the selected reaction monitoring (SRM) mode (Fig. 8) .", [["plasma", "ANATOMY", 4, 10], ["wogonin", "CHEMICAL", 33, 40], ["wogonin", "CHEMICAL", 33, 40], ["plasma", "ORGANISM_SUBSTANCE", 4, 10], ["wogonin", "SIMPLE_CHEMICAL", 33, 40], ["The plasma concentration of free wogonin", "TREATMENT", 0, 40], ["atmospheric pressure chemical ionization", "TREATMENT", 62, 102], ["free wogonin", "OBSERVATION", 28, 40]]], ["Incubation of the plasma samples with \u2424-glucuronidase allows the quantitation of wogonin 7\u2424-d-glucuronide.Gas chromatography-mass spectrometryBecause of the high polarity, low volatility and poor thermal stability, gas chromatography was not widely employed for the determination of baicalin, baicalein or wogonin.", [["plasma samples", "ANATOMY", 18, 32], ["\u2424-glucuronidase", "CHEMICAL", 38, 53], ["wogonin 7\u2424-d-glucuronide", "CHEMICAL", 81, 105], ["baicalin", "CHEMICAL", 283, 291], ["baicalein", "CHEMICAL", 293, 302], ["wogonin", "CHEMICAL", 306, 313], ["wogonin 7\u2424-d-glucuronide", "CHEMICAL", 81, 105], ["baicalin", "CHEMICAL", 283, 291], ["baicalein", "CHEMICAL", 293, 302], ["wogonin", "CHEMICAL", 306, 313], ["plasma samples", "ORGANISM_SUBSTANCE", 18, 32], ["\u2424-glucuronidase", "SIMPLE_CHEMICAL", 38, 53], ["wogonin", "SIMPLE_CHEMICAL", 81, 88], ["7\u2424-d-glucuronide", "SIMPLE_CHEMICAL", 89, 105], ["baicalin", "SIMPLE_CHEMICAL", 283, 291], ["baicalein", "SIMPLE_CHEMICAL", 293, 302], ["wogonin", "SIMPLE_CHEMICAL", 306, 313], ["the plasma samples", "TEST", 14, 32], ["\u2424-glucuronidase", "TREATMENT", 38, 53], ["wogonin", "TREATMENT", 81, 88], ["d-glucuronide", "TREATMENT", 92, 105], ["Gas chromatography", "TEST", 106, 124], ["mass spectrometry", "PROBLEM", 125, 142], ["the high polarity", "PROBLEM", 153, 170], ["low volatility", "PROBLEM", 172, 186], ["poor thermal stability", "PROBLEM", 191, 213], ["gas chromatography", "TEST", 215, 233], ["baicalin", "TREATMENT", 283, 291], ["baicalein", "TREATMENT", 293, 302], ["wogonin", "TREATMENT", 306, 313], ["mass", "OBSERVATION", 125, 129], ["high polarity", "OBSERVATION_MODIFIER", 157, 170], ["low volatility", "OBSERVATION_MODIFIER", 172, 186], ["stability", "OBSERVATION_MODIFIER", 204, 213]]], ["As a result, few gas chromatographic methods were developed and reported in the literature.", [["few gas chromatographic methods", "TEST", 13, 44], ["few", "OBSERVATION_MODIFIER", 13, 16]]], ["These active compounds in the crude extracts of S. baicalensis Georgi were identified by gas chromatography-mass spectrometry [23] .", [["extracts", "ANATOMY", 36, 44], ["extracts", "ORGANISM_SUBSTANCE", 36, 44], ["S. baicalensis", "ORGANISM", 48, 62], ["Georgi", "ORGANISM", 63, 69], ["S. baicalensis", "SPECIES", 48, 62], ["Georgi", "SPECIES", 63, 69], ["S. baicalensis", "SPECIES", 48, 62], ["gas chromatography", "TEST", 89, 107], ["mass spectrometry", "PROBLEM", 108, 125], ["active", "OBSERVATION_MODIFIER", 6, 12], ["compounds", "OBSERVATION_MODIFIER", 13, 22], ["baicalensis Georgi", "OBSERVATION", 51, 69]]], ["LC-MS n analysis of wogonin and its conjugated metabolites in plasma after an administration of 5 mg kg \u22121 wogonin to a Wistar rat.", [["plasma", "ANATOMY", 62, 68], ["wogonin", "CHEMICAL", 20, 27], ["wogonin", "CHEMICAL", 107, 114], ["wogonin", "CHEMICAL", 20, 27], ["wogonin", "CHEMICAL", 107, 114], ["wogonin", "SIMPLE_CHEMICAL", 20, 27], ["plasma", "ORGANISM_SUBSTANCE", 62, 68], ["wogonin", "SIMPLE_CHEMICAL", 107, 114], ["Wistar rat", "ORGANISM", 120, 130], ["rat", "SPECIES", 127, 130], ["rat", "SPECIES", 127, 130], ["LC", "TEST", 0, 2], ["wogonin", "PROBLEM", 20, 27]]], ["(A) Total ion current and selected ion monitoring chromatograms (A2, wogonin glucuronide; A3, wogonin sulfate; A4, wogonin glucoside; A5, free wogonin); (B) full scan MS-MS spectrum of peak at 6.18 min; (C) full scan MS 3 spectrum of peak at 6.18 min.", [["wogonin glucuronide", "CHEMICAL", 69, 88], ["wogonin", "CHEMICAL", 94, 101], ["wogonin", "CHEMICAL", 115, 122], ["wogonin", "CHEMICAL", 143, 150], ["wogonin glucuronide", "CHEMICAL", 69, 88], ["wogonin sulfate", "CHEMICAL", 94, 109], ["wogonin glucoside", "CHEMICAL", 115, 132], ["wogonin", "CHEMICAL", 143, 150], ["wogonin glucuronide", "SIMPLE_CHEMICAL", 69, 88], ["A3", "SIMPLE_CHEMICAL", 90, 92], ["wogonin sulfate", "SIMPLE_CHEMICAL", 94, 109], ["A4", "SIMPLE_CHEMICAL", 111, 113], ["wogonin glucoside", "SIMPLE_CHEMICAL", 115, 132], ["A5", "SIMPLE_CHEMICAL", 134, 136], ["wogonin", "SIMPLE_CHEMICAL", 143, 150], ["selected ion monitoring chromatograms", "TEST", 26, 63], ["A2", "TEST", 65, 67], ["wogonin", "TEST", 69, 76], ["glucuronide", "TEST", 77, 88], ["A3", "TEST", 90, 92], ["wogonin sulfate", "TREATMENT", 94, 109], ["A4", "TEST", 111, 113], ["wogonin glucoside", "TEST", 115, 132], ["full scan MS", "TEST", 157, 169], ["MS spectrum", "TEST", 170, 181], ["peak", "TEST", 185, 189], ["full scan MS", "TEST", 207, 219]]], ["HP-5MS (crosslinked 5% diphenyl-95% dimethylpolysiloxane) capillary column was used (0.25 m film thickness) with helium as carrier gas.", [["HP-5MS", "CHEMICAL", 0, 6], ["5% diphenyl-95% dimethylpolysiloxane", "CHEMICAL", 20, 56], ["HP-5MS", "CHEMICAL", 0, 6], ["diphenyl", "CHEMICAL", 23, 31], ["dimethylpolysiloxane", "CHEMICAL", 36, 56], ["helium", "CHEMICAL", 113, 119], ["HP-5MS", "SIMPLE_CHEMICAL", 0, 6], ["5% diphenyl-95% dimethylpolysiloxane", "SIMPLE_CHEMICAL", 20, 56], ["HP", "TEST", 0, 2], ["crosslinked 5% diphenyl-95% dimethylpolysiloxane) capillary column", "TREATMENT", 8, 74], ["carrier gas", "TEST", 123, 134]]], ["The molecular ion peaks of wogonin and baicalein were at m/z 284 and 270, respectively.", [["wogonin", "CHEMICAL", 27, 34], ["baicalein", "CHEMICAL", 39, 48], ["wogonin", "CHEMICAL", 27, 34], ["baicalein", "CHEMICAL", 39, 48], ["wogonin", "SIMPLE_CHEMICAL", 27, 34], ["baicalein", "SIMPLE_CHEMICAL", 39, 48], ["baicalein", "TEST", 39, 48], ["ion", "OBSERVATION_MODIFIER", 14, 17], ["peaks", "OBSERVATION_MODIFIER", 18, 23], ["wogonin", "OBSERVATION_MODIFIER", 27, 34], ["baicalein", "OBSERVATION_MODIFIER", 39, 48]]], ["As to baicalin, its molecular ion peak could not be observed at m/z 446.", [["baicalin", "CHEMICAL", 6, 14], ["baicalin", "CHEMICAL", 6, 14], ["baicalin", "SIMPLE_CHEMICAL", 6, 14], ["baicalin", "TREATMENT", 6, 14]]], ["All crude extracts showed the similar patterns of total ion chromatogram.", [["extracts", "ANATOMY", 10, 18], ["extracts", "ORGANISM_SUBSTANCE", 10, 18], ["ion", "SIMPLE_CHEMICAL", 56, 59], ["All crude extracts", "TEST", 0, 18], ["total ion chromatogram", "TEST", 50, 72]]], ["By comparison of MS fragments with library search software, wogonin was identified.", [["wogonin", "CHEMICAL", 60, 67], ["wogonin", "CHEMICAL", 60, 67], ["wogonin", "SIMPLE_CHEMICAL", 60, 67], ["MS fragments", "DNA", 17, 29], ["MS fragments", "PROBLEM", 17, 29], ["library search software", "TEST", 35, 58], ["wogonin", "PROBLEM", 60, 67]]], ["But at the retention time of 20.03 min, fragments of m/z 270 had a relatively low intensity compared with those of m/z 284, 269, 139 and 241.", [["fragments of m/z", "TEST", 40, 56], ["a relatively low intensity", "PROBLEM", 65, 91], ["relatively", "OBSERVATION_MODIFIER", 67, 77], ["low intensity", "OBSERVATION_MODIFIER", 78, 91]]], ["By comparison with the peak intensities of the library database, these peaks may be shown to represent the combinations of many constituents, such as baicalin, baicalein and oroxylin A. Therefore, optimal conditions for separation of the coexisting baicalein and baicalin by GC-MS require further investigation.Quantitation and validationOften minor reagent substitutions, changes in laboratory temperature, or lot-to-lot variations in extraction cartridges and analytical columns affect analytical results.", [["baicalin", "CHEMICAL", 150, 158], ["baicalein", "CHEMICAL", 160, 169], ["baicalein", "CHEMICAL", 249, 258], ["baicalin", "CHEMICAL", 263, 271], ["baicalin", "CHEMICAL", 150, 158], ["baicalein", "CHEMICAL", 160, 169], ["oroxylin", "CHEMICAL", 174, 182], ["baicalein", "CHEMICAL", 249, 258], ["baicalin", "CHEMICAL", 263, 271], ["baicalin", "SIMPLE_CHEMICAL", 150, 158], ["baicalein", "SIMPLE_CHEMICAL", 160, 169], ["oroxylin A.", "SIMPLE_CHEMICAL", 174, 185], ["baicalein", "SIMPLE_CHEMICAL", 249, 258], ["baicalin", "SIMPLE_CHEMICAL", 263, 271], ["the library database", "TEST", 43, 63], ["baicalin", "TREATMENT", 150, 158], ["baicalein", "TREATMENT", 160, 169], ["oroxylin A.", "TREATMENT", 174, 185], ["the coexisting baicalein", "TREATMENT", 234, 258], ["baicalin", "TREATMENT", 263, 271], ["further investigation", "TEST", 289, 310], ["Quantitation", "TEST", 311, 323], ["validationOften minor reagent substitutions", "PROBLEM", 328, 371], ["laboratory temperature", "TEST", 384, 406], ["extraction cartridges", "TREATMENT", 436, 457], ["reagent substitutions", "OBSERVATION", 350, 371]]], ["The use of internal standard method can compensate for sample losses occurring during extraction, clean-up and final analysis and for signal changes caused by variation in experimental conditions.", [["sample", "ANATOMY", 55, 61], ["internal standard method", "TREATMENT", 11, 35], ["sample losses", "PROBLEM", 55, 68], ["extraction", "TREATMENT", 86, 96], ["final analysis", "TEST", 111, 125], ["signal changes", "PROBLEM", 134, 148], ["variation in experimental conditions", "PROBLEM", 159, 195], ["experimental conditions", "OBSERVATION", 172, 195]]], ["An ideal internal standard should resemble the analyte as closely as possible in terms of chemical and physical properties and this requirement is fulfilled when a structural analogue is selected as an internal standard.", [["the analyte", "TREATMENT", 43, 54]]], ["Representative SRM chromatograms of: (A) a blank rat plasma sample; (B) a blank plasma sample spiked with 2.0 ng ml \u22121 wogonin and the internal standard daidzein (IS, 1000 ng ml \u22121 ); (C) plasma sample from a Wistar rat 0.5 h after an oral administration of wogonin (5 mg kg \u22121 ).", [["plasma sample", "ANATOMY", 53, 66], ["plasma sample", "ANATOMY", 80, 93], ["plasma sample", "ANATOMY", 188, 201], ["oral", "ANATOMY", 235, 239], ["wogonin", "CHEMICAL", 119, 126], ["daidzein", "CHEMICAL", 153, 161], ["wogonin", "CHEMICAL", 258, 265], ["wogonin", "CHEMICAL", 119, 126], ["daidzein", "CHEMICAL", 153, 161], ["wogonin", "CHEMICAL", 258, 265], ["rat", "ORGANISM", 49, 52], ["plasma", "ORGANISM_SUBSTANCE", 53, 59], ["plasma", "ORGANISM_SUBSTANCE", 80, 86], ["wogonin", "SIMPLE_CHEMICAL", 119, 126], ["daidzein", "SIMPLE_CHEMICAL", 153, 161], ["plasma", "ORGANISM_SUBSTANCE", 188, 194], ["Wistar rat", "ORGANISM", 209, 219], ["oral", "ORGANISM_SUBDIVISION", 235, 239], ["wogonin", "SIMPLE_CHEMICAL", 258, 265], ["rat", "SPECIES", 49, 52], ["rat", "SPECIES", 216, 219], ["rat", "SPECIES", 49, 52], ["Representative SRM chromatograms", "TEST", 0, 32], ["a blank rat plasma sample", "TEST", 41, 66], ["a blank plasma sample", "TEST", 72, 93], ["wogonin", "TREATMENT", 119, 126], ["the internal standard daidzein (IS", "TREATMENT", 131, 165], ["plasma sample", "TEST", 188, 201], ["a Wistar rat", "TREATMENT", 207, 219], ["wogonin", "TREATMENT", 258, 265]]], ["Peak I, wogonin; peak II, IS.", [["wogonin", "CHEMICAL", 8, 15], ["wogonin", "CHEMICAL", 8, 15], ["wogonin", "SIMPLE_CHEMICAL", 8, 15], ["Peak I", "TEST", 0, 6]]], ["Reprinted from [99] with permission from Elsevier.Quantitation and validationGood science and effective medical care demand inexpensive validated methods with high throughput which are capable of simultaneously analyzing multiple drugs in various matrices.", [["Quantitation", "TEST", 50, 62], ["effective medical care", "TREATMENT", 94, 116], ["inexpensive validated methods", "TREATMENT", 124, 153]]], ["The analytical methodology should be validated in terms of precision, accuracy, limit of detection, limit of quantitation, specificity, linearity and range, ruggedness and robustness [100] .Quantitation and validationIn a method for the HPLC-UV determination of baicalin, baicalein and wogonin in Scutellariae radix, ethyl paraben was used as internal standard.", [["baicalin", "CHEMICAL", 262, 270], ["baicalein", "CHEMICAL", 272, 281], ["wogonin", "CHEMICAL", 286, 293], ["Scutellariae radix", "CHEMICAL", 297, 315], ["ethyl paraben", "CHEMICAL", 317, 330], ["baicalin", "CHEMICAL", 262, 270], ["baicalein", "CHEMICAL", 272, 281], ["wogonin", "CHEMICAL", 286, 293], ["ethyl paraben", "CHEMICAL", 317, 330], ["baicalin", "SIMPLE_CHEMICAL", 262, 270], ["baicalein", "SIMPLE_CHEMICAL", 272, 281], ["wogonin", "SIMPLE_CHEMICAL", 286, 293], ["Scutellariae radix", "ORGANISM", 297, 315], ["ethyl paraben", "SIMPLE_CHEMICAL", 317, 330], ["Scutellariae radix", "SPECIES", 297, 315], ["quantitation", "TEST", 109, 121], ["specificity", "TEST", 123, 134], ["linearity", "TEST", 136, 145], ["Quantitation", "TEST", 190, 202], ["validation", "TEST", 207, 217], ["the HPLC", "TEST", 233, 241], ["baicalin", "TREATMENT", 262, 270], ["baicalein", "TREATMENT", 272, 281], ["wogonin in Scutellariae radix", "TREATMENT", 286, 315], ["ethyl paraben", "TREATMENT", 317, 330], ["baicalin", "ANATOMY", 262, 270], ["Scutellariae radix", "ANATOMY", 297, 315]]], ["The linearity ranges were 3.1-100, 2.5-80 and 2.5-80 g ml \u22121 , respectively.", [["The linearity ranges", "TEST", 0, 20], ["linearity", "OBSERVATION_MODIFIER", 4, 13], ["ranges", "OBSERVATION_MODIFIER", 14, 20]]], ["The determination and detection limits were 2.5-3.1 and 0.2-0.3 g ml \u22121 , respectively.", [["The determination", "TEST", 0, 17]]], ["The recoveries were 87.8-110% with the intra-and inter-run R.S.D. of 5.3% [47] .", [["The recoveries", "TEST", 0, 14], ["the intra-and inter-run R.S.D.", "TEST", 35, 65]]], ["In another HPLC-UV method for the determination of baicalin in rabbit serum, p-nitrobenzoic acid was used as internal standard.", [["serum", "ANATOMY", 70, 75], ["baicalin", "CHEMICAL", 51, 59], ["p-nitrobenzoic acid", "CHEMICAL", 77, 96], ["baicalin", "CHEMICAL", 51, 59], ["p-nitrobenzoic acid", "CHEMICAL", 77, 96], ["baicalin", "SIMPLE_CHEMICAL", 51, 59], ["rabbit", "ORGANISM", 63, 69], ["serum", "ORGANISM_SUBSTANCE", 70, 75], ["p-nitrobenzoic acid", "SIMPLE_CHEMICAL", 77, 96], ["rabbit", "SPECIES", 63, 69], ["rabbit", "SPECIES", 63, 69], ["another HPLC", "TEST", 3, 15], ["UV method", "TREATMENT", 16, 25], ["baicalin in rabbit serum", "TREATMENT", 51, 75], ["p-nitrobenzoic acid", "TREATMENT", 77, 96]]], ["The standard curve was linear from 0.5 to 200.0 mg l \u22121 with a correlation coefficient of 0.9994.", [["a correlation coefficient", "TEST", 61, 86]]], ["The recovery was 98.2-101.8%.", [["The recovery", "TEST", 0, 12]]], ["The intra-and inter-day R.S.D.s were 3.7-5.4 and 5.3-7.2%, respectively [54] .", [["The intra-and inter-day R.S.D.s", "TEST", 0, 31]]], ["When baicalin and baicalein in rat plasma were determined by HPLC with electrochemical detection, the linearity ranges were 5-2000 and 2-5000 ng ml \u22121 , respectively.", [["plasma", "ANATOMY", 35, 41], ["baicalin", "CHEMICAL", 5, 13], ["baicalein", "CHEMICAL", 18, 27], ["baicalin", "CHEMICAL", 5, 13], ["baicalein", "CHEMICAL", 18, 27], ["baicalin", "SIMPLE_CHEMICAL", 5, 13], ["baicalein", "SIMPLE_CHEMICAL", 18, 27], ["rat", "ORGANISM", 31, 34], ["plasma", "ORGANISM_SUBSTANCE", 35, 41], ["rat", "SPECIES", 31, 34], ["rat", "SPECIES", 31, 34], ["baicalin", "TREATMENT", 5, 13], ["baicalein in rat plasma", "TREATMENT", 18, 41], ["electrochemical detection", "TEST", 71, 96], ["the linearity ranges", "TEST", 98, 118]]], ["The detection limits were 5 and 2 ng ml \u22121 , respectively and corresponding coefficients of variation were 4.6-8.6% and 0.6-8.8% [59] .", [["variation", "TEST", 92, 101]]], ["The method was more sensitive than the HPLC method with UV detection [47] .Quantitation and validationFor determination of baicalin, ibuprofen, rhein and berberine hydrochloride in Sanhuang tablets by TLC scanning method, the calibration graphs were rectilinear for up to 2, 1.2, 5 and 10 g for ibuprofen, rhein, berberine hydrochloride and baicalin, respectively.", [["baicalin", "CHEMICAL", 123, 131], ["ibuprofen", "CHEMICAL", 133, 142], ["rhein", "CHEMICAL", 144, 149], ["berberine hydrochloride", "CHEMICAL", 154, 177], ["ibuprofen", "CHEMICAL", 295, 304], ["rhein", "CHEMICAL", 306, 311], ["berberine hydrochloride", "CHEMICAL", 313, 336], ["baicalin", "CHEMICAL", 341, 349], ["baicalin", "CHEMICAL", 123, 131], ["ibuprofen", "CHEMICAL", 133, 142], ["rhein", "CHEMICAL", 144, 149], ["berberine hydrochloride", "CHEMICAL", 154, 177], ["ibuprofen", "CHEMICAL", 295, 304], ["rhein", "CHEMICAL", 306, 311], ["berberine hydrochloride", "CHEMICAL", 313, 336], ["baicalin", "CHEMICAL", 341, 349], ["baicalin", "SIMPLE_CHEMICAL", 123, 131], ["ibuprofen", "SIMPLE_CHEMICAL", 133, 142], ["rhein", "SIMPLE_CHEMICAL", 144, 149], ["berberine", "SIMPLE_CHEMICAL", 154, 163], ["Sanhuang", "SIMPLE_CHEMICAL", 181, 189], ["ibuprofen", "SIMPLE_CHEMICAL", 295, 304], ["rhein", "SIMPLE_CHEMICAL", 306, 311], ["berberine", "SIMPLE_CHEMICAL", 313, 322], ["hydrochloride", "SIMPLE_CHEMICAL", 323, 336], ["baicalin", "SIMPLE_CHEMICAL", 341, 349], ["The method", "TEST", 0, 10], ["the HPLC method", "TEST", 35, 50], ["UV detection", "TEST", 56, 68], ["Quantitation", "TEST", 75, 87], ["validation", "TEST", 92, 102], ["baicalin", "TREATMENT", 123, 131], ["ibuprofen", "TREATMENT", 133, 142], ["rhein", "TREATMENT", 144, 149], ["berberine hydrochloride", "TREATMENT", 154, 177], ["Sanhuang tablets", "TREATMENT", 181, 197], ["the calibration graphs", "TEST", 222, 244], ["ibuprofen", "TREATMENT", 295, 304], ["rhein", "TREATMENT", 306, 311], ["berberine hydrochloride", "TREATMENT", 313, 336], ["baicalin", "TREATMENT", 341, 349]]], ["The recoveries averaged >94% with the coefficients of variation of <4% [81] .Quantitation and validationWhen baicalin, baicalein and quercetin in Scutellariae radix were determined by CE with electrochemical detection, the linearity ranges were 0.0010-1.0, 0.0005-1.0 and 0.0005-1.0 mmol l \u22121 , the limits of detection were 0.548, 0.224 and 0.274 mol l \u22121 , the recoveries were 95.24, 99.08 and 97.52%, and the R.S.D.s were 2.79, 0.94 and 4.76%, respectively [83] .", [["baicalin", "CHEMICAL", 109, 117], ["baicalein", "CHEMICAL", 119, 128], ["quercetin", "CHEMICAL", 133, 142], ["Scutellariae radix", "CHEMICAL", 146, 164], ["baicalin", "CHEMICAL", 109, 117], ["baicalein", "CHEMICAL", 119, 128], ["quercetin", "CHEMICAL", 133, 142], ["baicalin", "SIMPLE_CHEMICAL", 109, 117], ["baicalein", "SIMPLE_CHEMICAL", 119, 128], ["quercetin", "SIMPLE_CHEMICAL", 133, 142], ["Scutellariae radix", "ORGANISM", 146, 164], ["The recoveries", "TEST", 0, 14], ["Quantitation", "TEST", 77, 89], ["validationWhen baicalin", "TREATMENT", 94, 117], ["baicalein", "TREATMENT", 119, 128], ["quercetin in Scutellariae radix", "TREATMENT", 133, 164], ["electrochemical detection", "TEST", 192, 217], ["the linearity ranges", "TEST", 219, 239], ["detection", "TEST", 309, 318], ["the recoveries", "TEST", 358, 372], ["the R.S.D.s", "TEST", 407, 418]]], ["The method was less sensitive than the HPLC with electrochemical detection [59] , but it was more sensitive than the HPLC with UV detection [47] .", [["The method", "TEST", 0, 10], ["the HPLC", "TEST", 35, 43], ["electrochemical detection", "TEST", 49, 74], ["the HPLC", "TEST", 113, 121], ["UV detection", "TEST", 127, 139]]], ["For determination of baicalin in prescriptions containing S. baicalensis Georgi by high-performance capillary electrophoresis with UV detection, the linearity range was 10-640 mg l \u22121 .", [["baicalin", "CHEMICAL", 21, 29], ["baicalin", "CHEMICAL", 21, 29], ["baicalin", "SIMPLE_CHEMICAL", 21, 29], ["S. baicalensis", "ORGANISM", 58, 72], ["Georgi", "ORGANISM", 73, 79], ["S. baicalensis", "SPECIES", 58, 72], ["S. baicalensis", "SPECIES", 58, 72], ["baicalin in prescriptions", "TREATMENT", 21, 46], ["UV detection", "TEST", 131, 143]]], ["The recoveries were 100.3-100.6% with the R.S.D. of <5% [86] .", [["The recoveries", "TEST", 0, 14], ["the R.S.D.", "TEST", 38, 48]]], ["For determination of baicalin and chlorogenic acid in Yinhuang granules by capillary electrophoresis with UV detection, the calibration graphs were linear from 160-960 and 80-960 mg l \u22121 , respectively.", [["Yinhuang granules", "ANATOMY", 54, 71], ["baicalin", "CHEMICAL", 21, 29], ["chlorogenic acid", "CHEMICAL", 34, 50], ["baicalin", "CHEMICAL", 21, 29], ["chlorogenic acid", "CHEMICAL", 34, 50], ["baicalin", "SIMPLE_CHEMICAL", 21, 29], ["chlorogenic acid", "SIMPLE_CHEMICAL", 34, 50], ["Yinhuang", "SIMPLE_CHEMICAL", 54, 62], ["granules", "ORGANISM_SUBSTANCE", 63, 71], ["capillary", "TISSUE", 75, 84], ["baicalin", "TREATMENT", 21, 29], ["chlorogenic acid in Yinhuang granules", "PROBLEM", 34, 71], ["capillary electrophoresis", "TEST", 75, 100], ["UV detection", "TEST", 106, 118], ["the calibration graphs", "TEST", 120, 142], ["chlorogenic acid", "OBSERVATION", 34, 50], ["capillary electrophoresis", "OBSERVATION", 75, 100]]], ["The recoveries were 99.8-102.1% with the R.S.D. of 0.87-3.09% [87] .", [["The recoveries", "TEST", 0, 14], ["the R.S.D.", "TEST", 37, 47]]], ["When six flavonoids in Scutellariae radix were simultaneously determined by MEKC with UV detection, the calibration graphs were linear for 0.007-0.135 mg ml \u22121 of baicalein, wogonin and oroxylin A 7-O-glucuronide, 0.013-0.234 mg ml \u22121 of wogonin 7-O-glucuronide, 0.025-0.450 mg ml \u22121 of baicalin and 0.005-0.09 mg ml \u22121 of oroxylin A. The recoveries were 98.1-102.6% and the R.S.D.s were 0.9-2.4% [92] .Quantitation and validationFor determination of wogonin in rat plasma by liquid chromatography-tandem mass spectrometry, the linearity range was 0.25-20 ng ml \u22121 .", [["plasma", "ANATOMY", 466, 472], ["flavonoids", "CHEMICAL", 9, 19], ["Scutellariae radix", "CHEMICAL", 23, 41], ["baicalein", "CHEMICAL", 163, 172], ["wogonin", "CHEMICAL", 174, 181], ["oroxylin A 7-O-glucuronide", "CHEMICAL", 186, 212], ["wogonin", "CHEMICAL", 238, 245], ["7-O-glucuronide", "CHEMICAL", 246, 261], ["baicalin", "CHEMICAL", 287, 295], ["wogonin", "CHEMICAL", 451, 458], ["flavonoids", "CHEMICAL", 9, 19], ["baicalein", "CHEMICAL", 163, 172], ["wogonin", "CHEMICAL", 174, 181], ["oroxylin A 7-O-glucuronide", "CHEMICAL", 186, 212], ["wogonin", "CHEMICAL", 238, 245], ["7-O-glucuronide", "CHEMICAL", 246, 261], ["baicalin", "CHEMICAL", 287, 295], ["wogonin", "CHEMICAL", 451, 458], ["flavonoids", "SIMPLE_CHEMICAL", 9, 19], ["Scutellariae radix", "ORGANISM", 23, 41], ["baicalein", "SIMPLE_CHEMICAL", 163, 172], ["wogonin", "SIMPLE_CHEMICAL", 174, 181], ["oroxylin A 7-O-glucuronide", "SIMPLE_CHEMICAL", 186, 212], ["wogonin", "SIMPLE_CHEMICAL", 238, 245], ["7-O-glucuronide", "SIMPLE_CHEMICAL", 246, 261], ["baicalin", "SIMPLE_CHEMICAL", 287, 295], ["wogonin", "SIMPLE_CHEMICAL", 451, 458], ["rat", "ORGANISM", 462, 465], ["plasma", "ORGANISM_SUBSTANCE", 466, 472], ["Scutellariae radix", "SPECIES", 23, 41], ["rat", "SPECIES", 462, 465], ["rat", "SPECIES", 462, 465], ["Scutellariae radix", "TREATMENT", 23, 41], ["UV detection", "TEST", 86, 98], ["the calibration graphs", "TEST", 100, 122], ["baicalein", "TREATMENT", 163, 172], ["wogonin", "TREATMENT", 174, 181], ["oroxylin A", "TREATMENT", 186, 196], ["glucuronide", "TREATMENT", 201, 212], ["wogonin", "TREATMENT", 238, 245], ["glucuronide", "TREATMENT", 250, 261], ["baicalin", "TREATMENT", 287, 295], ["The recoveries", "TEST", 335, 349], ["the R.S.D.s", "TEST", 371, 382], ["Quantitation", "TEST", 403, 415], ["validation", "TEST", 420, 430], ["wogonin in rat plasma", "TEST", 451, 472], ["liquid chromatography", "TEST", 476, 497], ["tandem mass spectrometry", "PROBLEM", 498, 522], ["the linearity range", "TEST", 524, 543]]], ["The limit of detection was 0.25 ng ml \u22121 and the within-and between-day R.S.D.s were 2.2-19.1 and 5.9-7.3%, respectively [98] .", [["detection", "TEST", 13, 22], ["R.S.D.s", "TEST", 72, 79]]], ["The HPLC-MS [98] was the most sensitive, followed by the HPLC with electrochemical detection [59] , and the CE with electrochemical detection [83] .", [["The HPLC", "TEST", 0, 8], ["MS", "TEST", 9, 11], ["the HPLC", "TEST", 53, 61], ["electrochemical detection", "TEST", 67, 92], ["the CE", "TEST", 104, 110], ["electrochemical detection", "TEST", 116, 141]]], ["The HPLC-UV [47] was the least sensitive.Evaluation of the analytical resultsAnalytical methodology is an essential component not only in the developmental phase of a drug substance but also in the continuing evaluation of clinical efficacy.", [["The HPLC", "TEST", 0, 8], ["Evaluation", "TEST", 41, 51], ["the continuing evaluation", "TEST", 194, 219]]], ["The HPLC methods have been applied to pharmacokinetic studies.", [["The HPLC methods", "TREATMENT", 0, 16], ["pharmacokinetic studies", "TEST", 38, 61]]], ["The pharmacokinetics of wogonin in rats was studied by HPLC after a dose of 5 mg kg \u22121 by intravenous administration [101] .", [["intravenous", "ANATOMY", 90, 101], ["wogonin", "CHEMICAL", 24, 31], ["wogonin", "CHEMICAL", 24, 31], ["wogonin", "SIMPLE_CHEMICAL", 24, 31], ["rats", "ORGANISM", 35, 39], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 90, 101], ["rats", "SPECIES", 35, 39], ["wogonin in rats", "TREATMENT", 24, 39], ["wogonin", "OBSERVATION_MODIFIER", 24, 31]]], ["A biphasic phenomenon with a rapid distribution followed by a slower elimination phase was observed from the plasma concentration time profile.", [["plasma", "ANATOMY", 109, 115], ["plasma", "ORGANISM_SUBSTANCE", 109, 115], ["A biphasic phenomenon", "PROBLEM", 0, 21], ["a rapid distribution", "PROBLEM", 27, 47], ["a slower elimination phase", "PROBLEM", 60, 86], ["biphasic", "OBSERVATION_MODIFIER", 2, 10], ["phenomenon", "OBSERVATION", 11, 21], ["rapid", "OBSERVATION_MODIFIER", 29, 34], ["distribution", "OBSERVATION_MODIFIER", 35, 47]]], ["In another report, the metabolism of baicalin in human was studied by HPLC after oral administration of Sho-Saiko-To [102] .", [["oral", "ANATOMY", 81, 85], ["baicalin", "CHEMICAL", 37, 45], ["Sho-", "CHEMICAL", 104, 108], ["baicalin", "CHEMICAL", 37, 45], ["baicalin", "SIMPLE_CHEMICAL", 37, 45], ["human", "ORGANISM", 49, 54], ["oral", "ORGANISM_SUBDIVISION", 81, 85], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["baicalin in human", "TREATMENT", 37, 54]]], ["Baicalin is one of the major components of Sho-Saiko-To.", [["Baicalin", "CHEMICAL", 0, 8], ["Baicalin", "CHEMICAL", 0, 8], ["Baicalin", "SIMPLE_CHEMICAL", 0, 8], ["Baicalin", "TREATMENT", 0, 8], ["one of", "OBSERVATION_MODIFIER", 12, 18]]], ["Baicalein 6-O-sulfate was identified as the metabolite of baicalin.", [["Baicalein", "CHEMICAL", 0, 9], ["6-O-sulfate", "CHEMICAL", 10, 21], ["baicalin", "CHEMICAL", 58, 66], ["Baicalein 6-O-sulfate", "CHEMICAL", 0, 21], ["baicalin", "CHEMICAL", 58, 66], ["Baicalein 6-O-sulfate", "SIMPLE_CHEMICAL", 0, 21], ["baicalin", "SIMPLE_CHEMICAL", 58, 66], ["Baicalein 6-O-sulfate", "TREATMENT", 0, 21], ["baicalin", "TREATMENT", 58, 66]]], ["Baicalein 6-Osulfate was detected after 1 h, reached a maximum level at 5 h and then decreased to the level less than the quantitative limit (5 ng ml \u22121 ) after 36 h, and the plasma level of baicalein 6-Osulfate showed a small peak at 24 h.", [["plasma", "ANATOMY", 175, 181], ["Baicalein 6-Osulfate", "CHEMICAL", 0, 20], ["baicalein 6-Osulfate", "CHEMICAL", 191, 211], ["Baicalein 6-Osulfate", "CHEMICAL", 0, 20], ["baicalein 6-Osulfate", "CHEMICAL", 191, 211], ["Baicalein 6-Osulfate", "SIMPLE_CHEMICAL", 0, 20], ["plasma", "ORGANISM_SUBSTANCE", 175, 181], ["baicalein 6-Osulfate", "SIMPLE_CHEMICAL", 191, 211], ["Baicalein", "TREATMENT", 0, 9], ["Osulfate", "TREATMENT", 12, 20], ["the plasma level", "TEST", 171, 187], ["baicalein", "TEST", 191, 200], ["small", "OBSERVATION_MODIFIER", 221, 226]]], ["Baicalin was detected after 1 h, reached a maximum level at 5 h and then decreased to the level less than the quantitative limit (5 ng ml \u22121 ) after 36 h, and the plasma level of baicalin showed two peaks at 12 h and 24 h.Evaluation of the analytical resultsThe metabolic pharmacokinetics of baicalin and baicalein in rats were compared [103] .", [["plasma", "ANATOMY", 163, 169], ["Baicalin", "CHEMICAL", 0, 8], ["baicalin", "CHEMICAL", 179, 187], ["baicalin", "CHEMICAL", 292, 300], ["baicalein", "CHEMICAL", 305, 314], ["Baicalin", "CHEMICAL", 0, 8], ["baicalin", "CHEMICAL", 179, 187], ["baicalin", "CHEMICAL", 292, 300], ["baicalein", "CHEMICAL", 305, 314], ["Baicalin", "SIMPLE_CHEMICAL", 0, 8], ["plasma", "ORGANISM_SUBSTANCE", 163, 169], ["baicalin", "SIMPLE_CHEMICAL", 179, 187], ["baicalin", "SIMPLE_CHEMICAL", 292, 300], ["baicalein", "SIMPLE_CHEMICAL", 305, 314], ["rats", "ORGANISM", 318, 322], ["rats", "SPECIES", 318, 322], ["Baicalin", "TREATMENT", 0, 8], ["the plasma level of baicalin", "TEST", 159, 187], ["h.Evaluation", "TEST", 220, 232], ["the analytical results", "TEST", 236, 258], ["baicalin", "TREATMENT", 292, 300], ["baicalein in rats", "TREATMENT", 305, 322], ["metabolic pharmacokinetics", "OBSERVATION", 262, 288], ["baicalein", "OBSERVATION_MODIFIER", 305, 314]]], ["After intravenous administration of baicalein, 75.7% of the dose was circulated as its conjugated metabolites.", [["intravenous", "ANATOMY", 6, 17], ["baicalein", "CHEMICAL", 36, 45], ["baicalein", "CHEMICAL", 36, 45], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 6, 17], ["baicalein", "SIMPLE_CHEMICAL", 36, 45], ["baicalein", "TREATMENT", 36, 45]]], ["After oral administration of baicalein, absorption of baicalein itself was negligible, whereas the glucuronides/sulfates of baicalein were predominant in the plasma.", [["oral", "ANATOMY", 6, 10], ["plasma", "ANATOMY", 158, 164], ["baicalein", "CHEMICAL", 29, 38], ["baicalein", "CHEMICAL", 54, 63], ["glucuronides", "CHEMICAL", 99, 111], ["baicalein", "CHEMICAL", 124, 133], ["baicalein", "CHEMICAL", 29, 38], ["baicalein", "CHEMICAL", 54, 63], ["glucuronides", "CHEMICAL", 99, 111], ["sulfates", "CHEMICAL", 112, 120], ["baicalein", "CHEMICAL", 124, 133], ["oral", "ORGANISM_SUBDIVISION", 6, 10], ["baicalein", "SIMPLE_CHEMICAL", 29, 38], ["baicalein", "SIMPLE_CHEMICAL", 54, 63], ["glucuronides", "SIMPLE_CHEMICAL", 99, 111], ["sulfates", "SIMPLE_CHEMICAL", 112, 120], ["baicalein", "SIMPLE_CHEMICAL", 124, 133], ["plasma", "ORGANISM_SUBSTANCE", 158, 164], ["oral administration of baicalein", "TREATMENT", 6, 38], ["absorption of baicalein", "TREATMENT", 40, 63], ["the glucuronides/sulfates of baicalein", "TREATMENT", 95, 133]]], ["When compared with intravenous bolus administration with dose correction, the absolute absorption was 40%.", [["intravenous", "ANATOMY", 19, 30], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 19, 30], ["intravenous bolus administration", "TREATMENT", 19, 51], ["dose correction", "TREATMENT", 57, 72], ["the absolute absorption", "TEST", 74, 97]]], ["When baicalin was administered orally, glucuronides and sulfates of baicalein were exclusively circulated in the plasma.", [["plasma", "ANATOMY", 113, 119], ["baicalin", "CHEMICAL", 5, 13], ["glucuronides", "CHEMICAL", 39, 51], ["baicalein", "CHEMICAL", 68, 77], ["baicalin", "CHEMICAL", 5, 13], ["glucuronides", "CHEMICAL", 39, 51], ["sulfates", "CHEMICAL", 56, 64], ["baicalein", "CHEMICAL", 68, 77], ["baicalin", "SIMPLE_CHEMICAL", 5, 13], ["glucuronides", "SIMPLE_CHEMICAL", 39, 51], ["sulfates", "SIMPLE_CHEMICAL", 56, 64], ["baicalein", "SIMPLE_CHEMICAL", 68, 77], ["plasma", "ORGANISM_SUBSTANCE", 113, 119], ["baicalin", "TREATMENT", 5, 13], ["glucuronides", "TREATMENT", 39, 51], ["sulfates", "TREATMENT", 56, 64], ["baicalein", "TREATMENT", 68, 77]]], ["The relative absorption for baicalin was 65% when compared with baicalein.", [["baicalin", "CHEMICAL", 28, 36], ["baicalein", "CHEMICAL", 64, 73], ["baicalin", "CHEMICAL", 28, 36], ["baicalein", "CHEMICAL", 64, 73], ["baicalin", "SIMPLE_CHEMICAL", 28, 36], ["baicalein", "SIMPLE_CHEMICAL", 64, 73], ["baicalin", "TREATMENT", 28, 36]]], ["Profound differences of serum profile and pharmacokinetics were observed between oral baicalein and baicalin.", [["serum", "ANATOMY", 24, 29], ["oral", "ANATOMY", 81, 85], ["baicalein", "CHEMICAL", 86, 95], ["baicalin", "CHEMICAL", 100, 108], ["baicalein", "CHEMICAL", 86, 95], ["baicalin", "CHEMICAL", 100, 108], ["serum", "ORGANISM_SUBSTANCE", 24, 29], ["oral", "ORGANISM_SUBDIVISION", 81, 85], ["baicalein", "SIMPLE_CHEMICAL", 86, 95], ["baicalin", "SIMPLE_CHEMICAL", 100, 108], ["Profound differences of serum profile", "PROBLEM", 0, 37], ["pharmacokinetics", "TREATMENT", 42, 58], ["oral baicalein", "TREATMENT", 81, 95], ["baicalin", "TREATMENT", 100, 108]]], ["Baicalin demonstrated significantly a time lag to achieve the peak concentration t max , and the lower peak serum concentration (C max ) of baicalein conjugated metabolites compared to baicalein, indicating baicalin was absorbed more slowly and to poorly than baicalein.", [["serum", "ANATOMY", 108, 113], ["Baicalin", "CHEMICAL", 0, 8], ["baicalein", "CHEMICAL", 140, 149], ["baicalein", "CHEMICAL", 185, 194], ["baicalin", "CHEMICAL", 207, 215], ["baicalein", "CHEMICAL", 260, 269], ["Baicalin", "CHEMICAL", 0, 8], ["baicalein", "CHEMICAL", 140, 149], ["baicalein", "CHEMICAL", 185, 194], ["baicalin", "CHEMICAL", 207, 215], ["baicalein", "CHEMICAL", 260, 269], ["Baicalin", "SIMPLE_CHEMICAL", 0, 8], ["serum", "ORGANISM_SUBSTANCE", 108, 113], ["baicalein", "SIMPLE_CHEMICAL", 140, 149], ["baicalein", "SIMPLE_CHEMICAL", 185, 194], ["baicalin", "SIMPLE_CHEMICAL", 207, 215], ["baicalein", "SIMPLE_CHEMICAL", 260, 269], ["Baicalin", "TREATMENT", 0, 8], ["the peak concentration t max", "TEST", 58, 86], ["the lower peak serum concentration", "TEST", 93, 127], ["C max", "TEST", 129, 134], ["baicalein conjugated metabolites", "PROBLEM", 140, 172], ["baicalein", "TREATMENT", 185, 194], ["baicalin", "TREATMENT", 207, 215], ["baicalin", "OBSERVATION", 207, 215]]], ["In addition, the urinary pharmacokinetics of baicalein, wogonin and their glycosides in humans were studied after oral administration of Scutellariae radix [104] .", [["urinary", "ANATOMY", 17, 24], ["oral", "ANATOMY", 114, 118], ["baicalein", "CHEMICAL", 45, 54], ["wogonin", "CHEMICAL", 56, 63], ["Scutellariae radix", "CHEMICAL", 137, 155], ["baicalein", "CHEMICAL", 45, 54], ["wogonin", "CHEMICAL", 56, 63], ["urinary", "ORGANISM_SUBSTANCE", 17, 24], ["baicalein", "SIMPLE_CHEMICAL", 45, 54], ["wogonin", "SIMPLE_CHEMICAL", 56, 63], ["humans", "ORGANISM", 88, 94], ["oral", "ORGANISM_SUBDIVISION", 114, 118], ["humans", "SPECIES", 88, 94], ["humans", "SPECIES", 88, 94], ["baicalein", "TREATMENT", 45, 54], ["wogonin", "TREATMENT", 56, 63], ["their glycosides", "TREATMENT", 68, 84], ["oral administration of Scutellariae radix", "TREATMENT", 114, 155], ["urinary", "ANATOMY", 17, 24]]], ["Ten healthy male volunteers received a dose of 5.2 g commercial powder (comparable to 9 g crude drug), respectively.", [["volunteers", "ORGANISM", 17, 27], ["5.2 g commercial powder", "TREATMENT", 47, 70]]], ["The mean cumulated renal excretion of baicalein glucuronides and sulfates were 43.1 \u00b1 4.5 mol (2.9% of dose) and 64.8 \u00b1 6.3 mol (4.3% of dose), respectively, whereas wogonin glucuronides and sulfates were 21.6 \u00b1 2.0 mol (5.9% of dose) and 20.7 \u00b1 1.7 mol (5.7% of dose), respectively.", [["renal", "ANATOMY", 19, 24], ["baicalein glucuronides", "CHEMICAL", 38, 60], ["sulfates", "CHEMICAL", 65, 73], ["wogonin glucuronides", "CHEMICAL", 166, 186], ["sulfates", "CHEMICAL", 191, 199], ["baicalein glucuronides", "CHEMICAL", 38, 60], ["sulfates", "CHEMICAL", 65, 73], ["wogonin glucuronides", "CHEMICAL", 166, 186], ["sulfates", "CHEMICAL", 191, 199], ["renal", "ORGAN", 19, 24], ["baicalein glucuronides", "SIMPLE_CHEMICAL", 38, 60], ["sulfates", "SIMPLE_CHEMICAL", 65, 73], ["wogonin glucuronides", "SIMPLE_CHEMICAL", 166, 186], ["sulfates", "SIMPLE_CHEMICAL", 191, 199], ["baicalein glucuronides", "TREATMENT", 38, 60], ["sulfates", "TREATMENT", 65, 73], ["wogonin glucuronides", "TEST", 166, 186], ["sulfates", "TEST", 191, 199], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["renal", "ANATOMY", 19, 24], ["excretion", "OBSERVATION_MODIFIER", 25, 34], ["baicalein glucuronides", "OBSERVATION", 38, 60]]], ["The renal excretion of conjugated metabolites of wogonin (11.6% of dose) was higher than that of baicalein (7.2% of dose).", [["renal", "ANATOMY", 4, 9], ["wogonin", "CHEMICAL", 49, 56], ["baicalein", "CHEMICAL", 97, 106], ["wogonin", "CHEMICAL", 49, 56], ["baicalein", "CHEMICAL", 97, 106], ["renal", "ORGAN", 4, 9], ["wogonin", "SIMPLE_CHEMICAL", 49, 56], ["baicalein", "SIMPLE_CHEMICAL", 97, 106], ["The renal excretion of conjugated metabolites", "TEST", 0, 45], ["wogonin", "TEST", 49, 56], ["baicalein", "TREATMENT", 97, 106], ["renal", "ANATOMY", 4, 9], ["excretion", "OBSERVATION_MODIFIER", 10, 19]]], ["The baicalein sulfates was predominant than the corresponding glucuronides, whereas wogonin sulfates was comparable to the corresponding glucuronides.Evaluation of the analytical resultsThe metabolism of active constituents in Huangqin-Tang, a prescription in traditional Chinese medicine, was studied by human intestinal flora [105] .", [["intestinal", "ANATOMY", 311, 321], ["baicalein sulfates", "CHEMICAL", 4, 22], ["glucuronides", "CHEMICAL", 62, 74], ["wogonin sulfates", "CHEMICAL", 84, 100], ["glucuronides", "CHEMICAL", 137, 149], ["Huangqin-Tang", "CHEMICAL", 227, 240], ["baicalein sulfates", "CHEMICAL", 4, 22], ["glucuronides", "CHEMICAL", 62, 74], ["wogonin sulfates", "CHEMICAL", 84, 100], ["glucuronides", "CHEMICAL", 137, 149], ["baicalein sulfates", "SIMPLE_CHEMICAL", 4, 22], ["glucuronides", "SIMPLE_CHEMICAL", 62, 74], ["wogonin", "SIMPLE_CHEMICAL", 84, 91], ["sulfates", "SIMPLE_CHEMICAL", 92, 100], ["glucuronides", "SIMPLE_CHEMICAL", 137, 149], ["human", "ORGANISM", 305, 310], ["intestinal flora", "CELL", 311, 327], ["human", "SPECIES", 305, 310], ["human", "SPECIES", 305, 310], ["The baicalein sulfates", "TREATMENT", 0, 22], ["wogonin sulfates", "TREATMENT", 84, 100], ["Evaluation", "TEST", 150, 160], ["the analytical results", "TEST", 164, 186], ["traditional Chinese medicine", "TREATMENT", 260, 288], ["baicalein sulfates", "OBSERVATION", 4, 22], ["metabolism", "OBSERVATION_MODIFIER", 190, 200], ["active", "OBSERVATION_MODIFIER", 204, 210], ["constituents", "OBSERVATION_MODIFIER", 211, 223], ["intestinal", "ANATOMY", 311, 321]]], ["Huangqin-Tang and all individual herbs in the decoctions were incubated with a human fecal suspension separately.", [["Huangqin-Tang", "CHEMICAL", 0, 13], ["human", "ORGANISM", 79, 84], ["fecal", "ORGANISM_SUBSTANCE", 85, 90], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 79, 84], ["a human fecal suspension", "TREATMENT", 77, 101]]], ["The active con-stituents of Huangqin-Tang, including baicalin, wogonoside, oroxylin-A glucuronide, paconiflorin, liquiritin, isoliquirtin and glycyrrhizic acid, were converted to their metabolites baicalein, wogonin, oroxylin-A, paeonimetabolin-I, liquiritigenin, isoliquiritigenin and glycyrrhetinic acid by human intestinal flora.", [["intestinal flora", "ANATOMY", 315, 331], ["Huangqin-Tang", "CHEMICAL", 28, 41], ["baicalin", "CHEMICAL", 53, 61], ["wogonoside", "CHEMICAL", 63, 73], ["oroxylin-A glucuronide", "CHEMICAL", 75, 97], ["paconiflorin", "CHEMICAL", 99, 111], ["liquiritin", "CHEMICAL", 113, 123], ["isoliquirtin", "CHEMICAL", 125, 137], ["glycyrrhizic acid", "CHEMICAL", 142, 159], ["baicalein", "CHEMICAL", 197, 206], ["wogonin", "CHEMICAL", 208, 215], ["oroxylin-A, paeonimetabolin-I", "CHEMICAL", 217, 246], ["liquiritigenin", "CHEMICAL", 248, 262], ["isoliquiritigenin", "CHEMICAL", 264, 281], ["glycyrrhetinic acid", "CHEMICAL", 286, 305], ["baicalin", "CHEMICAL", 53, 61], ["wogonoside", "CHEMICAL", 63, 73], ["oroxylin-A glucuronide", "CHEMICAL", 75, 97], ["paconiflorin", "CHEMICAL", 99, 111], ["liquiritin", "CHEMICAL", 113, 123], ["isoliquirtin", "CHEMICAL", 125, 137], ["glycyrrhizic acid", "CHEMICAL", 142, 159], ["baicalein", "CHEMICAL", 197, 206], ["wogonin", "CHEMICAL", 208, 215], ["oroxylin-A", "CHEMICAL", 217, 227], ["paeonimetabolin-I", "CHEMICAL", 229, 246], ["liquiritigenin", "CHEMICAL", 248, 262], ["isoliquiritigenin", "CHEMICAL", 264, 281], ["glycyrrhetinic acid", "CHEMICAL", 286, 305], ["Huangqin-Tang", "SIMPLE_CHEMICAL", 28, 41], ["baicalin", "SIMPLE_CHEMICAL", 53, 61], ["wogonoside", "SIMPLE_CHEMICAL", 63, 73], ["oroxylin-A glucuronide", "SIMPLE_CHEMICAL", 75, 97], ["paconiflorin", "SIMPLE_CHEMICAL", 99, 111], ["liquiritin", "SIMPLE_CHEMICAL", 113, 123], ["isoliquirtin", "SIMPLE_CHEMICAL", 125, 137], ["glycyrrhizic acid", "SIMPLE_CHEMICAL", 142, 159], ["baicalein", "SIMPLE_CHEMICAL", 197, 206], ["wogonin", "SIMPLE_CHEMICAL", 208, 215], ["oroxylin-A", "SIMPLE_CHEMICAL", 217, 227], ["paeonimetabolin-I", "SIMPLE_CHEMICAL", 229, 246], ["liquiritigenin", "SIMPLE_CHEMICAL", 248, 262], ["isoliquiritigenin", "SIMPLE_CHEMICAL", 264, 281], ["glycyrrhetinic acid", "SIMPLE_CHEMICAL", 286, 305], ["human", "ORGANISM", 309, 314], ["intestinal flora", "PATHOLOGICAL_FORMATION", 315, 331], ["human", "SPECIES", 309, 314], ["human", "SPECIES", 309, 314], ["Huangqin-Tang", "TREATMENT", 28, 41], ["baicalin", "TREATMENT", 53, 61], ["wogonoside", "TREATMENT", 63, 73], ["oroxylin", "TREATMENT", 75, 83], ["A glucuronide", "TREATMENT", 84, 97], ["paconiflorin", "TREATMENT", 99, 111], ["liquiritin", "TREATMENT", 113, 123], ["isoliquirtin", "TREATMENT", 125, 137], ["glycyrrhizic acid", "TREATMENT", 142, 159], ["their metabolites baicalein", "TREATMENT", 179, 206], ["wogonin", "TREATMENT", 208, 215], ["oroxylin", "TREATMENT", 217, 225], ["paeonimetabolin", "TREATMENT", 229, 244], ["liquiritigenin", "TREATMENT", 248, 262], ["isoliquiritigenin", "TREATMENT", 264, 281], ["glycyrrhetinic acid", "TREATMENT", 286, 305], ["active", "OBSERVATION_MODIFIER", 4, 10], ["intestinal", "ANATOMY", 315, 325]]], ["The contents of the metabolites in Huangqin-Tang and in each single herb decoction increased significantly after incubation with intestinal flora.", [["intestinal flora", "ANATOMY", 129, 145], ["Huangqin-Tang", "CHEMICAL", 35, 48], ["intestinal flora", "PATHOLOGICAL_FORMATION", 129, 145], ["Huangqin-Tang", "TREATMENT", 35, 48], ["each single herb decoction", "TREATMENT", 56, 82], ["intestinal flora", "PROBLEM", 129, 145], ["metabolites", "OBSERVATION_MODIFIER", 20, 31], ["herb", "OBSERVATION_MODIFIER", 68, 72], ["decoction", "OBSERVATION", 73, 82], ["increased", "OBSERVATION_MODIFIER", 83, 92], ["intestinal", "ANATOMY", 129, 139], ["flora", "OBSERVATION", 140, 145]]], ["Comparing with single herb decoctions, the transformation of baicalin, wogonoside, oroxylin-A glucuronide, liquiritin and isoliquirtin in the compound prescription was promoted, however, that of paconiflorin and glycyrrhizic acid was inhibited.", [["baicalin", "CHEMICAL", 61, 69], ["wogonoside", "CHEMICAL", 71, 81], ["oroxylin-A glucuronide", "CHEMICAL", 83, 105], ["liquiritin", "CHEMICAL", 107, 117], ["isoliquirtin", "CHEMICAL", 122, 134], ["paconiflorin", "CHEMICAL", 195, 207], ["glycyrrhizic acid", "CHEMICAL", 212, 229], ["baicalin", "CHEMICAL", 61, 69], ["wogonoside", "CHEMICAL", 71, 81], ["oroxylin-A glucuronide", "CHEMICAL", 83, 105], ["liquiritin", "CHEMICAL", 107, 117], ["isoliquirtin", "CHEMICAL", 122, 134], ["paconiflorin", "CHEMICAL", 195, 207], ["glycyrrhizic acid", "CHEMICAL", 212, 229], ["baicalin", "SIMPLE_CHEMICAL", 61, 69], ["wogonoside", "SIMPLE_CHEMICAL", 71, 81], ["oroxylin-A glucuronide", "SIMPLE_CHEMICAL", 83, 105], ["liquiritin", "SIMPLE_CHEMICAL", 107, 117], ["isoliquirtin", "SIMPLE_CHEMICAL", 122, 134], ["paconiflorin", "SIMPLE_CHEMICAL", 195, 207], ["glycyrrhizic acid", "SIMPLE_CHEMICAL", 212, 229], ["single herb decoctions", "TREATMENT", 15, 37], ["baicalin", "TREATMENT", 61, 69], ["wogonoside", "TREATMENT", 71, 81], ["oroxylin", "TREATMENT", 83, 91], ["A glucuronide", "TREATMENT", 92, 105], ["liquiritin", "TREATMENT", 107, 117], ["isoliquirtin", "TREATMENT", 122, 134], ["paconiflorin", "TREATMENT", 195, 207], ["glycyrrhizic acid", "TREATMENT", 212, 229]]], ["All the results suggested that the glycosides of many medicinal herbs could be converted to aglycones by human intestinal flora, and the metabolism of most glycosides was improved in the compound prescription.", [["intestinal flora", "ANATOMY", 111, 127], ["aglycones", "SIMPLE_CHEMICAL", 92, 101], ["human", "ORGANISM", 105, 110], ["intestinal flora", "PATHOLOGICAL_FORMATION", 111, 127], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 105, 110], ["the glycosides", "TREATMENT", 31, 45], ["many medicinal herbs", "TREATMENT", 49, 69], ["aglycones", "TREATMENT", 92, 101], ["human intestinal flora", "PROBLEM", 105, 127], ["intestinal", "ANATOMY", 111, 121], ["flora", "OBSERVATION", 122, 127]]], ["In another report, the pharmacokinetics of multi-constituents in Huangqin-Tang decoction in rats were studied [106] .", [["Huangqin-Tang decoction", "CHEMICAL", 65, 88], ["Huangqin-Tang decoction", "ORGANISM", 65, 88], ["rats", "ORGANISM", 92, 96], ["rats", "SPECIES", 92, 96], ["multi-constituents", "TREATMENT", 43, 61], ["Huangqin-Tang decoction", "TREATMENT", 65, 88]]], ["At different intervals after oral administration of the Huangqin-Tang decoction or a single herb decoction at a dose of 10 g kg \u22121 , the concentrations of the constituents and their metabolites, baicalin, wogonoside, oroxylin-A glucuronide, baicalein, wogonin, oroxylin-A, paeoniflorin (PF), paeonimetabolin-I, liquiritin, liquiritigenin, glycyrrhizic acid and glycyrrhetinic acid, were detected in the rat plasma by HPLC.", [["oral", "ANATOMY", 29, 33], ["plasma", "ANATOMY", 407, 413], ["Huangqin-Tang decoction", "CHEMICAL", 56, 79], ["baicalin", "CHEMICAL", 195, 203], ["wogonoside", "CHEMICAL", 205, 215], ["oroxylin-A glucuronide", "CHEMICAL", 217, 239], ["baicalein", "CHEMICAL", 241, 250], ["wogonin", "CHEMICAL", 252, 259], ["oroxylin-A", "CHEMICAL", 261, 271], ["paeoniflorin", "CHEMICAL", 273, 285], ["paeonimetabolin-I", "CHEMICAL", 292, 309], ["liquiritin", "CHEMICAL", 311, 321], ["liquiritigenin", "CHEMICAL", 323, 337], ["glycyrrhizic acid", "CHEMICAL", 339, 356], ["glycyrrhetinic acid", "CHEMICAL", 361, 380], ["baicalin", "CHEMICAL", 195, 203], ["wogonoside", "CHEMICAL", 205, 215], ["oroxylin-A glucuronide", "CHEMICAL", 217, 239], ["baicalein", "CHEMICAL", 241, 250], ["wogonin", "CHEMICAL", 252, 259], ["oroxylin-A", "CHEMICAL", 261, 271], ["paeoniflorin", "CHEMICAL", 273, 285], ["paeonimetabolin-I", "CHEMICAL", 292, 309], ["liquiritin", "CHEMICAL", 311, 321], ["liquiritigenin", "CHEMICAL", 323, 337], ["glycyrrhizic acid", "CHEMICAL", 339, 356], ["glycyrrhetinic acid", "CHEMICAL", 361, 380], ["oral", "ORGANISM_SUBDIVISION", 29, 33], ["baicalin", "SIMPLE_CHEMICAL", 195, 203], ["wogonoside", "SIMPLE_CHEMICAL", 205, 215], ["oroxylin-A glucuronide", "SIMPLE_CHEMICAL", 217, 239], ["baicalein", "SIMPLE_CHEMICAL", 241, 250], ["wogonin", "SIMPLE_CHEMICAL", 252, 259], ["oroxylin-A", "SIMPLE_CHEMICAL", 261, 271], ["paeoniflorin", "SIMPLE_CHEMICAL", 273, 285], ["PF", "SIMPLE_CHEMICAL", 287, 289], ["paeonimetabolin-I", "SIMPLE_CHEMICAL", 292, 309], ["liquiritin", "SIMPLE_CHEMICAL", 311, 321], ["liquiritigenin", "SIMPLE_CHEMICAL", 323, 337], ["glycyrrhizic acid", "SIMPLE_CHEMICAL", 339, 356], ["glycyrrhetinic acid", "SIMPLE_CHEMICAL", 361, 380], ["rat", "ORGANISM", 403, 406], ["plasma", "ORGANISM_SUBSTANCE", 407, 413], ["rat", "SPECIES", 403, 406], ["rat", "SPECIES", 403, 406], ["oral administration", "TREATMENT", 29, 48], ["the Huangqin-Tang decoction", "TREATMENT", 52, 79], ["a single herb decoction", "TREATMENT", 83, 106], ["baicalin", "TREATMENT", 195, 203], ["wogonoside", "TREATMENT", 205, 215], ["oroxylin", "TREATMENT", 217, 225], ["A glucuronide", "TREATMENT", 226, 239], ["baicalein", "TREATMENT", 241, 250], ["wogonin", "TREATMENT", 252, 259], ["oroxylin", "TREATMENT", 261, 269], ["paeoniflorin (PF)", "TREATMENT", 273, 290], ["paeonimetabolin", "TREATMENT", 292, 307], ["liquiritin", "TREATMENT", 311, 321], ["liquiritigenin", "TREATMENT", 323, 337], ["glycyrrhizic acid", "TREATMENT", 339, 356], ["glycyrrhetinic acid", "TREATMENT", 361, 380]]], ["There were obvious differences in the pharmacoldnetic parameters of most constituents (especially constituent wogonoside) between the compound prescription and single herb decoction.", [["wogonoside", "CHEMICAL", 110, 120], ["wogonoside", "CHEMICAL", 110, 120], ["wogonoside", "SIMPLE_CHEMICAL", 110, 120], ["obvious differences", "PROBLEM", 11, 30], ["the pharmacoldnetic parameters", "TEST", 34, 64], ["single herb decoction", "TREATMENT", 160, 181], ["obvious", "OBSERVATION_MODIFIER", 11, 18], ["differences", "OBSERVATION_MODIFIER", 19, 30], ["herb decoction", "OBSERVATION", 167, 181]]], ["The constituents in the compound prescription had delayed absorption and elimination, a longer residence time in the body, and higher C max and AUC (0-lim), than those in the single herb decoction.", [["body", "ANATOMY", 117, 121], ["body", "ORGANISM_SUBDIVISION", 117, 121], ["delayed absorption", "PROBLEM", 50, 68], ["AUC", "TEST", 144, 147], ["body", "ANATOMY", 117, 121]]], ["Therefore, they were more efficient and durable, making them promising to exerting pharmacological effects in vivo.Evaluation of the analytical resultsThe degradation of thirteen flavonoid aglycones-wogonin, diosmetin, hesperetin, baicalein, morin, genistein, daidzein, quercetin, naringenin, luteolin, kaempferol, apigenin and neophellamuretin were investigated in rabbit, rat and human fecal flora suspensions as well as in artificial intestinal juice, using HPLC [107] .", [["fecal flora", "ANATOMY", 388, 399], ["intestinal juice", "ANATOMY", 437, 453], ["flavonoid aglycones", "CHEMICAL", 179, 198], ["wogonin", "CHEMICAL", 199, 206], ["diosmetin", "CHEMICAL", 208, 217], ["hesperetin", "CHEMICAL", 219, 229], ["baicalein", "CHEMICAL", 231, 240], ["morin", "CHEMICAL", 242, 247], ["genistein", "CHEMICAL", 249, 258], ["daidzein", "CHEMICAL", 260, 268], ["quercetin", "CHEMICAL", 270, 279], ["naringenin", "CHEMICAL", 281, 291], ["luteolin", "CHEMICAL", 293, 301], ["kaempferol", "CHEMICAL", 303, 313], ["apigenin", "CHEMICAL", 315, 323], ["neophellamuretin", "CHEMICAL", 328, 344], ["flavonoid aglycones", "CHEMICAL", 179, 198], ["wogonin", "CHEMICAL", 199, 206], ["diosmetin", "CHEMICAL", 208, 217], ["hesperetin", "CHEMICAL", 219, 229], ["baicalein", "CHEMICAL", 231, 240], ["morin", "CHEMICAL", 242, 247], ["genistein", "CHEMICAL", 249, 258], ["daidzein", "CHEMICAL", 260, 268], ["quercetin", "CHEMICAL", 270, 279], ["naringenin", "CHEMICAL", 281, 291], ["luteolin", "CHEMICAL", 293, 301], ["kaempferol", "CHEMICAL", 303, 313], ["apigenin", "CHEMICAL", 315, 323], ["neophellamuretin", "CHEMICAL", 328, 344], ["flavonoid aglycones-", "SIMPLE_CHEMICAL", 179, 199], ["wogonin", "SIMPLE_CHEMICAL", 199, 206], ["diosmetin", "SIMPLE_CHEMICAL", 208, 217], ["hesperetin", "SIMPLE_CHEMICAL", 219, 229], ["baicalein", "SIMPLE_CHEMICAL", 231, 240], ["morin", "SIMPLE_CHEMICAL", 242, 247], ["genistein", "SIMPLE_CHEMICAL", 249, 258], ["daidzein", "SIMPLE_CHEMICAL", 260, 268], ["quercetin", "SIMPLE_CHEMICAL", 270, 279], ["naringenin", "SIMPLE_CHEMICAL", 281, 291], ["luteolin", "SIMPLE_CHEMICAL", 293, 301], ["kaempferol", "SIMPLE_CHEMICAL", 303, 313], ["apigenin", "SIMPLE_CHEMICAL", 315, 323], ["neophellamuretin", "SIMPLE_CHEMICAL", 328, 344], ["rabbit", "ORGANISM", 366, 372], ["rat", "ORGANISM", 374, 377], ["human", "ORGANISM", 382, 387], ["intestinal juice", "ORGANISM_SUBSTANCE", 437, 453], ["rabbit", "SPECIES", 366, 372], ["rat", "SPECIES", 374, 377], ["human", "SPECIES", 382, 387], ["rabbit", "SPECIES", 366, 372], ["rat", "SPECIES", 374, 377], ["human", "SPECIES", 382, 387], ["Evaluation", "TEST", 115, 125], ["the analytical results", "TEST", 129, 151], ["thirteen flavonoid aglycones", "TREATMENT", 170, 198], ["wogonin", "TREATMENT", 199, 206], ["diosmetin", "TREATMENT", 208, 217], ["hesperetin", "TREATMENT", 219, 229], ["baicalein", "TREATMENT", 231, 240], ["morin", "TREATMENT", 242, 247], ["genistein", "TREATMENT", 249, 258], ["daidzein", "TREATMENT", 260, 268], ["quercetin", "TREATMENT", 270, 279], ["naringenin", "TREATMENT", 281, 291], ["luteolin", "TREATMENT", 293, 301], ["kaempferol", "TREATMENT", 303, 313], ["apigenin", "TREATMENT", 315, 323], ["neophellamuretin", "TREATMENT", 328, 344], ["human fecal flora suspensions", "TREATMENT", 382, 411], ["flavonoid aglycones", "OBSERVATION", 179, 198]]], ["The result indicated that all flavonoid aglycones except baicalein, diosmetin and quercetin were stable in artificial intestinal juice, whereas all were degraded in rabbit, rat and human feces suspension.", [["intestinal juice", "ANATOMY", 118, 134], ["flavonoid aglycones", "CHEMICAL", 30, 49], ["baicalein", "CHEMICAL", 57, 66], ["diosmetin", "CHEMICAL", 68, 77], ["quercetin", "CHEMICAL", 82, 91], ["flavonoid", "CHEMICAL", 30, 39], ["baicalein", "CHEMICAL", 57, 66], ["diosmetin", "CHEMICAL", 68, 77], ["quercetin", "CHEMICAL", 82, 91], ["flavonoid aglycones", "SIMPLE_CHEMICAL", 30, 49], ["baicalein", "SIMPLE_CHEMICAL", 57, 66], ["diosmetin", "SIMPLE_CHEMICAL", 68, 77], ["quercetin", "SIMPLE_CHEMICAL", 82, 91], ["intestinal juice", "ORGANISM_SUBSTANCE", 118, 134], ["rabbit", "ORGANISM", 165, 171], ["rat", "ORGANISM", 173, 176], ["human", "ORGANISM", 181, 186], ["rabbit", "SPECIES", 165, 171], ["rat", "SPECIES", 173, 176], ["human", "SPECIES", 181, 186], ["rabbit", "SPECIES", 165, 171], ["rat", "SPECIES", 173, 176], ["human", "SPECIES", 181, 186], ["all flavonoid aglycones", "TREATMENT", 26, 49], ["baicalein", "TREATMENT", 57, 66], ["diosmetin", "TREATMENT", 68, 77], ["quercetin", "TREATMENT", 82, 91], ["artificial intestinal juice", "TREATMENT", 107, 134], ["human feces suspension", "TREATMENT", 181, 203], ["flavonoid aglycones", "OBSERVATION", 30, 49], ["stable", "OBSERVATION_MODIFIER", 97, 103], ["intestinal juice", "ANATOMY", 118, 134]]], ["Wogonin and diosmetin were among the less degraded ones for all three feces tested.", [["Wogonin", "CHEMICAL", 0, 7], ["diosmetin", "CHEMICAL", 12, 21], ["Wogonin", "CHEMICAL", 0, 7], ["diosmetin", "CHEMICAL", 12, 21], ["Wogonin", "SIMPLE_CHEMICAL", 0, 7], ["diosmetin", "SIMPLE_CHEMICAL", 12, 21], ["feces", "ORGANISM", 70, 75], ["Wogonin", "TREATMENT", 0, 7], ["diosmetin", "TREATMENT", 12, 21]]], ["The presence of a methoxy group on the A or B ring of the flavonoid seems to protect the structure from bacterial degradation.", [["methoxy", "CHEMICAL", 18, 25], ["flavonoid", "CHEMICAL", 58, 67], ["methoxy", "CHEMICAL", 18, 25], ["flavonoid", "CHEMICAL", 58, 67], ["A", "SIMPLE_CHEMICAL", 39, 40], ["B ring", "SIMPLE_CHEMICAL", 44, 50], ["flavonoid", "SIMPLE_CHEMICAL", 58, 67], ["a methoxy group", "TREATMENT", 16, 31], ["B ring of the flavonoid", "TREATMENT", 44, 67], ["bacterial degradation", "PROBLEM", 104, 125], ["flavonoid", "OBSERVATION", 58, 67], ["bacterial degradation", "OBSERVATION", 104, 125]]], ["In addition, the bioavailability of baicalin-phospholipid complex was also studied by HPLC [108] .", [["baicalin", "CHEMICAL", 36, 44], ["baicalin", "CHEMICAL", 36, 44], ["baicalin", "SIMPLE_CHEMICAL", 36, 44], ["phospholipid", "SIMPLE_CHEMICAL", 45, 57], ["baicalin-phospholipid complex", "TREATMENT", 36, 65], ["HPLC", "TEST", 86, 90]]], ["A complex of baicalin with soy phospholipid was prepared to improve the bioabsorption of baicalin.", [["baicalin", "CHEMICAL", 13, 21], ["baicalin", "CHEMICAL", 89, 97], ["baicalin", "CHEMICAL", 13, 21], ["baicalin", "CHEMICAL", 89, 97], ["baicalin", "SIMPLE_CHEMICAL", 13, 21], ["soy phospholipid", "SIMPLE_CHEMICAL", 27, 43], ["baicalin", "SIMPLE_CHEMICAL", 89, 97], ["A complex of baicalin", "TREATMENT", 0, 21], ["soy phospholipid", "TREATMENT", 27, 43], ["baicalin", "TREATMENT", 89, 97]]], ["The concentration of baicalin in rat plasma reached a peak of 0.42 g ml \u22121 at 5.3 h after oral administration, 600 mg kg \u22121 .", [["plasma", "ANATOMY", 37, 43], ["oral", "ANATOMY", 90, 94], ["baicalin", "CHEMICAL", 21, 29], ["baicalin", "CHEMICAL", 21, 29], ["baicalin", "SIMPLE_CHEMICAL", 21, 29], ["rat", "ORGANISM", 33, 36], ["plasma", "ORGANISM_SUBSTANCE", 37, 43], ["oral", "ORGANISM_SUBDIVISION", 90, 94], ["rat", "SPECIES", 33, 36], ["rat", "SPECIES", 33, 36], ["The concentration of baicalin in rat plasma", "TREATMENT", 0, 43]]], ["However, after intake of its phospholipid complex, a peak of 0.90 g ml \u22121 occurred at a later time, 6.1 h.", [["phospholipid", "SIMPLE_CHEMICAL", 29, 41]]], ["The elimination of the complex tended to be slower than that of the free drug.", [["slower", "OBSERVATION_MODIFIER", 44, 50]]], ["There was a significant difference in the mean area under the concentration-time curves (AUC) between the free drug and the complex (P < 0.01).Evaluation of the analytical resultsThe HPLC method has been used for quality control of medical products based on S. baicalensis Georgi by the determination of baicalin content in Pharmacopoeia of the People's Republic of China [2] .", [["baicalin", "CHEMICAL", 304, 312], ["baicalin", "CHEMICAL", 304, 312], ["S. baicalensis", "ORGANISM", 258, 272], ["Georgi", "ORGANISM", 273, 279], ["baicalin", "SIMPLE_CHEMICAL", 304, 312], ["S. baicalensis", "SPECIES", 258, 272], ["People", "SPECIES", 345, 351], ["S. baicalensis", "SPECIES", 258, 272], ["a significant difference", "PROBLEM", 10, 34], ["AUC", "TEST", 89, 92], ["Evaluation", "TEST", 143, 153], ["The HPLC method", "TREATMENT", 179, 194], ["medical products", "TREATMENT", 232, 248], ["baicalin content", "PROBLEM", 304, 320], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["difference", "OBSERVATION_MODIFIER", 24, 34], ["baicalin content", "OBSERVATION", 304, 320]]], ["In addition, the fingerprinting technique on HPLC-UV has been used for quality control of raw medical material of S. baicalensis Georgi [109, 110] .Evaluation of the analytical resultsIn order to explore more effective herbal products based on S. baicalensis Georgi, more widely pharmacological studies should be carried out to determine new pharmacodynamic effects, such as anti-SARS coronavirus effect of baicalin [18] .", [["HPLC-UV", "CHEMICAL", 45, 52], ["baicalin", "CHEMICAL", 407, 415], ["baicalin", "CHEMICAL", 407, 415], ["S. baicalensis", "ORGANISM", 114, 128], ["S. baicalensis", "ORGANISM", 244, 258], ["Georgi", "ORGANISM", 259, 265], ["baicalin", "SIMPLE_CHEMICAL", 407, 415], ["S. baicalensis", "SPECIES", 114, 128], ["S. baicalensis", "SPECIES", 244, 258], ["S. baicalensis", "SPECIES", 114, 128], ["S. baicalensis", "SPECIES", 244, 258], ["the fingerprinting technique", "TREATMENT", 13, 41], ["HPLC-UV", "TREATMENT", 45, 52], ["Evaluation", "TEST", 148, 158], ["the analytical results", "TEST", 162, 184], ["effective herbal products", "TREATMENT", 209, 234], ["pharmacological studies", "TEST", 279, 302], ["new pharmacodynamic effects", "PROBLEM", 338, 365], ["baicalin", "TREATMENT", 407, 415]]], ["Secondly, more attention should be paid to minor components in S. baicalensis Georgi because special pharmacodynamic effects may be found from minor components.", [["S. baicalensis", "ORGANISM", 63, 77], ["Georgi", "ORGANISM", 78, 84], ["S. baicalensis", "SPECIES", 63, 77], ["S. baicalensis", "SPECIES", 63, 77], ["special pharmacodynamic effects", "PROBLEM", 93, 124]]], ["Finally, bioactive components at highly purity should be used instead of crude extracts in medicinal preparations.", [["extracts", "ANATOMY", 79, 87], ["extracts", "ORGANISM_SUBSTANCE", 79, 87], ["bioactive components", "TREATMENT", 9, 29], ["crude extracts", "TREATMENT", 73, 87], ["medicinal preparations", "TREATMENT", 91, 113]]], ["Therefore, separation and purification techniques will play an important role in these studies.ConclusionsS. baicalensis Georgi is widely explored for the treatment of inflammation, cancers, bacterial infections, and a variety of other diseases.", [["cancers", "ANATOMY", 182, 189], ["baicalensis Georgi", "CHEMICAL", 109, 127], ["inflammation", "DISEASE", 168, 180], ["cancers", "DISEASE", 182, 189], ["bacterial infections", "DISEASE", 191, 211], ["baicalensis Georgi", "ORGANISM", 109, 127], ["cancers", "CANCER", 182, 189], ["baicalensis", "SPECIES", 109, 120], ["separation", "TREATMENT", 11, 21], ["purification techniques", "TREATMENT", 26, 49], ["these studies", "TEST", 81, 94], ["inflammation", "PROBLEM", 168, 180], ["cancers", "PROBLEM", 182, 189], ["bacterial infections", "PROBLEM", 191, 211], ["other diseases", "PROBLEM", 230, 244], ["Georgi", "OBSERVATION", 121, 127], ["inflammation", "OBSERVATION", 168, 180], ["cancers", "OBSERVATION", 182, 189], ["bacterial", "OBSERVATION_MODIFIER", 191, 200], ["infections", "OBSERVATION", 201, 211], ["variety", "OBSERVATION_MODIFIER", 219, 226], ["diseases", "OBSERVATION", 236, 244]]], ["A wide range of separation, detection, and identification methods have been developed and employed for quantitative and qualitative determination of its main active components, baicalin, baicalein, wogonin and oroxylin A. Different sample preparation techniques such as supercritical fluid extraction, pressurized hot water extraction and solid-phase extraction have been also utilized prior to analysis.ConclusionsHigh-performance liquid chromatography with ultraviolet detection is the most frequently employed for the determination of these active components in various matrices.", [["sample", "ANATOMY", 232, 238], ["baicalin", "CHEMICAL", 177, 185], ["baicalein", "CHEMICAL", 187, 196], ["wogonin", "CHEMICAL", 198, 205], ["oroxylin", "CHEMICAL", 210, 218], ["ultraviolet", "CHEMICAL", 459, 470], ["baicalin", "CHEMICAL", 177, 185], ["baicalein", "CHEMICAL", 187, 196], ["wogonin", "CHEMICAL", 198, 205], ["oroxylin", "CHEMICAL", 210, 218], ["baicalin", "SIMPLE_CHEMICAL", 177, 185], ["baicalein", "SIMPLE_CHEMICAL", 187, 196], ["wogonin", "SIMPLE_CHEMICAL", 198, 205], ["oroxylin", "SIMPLE_CHEMICAL", 210, 218], ["identification methods", "TEST", 43, 65], ["baicalin", "TREATMENT", 177, 185], ["baicalein", "TREATMENT", 187, 196], ["wogonin", "TREATMENT", 198, 205], ["oroxylin", "TREATMENT", 210, 218], ["Different sample preparation techniques", "TREATMENT", 222, 261], ["supercritical fluid extraction", "TREATMENT", 270, 300], ["pressurized hot water extraction", "TREATMENT", 302, 334], ["solid-phase extraction", "TREATMENT", 339, 361], ["analysis", "TEST", 395, 403], ["Conclusions", "TEST", 404, 415], ["ultraviolet detection", "TREATMENT", 459, 480], ["wide", "OBSERVATION_MODIFIER", 2, 6], ["separation", "OBSERVATION_MODIFIER", 16, 26], ["main", "OBSERVATION_MODIFIER", 153, 157], ["active", "OBSERVATION_MODIFIER", 544, 550], ["various matrices", "OBSERVATION", 565, 581]]], ["The development of HPLC-mass spectrometry coupling is a major advance, offering greater sensitivity than ultraviolet detection and greater selectivity through selected ion monitoring or by using tandem mass spectrometry and selected reaction monitoring mode.", [["HPLC", "TEST", 19, 23], ["mass spectrometry", "PROBLEM", 24, 41], ["ultraviolet detection", "TEST", 105, 126], ["selected ion monitoring", "TEST", 159, 182], ["tandem mass spectrometry", "TEST", 195, 219], ["selected reaction monitoring mode", "TEST", 224, 257], ["mass", "OBSERVATION", 24, 28]]], ["These techniques are efficient for identification of these active components and their metabolites in complex matrices because of their excellent specificity, sensitivity and speed.", [["these active components", "PROBLEM", 53, 76], ["active", "OBSERVATION_MODIFIER", 59, 65]]], ["Capillary electrophoresis, micellar eletrokinetic capillary eletrochromatography, and thin layer chromatography are also often applied to the separation of these active components.", [["Capillary electrophoresis", "TEST", 0, 25], ["micellar eletrokinetic capillary eletrochromatography", "TREATMENT", 27, 80], ["thin layer chromatography", "TEST", 86, 111], ["active", "OBSERVATION_MODIFIER", 162, 168], ["components", "OBSERVATION_MODIFIER", 169, 179]]], ["High-speed counter-current chromatography has been used for the preparative separation and purification of baicalin from Scutellariae radix.ConclusionsIn the future, the automated high-throughput sample preparation in conjunction with parallel column HPLC with tandem mass spectrometry detection will play a key role in quantitative pharmaceutical and biological analyses of these active components.", [["baicalin", "CHEMICAL", 107, 115], ["Scutellariae radix", "CHEMICAL", 121, 139], ["baicalin", "CHEMICAL", 107, 115], ["baicalin", "SIMPLE_CHEMICAL", 107, 115], ["Scutellariae radix", "ORGANISM", 121, 139], ["Scutellariae radix", "SPECIES", 121, 139], ["Scutellariae radix", "SPECIES", 121, 139], ["current chromatography", "TREATMENT", 19, 41], ["the preparative separation", "TREATMENT", 60, 86], ["baicalin", "TREATMENT", 107, 115], ["Scutellariae radix", "TREATMENT", 121, 139], ["parallel column HPLC", "TEST", 235, 255], ["tandem mass spectrometry detection", "PROBLEM", 261, 295], ["active", "OBSERVATION_MODIFIER", 381, 387]]], ["Combined use of HPLC-MS and HPLC-NMR will be the most efficient approach for identification of these active components and their metabolites in complex matrices.", [["HPLC", "TEST", 16, 20], ["MS", "PROBLEM", 21, 23], ["HPLC", "TEST", 28, 32], ["these active components", "PROBLEM", 95, 118], ["active", "OBSERVATION_MODIFIER", 101, 107]]], ["High-speed counter-current chromatography will be more widely used for the preparative separation and purification of S. baicalensis active components on a large scale.", [["S. baicalensis", "ORGANISM", 118, 132], ["S. baicalensis", "SPECIES", 118, 132], ["S. baicalensis", "SPECIES", 118, 132], ["High-speed counter", "TREATMENT", 0, 18], ["current chromatography", "TREATMENT", 19, 41], ["the preparative separation", "TREATMENT", 71, 97], ["S. baicalensis active components", "TREATMENT", 118, 150], ["a large scale", "TREATMENT", 154, 167]]]], "db3109e1e24c2df463dded1454b2d7b023048b09": [["IntroductionThe SIR model [1] in the theory of infection is powerful to analyze an epidemic about how it spreads and how it ends [2] [3] [4] [5] [6] [7] [8] .", [["infection", "DISEASE", 47, 56], ["[2] [3] [4] [5] [6] [7]", "CHEMICAL", 129, 152], ["[2] [3] [4] [5] [6] [7] [8]", "SIMPLE_CHEMICAL", 129, 156], ["infection", "PROBLEM", 47, 56], ["infection", "OBSERVATION", 47, 56]]], ["The SIR model is composed of three equations for S, I and R, where they are numbers for susceptibles, infectives and removed, respectively.", [["susceptibles", "PROBLEM", 88, 100]]], ["Three equations can be solved numerically, if two parameters \u03b1 and c are given, where \u03b1 is the basic reproduction number and c the removed ratio.", [["\u03b1", "PROTEIN", 86, 87]]], ["2 we summarize approximate solutions of the SIR equations, based on the logistic formula in biology [9] , which have been derived in a previous work [10] .", [["the SIR equations", "TREATMENT", 40, 57]]], ["These approximate solutions have simple forms, so that they are very useful to discuss an epidemic.", [["an epidemic", "PROBLEM", 87, 98]]], ["3 these solutions are applied to fix the basic reproduction number \u03b1 and the removed ratio c, especially from data of accumulated number of deaths by COVID-19 for the first wave in Japan.", [["deaths", "DISEASE", 140, 146], ["these solutions", "TREATMENT", 2, 17], ["COVID", "TEST", 150, 155]]], ["Here, our policy is to use only data of deaths, but not of cases.", [["deaths", "DISEASE", 40, 46]]], ["The mortality ratio for the first wave is also calculated.", [["The mortality ratio", "TEST", 0, 19]]], ["In Appendix data of deaths for the first and the second waves are summarized.A logistic curve from the SIR modelEquations of the SIR model [1] are given byA logistic curve from the SIR modelwhere S, I and R are numbers for susceptibles, infectives and removed, respectively,b the infection ratio and c the removed ratio.", [["deaths", "DISEASE", 20, 26], ["infection", "DISEASE", 280, 289], ["A logistic curve", "TEST", 77, 93], ["susceptibles", "PROBLEM", 223, 235], ["infectives", "PROBLEM", 237, 247], ["the infection ratio", "TEST", 276, 295], ["Appendix", "ANATOMY", 3, 11], ["infection", "OBSERVATION", 280, 289]]], ["(2.1) and (2.3) we get dS/dR = \u2212\u03b1S, (\u03b1 = b/c), which is integrated to be S = exp(\u2212\u03b1R), (2.4) where \u03b1 stands for the basic reproduction number.", [["\u03b1", "PROTEIN", 99, 100], ["dS", "TEST", 23, 25], ["dR", "TEST", 26, 28], ["S", "TEST", 33, 34]]], ["(2.2) and (2.3), we have dI/dR = \u03b1S \u2212 1 = \u03b1 exp(\u2212\u03b1R) \u2212 1, which is integrated to beA logistic curve from the SIR modelThe solutions (2.4) and (2.5) satisfy boundary conditions S = 1 and I = 0 at R = 0.", [["dI", "PROTEIN", 25, 27], ["dI", "TEST", 25, 27], ["dR", "TEST", 28, 30], ["S", "TEST", 34, 35], ["exp", "TEST", 44, 47], ["The solutions", "TREATMENT", 118, 131], ["boundary conditions S", "TEST", 156, 177], ["I", "TEST", 186, 187]]], ["SinceA logistic curve from the SIR modelHence, it follows a useful formulaA logistic curve from the SIR modelSome exact formulas at the infection peak t = T are summarized as follows:A logistic curve from the SIR modelThe first one is derived as follows: Since the peak point is given by dI/dt = c(\u03b1S with t the true time.", [["infection", "DISEASE", 136, 145], ["dI", "PROTEIN", 288, 290], ["\u03b1S", "PROTEIN", 298, 300], ["Some exact formulas", "PROBLEM", 109, 128], ["A logistic curve", "TEST", 183, 199], ["infection", "OBSERVATION", 136, 145]]], ["Let us expand the exponential factor in the second order of x = \u03b1R,A logistic curve from the SIR model(2.10)A logistic curve from the SIR modelwith A = \u03b1 2 /2, B = 2(\u03b1 \u2212 1)/\u03b1 2 .", [["\u03b1 \u2212 1", "GENE_OR_GENE_PRODUCT", 166, 171], ["\u03b1 2", "GENE_OR_GENE_PRODUCT", 173, 176], ["A logistic curve", "TEST", 108, 124], ["the SIR", "TEST", 130, 137]]], ["This equation is a type of the logistic growth curve in the biology [9] , easily solved asA logistic curve from the SIR modelNote that peak values of I(t) and R(t) at t = T are given byA logistic curve from the SIR model(2.14)A logistic curve from the SIR modelHence we have a useful formulaA logistic curve from the SIR model(2.15) 3 Application to COVID-19 for the first waveA logistic curve from the SIR modelWe make use of data [11] of deaths rather than cases.", [["deaths", "DISEASE", 440, 446], ["the logistic growth curve", "PROBLEM", 27, 52], ["easily solved asA logistic curve", "TREATMENT", 74, 106], ["peak values", "TEST", 135, 146], ["A logistic curve", "TEST", 226, 242], ["COVID", "TEST", 350, 355]]], ["Define the mortality ratio \u03bb byA logistic curve from the SIR modelwhere D(t) is the accumulated number of deaths.", [["deaths", "DISEASE", 106, 112], ["accumulated", "OBSERVATION_MODIFIER", 84, 95], ["number", "OBSERVATION_MODIFIER", 96, 102]]], ["For the population N , the total number of deaths at t is given byA logistic curve from the SIR modelstands for the final total number of deaths.", [["deaths", "DISEASE", 43, 49], ["deaths", "DISEASE", 138, 144]]], ["Note that from Eq.(3.2) we have a theorem, N D(T ) = d/2, which means the total number of deaths at the peak is just a half of the final ones.", [["deaths", "DISEASE", 90, 96], ["a theorem, N D(T )", "TEST", 32, 50]]], ["Let us rewrite Eq.(3.2) into the form asA logistic curve from the SIR modelAccordingly, for different times t 1 , t 2 and t 3 we have (N D(t) is the total number of deaths in the first wave at t in Japan, which is an average of 5-day deaths of t \u2212 2, t \u2212 1, t, t + 1, t + 2.", [["deaths", "DISEASE", 165, 171], ["deaths", "DISEASE", 234, 240]]], ["The t is the number of date starting from Feb. 16) A use is made of data of deaths [11] .", [["deaths", "DISEASE", 76, 82]]], ["Substituting data on the Table 1 into Eqs.(3.4) and (3.5) , and eliminating ac, we getA logistic curve from the SIR modelThis is nothing but the equation for d, that is,A logistic curve from the SIR modelWe find a solution of this equation to be d=984.", [["Eqs.", "TEST", 38, 42]]], ["According to the theorem N D(T ) = d/2, the number of deaths at t = T is d/2 = 492.", [["deaths", "DISEASE", 54, 60]]], ["Also, from the formula (2.6) it follows R(\u221e) = 0.94.A logistic curve from the SIR model3 reuse, remix, or adapt this material for any purpose without crediting the original authors.A logistic curve from the SIR modelthis preprint (which was not certified by peer review) in the Public Domain.", [["A logistic curve", "TEST", 52, 68], ["the SIR model3 reuse", "TREATMENT", 74, 94], ["remix", "TREATMENT", 96, 101], ["A logistic curve", "TEST", 181, 197]]], ["It is no longer restricted by copyright.", [["no longer", "UNCERTAINTY", 6, 15]]], ["Anyone can legally share,A logistic curve from the SIR modelThe copyright holder has placed this version posted September 18, 2020. .", [["The copyright holder", "TREATMENT", 60, 80]]], ["Their curves are drawn in Figure 1 .A logistic curve from the SIR modelFrom the curve of I(t ) we find that t = 3.00 gives a peak, which is compared with the formula t = ct = 0.04 \u00d7 77 = 3.08.", [["Their curves", "TEST", 0, 12], ["A logistic curve", "TEST", 36, 52], ["ct", "TEST", 170, 172]]], ["However, such a small difference may be allowed for a margin of error arising from our approximate method.", [["a small difference", "PROBLEM", 14, 32], ["small", "OBSERVATION_MODIFIER", 16, 21], ["margin", "OBSERVATION_MODIFIER", 54, 60]]], ["After approximately 77 days later, the first epidemic will end around a middle of July(7/18) with the total number 984 of deaths.", [["deaths", "DISEASE", 122, 128]]], ["Finally let us calculate the mortality ratio \u03bb = D(t)/R(t).", [["the mortality ratio", "TEST", 25, 44]]], ["The removed number R(t) is given by R(t) = r(t) + D(t), where r(t) is the accumulated number of people discharged from hospital and D(t) is the accumulated number of deaths.", [["deaths", "DISEASE", 166, 172], ["people", "ORGANISM", 96, 102], ["people", "SPECIES", 96, 102], ["accumulated", "OBSERVATION_MODIFIER", 144, 155], ["number", "OBSERVATION_MODIFIER", 156, 162]]], ["We find its mean value is < \u03bb >= 0.1 with \u03c3 = 0.002.", [["its mean value", "TEST", 8, 22]]], ["From Eq.(2.7) it follows R(T ) = ln \u03b1/\u03b1 = 0.37 for \u03b1 = 3, whereas N R(T ) = 4877 from the data.", [["ln \u03b1/\u03b1", "TEST", 33, 39], ["\u03b1", "TEST", 51, 52], ["the data", "TEST", 86, 94]]], ["In order to discuss this question, we divide the Japan population into two groups A and B, A is immune to the present epidemic and B is not immune the epidemic.", [["A", "CANCER", 91, 92], ["B", "CELL", 131, 132]]], ["We can add also people who completely quarantine themselves to A. We then conclude that such a small population as N = 13000 corresponds to B, because A is irrelevant to infection.The second waveThe second wave of COVID-19 in Japan seems to start from around June 22.", [["infection", "DISEASE", 170, 179], ["people", "ORGANISM", 16, 22], ["COVID-19", "DNA", 214, 222], ["people", "SPECIES", 16, 22], ["infection", "PROBLEM", 170, 179], ["COVID", "TEST", 214, 219], ["small", "OBSERVATION_MODIFIER", 95, 100], ["infection", "OBSERVATION", 170, 179]]], ["The virus is now called the Tokyo type.The second waveis the total number of deaths with 3-day average in the second wave at t.", [["deaths", "DISEASE", 77, 83], ["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["total", "OBSERVATION_MODIFIER", 61, 66], ["number", "OBSERVATION_MODIFIER", 67, 73]]], ["It is no longer restricted by copyright.", [["no longer", "UNCERTAINTY", 6, 15]]], ["We make use of data in the appendix, where the number of deaths in the second wave is completely separated from that of the first wave.", [["deaths", "DISEASE", 57, 63], ["appendix", "ORGAN", 27, 35], ["appendix", "ANATOMY", 27, 35]]], ["It is shown that the first death of the second wave appears on July 20.)", [["death", "DISEASE", 27, 32]]], ["The corresponding equation to Eq.(3.7) is, from Table 2 ,The second waveWe have a solution d = 482, so that d/2 = 241 is the death number at the peak.", [["death", "DISEASE", 125, 130], ["Eq.", "TEST", 30, 33]]], ["Hence the peak day is Aug. 26 and T = 38, as seen from Appendix.", [["Aug.", "TEST", 22, 26], ["T", "TEST", 34, 35], ["Appendix", "ANATOMY", 55, 63]]], ["Once having the basic reproduction number \u03b1 = 4.6 with the removed ratio c = 0.028, we can draw curves of S, I and R by means of Excel in Figure 2 .The second waveFrom the curve of I(t ) we find that the peak day is t = 1.51, which is compared with Figure 2 : Graph of S, I and R for \u03b1 = 4.6 and c = 0.028 the formula t = ct = 0.028 \u00d7 38 = 1.06.", [["Graph of S", "TEST", 260, 270], ["I", "TEST", 272, 273], ["\u03b1", "TEST", 284, 285], ["c", "TEST", 296, 297], ["the formula t", "TEST", 306, 319], ["ct", "TEST", 322, 324]]], ["However, such a small difference may be allowed for a margin of error arising from our approximate method.", [["a small difference", "PROBLEM", 14, 32], ["small", "OBSERVATION_MODIFIER", 16, 21], ["margin", "OBSERVATION_MODIFIER", 54, 60]]], ["Since the second infection begins from July 20, the t = 1.51 corresponds with the true time t = 38 days, so that the peak day is Aug. 26, with the total number 241 of deaths.", [["infection", "DISEASE", 17, 26], ["deaths", "DISEASE", 167, 173], ["the second infection", "PROBLEM", 6, 26], ["infection", "OBSERVATION", 17, 26]]], ["After approximately 38 days later, the epidemic will end around Oct. 3 with the total number 241\u00d72 = 482 of deaths.", [["deaths", "DISEASE", 108, 114]]], ["One can see that a ratio of both infectives on peak days is I 2 /I 1 = 3/2, where I 1 and I 2 stand for infectives of 1 st and 2 nd waves.", [["infectives", "TEST", 104, 114]]], ["Finally let us calculate the mortality ratio \u03bb = D(t)/R(t).", [["the mortality ratio", "TEST", 25, 44]]], ["We find that its mean value between July 20 and Aug. 22 is < \u03bb >= 0.005 with \u03c3 = 0.0006.Concluding remarksOur logistic formulas have been applied to analyze deaths by COVID-19 in Japan.", [["deaths", "DISEASE", 157, 163], ["its mean value", "TEST", 13, 27], ["Aug.", "TEST", 48, 52], ["Our logistic formulas", "TREATMENT", 106, 127], ["COVID", "TEST", 167, 172]]], ["Our policy is to use only data of deaths, but not of cases.", [["deaths", "DISEASE", 34, 40]]], ["For the first wave, the basic reproduction number \u03b1 is determined to be \u03b1 = 3 and the removed 5 reuse, remix, or adapt this material for any purpose without crediting the original authors.Concluding remarksthis preprint (which was not certified by peer review) in the Public Domain.", [["remix", "TREATMENT", 103, 108]]], ["It is no longer restricted by copyright.", [["no longer", "UNCERTAINTY", 6, 15]]], ["Anyone can legally share,Concluding remarksThe copyright holder has placed this version posted September 18, 2020. . ratio c = 0.04.", [["The copyright holder", "TREATMENT", 43, 63], ["ratio c", "TEST", 117, 124]]], ["The corresponding curves of S, I and R are given in Figure 1 .", [["curves", "OBSERVATION_MODIFIER", 18, 24]]], ["From the curve of I(t ) we find that the infection peak day is May 2 nd , then after approximately 77 days later, the first epidemic will end around a middle of July(7/18) with the total number 984 of deaths.", [["infection", "DISEASE", 41, 50], ["deaths", "DISEASE", 201, 207], ["the infection", "PROBLEM", 37, 50], ["infection", "OBSERVATION", 41, 50]]], ["The mortality ratio \u03bb = D(t)/R(t) is also calculated to be its mean value < \u03bb >= 0.1 with \u03c3 = 0.002.", [["The mortality ratio", "TEST", 0, 19]]], ["We find N being calculable from the formula R(T ) = ln \u03b1/\u03b1 = 0.37 for \u03b1 = 3.", [["ln \u03b1/\u03b1", "TEST", 52, 58]]], ["In order to discuss this question, we divide the Japan population into two groups A and B, A is immune to the present epidemic and B is not immune the epidemic.", [["A", "CANCER", 91, 92], ["B", "CELL", 131, 132]]], ["We can add also people who completely quarantine themselves to A. We then conclude that such a small population as N = 13000 corresponds to B, because A is irrelevant to infection.", [["infection", "DISEASE", 170, 179], ["people", "ORGANISM", 16, 22], ["people", "SPECIES", 16, 22], ["infection", "PROBLEM", 170, 179], ["small", "OBSERVATION_MODIFIER", 95, 100], ["infection", "OBSERVATION", 170, 179]]], ["The corresponding curves of S, I and R are given in Figure 2 .", [["curves", "OBSERVATION_MODIFIER", 18, 24]]], ["From the curve of I(t ) we find that the infection peak day is Aug. 26, then after approximately 38 days later, the second epidemic will end around Oct. 3, with the total number 482 of deaths.", [["infection", "DISEASE", 41, 50], ["deaths", "DISEASE", 185, 191], ["the infection", "PROBLEM", 37, 50], ["infection", "OBSERVATION", 41, 50]]], ["The mortality ratio \u03bb is also calculated to be its mean value < \u03bb >= 0.005 with \u03c3 = 0.0006.", [["The mortality ratio", "TEST", 0, 19]]], ["A ratio of both infectives of 1 st and 2 nd waves on peak days can be seen to be 2/3.", [["A ratio", "TEST", 0, 7]]], ["D 12 : Accumulated number of deaths for 1 st +2 nd waves D 2 : Accumulated number of deaths for 2 nd wave r 12 : Accumulated number of discharged for 1 st +2 nd waves r 2 : Accumulated number of discharged for 2 nd waves R 2 = D 2 + r 2 : Removed number for 2 nd wave \u03bb 2 = D 2 /R 2 : Mortality rate for 2 nd wave(\u00d710 \u22124 ) 8 reuse, remix, or adapt this material for any purpose without crediting the original authors. this preprint (which was not certified by peer review) in the Public Domain.", [["deaths", "DISEASE", 29, 35], ["deaths", "DISEASE", 85, 91], ["Mortality rate", "TEST", 285, 299]]], ["It is no longer restricted by copyright.", [["no longer", "UNCERTAINTY", 6, 15]]], ["Anyone can legally share,Concluding remarksThe copyright holder has placed this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.15.20195081 doi: medRxiv preprint", [["The copyright holder", "TREATMENT", 43, 63], ["medRxiv", "TREATMENT", 166, 173]]]], "PMC3291347": [["Animal Origin of SARS CoronavirusesBecause of the sudden and unpredictable nature of the SARS outbreaks that started in November 2002 in southern People's Republic of China, structured and reliable epidemiologic studies to conclusively trace the origin of SARS-CoV were not conducted.", [["SARS", "DISEASE", 17, 21], ["SARS", "DISEASE", 89, 93], ["SARS", "DISEASE", 256, 260], ["SARS-CoV", "ORGANISM", 256, 264], ["SARS-CoV", "SPECIES", 256, 264], ["SARS", "PROBLEM", 17, 21], ["the sudden", "PROBLEM", 46, 56], ["the SARS outbreaks", "PROBLEM", 85, 103], ["reliable epidemiologic studies", "TEST", 189, 219], ["SARS", "PROBLEM", 256, 260], ["CoV", "PROBLEM", 261, 264], ["SARS", "OBSERVATION", 17, 21], ["SARS", "OBSERVATION", 256, 260]]], ["However, accumulated studies from different groups, which used a variety of approaches, indicated an animal origin on the basis of the following findings.", [["accumulated studies", "TEST", 9, 28]]], ["1) Genome sequencing indicated that SARS-CoV is a new virus with no genetic relatedness to any known human coronaviruses (4,5).", [["SARS", "DISEASE", 36, 40], ["SARS-CoV", "ORGANISM", 36, 44], ["human", "ORGANISM", 101, 106], ["human", "SPECIES", 101, 106], ["SARS-CoV", "SPECIES", 36, 44], ["human coronaviruses", "SPECIES", 101, 120], ["Genome sequencing", "TEST", 3, 20], ["SARS", "PROBLEM", 36, 40], ["CoV", "PROBLEM", 41, 44], ["a new virus", "PROBLEM", 48, 59], ["genetic relatedness", "PROBLEM", 68, 87], ["any known human coronaviruses", "PROBLEM", 91, 120]]], ["2) Retrospective serologic studies found no evidence of seroprevalence to SARS-CoV or related viruses in the human population (6).", [["SARS", "DISEASE", 74, 78], ["SARS-CoV", "ORGANISM", 74, 82], ["human", "ORGANISM", 109, 114], ["human", "SPECIES", 109, 114], ["SARS-CoV", "SPECIES", 74, 82], ["human", "SPECIES", 109, 114], ["Retrospective serologic studies", "TEST", 3, 34], ["seroprevalence to SARS", "PROBLEM", 56, 78], ["CoV", "PROBLEM", 79, 82], ["related viruses", "PROBLEM", 86, 101], ["no evidence of", "UNCERTAINTY", 41, 55], ["viruses", "OBSERVATION", 94, 101]]], ["3) Serologic surveys among market traders during the 2002\u20132003 outbreaks showed that antibodies against SARS-CoV or related viruses were present at a higher ratio in animal traders than control populations (7\u20139).", [["SARS", "DISEASE", 104, 108], ["SARS-CoV", "ORGANISM", 104, 112], ["antibodies", "PROTEIN", 85, 95], ["SARS-CoV", "SPECIES", 104, 112], ["Serologic surveys", "TEST", 3, 20], ["antibodies", "TEST", 85, 95], ["SARS", "PROBLEM", 104, 108], ["CoV", "PROBLEM", 109, 112], ["related viruses", "PROBLEM", 116, 131], ["viruses", "OBSERVATION", 124, 131]]], ["4) Epidemiologic studies indicated that early case-patients were more likely than later case-patients to report living near a produce market but not near a farm, and almost half of them were food handlers with probable animal contact (7).", [["patients", "ORGANISM", 51, 59], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 93, 101], ["Epidemiologic studies", "TEST", 3, 24]]], ["5) SARS-CoVs isolated from animals in markets were almost identical to human isolates (9).", [["SARS", "DISEASE", 3, 7], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 3, 12], ["human", "ORGANISM", 71, 76], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["SARS", "PROBLEM", 3, 7], ["CoVs", "PROBLEM", 8, 12]]], ["6) Molecular epidemiologic analyses indicated that human SARS-CoV isolates could be divided into 3 groups from the early, middle, and late phases of the outbreaks and that early-phase isolates were more closely related to the animal isolates (10).", [["SARS", "DISEASE", 57, 61], ["human", "ORGANISM", 51, 56], ["SARS-CoV isolates", "ORGANISM", 57, 74], ["human", "SPECIES", 51, 56], ["human SARS-CoV", "SPECIES", 51, 65], ["Molecular epidemiologic analyses", "TEST", 3, 35], ["human SARS-CoV isolates", "PROBLEM", 51, 74], ["the outbreaks", "PROBLEM", 149, 162], ["early-phase isolates", "PROBLEM", 172, 192], ["middle", "ANATOMY_MODIFIER", 122, 128], ["late phases", "OBSERVATION_MODIFIER", 134, 145]]], ["7) Human SARS-CoVs isolates from the 2003\u20132004 outbreaks had higher sequence identity to animal isolates of the same period than to human isolates from the 2002\u20132003 outbreaks (3).Susceptible Animals in Markets and LaboratoriesThe first evidence of SARS-CoV infection in animals came from a study conducted in a live animal market in early 2003 (9).", [["SARS-CoV infection", "DISEASE", 249, 267], ["Human", "ORGANISM", 3, 8], ["SARS-CoVs", "ORGANISM", 9, 18], ["human", "ORGANISM", 132, 137], ["SARS-CoV", "ORGANISM", 249, 257], ["Human", "SPECIES", 3, 8], ["human", "SPECIES", 132, 137], ["Human SARS-CoVs", "SPECIES", 3, 18], ["human", "SPECIES", 132, 137], ["SARS-CoV", "SPECIES", 249, 257], ["Human SARS", "PROBLEM", 3, 13], ["CoVs isolates", "PROBLEM", 14, 27], ["SARS", "PROBLEM", 249, 253], ["CoV infection", "PROBLEM", 254, 267], ["a study", "TEST", 289, 296], ["SARS", "OBSERVATION", 249, 253], ["CoV", "OBSERVATION_MODIFIER", 254, 257], ["infection", "OBSERVATION", 258, 267]]], ["From the 25 animals sampled, viruses closely related to SARS-CoV were detected in 3 masked palm civets (Paguma larvata) and 1 raccoon dog (Nyctereutes procyonoides).", [["SARS", "DISEASE", 56, 60], ["SARS-CoV", "ORGANISM", 56, 64], ["Paguma larvata", "ORGANISM", 104, 118], ["raccoon", "ORGANISM", 126, 133], ["dog", "ORGANISM_SUBDIVISION", 134, 137], ["Nyctereutes procyonoides", "ORGANISM", 139, 163], ["Paguma larvata", "SPECIES", 104, 118], ["raccoon dog", "SPECIES", 126, 137], ["Nyctereutes procyonoides", "SPECIES", 139, 163], ["SARS-CoV", "SPECIES", 56, 64], ["palm civets", "SPECIES", 91, 102], ["Paguma larvata", "SPECIES", 104, 118], ["raccoon dog", "SPECIES", 126, 137], ["Nyctereutes procyonoides", "SPECIES", 139, 163], ["viruses", "PROBLEM", 29, 36], ["SARS", "PROBLEM", 56, 60], ["CoV", "PROBLEM", 61, 64], ["Paguma larvata", "TREATMENT", 104, 118], ["1 raccoon dog (Nyctereutes procyonoides", "TREATMENT", 124, 163]]], ["In addition, neutralizing antibodies against SARS-CoV were detected in 2 Chinese ferret badgers (Melogale moschata).", [["SARS-CoV", "ORGANISM", 45, 53], ["ferret", "ORGANISM", 81, 87], ["badgers", "ORGANISM", 88, 95], ["Melogale moschata", "ORGANISM", 97, 114], ["neutralizing antibodies", "PROTEIN", 13, 36], ["ferret", "SPECIES", 81, 87], ["Melogale moschata", "SPECIES", 97, 114], ["SARS-CoV", "SPECIES", 45, 53], ["Chinese ferret badgers", "SPECIES", 73, 95], ["Melogale moschata", "SPECIES", 97, 114], ["neutralizing antibodies", "TEST", 13, 36], ["SARS", "PROBLEM", 45, 49], ["CoV", "PROBLEM", 50, 53]]], ["This initial study indicated that at least 3 different animal species in the Shenzhen market were infected by coronaviruses that are closely related to SARS-CoV.Susceptible Animals in Markets and LaboratoriesGiven the vast number of live animals being traded in animal markets in southern People's Republic of China, knowing which other animals are also susceptible to these viruses is crucial.", [["SARS", "DISEASE", 152, 156], ["coronaviruses", "ORGANISM", 110, 123], ["SARS-CoV", "ORGANISM", 152, 160], ["SARS-CoV", "SPECIES", 152, 160], ["This initial study", "TEST", 0, 18], ["3 different animal species", "PROBLEM", 43, 69], ["coronaviruses", "PROBLEM", 110, 123], ["animal species", "OBSERVATION", 55, 69], ["infected", "OBSERVATION", 98, 106], ["viruses", "OBSERVATION", 375, 382]]], ["Unfortunately, for a variety of reasons no systematic studies were conducted on traded animals during the outbreak period.", [["systematic studies", "TEST", 43, 61]]], ["Experimental infection of different animals therefore became a component of the SARS-CoV investigation.Susceptible Animals in Markets and LaboratoriesCurrently, >10 mammalian species have been proven to be susceptible to infection by SARS-CoV or related viruses (Table 1).", [["infection", "DISEASE", 13, 22], ["SARS", "DISEASE", 80, 84], ["infection", "DISEASE", 221, 230], ["SARS-CoV", "DISEASE", 234, 242], ["SARS-CoV", "ORGANISM", 234, 242], ["SARS-CoV", "SPECIES", 80, 88], ["SARS-CoV", "SPECIES", 234, 242], ["Experimental infection of different animals", "PROBLEM", 0, 43], ["the SARS", "PROBLEM", 76, 84], ["CoV investigation", "TEST", 85, 102], ["Laboratories", "TEST", 138, 150], ["infection", "PROBLEM", 221, 230], ["SARS", "PROBLEM", 234, 238], ["CoV", "PROBLEM", 239, 242], ["related viruses", "PROBLEM", 246, 261], ["infection", "OBSERVATION", 13, 22], ["infection", "OBSERVATION", 221, 230]]], ["Rats were also implicated as potentially susceptible animals that may have played a role in the transmission and spread of SARS-CoV in the well-publicized SARS outbreaks in the Amoy Gardens apartment block in Hong Kong Special Administrative Region, People's Republic of China (23).", [["SARS-CoV", "DISEASE", 123, 131], ["SARS", "DISEASE", 155, 159], ["Rats", "ORGANISM", 0, 4], ["SARS-CoV", "ORGANISM", 123, 131], ["Rats", "SPECIES", 0, 4], ["SARS-CoV", "SPECIES", 123, 131], ["SARS", "PROBLEM", 123, 127]]], ["In Guangdong in 2004, the first human with a confirmed case of SARS was reported to have had no contact with any animals except rats (2).", [["SARS", "DISEASE", 63, 67], ["human", "ORGANISM", 32, 37], ["rats", "ORGANISM", 128, 132], ["human", "SPECIES", 32, 37], ["rats", "SPECIES", 128, 132], ["human", "SPECIES", 32, 37]]], ["Experimentally, we have obtained serologic evidence that SARS-CoV replicates asymptomatically in rats (B.T. Eaton et al., unpub. data).", [["SARS-CoV", "ORGANISM", 57, 65], ["rats", "ORGANISM", 97, 101], ["rats", "SPECIES", 97, 101], ["SARS-CoV", "SPECIES", 57, 65], ["SARS", "PROBLEM", 57, 61]]], ["Further studies are needed to clarify the potential role of rats in the transmission of SARS-CoV.", [["SARS", "DISEASE", 88, 92], ["rats", "ORGANISM", 60, 64], ["SARS-CoV", "ORGANISM", 88, 96], ["rats", "SPECIES", 60, 64], ["SARS-CoV", "SPECIES", 88, 96], ["Further studies", "TEST", 0, 15]]], ["Studies by 2 independent groups suggested that avian species were not susceptible to SARS-CoV infection and that, hence, domestic poultry were unlikely to be the reservoir or associated with the dissemination of SARS-CoV in the animal markets of southern People's Republic of China (22,24).Role of Masked Palm CivetsAlthough in 1 live animal market, 3 species were found to be infected by viruses related to SARS-CoV (9), all subsequent studies have focused mainly on palm civets, possibly because the rate of detection was higher in civets or because the number of civets traded in southern People's Republic of China exceeds that of other wildlife groups.Role of Masked Palm CivetsThe isolation of closely related SARS-CoV in civets during the 2002\u20132003 and 2003\u20132004 outbreaks and the close match of virus sequences between the human and civet isolates from each outbreak (3,9,25) strongly suggest that civets are a direct source of human infection.", [["SARS-CoV infection", "DISEASE", 85, 103], ["SARS", "DISEASE", 212, 216], ["SARS", "DISEASE", 408, 412], ["civets", "DISEASE", 566, 572], ["SARS", "DISEASE", 716, 720], ["infection", "DISEASE", 942, 951], ["avian", "ORGANISM", 47, 52], ["SARS-CoV", "ORGANISM", 85, 93], ["SARS-CoV", "ORGANISM", 212, 220], ["SARS-CoV", "ORGANISM", 408, 416], ["palm", "ORGANISM_SUBDIVISION", 468, 472], ["SARS-CoV", "ORGANISM", 716, 724], ["human", "ORGANISM", 831, 836], ["civet isolates", "ORGANISM", 841, 855], ["human", "ORGANISM", 936, 941], ["human", "SPECIES", 831, 836], ["human", "SPECIES", 936, 941], ["SARS-CoV", "SPECIES", 85, 93], ["poultry", "SPECIES", 130, 137], ["SARS-CoV", "SPECIES", 212, 220], ["SARS-CoV", "SPECIES", 408, 416], ["SARS-CoV", "SPECIES", 716, 724], ["human", "SPECIES", 831, 836], ["human", "SPECIES", 936, 941], ["avian species", "PROBLEM", 47, 60], ["SARS", "PROBLEM", 85, 89], ["CoV infection", "PROBLEM", 90, 103], ["SARS", "PROBLEM", 212, 216], ["CoV", "PROBLEM", 217, 220], ["3 species", "PROBLEM", 350, 359], ["viruses", "PROBLEM", 389, 396], ["SARS", "PROBLEM", 408, 412], ["all subsequent studies", "TEST", 422, 444], ["palm civets", "TEST", 468, 479], ["virus sequences", "TREATMENT", 803, 818], ["human infection", "PROBLEM", 936, 951], ["infection", "OBSERVATION", 94, 103], ["infected", "OBSERVATION", 377, 385], ["infection", "OBSERVATION", 942, 951]]], ["However, these studies did not clarify whether animals other than civets were involved in transmission of SARS-CoV to humans or whether civets were an intermediate host or the natural reservoir host of SARS-CoVs.Role of Masked Palm CivetsDuring the 2002\u20132003 outbreaks, none of the animal traders surveyed in the markets, who supposedly had very close contact with live civets, displayed SARS symptoms (7\u20139).", [["SARS", "DISEASE", 106, 110], ["SARS", "DISEASE", 202, 206], ["SARS", "DISEASE", 388, 392], ["SARS-CoV", "ORGANISM", 106, 114], ["humans", "ORGANISM", 118, 124], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 202, 211], ["humans", "SPECIES", 118, 124], ["SARS-CoV", "SPECIES", 106, 114], ["humans", "SPECIES", 118, 124], ["these studies", "TEST", 9, 22], ["SARS", "PROBLEM", 106, 110], ["CoVs", "PROBLEM", 207, 211], ["SARS symptoms", "PROBLEM", 388, 401]]], ["During the 2003\u20132004 outbreaks, at least 1 human SARS patient had had no contact with civets (2).", [["SARS", "DISEASE", 49, 53], ["human", "ORGANISM", 43, 48], ["patient", "ORGANISM", 54, 61], ["human", "SPECIES", 43, 48], ["patient", "SPECIES", 54, 61], ["human", "SPECIES", 43, 48]]], ["These observations seem to indicate that >1 other animal species may play a role in transmission of SARS-CoV to humans.Role of Masked Palm CivetsMost, if not all, civets traded in the markets are not truly wildlife animals; rather, they are farmed animals.", [["SARS", "DISEASE", 100, 104], ["SARS-CoV", "ORGANISM", 100, 108], ["humans", "ORGANISM", 112, 118], ["humans", "SPECIES", 112, 118], ["SARS-CoV", "SPECIES", 100, 108], ["humans", "SPECIES", 112, 118], ["SARS", "PROBLEM", 100, 104]]], ["Civet farming is relatively new in People's Republic of China and has rapidly expanded during the past 15 years or so.", [["relatively", "OBSERVATION_MODIFIER", 17, 27], ["new", "OBSERVATION_MODIFIER", 28, 31]]], ["Serologic testing was performed on 103 serum samples taken from civets in an animal market in Guangdong and several civet farms in different regions of People's Republic of China in June 2003 and January 2004.", [["serum samples", "ANATOMY", 39, 52], ["serum samples", "ORGANISM_SUBSTANCE", 39, 52], ["Serologic testing", "TEST", 0, 17], ["serum samples", "TEST", 39, 52]]], ["No significant level of SARS-CoV antibody was detected in any of the 75 samples taken from 6 farms in 3 provinces.", [["samples", "ANATOMY", 72, 79], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 24, 32], ["SARS-CoV antibody", "PROTEIN", 24, 41], ["SARS-CoV", "SPECIES", 24, 32], ["significant level of SARS", "PROBLEM", 3, 28], ["CoV antibody", "TEST", 29, 41], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["SARS", "OBSERVATION", 24, 28]]], ["In contrast, of the 18 samples taken from an animal market in Guangdong Province in January 2004, 14 (79%) had neutralizing antibodies to SARS-CoV.Role of Masked Palm CivetsIn a parallel study conducted between January and September 2004 (27), molecular analysis was used to investigate the distribution of SARS-CoV in palm civets in markets and on farms.", [["samples", "ANATOMY", 23, 30], ["SARS", "DISEASE", 138, 142], ["SARS", "DISEASE", 307, 311], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 138, 146], ["SARS-CoV", "ORGANISM", 307, 315], ["palm", "ORGANISM_SUBDIVISION", 319, 323], ["neutralizing antibodies", "PROTEIN", 111, 134], ["SARS-CoV", "SPECIES", 138, 146], ["SARS-CoV", "SPECIES", 307, 315], ["neutralizing antibodies", "TREATMENT", 111, 134], ["a parallel study", "TEST", 176, 192], ["molecular analysis", "TEST", 244, 262], ["SARS", "PROBLEM", 307, 311], ["SARS", "OBSERVATION", 307, 311]]], ["PCR analysis of samples from 91 palm civets and 15 raccoon dogs in 1 animal market and 1,107 civets from 25 farms in 12 provinces showed positive results for all animals from the market and negative results for all animals from the farms.", [["samples", "ANATOMY", 16, 23], ["dogs", "ORGANISM", 59, 63], ["dogs", "SPECIES", 59, 63], ["PCR analysis", "TEST", 0, 12], ["samples", "TEST", 16, 23], ["palm civets", "TEST", 32, 43], ["raccoon dogs", "TEST", 51, 63], ["civets", "TEST", 93, 99]]], ["Similar results were obtained in wild-trapped civets in Hong Kong; none of the 21 wild civets sampled had positive antibody or PCR results for SARS-CoV (28).Role of Masked Palm CivetsAlthough not universally true, natural reservoir hosts tend to have coevolved with their viruses and usually do not display clinical signs of infection (29).", [["SARS", "DISEASE", 143, 147], ["infection", "DISEASE", 325, 334], ["civets", "CANCER", 87, 93], ["SARS-CoV", "SPECIES", 143, 151], ["positive antibody", "PROBLEM", 106, 123], ["PCR", "TEST", 127, 130], ["SARS", "TEST", 143, 147], ["CoV", "TEST", 148, 151], ["natural reservoir hosts", "TREATMENT", 214, 237], ["their viruses", "PROBLEM", 266, 279], ["infection", "PROBLEM", 325, 334], ["infection", "OBSERVATION", 325, 334]]], ["However, when palm civets were experimentally infected with 2 strains of human SARS-CoV, all developed clinical signs of fever, lethargy, and loss of aggressiveness (11).Role of Masked Palm CivetsCivits' high susceptibility to SARS-CoV infection and wide presence in markets and restaurants strongly indicates an important role for civets in the 2002\u20132003 and 2003\u20132004 SARS outbreaks.", [["SARS-CoV", "DISEASE", 79, 87], ["fever", "DISEASE", 121, 126], ["lethargy", "DISEASE", 128, 136], ["loss of aggressiveness", "DISEASE", 142, 164], ["SARS-CoV infection", "DISEASE", 227, 245], ["SARS", "DISEASE", 370, 374], ["human", "ORGANISM", 73, 78], ["SARS-CoV", "ORGANISM", 79, 87], ["SARS-CoV", "ORGANISM", 227, 235], ["human", "SPECIES", 73, 78], ["human SARS-CoV", "SPECIES", 73, 87], ["SARS-CoV", "SPECIES", 227, 235], ["human SARS", "PROBLEM", 73, 83], ["fever", "PROBLEM", 121, 126], ["lethargy", "PROBLEM", 128, 136], ["loss of aggressiveness", "PROBLEM", 142, 164], ["SARS", "PROBLEM", 227, 231], ["CoV infection", "PROBLEM", 232, 245], ["fever", "OBSERVATION", 121, 126]]], ["However, the lack of widespread infection in wild or farmed palm civets makes them unlikely to have been the natural reservoir host.Diversity of Coronaviruses in Bats ::: SARS-like Coronaviruses in BatsThe discovery of SARS-CoV has boosted the search for novel coronaviruses of human and animal origin.", [["infection", "DISEASE", 32, 41], ["SARS", "DISEASE", 171, 175], ["SARS", "DISEASE", 219, 223], ["palm", "ORGANISM_SUBDIVISION", 60, 64], ["SARS-like Coronaviruses", "ORGANISM", 171, 194], ["Bats", "CELL", 198, 202], ["SARS-CoV", "ORGANISM", 219, 227], ["coronaviruses", "ORGANISM", 261, 274], ["human", "ORGANISM", 278, 283], ["human", "SPECIES", 278, 283], ["SARS-CoV", "SPECIES", 219, 227], ["human", "SPECIES", 278, 283], ["widespread infection", "PROBLEM", 21, 41], ["SARS", "PROBLEM", 171, 175], ["Coronaviruses", "PROBLEM", 181, 194], ["SARS", "PROBLEM", 219, 223], ["widespread", "OBSERVATION_MODIFIER", 21, 31], ["infection", "OBSERVATION", 32, 41], ["Coronaviruses", "OBSERVATION", 145, 158], ["Coronaviruses", "OBSERVATION", 181, 194]]], ["Bats have been chosen as the main target because of their species diversity, large population size, broad geographic distribution, ability for long-distance migration, and habit of roosting in large groups.", [["Bats", "CELL", 0, 4], ["their species diversity", "PROBLEM", 52, 75], ["large population size", "PROBLEM", 77, 98], ["long-distance migration", "PROBLEM", 143, 166], ["habit of roosting in large groups", "PROBLEM", 172, 205], ["large", "OBSERVATION_MODIFIER", 77, 82], ["population", "OBSERVATION_MODIFIER", 83, 93], ["size", "OBSERVATION_MODIFIER", 94, 98], ["broad", "OBSERVATION_MODIFIER", 100, 105], ["geographic", "OBSERVATION_MODIFIER", 106, 116], ["distribution", "OBSERVATION_MODIFIER", 117, 129], ["large", "OBSERVATION_MODIFIER", 193, 198]]], ["In addition to the SARS-like\u2013CoVs described above, many other coronaviruses have been detected by PCR among diverse bat populations in Hong Kong (Table 2).Diversity of Coronaviruses in Bats ::: SARS-like Coronaviruses in BatsPoon et al. (28) conducted a surveillance study in Hong Kong during the summers of 2003 and 2004.", [["SARS", "DISEASE", 19, 23], ["SARS-like Coronaviruses", "DISEASE", 194, 217], ["coronaviruses", "ORGANISM", 62, 75], ["SARS-like Coronaviruses", "ORGANISM", 194, 217], ["SARS-like\u2013CoVs", "DNA", 19, 33], ["the SARS-like\u2013CoVs", "PROBLEM", 15, 33], ["many other coronaviruses", "PROBLEM", 51, 75], ["SARS", "PROBLEM", 194, 198], ["a surveillance study", "TEST", 252, 272], ["SARS", "OBSERVATION", 19, 23], ["coronaviruses", "OBSERVATION", 62, 75], ["Coronaviruses", "OBSERVATION", 168, 181]]], ["From 162 swab samples collected from 12 bat species, they detected a novel group 1 coronavirus by sequencing of PCR products from the RNA-dependent RNA polymerase (RdRp) gene.", [["swab samples", "ANATOMY", 9, 21], ["swab samples", "CANCER", 9, 21], ["coronavirus", "ORGANISM", 83, 94], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 134, 162], ["PCR products", "PROTEIN", 112, 124], ["RNA-dependent RNA polymerase (RdRp) gene", "DNA", 134, 174], ["group 1 coronavirus", "SPECIES", 75, 94], ["1 coronavirus", "SPECIES", 81, 94], ["swab samples", "TEST", 9, 21], ["a novel group 1 coronavirus", "PROBLEM", 67, 94], ["PCR products", "TREATMENT", 112, 124], ["the RNA", "TREATMENT", 130, 137]]], ["The same virus or viruses of the same genetic lineage were found in 3 Miniopterus species (M. pusillus, M. magnater, and M. schreibersii).", [["M. pusillus", "ORGANISM", 91, 102], ["M. magnater", "ORGANISM", 104, 115], ["M. schreibersii", "ORGANISM", 121, 136], ["M. pusillus", "SPECIES", 91, 102], ["M. magnater", "SPECIES", 104, 115], ["M. schreibersii", "SPECIES", 121, 136], ["M. pusillus", "SPECIES", 91, 102], ["M. magnater", "SPECIES", 104, 115], ["M. schreibersii", "SPECIES", 121, 136], ["The same virus", "PROBLEM", 0, 14], ["virus", "OBSERVATION", 9, 14], ["viruses", "OBSERVATION", 18, 25]]], ["However, attempts to isolate virus by using 3 different cell lines (MDCK, FRhK4, and VeroE6) were unsuccessful.Diversity of Coronaviruses in Bats ::: SARS-like Coronaviruses in BatsIn another study in Hong Kong during April 2004\u2013July 2005, Woo et al. (32) sampled 309 individual bats representing 13 species from 20 different locations in rural Hong Kong.", [["cell lines", "ANATOMY", 56, 66], ["MDCK", "ANATOMY", 68, 72], ["SARS", "DISEASE", 150, 154], ["cell lines", "CELL", 56, 66], ["MDCK", "CELL", 68, 72], ["FRhK4", "CELL", 74, 79], ["VeroE6", "GENE_OR_GENE_PRODUCT", 85, 91], ["cell lines", "CELL_LINE", 56, 66], ["MDCK", "CELL_LINE", 68, 72], ["FRhK4", "CELL_LINE", 74, 79], ["VeroE6", "CELL_LINE", 85, 91], ["isolate virus", "TREATMENT", 21, 34], ["3 different cell lines", "TREATMENT", 44, 66], ["VeroE6", "TREATMENT", 85, 91], ["SARS", "PROBLEM", 150, 154], ["cell lines", "OBSERVATION", 56, 66], ["Coronaviruses", "OBSERVATION", 124, 137], ["13 species", "OBSERVATION_MODIFIER", 297, 307]]], ["They detected coronavirus-related viral genomic RNA in 37 bats, representing a prevalence of 12%.", [["coronavirus", "ORGANISM", 14, 25], ["viral genomic RNA", "RNA", 34, 51], ["coronavirus", "PROBLEM", 14, 25], ["viral genomic RNA", "PROBLEM", 34, 51], ["coronavirus", "OBSERVATION", 14, 25], ["viral genomic RNA", "OBSERVATION", 34, 51]]], ["Partial sequencing of RdRp and helicase genes identified 8 coronavirus genome types, 2 of which were the same as those reported previously (28,30,31).", [["RdRp", "GENE_OR_GENE_PRODUCT", 22, 26], ["RdRp and helicase genes", "DNA", 22, 45], ["RdRp", "PROBLEM", 22, 26], ["helicase genes", "PROBLEM", 31, 45], ["8 coronavirus genome types", "PROBLEM", 57, 83], ["RdRp", "OBSERVATION", 22, 26], ["helicase genes", "OBSERVATION", 31, 45]]], ["The other 6 novel types of coronaviruses were obtained from 6 different bat species and phylogenetically positioned in 2 of the existing 3 coronavirus groups.", [["coronaviruses", "ORGANISM", 27, 40], ["coronavirus", "ORGANISM", 139, 150], ["coronaviruses", "PROBLEM", 27, 40], ["6 different bat species", "PROBLEM", 60, 83], ["coronaviruses", "OBSERVATION", 27, 40]]], ["Four were in group 1, derived from bat species M. magnater, M. pusillus, Myotis ricketti, and R. sinicus; the other 2 were in group 2, from bat species Pipistrellus abramus and Tylonycteris pachypus.", [["bat", "ORGANISM", 35, 38], ["M. magnater", "ORGANISM", 47, 58], ["M. pusillus", "ORGANISM", 60, 71], ["Myotis ricketti", "ORGANISM", 73, 88], ["R. sinicus", "ORGANISM", 94, 104], ["Pipistrellus abramus", "ORGANISM", 152, 172], ["Tylonycteris pachypus", "ORGANISM", 177, 198], ["M. magnater", "SPECIES", 47, 58], ["M. pusillus", "SPECIES", 60, 71], ["Myotis ricketti", "SPECIES", 73, 88], ["R. sinicus", "SPECIES", 94, 104], ["Pipistrellus abramus", "SPECIES", 152, 172], ["Tylonycteris pachypus", "SPECIES", 177, 198], ["M. magnater", "SPECIES", 47, 58], ["M. pusillus", "SPECIES", 60, 71], ["Myotis ricketti", "SPECIES", 73, 88], ["R. sinicus", "SPECIES", 94, 104], ["Pipistrellus abramus", "SPECIES", 152, 172], ["Tylonycteris pachypus", "SPECIES", 177, 198], ["Myotis ricketti", "PROBLEM", 73, 88], ["Tylonycteris pachypus", "PROBLEM", 177, 198], ["M. pusillus", "OBSERVATION", 60, 71], ["Myotis ricketti", "OBSERVATION", 73, 88], ["Pipistrellus abramus", "ANATOMY", 152, 172], ["Tylonycteris pachypus", "OBSERVATION", 177, 198]]], ["To accommodate the newly discovered genetic diversity of group 2 coronaviruses, the authors proposed the following subdivisions: group 2a (coronaviruses existing before the discovery of SARS-CoV), group 2b (SARS-CoV and SARS-like\u2013CoVs), and group 2c (novel bat coronaviruses discovered in this study).", [["SARS-CoV)", "DISEASE", 186, 195], ["coronaviruses", "ORGANISM", 139, 152], ["SARS-CoV", "ORGANISM", 186, 194], ["SARS-CoV", "ORGANISM", 207, 215], ["SARS-like\u2013CoVs", "ORGANISM", 220, 234], ["bat coronaviruses", "ORGANISM", 257, 274], ["SARS-CoV", "SPECIES", 186, 194], ["SARS-CoV", "SPECIES", 207, 215], ["SARS", "PROBLEM", 186, 190], ["CoV", "TEST", 191, 194], ["group 2b", "TEST", 197, 205], ["SARS", "TEST", 207, 211], ["CoV", "TEST", 212, 215], ["SARS", "PROBLEM", 220, 224], ["novel bat coronaviruses", "PROBLEM", 251, 274], ["this study", "TEST", 289, 299]]], ["Attempts to isolate virus in VeroE6, MRC-5, LLC-Mk2, FRhK-4, Huh-7.5, and HRT-18 were unsuccessful.Diversity of Coronaviruses in Bats ::: SARS-like Coronaviruses in BatsIn another extensive study conducted in mainland People's Republic of China during November 2004\u2013March 2006, Tang et al. (33) collected samples from 985 bats: 35 species in 14 genera and 3 families at 82 different sites in 15 provinces.", [["LLC-Mk2", "ANATOMY", 44, 51], ["samples", "ANATOMY", 305, 312], ["SARS", "DISEASE", 138, 142], ["VeroE6", "CELL", 29, 35], ["MRC-5", "ORGANISM", 37, 42], ["LLC-Mk2", "CELL", 44, 51], ["FRhK-4", "CELL", 53, 59], ["Huh-7.5", "CELL", 61, 68], ["HRT-18", "CELL", 74, 80], ["isolate virus", "TEST", 12, 25], ["VeroE6", "TEST", 29, 35], ["MRC", "TEST", 37, 40], ["LLC", "TEST", 44, 47], ["Mk2", "TEST", 48, 51], ["FRhK", "TEST", 53, 57], ["Huh", "TEST", 61, 64], ["HRT", "TEST", 74, 77], ["SARS", "PROBLEM", 138, 142], ["Coronaviruses", "PROBLEM", 148, 161], ["LLC", "ANATOMY", 44, 47], ["Coronaviruses", "OBSERVATION", 112, 125]]], ["A total of 64 (6.5%) bats had positive results from a PCR directed to a highly conserved 440-bp RdRp region.", [["bats", "ORGANISM", 21, 25], ["440-bp RdRp region", "DNA", 89, 107], ["a PCR", "TEST", 52, 57]]], ["Among the 64 PCR-positive products sequenced, only 3 (all from the genus Rhinolophus) were clustered with known bat SARS-like\u2013CoVs (or group 2b), 40 belonged to group 1, and the remaining 22 formed a separate cluster in group 2, most likely clustering with the group 2c viruses reported by Woo et al. (32).", [["PCR-positive products", "DNA", 13, 34], ["bat SARS-like\u2013CoVs", "DNA", 112, 130], ["the 64 PCR", "TEST", 6, 16], ["known bat SARS", "PROBLEM", 106, 120], ["CoVs", "PROBLEM", 126, 130], ["most likely", "UNCERTAINTY", 229, 240]]], ["Attempts to isolate virus in VeroE6, FRHK4, and CV1 were unsuccessful.Diversity of Coronaviruses in Bats ::: SARS-like Coronaviruses in BatsIn addition to the diversity of coronaviruses in bats, 3 more observations can be drawn from these studies.", [["SARS", "DISEASE", 109, 113], ["VeroE6", "GENE_OR_GENE_PRODUCT", 29, 35], ["FRHK4", "GENE_OR_GENE_PRODUCT", 37, 42], ["CV1", "ORGANISM", 48, 51], ["coronaviruses", "ORGANISM", 172, 185], ["isolate virus", "PROBLEM", 12, 25], ["FRHK4", "TEST", 37, 42], ["CV1", "TEST", 48, 51], ["SARS", "PROBLEM", 109, 113], ["Coronaviruses", "PROBLEM", 119, 132], ["coronaviruses", "PROBLEM", 172, 185], ["these studies", "TEST", 233, 246], ["Coronaviruses", "OBSERVATION", 83, 96], ["Coronaviruses", "OBSERVATION", 119, 132], ["coronaviruses", "OBSERVATION", 172, 185]]], ["First, none of the bat coronaviruses discovered so far belonged to group 3.", [["bat coronaviruses", "ORGANISM", 19, 36], ["bat coronaviruses", "SPECIES", 19, 36], ["the bat coronaviruses", "PROBLEM", 15, 36]]], ["Second, with very few exceptions, most bat coronaviruses seem to be species-specific; i.e., different bat species from a similar location harbor different coronaviruses, whereas the same bat species from different geographic locations carry coronaviruses of the same genetic lineage (32,33).", [["bat coronaviruses", "ORGANISM", 39, 56], ["bat species", "ORGANISM", 102, 113], ["coronaviruses", "ORGANISM", 155, 168], ["bat species", "ORGANISM", 187, 198], ["coronaviruses", "ORGANISM", 241, 254], ["bat coronaviruses", "SPECIES", 39, 56], ["most bat coronaviruses", "PROBLEM", 34, 56], ["different bat species", "PROBLEM", 92, 113], ["different coronaviruses", "PROBLEM", 145, 168], ["the same bat species", "PROBLEM", 178, 198], ["different coronaviruses", "OBSERVATION", 145, 168]]], ["Third, among the 5 published studies involving bat coronaviruses (28,30\u201333), no researchers were able to isolate live virus from any of the swab samples collected despite the use of many different cell lines and the presence of high levels of viral genetic materials shown by quantitative PCR.Cross-species Transmission ::: SARS-like Coronaviruses in BatsEmergence of zoonotic viruses from a wildlife reservoir requires 4 events: 1) interspecies contact, 2) cross-species virus transmission (i.e., spillover), 3) sustained transmission, and 4) virus adaptation within the spillover species (34).", [["swab samples", "ANATOMY", 140, 152], ["cell lines", "ANATOMY", 197, 207], ["SARS", "DISEASE", 324, 328], ["zoonotic viruses", "DISEASE", 368, 384], ["bat coronaviruses", "ORGANISM", 47, 64], ["cell lines", "CELL", 197, 207], ["SARS-like Coronaviruses", "ORGANISM", 324, 347], ["cell lines", "CELL_LINE", 197, 207], ["bat coronaviruses", "SPECIES", 47, 64], ["the 5 published studies", "TEST", 13, 36], ["bat coronaviruses", "PROBLEM", 47, 64], ["the swab samples", "TEST", 136, 152], ["many different cell lines", "TREATMENT", 182, 207], ["high levels of viral genetic materials", "PROBLEM", 228, 266], ["quantitative PCR", "TEST", 276, 292], ["SARS", "PROBLEM", 324, 328], ["Coronaviruses", "PROBLEM", 334, 347], ["zoonotic viruses", "PROBLEM", 368, 384], ["a wildlife reservoir", "TREATMENT", 390, 410], ["cross-species virus transmission", "PROBLEM", 458, 490], ["sustained transmission, and 4) virus adaptation", "PROBLEM", 513, 560], ["different cell lines", "OBSERVATION", 187, 207], ["spillover species", "OBSERVATION", 572, 589]]], ["These 4 transition events occurred during the SARS outbreaks and contributed to the rapid spread of the disease around the world.Cross-species Transmission ::: SARS-like Coronaviruses in BatsThe role of civets in directly transmitting SARS-CoV to humans has been well established.", [["SARS", "DISEASE", 46, 50], ["SARS-like Coronaviruses", "DISEASE", 160, 183], ["SARS", "DISEASE", 235, 239], ["SARS-like Coronaviruses", "ORGANISM", 160, 183], ["Bats", "CELL", 187, 191], ["SARS-CoV", "ORGANISM", 235, 243], ["humans", "ORGANISM", 247, 253], ["humans", "SPECIES", 247, 253], ["SARS-CoV", "SPECIES", 235, 243], ["humans", "SPECIES", 247, 253], ["These 4 transition events", "PROBLEM", 0, 25], ["the SARS outbreaks", "PROBLEM", 42, 60], ["the disease", "PROBLEM", 100, 111], ["SARS", "PROBLEM", 160, 164], ["Coronaviruses", "PROBLEM", 170, 183], ["rapid", "OBSERVATION_MODIFIER", 84, 89], ["spread", "OBSERVATION_MODIFIER", 90, 96], ["disease", "OBSERVATION", 104, 111], ["Coronaviruses", "OBSERVATION", 170, 183]]], ["The most convincing case was the infection of a waitress and a customer in a restaurant where SARS-CoV\u2013positive civets were housed in cages (25).", [["infection", "DISEASE", 33, 42], ["SARS", "DISEASE", 94, 98], ["SARS-CoV\u2013positive civets", "TREATMENT", 94, 118], ["infection", "OBSERVATION", 33, 42]]], ["Two key questions remain: What is the natural reservoir host for the outbreak SARS-CoV strains, and how were the viruses transmitted to civets or other intermediate hosts?", [["SARS", "DISEASE", 78, 82], ["SARS-CoV", "ORGANISM", 78, 86], ["SARS-CoV", "SPECIES", 78, 86], ["CoV strains", "PROBLEM", 83, 94]]], ["Although not conclusive, the data obtained so far strongly suggest that bats (horseshoe bats in particular) are most likely the reservoir host of SARS-CoV.", [["SARS", "DISEASE", 146, 150], ["bats", "ORGANISM", 72, 76], ["horseshoe bats", "ORGANISM", 78, 92], ["SARS-CoV", "ORGANISM", 146, 154], ["SARS-CoV", "SPECIES", 146, 154], ["the data", "TEST", 25, 33], ["bats (horseshoe bats", "PROBLEM", 72, 92], ["most likely", "UNCERTAINTY", 112, 123]]], ["As indicated above, bat coronaviruses seem to be species-specific and SARS-like\u2013CoVs discovered so far are exclusively associated with horseshoe bats.", [["SARS", "DISEASE", 70, 74], ["bat coronaviruses", "ORGANISM", 20, 37], ["SARS-like\u2013CoVs", "ORGANISM", 70, 84], ["horseshoe bats", "ORGANISM", 135, 149], ["bat coronaviruses", "SPECIES", 20, 37], ["bat coronaviruses", "PROBLEM", 20, 37], ["SARS", "PROBLEM", 70, 74]]], ["We hope that continued field study will eventually identify the direct progenitor of SARS-CoV among the 69 different known horseshoe species.", [["SARS", "DISEASE", 85, 89], ["progenitor", "CELL", 71, 81], ["SARS-CoV", "ORGANISM", 85, 93], ["SARS-CoV", "SPECIES", 85, 93], ["continued field study", "TEST", 13, 34], ["SARS", "PROBLEM", 85, 89], ["horseshoe species", "PROBLEM", 123, 140], ["horseshoe species", "OBSERVATION", 123, 140]]], ["The facts that the cross-species transmission of SARS-CoV seems to be a relatively rare event and that legal and illegal trading of wildlife animals between People's Republic of China and other countries occurs raise the possibility that the natural reservoir species may not be native to People's Republic of China.", [["SARS", "DISEASE", 49, 53], ["SARS-CoV", "ORGANISM", 49, 57], ["People", "SPECIES", 157, 163], ["People", "SPECIES", 289, 295], ["SARS-CoV", "SPECIES", 49, 57], ["SARS-CoV", "PROBLEM", 49, 57], ["the natural reservoir species", "PROBLEM", 238, 267], ["may not be", "UNCERTAINTY", 268, 278]]], ["Another approach to search for the natural reservoir of SARS-CoV is to conduct infection experiments in different bat species.", [["SARS", "DISEASE", 56, 60], ["infection", "DISEASE", 79, 88], ["SARS-CoV", "ORGANISM", 56, 64], ["SARS-CoV", "SPECIES", 56, 64], ["SARS", "PROBLEM", 56, 60], ["CoV", "PROBLEM", 61, 64], ["infection experiments", "PROBLEM", 79, 100], ["infection", "OBSERVATION", 79, 88]]], ["If we assume that the progenitor viruses come from bats, chances are high that the human/civet SARS-CoVs are still capable of infecting the original reservoir species.Cross-species Transmission ::: SARS-like Coronaviruses in BatsWithout knowing the natural reservoir of SARS-CoV, predicting the exact mechanism of transmission from reservoir host to intermediate host is difficult.", [["progenitor", "ANATOMY", 22, 32], ["SARS", "DISEASE", 95, 99], ["SARS-like Coronaviruses", "DISEASE", 198, 221], ["SARS", "DISEASE", 270, 274], ["progenitor", "CELL", 22, 32], ["human", "ORGANISM", 83, 88], ["civet SARS-CoVs", "ORGANISM", 89, 104], ["SARS-like Coronaviruses", "ORGANISM", 198, 221], ["SARS-CoV", "ORGANISM", 270, 278], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["SARS-CoV", "SPECIES", 270, 278], ["the progenitor viruses", "PROBLEM", 18, 40], ["the human/civet SARS", "TREATMENT", 79, 99], ["CoVs", "PROBLEM", 100, 104], ["SARS", "PROBLEM", 198, 202], ["Coronaviruses", "PROBLEM", 208, 221], ["CoV", "PROBLEM", 275, 278], ["reservoir species", "OBSERVATION", 149, 166], ["Coronaviruses", "OBSERVATION", 208, 221]]], ["However, the fecal-oral route represents the main mode of transmission among animals.", [["fecal", "ANATOMY", 13, 18], ["oral", "ANATOMY", 19, 23], ["fecal", "ORGANISM_SUBDIVISION", 13, 18], ["oral", "ORGANISM_SUBDIVISION", 19, 23], ["fecal", "ANATOMY", 13, 18], ["main", "OBSERVATION_MODIFIER", 45, 49]]], ["Although mixing of live reservoir hosts (e.g., bats) and intermediate hosts (e.g., civets) would be an efficient means of transmission, the main source of cross-species transmission in the animal trading chain (including warehouses, transportation vehicles, markets) may come from contaminated feces, urine, blood, or aerosols.", [["feces", "ANATOMY", 294, 299], ["urine", "ANATOMY", 301, 306], ["blood", "ANATOMY", 308, 313], ["feces", "ORGANISM_SUBSTANCE", 294, 299], ["urine", "ORGANISM_SUBSTANCE", 301, 306], ["blood", "ORGANISM_SUBSTANCE", 308, 313]]], ["This may also be true for civet-to-human transmission.", [["human", "ORGANISM", 35, 40], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 35, 40], ["may also be", "UNCERTAINTY", 5, 16]]], ["As shown in the case of the infected restaurant customer in 2004, the customer had no direct contact with civets and was sitting at a table \u22485 m from the civet cages (25).Cross-species Transmission ::: SARS-like Coronaviruses in BatsAlthough at this stage we cannot rule out the possibility of direct transmission from the natural reservoir host to humans, molecular epidemiologic studies (2,10) and studies of the receptor-S protein interaction (35) indicate that the progenitor viruses are unlikely to be able to infect humans and that a rapid viral evolution in an intermediate host (such as civets) seems to be necessary to adapt the virus for human infection.", [["progenitor", "ANATOMY", 469, 479], ["SARS-like Coronaviruses", "DISEASE", 202, 225], ["infection", "DISEASE", 654, 663], ["SARS-like Coronaviruses", "ORGANISM", 202, 225], ["humans", "ORGANISM", 349, 355], ["receptor-S protein", "GENE_OR_GENE_PRODUCT", 415, 433], ["progenitor viruses", "CELL", 469, 487], ["humans", "ORGANISM", 522, 528], ["human", "ORGANISM", 648, 653], ["humans", "SPECIES", 349, 355], ["humans", "SPECIES", 522, 528], ["human", "SPECIES", 648, 653], ["humans", "SPECIES", 349, 355], ["humans", "SPECIES", 522, 528], ["human", "SPECIES", 648, 653], ["SARS", "PROBLEM", 202, 206], ["Coronaviruses", "PROBLEM", 212, 225], ["molecular epidemiologic studies", "TEST", 357, 388], ["the receptor", "TEST", 411, 423], ["the progenitor viruses", "PROBLEM", 465, 487], ["a rapid viral evolution", "PROBLEM", 538, 561], ["the virus", "PROBLEM", 634, 643], ["human infection", "PROBLEM", 648, 663], ["infected", "OBSERVATION_MODIFIER", 28, 36], ["SARS", "OBSERVATION", 202, 206], ["Coronaviruses", "OBSERVATION", 212, 225], ["progenitor viruses", "OBSERVATION", 469, 487], ["infection", "OBSERVATION", 654, 663]]], ["Ability to efficiently use the receptor molecules (ACE2 for human and civet) seems to be a major limiting factor for animal-to-human and human-to-human transmission (35).", [["ACE2", "GENE_OR_GENE_PRODUCT", 51, 55], ["human", "ORGANISM", 60, 65], ["human", "ORGANISM", 127, 132], ["human", "ORGANISM", 137, 142], ["human", "ORGANISM", 146, 151], ["receptor molecules", "PROTEIN", 31, 49], ["ACE2", "PROTEIN", 51, 55], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 137, 142], ["human", "SPECIES", 146, 151], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 137, 142], ["human", "SPECIES", 146, 151], ["the receptor molecules", "TREATMENT", 27, 49]]], ["This also explains why the SARS-CoV was able to cause the human pandemic but the closely related bat SARS-like\u2013CoVs were not.", [["SARS", "DISEASE", 27, 31], ["SARS", "DISEASE", 101, 105], ["SARS-CoV", "ORGANISM", 27, 35], ["human", "ORGANISM", 58, 63], ["bat", "ORGANISM", 97, 100], ["human", "SPECIES", 58, 63], ["SARS-CoV", "SPECIES", 27, 35], ["human", "SPECIES", 58, 63], ["the SARS-CoV", "PROBLEM", 23, 35], ["the human pandemic", "PROBLEM", 54, 72]]], ["For the SARS-like\u2013CoVs to infect humans, substantial genetic changes in the S1 receptor-binding domain will be necessary.", [["SARS", "DISEASE", 8, 12], ["humans", "ORGANISM", 33, 39], ["S1 receptor-binding domain", "PROTEIN", 76, 102], ["humans", "SPECIES", 33, 39], ["humans", "SPECIES", 33, 39], ["the SARS", "PROBLEM", 4, 12], ["substantial genetic changes", "PROBLEM", 41, 68]]], ["They could be achieved by genetic recombination, as coronaviruses are known to be able to recombine.", [["coronaviruses", "ORGANISM", 52, 65], ["coronaviruses", "PROBLEM", 52, 65]]], ["For example, bat SARS-like\u2013CoVs and another yet unknown coronavirus could coinfect an intermediate host, and the bat viruses would gain the ACE2 binding site in the S1 domain by recombination.", [["bat SARS-like\u2013CoVs", "ORGANISM", 13, 31], ["coronavirus", "ORGANISM", 56, 67], ["bat viruses", "ORGANISM", 113, 124], ["ACE2", "GENE_OR_GENE_PRODUCT", 140, 144], ["ACE2 binding site", "DNA", 140, 157], ["S1 domain", "DNA", 165, 174], ["bat SARS-like\u2013CoVs", "PROBLEM", 13, 31], ["coronavirus", "PROBLEM", 56, 67], ["the bat viruses", "PROBLEM", 109, 124], ["coronavirus", "OBSERVATION", 56, 67], ["intermediate host", "OBSERVATION", 86, 103], ["S1", "ANATOMY", 165, 167]]], ["Coronaviruses in bats could have a spectrum sufficiently diverse to encompass the progenitor virus for SARS-CoVs.", [["SARS", "DISEASE", 103, 107], ["bats", "ORGANISM", 17, 21], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 103, 112], ["Coronaviruses", "PROBLEM", 0, 13], ["SARS", "PROBLEM", 103, 107], ["CoVs", "PROBLEM", 108, 112], ["progenitor virus", "OBSERVATION", 82, 98]]], ["The progenitor virus's ability to bind human ACE2 may be acquired or improved by adaptation (i.e., point mutations) in >1 intermediate host before it could efficiently infect humans.", [["human", "ORGANISM", 39, 44], ["ACE2", "GENE_OR_GENE_PRODUCT", 45, 49], ["humans", "ORGANISM", 175, 181], ["human ACE2", "PROTEIN", 39, 49], ["human", "SPECIES", 39, 44], ["humans", "SPECIES", 175, 181], ["human", "SPECIES", 39, 44], ["humans", "SPECIES", 175, 181], ["The progenitor virus", "PROBLEM", 0, 20]]], ["The existence of at least 3 discontinuous highly variable genomic regions between SARS-CoV and SARS-like\u2013CoV indicates that the second mechanism is more likely.Cross-species Transmission ::: SARS-like Coronaviruses in BatsIn conclusion, the discovery of bat SARS-like\u2013CoVs and the great genetic diversity of coronaviruses in bats have shed new light on the origin and transmission of SARS-CoV.", [["SARS", "DISEASE", 82, 86], ["SARS", "DISEASE", 191, 195], ["SARS", "DISEASE", 258, 262], ["SARS", "DISEASE", 384, 388], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 82, 90], ["SARS-like\u2013CoV", "ORGANISM", 95, 108], ["SARS-like Coronaviruses", "ORGANISM", 191, 214], ["bat SARS-like\u2013CoVs", "ORGANISM", 254, 272], ["coronaviruses", "ORGANISM", 308, 321], ["SARS-CoV", "ORGANISM", 384, 392], ["genomic regions", "DNA", 58, 73], ["SARS-CoV and SARS-like\u2013CoV", "DNA", 82, 108], ["SARS-CoV", "SPECIES", 82, 90], ["SARS-like\u2013CoV", "SPECIES", 95, 108], ["SARS-CoV", "SPECIES", 384, 392], ["3 discontinuous highly variable genomic regions between SARS", "PROBLEM", 26, 86], ["SARS", "PROBLEM", 95, 99], ["CoV", "PROBLEM", 105, 108], ["SARS", "PROBLEM", 191, 195], ["Coronaviruses", "PROBLEM", 201, 214], ["bat SARS-like\u2013CoVs", "PROBLEM", 254, 272], ["coronaviruses", "PROBLEM", 308, 321], ["CoV", "PROBLEM", 389, 392], ["at least", "OBSERVATION_MODIFIER", 17, 25], ["highly", "OBSERVATION_MODIFIER", 42, 48], ["variable", "OBSERVATION_MODIFIER", 49, 57], ["genomic", "OBSERVATION", 58, 65], ["more likely", "UNCERTAINTY", 148, 159], ["coronaviruses", "OBSERVATION", 308, 321]]], ["Although the exact natural reservoir host for the progenitor virus of SARS-CoV is still unknown, we believe that a continued search in different bat populations in People's Republic of China and neighboring countries, combined with experimental infection of different bat species with SARS-CoV, will eventually identify the native reservoir species.", [["SARS", "DISEASE", 70, 74], ["infection", "DISEASE", 245, 254], ["progenitor", "CELL", 50, 60], ["SARS-CoV", "ORGANISM", 70, 78], ["SARS-CoV", "ORGANISM", 285, 293], ["People", "SPECIES", 164, 170], ["SARS-CoV", "SPECIES", 70, 78], ["SARS-CoV", "SPECIES", 285, 293], ["the progenitor virus", "PROBLEM", 46, 66], ["SARS", "PROBLEM", 70, 74], ["a continued search in different bat populations", "PROBLEM", 113, 160], ["experimental infection", "PROBLEM", 232, 254], ["different bat species", "PROBLEM", 258, 279], ["SARS-CoV", "PROBLEM", 285, 293], ["infection", "OBSERVATION", 245, 254], ["reservoir species", "OBSERVATION", 331, 348]]], ["A positive outcome of these investigations will greatly enhance our understanding of spillover mechanisms, which will in turn facilitate development and implementation of effective prevention strategies.", [["these investigations", "TEST", 22, 42], ["effective prevention strategies", "TREATMENT", 171, 202]]], ["The discovery of SARS-like\u2013CoVs in bats highlights the increasingly recognized importance of bats as reservoirs of emerging viruses (36).", [["SARS", "DISEASE", 17, 21], ["SARS-like\u2013CoVs", "GENE_OR_GENE_PRODUCT", 17, 31], ["bats", "ORGANISM", 93, 97], ["SARS", "PROBLEM", 17, 21], ["SARS", "OBSERVATION", 17, 21]]], ["Moreover, the recent emergence of SARS-CoVs and other bat-associated viruses such as henipaviruses (37,38), Menangle, and Tioman viruses (36), and variants of rabies viruses and bat lyssaviruses (38,39) also supports the contention that viruses, especially RNA viruses, possess more risk than other pathogens for disease emergence in human and domestic mammals because of their higher mutation rates (40).", [["SARS-CoVs", "DISEASE", 34, 43], ["rabies viruses", "DISEASE", 159, 173], ["SARS-CoVs", "ORGANISM", 34, 43], ["bat", "ORGANISM", 54, 57], ["Tioman viruses", "ORGANISM", 122, 136], ["rabies viruses", "ORGANISM", 159, 173], ["bat lyssaviruses", "ORGANISM", 178, 194], ["human", "ORGANISM", 334, 339], ["human", "SPECIES", 334, 339], ["SARS-CoVs", "SPECIES", 34, 43], ["Tioman viruses", "SPECIES", 122, 136], ["rabies viruses", "SPECIES", 159, 173], ["human", "SPECIES", 334, 339], ["SARS", "PROBLEM", 34, 38], ["CoVs", "PROBLEM", 39, 43], ["other bat-associated viruses", "PROBLEM", 48, 76], ["henipaviruses", "TEST", 85, 98], ["Menangle, and Tioman viruses", "PROBLEM", 108, 136], ["rabies viruses", "PROBLEM", 159, 173], ["RNA viruses", "PROBLEM", 257, 268], ["disease", "PROBLEM", 313, 320], ["viruses", "OBSERVATION", 69, 76], ["rabies viruses", "OBSERVATION", 159, 173], ["viruses", "OBSERVATION", 237, 244]]]], "PMC7443060": [["IntroductionThe SARS-CoV-2 infection has now reached 188 countries across all continents, except Antarctica.", [["SARS-CoV-2 infection", "DISEASE", 16, 36], ["SARS-CoV-2", "ORGANISM", 16, 26], ["SARS-CoV-2", "SPECIES", 16, 26], ["The SARS", "PROBLEM", 12, 20], ["2 infection", "PROBLEM", 25, 36]]], ["SARS-CoV-2 belongs to the Coronaviridae family, genus Betacoronavirus, which are enveloped, positive-sense, single-stranded RNA viruses, of zoonotic origin.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 26, 39], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 54, 69], ["SARS-CoV", "SPECIES", 0, 8], ["genus Betacoronavirus", "PROBLEM", 48, 69], ["zoonotic origin", "OBSERVATION", 140, 155]]], ["Among human RNA viruses, coronaviruses have the largest known genome (\u223c30 kb), which encodes the structural proteins (spike, envelope, membrane and nucleocapsid), nonstructural proteins (nsp1-16), and accessory proteins (ORF3a, ORF6, ORF7a and b, ORF8, ORF10).", [["membrane", "ANATOMY", 135, 143], ["human", "ORGANISM", 6, 11], ["coronaviruses", "ORGANISM", 25, 38], ["membrane", "CELLULAR_COMPONENT", 135, 143], ["nucleocapsid", "GENE_OR_GENE_PRODUCT", 148, 160], ["nsp1-16", "GENE_OR_GENE_PRODUCT", 187, 194], ["ORF3a", "GENE_OR_GENE_PRODUCT", 221, 226], ["ORF6", "GENE_OR_GENE_PRODUCT", 228, 232], ["ORF7a", "GENE_OR_GENE_PRODUCT", 234, 239], ["b", "GENE_OR_GENE_PRODUCT", 244, 245], ["ORF8", "GENE_OR_GENE_PRODUCT", 247, 251], ["ORF10", "GENE_OR_GENE_PRODUCT", 253, 258], ["structural proteins", "PROTEIN", 97, 116], ["spike, envelope, membrane and nucleocapsid", "PROTEIN", 118, 160], ["nonstructural proteins", "PROTEIN", 163, 185], ["nsp1", "PROTEIN", 187, 191], ["16", "PROTEIN", 192, 194], ["accessory proteins", "PROTEIN", 201, 219], ["ORF3a", "PROTEIN", 221, 226], ["ORF6", "PROTEIN", 228, 232], ["ORF7a", "PROTEIN", 234, 239], ["b", "PROTEIN", 244, 245], ["ORF8", "PROTEIN", 247, 251], ["ORF10", "PROTEIN", 253, 258], ["human", "SPECIES", 6, 11], ["human", "SPECIES", 6, 11], ["Among human RNA viruses", "PROBLEM", 0, 23], ["coronaviruses", "PROBLEM", 25, 38], ["the structural proteins", "PROBLEM", 93, 116], ["nonstructural proteins", "TEST", 163, 185], ["nsp1", "TEST", 187, 191], ["accessory proteins", "PROBLEM", 201, 219], ["RNA viruses", "OBSERVATION", 12, 23], ["largest", "OBSERVATION_MODIFIER", 48, 55], ["accessory proteins", "ANATOMY", 201, 219]]], ["Structural proteins are required for host cell entry, viral assembly and exit (B\u00e1rcena et al., 2009, Hoffmann et al., 2020).", [["cell", "ANATOMY", 42, 46], ["cell", "CELL", 42, 46], ["Structural proteins", "PROBLEM", 0, 19], ["host cell entry", "PROBLEM", 37, 52]]], ["Nonstructural proteins are involved in genome replication-transcription and formation of vesicles (Hagemeijer et al. 2014), whereas accessory proteins interfere with host innate defense mechanisms (Wu et al., 2020a, Wu et al., 2020b, Liu et al., 2014).", [["vesicles", "ANATOMY", 89, 97], ["genome", "CELLULAR_COMPONENT", 39, 45], ["vesicles", "CELLULAR_COMPONENT", 89, 97], ["Nonstructural proteins", "PROTEIN", 0, 22], ["accessory proteins", "PROTEIN", 132, 150], ["Nonstructural proteins", "PROBLEM", 0, 22], ["genome replication", "TREATMENT", 39, 57], ["vesicles", "PROBLEM", 89, 97], ["genome replication", "OBSERVATION", 39, 57], ["vesicles", "ANATOMY", 89, 97]]], ["During genome replication within the host, the virus acquires genome mutations, which can be passed on to virus progeny in subsequently infected individuals.IntroductionMore than 52,600 complete and high coverage genomes are available on GISAID as of August 11.", [["the virus acquires genome mutations", "PROBLEM", 43, 78], ["genome mutations", "OBSERVATION", 62, 78], ["infected", "OBSERVATION_MODIFIER", 136, 144]]], ["Systematically tracking of mutations in SARS-CoV-2 genomes is therefore important as it allows monitoring of the molecular epidemiology of circulating viral sequences nationally and internationally.", [["SARS", "DISEASE", 40, 44], ["SARS-CoV-2", "ORGANISM", 40, 50], ["SARS-CoV-2 genomes", "DNA", 40, 58], ["SARS-CoV", "SPECIES", 40, 48], ["mutations in SARS", "PROBLEM", 27, 44]]], ["Here, we have investigated the nucleotide variation landscape of a large set of globally derived SARS-CoV-2 genomes and defined major mutation events.", [["nucleotide", "CHEMICAL", 31, 41], ["SARS-CoV-2 genomes", "DNA", 97, 115], ["SARS-CoV", "SPECIES", 97, 105], ["the nucleotide variation landscape", "PROBLEM", 27, 61], ["globally derived SARS", "PROBLEM", 80, 101], ["major mutation events", "PROBLEM", 128, 149], ["large", "OBSERVATION_MODIFIER", 67, 72], ["major mutation", "OBSERVATION", 128, 142]]], ["This analysis allowed us to produce a first-generation genetic classifier, or \u2018barcode\u2019, defining the major clades of the virus circulating up to May 28, 2020.", [["This analysis", "TEST", 0, 13], ["\u2018barcode\u2019", "TREATMENT", 78, 87], ["the virus", "PROBLEM", 118, 127], ["virus", "OBSERVATION", 122, 127]]], ["Notably, this barcode allowed reliable tracking of the spatial distribution and prevalence of these viral clades over time.", [["this barcode", "TEST", 9, 21], ["these viral clades", "PROBLEM", 94, 112], ["spatial", "OBSERVATION_MODIFIER", 55, 62], ["distribution", "OBSERVATION_MODIFIER", 63, 75], ["viral clades", "OBSERVATION", 100, 112]]], ["While most of the nonsynonymous mutation events appear neutral with respect to protein function and stability, we also found evidence of mutations in the spike protein that may modulate interactions between SARS-CoV-2 and the human host.Phylogenomic Analysis ::: Materials and Methods1,427 coronavirus genomes were downloaded from Virus Pathogen Database and Analysis Resource (ViPR)(Pickett et al. 2012) on February 14, 2020, including 329 SARS, 35 SARS-CoV-2, 61 HCoV-NL63, 521 MERS, 52 HCoV-HKU1, 170 HCoV-OC43, 97 bovine coronaviruses and 61 mouse hepatitis viruses.", [["SARS", "DISEASE", 441, 445], ["bovine coronaviruses", "DISEASE", 518, 538], ["hepatitis viruses", "DISEASE", 552, 569], ["SARS-CoV-2", "ORGANISM", 207, 217], ["human", "ORGANISM", 226, 231], ["coronavirus", "ORGANISM", 290, 301], ["HCoV-NL63", "CELL", 465, 474], ["MERS", "CANCER", 480, 484], ["HCoV-HKU1", "CELL", 489, 498], ["HCoV-OC43", "CELL", 504, 513], ["bovine", "ORGANISM", 518, 524], ["coronaviruses", "ORGANISM", 525, 538], ["mouse hepatitis viruses", "ORGANISM", 546, 569], ["spike protein", "PROTEIN", 154, 167], ["coronavirus genomes", "DNA", 290, 309], ["human", "SPECIES", 226, 231], ["bovine", "SPECIES", 518, 524], ["mouse", "SPECIES", 546, 551], ["human", "SPECIES", 226, 231], ["SARS-CoV", "SPECIES", 450, 458], ["HCoV-OC43", "SPECIES", 504, 513], ["bovine coronaviruses", "SPECIES", 518, 538], ["mouse", "SPECIES", 546, 551], ["the nonsynonymous mutation events", "PROBLEM", 14, 47], ["protein function", "TEST", 79, 95], ["mutations in the spike protein", "PROBLEM", 137, 167], ["SARS", "TEST", 207, 211], ["CoV", "TEST", 212, 215], ["Materials", "TREATMENT", 263, 272], ["Methods", "TREATMENT", 277, 284], ["coronavirus genomes", "PROBLEM", 290, 309], ["CoV", "TEST", 455, 458], ["HCoV", "TEST", 465, 469], ["MERS", "TEST", 480, 484], ["HCoV", "TEST", 489, 493], ["HKU1", "TEST", 494, 498], ["HCoV", "TEST", 504, 508], ["OC43", "TEST", 509, 513], ["bovine coronaviruses", "TEST", 518, 538], ["mouse hepatitis viruses", "PROBLEM", 546, 569], ["stability", "OBSERVATION_MODIFIER", 100, 109], ["mutations", "OBSERVATION", 137, 146], ["hepatitis viruses", "OBSERVATION", 552, 569]]], ["Sequence alignment was performed using MAFFT (version 7.407) (Katoh and Standley 2013) software and then trimmed by trimAL (version 1.4.1) (Capella-Guti\u00e9rrez et al. 2009).", [["Sequence alignment", "TEST", 0, 18]]], ["Phylogenetic analyses of the complete genomes were done with FastTree (version 2.1.10) (Price et al. 2009) software with default parameters, and iTOL (version 5) (Letunic and Bork 2007) was used for phylogenetic tree visualisation.Phylogenomic Analysis ::: Materials and Methods21,789 complete SARS-CoV2 genomes were downloaded from GISAID (Shu and McCauley 2017) (May 28, 2020).", [["SARS-CoV2 genomes", "DNA", 294, 311], ["Phylogenetic analyses", "TEST", 0, 21], ["default parameters", "TEST", 121, 139], ["phylogenetic tree visualisation", "PROBLEM", 199, 230], ["Phylogenomic Analysis", "TEST", 231, 252], ["Methods", "TEST", 271, 278], ["complete SARS", "PROBLEM", 285, 298], ["CoV2 genomes", "PROBLEM", 299, 311], ["tree visualisation", "OBSERVATION", 212, 230]]], ["Sequence alignment was performed with MAFFT (version 7.407) (Katoh and Standley 2013) and trimmed by trimAL (version 1.4.1) (Capella-Guti\u00e9rrez et al. 2009).", [["Sequence alignment", "TEST", 0, 18], ["Capella", "TEST", 125, 132]]], ["Phylogenetic analyses of the complete genomes were performed with RAxML (version 8.2.12) (Stamatakis 2014) with 10,000 bootstrap replicates, employing the GTRCAT model.", [["Phylogenetic analyses", "TEST", 0, 21], ["RAxML", "TEST", 66, 71], ["version", "TEST", 73, 80], ["the GTRCAT model", "TREATMENT", 151, 167]]], ["A random set of genomes from each defined subclade was used to generate a simplified phylogenetic tree using the same method. iTOL (version 5) (Letunic and Bork 2007) was used for the phylogenetic tree visualisation.", [["tree visualisation", "OBSERVATION", 197, 215]]], ["Single nucleotide polymorphisms (SNPs) from each of the genomes were called by Parsnp (version 1.2) from the Harvest suite (Treangen et al. 2014) using MN908947.3 as the reference genome, and the SNPs were further annotated by SnpEff (version 4.3 m) (Cingolani et al. 2012).", [["MN908947.3", "DNA", 152, 162], ["Single nucleotide polymorphisms (SNPs)", "TREATMENT", 0, 38], ["the SNPs", "TREATMENT", 192, 200]]], ["To compare the lineages recently defined by Rambaut and colleagues (Rambaut et al. 2020), Pangolin software (version 1.1.2) was applied to assign the assemblies belonging to each clade in our study.Sequencing-based multiplexed genotyping ::: Materials and MethodsSequencing-based multiplexed genotyping primers (Table 1) were designed and tested on SARS-CoV-2-positive RNA samples collected from nasopharyngeal swabs of critical patients in Sulaiman Alhabib Hospital from Riyadh, Saudi Arabia.", [["samples", "ANATOMY", 373, 380], ["nasopharyngeal swabs", "ANATOMY", 396, 416], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 349, 359], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 396, 416], ["patients", "ORGANISM", 429, 437], ["patients", "SPECIES", 429, 437], ["SARS-CoV", "SPECIES", 349, 357], ["our study", "TEST", 188, 197], ["MethodsSequencing", "TEST", 256, 273], ["multiplexed genotyping primers", "TEST", 280, 310], ["SARS", "TEST", 349, 353], ["CoV", "TEST", 354, 357], ["positive RNA samples", "PROBLEM", 360, 380], ["nasopharyngeal swabs", "TEST", 396, 416], ["nasopharyngeal", "ANATOMY", 396, 410]]], ["The swab was placed in 1 mL of TRIzol (Ambion, USA) and transported to King Abdullah University of Science and Technology (KAUST) for further downstream applications.", [["swab", "ANATOMY", 4, 8], ["The swab", "TREATMENT", 0, 8], ["TRIzol", "TREATMENT", 31, 37], ["further downstream applications", "TREATMENT", 134, 165]]], ["RNA was extracted using the Direct-zol RNA Miniprep kit (Zymo Research, USA) following the manufacturer\u2019s instructions.", [["Miniprep", "ORGANISM", 43, 51], ["RNA", "RNA", 0, 3], ["the Direct-zol RNA", "TREATMENT", 24, 42]]], ["RT-PCR was done using the one-step SuperScript III with Platinum Taq DNA Polymerase (Thermo Fisher, USA) on the 7900 H T Fast Real-Time PCR instrument (Applied Biosystems, USA).", [["DNA", "CELLULAR_COMPONENT", 69, 72], ["SuperScript III", "DNA", 35, 50], ["Platinum Taq DNA Polymerase", "DNA", 56, 83], ["RT-PCR", "TEST", 0, 6]]], ["We chose 24 SARS-CoV-2 positive samples and generated cDNA using the VILOTM SuperscriptTM III kit (ThermoFisher, USA) and amplicons encompassing clade-specific SNPs were produced with the Q5 Hot Start High-Fidelity Master Mix (NEB, USA).", [["samples", "ANATOMY", 32, 39], ["SARS-CoV-2 positive samples", "DNA", 12, 39], ["cDNA", "DNA", 54, 58], ["VILOTM SuperscriptTM III kit", "DNA", 69, 97], ["clade-specific SNPs", "DNA", 145, 164], ["SARS-CoV", "SPECIES", 12, 20], ["SARS", "TEST", 12, 16], ["CoV", "TEST", 17, 20], ["the VILOTM SuperscriptTM III kit (ThermoFisher, USA)", "TREATMENT", 65, 117], ["amplicons encompassing clade", "TREATMENT", 122, 150], ["specific SNPs", "TREATMENT", 151, 164]]], ["The thermocycling conditions employed in this study were as follows: 1 cycle of 98 \u00b0C for 30 sec followed by 35 cycles of 98 \u00b0C for 10 sec,64 \u00b0C for 30 sec and 72 \u00b0C for 30 sec, followed by the final extension at 72 \u00b0C for 2 min.", [["The thermocycling conditions", "TREATMENT", 0, 28], ["this study", "TEST", 41, 51]]], ["The PCR products were elecctrophoesed on a 2% (w/v) agarose gel.", [["agarose", "SIMPLE_CHEMICAL", 52, 59], ["The PCR products", "TREATMENT", 0, 16], ["a 2% (w/v) agarose gel", "TREATMENT", 41, 63]]], ["The Illumina library preparation was performed using the ARTIC V3 PCR tiling protocol (https://artic.network/ncov-2019) with 20% PhiX control and a loading concentration of 8 pmol.", [["The Illumina library preparation", "TREATMENT", 0, 32], ["the ARTIC V3 PCR tiling protocol", "TREATMENT", 53, 85], ["20% PhiX control", "TREATMENT", 125, 141], ["a loading concentration", "TREATMENT", 146, 169]]], ["The prepared library were sequenced using on a MiSeq platform using a 600 cycle V3 kit with paired-end sequencing.", [["a MiSeq platform", "TREATMENT", 45, 61], ["a 600 cycle V3 kit", "TREATMENT", 68, 86], ["paired-end sequencing", "TREATMENT", 92, 113]]], ["To facilities the virus clade typing from the data generated by MiSeq, a Python script was developed using the mapped. bam file as the input.", [["MiSeq", "PROTEIN", 64, 69], ["the virus clade typing", "TEST", 14, 36], ["a Python script", "TREATMENT", 71, 86]]], ["The barcode and clade information can be obtained using the script from the. vcf files generated by bcftools outputs (https://github.com/raeece/sarscov2barcode).Sequencing-based multiplexed genotyping ::: Materials and MethodsWe calculated the maximum throughput of samples for genotyping on the MiSeq run based on the following assumptions: (i) targeted sequencing depth of at least 100X, pair-end reads across 10 positions per sample except the position 28688 for which the targeted depth was 30X, (ii) MiSeq V3 kit generates 44-50 million reads and 70% of the total reads are higher than Q30 as specified by Illumina (https://www.illumina.com/systems/sequencing-platforms/miseq/specifications.html).Protein Structure Analysis ::: Materials and MethodsExperimentally determined protein structures were obtained from the Protein Data Bank (PDB).", [["samples", "ANATOMY", 266, 273], ["vcf", "PROTEIN", 77, 80], ["100X, pair-end reads", "RNA", 384, 404], ["position 28688", "DNA", 447, 461], ["Q30", "DNA", 591, 594], ["vcf files", "TEST", 77, 86], ["MethodsWe", "TREATMENT", 219, 228], ["the MiSeq run", "TREATMENT", 292, 305], ["MiSeq V3 kit", "TEST", 505, 517], ["the total reads", "TEST", 559, 574], ["Protein", "TEST", 702, 709]]], ["SwissModel (Arnold et al. 2006), I-Tasser (Yang et al. 2014), RaptorX (K\u00e4llberg et al. 2014) and an in-house modelling pipeline was used to produce protein structure homology models.", [["an in-house modelling pipeline", "TREATMENT", 97, 127]]], ["Phobius (K\u00e4ll et al. 2007) was used for prediction of trans-membrane regions.", [["membrane", "ANATOMY", 60, 68], ["trans-membrane regions", "PROTEIN", 54, 76], ["trans-membrane regions", "TREATMENT", 54, 76], ["membrane", "ANATOMY_MODIFIER", 60, 68]]], ["RaptorX was also used for predicting secondary structure, protein disorder and solvent exposure of amino acids.", [["disorder", "DISEASE", 66, 74], ["amino acids", "CHEMICAL", 99, 110], ["amino acids", "CHEMICAL", 99, 110], ["amino acids", "AMINO_ACID", 99, 110], ["RaptorX", "PROTEIN", 0, 7], ["RaptorX", "TREATMENT", 0, 7], ["secondary structure", "PROBLEM", 37, 56], ["protein disorder", "PROBLEM", 58, 74], ["amino acids", "TREATMENT", 99, 110], ["secondary structure", "OBSERVATION", 37, 56], ["protein disorder", "OBSERVATION", 58, 74]]], ["Pymol (version 1.8.6.2) was used for visualisation.Five clades of SARS-CoV-2 are characterised by 11 major mutations across the globe ::: ResultsThe SARS-CoV-2 genome is genetically most closely related to horseshoe bat SARS-related coronaviruses (Lu et al., 2020, Zhu et al., 2019) (SARSr-CoV), 96% to RaTG13, 93% to RmYN02(Zhou et al. 2020) and 88% to bat-SL-CoVZC45 and bat-SL-CoVZXC21 and also to SARSr-CoVs from pangolins (Tang et al. 2020) (Fig. S1).", [["Pymol", "CHEMICAL", 0, 5], ["SARS", "DISEASE", 66, 70], ["SARS", "DISEASE", 220, 224], ["Pymol", "CHEMICAL", 0, 5], ["SARS-CoV-2", "ORGANISM", 66, 76], ["SARS-CoV-2", "ORGANISM", 149, 159], ["horseshoe bat", "ORGANISM", 206, 219], ["coronaviruses", "ORGANISM", 233, 246], ["SARSr-CoV", "ORGANISM", 284, 293], ["SL-CoVZC45", "GENE_OR_GENE_PRODUCT", 358, 368], ["bat-SL-CoVZXC21", "GENE_OR_GENE_PRODUCT", 373, 388], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 401, 411], ["SARS-CoV-2 genome", "DNA", 149, 166], ["bat-SL-CoVZC45 and bat-SL-CoVZXC21", "DNA", 354, 388], ["SARSr", "DNA", 401, 406], ["CoVs", "DNA", 407, 411], ["SARS-CoV", "SPECIES", 66, 74], ["SARS-CoV", "SPECIES", 66, 74], ["SARS-CoV", "SPECIES", 149, 157], ["SARSr-CoV", "SPECIES", 284, 293], ["Pymol (version", "TREATMENT", 0, 14], ["visualisation", "TEST", 37, 50], ["SARS", "TEST", 66, 70], ["CoV", "TEST", 71, 74], ["The SARS", "TEST", 145, 153], ["CoV", "TEST", 154, 157], ["horseshoe bat SARS", "PROBLEM", 206, 224], ["SARSr", "TEST", 284, 289], ["RaTG13", "TEST", 303, 309], ["bat", "TEST", 354, 357], ["SL", "TEST", 358, 360], ["CoVZC45", "TEST", 361, 368], ["bat", "TEST", 373, 376], ["CoVZXC21", "TREATMENT", 380, 388], ["SARSr", "TEST", 401, 406], ["CoVs", "PROBLEM", 407, 411], ["SARS", "OBSERVATION", 66, 70], ["globe", "ANATOMY", 128, 133], ["bat", "ANATOMY", 373, 376], ["CoVs", "ANATOMY", 407, 411], ["S1", "ANATOMY", 452, 454]]], ["We studied their chronological occurrences of SARS-CoV-2 genomes during the early stages of the pandemic and global spread of the SARS-CoV-2 across human populations, which allowed us to define several clades of the virus that share unique SNPs.", [["SARS", "DISEASE", 46, 50], ["SARS", "DISEASE", 130, 134], ["SARS-CoV-2", "ORGANISM", 46, 56], ["SARS-CoV-2", "ORGANISM", 130, 140], ["human", "ORGANISM", 148, 153], ["SARS-CoV-2 genomes", "DNA", 46, 64], ["human", "SPECIES", 148, 153], ["SARS-CoV", "SPECIES", 46, 54], ["SARS-CoV", "SPECIES", 130, 138], ["human", "SPECIES", 148, 153], ["SARS", "PROBLEM", 46, 50], ["CoV-2 genomes", "PROBLEM", 51, 64], ["the pandemic", "PROBLEM", 92, 104], ["the SARS", "PROBLEM", 126, 134], ["CoV", "TEST", 135, 138], ["the virus", "PROBLEM", 212, 221], ["global", "OBSERVATION_MODIFIER", 109, 115], ["spread", "OBSERVATION_MODIFIER", 116, 122]]], ["The clades were named by the respective amino acid mutations: S84 (Orf8, L84S), V251 (Orf3a, G251V), I378 (Orf1ab, V378I), D392 (Orf1ab, G392D) and G614 (S, D614G).", [["amino acid", "CHEMICAL", 40, 50], ["amino acid", "CHEMICAL", 40, 50], ["amino acid", "AMINO_ACID", 40, 50], ["the respective amino acid mutations", "TEST", 25, 60], ["L84S", "TEST", 73, 77], ["Orf3a", "TEST", 86, 91], ["Orf1ab", "TEST", 107, 113], ["D392", "TEST", 123, 127], ["Orf1ab", "TEST", 129, 135]]], ["A collapsed simplified phylogenetic tree to illustrate the correspondence of the subclades is shown in Fig.1B along with the clade-defining mutations (Fig.1C).", [["A collapsed simplified phylogenetic tree", "PROBLEM", 0, 40], ["collapsed", "OBSERVATION", 2, 11], ["phylogenetic tree", "OBSERVATION", 23, 40], ["subclades", "OBSERVATION_MODIFIER", 81, 90]]], ["Recent work has defined (Rambaut et al. 2020) 2 viral lineages - A and B (analogous to clades L and S described in (Tang et al. 2020)).", [["viral lineages", "TEST", 48, 62]]], ["The major clades proposed here correspond to lineage A (Clade S84), lineage B.2, B.7 and B.10 (Clade V251), lineage B.1 (Clade G614), lineage B.4 (Clade I378), B.3 (Clade D392) (Fig.1D).", [["Clade S84", "CELL", 56, 65], ["lineage B.2", "CELL", 68, 79]]], ["Due to intrinsic virus mutation rates, further refinements in nomenclature will likely need be defined in the future; however, a robust, high throughput barcoding scheme will be required to breach the surveillance gap and lag time between molecular diagnostics and full-genome sequencing to provide actionable genetic surveillance data.Five clades of SARS-CoV-2 are characterised by 11 major mutations across the globe ::: ResultsTo obtain a global picture of the regional distribution of the clades over time during 6 month period (December 24, 2019 to June 30, 2020), we plotted the relative proportions of the major clades and their cumulative trends (Fig.2).", [["SARS", "DISEASE", 351, 355], ["SARS-CoV-2", "ORGANISM", 351, 361], ["SARS-CoV", "SPECIES", 351, 359], ["intrinsic virus mutation rates", "PROBLEM", 7, 37], ["the surveillance gap", "TEST", 197, 217], ["molecular diagnostics", "TEST", 239, 260], ["actionable genetic surveillance data", "TEST", 299, 335], ["SARS", "PROBLEM", 351, 355], ["CoV", "TEST", 356, 359], ["virus", "OBSERVATION", 17, 22], ["SARS", "OBSERVATION", 351, 355], ["globe", "ANATOMY", 413, 418], ["regional", "OBSERVATION_MODIFIER", 464, 472], ["distribution", "OBSERVATION_MODIFIER", 473, 485]]], ["We observed major differences in the apparent spread for individual clades: Clade G614 represents 71.14% of all the sequenced viral sequences, followed by S84 (10.85%), V251 (7.66%), D392 (1.03%) and I378 (1.70%).", [["sequenced viral sequences", "DNA", 116, 141], ["D392", "TEST", 183, 187]]], ["Clade G614 is widely distributed globally; whereas Clade S84 represents 17% of North American sampled genomes, and 16% of those from Oceania.", [["widely", "OBSERVATION_MODIFIER", 14, 20], ["distributed", "OBSERVATION_MODIFIER", 21, 32], ["globally", "OBSERVATION_MODIFIER", 33, 41]]], ["Asia has the greatest number of unassigned genomes (36%).", [["greatest", "OBSERVATION_MODIFIER", 13, 21], ["unassigned genomes", "OBSERVATION", 32, 50]]], ["The global and regional cumulative trends were plotted over time, with the majority of the trends revealing the increasing dominance of one or two clades in each geographic region in the sampled genomes (Fig.2).", [["global", "OBSERVATION_MODIFIER", 4, 10], ["regional", "OBSERVATION_MODIFIER", 15, 23], ["cumulative", "OBSERVATION_MODIFIER", 24, 34], ["increasing", "OBSERVATION_MODIFIER", 112, 122], ["dominance", "OBSERVATION", 123, 132], ["clades", "OBSERVATION_MODIFIER", 147, 153], ["geographic", "OBSERVATION_MODIFIER", 162, 172], ["sampled genomes", "OBSERVATION", 187, 202]]], ["This is likely attributable to founder effects during the early phases of the seeding of the local epidemics from imported cases and subsequent dissemination in the regions.Newly sequenced SARS-CoV-2 genomes could be assigned to clades using a rapid NGS-based genotyping protocol ::: ResultsWe have validated a set of oligonucleotide primers (Fig.S3) that can be utilised for rapid NGS sequencing-based genotyping of the major clades of SARS-CoV-2 using an Illumina MiSeq 600 V3 kit (Fig.3A).", [["SARS", "DISEASE", 437, 441], ["SARS-CoV-2", "ORGANISM", 189, 199], ["SARS-CoV-2", "ORGANISM", 437, 447], ["SARS-CoV-2 genomes", "DNA", 189, 207], ["SARS-CoV", "SPECIES", 189, 197], ["SARS-CoV", "SPECIES", 437, 445], ["subsequent dissemination in the regions", "PROBLEM", 133, 172], ["Newly sequenced SARS", "PROBLEM", 173, 193], ["a rapid NGS", "TEST", 242, 253], ["oligonucleotide primers", "TREATMENT", 318, 341], ["rapid NGS sequencing", "TEST", 376, 396], ["SARS", "PROBLEM", 437, 441], ["CoV", "TEST", 442, 445], ["an Illumina MiSeq", "TREATMENT", 454, 471], ["likely attributable to", "UNCERTAINTY", 8, 30], ["founder effects", "OBSERVATION", 31, 46], ["regions", "ANATOMY_MODIFIER", 165, 172]]], ["We have tested this protocol on 24 RNA samples from COVID-19 patients, and generated the barcode information from the publicly accessible Python script (https://github.com/raeece/sarscov2barcode).", [["samples", "ANATOMY", 39, 46], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["this protocol", "TEST", 15, 28]]], ["The sequencing results show a high coverage of reads in the amplified regions across all 24 samples except for the position 28688, which accompany a G1397A mutation (Fig.3B).", [["samples", "ANATOMY", 92, 99], ["G1397A", "GENE_OR_GENE_PRODUCT", 149, 155], ["amplified regions", "DNA", 60, 77], ["The sequencing", "TEST", 0, 14], ["high", "OBSERVATION_MODIFIER", 30, 34]]], ["We observed the C241 T, C3037 T, C14408 T and G23403A substitutions in all 24 tested samples, indicating that they all belong to Clade G614.Newly sequenced SARS-CoV-2 genomes could be assigned to clades using a rapid NGS-based genotyping protocol ::: ResultsBased on our calculation, roughly 78 K reads are needed for a given sample to obtain >800X genome coverage in 10 clade-defining sites (Table S1) except position 28688 (30X coverage).", [["samples", "ANATOMY", 85, 92], ["C241 T", "GENE_OR_GENE_PRODUCT", 16, 22], ["C3037 T", "GENE_OR_GENE_PRODUCT", 24, 31], ["C14408 T", "GENE_OR_GENE_PRODUCT", 33, 41], ["G23403A", "AMINO_ACID", 46, 53], ["SARS-CoV-2", "ORGANISM", 156, 166], ["Clade G614", "PROTEIN", 129, 139], ["SARS-CoV-2 genomes", "DNA", 156, 174], ["800X genome", "DNA", 344, 355], ["position 28688", "DNA", 410, 424], ["SARS-CoV", "SPECIES", 156, 164], ["Newly sequenced SARS", "PROBLEM", 140, 160], ["a rapid NGS", "TEST", 209, 220], ["our calculation", "TEST", 267, 282], ["K reads", "TEST", 295, 302], ["800X genome coverage", "TREATMENT", 344, 364]]], ["Based on the commercially-available multiplexing solutions available for Illumina library preparations, up to 384 samples can be processed with a MiSeq V3 600 Cycles kit in a single run to obtain reliable genotype information on the major clades.", [["samples", "ANATOMY", 114, 121], ["Illumina library preparations", "TREATMENT", 73, 102], ["a MiSeq V3 600 Cycles kit", "TREATMENT", 144, 169]]], ["A higher number of samples could be genotyped with higher levels of multiplexing with custom-made index sequences for significant cost reduction in the future.Newly sequenced SARS-CoV-2 genomes could be assigned to clades using a rapid NGS-based genotyping protocol ::: ResultsThe robustness of our 11-site genomic barcoding method was verified by assigning \u223c93.68% of the 79,486 SARS-CoV-2 genomes that became available in GISAID until August 3, 2020 to one of the 5 major clades.", [["samples", "ANATOMY", 19, 26], ["samples", "CANCER", 19, 26], ["SARS-CoV-2", "ORGANISM", 175, 185], ["SARS-CoV-2 genomes", "DNA", 175, 193], ["79,486 SARS-CoV-2 genomes", "DNA", 373, 398], ["SARS-CoV", "SPECIES", 175, 183], ["index sequences", "TREATMENT", 98, 113], ["significant cost reduction", "TREATMENT", 118, 144], ["Newly sequenced SARS", "PROBLEM", 159, 179], ["a rapid NGS", "TEST", 228, 239], ["CoV", "TEST", 385, 388], ["higher", "OBSERVATION_MODIFIER", 2, 8], ["significant", "OBSERVATION_MODIFIER", 118, 129], ["cost", "OBSERVATION", 130, 134]]], ["This barcode represents a snapshot of the early phases of the genetic diversity of the virus during the first 6 months of its global spread and is expected to change over time, however, a barcoding strategy to monitor the progress of virus elimination after vaccines become widely available will be strategically useful to monitor decreases in viral genetic diversity over time.", [["the virus", "PROBLEM", 83, 92], ["a barcoding strategy", "TREATMENT", 186, 206], ["virus elimination", "TREATMENT", 234, 251], ["vaccines", "TREATMENT", 258, 266], ["early", "OBSERVATION_MODIFIER", 42, 47], ["phases", "OBSERVATION_MODIFIER", 48, 54], ["virus", "OBSERVATION", 87, 92], ["global", "OBSERVATION_MODIFIER", 126, 132], ["spread", "OBSERVATION", 133, 139], ["viral genetic diversity", "OBSERVATION", 344, 367]]], ["In addition, our barcode could serve as a reference for setting the baseline for global genomic diversity analysis at the beginning of the pandemic.Mutations are not equally distributed across the SARS-CoV-2 genome ::: ResultsBased on our analysis, we observed that the genes Orf3a, Orf6, Orf7, Orf8, N and Orf10 accumulated markedly more mutations than expected solely by random drift (Fig.S4) (e.g., Real/Expected ratio: N: 1.43; ORF3a: 1.52; E:1.17).", [["SARS", "DISEASE", 197, 201], ["Orf3a", "GENE_OR_GENE_PRODUCT", 276, 281], ["Orf6", "GENE_OR_GENE_PRODUCT", 283, 287], ["Orf7", "GENE_OR_GENE_PRODUCT", 289, 293], ["Orf8", "GENE_OR_GENE_PRODUCT", 295, 299], ["N", "GENE_OR_GENE_PRODUCT", 301, 302], ["Orf10", "GENE_OR_GENE_PRODUCT", 307, 312], ["SARS-CoV-2 genome", "DNA", 197, 214], ["Orf3a", "DNA", 276, 281], ["Orf6", "DNA", 283, 287], ["Orf7", "DNA", 289, 293], ["Orf8", "DNA", 295, 299], ["N", "DNA", 301, 302], ["Orf10", "DNA", 307, 312], ["SARS-CoV", "SPECIES", 197, 205], ["global genomic diversity analysis", "PROBLEM", 81, 114], ["the pandemic", "PROBLEM", 135, 147], ["Mutations", "PROBLEM", 148, 157], ["our analysis", "TEST", 235, 247], ["Orf8", "TEST", 295, 299], ["markedly more mutations", "PROBLEM", 325, 348], ["ORF3a", "TEST", 432, 437]]], ["This mutation rate may indicate adaptation to the human host following recent spill over from an, as yet, unknown animal reservoir.", [["human", "ORGANISM", 50, 55], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["This mutation rate", "TEST", 0, 18], ["spill", "OBSERVATION", 78, 83]]], ["Conversely, several nonstructural proteins showed a lower-than-expected mutation rate (e.g., Real/Expected ratio: nsp5: 0.81; nsp10: 0.74).", [["nonstructural proteins", "PROTEIN", 20, 42], ["several nonstructural proteins", "TEST", 12, 42], ["mutation rate", "TEST", 72, 85], ["nsp5", "TEST", 114, 118], ["nsp10", "TEST", 126, 131]]], ["These proteins are predicted to be involved in evading host immune defenses, in enhancing viral expression and in cleavage of the replicase polyprotein, based on prior studies of related betacoronaviruses (B\u00e1ez-Santos et al., 2015, Posthuma et al., 2017).", [["replicase polyprotein", "PROTEIN", 130, 151], ["enhancing viral expression", "PROBLEM", 80, 106], ["the replicase polyprotein", "PROBLEM", 126, 151], ["prior studies", "TEST", 162, 175], ["enhancing", "OBSERVATION_MODIFIER", 80, 89], ["viral expression", "OBSERVATION", 90, 106], ["replicase polyprotein", "OBSERVATION", 130, 151]]], ["Hence, this lower mutation rate may indicate purifying selection to maintain these functions essential for efficient immune evasion and subsequent viral dissemination.", [["this lower mutation rate", "PROBLEM", 7, 31], ["purifying selection", "TREATMENT", 45, 64], ["efficient immune evasion", "TREATMENT", 107, 131], ["subsequent viral dissemination", "PROBLEM", 136, 166], ["viral dissemination", "OBSERVATION", 147, 166]]], ["Indeed, structural proteins in coronaviruses undergo a greater degree of antigenic variation which increases the fitness of the virus by means of adaptation to the host and by facilitating immune escape (Walls et al. 2020).Mutations are not equally distributed across the SARS-CoV-2 genome ::: ResultsStructural protein modeling confirmed that most of the nonsynonymous mutations in the nonstructural proteins were neutral (Figs.S5-S11).", [["SARS", "DISEASE", 272, 276], ["coronaviruses", "ORGANISM", 31, 44], ["S5-S11", "GENE_OR_GENE_PRODUCT", 429, 435], ["structural proteins", "PROTEIN", 8, 27], ["SARS-CoV-2 genome", "DNA", 272, 289], ["nonstructural proteins", "PROTEIN", 387, 409], ["S5", "PROTEIN", 429, 431], ["S11", "PROTEIN", 432, 435], ["SARS-CoV", "SPECIES", 272, 280], ["structural proteins in coronaviruses", "PROBLEM", 8, 44], ["antigenic variation", "PROBLEM", 73, 92], ["the virus", "PROBLEM", 124, 133], ["Mutations", "PROBLEM", 223, 232], ["ResultsStructural protein modeling", "TEST", 294, 328], ["the nonsynonymous mutations", "PROBLEM", 352, 379], ["greater degree", "OBSERVATION_MODIFIER", 55, 69], ["antigenic variation", "OBSERVATION", 73, 92], ["nonsynonymous mutations", "OBSERVATION", 356, 379]]], ["Conversely, several nonsynonymous mutations in the spike protein might have functional consequences: notably, the G614 clade\u2013defining mutation D614 G is located in subdomain 1 (SD1; Fig.4, Fig.S5).", [["D614 G", "GENE_OR_GENE_PRODUCT", 143, 149], ["S5", "GENE_OR_GENE_PRODUCT", 193, 195], ["spike protein", "PROTEIN", 51, 64], ["G614", "PROTEIN", 114, 118], ["D614 G", "PROTEIN", 143, 149], ["subdomain 1", "PROTEIN", 164, 175], ["SD1", "PROTEIN", 177, 180], ["S5", "PROTEIN", 193, 195], ["several nonsynonymous mutations", "PROBLEM", 12, 43], ["the spike protein", "PROBLEM", 47, 64], ["nonsynonymous mutations", "OBSERVATION", 20, 43]]], ["In the trimeric S, D614 engages stabilising interactions within SD1 (R646 or the backbone of F592, depending on the chain) and with the S1 of the adjacent chain (T859 and K854).", [["D614", "CHEMICAL", 19, 23], ["trimeric S", "PROTEIN", 7, 17], ["D614", "PROTEIN", 19, 23], ["SD1", "PROTEIN", 64, 67], ["R646", "PROTEIN", 69, 73], ["F592", "PROTEIN", 93, 97], ["S1", "PROTEIN", 136, 138], ["adjacent chain", "PROTEIN", 146, 160], ["T859", "PROTEIN", 162, 166], ["K854", "PROTEIN", 171, 175], ["S1", "ANATOMY_MODIFIER", 136, 138], ["chain", "ANATOMY_MODIFIER", 155, 160]]], ["Replacement of D614 with a glycine would entail losing these stabilising electrostatic interactions and increase the dynamics in this region.", [["D614", "CHEMICAL", 15, 19], ["glycine", "CHEMICAL", 27, 34], ["D614", "CHEMICAL", 15, 19], ["glycine", "CHEMICAL", 27, 34], ["D614", "SIMPLE_CHEMICAL", 15, 19], ["glycine", "SIMPLE_CHEMICAL", 27, 34], ["Replacement of D614", "TREATMENT", 0, 19], ["a glycine", "TREATMENT", 25, 34], ["these stabilising electrostatic interactions", "TREATMENT", 55, 99]]], ["Recent studies have shown D614 G disrupts a critical interprotomer contact and that this dramatically shifts the S proteintrimer conformation toward an ACE2-binding and fusion-competent state (Pascal et al. 2020).", [["D614 G", "CHEMICAL", 26, 32], ["D614 G", "GENE_OR_GENE_PRODUCT", 26, 32], ["ACE2", "GENE_OR_GENE_PRODUCT", 152, 156], ["D614 G", "PROTEIN", 26, 32], ["ACE2", "PROTEIN", 152, 156], ["Recent studies", "TEST", 0, 14]]], ["Hospitalised patients with G614 had higher viral titres in upper respiratory tract specimens but no discernible differences in disease outcome (Korber et al., 2020).", [["upper respiratory tract specimens", "ANATOMY", 59, 92], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["higher viral titres in upper respiratory tract specimens", "PROBLEM", 36, 92], ["discernible differences in disease outcome", "PROBLEM", 100, 142], ["viral titres", "OBSERVATION", 43, 55], ["upper", "ANATOMY_MODIFIER", 59, 64], ["respiratory tract", "ANATOMY", 65, 82], ["no", "UNCERTAINTY", 97, 99]]], ["Notably, V483A, V367 F and G476S are localised in the receptor-binding domain (RBD) of the spike protein which mediates binding to the host receptor angiotensin-converting enzyme 2 (ACE2) (Fig. 4) (Hoffmann et al. 2020).", [["angiotensin", "CHEMICAL", 149, 160], ["V367 F", "GENE_OR_GENE_PRODUCT", 16, 22], ["G476S", "GENE_OR_GENE_PRODUCT", 27, 32], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 149, 180], ["ACE2", "GENE_OR_GENE_PRODUCT", 182, 186], ["receptor-binding domain", "PROTEIN", 54, 77], ["RBD", "PROTEIN", 79, 82], ["spike protein", "PROTEIN", 91, 104], ["host receptor angiotensin-converting enzyme 2", "PROTEIN", 135, 180], ["ACE2", "PROTEIN", 182, 186], ["G476S", "PROBLEM", 27, 32], ["the spike protein", "PROBLEM", 87, 104], ["angiotensin", "TEST", 149, 160], ["converting enzyme", "TEST", 161, 178]]], ["All of the viral genomes harbouring V483A and G476S mutations belong to Clade S84.", [["V483A", "GENE_OR_GENE_PRODUCT", 36, 41], ["G476S", "GENE_OR_GENE_PRODUCT", 46, 51], ["viral genomes", "DNA", 11, 24], ["Clade S84", "DNA", 72, 81], ["viral genomes", "OBSERVATION", 11, 24]]], ["Interestingly, the V367 F mutation has appeared independently in Clade V251 and Clade S84, suggesting that this mutation is under positive selection and contributes to viral fitness.Mutations are not equally distributed across the SARS-CoV-2 genome ::: ResultsWe found the V483A substitution has an equivalent amino acid substitution located in a similar position within the RBD in the MERS-CoV spike protein which reduces its binding to its cognate receptor DPP4/CD26 (Kleine-Weber et al. 2018).", [["SARS", "DISEASE", 231, 235], ["amino acid", "CHEMICAL", 310, 320], ["amino acid", "CHEMICAL", 310, 320], ["V367 F", "GENE_OR_GENE_PRODUCT", 19, 25], ["Clade S84", "GENE_OR_GENE_PRODUCT", 80, 89], ["V483A", "GENE_OR_GENE_PRODUCT", 273, 278], ["amino acid", "AMINO_ACID", 310, 320], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 386, 394], ["DPP4", "GENE_OR_GENE_PRODUCT", 459, 463], ["CD26", "GENE_OR_GENE_PRODUCT", 464, 468], ["Clade V251", "DNA", 65, 75], ["SARS-CoV-2 genome", "DNA", 231, 248], ["RBD", "PROTEIN", 375, 378], ["MERS-CoV spike protein", "PROTEIN", 386, 408], ["DPP4", "PROTEIN", 459, 463], ["CD26", "PROTEIN", 464, 468], ["SARS-CoV", "SPECIES", 231, 239], ["this mutation", "PROBLEM", 107, 120], ["viral fitness", "PROBLEM", 168, 181], ["Mutations", "PROBLEM", 182, 191], ["the V483A substitution", "PROBLEM", 269, 291], ["an equivalent amino acid substitution", "TREATMENT", 296, 333], ["the RBD", "PROBLEM", 371, 378], ["CoV spike protein", "PROBLEM", 391, 408], ["viral fitness", "OBSERVATION", 168, 181], ["amino acid substitution", "OBSERVATION", 310, 333], ["similar", "OBSERVATION_MODIFIER", 347, 354], ["position", "OBSERVATION_MODIFIER", 355, 363], ["RBD", "OBSERVATION", 375, 378], ["CoV spike", "OBSERVATION", 391, 400]]], ["However, V483 is more than 10 \u00c5 away from ACE2 and could affect receptor binding by SARS-CoV-2 only indirectly by altering the structural dynamics of the RBD loop it is a part of.", [["ACE2", "GENE_OR_GENE_PRODUCT", 42, 46], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 84, 94], ["V483", "PROTEIN", 9, 13], ["ACE2", "PROTEIN", 42, 46], ["RBD loop", "PROTEIN", 154, 162], ["ACE2", "TEST", 42, 46], ["receptor binding", "PROBLEM", 64, 80], ["CoV", "TEST", 89, 92], ["the RBD loop", "PROBLEM", 150, 162], ["RBD loop", "OBSERVATION", 154, 162]]], ["The V367 F mutation is located an even greater distance from ACE2 (Fig.4, Fig.S5).", [["V367 F", "GENE_OR_GENE_PRODUCT", 4, 10], ["ACE2", "GENE_OR_GENE_PRODUCT", 61, 65], ["S5", "GENE_OR_GENE_PRODUCT", 78, 80], ["V367 F mutation", "DNA", 4, 19], ["ACE2", "PROTEIN", 61, 65], ["Fig.4", "PROTEIN", 67, 72], ["S5", "PROTEIN", 78, 80], ["greater", "OBSERVATION_MODIFIER", 39, 46]]], ["The exchange of the small hydrophobic residue valine with a bulky hydrophobic phenylalanine might influence the efficiency of glycosylation of the nearby N343, or the positioning of the sugars.", [["valine", "CHEMICAL", 46, 52], ["phenylalanine", "CHEMICAL", 78, 91], ["valine", "CHEMICAL", 46, 52], ["phenylalanine", "CHEMICAL", 78, 91], ["sugars", "CHEMICAL", 186, 192], ["valine", "AMINO_ACID", 46, 52], ["phenylalanine", "AMINO_ACID", 78, 91], ["N343", "SIMPLE_CHEMICAL", 154, 158], ["sugars", "SIMPLE_CHEMICAL", 186, 192], ["the small hydrophobic residue valine", "TREATMENT", 16, 52], ["a bulky hydrophobic phenylalanine", "TREATMENT", 58, 91], ["glycosylation", "TREATMENT", 126, 139], ["the sugars", "TEST", 182, 192], ["small", "OBSERVATION_MODIFIER", 20, 25], ["hydrophobic residue valine", "OBSERVATION", 26, 52]]], ["The substitution G476S would lead to possible clashes with predicted interacting ACE2 residues and with the RBD residue N487.", [["G476S", "CHEMICAL", 17, 22], ["ACE2", "GENE_OR_GENE_PRODUCT", 81, 85], ["ACE2 residues", "PROTEIN", 81, 94], ["RBD residue N487", "PROTEIN", 108, 124], ["The substitution G476S", "TREATMENT", 0, 22], ["clashes with predicted interacting ACE2 residues", "PROBLEM", 46, 94], ["the RBD residue", "PROBLEM", 104, 119]]], ["However, minor reorientation of the side chains might allow an additional hydrogen bond to be formed between S476 and ACE2 Q24 and E23, thus enhancing the affinity to ACE2 (Fig.S5).", [["hydrogen", "CHEMICAL", 74, 82], ["S476", "CHEMICAL", 109, 113], ["S476", "SIMPLE_CHEMICAL", 109, 113], ["ACE2", "GENE_OR_GENE_PRODUCT", 118, 122], ["E23", "SIMPLE_CHEMICAL", 131, 134], ["ACE2", "GENE_OR_GENE_PRODUCT", 167, 171], ["S5", "GENE_OR_GENE_PRODUCT", 177, 179], ["ACE2", "PROTEIN", 118, 122], ["E23", "PROTEIN", 131, 134], ["ACE2", "PROTEIN", 167, 171], ["S5", "PROTEIN", 177, 179], ["minor reorientation of the side chains", "PROBLEM", 9, 47], ["an additional hydrogen bond", "TREATMENT", 60, 87]]], ["An equivalent amino acid substitution located in an analogous position within the RBD in the SARS-CoV spike protein was associated with neutralisation escape from monoclonal antibodies, together with other mutations observed previously (Rockx et al. 2010).", [["amino acid", "CHEMICAL", 14, 24], ["SARS", "DISEASE", 93, 97], ["amino acid", "CHEMICAL", 14, 24], ["amino acid", "AMINO_ACID", 14, 24], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 93, 101], ["RBD", "PROTEIN", 82, 85], ["SARS-CoV spike protein", "PROTEIN", 93, 115], ["monoclonal antibodies", "PROTEIN", 163, 184], ["SARS-CoV", "SPECIES", 93, 101], ["An equivalent amino acid substitution", "TREATMENT", 0, 37], ["the RBD", "PROBLEM", 78, 85], ["the SARS", "PROBLEM", 89, 97], ["CoV spike protein", "PROBLEM", 98, 115], ["neutralisation escape", "PROBLEM", 136, 157], ["monoclonal antibodies", "PROBLEM", 163, 184], ["other mutations", "PROBLEM", 200, 215], ["amino", "OBSERVATION", 14, 19], ["acid substitution", "OBSERVATION", 20, 37], ["analogous position", "OBSERVATION", 52, 70], ["RBD", "OBSERVATION", 82, 85], ["CoV spike", "OBSERVATION", 98, 107], ["associated with", "UNCERTAINTY", 120, 135], ["neutralisation escape", "OBSERVATION", 136, 157], ["monoclonal antibodies", "OBSERVATION", 163, 184]]], ["Given that V483A and V367 F are solvent exposed and markedly alter the surface characteristics of the RBD, they might also facilitate antibody escape.", [["surface", "ANATOMY", 71, 78], ["V367 F", "GENE_OR_GENE_PRODUCT", 21, 27], ["RBD", "PROTEIN", 102, 105], ["the RBD", "PROBLEM", 98, 105], ["antibody escape", "PROBLEM", 134, 149], ["RBD", "OBSERVATION", 102, 105], ["antibody escape", "OBSERVATION", 134, 149]]], ["Indeed, V483A mutation was shown to give a selective advantage to the virus by escaping several neutralising antibodies (Li et al. 2020).", [["V483A", "GENE_OR_GENE_PRODUCT", 8, 13], ["V483A", "PROTEIN", 8, 13], ["neutralising antibodies", "PROTEIN", 96, 119], ["the virus", "PROBLEM", 66, 75]]], ["Escape mutations in the RBD of the SARS-CoV S protein (T332I, F460C and L443R) were identified previously (Rockx et al. 2010).", [["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 35, 45], ["RBD", "PROTEIN", 24, 27], ["SARS-CoV S protein", "PROTEIN", 35, 53], ["T332I", "PROTEIN", 55, 60], ["F460C", "PROTEIN", 62, 67], ["L443R", "PROTEIN", 72, 77], ["SARS-CoV", "SPECIES", 35, 43], ["Escape mutations", "PROBLEM", 0, 16], ["the SARS", "TEST", 31, 39], ["CoV S protein", "TEST", 40, 53], ["T332I", "TEST", 55, 60]]], ["These mutations negatively impact viral fitness through reducing the affinity to the host receptor (Tang et al. 2014).", [["These mutations", "PROBLEM", 0, 15], ["viral fitness", "OBSERVATION", 34, 47]]], ["The nonsynonymous mutations in the N protein, which have key roles in viral assembly, might also have functional implications.", [["N protein", "PROTEIN", 35, 44], ["The nonsynonymous mutations", "PROBLEM", 0, 27], ["nonsynonymous mutations", "OBSERVATION", 4, 27]]], ["The hotspot mutations S202 N, R203 K and G204R all cluster in a linker region where they might potentially enhance RNA binding and alter the response to serine phosphorylation events (Fig.S5).", [["serine", "CHEMICAL", 153, 159], ["serine", "AMINO_ACID", 153, 159], ["S5", "GENE_OR_GENE_PRODUCT", 188, 190], ["linker region", "DNA", 64, 77], ["S5", "PROTEIN", 188, 190], ["The hotspot mutations", "TEST", 0, 21], ["a linker region", "TREATMENT", 62, 77], ["RNA binding", "PROBLEM", 115, 126], ["serine phosphorylation events", "PROBLEM", 153, 182]]], ["The clade I378\u2013defining mutation (T28688C) in the nucleocapsid protein, which has key roles in viral assembly, is synonymous.", [["I378", "GENE_OR_GENE_PRODUCT", 10, 14], ["nucleocapsid protein", "PROTEIN", 50, 70], ["the nucleocapsid protein", "TEST", 46, 70], ["viral assembly", "OBSERVATION", 95, 109]]], ["However, we observed nonsynonymous mutations in the nucleocapsid protein that are predicted to have functional implications.", [["nucleocapsid protein", "PROTEIN", 52, 72], ["nonsynonymous mutations in the nucleocapsid protein", "PROBLEM", 21, 72], ["nonsynonymous mutations", "OBSERVATION", 21, 44]]], ["The hotspot mutations S202 N, R203 K and G204R all cluster in a linker region where they might potentially enhance RNA binding and alter the response to serine phosphorylation events (Fig. S6).DiscussionIn this study, we have defined 5 major clades (G614, S84, V251, I378 and D392) of fully-sequenced SARS-CoV-2 genomes available until May 28, 2020 in the GISAID database.", [["serine", "CHEMICAL", 153, 159], ["serine", "AMINO_ACID", 153, 159], ["S6", "GENE_OR_GENE_PRODUCT", 189, 191], ["linker region", "DNA", 64, 77], ["S6", "PROTEIN", 189, 191], ["SARS-CoV-2 genomes", "DNA", 301, 319], ["SARS-CoV", "SPECIES", 301, 309], ["The hotspot mutations", "TEST", 0, 21], ["a linker region", "TREATMENT", 62, 77], ["RNA binding", "PROBLEM", 115, 126], ["serine phosphorylation events", "PROBLEM", 153, 182], ["this study", "TEST", 206, 216], ["CoV", "TEST", 306, 309]]], ["The clustering of these genomes revealed the spread of clades to diverse geographical regions (Fig. 1, Fig. 2).", [["spread", "OBSERVATION_MODIFIER", 45, 51], ["diverse", "OBSERVATION_MODIFIER", 65, 72], ["geographical", "OBSERVATION_MODIFIER", 73, 85]]], ["This pattern contrasts with those observed for other epidemic coronaviruses, such as MERS-CoV, which display distinct geographical clustering (Kim et al. 2016).", [["coronaviruses", "ORGANISM", 62, 75], ["MERS-CoV", "ORGANISM", 85, 93], ["MERS-CoV", "SPECIES", 85, 93], ["other epidemic coronaviruses", "PROBLEM", 47, 75], ["distinct", "OBSERVATION_MODIFIER", 109, 117], ["geographical", "OBSERVATION_MODIFIER", 118, 130]]], ["For example, clade G614, which was first detected on January is now dominant in the sampled genomes globally and its percentage is increasing globally from Europe, to North America, Oceania, and then to Asia (Korber et al. 2020).", [["G614", "GENE_OR_GENE_PRODUCT", 19, 23], ["dominant", "OBSERVATION", 68, 76], ["percentage", "OBSERVATION_MODIFIER", 117, 127], ["increasing", "OBSERVATION_MODIFIER", 131, 141], ["globally", "OBSERVATION_MODIFIER", 142, 150]]], ["This pattern demonstrates efficient viral transmission through frequent intercontinental travel during the period when international travel restrictions were only present sporadically and which has enabled the virus to spread to multiple distant locations within a short period of time.", [["the virus", "PROBLEM", 206, 215], ["efficient", "OBSERVATION_MODIFIER", 26, 35], ["viral", "OBSERVATION", 36, 41]]], ["This observation reinforces the importance of curtailing international travel and imposing restrictions early in pandemics and imposing social distancing in order to contain the global spread of viruses.DiscussionWe have observed a distinct distribution of the major clades in different parts of the world (Fig.2).", [["the global spread of viruses", "PROBLEM", 174, 202], ["viruses", "OBSERVATION", 195, 202], ["distinct", "OBSERVATION_MODIFIER", 232, 240], ["distribution", "OBSERVATION_MODIFIER", 241, 253], ["major", "OBSERVATION_MODIFIER", 261, 266], ["clades", "OBSERVATION", 267, 273]]], ["Most of the viral genomes which have not been assigned to a major clade are found in Asia and have earlier detection dates in January and February around the start of the epidemic in China.", [["viral genomes", "DNA", 12, 25], ["the viral genomes", "PROBLEM", 8, 25], ["viral genomes", "OBSERVATION", 12, 25]]], ["We observed a decrease in the genetic diversity of the virus over time following dissemination from China, especially in Europe and North America that each notably now has clade G614 as the predominant clade type, which is likely due the increased fitness advantage that this mutation brings to the virus as was reported recently (Korber et al. 2020).", [["G614", "GENE_OR_GENE_PRODUCT", 178, 182], ["a decrease", "PROBLEM", 12, 22], ["the virus", "PROBLEM", 51, 60], ["this mutation", "PROBLEM", 271, 284], ["the virus", "PROBLEM", 295, 304], ["decrease", "OBSERVATION_MODIFIER", 14, 22], ["virus", "OBSERVATION", 55, 60], ["clade type", "OBSERVATION", 202, 212], ["likely due", "UNCERTAINTY", 223, 233]]], ["An important caveat of the present study is that the current sampling of available public genomes does likely not represent the extant genetic diversity of virus populations in circulation.", [["the present study", "TEST", 23, 40], ["likely not represent", "UNCERTAINTY", 103, 123], ["virus populations", "OBSERVATION", 156, 173]]], ["This is due to biases of genome data deposits from the sequencing laboratories based mainly in the Northern hemisphere and new datasets may define new clades or subclades in the near future from other regions, including Africa, the Indian subcontinent and Latin America from where there are comparably few genomes available at present.", [["genome data deposits", "PROBLEM", 25, 45], ["the sequencing laboratories", "TEST", 51, 78], ["new clades", "PROBLEM", 147, 157], ["Africa", "PROBLEM", 220, 226]]], ["In this case, additional identifiers within an evolving barcode scheme can be added to track and monitor future emerging clades with higher resolution.", [["an evolving barcode scheme", "TREATMENT", 44, 70]]], ["On the other hand, the genetic stability of SARS-CoV-2 (Jia et al. 2020) may result in the continuing circulation of a limited number of clades until such time as mitigation measures including the isolation of vulnerable populations and the availability of efficacious antivirals and vaccines might reduce the genetic diversity in circulation.", [["SARS", "DISEASE", 44, 48], ["SARS-CoV-2", "ORGANISM", 44, 54], ["SARS-CoV", "SPECIES", 44, 52], ["SARS", "TEST", 44, 48], ["mitigation measures", "TREATMENT", 163, 182], ["vulnerable populations", "PROBLEM", 210, 232], ["efficacious antivirals", "TREATMENT", 257, 279], ["vaccines", "TREATMENT", 284, 292]]], ["This molecular genotyping approach has been demonstrated for other viruses (e.g. measles, poliovirus, rotavirus and human papillomaviruses) with herd-immunity vaccination programmes working to eliminate pathogens from endemic circulation in humans (Brown et al., 2019, Mankertz et al., 2011, Grassly, 2013, Soares-Weiser et al., 2012).", [["measles, poliovirus, rotavirus and human papillomaviruses", "DISEASE", 81, 138], ["poliovirus", "ORGANISM", 90, 100], ["rotavirus", "ORGANISM", 102, 111], ["human", "ORGANISM", 116, 121], ["papillomaviruses", "ORGANISM", 122, 138], ["humans", "ORGANISM", 241, 247], ["human", "SPECIES", 116, 121], ["humans", "SPECIES", 241, 247], ["rotavirus", "SPECIES", 102, 111], ["human papillomaviruses", "SPECIES", 116, 138], ["humans", "SPECIES", 241, 247], ["This molecular genotyping approach", "TREATMENT", 0, 34], ["other viruses", "PROBLEM", 61, 74], ["measles", "PROBLEM", 81, 88], ["poliovirus", "PROBLEM", 90, 100], ["rotavirus and human papillomaviruses", "TREATMENT", 102, 138], ["herd-immunity vaccination programmes", "TREATMENT", 145, 181], ["pathogens", "PROBLEM", 203, 212]]], ["The availability of a barcoding scheme that rapidly generates SNPs allowing clade assignment will be critical in this elimination phase when widespread availability of vaccines permits eradication of SARS-CoV-2 from endemicity in humans.DiscussionIn this study, we have designed and tested the first iteration of a multiplexed sequencing-based SARS-CoV-2 genotyping protocol for major clade assignment (Fig.3).", [["SARS", "DISEASE", 200, 204], ["SARS-CoV-2", "ORGANISM", 200, 210], ["humans", "ORGANISM", 230, 236], ["humans", "SPECIES", 230, 236], ["SARS-CoV-2", "SPECIES", 200, 210], ["humans", "SPECIES", 230, 236], ["a barcoding scheme", "PROBLEM", 20, 38], ["vaccines", "TREATMENT", 168, 176], ["SARS", "PROBLEM", 200, 204], ["CoV", "TEST", 205, 208], ["this study", "TEST", 250, 260], ["a multiplexed sequencing", "TEST", 313, 337], ["CoV-2 genotyping protocol", "TREATMENT", 349, 374]]], ["This will facilitate genetic surveillance to be performed at high-throughput level from SARS-CoV-2 detection to clade assignment.", [["genetic surveillance", "TEST", 21, 41], ["SARS", "PROBLEM", 88, 92], ["CoV", "TEST", 93, 96]]], ["Future versions of the multiplexed primer sets can be optimised to cover the relatively low coverage regions (position 26144 and 28688).", [["the multiplexed primer sets", "TREATMENT", 19, 46], ["relatively", "OBSERVATION_MODIFIER", 77, 87], ["low", "OBSERVATION_MODIFIER", 88, 91]]], ["We concluded that the relatively low coverage at these two positions was a result of the position of mutation relative to the amplicon sites and not related to the PCR conditions used (Fig.S12).", [["amplicon sites", "DNA", 126, 140], ["the relatively low coverage", "PROBLEM", 18, 45], ["mutation", "PROBLEM", 101, 109], ["the amplicon sites", "TREATMENT", 122, 140], ["the PCR conditions", "TEST", 160, 178], ["relatively", "OBSERVATION_MODIFIER", 22, 32], ["low", "OBSERVATION_MODIFIER", 33, 36]]], ["Our approach is also compatible with genotyping by other platforms, such as the MinION nanopore sequencer from Oxford Nanopore Technologies (ONT).", [["the MinION nanopore sequencer", "TREATMENT", 76, 105], ["compatible with", "UNCERTAINTY", 21, 36]]], ["Different sets of primers can also be designed to meet the requirements of different sequencing platforms.", [["different sequencing platforms", "TEST", 75, 105]]], ["For example, the amplicon sizes could be optimised for the Illumina iSeq100 for rapid genotyping of a large number of samples without compromising the robustness of the genotyping calls at a fraction of current costs using a MiSeq.", [["samples", "ANATOMY", 118, 125], ["Illumina iSeq100", "DNA", 59, 75], ["MiSeq", "PROTEIN", 225, 230], ["the amplicon sizes", "TREATMENT", 13, 31], ["a MiSeq", "TREATMENT", 223, 230], ["large", "OBSERVATION_MODIFIER", 102, 107]]], ["Moving forward, further studies may also include subclade-defining sites to have a higher resolution of each sequenced sample to assist in tracking and surveillance of the virus.", [["further studies", "TEST", 16, 31], ["subclade-defining sites", "PROBLEM", 49, 72], ["the virus", "PROBLEM", 168, 177]]], ["The U.S. Food and Drug Administration (USFDA) has authorised Illumina COVIDSeq test which is intended for the detection of SARS-CoV-2 virus RNA for research use (https://www.illumina.com/products/by-type/ivd-products/covidseq.html).", [["SARS-CoV-2 virus", "ORGANISM", 123, 139], ["CoV-2 virus", "SPECIES", 128, 139], ["SARS-CoV-2 virus", "SPECIES", 123, 139], ["Illumina COVIDSeq test", "TEST", 61, 83], ["the detection", "TEST", 106, 119], ["SARS", "PROBLEM", 123, 127], ["CoV", "TEST", 128, 131]]], ["According to the COVIDseq instructions, up to 384 results per lane can be processed on the NovaSeq 6000 System for whole-genome sequecing.", [["COVIDseq", "DNA", 17, 25]]], ["Our methodology is complementary to the COVIDSeq test and aimed at revealing the major clades of the virus in a given sample.DiscussionOur work provides a baseline genomic epidemiology of SARS-CoV-2 prior to the introduction of therapeutic and prophylactic approaches.", [["SARS", "DISEASE", 188, 192], ["SARS-CoV-2", "ORGANISM", 188, 198], ["SARS-CoV", "SPECIES", 188, 196], ["the COVIDSeq test", "TEST", 36, 53], ["the virus", "PROBLEM", 97, 106], ["SARS", "PROBLEM", 188, 192], ["CoV", "TEST", 193, 196], ["therapeutic and prophylactic approaches", "TREATMENT", 228, 267], ["virus", "OBSERVATION", 101, 106]]], ["The mutational landscape of global populations of over 21,789 SARS-CoV-2 genomes provides an evidence-based framework for tracking the clades that comprise the pandemic on different continents.", [["SARS", "DISEASE", 62, 66], ["21,789 SARS-CoV-2 genomes", "DNA", 55, 80], ["SARS", "TEST", 62, 66], ["tracking the clades", "PROBLEM", 122, 141], ["landscape", "OBSERVATION_MODIFIER", 15, 24], ["global", "OBSERVATION_MODIFIER", 28, 34], ["populations", "OBSERVATION_MODIFIER", 35, 46]]], ["However, due to the biases in the representation of countries depositing SARS-CoV-2 genomes, with over-representation of North American and European genomes, the available genome data represents only a minute proportion of the total COVID-19 positive cases from each of these regions.", [["SARS", "DISEASE", 73, 77], ["SARS-CoV-2 genomes", "DNA", 73, 91], ["SARS-CoV", "SPECIES", 73, 81], ["SARS", "PROBLEM", 73, 77], ["the total COVID", "TEST", 223, 238]]], ["As viral genetic diversity is anticipated to decrease with the advent of widespread vaccination, the barcoding approach will allow more rapid discrimination of autochthonous and imported cases to monitor interruption of viral transmission.ConclusionThis study provides a baseline reference of genomic diversity at the early stages of the COVID-19 pandeic and will prove useful for the monitoring of changes in circulating clades of SARS-CoV-2 in different geographic regions over time..", [["SARS", "DISEASE", 432, 436], ["SARS-CoV-2", "ORGANISM", 432, 442], ["SARS-CoV", "SPECIES", 432, 440], ["widespread vaccination", "TREATMENT", 73, 95], ["the barcoding approach", "TREATMENT", 97, 119], ["viral transmission", "PROBLEM", 220, 238], ["This study", "TEST", 249, 259], ["genomic diversity", "PROBLEM", 293, 310], ["the COVID", "TEST", 334, 343], ["the monitoring", "TEST", 381, 395], ["SARS", "PROBLEM", 432, 436], ["CoV", "TEST", 437, 440], ["viral transmission", "OBSERVATION", 220, 238]]], ["An 11-nucleotide genetic barcode of SARS-CoV-2 is presented which identifies the 5 major clades of circulating viral genomes.", [["circulating viral genomes", "DNA", 99, 124], ["SARS-CoV", "SPECIES", 36, 44], ["circulating viral genomes", "PROBLEM", 99, 124], ["circulating", "OBSERVATION_MODIFIER", 99, 110], ["viral genomes", "OBSERVATION", 111, 124]]], ["The robustness of our 11-site genomic barcoding approach was validated by coreectly assigning \u223c94% of the 79,486 SARS-CoV-2 genomes available in GISAID until August 3, 2020 to one of the 5 major clades.", [["79,486 SARS-CoV-2 genomes", "DNA", 106, 131], ["CoV", "TEST", 118, 121]]], ["We have designed the first version of a high-throughput and robust genotyping protocol that can be readily applied for SARS-CoV-2 detection and clade assignment.This barcoding strategy will be important to target genomic sequencing efforts and to monitor decreases in viral genetic diversity as intervention approaches become widely available.FundingWork in AP\u2019s laboratory is supported by the KAUST faculty baseline fund (BAS/1/1020-01- 01) and research grants from the Office for Sponsored Research (OSR-2015-CRG4-2610, OCRF-2014-CRG3-2267).", [["OSR-2015-CRG4-2610, OCRF-2014-CRG3-2267", "CHEMICAL", 502, 541], ["OSR-2015-CRG4-2610", "CHEMICAL", 502, 520], ["SARS-CoV", "SPECIES", 119, 127], ["robust genotyping protocol", "TREATMENT", 60, 86], ["SARS", "PROBLEM", 119, 123], ["This barcoding strategy", "TREATMENT", 161, 184], ["viral genetic diversity", "TREATMENT", 268, 291], ["intervention approaches", "TREATMENT", 295, 318], ["AP\u2019s laboratory", "TEST", 358, 373]]], ["This work was also supported by funding from King Abdullah University of Science and Technology (KAUST), Office of Sponsored Research (OSR), under award number FCC/1/1976-25-01 to STA.Ethical approvalThis study is covered by IRB approval 20IBEC14 and HAP-01-R-082 to work on the SARS-CoV-2 positive RNA samples derived from COVID-19 positive patients at the Dr.Suliman Al-Habib Medical group in KSA.Author ContributionsA.P. conceived the study and supervised the work; A.P., W.W.H., S.T.A. and Q.G. designed the research; Q.G., M.S., R.Na and S.T.A. analysed data; Q.G., M.S., S.T.A. and M.J.C. wrote the initial draft of the manuscript, followed by edits from A.P, M.J.C, W.W.H and R.Nu; R.Nu. and S.M. contributed new reagents; Q.G., S.H., S.M., R.Nu., A.A.O., S.S and A.A.M provided samples, designed and preformed the genotyping experiment.", [["samples", "ANATOMY", 303, 310], ["samples", "ANATOMY", 786, 793], ["HAP-01-R-082", "CHEMICAL", 251, 263], ["20IBEC14", "SIMPLE_CHEMICAL", 238, 246], ["HAP-01-R-082", "SIMPLE_CHEMICAL", 251, 263], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 279, 289], ["patients", "ORGANISM", 342, 350], ["patients", "SPECIES", 342, 350], ["SARS-CoV", "SPECIES", 279, 287], ["Ethical approval", "TREATMENT", 184, 200], ["This study", "TEST", 200, 210], ["HAP", "TEST", 251, 254], ["the SARS", "TEST", 275, 283], ["CoV", "TEST", 284, 287], ["RNA samples", "TEST", 299, 310], ["COVID", "TEST", 324, 329], ["the study", "TEST", 434, 443]]]], "8d8e3f09073daa21f19139ec94720ba9e1c5e5df": [["INTRODUCTIONFive coronaviruses can induce clusters of severe respiratory diseases in humans: 229E, OC43, SARS, MERS and SARS-CoV-2 1,2 .", [["respiratory", "ANATOMY", 61, 72], ["respiratory diseases", "DISEASE", 61, 81], ["SARS", "DISEASE", 105, 109], ["coronaviruses", "ORGANISM", 17, 30], ["humans", "ORGANISM", 85, 91], ["humans", "SPECIES", 85, 91], ["humans", "SPECIES", 85, 91], ["SARS-CoV", "SPECIES", 120, 128], ["severe respiratory diseases in humans", "PROBLEM", 54, 91], ["SARS", "TEST", 120, 124], ["CoV", "TEST", 125, 128], ["severe", "OBSERVATION_MODIFIER", 54, 60], ["respiratory diseases", "OBSERVATION", 61, 81]]], ["The outbreak of Severe Acute Respiratory Syndrome (SARS-CoV) in 2003 and Middle East Respiratory Syndrome (MERS-CoV) in 2012, showed a high fatality rate of 11% and 34%, respectively, but had limited geographical spread 3, 4 .", [["Acute Respiratory Syndrome", "DISEASE", 23, 49], ["SARS-CoV)", "DISEASE", 51, 60], ["Respiratory Syndrome", "DISEASE", 85, 105], ["Severe Acute Respiratory Syndrome (SARS-CoV", "SPECIES", 16, 59], ["Middle East Respiratory Syndrome (MERS-CoV", "SPECIES", 73, 115], ["Severe Acute Respiratory Syndrome", "PROBLEM", 16, 49], ["SARS", "PROBLEM", 51, 55], ["Middle East Respiratory Syndrome", "PROBLEM", 73, 105], ["a high fatality rate", "TEST", 133, 153], ["Severe", "OBSERVATION_MODIFIER", 16, 22], ["Acute", "OBSERVATION_MODIFIER", 23, 28], ["Respiratory Syndrome", "OBSERVATION", 29, 49], ["Middle", "ANATOMY_MODIFIER", 73, 79], ["Respiratory Syndrome", "OBSERVATION", 85, 105]]], ["In contrast, in the past 7 months SARS-CoV-2 (the cause of COVID-19) has spread rapidly around the world and infected millions of people, killing over half a million.", [["SARS", "DISEASE", 34, 38], ["SARS-CoV-2", "ORGANISM", 34, 44], ["people", "ORGANISM", 130, 136], ["people", "SPECIES", 130, 136], ["SARS-CoV", "SPECIES", 34, 42], ["SARS", "TEST", 34, 38], ["CoV", "TEST", 39, 42], ["COVID", "TEST", 59, 64], ["infected", "OBSERVATION_MODIFIER", 109, 117], ["millions", "OBSERVATION_MODIFIER", 118, 126]]], ["Though, it has a significantly lower fatality rate (estimated at 0.5 -2%) than MERS and SARS the amount of people infected is hundreds of times higher, and it caused significant economic hardship and extraordinary social restrictions.", [["SARS", "DISEASE", 88, 92], ["people", "ORGANISM", 107, 113], ["people", "SPECIES", 107, 113], ["a significantly lower fatality rate", "PROBLEM", 15, 50], ["significantly", "OBSERVATION_MODIFIER", 17, 30], ["lower", "OBSERVATION_MODIFIER", 31, 36], ["fatality", "OBSERVATION_MODIFIER", 37, 45], ["amount", "OBSERVATION_MODIFIER", 97, 103], ["hundreds", "OBSERVATION_MODIFIER", 126, 134], ["significant", "OBSERVATION_MODIFIER", 166, 177], ["economic", "OBSERVATION_MODIFIER", 178, 186], ["hardship", "OBSERVATION", 187, 195], ["extraordinary", "OBSERVATION_MODIFIER", 200, 213], ["social restrictions", "OBSERVATION", 214, 233]]], ["In many countries, after six months from the first reports of COVID-19, the number of cases is still increasing 5 .", [["COVID", "TEST", 62, 67]]], ["In the absence of herd immunity, vaccines, or drugs against the virus, the situation is frightful.", [["herd immunity", "TREATMENT", 18, 31], ["vaccines", "TREATMENT", 33, 41], ["drugs", "TREATMENT", 46, 51], ["the virus", "PROBLEM", 60, 69]]], ["Since the beginning of the worldwide outbreak of COVID-19, the scientific community has joined efforts to understand SARS-CoV-2 biology and to find chemical compounds that either block virus replication or enhance human immunological response.", [["SARS", "DISEASE", 117, 121], ["CoV-2", "ORGANISM", 122, 127], ["human", "ORGANISM", 214, 219], ["human", "SPECIES", 214, 219], ["human", "SPECIES", 214, 219], ["COVID", "TEST", 49, 54], ["chemical compounds", "TREATMENT", 148, 166], ["block virus replication", "TREATMENT", 179, 202]]], ["Initial focus on repurposing existing drugs that potentially could provide immediate treatment has thus far resulted only in limited success.", [["repurposing existing drugs", "TREATMENT", 17, 43], ["immediate treatment", "TREATMENT", 75, 94]]], ["Finding inhibitors of a biological cycle of SARS-CoV-2 or vaccines is, therefore, critical for global health, safety, and wellbeing.", [["SARS", "DISEASE", 44, 48], ["SARS-CoV-2", "ORGANISM", 44, 54], ["SARS", "PROBLEM", 44, 48], ["CoV", "TEST", 49, 52], ["vaccines", "TREATMENT", 58, 66]]], ["SARS-CoV-2 \u03b2-coronavirus has a large (~ 30 kb) and complex (29 proteins) (+) sense singlestranded RNA genome 6 .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2 \u03b2-coronavirus", "ORGANISM", 0, 24], ["29 proteins", "PROTEIN", 60, 71], ["singlestranded RNA genome 6", "DNA", 83, 110], ["coronavirus", "SPECIES", 13, 24], ["SARS-CoV-2 \u03b2-coronavirus", "SPECIES", 0, 24], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["coronavirus", "PROBLEM", 13, 24], ["sense singlestranded RNA genome", "PROBLEM", 77, 108], ["large", "OBSERVATION_MODIFIER", 31, 36], ["RNA genome", "OBSERVATION", 98, 108]]], ["The RNA present in the mature virion resembles human mRNA: (i) it is capped on its 5\u2032-end, (ii) contains a 3\u2032-poly-A tail, and (iii) after infection can be directly translated to the two polyproteins Pp1a and Pp1ab using host machinery.", [["infection", "DISEASE", 139, 148], ["human", "ORGANISM", 47, 52], ["Pp1a", "GENE_OR_GENE_PRODUCT", 200, 204], ["Pp1ab", "GENE_OR_GENE_PRODUCT", 209, 214], ["human mRNA", "RNA", 47, 57], ["5\u2032-end", "DNA", 83, 89], ["3\u2032-poly-A tail", "PROTEIN", 107, 121], ["polyproteins", "PROTEIN", 187, 199], ["Pp1a", "PROTEIN", 200, 204], ["Pp1ab", "PROTEIN", 209, 214], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52], ["infection", "PROBLEM", 139, 148], ["mature", "OBSERVATION_MODIFIER", 23, 29], ["virion", "OBSERVATION", 30, 36], ["tail", "ANATOMY", 117, 121], ["infection", "OBSERVATION", 139, 148]]], ["These polyproteins are then matured into 15 non-structural proteins (Nsp), that assemble into a large replication-transcription complex.INTRODUCTIONThe RNA is also used as a template for biosynthesis of (-) sense RNA that serves to make additional copies of (+) sense RNA and several sub-genomic RNAs for the translation of four structural and 9-10 accessory proteins 6 .", [["Nsp", "GENE_OR_GENE_PRODUCT", 69, 72], ["structural proteins", "PROTEIN", 48, 67], ["Nsp", "PROTEIN", 69, 72], ["replication-transcription complex", "PROTEIN", 102, 135], ["(-) sense RNA", "RNA", 203, 216], ["(+) sense RNA", "RNA", 258, 271], ["sub-genomic RNAs", "RNA", 284, 300], ["structural and 9-10 accessory proteins 6", "PROTEIN", 329, 369], ["These polyproteins", "PROBLEM", 0, 18], ["a large replication-transcription complex", "TREATMENT", 94, 135], ["a template", "TREATMENT", 172, 182], ["biosynthesis of (-) sense RNA", "TREATMENT", 187, 216], ["(+) sense RNA", "PROBLEM", 258, 271], ["several sub-genomic RNAs", "PROBLEM", 276, 300], ["polyproteins", "OBSERVATION", 6, 18], ["large", "OBSERVATION_MODIFIER", 96, 101], ["replication", "OBSERVATION", 102, 113], ["genomic RNAs", "OBSERVATION", 288, 300]]], ["For these RNAs to serve as mRNAs, they must undergo post-transcription modifications to resemble human mRNA.", [["human", "ORGANISM", 97, 102], ["mRNAs", "RNA", 27, 32], ["human mRNA", "RNA", 97, 107], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102]]], ["The RNA maturation involves several enzymatic steps performed by viral Nsps; Nsp13 is a bifunctional RNA/NTP triphosphatase (TPase) and helicase; Nsp14 is a bifunctional 3\u2032-5\u2032 exonuclease and guanine N7 methyltransferase;INTRODUCTIONand Nsp16 is Mg 2+ dependent ribose 2\u2032-O methyltransferase and an elusive guanylyltransferase.INTRODUCTIONIn eukaryotes, the attachment of the m7 G Cap at the 5\u2032-end of RNA protects the transcript from mRNA turnover in the pathway dependent on 5\u2032 \u2192 3\u2032 exoribonucleases activity, such as XRNs 7 , and is required for several cellular processes: maturation of mRNA, pre-mRNA nuclear export, and protein synthesis 8 .", [["cellular", "ANATOMY", 557, 565], ["nuclear", "ANATOMY", 606, 613], ["guanine", "CHEMICAL", 192, 199], ["Mg", "CHEMICAL", 246, 248], ["ribose", "CHEMICAL", 262, 268], ["guanine", "CHEMICAL", 192, 199], ["Mg 2+", "CHEMICAL", 246, 251], ["ribose", "CHEMICAL", 262, 268], ["O", "CHEMICAL", 272, 273], ["Nsps", "GENE_OR_GENE_PRODUCT", 71, 75], ["Nsp13", "GENE_OR_GENE_PRODUCT", 77, 82], ["NTP triphosphatase", "GENE_OR_GENE_PRODUCT", 105, 123], ["TPase", "GENE_OR_GENE_PRODUCT", 125, 130], ["Nsp14", "GENE_OR_GENE_PRODUCT", 146, 151], ["guanine N7 methyltransferase", "GENE_OR_GENE_PRODUCT", 192, 220], ["Nsp16", "GENE_OR_GENE_PRODUCT", 237, 242], ["Mg 2+", "SIMPLE_CHEMICAL", 246, 251], ["ribose 2\u2032-O methyltransferase", "GENE_OR_GENE_PRODUCT", 262, 291], ["guanylyltransferase", "GENE_OR_GENE_PRODUCT", 307, 326], ["m7 G Cap", "GENE_OR_GENE_PRODUCT", 376, 384], ["5\u2032 \u2192 3", "GENE_OR_GENE_PRODUCT", 477, 483], ["XRNs 7", "GENE_OR_GENE_PRODUCT", 520, 526], ["cellular", "CELL", 557, 565], ["nuclear", "CELLULAR_COMPONENT", 606, 613], ["viral Nsps", "PROTEIN", 65, 75], ["Nsp13", "PROTEIN", 77, 82], ["bifunctional RNA/NTP triphosphatase", "PROTEIN", 88, 123], ["TPase", "PROTEIN", 125, 130], ["helicase", "PROTEIN", 136, 144], ["Nsp14", "PROTEIN", 146, 151], ["bifunctional 3\u2032-5\u2032 exonuclease", "PROTEIN", 157, 187], ["guanine N7 methyltransferase", "PROTEIN", 192, 220], ["Nsp16", "PROTEIN", 237, 242], ["Mg 2+ dependent ribose 2\u2032-O methyltransferase", "PROTEIN", 246, 291], ["guanylyltransferase", "PROTEIN", 307, 326], ["m7 G Cap", "PROTEIN", 376, 384], ["5\u2032-end", "DNA", 392, 398], ["RNA", "RNA", 402, 405], ["XRNs 7", "PROTEIN", 520, 526], ["mRNA", "RNA", 591, 595], ["The RNA maturation", "PROBLEM", 0, 18], ["several enzymatic steps", "PROBLEM", 28, 51], ["viral Nsps", "TEST", 65, 75], ["a bifunctional RNA", "TEST", 86, 104], ["Nsp14", "TEST", 146, 151], ["exonuclease", "TREATMENT", 176, 187], ["guanine N7 methyltransferase", "TREATMENT", 192, 220], ["INTRODUCTIONand Nsp16", "TREATMENT", 221, 242], ["Mg", "TEST", 246, 248], ["dependent ribose", "TREATMENT", 252, 268], ["methyltransferase", "TREATMENT", 274, 291], ["an elusive guanylyltransferase", "TREATMENT", 296, 326], ["the m7 G Cap", "TREATMENT", 372, 384], ["XRNs", "TEST", 520, 524], ["pre-mRNA nuclear export", "TEST", 597, 620], ["protein synthesis", "TEST", 626, 643], ["RNA maturation", "OBSERVATION", 4, 18]]], ["The Cap at the 5\u2032 terminus of eukaryotic transcripts starts with 7methylguanosine at the reversed position and is connected through an uncommon 5\u2032 to 5\u2032 triphosphate bridge, which is attached to a nucleotide that undergoes methylation at 2\u2032-O-ribose.INTRODUCTIONThe canonical pathway of the mRNA capping mechanism requires the subsequent action of multiple enzymes 8 .", [["7methylguanosine", "CHEMICAL", 65, 81], ["5\u2032 to 5\u2032 triphosphate", "CHEMICAL", 144, 165], ["nucleotide", "CHEMICAL", 197, 207], ["2\u2032-O-ribose", "CHEMICAL", 238, 249], ["7methylguanosine", "CHEMICAL", 65, 81], ["5\u2032 to 5\u2032 triphosphate", "CHEMICAL", 144, 165], ["nucleotide", "CHEMICAL", 197, 207], ["2\u2032-O-ribose", "CHEMICAL", 238, 249], ["Cap", "GENE_OR_GENE_PRODUCT", 4, 7], ["7methylguanosine", "SIMPLE_CHEMICAL", 65, 81], ["5\u2032 triphosphate", "SIMPLE_CHEMICAL", 150, 165], ["2\u2032-O-ribose", "SIMPLE_CHEMICAL", 238, 249], ["Cap", "PROTEIN", 4, 7], ["5\u2032 terminus", "PROTEIN", 15, 26], ["eukaryotic transcripts", "PROTEIN", 30, 52], ["enzymes 8", "PROTEIN", 357, 366], ["The Cap", "TREATMENT", 0, 7], ["eukaryotic transcripts", "TREATMENT", 30, 52], ["7methylguanosine", "TREATMENT", 65, 81], ["5\u2032 triphosphate bridge", "TREATMENT", 150, 172], ["a nucleotide", "TREATMENT", 195, 207], ["methylation at 2\u2032-O-ribose", "TREATMENT", 223, 249], ["the mRNA capping mechanism", "TREATMENT", 287, 313], ["multiple enzymes", "TEST", 348, 364], ["Cap", "OBSERVATION_MODIFIER", 4, 7], ["eukaryotic transcripts", "OBSERVATION", 30, 52]]], ["At first, RNA 5\u2032-triphosphatase (RTPase) cleaves the 5\u2032-terminal \u03b3-\u03b2 phosphoanhydride bond of the nascent mRNA and enables further modification of the newly synthesized transcript at its 5\u2032-terminus.", [["phosphoanhydride", "CHEMICAL", 69, 85], ["RNA 5\u2032-triphosphatase", "GENE_OR_GENE_PRODUCT", 10, 31], ["RTPase", "GENE_OR_GENE_PRODUCT", 33, 39], ["RNA 5\u2032-triphosphatase", "PROTEIN", 10, 31], ["RTPase", "PROTEIN", 33, 39], ["5\u2032-terminal \u03b3-\u03b2 phosphoanhydride bond", "PROTEIN", 53, 90], ["nascent mRNA", "RNA", 98, 110], ["5\u2032-terminus", "PROTEIN", 187, 198], ["RNA", "TEST", 10, 13], ["triphosphatase", "TEST", 17, 31], ["RTPase", "TEST", 33, 39], ["the newly synthesized transcript", "TREATMENT", 147, 179], ["nascent mRNA", "OBSERVATION", 98, 110]]], ["Secondly, the diphosphate mRNA is capped using GMP by guanylyltransferase (GTase).", [["diphosphate", "CHEMICAL", 14, 25], ["GMP", "CHEMICAL", 47, 50], ["diphosphate", "CHEMICAL", 14, 25], ["GMP", "CHEMICAL", 47, 50], ["diphosphate", "SIMPLE_CHEMICAL", 14, 25], ["GMP", "SIMPLE_CHEMICAL", 47, 50], ["guanylyltransferase", "SIMPLE_CHEMICAL", 54, 73], ["GTase", "SIMPLE_CHEMICAL", 75, 80], ["diphosphate mRNA", "RNA", 14, 30], ["guanylyltransferase", "PROTEIN", 54, 73], ["GTase", "PROTEIN", 75, 80], ["the diphosphate mRNA", "TREATMENT", 10, 30], ["diphosphate mRNA", "OBSERVATION", 14, 30]]], ["Next, the (guanine-N7)-methyltransferase adds the methyl group to the 5\u2032-terminal guanosine creating a precursor: Cap-0.", [["guanine", "CHEMICAL", 11, 18], ["methyl", "CHEMICAL", 50, 56], ["guanosine", "CHEMICAL", 82, 91], ["(guanine-N7)", "CHEMICAL", 10, 22], ["methyl", "CHEMICAL", 50, 56], ["guanosine", "CHEMICAL", 82, 91], ["methyl", "SIMPLE_CHEMICAL", 50, 56], ["5\u2032-terminal guanosine", "SIMPLE_CHEMICAL", 70, 91], ["Cap-0", "GENE_OR_GENE_PRODUCT", 114, 119], ["methyltransferase", "PROTEIN", 23, 40], ["Cap-0", "PROTEIN", 114, 119], ["the (guanine-N7)-methyltransferase adds the methyl group", "TREATMENT", 6, 62], ["the 5\u2032-terminal guanosine", "TREATMENT", 66, 91], ["Cap", "TEST", 114, 117]]], ["Additionally, the 2\u2032-O methyltransferase transfers the methyl group to the 2\u2032-O-ribose of the first transcribed nucleotide at mRNA, making the m7 GpppNm2\u2032-O (Cap-1) structure 9 .", [["methyl", "CHEMICAL", 55, 61], ["2\u2032-O-ribose", "CHEMICAL", 75, 86], ["nucleotide", "CHEMICAL", 112, 122], ["2\u2032-O", "CHEMICAL", 18, 22], ["methyl", "CHEMICAL", 55, 61], ["2\u2032-O-ribose", "CHEMICAL", 75, 86], ["nucleotide", "CHEMICAL", 112, 122], ["2\u2032-O methyltransferase", "GENE_OR_GENE_PRODUCT", 18, 40], ["methyl", "SIMPLE_CHEMICAL", 55, 61], ["2\u2032-O-ribose", "SIMPLE_CHEMICAL", 75, 86], ["Cap-1", "GENE_OR_GENE_PRODUCT", 158, 163], ["2\u2032-O methyltransferase", "PROTEIN", 18, 40], ["mRNA", "RNA", 126, 130], ["O (Cap-1) structure 9", "PROTEIN", 155, 176], ["the 2\u2032-O methyltransferase transfers the methyl group", "TREATMENT", 14, 67], ["the m7 GpppNm2\u2032", "TEST", 139, 154]]], ["S-adenosyl-L-methionine (SAM) is a donor of the methyl group and is converted to S-adenosyl-L-homocysteine (SAH) during the reaction 10 .", [["S-adenosyl-L-methionine", "CHEMICAL", 0, 23], ["SAM", "CHEMICAL", 25, 28], ["methyl", "CHEMICAL", 48, 54], ["S-adenosyl-L-homocysteine", "CHEMICAL", 81, 106], ["SAH", "DISEASE", 108, 111], ["S-adenosyl-L-methionine", "CHEMICAL", 0, 23], ["SAM", "CHEMICAL", 25, 28], ["methyl", "CHEMICAL", 48, 54], ["S-adenosyl-L-homocysteine", "CHEMICAL", 81, 106], ["SAH", "CHEMICAL", 108, 111], ["S-adenosyl-L-methionine", "SIMPLE_CHEMICAL", 0, 23], ["SAM", "SIMPLE_CHEMICAL", 25, 28], ["methyl", "SIMPLE_CHEMICAL", 48, 54], ["S-adenosyl-L-homocysteine", "SIMPLE_CHEMICAL", 81, 106], ["SAH", "SIMPLE_CHEMICAL", 108, 111], ["the methyl group", "TREATMENT", 44, 60], ["S-adenosyl-L-homocysteine (SAH", "TREATMENT", 81, 111]]], ["In humans and other higher eukaryotes, the second nucleotide of mRNA then undergoes methylation to produce Cap-2 11 .INTRODUCTIONThe post-transcriptional modification of RNA is also essential for efficient translation of viral transcript in a eukaryotic host 12 .", [["nucleotide", "CHEMICAL", 50, 60], ["nucleotide", "CHEMICAL", 50, 60], ["humans", "ORGANISM", 3, 9], ["Cap-2", "GENE_OR_GENE_PRODUCT", 107, 112], ["mRNA", "RNA", 64, 68], ["Cap-2 11", "DNA", 107, 115], ["viral transcript", "RNA", 221, 237], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["the second nucleotide of mRNA", "TREATMENT", 39, 68], ["Cap", "TEST", 107, 110], ["The post-transcriptional modification of RNA", "PROBLEM", 129, 173], ["viral transcript", "PROBLEM", 221, 237], ["viral transcript", "OBSERVATION", 221, 237]]], ["Influenza, Ebola, measles, poxvirus, and coronaviruses attach Cap to their genomic and sub-genomic RNA transcripts to mimic host molecules and escape from the innate immunological response 13 .", [["Influenza", "DISEASE", 0, 9], ["Ebola, measles, poxvirus", "DISEASE", 11, 35], ["Ebola", "ORGANISM", 11, 16], ["coronaviruses", "ORGANISM", 41, 54], ["Cap", "GENE_OR_GENE_PRODUCT", 62, 65], ["genomic and sub-genomic RNA transcripts", "RNA", 75, 114], ["Influenza", "SPECIES", 0, 9], ["Ebola", "SPECIES", 11, 16], ["Influenza", "PROBLEM", 0, 9], ["Ebola", "PROBLEM", 11, 16], ["measles", "PROBLEM", 18, 25], ["poxvirus", "TREATMENT", 27, 35], ["coronaviruses attach Cap", "TREATMENT", 41, 65]]], ["Studies done in the last decade show that the 2\u2032-O methylation of the Cap-0 facilitates this process by preventing activation of type I interferon that is induced by the cytoplasmic RNA sensors, melanoma differentiation-associated protein 5 (MDA5), and retinoic acid inducible gene-I (RIG-1) [14] [15] [16] they all utilize a Lys-Asp-Lys-Glu catalytic tetrad essential for the enzymatic activity 22, 23 .INTRODUCTIONIt has been shown that the Nsp10/16 complex methylates the Cap-0 ( m7 GpppA2\u2032-OH) to form Cap-1 ( m7 GpppAm2\u2032-O) by adding a methyl group to the ribose 2\u2032-O of the first nucleotide (usually adenosine, in CoVs) of the nascent mRNA using SAM as the methyl group donor 24 .", [["cytoplasmic", "ANATOMY", 170, 181], ["melanoma", "ANATOMY", 195, 203], ["retinoic acid", "CHEMICAL", 253, 266], ["Lys-Asp-Lys", "CHEMICAL", 326, 337], ["Glu", "CHEMICAL", 338, 341], ["methyl", "CHEMICAL", 541, 547], ["nucleotide", "CHEMICAL", 586, 596], ["adenosine", "CHEMICAL", 606, 615], ["methyl", "CHEMICAL", 663, 669], ["retinoic acid", "CHEMICAL", 253, 266], ["Asp", "CHEMICAL", 330, 333], ["Lys", "CHEMICAL", 334, 337], ["Glu", "CHEMICAL", 338, 341], ["Cap-0", "CHEMICAL", 475, 480], ["OH", "CHEMICAL", 494, 496], ["methyl", "CHEMICAL", 541, 547], ["ribose", "CHEMICAL", 561, 567], ["nucleotide", "CHEMICAL", 586, 596], ["adenosine", "CHEMICAL", 606, 615], ["SAM", "CHEMICAL", 652, 655], ["methyl", "CHEMICAL", 663, 669], ["Cap-0", "GENE_OR_GENE_PRODUCT", 70, 75], ["type I interferon", "GENE_OR_GENE_PRODUCT", 129, 146], ["cytoplasmic", "ORGANISM_SUBSTANCE", 170, 181], ["melanoma differentiation-associated protein 5", "GENE_OR_GENE_PRODUCT", 195, 240], ["MDA5", "GENE_OR_GENE_PRODUCT", 242, 246], ["retinoic acid inducible gene-I", "GENE_OR_GENE_PRODUCT", 253, 283], ["RIG-1) [14] [15] [16]", "SIMPLE_CHEMICAL", 285, 306], ["Nsp10", "GENE_OR_GENE_PRODUCT", 443, 448], ["Cap-0", "GENE_OR_GENE_PRODUCT", 475, 480], ["Cap-1", "GENE_OR_GENE_PRODUCT", 506, 511], ["methyl", "SIMPLE_CHEMICAL", 541, 547], ["adenosine", "SIMPLE_CHEMICAL", 606, 615], ["methyl", "SIMPLE_CHEMICAL", 663, 669], ["Cap-0", "PROTEIN", 70, 75], ["type I interferon", "PROTEIN", 129, 146], ["melanoma differentiation-associated protein 5", "PROTEIN", 195, 240], ["MDA5", "PROTEIN", 242, 246], ["enzymatic activity 22, 23 .INTRODUCTIONIt", "PROTEIN", 377, 418], ["Nsp10/16 complex", "PROTEIN", 443, 459], ["Cap-0", "PROTEIN", 475, 480], ["OH", "PROTEIN", 494, 496], ["Cap-1", "PROTEIN", 506, 511], ["m7 GpppAm2\u2032-O", "PROTEIN", 514, 527], ["nascent mRNA", "RNA", 633, 645], ["Studies", "TEST", 0, 7], ["type I interferon", "TREATMENT", 129, 146], ["melanoma differentiation", "PROBLEM", 195, 219], ["protein", "TEST", 231, 238], ["retinoic acid inducible gene", "TEST", 253, 281], ["a Lys-Asp", "TEST", 324, 333], ["Lys", "TEST", 334, 337], ["Glu catalytic tetrad", "TEST", 338, 358], ["the enzymatic activity", "TEST", 373, 395], ["the Cap", "TEST", 471, 478], ["Cap", "TEST", 506, 509], ["a methyl group to the ribose", "TREATMENT", 539, 567], ["the first nucleotide (usually adenosine", "TREATMENT", 576, 615], ["the methyl group donor", "TREATMENT", 659, 681]]], ["The Nsp16 activity is necessary for Nsps' translation from new copies of viral (+) sense RNA as well as structural and accessory proteins translation from sub-genomic RNA which are all transcribed from the viral (-) sense RNA template.", [["Nsp16", "GENE_OR_GENE_PRODUCT", 4, 9], ["Nsps", "GENE_OR_GENE_PRODUCT", 36, 40], ["Nsp16", "PROTEIN", 4, 9], ["Nsps", "PROTEIN", 36, 40], ["viral (+) sense RNA", "RNA", 73, 92], ["sub-genomic RNA", "RNA", 155, 170], ["viral (-) sense RNA template", "RNA", 206, 234], ["Nsps' translation", "PROBLEM", 36, 53], ["viral (+) sense RNA", "PROBLEM", 73, 92], ["structural and accessory proteins translation", "PROBLEM", 104, 149], ["sub-genomic RNA", "PROBLEM", 155, 170], ["genomic RNA", "OBSERVATION", 159, 170]]], ["Vaccination with Nsp16 defective SARS-CoV or an immunogenic disruption of the Nsp10/16 interface protects mice from a lethal SARS challenge 25 .INTRODUCTIONTherefore, blocking Nsp16 activity should reduce viral proliferation, making the protein an attractive drug target.INTRODUCTIONWhile several structures of Nsp10/16 in a complex with Cap-0 have been determined by crystallography (PDB entries: 6WQ3, 6WRZ, 6WVN, 6WKS), none have captured the postmethylation state.", [["Nsp16", "CHEMICAL", 17, 22], ["SARS", "DISEASE", 33, 37], ["SARS", "DISEASE", 125, 129], ["Nsp16", "GENE_OR_GENE_PRODUCT", 17, 22], ["SARS-CoV", "ORGANISM", 33, 41], ["Nsp10/16", "GENE_OR_GENE_PRODUCT", 78, 86], ["mice", "ORGANISM", 106, 110], ["Nsp16", "GENE_OR_GENE_PRODUCT", 176, 181], ["Nsp10/16", "GENE_OR_GENE_PRODUCT", 311, 319], ["Cap-0", "GENE_OR_GENE_PRODUCT", 338, 343], ["Nsp16", "PROTEIN", 17, 22], ["Nsp10/16 interface", "DNA", 78, 96], ["Nsp16", "PROTEIN", 176, 181], ["Nsp10/16", "PROTEIN", 311, 319], ["Cap-0", "PROTEIN", 338, 343], ["6WKS", "PROTEIN", 416, 420], ["mice", "SPECIES", 106, 110], ["SARS-CoV", "SPECIES", 33, 41], ["mice", "SPECIES", 106, 110], ["Vaccination", "TREATMENT", 0, 11], ["Nsp16 defective SARS", "PROBLEM", 17, 37], ["CoV", "PROBLEM", 38, 41], ["an immunogenic disruption", "PROBLEM", 45, 70], ["a lethal SARS challenge", "TREATMENT", 116, 139], ["blocking Nsp16 activity", "TREATMENT", 167, 190], ["viral proliferation", "PROBLEM", 205, 224], ["Cap", "TEST", 338, 341], ["PDB entries", "TEST", 385, 396], ["viral proliferation", "OBSERVATION", 205, 224]]], ["We conducted serial synchrotron crystallography (SSX) experiments at 297 K to test whether low radiation dose could help uncover the structure of Nsp10/16 in a complex with Cap-1.", [["Nsp10/16", "GENE_OR_GENE_PRODUCT", 146, 154], ["Cap-1", "GENE_OR_GENE_PRODUCT", 173, 178], ["Nsp10/16", "PROTEIN", 146, 154], ["Cap-1", "PROTEIN", 173, 178], ["serial synchrotron crystallography", "TEST", 13, 47], ["low radiation dose", "TREATMENT", 91, 109], ["Cap", "TEST", 173, 176]]], ["Previously, x-ray free-electron laser (XFEL) serial crystallography (SFX) had established methods to study molecular dynamics and chemical reactions in protein crystals occurring at femtosecond to millisecond timescales [26] [27] [28] .", [["x-ray", "TEST", 12, 17], ["serial crystallography (SFX", "TEST", 45, 72], ["chemical reactions in protein crystals", "PROBLEM", 130, 168]]], ["The XFEL-based protocol enabled to analyze protein structures with no radiation damage, in the so-called \"diffraction before destruction\" mode 29, 30 .", [["XFEL", "PROTEIN", 4, 8], ["The XFEL-based protocol", "TREATMENT", 0, 23], ["radiation damage", "PROBLEM", 70, 86], ["no", "UNCERTAINTY", 67, 69], ["radiation damage", "OBSERVATION", 70, 86]]], ["SFX has been successfully applied to determine the structure of the membrane protein complex of photosystem I and of several other macromolecules using time-resolved approach 29 .INTRODUCTIONThe synchrotron equivalent, SSX, uses a similar approach to SFX but can access longer, biologically relevant time scales.", [["membrane", "ANATOMY", 68, 76], ["SFX", "CHEMICAL", 0, 3], ["membrane", "CELLULAR_COMPONENT", 68, 76], ["photosystem I", "GENE_OR_GENE_PRODUCT", 96, 109], ["SFX", "SIMPLE_CHEMICAL", 251, 254], ["SFX", "PROTEIN", 0, 3], ["membrane protein complex", "PROTEIN", 68, 92], ["photosystem I", "PROTEIN", 96, 109], ["SSX", "CELL_LINE", 219, 222], ["a similar approach", "TREATMENT", 229, 247]]], ["Moreover SSX is a much more accessible technique at a number of light sources and less sample consuming than SFX 31 .", [["SSX", "CHEMICAL", 9, 12], ["SSX", "SIMPLE_CHEMICAL", 9, 12]]], ["Nonetheless, delivering hundreds of thousands of batch-grown crystals to the x-ray beam still presents challenges.", [["batch", "TREATMENT", 49, 54], ["grown crystals", "PROBLEM", 55, 69], ["the x-ray beam", "TEST", 73, 87]]], ["Two approaches are common: the first uses a liquid injector of microcrystals 29, 32, 33 , and the second uses a fixed-target system where crystals are deposited on a chip and scanned through the x-ray beam 34, 35 .", [["a liquid injector of microcrystals", "TREATMENT", 42, 76], ["a fixed-target system", "TREATMENT", 110, 131], ["a chip", "TREATMENT", 164, 170], ["the x-ray beam", "TEST", 191, 205]]], ["Here we present three crystal structures of the Nsp10/16 complex determined by fixed-target SSX at 297 K:INTRODUCTIONin the presence of SAM, Cap-0/SAM, and with Cap-1/SAH generated by metal-dependent conversion of Cap-0/SAM substrates.", [["SAH", "DISEASE", 167, 170], ["Cap-0", "CHEMICAL", 214, 219], ["SAM", "CHEMICAL", 220, 223], ["Nsp10/16", "GENE_OR_GENE_PRODUCT", 48, 56], ["Cap-0", "GENE_OR_GENE_PRODUCT", 141, 146], ["Cap-1", "GENE_OR_GENE_PRODUCT", 161, 166], ["Cap-0", "SIMPLE_CHEMICAL", 214, 219], ["SAM substrates", "SIMPLE_CHEMICAL", 220, 234], ["Nsp10/16 complex", "PROTEIN", 48, 64], ["SAM", "PROTEIN", 136, 139], ["Cap-0", "PROTEIN", 141, 146], ["SAM", "PROTEIN", 147, 150], ["Cap", "PROTEIN", 161, 164], ["Cap-0/SAM substrates", "PROTEIN", 214, 234], ["SAM", "TEST", 136, 139], ["Cap", "TEST", 141, 144], ["Cap", "TEST", 161, 164], ["SAH", "PROBLEM", 167, 170], ["Cap", "TEST", 214, 217]]], ["We compare these structures with structures of Nsp10/16 at 297 K and 100 K collected from a single crystal.", [["Nsp10/16", "CHEMICAL", 47, 55], ["Nsp10/16", "SIMPLE_CHEMICAL", 47, 55], ["Nsp10/16", "PROTEIN", 47, 55], ["K", "TEST", 63, 64], ["K", "TEST", 73, 74]]], ["The uniqueness of the Cap-1 structure shows the advantages of the SSX method in structural studies: allowing the use of larger crystals, reducing radiation damage, and being closer to physiological temperatures.Serial crystallography for the Nsp10/16 2\u2032-O MTase from SARS-CoV-2We collected SSX data for the Nsp10/16 crystals using the fixed-target SSX system (Advanced Lightweight Encapsulation Crystallography (ALEX) mesh-holder) as depicted in Figure 1A For initial data processing, we used the Kanzus automated data pipeline.", [["Cap-1", "GENE_OR_GENE_PRODUCT", 22, 27], ["Cap-1 structure", "PROTEIN", 22, 37], ["Nsp10/16 2\u2032-O MTase", "PROTEIN", 242, 261], ["SARS-CoV-2We", "DNA", 267, 279], ["Nsp10", "PROTEIN", 307, 312], ["SARS-CoV-2We", "SPECIES", 267, 279], ["larger crystals", "PROBLEM", 120, 135], ["reducing radiation damage", "PROBLEM", 137, 162], ["Serial crystallography", "TEST", 211, 233], ["SARS", "PROBLEM", 267, 271], ["CoV", "TEST", 272, 275], ["the Nsp10/16 crystals", "TREATMENT", 303, 324], ["the fixed-target SSX system", "TREATMENT", 331, 358], ["Advanced Lightweight Encapsulation Crystallography (ALEX) mesh-holder", "TREATMENT", 360, 429], ["Cap", "OBSERVATION_MODIFIER", 22, 25], ["radiation damage", "OBSERVATION", 146, 162]]], ["Extended Figure 3A presents an image with labeled indexed reflections and shows that most observed reflections of Nsp10/16 crystals were indexed.", [["Nsp10/16", "CHEMICAL", 114, 122], ["Nsp10/16", "GENE_OR_GENE_PRODUCT", 114, 122], ["an image", "TEST", 28, 36], ["Nsp10/16 crystals", "PROBLEM", 114, 131]]], ["PRIME identified inadequate low-resolution statistics from the integration files, thus we subjected them to outlier rejection.", [["outlier rejection", "PROBLEM", 108, 125], ["inadequate", "OBSERVATION_MODIFIER", 17, 27], ["low-resolution", "OBSERVATION_MODIFIER", 28, 42], ["rejection", "OBSERVATION", 116, 125]]], ["Integration files with resolution lower than 3.5 \u00c5, containing less than 90 reflections, or with a unit cell volume 4.5% different from the average were removed from the scaling process (Extended Data Tab.", [["cell", "ANATOMY", 104, 108], ["cell", "CELL", 104, 108], ["Integration files", "TEST", 0, 17], ["a unit cell volume", "TREATMENT", 97, 115], ["scaling", "OBSERVATION_MODIFIER", 170, 177]]], ["The total number of integrated files that went into PRIME for Nsp10/16 bound with SAM, Cap-1/SAH, and Cap-0/SAM were 7,951; 5,038 and 4,704 respectively.", [["SAH", "DISEASE", 93, 96], ["Nsp10/16", "GENE_OR_GENE_PRODUCT", 62, 70], ["Cap-1", "GENE_OR_GENE_PRODUCT", 87, 92], ["Cap-0", "GENE_OR_GENE_PRODUCT", 102, 107], ["PRIME", "PROTEIN", 52, 57], ["Nsp10/16", "PROTEIN", 62, 70], ["SAM", "PROTEIN", 82, 85], ["Cap", "PROTEIN", 87, 90], ["SAH", "PROTEIN", 93, 96], ["Cap", "PROTEIN", 102, 105], ["SAM", "TEST", 82, 85], ["Cap", "TEST", 87, 90], ["SAH", "PROBLEM", 93, 96], ["Cap", "TEST", 102, 105], ["SAM", "TEST", 108, 111], ["total", "OBSERVATION_MODIFIER", 4, 9], ["SAH", "OBSERVATION", 93, 96]]], ["The overall hit-rate (images used for structure divided by images taken) for the five meshes was 7%.", [["the five meshes", "TREATMENT", 77, 92]]], ["Some positions on the mesh had multiple crystals, 11% of 'hits' had two lattices, and fewer than 1% had three (Extended Data Tab.", [["the mesh", "TREATMENT", 18, 26], ["multiple crystals", "PROBLEM", 31, 48], ["positions", "OBSERVATION_MODIFIER", 5, 14], ["mesh", "OBSERVATION", 22, 26], ["multiple", "OBSERVATION_MODIFIER", 31, 39], ["crystals", "OBSERVATION_MODIFIER", 40, 48]]], ["For structure determination we used all indexed lattices in each diffraction image.Serial crystallography for the Nsp10/16 2\u2032-O MTase from SARS-CoV-2Two structures from SSX were solved at 2.25 \u00c5 (Nsp10/16/SAM and Nsp10/16/Cap-1/SAH), and a third at 2.18 \u00c5 (Nsp10/16/Cap-0/SAM) (Extended Data Tab.", [["SARS-CoV", "ORGANISM", 139, 147], ["SSX", "CANCER", 169, 172], ["Cap-1", "GENE_OR_GENE_PRODUCT", 222, 227], ["Nsp10/16 2\u2032-O MTase", "PROTEIN", 114, 133], ["SARS-CoV-2Two structures", "DNA", 139, 163], ["SAM", "PROTEIN", 205, 208], ["Cap", "PROTEIN", 222, 225], ["SAH", "PROTEIN", 228, 231], ["Nsp10/16", "PROTEIN", 257, 265], ["Cap", "PROTEIN", 266, 269], ["SAM", "PROTEIN", 272, 275], ["Extended Data Tab", "PROTEIN", 278, 295], ["SARS-CoV", "SPECIES", 139, 147], ["structure determination", "TEST", 4, 27], ["all indexed lattices", "TREATMENT", 36, 56], ["each diffraction image", "TEST", 60, 82], ["Serial crystallography", "TEST", 83, 105], ["SARS", "PROBLEM", 139, 143], ["CoV", "TEST", 144, 147], ["SSX", "TEST", 169, 172], ["SAM", "TEST", 205, 208], ["Nsp10/", "TEST", 213, 219], ["Cap", "TEST", 222, 225], ["SAH", "PROBLEM", 228, 231], ["Cap", "TEST", 266, 269]]], ["The highest resolution shell in PRIME analysis was specified using a CC1/2 cut-off below 0.40.", [["PRIME", "DNA", 32, 37], ["CC1", "PROTEIN", 69, 72], ["a CC1", "TREATMENT", 67, 72], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["resolution", "OBSERVATION_MODIFIER", 12, 22], ["shell", "OBSERVATION_MODIFIER", 23, 28]]], ["Completeness for the SSX data was close to 100% and Rwork was 20.65%, 22.31%, and 21.70% for Nsp10/16/SAM, Nsp10/16/Cap-1/SAH, and Nsp10/16/Cap-0/SAM, respectively (Extended Data Tab.", [["Cap-1", "GENE_OR_GENE_PRODUCT", 116, 121], ["SAH", "GENE_OR_GENE_PRODUCT", 122, 125], ["Cap-0", "GENE_OR_GENE_PRODUCT", 140, 145], ["SSX", "DNA", 21, 24], ["Nsp10/16", "PROTEIN", 93, 101], ["SAM", "PROTEIN", 102, 105], ["Nsp10", "PROTEIN", 107, 112], ["Cap", "PROTEIN", 116, 119], ["SAH", "PROTEIN", 122, 125], ["Nsp10", "PROTEIN", 131, 136], ["Cap", "DNA", 140, 143], ["SAM", "DNA", 146, 149], ["the SSX data", "TEST", 17, 29], ["Nsp10/16", "TEST", 93, 101], ["SAM", "TEST", 102, 105], ["Nsp10", "TEST", 107, 112], ["Cap", "TEST", 116, 119], ["SAH", "PROBLEM", 122, 125], ["Nsp10", "TEST", 131, 136], ["Cap", "TEST", 140, 143], ["SAH", "OBSERVATION", 122, 125]]], ["For a comparison to SSX data, we also collected data from a single crystal of the Nsp10/16 with Cap-0/SAM and Cap-1/SAH in a capillary at 297 K. These data could only beprocessed to 2.65 \u00c5 with reasonable statistics (Extended Data Tab.", [["capillary", "ANATOMY", 125, 134], ["SAH", "DISEASE", 116, 119], ["Cap-0", "CHEMICAL", 96, 101], ["Nsp10/16", "SIMPLE_CHEMICAL", 82, 90], ["Cap-0", "SIMPLE_CHEMICAL", 96, 101], ["Cap-1", "SIMPLE_CHEMICAL", 110, 115], ["SAH", "SIMPLE_CHEMICAL", 116, 119], ["capillary", "TISSUE", 125, 134], ["Cap-0", "PROTEIN", 96, 101], ["SAM", "PROTEIN", 102, 105], ["Cap", "PROTEIN", 110, 113], ["Cap", "TEST", 96, 99], ["SAM", "TEST", 102, 105], ["Cap", "TEST", 110, 113], ["SAH", "PROBLEM", 116, 119], ["SAH", "OBSERVATION", 116, 119]]], ["Using RADDOSE-3D 37 , we estimated the accumulated dose of x-ray for Nsp10/16 from SSX to be 0.12 MGy, whereas the dose for the capillary-mounted crystal was 4.97 MGy over 40 times higher.K structure of the Nsp10/16 heterodimer from SARS-CoV-2The Nsp10/16 complex is an a/b heterodimer (Fig. 2) .", [["capillary", "ANATOMY", 128, 137], ["K", "CHEMICAL", 188, 189], ["capillary", "TISSUE", 128, 137], ["Nsp10/16", "GENE_OR_GENE_PRODUCT", 207, 215], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 233, 243], ["Nsp10/16", "GENE_OR_GENE_PRODUCT", 247, 255], ["RADDOSE-3D 37", "DNA", 6, 19], ["Nsp10/16 heterodimer", "PROTEIN", 207, 227], ["Nsp10/16 complex", "PROTEIN", 247, 263], ["/b heterodimer", "PROTEIN", 271, 285], ["SARS-CoV", "SPECIES", 233, 241], ["x-ray", "TEST", 59, 64], ["SSX", "TEST", 83, 86], ["the capillary-mounted crystal", "TREATMENT", 124, 153], ["K structure", "TEST", 188, 199], ["SARS", "TEST", 233, 237], ["CoV", "TEST", 238, 241], ["an a/b heterodimer", "TREATMENT", 267, 285]]], ["The 139 amino acid long Nsp10 has unique fold formed by 5 \u03b1-helices and a pair of antiparallel \u03b2-strands which are facing Nsp16 in the complex.", [["amino acid", "CHEMICAL", 8, 18], ["Nsp10", "CHEMICAL", 24, 29], ["amino acid", "CHEMICAL", 8, 18], ["amino acid", "AMINO_ACID", 8, 18], ["Nsp10", "AMINO_ACID", 24, 29], ["Nsp16", "GENE_OR_GENE_PRODUCT", 122, 127], ["139 amino acid long Nsp10", "PROTEIN", 4, 29], ["\u03b1-helices", "PROTEIN", 58, 67], ["antiparallel \u03b2-strands", "PROTEIN", 82, 104], ["Nsp16", "PROTEIN", 122, 127], ["The 139 amino acid long Nsp10", "TREATMENT", 0, 29], ["a pair of antiparallel \u03b2-strands", "TREATMENT", 72, 104]]], ["Nsp10 possesses two zinc ions coordinated by the CCHC and CCCC motifs that are 100% conserved in \u03b2-coronaviruses 20 .", [["Nsp10", "CHEMICAL", 0, 5], ["zinc", "CHEMICAL", 20, 24], ["zinc", "CHEMICAL", 20, 24], ["Nsp10", "GENE_OR_GENE_PRODUCT", 0, 5], ["CCHC", "GENE_OR_GENE_PRODUCT", 49, 53], ["Nsp10", "PROTEIN", 0, 5], ["CCHC and CCCC motifs", "DNA", 49, 69], ["two zinc ions", "TREATMENT", 16, 29], ["two", "OBSERVATION_MODIFIER", 16, 19], ["zinc ions", "OBSERVATION", 20, 29]]], ["Nsp10 is involved in forming the complexes with multiple SARS-CoV-1 and -2 proteins.", [["Nsp10", "GENE_OR_GENE_PRODUCT", 0, 5], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 57, 67], ["-2", "GENE_OR_GENE_PRODUCT", 72, 74], ["Nsp10", "PROTEIN", 0, 5], ["SARS-CoV-1 and -2 proteins", "PROTEIN", 57, 83], ["Nsp10", "TEST", 0, 5], ["multiple SARS", "TEST", 48, 61], ["CoV", "TEST", 62, 65]]], ["The best characterized is the complex with Nsp14 3\u2032-5\u2032 exoribonuclease (and guanine N7 methyltransferase) and Nsp16 that is 2\u2032-O-ribose methylase.K structure of the Nsp10/16 heterodimer from SARS-CoV-2Previous research showed that Nsp16 is only active in the presence of Nsp10 19 .", [["guanine", "CHEMICAL", 76, 83], ["2\u2032-O-ribose", "CHEMICAL", 124, 135], ["K", "CHEMICAL", 146, 147], ["guanine", "CHEMICAL", 76, 83], ["2\u2032-O-ribose", "CHEMICAL", 124, 135], ["Nsp14", "GENE_OR_GENE_PRODUCT", 43, 48], ["guanine N7 methyltransferase", "GENE_OR_GENE_PRODUCT", 76, 104], ["Nsp16", "GENE_OR_GENE_PRODUCT", 110, 115], ["2\u2032-O-ribose methylase", "SIMPLE_CHEMICAL", 124, 145], ["Nsp10/16", "GENE_OR_GENE_PRODUCT", 165, 173], ["SARS-CoV", "ORGANISM", 191, 199], ["Nsp16", "GENE_OR_GENE_PRODUCT", 231, 236], ["Nsp14 3\u2032-5\u2032 exoribonuclease", "PROTEIN", 43, 70], ["guanine N7 methyltransferase", "PROTEIN", 76, 104], ["Nsp16", "PROTEIN", 110, 115], ["2\u2032-O-ribose methylase", "PROTEIN", 124, 145], ["Nsp10/16 heterodimer", "PROTEIN", 165, 185], ["Nsp16", "PROTEIN", 231, 236], ["Nsp10 19", "PROTEIN", 271, 279], ["Nsp14", "TEST", 43, 48], ["exoribonuclease", "TREATMENT", 55, 70], ["guanine N7 methyltransferase", "TREATMENT", 76, 104], ["ribose methylase", "TREATMENT", 129, 145], ["K structure", "TEST", 146, 157], ["SARS-CoV", "TEST", 191, 199], ["Nsp10", "TEST", 271, 276], ["ribose methylase", "OBSERVATION", 129, 145], ["active", "OBSERVATION_MODIFIER", 245, 251]]], ["Interestingly, the activity of 2\u2032-O MTase of the Nsp10/16 complex was reduced by using a peptide compound based on the Nsp10 sequence 38 .", [["2\u2032-O MTase", "GENE_OR_GENE_PRODUCT", 31, 41], ["Nsp10/16", "GENE_OR_GENE_PRODUCT", 49, 57], ["2\u2032-O MTase", "PROTEIN", 31, 41], ["Nsp10/16 complex", "PROTEIN", 49, 65], ["Nsp10 sequence 38", "DNA", 119, 136], ["a peptide compound", "TREATMENT", 87, 105], ["the Nsp10 sequence", "TEST", 115, 133], ["activity", "OBSERVATION_MODIFIER", 19, 27]]], ["Nsp10 is a molecular co-factor for various SARS-CoV-2 enzymes and therefore a good candidate for design of molecules that will affect its structure or disrupt the interaction with Nsp14 or Nsp16 2\u2032-O MTases.K structure of the Nsp10/16 heterodimer from SARS-CoV-2The structure of Nsp16 is characterized by a Rossmann fold, with a large \u03b2-sheet surrounded by \u03b1-helices, \u03b2-strands and loops.", [["K", "CHEMICAL", 207, 208], ["Nsp10", "GENE_OR_GENE_PRODUCT", 0, 5], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 43, 53], ["Nsp14", "GENE_OR_GENE_PRODUCT", 180, 185], ["\u2032-O MTases", "GENE_OR_GENE_PRODUCT", 196, 206], ["Nsp10/16", "GENE_OR_GENE_PRODUCT", 226, 234], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 252, 262], ["Nsp16", "GENE_OR_GENE_PRODUCT", 279, 284], ["\u03b1-helices", "SIMPLE_CHEMICAL", 357, 366], ["Nsp10", "PROTEIN", 0, 5], ["SARS-CoV-2 enzymes", "PROTEIN", 43, 61], ["Nsp14", "PROTEIN", 180, 185], ["Nsp16 2\u2032-O MTases", "PROTEIN", 189, 206], ["Nsp10/16 heterodimer", "PROTEIN", 226, 246], ["Nsp16", "PROTEIN", 279, 284], ["Rossmann fold", "PROTEIN", 307, 320], ["\u03b2-sheet", "PROTEIN", 335, 342], ["\u03b1-helices", "PROTEIN", 357, 366], ["\u03b2-strands", "PROTEIN", 368, 377], ["various SARS", "TEST", 35, 47], ["CoV-2 enzymes", "TEST", 48, 61], ["design of molecules", "TREATMENT", 97, 116], ["Nsp", "TEST", 189, 192], ["K structure", "TEST", 207, 218], ["SARS-CoV", "TEST", 252, 260], ["a Rossmann fold", "PROBLEM", 305, 320], ["a large \u03b2-sheet", "TREATMENT", 327, 342], ["Rossmann fold", "OBSERVATION", 307, 320], ["large", "OBSERVATION_MODIFIER", 329, 334], ["loops", "ANATOMY_MODIFIER", 382, 387]]], ["Nsp16 contains 11 \u03b1-helices, 12 \u03b2-strands and 7 loops.", [["Nsp16", "GENE_OR_GENE_PRODUCT", 0, 5], ["Nsp16", "PROTEIN", 0, 5], ["\u03b1-helices", "PROTEIN", 18, 27], ["\u03b2", "PROTEIN", 32, 33], ["Nsp16", "TEST", 0, 5], ["helices", "TEST", 20, 27]]], ["Nsp16 has a centrally positioned \u03b2-sheet (\u03b23\u2191,\u03b22\u2191,\u03b21\u2191,\u03b24\u2191,\u03b25\u2191,\u03b27\u2193,\u03b26\u2191) with only one antiparallel strand \u03b27.", [["Nsp16", "CHEMICAL", 0, 5], ["Nsp16", "GENE_OR_GENE_PRODUCT", 0, 5], ["\u03b23\u2191", "GENE_OR_GENE_PRODUCT", 42, 45], ["\u03b22\u2191", "GENE_OR_GENE_PRODUCT", 46, 49], ["\u03b21\u2191", "GENE_OR_GENE_PRODUCT", 50, 53], ["\u03b24\u2191", "GENE_OR_GENE_PRODUCT", 54, 57], ["\u03b25\u2191", "GENE_OR_GENE_PRODUCT", 58, 61], ["\u03b27\u2193", "GENE_OR_GENE_PRODUCT", 62, 65], ["\u03b26\u2191", "GENE_OR_GENE_PRODUCT", 66, 69], ["Nsp16", "PROTEIN", 0, 5], ["\u03b2-sheet", "PROTEIN", 33, 40], ["\u03b23\u2191", "DNA", 42, 45], ["\u03b22\u2191", "DNA", 46, 49], ["\u03b21\u2191", "DNA", 50, 53], ["\u03b24\u2191", "DNA", 54, 57], ["\u03b25\u2191", "DNA", 58, 61], ["\u03b27\u2193", "DNA", 62, 65], ["\u03b26\u2191", "DNA", 66, 69], ["antiparallel strand \u03b27", "DNA", 85, 107], ["Nsp16", "TEST", 0, 5], ["sheet", "TEST", 35, 40], ["\u03b2", "TEST", 46, 47], ["\u03b2", "TEST", 50, 51], ["\u03b2", "TEST", 54, 55], ["\u03b2", "TEST", 58, 59], ["\u03b2", "TEST", 62, 63], ["antiparallel strand", "OBSERVATION", 85, 104]]], ["The SAM and the Cap binding sites are located at the surface of Nsp16.", [["surface", "ANATOMY", 53, 60], ["Cap", "GENE_OR_GENE_PRODUCT", 16, 19], ["surface", "CELLULAR_COMPONENT", 53, 60], ["Nsp16", "GENE_OR_GENE_PRODUCT", 64, 69], ["SAM and the Cap binding sites", "DNA", 4, 33], ["Nsp16", "PROTEIN", 64, 69], ["The SAM and the Cap binding sites", "PROBLEM", 0, 33], ["SAM", "OBSERVATION_MODIFIER", 4, 7], ["Cap", "OBSERVATION_MODIFIER", 16, 19], ["binding sites", "OBSERVATION", 20, 33]]], ["None of the Nsp10 residues have a direct connection with the ligands' binding sites ( Fig. 2A, 2C ), but Nsp10 is required for Nsp16 MTase activity 21 .", [["Nsp10", "GENE_OR_GENE_PRODUCT", 12, 17], ["Nsp10", "GENE_OR_GENE_PRODUCT", 105, 110], ["Nsp16 MTase", "GENE_OR_GENE_PRODUCT", 127, 138], ["Nsp10 residues", "PROTEIN", 12, 26], ["binding sites", "PROTEIN", 70, 83], ["Nsp10", "PROTEIN", 105, 110], ["Nsp16", "PROTEIN", 127, 132], ["the Nsp10 residues", "PROBLEM", 8, 26]]], ["Additionally, we observed partial electron density for the 7-methyl-guanosite-5\u2032-triphosphate ( m7 Gppp) of the Cap in the possible allosteric site of the We also compared the two structures of Nsp10/16/SAM determined at 297 K (this work PDB entry 7JIB) and 100 K (PDB entry 6W4H) (C\u03b1 RMSD: 0.35 \u00c5) and observed significant differences: one loop from the Cap binding pocket is shifted approximately 1.4 \u00c5 in 297 K structures, which makes the Cap binding site more accessible (Extended Data Fig. 4D) .", [["7-methyl-guanosite-5\u2032-triphosphate", "CHEMICAL", 59, 93], ["Nsp10", "CHEMICAL", 194, 199], ["7-methyl-guanosite-5\u2032-triphosphate", "CHEMICAL", 59, 93], ["m7 Gppp", "CHEMICAL", 96, 103], ["electron", "SIMPLE_CHEMICAL", 34, 42], ["7-methyl-guanosite-5\u2032-triphosphate", "SIMPLE_CHEMICAL", 59, 93], ["m7 Gppp", "SIMPLE_CHEMICAL", 96, 103], ["Cap", "GENE_OR_GENE_PRODUCT", 112, 115], ["Cap", "PROTEIN", 112, 115], ["Nsp10/16/SAM", "PROTEIN", 194, 206], ["7JIB", "PROTEIN", 248, 252], ["PDB entry 6W4H", "PROTEIN", 265, 279], ["C\u03b1 RMSD", "PROTEIN", 282, 289], ["Cap binding pocket", "PROTEIN", 355, 373], ["Cap binding site", "DNA", 442, 458], ["partial electron density", "TEST", 26, 50], ["guanosite", "TEST", 68, 77], ["the Cap", "PROBLEM", 108, 115], ["Nsp10", "TEST", 194, 199], ["K (PDB entry", "TEST", 262, 274], ["RMSD", "TEST", 285, 289], ["the Cap binding pocket", "PROBLEM", 351, 373], ["the Cap binding site", "PROBLEM", 438, 458], ["partial", "OBSERVATION_MODIFIER", 26, 33], ["electron density", "OBSERVATION", 34, 50], ["Cap", "OBSERVATION_MODIFIER", 112, 115], ["possible", "UNCERTAINTY", 123, 131], ["allosteric site", "OBSERVATION", 132, 147], ["significant", "OBSERVATION_MODIFIER", 312, 323], ["Cap", "OBSERVATION_MODIFIER", 355, 358], ["binding pocket", "OBSERVATION", 359, 373]]], ["Therefore, the 297 K structures of Nsp10/16 in a complex with SAM, Cap-0/SAM, and Cap-1/SAH, as determined by SSX, depict states important for molecular modeling studies and structure-based drug design.K structure of the Nsp10/16 heterodimer from SARS-CoV-2To better understand Nsp16 activity from SARS-CoV-2, we compared it with NS5 2\u2032-O MTase from Dengue virus (PDB entry 5DTO) (Fig. 3) .", [["SAH", "DISEASE", 88, 91], ["K", "CHEMICAL", 202, 203], ["Nsp10/16", "GENE_OR_GENE_PRODUCT", 35, 43], ["Cap-0", "GENE_OR_GENE_PRODUCT", 67, 72], ["SAM", "GENE_OR_GENE_PRODUCT", 73, 76], ["Cap-1", "GENE_OR_GENE_PRODUCT", 82, 87], ["SAH", "SIMPLE_CHEMICAL", 88, 91], ["SSX", "SIMPLE_CHEMICAL", 110, 113], ["Nsp10/16", "GENE_OR_GENE_PRODUCT", 221, 229], ["SARS-CoV-2To", "ORGANISM", 247, 259], ["Nsp16", "GENE_OR_GENE_PRODUCT", 278, 283], ["Dengue virus", "ORGANISM", 350, 362], ["Nsp10/16", "PROTEIN", 35, 43], ["SAM", "PROTEIN", 62, 65], ["Cap", "PROTEIN", 67, 70], ["SAM", "PROTEIN", 73, 76], ["Cap", "PROTEIN", 82, 85], ["SSX", "PROTEIN", 110, 113], ["Nsp10/16 heterodimer", "PROTEIN", 221, 241], ["Nsp16", "PROTEIN", 278, 283], ["NS5 2\u2032-O MTase", "PROTEIN", 330, 344], ["Dengue virus", "SPECIES", 350, 362], ["Dengue virus", "SPECIES", 350, 362], ["Nsp10", "TEST", 35, 40], ["SAM", "TEST", 62, 65], ["Cap", "TEST", 67, 70], ["SAM", "TEST", 73, 76], ["Cap", "TEST", 82, 85], ["SAH", "PROBLEM", 88, 91], ["molecular modeling studies", "TEST", 143, 169], ["K structure", "TEST", 202, 213], ["the Nsp10/16 heterodimer", "TEST", 217, 241], ["SARS", "TEST", 247, 251], ["CoV", "TEST", 252, 255], ["SARS", "PROBLEM", 298, 302], ["CoV", "TEST", 303, 306], ["Dengue virus", "PROBLEM", 350, 362], ["SAH", "OBSERVATION", 88, 91]]], ["We aligned the structure of Nsp16 with the Nterminal domain of NS5 that spans 298 residues from N-terminus.", [["N", "CHEMICAL", 96, 97], ["Nsp16", "GENE_OR_GENE_PRODUCT", 28, 33], ["NS5", "GENE_OR_GENE_PRODUCT", 63, 66], ["Nsp16", "PROTEIN", 28, 33], ["Nterminal domain", "PROTEIN", 43, 59], ["NS5", "PROTEIN", 63, 66], ["N-terminus", "PROTEIN", 96, 106], ["Nsp16", "TREATMENT", 28, 33], ["the Nterminal domain of NS5", "TREATMENT", 39, 66]]], ["Both Nsp16 and NS5 2\u2032-O MTases assume a Rossmann fold with a large \u03b2-sheet decorated with \u03b1-helices (Fig. 3B, D) .K structure of the Nsp10/16 heterodimer from SARS-CoV-2MTases contain a central \u03b2-sheet that is composed of six parallel and one antiparallel strands.K structure of the Nsp10/16 heterodimer from SARS-CoV-2Despite low sequence identity (13.6%) the RMSD between the two MTases is reasonable (3.01 \u00c5).K structure of the Nsp10/16 heterodimer from SARS-CoV-2Both enzymes possess a canonical 2\u2032-O MTase catalytic tetrad Lys-Asp-Lys-Glu with the aspartic acid residue forming a hydrogen bond with a water molecule potentially relevant for catalysis ( Fig. 3A, C) .", [["K", "CHEMICAL", 114, 115], ["K", "CHEMICAL", 264, 265], ["SARS", "DISEASE", 309, 313], ["K", "CHEMICAL", 412, 413], ["Lys-", "CHEMICAL", 528, 532], ["Asp-Lys-Glu", "CHEMICAL", 532, 543], ["aspartic acid", "CHEMICAL", 553, 566], ["2\u2032-O", "CHEMICAL", 500, 504], ["Lys-Asp-Lys-Glu", "CHEMICAL", 528, 543], ["aspartic acid", "CHEMICAL", 553, 566], ["hydrogen", "CHEMICAL", 585, 593], ["Nsp16", "GENE_OR_GENE_PRODUCT", 5, 10], ["NS5 2\u2032-O MTases", "GENE_OR_GENE_PRODUCT", 15, 30], ["Nsp10/16", "GENE_OR_GENE_PRODUCT", 133, 141], ["Nsp10/16", "GENE_OR_GENE_PRODUCT", 283, 291], ["SARS-CoV", "ORGANISM", 309, 317], ["Nsp10/16", "GENE_OR_GENE_PRODUCT", 431, 439], ["SARS-CoV-2Both enzymes", "GENE_OR_GENE_PRODUCT", 457, 479], ["Lys-Asp-Lys-Glu", "SIMPLE_CHEMICAL", 528, 543], ["aspartic acid", "AMINO_ACID", 553, 566], ["residue", "AMINO_ACID", 567, 574], ["Nsp16", "PROTEIN", 5, 10], ["NS5 2\u2032-O MTases", "PROTEIN", 15, 30], ["Rossmann fold", "PROTEIN", 40, 53], ["\u03b2-sheet", "PROTEIN", 67, 74], ["\u03b1-helices", "PROTEIN", 90, 99], ["Fig. 3B, D", "PROTEIN", 101, 111], ["Nsp10/16 heterodimer", "PROTEIN", 133, 153], ["SARS-CoV-2MTases", "PROTEIN", 159, 175], ["\u03b2-sheet", "PROTEIN", 194, 201], ["antiparallel strands", "PROTEIN", 243, 263], ["Nsp10/16 heterodimer", "PROTEIN", 283, 303], ["Nsp10/16 heterodimer", "PROTEIN", 431, 451], ["SARS-CoV-2Both enzymes", "PROTEIN", 457, 479], ["canonical 2\u2032-O MTase", "PROTEIN", 490, 510], ["SARS-CoV", "SPECIES", 309, 317], ["SARS-CoV", "SPECIES", 457, 465], ["NS5", "TREATMENT", 15, 18], ["a Rossmann fold", "PROBLEM", 38, 53], ["a large \u03b2-sheet", "TREATMENT", 59, 74], ["K structure", "TEST", 114, 125], ["the Nsp10/16 heterodimer", "TEST", 129, 153], ["SARS", "TEST", 159, 163], ["CoV", "TEST", 164, 167], ["a central \u03b2-sheet", "TREATMENT", 184, 201], ["K structure", "TEST", 264, 275], ["the Nsp10/16 heterodimer", "TEST", 279, 303], ["SARS", "TEST", 309, 313], ["CoV", "TEST", 314, 317], ["low sequence identity", "PROBLEM", 327, 348], ["K structure", "TEST", 412, 423], ["the Nsp10/16 heterodimer", "TEST", 427, 451], ["SARS", "TEST", 457, 461], ["CoV", "TEST", 462, 465], ["2Both enzymes", "TEST", 466, 479], ["Asp", "TEST", 532, 535], ["Lys", "TEST", 536, 539], ["Glu", "TEST", 540, 543], ["the aspartic acid residue", "PROBLEM", 549, 574], ["a hydrogen bond", "PROBLEM", 583, 598], ["a water molecule", "TREATMENT", 604, 620], ["large", "OBSERVATION_MODIFIER", 61, 66], ["central", "ANATOMY_MODIFIER", 186, 193], ["antiparallel strands", "OBSERVATION", 243, 263], ["hydrogen bond", "OBSERVATION", 585, 598]]], ["The SAM binding sites share high similarity but there are major differences in the mRNA Cap binding sites.", [["Cap", "GENE_OR_GENE_PRODUCT", 88, 91], ["SAM binding sites", "DNA", 4, 21], ["mRNA Cap binding sites", "DNA", 83, 105], ["The SAM binding sites", "PROBLEM", 0, 21], ["high similarity", "OBSERVATION", 28, 43], ["major", "OBSERVATION_MODIFIER", 58, 63], ["differences", "OBSERVATION_MODIFIER", 64, 75], ["Cap", "OBSERVATION_MODIFIER", 88, 91], ["binding sites", "OBSERVATION", 92, 105]]], ["The Mg 2+ or Mn 2+ ion is necessary for Nsp16 activity 39 , however is not localized near the active site in the currently available structures of Nsp10/16 from SARS-CoV-1 and SARS-CoV-2.", [["Mg", "CHEMICAL", 4, 6], ["Mn", "CHEMICAL", 13, 15], ["Mg 2+", "CHEMICAL", 4, 9], ["Mn 2+", "CHEMICAL", 13, 18], ["Mg 2+", "SIMPLE_CHEMICAL", 4, 9], ["Mn 2+", "SIMPLE_CHEMICAL", 13, 18], ["Nsp16", "GENE_OR_GENE_PRODUCT", 40, 45], ["Nsp10/16", "GENE_OR_GENE_PRODUCT", 147, 155], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 161, 171], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 176, 186], ["Nsp16", "PROTEIN", 40, 45], ["Nsp10/16", "PROTEIN", 147, 155], ["SARS-CoV", "SPECIES", 176, 184], ["The Mg", "TEST", 0, 6], ["Mn", "TEST", 13, 15], ["Nsp16 activity", "TEST", 40, 54], ["SARS", "TEST", 161, 165], ["CoV", "TEST", 166, 169], ["SARS", "TEST", 176, 180], ["CoV", "TEST", 181, 184], ["active", "OBSERVATION_MODIFIER", 94, 100], ["site", "OBSERVATION", 101, 105]]], ["The Mg 2+ ion in the N-terminal domain of NS5 2\u2032-O MTase is coordinated by the phosphate oxygens of the Cap 5\u2032 to 5\u2032 triphosphate linker and three water molecules that bridge to three bases (A1-G2-U3) on the 5\u2032-end.2\u2032-O methylation of the SARS-CoV-2 transcriptsThe SARS-CoV-2 Nsp10/16 2\u2032-O MTase complex provides a molecular arrangement for binding of the mRNA Cap-0 and subsequent methylation of the first transcribed nucleotide.2\u2032-O methylation of the SARS-CoV-2 transcriptsThe catalytic core is in the center of the Rossmann fold and it binds the SAM molecule in the deep, narrow grove that is buried inside the Nsp16 active site.", [["Mg", "CHEMICAL", 4, 6], ["phosphate", "CHEMICAL", 79, 88], ["Cap 5\u2032 to 5\u2032 triphosphate", "CHEMICAL", 104, 129], ["nucleotide", "CHEMICAL", 419, 429], ["Mg 2+", "CHEMICAL", 4, 9], ["N", "CHEMICAL", 21, 22], ["phosphate oxygens", "CHEMICAL", 79, 96], ["Cap 5\u2032 to 5\u2032 triphosphate", "CHEMICAL", 104, 129], ["2\u2032-O", "CHEMICAL", 215, 219], ["nucleotide", "CHEMICAL", 419, 429], ["2\u2032-O", "CHEMICAL", 430, 434], ["SAM", "CHEMICAL", 550, 553], ["Mg 2+", "SIMPLE_CHEMICAL", 4, 9], ["NS5 2\u2032-O MTase", "GENE_OR_GENE_PRODUCT", 42, 56], ["phosphate oxygens", "SIMPLE_CHEMICAL", 79, 96], ["5\u2032 triphosphate linker", "SIMPLE_CHEMICAL", 114, 136], ["2\u2032-O", "SIMPLE_CHEMICAL", 215, 219], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 239, 249], ["2\u2032-O MTase", "GENE_OR_GENE_PRODUCT", 285, 295], ["Cap-0", "GENE_OR_GENE_PRODUCT", 361, 366], ["2\u2032-O", "SIMPLE_CHEMICAL", 430, 434], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 454, 464], ["N-terminal domain", "PROTEIN", 21, 38], ["NS5 2\u2032-O MTase", "PROTEIN", 42, 56], ["Cap 5\u2032 to 5\u2032 triphosphate linker", "PROTEIN", 104, 136], ["A1", "PROTEIN", 191, 193], ["G2", "PROTEIN", 194, 196], ["U3", "PROTEIN", 197, 199], ["5\u2032-end", "PROTEIN", 208, 214], ["SARS-CoV-2 transcripts", "RNA", 239, 261], ["SARS-CoV-2 Nsp10/16 2\u2032-O MTase complex", "PROTEIN", 265, 303], ["mRNA Cap-0", "DNA", 356, 366], ["SARS-CoV-2 transcripts", "RNA", 454, 476], ["Rossmann fold", "PROTEIN", 519, 532], ["SAM molecule", "PROTEIN", 550, 562], ["Nsp16 active site", "PROTEIN", 615, 632], ["The Mg", "TEST", 0, 6], ["NS5", "TEST", 42, 45], ["the phosphate oxygens of the Cap", "TREATMENT", 75, 107], ["triphosphate linker", "TREATMENT", 117, 136], ["three water molecules", "TREATMENT", 141, 162], ["the SARS", "TEST", 235, 243], ["CoV", "TEST", 244, 247], ["The SARS", "TEST", 261, 269], ["CoV", "TEST", 270, 273], ["Nsp", "TEST", 276, 279], ["the mRNA Cap", "TEST", 352, 364], ["the SARS", "PROBLEM", 450, 458], ["bases", "ANATOMY_MODIFIER", 184, 189], ["catalytic", "OBSERVATION_MODIFIER", 480, 489], ["core", "OBSERVATION_MODIFIER", 490, 494], ["center", "ANATOMY_MODIFIER", 505, 511], ["Rossmann fold", "ANATOMY", 519, 532], ["SAM", "OBSERVATION_MODIFIER", 550, 553], ["molecule", "OBSERVATION_MODIFIER", 554, 562], ["deep", "ANATOMY_MODIFIER", 570, 574], ["narrow", "OBSERVATION_MODIFIER", 576, 582], ["grove", "OBSERVATION_MODIFIER", 583, 588], ["buried", "OBSERVATION_MODIFIER", 597, 603], ["Nsp16", "OBSERVATION_MODIFIER", 615, 620], ["active", "OBSERVATION_MODIFIER", 621, 627], ["site", "OBSERVATION_MODIFIER", 628, 632]]], ["We observed that Nsp16 had recruited SAM during expression in E. coli (PDB entry 6W61) 20 .", [["Nsp16", "GENE_OR_GENE_PRODUCT", 17, 22], ["E. coli", "ORGANISM", 62, 69], ["Nsp16", "PROTEIN", 17, 22], ["SAM", "PROTEIN", 37, 40], ["E. coli", "SPECIES", 62, 69], ["E. coli", "SPECIES", 62, 69], ["E. coli (PDB entry", "TREATMENT", 62, 80]]], ["However, addition of 2 mM SAM to the crystallization solution improves crystallization efficiency, reduces crystallization time, and increases the number of crystals -three highly desirable traits for SSX batch crystallization.2\u2032-O methylation of the SARS-CoV-2 transcriptsThe SAM binding site is negatively charged and is formed by several Nsp16 residues: Asn43, Tyr47, Gly71, Ala72, Gly73, Ser 74, Gly81, Thr82, Asp99, Leu100, Asn101, Asp114, Cys115, Asp130, Met131, and Phe149 (Fig. 2, 4, Extended Data Fig. 5B ).", [["SAM", "CHEMICAL", 26, 29], ["SSX", "CHEMICAL", 201, 204], ["SAM", "CHEMICAL", 26, 29], ["2\u2032-O", "CHEMICAL", 227, 231], ["Nsp16", "CHEMICAL", 341, 346], ["Asn43", "CHEMICAL", 357, 362], ["Tyr47", "CHEMICAL", 364, 369], ["Gly71", "CHEMICAL", 371, 376], ["Ala72", "CHEMICAL", 378, 383], ["Gly73", "CHEMICAL", 385, 390], ["Ser", "CHEMICAL", 392, 395], ["Gly81", "CHEMICAL", 400, 405], ["Thr82", "CHEMICAL", 407, 412], ["Asp99", "CHEMICAL", 414, 419], ["Leu100", "CHEMICAL", 421, 427], ["Asn101", "CHEMICAL", 429, 435], ["Asp", "CHEMICAL", 437, 440], ["Cys", "CHEMICAL", 445, 448], ["Asp", "CHEMICAL", 453, 456], ["Met131", "CHEMICAL", 461, 467], ["Phe149", "CHEMICAL", 473, 479], ["SSX", "SIMPLE_CHEMICAL", 201, 204], ["2\u2032-O", "SIMPLE_CHEMICAL", 227, 231], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 251, 261], ["Asn43", "GENE_OR_GENE_PRODUCT", 357, 362], ["Tyr47", "GENE_OR_GENE_PRODUCT", 364, 369], ["Gly71", "GENE_OR_GENE_PRODUCT", 371, 376], ["Ala72", "GENE_OR_GENE_PRODUCT", 378, 383], ["Gly73", "GENE_OR_GENE_PRODUCT", 385, 390], ["Ser 74", "AMINO_ACID", 392, 398], ["Gly81", "GENE_OR_GENE_PRODUCT", 400, 405], ["Thr82", "GENE_OR_GENE_PRODUCT", 407, 412], ["Asp99", "GENE_OR_GENE_PRODUCT", 414, 419], ["Leu100", "GENE_OR_GENE_PRODUCT", 421, 427], ["Asn101", "GENE_OR_GENE_PRODUCT", 429, 435], ["Asp114", "AMINO_ACID", 437, 443], ["Cys115", "AMINO_ACID", 445, 451], ["Asp130", "AMINO_ACID", 453, 459], ["Met131", "GENE_OR_GENE_PRODUCT", 461, 467], ["SARS-CoV-2 transcripts", "RNA", 251, 273], ["SAM binding site", "DNA", 277, 293], ["Nsp16 residues", "PROTEIN", 341, 355], ["Thr82", "PROTEIN", 407, 412], ["Asp99", "PROTEIN", 414, 419], ["Asn101", "PROTEIN", 429, 435], ["2 mM SAM to the crystallization solution", "TREATMENT", 21, 61], ["crystallization efficiency", "PROBLEM", 71, 97], ["SSX batch crystallization", "TREATMENT", 201, 226], ["the SARS", "PROBLEM", 247, 255], ["The SAM binding site", "PROBLEM", 273, 293], ["Asn43", "TEST", 357, 362], ["Tyr47", "TEST", 364, 369], ["Gly71", "TEST", 371, 376], ["Ala72", "TEST", 378, 383], ["Ser", "TEST", 392, 395], ["Gly81", "TEST", 400, 405], ["Asp99", "TEST", 414, 419], ["Leu100", "TEST", 421, 427], ["Asn101", "TEST", 429, 435], ["Asp", "TEST", 437, 440], ["Cys", "TEST", 445, 448], ["Asp", "TEST", 453, 456], ["Met131", "TEST", 461, 467], ["Phe149", "TEST", 473, 479], ["Fig.", "TEST", 481, 485], ["crystallization efficiency", "OBSERVATION", 71, 97], ["increases", "OBSERVATION_MODIFIER", 133, 142], ["negatively", "OBSERVATION_MODIFIER", 297, 307], ["charged", "OBSERVATION", 308, 315]]], ["The SAM carboxylate moiety binds to the positively charged N-terminus of the third a-helix spanning Pro80-Trp88.", [["SAM carboxylate", "CHEMICAL", 4, 19], ["SAM carboxylate", "CHEMICAL", 4, 19], ["N", "CHEMICAL", 59, 60], ["SAM carboxylate", "SIMPLE_CHEMICAL", 4, 19], ["Pro80-Trp88", "GENE_OR_GENE_PRODUCT", 100, 111], ["N-terminus", "PROTEIN", 59, 69], ["a-helix", "PROTEIN", 83, 90], ["Pro80", "PROTEIN", 100, 105], ["Trp88", "PROTEIN", 106, 111], ["The SAM carboxylate moiety binds", "TREATMENT", 0, 32]]], ["This interaction provides additional electrostatic stabilization.", [["additional electrostatic stabilization", "TREATMENT", 26, 64], ["electrostatic stabilization", "OBSERVATION", 37, 64]]], ["Nsp16 directly interacts with Cap-1 through several residues that form a positively charged, elongated binding groove accommodating the mRNA Cap-0 (Fig. 2, 4 , Extended Data 5A).", [["Nsp16", "GENE_OR_GENE_PRODUCT", 0, 5], ["Cap-1", "GENE_OR_GENE_PRODUCT", 30, 35], ["Nsp16", "PROTEIN", 0, 5], ["Cap-1", "PROTEIN", 30, 35], ["mRNA Cap-0", "DNA", 136, 146], ["Cap", "TEST", 30, 33], ["the mRNA Cap", "TEST", 132, 144], ["groove", "OBSERVATION_MODIFIER", 111, 117]]], ["The N7-metyl guanosine binding pocket is formed by Cys25, Asp26, Leu27, Tyr30, Thr172, Glu173, and Ser202.", [["N7-metyl guanosine", "CHEMICAL", 4, 22], ["N7-metyl guanosine", "CHEMICAL", 4, 22], ["Cys25", "CHEMICAL", 51, 56], ["Asp26", "CHEMICAL", 58, 63], ["Leu27", "CHEMICAL", 65, 70], ["Tyr30", "CHEMICAL", 72, 77], ["Thr", "CHEMICAL", 79, 82], ["Glu173", "CHEMICAL", 87, 93], ["Ser202", "CHEMICAL", 99, 105], ["N7-metyl guanosine", "SIMPLE_CHEMICAL", 4, 22], ["Cys25", "GENE_OR_GENE_PRODUCT", 51, 56], ["Asp26", "GENE_OR_GENE_PRODUCT", 58, 63], ["Leu27", "GENE_OR_GENE_PRODUCT", 65, 70], ["Tyr30", "GENE_OR_GENE_PRODUCT", 72, 77], ["Thr172", "AMINO_ACID", 79, 85], ["Glu173", "GENE_OR_GENE_PRODUCT", 87, 93], ["Ser202", "AMINO_ACID", 99, 105], ["Cys25", "PROTEIN", 51, 56], ["Asp26", "PROTEIN", 58, 63], ["Tyr30", "PROTEIN", 72, 77], ["Ser202", "PROTEIN", 99, 105], ["The N7-metyl guanosine binding pocket", "PROBLEM", 0, 37], ["Cys25", "TEST", 51, 56], ["Asp26", "TEST", 58, 63], ["Leu27", "TEST", 65, 70], ["Tyr30", "TEST", 72, 77], ["Thr", "TEST", 79, 82], ["Glu173", "TEST", 87, 93], ["binding pocket", "OBSERVATION", 23, 37]]], ["The 5\u2032 to 5\u2032 triphosphate bridge of the Cap is stabilized through interaction with Tyr30, Lys137, Thr172, His174, Ser201, Ser202, and Glu203.", [["5\u2032 to 5\u2032 triphosphate", "CHEMICAL", 4, 25], ["5\u2032 to 5\u2032 triphosphate", "CHEMICAL", 4, 25], ["Tyr30", "CHEMICAL", 83, 88], ["Lys137", "CHEMICAL", 90, 96], ["Thr", "CHEMICAL", 98, 101], ["His", "CHEMICAL", 106, 109], ["Ser201", "CHEMICAL", 114, 120], ["Ser202", "CHEMICAL", 122, 128], ["Glu203", "CHEMICAL", 134, 140], ["5\u2032", "SIMPLE_CHEMICAL", 4, 6], ["5\u2032 triphosphate", "SIMPLE_CHEMICAL", 10, 25], ["Cap", "GENE_OR_GENE_PRODUCT", 40, 43], ["Tyr30", "GENE_OR_GENE_PRODUCT", 83, 88], ["Lys137", "AMINO_ACID", 90, 96], ["Thr172", "AMINO_ACID", 98, 104], ["His174", "AMINO_ACID", 106, 112], ["Ser201", "GENE_OR_GENE_PRODUCT", 114, 120], ["Ser202", "GENE_OR_GENE_PRODUCT", 122, 128], ["Glu203", "GENE_OR_GENE_PRODUCT", 134, 140], ["Cap", "PROTEIN", 40, 43], ["Glu203", "PROTEIN", 134, 140], ["Tyr30", "TEST", 83, 88], ["Thr", "TEST", 98, 101], ["His", "TEST", 106, 109], ["Ser202", "TEST", 122, 128], ["Glu203", "TEST", 134, 140], ["Cap", "OBSERVATION", 40, 43], ["stabilized", "OBSERVATION", 47, 57]]], ["The first nucleotide of the mRNA Cap (adenosine in the presented structure)2\u2032-O methylation of the SARS-CoV-2 transcriptsis bound through Lys46, Asp130, Tyr132, Pro134, Lys170, Asn198, and Glu203.2\u2032-O methylation of the SARS-CoV-2 transcriptsSAM-dependent MTases share a conserved catalytic mechanism wherein the methyl group is transferred to the acceptor substrate via an SN2 reaction 40 , which requires a linear alignment of the acceptor substrate (nucleophile), methyl group (electrophile), and the sulfur atom (leaving group) of the SAH product 41 .", [["nucleotide", "CHEMICAL", 10, 20], ["adenosine", "CHEMICAL", 38, 47], ["methyl", "CHEMICAL", 313, 319], ["methyl", "CHEMICAL", 467, 473], ["electrophile", "CHEMICAL", 481, 493], ["sulfur", "CHEMICAL", 504, 510], ["SAH", "DISEASE", 539, 542], ["nucleotide", "CHEMICAL", 10, 20], ["adenosine", "CHEMICAL", 38, 47], ["2\u2032-O", "CHEMICAL", 75, 79], ["Lys46", "CHEMICAL", 138, 143], ["Asp", "CHEMICAL", 145, 148], ["Tyr132", "CHEMICAL", 153, 159], ["Pro", "CHEMICAL", 161, 164], ["Lys170", "CHEMICAL", 169, 175], ["Asn198", "CHEMICAL", 177, 183], ["Glu203.2\u2032-O", "CHEMICAL", 189, 200], ["methyl", "CHEMICAL", 313, 319], ["methyl", "CHEMICAL", 467, 473], ["sulfur", "CHEMICAL", 504, 510], ["Cap", "GENE_OR_GENE_PRODUCT", 33, 36], ["adenosine", "SIMPLE_CHEMICAL", 38, 47], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 99, 109], ["Lys46", "GENE_OR_GENE_PRODUCT", 138, 143], ["Asp130", "AMINO_ACID", 145, 151], ["Tyr132", "GENE_OR_GENE_PRODUCT", 153, 159], ["Pro", "AMINO_ACID", 161, 164], ["134", "AMINO_ACID", 164, 167], ["Lys170", "GENE_OR_GENE_PRODUCT", 169, 175], ["Asn198", "GENE_OR_GENE_PRODUCT", 177, 183], ["methyl", "SIMPLE_CHEMICAL", 313, 319], ["methyl group", "SIMPLE_CHEMICAL", 467, 479], ["electrophile", "SIMPLE_CHEMICAL", 481, 493], ["sulfur atom", "SIMPLE_CHEMICAL", 504, 515], ["SARS-CoV-2 transcriptsis", "DNA", 99, 123], ["SARS-CoV-2 transcriptsSAM-dependent MTases", "PROTEIN", 220, 262], ["the SARS", "TEST", 95, 103], ["CoV", "TEST", 104, 107], ["Lys46", "TEST", 138, 143], ["Asp", "TEST", 145, 148], ["Pro", "TEST", 161, 164], ["Lys170", "TEST", 169, 175], ["Asn198", "TEST", 177, 183], ["Glu203.2", "TEST", 189, 197], ["\u2032", "TEST", 197, 198], ["the SARS", "TEST", 216, 224], ["CoV", "TEST", 225, 228], ["2 transcriptsSAM-dependent MTases", "TREATMENT", 229, 262], ["an SN2 reaction", "TREATMENT", 371, 386], ["the SAH product", "TREATMENT", 535, 550], ["Cap", "OBSERVATION_MODIFIER", 33, 36], ["SAH", "OBSERVATION", 539, 542]]], ["It was proposed that Nsp16 2\u2032-O MTases follow the same general mechanism 42 .", [["Nsp16 2\u2032-O", "CHEMICAL", 21, 31], ["\u2032-O MTases", "GENE_OR_GENE_PRODUCT", 28, 38], ["Nsp16 2\u2032-O MTases", "PROTEIN", 21, 38], ["Nsp", "TEST", 21, 24]]], ["In these enzymes, the reaction is facilitated by the catalytic tetrad Lys-Asp-Lys-Glu, where Lys170 sandwiched between the two acidic residues (Asp130 and Glu203) serves as a proton abstractor (Fig. 4A, B) .", [["Asp-Lys-Glu", "CHEMICAL", 74, 85], ["Lys170", "CHEMICAL", 93, 99], ["Lys-Asp-Lys-Glu", "CHEMICAL", 70, 85], ["Lys170", "CHEMICAL", 93, 99], ["Asp", "CHEMICAL", 144, 147], ["Glu203", "CHEMICAL", 155, 161], ["Lys-Glu", "AMINO_ACID", 78, 85], ["Lys170", "AMINO_ACID", 93, 99], ["Asp130", "AMINO_ACID", 144, 150], ["Glu203", "AMINO_ACID", 155, 161], ["enzymes", "PROTEIN", 9, 16], ["these enzymes", "TEST", 3, 16], ["the reaction", "PROBLEM", 18, 30], ["Asp", "TEST", 74, 77], ["the two acidic residues", "PROBLEM", 119, 142], ["Asp", "TEST", 144, 147], ["a proton abstractor", "TREATMENT", 173, 192], ["acidic residues", "OBSERVATION", 127, 142]]], ["It was shown previously in biochemical studies that substitution to Ala of any residue of the 2\u2032O-MTase catalytic tetrad results in an inactive enzyme 10, 43 .", [["Ala", "CHEMICAL", 68, 71], ["Ala", "AMINO_ACID", 68, 71], ["2\u2032O-MTase", "GENE_OR_GENE_PRODUCT", 94, 103], ["2\u2032O", "PROTEIN", 94, 97], ["MTase", "PROTEIN", 98, 103], ["biochemical studies", "TEST", 27, 46], ["an inactive enzyme", "TEST", 132, 150]]], ["In SARS-CoV-2 Nsp16 the catalytic tetrad Lys46-Asp130-Lys170-Glu203, is superposing well with Lys61-D146-Lys180-Glu216 of the Dengue virus homolog (Fig. 3A, C) .", [["Lys46-Asp130-Lys170-Glu203", "CHEMICAL", 41, 67], ["Lys61", "CHEMICAL", 94, 99], ["SARS-CoV-2 Nsp16", "GENE_OR_GENE_PRODUCT", 3, 19], ["Dengue virus", "ORGANISM", 126, 138], ["SARS-CoV-2 Nsp16", "DNA", 3, 19], ["Asp130", "PROTEIN", 47, 53], ["Lys170", "PROTEIN", 54, 60], ["Glu203", "PROTEIN", 61, 67], ["Lys61", "PROTEIN", 94, 99], ["Glu216", "PROTEIN", 112, 118], ["Fig. 3A, C", "PROTEIN", 148, 158], ["Dengue virus", "SPECIES", 126, 138], ["SARS-CoV", "SPECIES", 3, 11], ["Dengue virus", "SPECIES", 126, 138], ["SARS", "TEST", 3, 7], ["CoV", "TEST", 8, 11], ["the catalytic tetrad", "TEST", 20, 40], ["Asp130", "TEST", 47, 53], ["Lys61", "TEST", 94, 99], ["the Dengue virus homolog", "TREATMENT", 122, 146]]], ["In the 3D context, Lys46 binds to Glu203 which then binds to Lys170 interacting with Asp130, which further links to the amino group of SAM.", [["Lys46", "CHEMICAL", 19, 24], ["Glu203", "CHEMICAL", 34, 40], ["Asp130", "CHEMICAL", 85, 91], ["Lys46", "CHEMICAL", 19, 24], ["Glu203", "CHEMICAL", 34, 40], ["Lys170", "CHEMICAL", 61, 67], ["Asp", "CHEMICAL", 85, 88], ["amino", "CHEMICAL", 120, 125], ["SAM", "CHEMICAL", 135, 138], ["Lys46", "GENE_OR_GENE_PRODUCT", 19, 24], ["Glu203", "GENE_OR_GENE_PRODUCT", 34, 40], ["Lys170", "GENE_OR_GENE_PRODUCT", 61, 67], ["Asp130", "AMINO_ACID", 85, 91], ["SAM", "SIMPLE_CHEMICAL", 135, 138], ["Lys46", "PROTEIN", 19, 24], ["Glu203", "PROTEIN", 34, 40], ["SAM", "PROTEIN", 135, 138], ["Asp", "TEST", 85, 88]]], ["In this network, a proton can be transferred between multiple residues, occupying different sites potentially depending on the reaction state (Fig. 4) .", [["proton", "SIMPLE_CHEMICAL", 19, 25], ["a proton", "TREATMENT", 17, 25], ["multiple residues", "PROBLEM", 53, 70], ["occupying different sites", "PROBLEM", 72, 97]]], ["Lys170 is well-positioned to act as a general base deprotonating 2\u2032-OH.", [["Lys170", "CHEMICAL", 0, 6], ["2\u2032-OH", "CHEMICAL", 65, 70], ["Lys170", "CHEMICAL", 0, 6], ["2\u2032-OH", "CHEMICAL", 65, 70], ["Lys170", "AMINO_ACID", 0, 6], ["2\u2032-OH", "SIMPLE_CHEMICAL", 65, 70]]], ["Asp130 may serve multiple functions -as an acid deprotonating Lys170 (alternating with Glu203), and an anchoring point for the cofactor via interaction with its amino group, and as a stabilization for the sulfonium cation.", [["Asp130", "CHEMICAL", 0, 6], ["sulfonium", "CHEMICAL", 205, 214], ["Asp", "CHEMICAL", 0, 3], ["Lys170", "CHEMICAL", 62, 68], ["Glu203", "CHEMICAL", 87, 93], ["amino", "CHEMICAL", 161, 166], ["sulfonium", "CHEMICAL", 205, 214], ["Asp130", "AMINO_ACID", 0, 6], ["Lys170", "SIMPLE_CHEMICAL", 62, 68], ["Glu203", "SIMPLE_CHEMICAL", 87, 93], ["sulfonium cation", "SIMPLE_CHEMICAL", 205, 221], ["Glu203", "PROTEIN", 87, 93], ["Asp", "TEST", 0, 3], ["an acid deprotonating", "TEST", 40, 61], ["its amino group", "TREATMENT", 157, 172], ["a stabilization", "TREATMENT", 181, 196], ["the sulfonium cation", "TREATMENT", 201, 221]]], ["However, the reaction does not occur in a presence of EDTA, as demonstrated by the ability to capture the Cap-0/SAM complex.", [["EDTA", "CHEMICAL", 54, 58], ["EDTA", "CHEMICAL", 54, 58], ["Cap-0", "CHEMICAL", 106, 111], ["EDTA", "SIMPLE_CHEMICAL", 54, 58], ["Cap-0", "GENE_OR_GENE_PRODUCT", 106, 111], ["SAM complex", "GENE_OR_GENE_PRODUCT", 112, 123], ["Cap-0", "PROTEIN", 106, 111], ["SAM complex", "PROTEIN", 112, 123], ["the reaction", "PROBLEM", 9, 21], ["the Cap", "TEST", 102, 109], ["EDTA", "OBSERVATION", 54, 58]]], ["It was reported previously using biochemical assays that the activity of Nsp10/16 2\u2032-O MTase is magnesium dependent 39 .", [["magnesium", "CHEMICAL", 96, 105], ["magnesium", "CHEMICAL", 96, 105], ["Nsp10/16 2\u2032-O MTase", "GENE_OR_GENE_PRODUCT", 73, 92], ["magnesium", "SIMPLE_CHEMICAL", 96, 105], ["Nsp10/16 2\u2032-O MTase", "PROTEIN", 73, 92], ["biochemical assays", "TEST", 33, 51], ["magnesium dependent", "PROBLEM", 96, 115]]], ["Though, we did not observe any trace of metal near the active site in the 297 K structures reported in this work, and any other CoV-2 Nsp10/16 structures reported to date, despite the presence of magnesium in the crystallization buffer.", [["magnesium", "CHEMICAL", 196, 205], ["magnesium", "CHEMICAL", 196, 205], ["magnesium", "SIMPLE_CHEMICAL", 196, 205], ["any other CoV", "TEST", 118, 131], ["magnesium in the crystallization buffer", "TREATMENT", 196, 235], ["metal", "OBSERVATION", 40, 45], ["active", "OBSERVATION_MODIFIER", 55, 61], ["site", "OBSERVATION_MODIFIER", 62, 66]]], ["We hypothesize that the magnesium ion (or other metal ion) can transiently bind to the active site possibly replacing one of the water molecules (for example water 38) and promoting formation of a reactive conformation by changing electrostatics and geometry of the catalytic residues to stimulate methylation reaction.", [["magnesium", "CHEMICAL", 24, 33], ["magnesium", "CHEMICAL", 24, 33], ["magnesium ion", "SIMPLE_CHEMICAL", 24, 37], ["the magnesium ion", "TREATMENT", 20, 37], ["the water molecules", "TREATMENT", 125, 144], ["a reactive conformation", "PROBLEM", 195, 218], ["changing electrostatics", "TREATMENT", 222, 245], ["the catalytic residues", "TREATMENT", 262, 284], ["methylation reaction", "PROBLEM", 298, 318], ["active", "OBSERVATION", 87, 93], ["reactive conformation", "OBSERVATION", 197, 218]]], ["Magnesium has a compact and tight coordination sphere with strict octahedral geometry and a typically short Mg-O distance of 2.08 \u00c5 44 .", [["Magnesium", "CHEMICAL", 0, 9], ["Mg", "CHEMICAL", 108, 110], ["Magnesium", "CHEMICAL", 0, 9], ["Mg", "CHEMICAL", 108, 110], ["O", "CHEMICAL", 111, 112], ["Magnesium", "SIMPLE_CHEMICAL", 0, 9], ["Magnesium", "TREATMENT", 0, 9], ["strict octahedral geometry", "TREATMENT", 59, 85]]], ["By coordinating 2\u2032 oxygen and several water molecules magnesium could shortened the distance between 2\u2032 oxygen and SAM methyl moiety thus promoting formation of transition state and methyl transfer.", [["oxygen", "CHEMICAL", 19, 25], ["magnesium", "CHEMICAL", 54, 63], ["oxygen", "CHEMICAL", 104, 110], ["SAM methyl", "CHEMICAL", 115, 125], ["methyl", "CHEMICAL", 182, 188], ["2\u2032 oxygen", "CHEMICAL", 16, 25], ["magnesium", "CHEMICAL", 54, 63], ["2\u2032 oxygen", "CHEMICAL", 101, 110], ["SAM methyl", "CHEMICAL", 115, 125], ["methyl", "CHEMICAL", 182, 188], ["2\u2032 oxygen", "SIMPLE_CHEMICAL", 16, 25], ["magnesium", "SIMPLE_CHEMICAL", 54, 63], ["2\u2032 oxygen", "SIMPLE_CHEMICAL", 101, 110], ["SAM methyl moiety", "SIMPLE_CHEMICAL", 115, 132], ["methyl", "SIMPLE_CHEMICAL", 182, 188], ["oxygen", "TREATMENT", 19, 25], ["several water molecules magnesium", "TREATMENT", 30, 63], ["2\u2032 oxygen", "TREATMENT", 101, 110], ["SAM methyl moiety", "TREATMENT", 115, 132], ["transition state", "PROBLEM", 161, 177]]], ["During the reaction a positively charged, sp2 planar transition state is formed and the methyl group inverts its stereochemistry.2\u2032-O methylation of the SARS-CoV-2 transcriptsAfter the methyl-transfer reaction is completed the product is released from the active site.", [["methyl", "CHEMICAL", 88, 94], ["methyl", "CHEMICAL", 185, 191], ["sp2", "CHEMICAL", 42, 45], ["methyl", "CHEMICAL", 88, 94], ["2\u2032-O", "CHEMICAL", 129, 133], ["methyl", "CHEMICAL", 185, 191], ["methyl", "SIMPLE_CHEMICAL", 88, 94], ["2\u2032-O", "SIMPLE_CHEMICAL", 129, 133], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 153, 163], ["methyl", "SIMPLE_CHEMICAL", 185, 191], ["SARS-CoV-2 transcripts", "RNA", 153, 175], ["the reaction", "PROBLEM", 7, 19], ["sp2 planar transition state", "PROBLEM", 42, 69], ["the SARS", "PROBLEM", 149, 157], ["the methyl-transfer reaction", "TREATMENT", 181, 209], ["active site", "OBSERVATION", 256, 267]]], ["This is consistent with the structure of Cap-1/SAH where several active site residues move, these include Tyr132, the entire \u03b1-helix spanning Pro134-Lys137, and Tyr30 on the opposite site ( Fig. 4A, Extended Data Fig. 4C ).", [["SAH", "DISEASE", 47, 50], ["Tyr132", "CHEMICAL", 106, 112], ["Tyr30", "CHEMICAL", 161, 166], ["Cap-1", "GENE_OR_GENE_PRODUCT", 41, 46], ["SAH", "GENE_OR_GENE_PRODUCT", 47, 50], ["Tyr132", "GENE_OR_GENE_PRODUCT", 106, 112], ["Pro134-Lys137", "GENE_OR_GENE_PRODUCT", 142, 155], ["Tyr30", "AMINO_ACID", 161, 166], ["Cap", "PROTEIN", 41, 44], ["Tyr132", "PROTEIN", 106, 112], ["\u03b1-helix", "PROTEIN", 125, 132], ["Pro134", "PROTEIN", 142, 148], ["Lys137", "PROTEIN", 149, 155], ["Tyr30", "PROTEIN", 161, 166], ["Cap", "TEST", 41, 44], ["SAH", "PROBLEM", 47, 50], ["several active site residues", "PROBLEM", 57, 85], ["consistent with", "UNCERTAINTY", 8, 23], ["Cap", "OBSERVATION_MODIFIER", 41, 44], ["SAH", "OBSERVATION", 47, 50], ["active", "OBSERVATION_MODIFIER", 65, 71], ["site residues", "OBSERVATION", 72, 85]]], ["All these residues are involved in interactions with Cap-0 and observed changes perhaps allow Cap-1 to leave.", [["Cap-0", "GENE_OR_GENE_PRODUCT", 53, 58], ["Cap-1", "GENE_OR_GENE_PRODUCT", 94, 99], ["Cap", "PROTEIN", 53, 56], ["Cap", "PROTEIN", 94, 97], ["Cap", "TEST", 53, 56], ["residues", "OBSERVATION", 10, 18]]], ["Interestingly, the SAM/SAH binding site remains virtually unchanged in all three structures (Extended Data Fig. 4) , suggesting that the SAH exchange with SAM may require dissociation of Nsp10 that controls conformation of important loop Gly73-Gly77.", [["SAH", "DISEASE", 23, 26], ["SAH", "DISEASE", 137, 140], ["SAM", "CHEMICAL", 155, 158], ["SAM", "CHEMICAL", 155, 158], ["Gly77", "CHEMICAL", 244, 249], ["SAH", "SIMPLE_CHEMICAL", 137, 140], ["Nsp10", "GENE_OR_GENE_PRODUCT", 187, 192], ["Gly73-Gly77", "GENE_OR_GENE_PRODUCT", 238, 249], ["SAM/SAH binding site", "DNA", 19, 39], ["Nsp10", "PROTEIN", 187, 192], ["Gly73", "PROTEIN", 238, 243], ["Gly77", "PROTEIN", 244, 249], ["the SAM/SAH binding site", "PROBLEM", 15, 39], ["the SAH exchange", "PROBLEM", 133, 149], ["dissociation", "TREATMENT", 171, 183], ["Nsp10", "TREATMENT", 187, 192], ["SAM", "OBSERVATION_MODIFIER", 19, 22], ["SAH", "OBSERVATION", 23, 26], ["virtually", "OBSERVATION_MODIFIER", 48, 57], ["unchanged", "OBSERVATION_MODIFIER", 58, 67], ["SAH", "OBSERVATION", 137, 140]]], ["Opening this loop may help SAH to leave and then a new SAM molecule can bind.2\u2032-O methylation of the SARS-CoV-2 transcriptsThe biochemical assays show that optimal pH for MERS-CoV Nsp10/16 activity is approximately 8 -8.5 39 .", [["SAH", "DISEASE", 27, 30], ["2\u2032-O", "CHEMICAL", 77, 81], ["2\u2032-O", "SIMPLE_CHEMICAL", 77, 81], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 101, 111], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 171, 179], ["SAM molecule", "PROTEIN", 55, 67], ["SARS-CoV-2 transcripts", "RNA", 101, 123], ["MERS-CoV", "SPECIES", 171, 179], ["SAH", "PROBLEM", 27, 30], ["a new SAM molecule can bind", "PROBLEM", 49, 76], ["the SARS", "PROBLEM", 97, 105], ["The biochemical assays", "TEST", 123, 145], ["optimal pH", "TEST", 156, 166], ["MERS", "TEST", 171, 175], ["CoV Nsp10/16 activity", "TEST", 176, 197]]], ["Additionally, the 2\u2032-O MTase activity of Nsp10/16 from the MERS is significantly reduced at pH below 7.", [["Nsp10/16", "GENE_OR_GENE_PRODUCT", 41, 49], ["Nsp10/16", "PROTEIN", 41, 49], ["MERS", "DNA", 59, 63], ["Nsp10", "TEST", 41, 46], ["significantly", "OBSERVATION_MODIFIER", 67, 80], ["reduced", "OBSERVATION_MODIFIER", 81, 88]]], ["Assuming that Nsp10/16 2\u2032-O MTase efficiency is pH dependent, we performed the 297 K SSX data collection using a buffer with pH 6.5 that could potentially slow down the reaction.", [["K", "CHEMICAL", 83, 84], ["Nsp10/16 2\u2032-O", "CHEMICAL", 14, 27], ["\u2032-O MTase", "GENE_OR_GENE_PRODUCT", 24, 33], ["pH dependent", "PROBLEM", 48, 60], ["a buffer", "TREATMENT", 111, 119], ["pH", "TEST", 125, 127], ["the reaction", "PROBLEM", 165, 177], ["pH dependent", "OBSERVATION_MODIFIER", 48, 60]]], ["Comparison of the 100 K and the 297 K structures revealed clear methylation only at 297 K, we hypothesize that Cap-1 could be sensitive to radiation damage and thus can be only observed in low x-ray dose experiments.", [["Cap-1", "GENE_OR_GENE_PRODUCT", 111, 116], ["Cap-1", "PROTEIN", 111, 116], ["the 297 K structures", "TEST", 28, 48], ["Cap", "TEST", 111, 114], ["radiation damage", "PROBLEM", 139, 155], ["clear", "OBSERVATION", 58, 63], ["radiation", "OBSERVATION", 139, 148]]], ["Interestingly, the 297 K structure of Nsp10/16 obtained from a single crystal has a mixture of states with 30% of the Cap-1/SAH products and 70% of the Cap-0/SAM substrates.", [["K", "CHEMICAL", 23, 24], ["Nsp10/", "CHEMICAL", 38, 44], ["SAH", "DISEASE", 124, 127], ["SAM", "CHEMICAL", 158, 161], ["Cap-1", "GENE_OR_GENE_PRODUCT", 118, 123], ["Cap-0", "SIMPLE_CHEMICAL", 152, 157], ["Nsp10/16", "PROTEIN", 38, 46], ["Cap-1/SAH products", "PROTEIN", 118, 136], ["Cap-0/SAM substrates", "PROTEIN", 152, 172], ["Nsp10/", "TEST", 38, 44], ["the Cap", "TEST", 114, 121], ["SAH products", "TREATMENT", 124, 136], ["the Cap", "TEST", 148, 155], ["SAH", "OBSERVATION", 124, 127]]], ["It is well known that radiation damage can impact redox systems.", [["radiation damage", "PROBLEM", 22, 38]]], ["High x-ray dose could affect electron density around amino acid residues and lead to photoreduction of metalloproteins 45, 46, 47 .", [["amino acid", "CHEMICAL", 53, 63], ["amino acid", "CHEMICAL", 53, 63], ["electron", "SIMPLE_CHEMICAL", 29, 37], ["amino acid", "AMINO_ACID", 53, 63], ["metalloproteins 45, 46, 47", "PROTEIN", 103, 129], ["High x-ray dose", "TREATMENT", 0, 15], ["electron density around amino acid residues", "PROBLEM", 29, 72], ["photoreduction of metalloproteins", "TEST", 85, 118], ["amino acid", "OBSERVATION", 53, 63]]], ["These free radical reactions can occur in crystals under cryogenic conditions 48 .CONCLUSIONSEnzymes that catalyze transmethylation reactions using SAM as the methyl group donor have been described in many cellular processes involving nucleic acids, proteins, phospholipids, and This clearly needs further investigation because SSX low radiation dose may be advantageous in helping reveal subtle and diverse chemical transformations in enzymes that otherwise may be degraded during x-ray or electron diffraction experiments.", [["cellular", "ANATOMY", 206, 214], ["nucleic acids", "CHEMICAL", 235, 248], ["SSX", "CHEMICAL", 328, 331], ["SAM", "CHEMICAL", 148, 151], ["methyl", "CHEMICAL", 159, 165], ["SAM", "SIMPLE_CHEMICAL", 148, 151], ["methyl", "SIMPLE_CHEMICAL", 159, 165], ["cellular", "CELL", 206, 214], ["nucleic acids", "SIMPLE_CHEMICAL", 235, 248], ["phospholipids", "SIMPLE_CHEMICAL", 260, 273], ["SSX", "SIMPLE_CHEMICAL", 328, 331], ["enzymes", "PROTEIN", 436, 443], ["These free radical reactions", "PROBLEM", 0, 28], ["transmethylation reactions", "PROBLEM", 115, 141], ["nucleic acids", "TEST", 235, 248], ["phospholipids", "TREATMENT", 260, 273], ["further investigation", "TEST", 298, 319], ["SSX low radiation dose", "TREATMENT", 328, 350], ["subtle and diverse chemical transformations in enzymes", "PROBLEM", 389, 443], ["free", "OBSERVATION_MODIFIER", 6, 10], ["radical", "OBSERVATION", 11, 18], ["subtle", "OBSERVATION_MODIFIER", 389, 395], ["diverse", "OBSERVATION_MODIFIER", 400, 407], ["chemical transformations", "OBSERVATION", 408, 432]]], ["Therefore, the structure of Nsp10/16 with Cap-1 presented here provides unique information for understanding the mechanism that allows SARS-CoV-2 to mimic mature eukaryotic mRNA and escape recognition by human innate immune response.CONCLUSIONSThe recent developments in micro focusing x-ray beams at synchrotron light sources and improvement in sample delivery technology, data collection, detectors, and computing will allow rapid determination of new structures using SSX and revealing significant biological information.CONCLUSIONSThe further development of SSX and implementation of time-resolved SSX crystallography is an approach that could visualize chemical processes and protein molecular dynamics -such as of the transfer of the methyl group catalyzed by Nsp10/16 2\u2032O-MTase from SARS-CoV-2.", [["sample", "ANATOMY", 346, 352], ["methyl", "CHEMICAL", 740, 746], ["methyl", "CHEMICAL", 740, 746], ["Nsp10/16", "GENE_OR_GENE_PRODUCT", 28, 36], ["Cap-1", "GENE_OR_GENE_PRODUCT", 42, 47], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 135, 145], ["human", "ORGANISM", 204, 209], ["methyl", "SIMPLE_CHEMICAL", 740, 746], ["\u2032O-MTase", "GENE_OR_GENE_PRODUCT", 776, 784], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 790, 800], ["Nsp10/16", "PROTEIN", 28, 36], ["Cap-1", "PROTEIN", 42, 47], ["mature eukaryotic mRNA", "RNA", 155, 177], ["SSX", "PROTEIN", 471, 474], ["Nsp10/16 2\u2032O-MTase", "PROTEIN", 766, 784], ["human", "SPECIES", 204, 209], ["human", "SPECIES", 204, 209], ["Cap", "TEST", 42, 45], ["sample delivery technology", "TEST", 346, 372], ["SSX", "TREATMENT", 471, 474], ["SSX", "PROBLEM", 562, 565], ["SSX crystallography", "TREATMENT", 602, 621], ["the methyl group catalyzed", "TREATMENT", 736, 762]]], ["Thus far the Cap-1 was only observed in the structure obtained using SSX.", [["Cap-1", "GENE_OR_GENE_PRODUCT", 13, 18], ["SSX", "SIMPLE_CHEMICAL", 69, 72], ["Cap-1", "DNA", 13, 18], ["SSX", "PROTEIN", 69, 72], ["the Cap", "TEST", 9, 16], ["SSX", "TREATMENT", 69, 72], ["Cap", "OBSERVATION_MODIFIER", 13, 16]]], ["For diffraction experiments conducted at 297 K, SSX provides significant advantages over data collected using a single crystal as it considerably increases resolution, use less sample in comparison with a liquid jet delivery system and reduces levels of x-ray dose.", [["diffraction experiments", "TEST", 4, 27], ["a single crystal", "TREATMENT", 110, 126], ["a liquid jet delivery system", "TREATMENT", 203, 231], ["x-ray dose", "TEST", 254, 264]]], ["Studies of other enzymes can also significantly benefit from using this approach.Crystallization of Nsp10/16 complexThe recombinant proteins Nsp10 and Nsp16 from SARS-CoV-2 were expressed in E. coli and tube.", [["tube", "ANATOMY", 203, 207], ["Nsp10/16", "GENE_OR_GENE_PRODUCT", 100, 108], ["Nsp10", "GENE_OR_GENE_PRODUCT", 141, 146], ["Nsp16", "GENE_OR_GENE_PRODUCT", 151, 156], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 162, 172], ["E. coli", "ORGANISM", 191, 198], ["tube", "TISSUE", 203, 207], ["Nsp10/16 complex", "PROTEIN", 100, 116], ["recombinant proteins", "PROTEIN", 120, 140], ["Nsp10", "PROTEIN", 141, 146], ["Nsp16", "PROTEIN", 151, 156], ["E. coli", "SPECIES", 191, 198], ["SARS-CoV", "SPECIES", 162, 170], ["E. coli", "SPECIES", 191, 198], ["Studies of other enzymes", "TEST", 0, 24], ["this approach", "TREATMENT", 67, 80], ["The recombinant proteins Nsp10", "TEST", 116, 146], ["Nsp16", "TEST", 151, 156], ["SARS", "TEST", 162, 166], ["CoV", "TEST", 167, 170], ["E. coli", "PROBLEM", 191, 198], ["tube", "TREATMENT", 203, 207], ["E. coli", "OBSERVATION", 191, 198], ["tube", "OBSERVATION", 203, 207]]], ["These volumes allowed us to get the number of crystals suitable for data collection from one chip.", [["data collection", "TEST", 68, 83]]], ["We have prepared several batches using same conditions to get reproducible data collection and have the ability to merge data from multiple chips.", [["reproducible data collection", "PROBLEM", 62, 90], ["multiple chips", "TREATMENT", 131, 145]]], ["The crystals grew to optimum sizes in 10 days at 21\u00b0C before the SSX data collection.", [["the SSX data collection", "TEST", 61, 84], ["crystals", "OBSERVATION_MODIFIER", 4, 12], ["optimum", "OBSERVATION_MODIFIER", 21, 28], ["sizes", "OBSERVATION_MODIFIER", 29, 34]]], ["To obtain the structure of Nsp10/16/Cap-0/SAM, the crystal batch was supplemented with 1 mM EDTA two days before data collection.Preparation of the sample for data collectionThe crystals from batch crystallization were centrifuged at 100 RCF for 2 minutes at 297 K.Preparation of the sample for data collectionThe excess solution was removed with a pipette, until 15 \u00b5l was left.", [["EDTA", "CHEMICAL", 92, 96], ["Cap-0", "GENE_OR_GENE_PRODUCT", 36, 41], ["Nsp10", "PROTEIN", 27, 32], ["Cap", "PROTEIN", 36, 39], ["SAM", "PROTEIN", 42, 45], ["Nsp10", "TEST", 27, 32], ["Cap", "TEST", 36, 39], ["the crystal batch", "TREATMENT", 47, 64], ["1 mM EDTA", "TREATMENT", 87, 96], ["data collection", "TEST", 113, 128], ["the sample", "TEST", 144, 154], ["data collection", "TEST", 159, 174], ["The crystals from batch crystallization", "TREATMENT", 174, 213], ["the sample", "TEST", 280, 290], ["data collection", "TEST", 295, 310], ["The excess solution", "TREATMENT", 310, 329], ["a pipette", "TREATMENT", 347, 356], ["crystals", "OBSERVATION_MODIFIER", 178, 186], ["left", "ANATOMY_MODIFIER", 374, 378]]], ["Crystals sedimented on the walls of Eppendorf polypropylene tube were gently resuspended using 20 \u00b5l pipette tips with a cut end to increase the diameter of the tip to minimize mechanical damage to crystals.", [["polypropylene", "CHEMICAL", 46, 59], ["Crystals sedimented", "PROBLEM", 0, 19], ["Eppendorf polypropylene tube", "TREATMENT", 36, 64], ["20 \u00b5l pipette tips", "TREATMENT", 95, 113], ["a cut end", "TREATMENT", 119, 128], ["the diameter of the tip", "TREATMENT", 141, 164], ["mechanical damage to crystals", "PROBLEM", 177, 206], ["sedimented", "OBSERVATION", 9, 19], ["polypropylene tube", "OBSERVATION", 46, 64], ["diameter", "OBSERVATION_MODIFIER", 145, 153], ["tip", "OBSERVATION_MODIFIER", 161, 164], ["mechanical damage", "OBSERVATION", 177, 194], ["crystals", "OBSERVATION_MODIFIER", 198, 206]]], ["Then 1.5 \u00b5l of 10 mM stock of the m7 GpppA (S1405L, New England Biolabs) was added to crystal slurry and the mix was loaded on a 60 \u00b5m grid made from nylon (NY6004700, Millipore) which was placed on a 6 \u00b5m layer of mylar polyester film.", [["polyester", "CHEMICAL", 221, 230], ["Biolabs", "GENE_OR_GENE_PRODUCT", 64, 71], ["New England Biolabs)", "TREATMENT", 52, 72], ["crystal slurry", "TREATMENT", 86, 100], ["nylon (NY6004700, Millipore", "TREATMENT", 150, 177], ["a 6 \u00b5m layer of mylar polyester film", "TREATMENT", 199, 235]]], ["The nylon mesh was covered on the top with a second layer of 6 \u00b5m mylar and sealed with the ALEX magnetic holder, such that sample is hermetically sealed from the outside environment.", [["sample", "ANATOMY", 124, 130], ["nylon", "CHEMICAL", 4, 9], ["The nylon mesh", "TREATMENT", 0, 14], ["a second layer of 6 \u00b5m mylar", "TREATMENT", 43, 71], ["the ALEX magnetic holder", "TREATMENT", 88, 112], ["nylon mesh", "OBSERVATION", 4, 14], ["top", "OBSERVATION_MODIFIER", 34, 37], ["6 \u00b5m", "OBSERVATION_MODIFIER", 61, 65]]], ["Data collection was started approximately 20 minutes after assembly of the chip.Serial crystallography data collectionWe collected SSX data for the Nsp10/16 crystals at the 19-ID beamline at the Advanced Photon Source using the fixed-target SSX (ALEX) mesh-holder developed at the Structural Biology Center (SBC) as depicted in Figure 1A and Extended Data Fig. 1 .", [["Data collection", "TEST", 0, 15], ["the chip", "TREATMENT", 71, 79], ["Serial crystallography data", "TEST", 80, 107], ["the Nsp10/16 crystals", "TREATMENT", 144, 165], ["the fixed-target SSX (ALEX) mesh", "TREATMENT", 224, 256]]], ["A crystal slurry is deposited on a nylon mesh, which immobilizes the crystals; they are then encapsulated between two polyester films 36 .Serial crystallography data collectionThe rod-shape crystals grew without seeding and the average crystal size was 120x25x25 \u00b5m (Extended Data Fig. 2A) .", [["nylon", "CHEMICAL", 35, 40], ["polyester", "CHEMICAL", 118, 127], ["A crystal slurry", "PROBLEM", 0, 16], ["a nylon mesh", "TREATMENT", 33, 45], ["two polyester films", "TEST", 114, 133], ["Serial crystallography data collection", "TEST", 138, 176], ["The rod-shape crystals", "TEST", 176, 198], ["seeding", "PROBLEM", 212, 219], ["the average crystal size", "TEST", 224, 248], ["crystal", "OBSERVATION_MODIFIER", 2, 9], ["slurry", "OBSERVATION", 10, 16], ["nylon mesh", "OBSERVATION", 35, 45], ["crystals", "OBSERVATION_MODIFIER", 69, 77], ["rod", "OBSERVATION_MODIFIER", 180, 183], ["shape", "OBSERVATION_MODIFIER", 184, 189], ["crystals", "OBSERVATION_MODIFIER", 190, 198], ["grew", "OBSERVATION_MODIFIER", 199, 203], ["without", "UNCERTAINTY", 204, 211], ["seeding", "OBSERVATION_MODIFIER", 212, 219], ["average", "OBSERVATION_MODIFIER", 228, 235], ["crystal", "OBSERVATION_MODIFIER", 236, 243], ["size", "OBSERVATION_MODIFIER", 244, 248]]], ["Serial data collection was collected using three SmarAct SLC-17 stages configured in an XYZ geometry, with each having sufficient movement range to cover the sample area of the specially designed ALEX holder (patent application serial #16/903,601).", [["SLC", "PROTEIN", 57, 60], ["Serial data collection", "TEST", 0, 22], ["three SmarAct SLC", "TREATMENT", 43, 60], ["an XYZ geometry", "TREATMENT", 85, 100], ["ALEX holder", "TREATMENT", 196, 207], ["movement range", "OBSERVATION", 130, 144], ["patent", "OBSERVATION", 209, 215]]], ["The beamline was configured at an energy of 12,662 eV, with collimator slit sizes set to 75 x 75 \u00b5m, and step size (distance between exposures) of 50 \u00b5m: overlapping exposed area to maximize crystal hits.Serial crystallography data collectionThe five mesh-covered samples used a grid of 170 steps in the x-direction (columns) by 210 steps in the y-direction (rows), covering a total area of approximately 8.5 x 10.5 mm.", [["samples", "ANATOMY", 264, 271], ["collimator slit sizes", "TREATMENT", 60, 81], ["crystal hits", "PROBLEM", 191, 203], ["Serial crystallography data collection", "TEST", 204, 242], ["The five mesh", "TREATMENT", 242, 255], ["size", "OBSERVATION_MODIFIER", 110, 114], ["crystal hits", "OBSERVATION", 191, 203], ["five", "OBSERVATION_MODIFIER", 246, 250], ["mesh", "OBSERVATION", 251, 255], ["total", "OBSERVATION_MODIFIER", 377, 382], ["area", "OBSERVATION_MODIFIER", 383, 387], ["8.5 x 10.5 mm", "OBSERVATION_MODIFIER", 405, 418]]], ["The number of steps and the resulting area varied slightly per sample depending on the chip mount position or possible false-starts.", [["the resulting area", "PROBLEM", 24, 42], ["area", "OBSERVATION_MODIFIER", 38, 42], ["possible", "UNCERTAINTY", 110, 118], ["false", "OBSERVATION", 119, 124]]], ["Extended Data Table 1 contains details of number of chips and detector distances used for data collection for Nsp10/16 SSX structures.Serial crystallography data collectionCrispy, the data acquisition GUI for serial collection at sector 19, allows for quick alignment and acts as a source of information for downstream processing.", [["data collection", "TEST", 90, 105], ["Serial crystallography data", "TEST", 134, 161], ["the data acquisition", "TEST", 180, 200], ["serial collection at sector", "TEST", 209, 236], ["downstream processing", "TREATMENT", 308, 329]]], ["Metadata in the form of JSON files and beamline/collection strategy parameters are input and passed into the system before collection.Serial crystallography data collectionThese parameters include grid dimensions, detector distance/resolution, unit cell dimension, protein PDB coordinates, and a handful of others.Serial crystallography data processingThe Kanzus pipeline orchestrates SSX data acquisition, analysis, cataloging, and publishes processing metrics.", [["cell", "ANATOMY", 249, 253], ["JSON", "DNA", 24, 28], ["protein PDB coordinates", "PROTEIN", 265, 288], ["beamline/collection strategy parameters", "TREATMENT", 39, 78], ["Serial crystallography data collection", "TEST", 134, 172], ["detector distance/resolution", "TEST", 214, 242], ["Serial crystallography data", "TEST", 314, 341], ["analysis", "TEST", 407, 415]]], ["The first phase of the pipeline is integrated with the APS Data Management System at the beamline, which deposits each newly acquired image into an Globus-accessible storage system at the APS.", [["APS", "DISEASE", 188, 191]]], ["As new images are acquired, Globus Automate \"flows\" are launched to process them as follow: 1) moves new files from APS to Theta by using the Globus Transfer service 55 ; 2) performs DIALS stills_process 56 on batches of 256 images by using funcX 57 , a function-as-a-service computation system (funcX uses Parsl 58 to abstract and acquire nodes on Theta as needed, and dispatches tasks to available nodes); 3) extracts metadata from files regarding identified diffractions, and generates visualizations (funcX)Serial crystallography data processingshowing the locations of positive hits on the mesh; and 4) publishes raw data, metadata, and visualizations to a portal on the ALCF Petrel data system 59 .", [["APS", "DISEASE", 116, 119], ["Theta", "PROTEIN", 349, 354], ["new images", "TEST", 3, 13], ["a function", "TEST", 252, 262], ["Serial crystallography data", "TEST", 511, 538], ["positive hits", "PROBLEM", 574, 587], ["the mesh", "TREATMENT", 591, 599], ["positive hits", "OBSERVATION", 574, 587], ["portal", "ANATOMY", 662, 668]]], ["The result of this automated process is an indexed, searchable data collection that provides full traceability from data acquisition to processed data, and that can be used to inspect and update the running experiment.Serial crystallography data processingImages were collected at 7 Hz, meaning that a 256-image batch totaling 1.56 GB, was generated every 35 seconds.", [["data acquisition", "TEST", 116, 132], ["Serial crystallography data", "TEST", 218, 245], ["Images", "TEST", 256, 262], ["image batch", "TEST", 306, 317], ["GB", "TEST", 332, 334]]], ["The data transfers to ALCF ran at up to 700 MB/s via Globus, and 30 Theta nodes processed images by using DIALS stills_process at 22 images per second in steadystate.", [["ALCF", "DNA", 22, 26]]], ["As experimental configuration values were refined, reprocessing tasks were submitted as required.", [["reprocessing tasks", "TEST", 51, 69]]], ["FuncX managed these tasks by expanding the number of Theta nodes being used to a maximum of 250, which enabled a processing rate of greater than 200 images a second.Serial crystallography data processingSuccessfully processed images with diffraction-produced integration files were returned to the beamline computers and later refined and merged using PRIME 60 .Structure solution and refinementThe crystal structures of the Nsp10/16 complex were solved by molecular replacement using", [["Theta nodes", "MULTI-TISSUE_STRUCTURE", 53, 64], ["Nsp10/16 complex", "GENE_OR_GENE_PRODUCT", 425, 441], ["Nsp10/16 complex", "PROTEIN", 425, 441], ["these tasks", "TEST", 14, 25], ["a processing rate", "TEST", 111, 128], ["Serial crystallography data", "TEST", 165, 192], ["diffraction", "TEST", 238, 249], ["Structure solution", "TREATMENT", 362, 380], ["molecular replacement", "TREATMENT", 457, 478], ["Theta nodes", "OBSERVATION", 53, 64], ["crystal", "OBSERVATION_MODIFIER", 399, 406]]]], "PMC7254898": []}